0001558370-24-01475510-Q XOMA Royalty Corp 20241107202411070735470735470735470735470 0001558370-24-014755 10-Q 108 20240930 20241107 20241107 XOMA Royalty Corp 0000791908 2834 522154066 1231 10-Q 34 001-39801 241433210 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 XOMA Corp 20120119 XOMA LTD /DE/ 19990107 XOMA CORP /DE/ 19920703 10-Q 1 xoma-20240930x10q.htm 10-Q 0000791908--12-312024Q3false000.02310000020000020.3330.3330.3330000791908xoma:ChiefInvestmentOfficerMemberxoma:StockOptionInducementAwardsMember2023-01-032023-01-030000791908xoma:ChiefExecutiveOfficerInterimMemberxoma:StockOptionInducementAwardsMember2023-01-032023-01-030000791908xoma:PerformanceStockUnitsMember2023-05-310000791908xoma:TalpheraMemberxoma:U.s.DepartmentOfDefenseMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-122024-01-120000791908xoma:TalpheraMemberxoma:AllCustomersExcludingU.s.DepartmentOfDefenseMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-122024-01-120000791908xoma:DareMemberxoma:SildenafilCreamMemberxoma:ScenarioOneMemberxoma:RoyaltyPurchaseAgreementMember2024-04-292024-04-290000791908xoma:DareMemberxoma:OvapreneMemberxoma:ScenarioOneMemberxoma:RoyaltyPurchaseAgreementMember2024-04-292024-04-290000791908xoma:DareMemberxoma:SildenafilCreamMemberxoma:RoyaltyPurchaseAgreementMember2024-04-292024-04-290000791908xoma:DareMemberxoma:OvapreneMemberxoma:RoyaltyPurchaseAgreementMember2024-04-292024-04-290000791908xoma:TalpheraMemberxoma:AloraPharmaceuticalsMemberxoma:U.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAgreementMember2024-01-122024-01-120000791908xoma:TalpheraMemberxoma:AloraPharmaceuticalsMemberxoma:AllCustomersExcludingU.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAgreement
01-122024-01-120000791908xoma:TalpheraMemberxoma:AloraPharmaceuticalsMemberxoma:U.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAgreementMember2023-04-012023-04-300000791908xoma:TalpheraMemberxoma:AloraPharmaceuticalsMemberxoma:AllCustomersExcludingU.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAgreement
04-012023-04-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2017-12-062017-12-060000791908xoma:RezoluteIncMemberxoma:LicenseAgreementNonRz358ProductsMember2017-12-062017-12-060000791908xoma:AffitechResearchAsMember2024-09-300000791908xoma:LadrxMember2024-01-012024-09-300000791908xoma:ViractaTherapeuticsInc.Member2024-01-012024-09-300000791908xoma:AptevoMember2024-01-012024-09-300000791908xoma:AffitechResearchAsMember2024-01-012024-09-300000791908xoma:AronoraIncMember2024-01-012024-09-300000791908xoma:AgenusIncMember2024-01-012024-09-300000791908xoma:TalpheraMember2024-01-012024-09-300000791908xoma:DareMember2024-01-012024-09-300000791908xoma:TalpheraMember2024-09-300000791908xoma:PalobiofarmaSLMember2024-09-300000791908xoma:LadrxMember2024-09-300000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember2024-09-300000791908xoma:DareMember2024-09-300000791908xoma:AptevoMember2024-09-300000791908xoma:ViractaTherapeuticsInc.Member2023-12-310000791908xoma:PalobiofarmaSLMember2023-12-310000791908xoma:LadrxMember2023-12-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember2023-12-310000791908xoma:AronoraIncMember2023-12-310000791908xoma:AptevoMember2023-12-310000791908xoma:AgenusIncMember2023-12-310000791908xoma:AffitechResearchAsMember2023-12-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2024-04-010000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2024-07-012024-09-300000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2024-01-012024-09-300000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2023-07-012023-09-300000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2023-01-012023-09-3000007919082024-09-012024-09-300000791908srt:ScenarioForecastMemberxoma:CashReserveAccountsInterestAndAdministrativeFeesMember2027-07-012027-07-010000791908xoma:TalpheraMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-012024-09-300000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-012024-09-300000791908xoma:AptevoMembersrt:MinimumMemberxoma:CommercialPaymentPurchaseAgreementMember2023-06-012023-06-300000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-01-012023-12-310000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:NovartisPharmaAGMemberxoma:IL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:SecondRoyaltyInterestAcquisitionAgreementMember2016-12-212016-12-210000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember2016-12-212016-12-210000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2024-05-302024-05-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember2006-11-012006-11-010000791908srt:MaximumMemberdei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052021-08-050000791908srt:MaximumMemberdei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2018-12-182018-12-180000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2023-12-152023-12-150000791908xoma:DareMemberxoma:RoyaltyPurchaseAgreementMember2024-04-292024-04-290000791908xoma:TalpheraMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-122024-01-120000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-01-112024-01-110000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-01-012024-09-300000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-01-012024-03-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-012024-03-310000791908xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2023-06-212023-06-210000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-06-012023-06-300000791908xoma:AffitechResearchAsMembersrt:EuropeMemberxoma:CommercialPaymentPurchaseAgreementMember2022-01-012022-12-310000791908xoma:AffitechResearchAsMembercountry:USxoma:CommercialPaymentPurchaseAgreementMember2022-01-012022-12-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-062021-10-060000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-03-222021-03-220000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2019-09-262019-09-260000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-09-012019-09-300000791908xoma:AronoraIncMemberxoma:SiliconValleyBankMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:DareMemberxoma:RoyaltyPurchaseAgreementMember2024-04-290000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000791908xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2022-05-012022-05-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2022-07-012022-07-310000791908xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember2024-01-012024-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2024-04-232024-04-230000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2023-10-302023-10-300000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2020-11-012020-11-300000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2020-11-012020-11-300000791908dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052021-08-050000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2021-03-102021-03-100000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182018-12-180000791908xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2023-06-210000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-060000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-07-140000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2017-12-062020-10-310000791908xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-06-032024-06-030000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2024-07-012024-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:PriorityReviewVoucherMemberxoma:RoyaltyPurchaseAgreementMember2024-05-302024-05-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:PriorityReviewVoucherMemberxoma:RoyaltyPurchaseAgreementMember2024-01-012024-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2024-01-012024-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2023-07-012023-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:TovorafenibMemberxoma:RoyaltyPurchaseAgreementMember2023-04-232023-04-230000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2023-01-012023-09-300000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2024-07-012024-09-300000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2024-01-012024-09-300000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2024-07-012024-09-300000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember2016-12-210000791908xoma:TwistBioscienceCorporationMemberus-gaap:SubsequentEventMemberxoma:RoyaltyPurchaseAgreementMember2024-10-212024-10-210000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-07-142021-07-140000791908xoma:TwistBioscienceCorporationMemberus-gaap:SubsequentEventMemberxoma:RoyaltyPurchaseAgreementMember2024-10-210000791908xoma:TalpheraMemberxoma:AloraPharmaceuticalsMemberxoma:AssetPurchaseAgreementAndMarketingAgreementMember2023-04-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2017-12-060000791908xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember2017-08-240000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember2006-11-010000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2019-08-012019-08-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:OtherAntibodiesMemberxoma:CollaborationAgreementMember2009-02-012009-02-280000791908xoma:AronoraIncMembersrt:MinimumMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-09-300000791908xoma:AffitechResearchAsMemberxoma:ContingentConsiderationSalesMilestonesThreeMemberxoma:CommercialPaymentPurchaseAgreementMember2024-09-300000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-06-030000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-03-310000791908xoma:AffitechResearchAsMemberxoma:ContingentConsiderationSalesMilestonesOneAndTwoMemberxoma:CommercialPaymentPurchaseAgreementMember2024-03-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2024-03-310000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2023-12-310000791908xoma:AffitechResearchAsMemberxoma:ContingentConsiderationSalesMilestonesOneAndTwoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-12-310000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-03-290000791908xoma:AffitechResearchAsMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-060000791908xoma:AronoraIncMemberxoma:BayerProductsMembersrt:MaximumMemberxoma:RoyaltyPurchaseAgreementMember2019-04-

070000791908xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember2024-04-032024-04-030000791908xoma:KinnateMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberxoma:ExarafenibAndRelatedIntellectualPropertyMember2024-02-272024-02-270000791908xoma:KinnateCvrHoldersMemberxoma:ExarafenibAndRelatedIntellectualPropertyMemberxoma:ContingentValueRightsAgreementMember2024-02-272024-02-270000791908us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000791908xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2023-06-210000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-03-292023-03-290000791908xoma:AffitechResearchAsMemberxoma:FaricimabProductMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-062021-10-060000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2023-01-012023-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2017-12-062017-12-060000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-302015-09-300000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-03-220000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2019-09-260000791908xoma:AronoraIncMemberxoma:NonBayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-150000791908xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2023-12-150000791908us-gaap:CommonStockMember2024-07-012024-09-300000791908us-gaap:CommonStockMember2024-01-012024-03-310000791908us-gaap:CommonStockMember2023-01-012023-03-310000791908dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052024-09-300000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182024-09-300000791908xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember2017-08-242017-08-240000791908us-gaap:CommonStockMember2024-04-012024-06-300000791908us-gaap:CommonStockMember2023-04-012023-06-300000791908xoma:RezoluteIncMember2020-10-012020-10-310000791908us-gaap:RetainedEarningsMember2024-09-300000791908us-gaap:AdditionalPaidInCapitalMember2024-09-300000791908us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000791908us-gaap:RetainedEarningsMember2024-06-300000791908us-gaap:AdditionalPaidInCapitalMember2024-06-300000791908us-gaap:RetainedEarningsMember2024-03-310000791908us-gaap:AdditionalPaidInCapitalMember2024-03-310000791908us-gaap:RetainedEarningsMember2023-12-310000791908us-gaap:AdditionalPaidInCapitalMember2023-12-310000791908us-gaap:RetainedEarningsMember2023-09-300000791908us-gaap:AdditionalPaidInCapitalMember2023-09-300000791908us-gaap:RetainedEarningsMember2023-06-300000791908us-gaap:AdditionalPaidInCapitalMember2023-06-300000791908us-gaap:RetainedEarningsMember2023-03-310000791908us-gaap:AdditionalPaidInCapitalMember2023-03-310000791908us-gaap:RetainedEarningsMember2022-12-310000791908us-gaap:AdditionalPaidInCapitalMember2022-12-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2024-09-300000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2024-09-300000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-09-300000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2024-06-300000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2024-06-300000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-06-300000791908us-gaap:CommonStockMember2024-06-300000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2024-03-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2024-03-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-03-310000791908us-gaap:CommonStockMember2024-03-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2023-12-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2023-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-12-310000791908us-gaap:CommonStockMember2023-12-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2023-09-300000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2023-09-300000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-09-300000791908us-gaap:CommonStockMember2023-09-300000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2023-06-300000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2023-06-300000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-06-300000791908us-gaap:CommonStockMember2023-06-300000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2023-03-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2023-03-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-03-310000791908us-gaap:CommonStockMember2023-03-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2022-12-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2022-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-12-310000791908us-gaap:CommonStockMember2022-12-310000791908xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-09-300000791908xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-09-300000791908xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-09-300000791908xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-09-300000791908us-gaap:CommonStockMember2024-09-300000791908xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-12-310000791908xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-12-310000791908xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-12-310000791908xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-12-310000791908xoma:StockOptionInducementAwardsMember2023-01-030000791908xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember2017-08-240000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember2024-01-012024-09-300000791908xoma:StockOptionInducementAwardTwoMember2023-01-012023-03-310000791908xoma:StockOptionInducementAwardOneMember2023-01-012023-03-310000791908xoma:StockOptionInducementAwardsMember2024-01-012024-09-300000791908us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2024-01-012024-09-300000791908us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023-01-012023-09-300000791908xoma:PerformanceStockUnitsMember2023-12-310000791908xoma:PerformanceStockUnitsMember2024-04-012024-04-300000791908xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908xoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:ChiefExecutiveOfficerMemberxoma:PerformanceStockUnitsMember2024-01-012024-01-310000791908xoma:PerformanceStockUnitsMember2023-10-012023-10-310000791908xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908xoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908xoma:PerformanceStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-05-012023-05-310000791908us-gaap:RestrictedStockUnitsRSUMember2024-05-012024-05-310000791908xoma:EmployeeMemberus-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2024-01-012024-09-300000791908srt:DirectorMemberus-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2024-01-012024-09-300000791908xoma:PerformanceStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-05-012023-05-310000791908xoma:PerformanceStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2023-05-012023-05-310000791908xoma:PerformanceStockUnitsMember2023-05-012023-05-310000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MinimumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908srt:MaximumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember2023-01-012023-12-310000791908xoma:KinnateMember2024-01-012024-09-300000791908us-gaap:ScenarioAdjustmentMemberxoma:KinnateMember2024-01-012024-09-300000791908us-gaap:ScenarioAdjustmentMemberxoma:KinnateMember2023-01-012023-12-310000791908xoma:KinnateMember2023-01-012023-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2024-07-012024-09-300000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2024-07-012024-09-300000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2024-07-012024-09-300000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2024-07-012024-09-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2024-04-012024-04-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2024-01-012024-09-300000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2024-01-012024-09-300000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2024-01-012024-09-300000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2024-01-012024-09-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2023-07-012023-09-300000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2023-07-012023-09-300000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2023-07-012023-09-300000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2023-07-012023-09-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2023-01-012023-09-300000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2023-01-012023-09-300000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2023-01-012023-09-300000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2023-01-012023-09-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2022-01-012022-01-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2019-01-012019-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-01-012017-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2017-01-012017-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-01-012015-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2006-11-012024-09-300000791908xoma:CashReserveAccountsOperatingExpensesMember2023-12-150000791908xoma:CashReserveAccountsInterestAndAdministrativeFeesMember2023-12-150000791908xoma:CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember2023-12-150000791908xoma:KinnateMemberxoma:KinnateCvrHoldersMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberxoma:ExarafenibAndRelatedIntellectualPropertyMemberxoma:ContingentValueRightsAgreementMember2024-02-272024-02-270000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember2024-01-012024-09-300000791908xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember2017-08-242017-08-240000791908us-gaap:SeriesBPreferredStockMember2024-09-300000791908us-gaap:SeriesAPreferredStockMember2024-09-300000791908us-gaap:ConvertiblePreferredStockMember2024-09-300000791908us-gaap:SeriesBPreferredStockMember2023-12-310000791908us-gaap:SeriesAPreferredStockMember2023-12-310000791908us-gaap:ConvertiblePreferredStockMember2023-12-310000791908xoma:O2024Q3DividendsMemberus-gaap:SeriesAPreferredStockMember2024-07-012024-09-300000791908xoma:O2024Q3DividendsMemberdei:AdrMember2024-07-012024-09-300000791908xoma:O2024Q2DividendsMemberus-

gaap:SeriesAPreferredStockMember2024-04-012024-06-300000791908xoma:O2024Q2DividendsMemberdei:AdrMember2024-04-012024-06-300000791908xoma:O2024Q1DividendsMemberus-gaap:SeriesAPreferredStockMember2024-01-012024-03-310000791908xoma:O2024Q1DividendsMemberdei:AdrMember2024-01-012024-03-310000791908xoma:O2023Q4DividendsMemberus-gaap:SeriesAPreferredStockMember2023-10-012023-12-310000791908xoma:O2023Q4DividendsMemberdei:AdrMember2023-10-012023-12-310000791908us-gaap:SeriesBPreferredStockMember2024-07-012024-09-300000791908us-gaap:SeriesAPreferredStockMember2024-07-012024-09-300000791908us-gaap:SeriesBPreferredStockMember2023-07-012023-09-300000791908us-gaap:SeriesAPreferredStockMember2023-07-012023-09-300000791908us-gaap:SeriesBPreferredStockMember2023-01-012023-09-300000791908us-gaap:SeriesAPreferredStockMember2023-01-012023-09-300000791908us-gaap:SeriesBPreferredStockMember2024-01-012024-09-300000791908us-gaap:SeriesBPreferredStockMember2023-01-012023-12-310000791908us-gaap:SeriesAPreferredStockMember2023-01-012023-12-310000791908us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000791908xoma:LeasedFacilitiesSanFranciscoCaliforniaMember2024-04-030000791908us-gaap:RetainedEarningsMember2024-07-012024-09-300000791908us-gaap:RetainedEarningsMember2024-04-012024-06-300000791908srt:ProFormaMemberxoma:KinnateMember2024-01-012024-09-300000791908us-gaap:RetainedEarningsMember2024-01-012024-03-310000791908us-gaap:RetainedEarningsMember2023-07-012023-09-300000791908us-gaap:RetainedEarningsMember2023-04-012023-06-300000791908srt:ProFormaMemberxoma:KinnateMember2023-01-012023-12-310000791908us-gaap:RetainedEarningsMember2023-01-012023-03-310000791908xoma:BiotechnologyValueFundLPMemberxoma:XomaCorporationMemberus-gaap:CommonStockMember2024-09-300000791908xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember2023-11-100000791908xoma:LeasedFacilitiesEmeryvilleCaliforniaMember2023-01-310000791908xoma:LeasedFacilitiesEmeryvilleCaliforniaMember2023-01-012023-01-310000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2024-09-012024-09-300000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2024-01-012024-03-310000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2023-01-012023-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2016-12-212016-12-210000791908xoma:RezoluteIncMember2024-07-012024-09-300000791908xoma:RezoluteIncMember2024-01-012024-09-300000791908xoma:RezoluteIncMember2023-07-012023-09-300000791908xoma:RezoluteIncMember2023-01-012023-09-300000791908xoma:RezoluteIncMemberus-gaap:MeasurementInputSharePriceMember2024-09-300000791908xoma:RezoluteIncMemberus-gaap:MeasurementInputSharePriceMember2023-12-310000791908xoma:RezoluteIncMember2024-09-300000791908xoma:RezoluteIncMember2023-12-310000791908us-gaap:EmployeeStockOptionMember2024-09-300000791908xoma:PerformanceStockUnitsMember2024-09-300000791908us-gaap:RestrictedStockUnitsRSUMember2024-09-300000791908xoma:O2024Q3DividendsMember2024-07-012024-09-300000791908xoma:O2024Q2DividendsMember2024-04-012024-06-300000791908xoma:O2024Q1DividendsMember2024-01-012024-03-310000791908xoma:O2023Q4DividendsMember2023-10-012023-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2023-12-310000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember2023-12-150000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-150000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2024-09-300000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2023-12-310000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2023-12-150000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2024-04-012024-06-300000791908xoma:TalpheraMemberxoma:CommercialPaymentPurchaseAgreementMember2024-09-300000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2024-09-300000791908xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2024-09-300000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2024-09-300000791908xoma:DareMemberxoma:RoyaltyPurchaseAgreementMember2024-09-300000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2024-09-300000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2024-09-300000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2024-09-300000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2023-12-310000791908xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember2023-12-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2023-12-310000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2023-12-310000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-12-310000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2023-12-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2023-12-310000791908xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner1Memberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000791908xoma:Partner1Memberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2023-01-012023-12-310000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000791908xoma:TenYearWarrantsIssuedThirdRangeMember2023-12-310000791908xoma:TenYearWarrantsIssuedThirdRangeMember2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember2024-09-300000791908xoma:CommonStockWarrantExercisePrice14.71Member2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember2023-12-310000791908xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember2023-12-310000791908xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember2023-12-310000791908xoma:CommonStockWarrantExercisePrice14.71Member2023-12-150000791908xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-150000791908xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-150000791908xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-1500007919082023-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000791908xoma:TenYearWarrantsIssuedThirdRangeMember2023-12-310000791908xoma:TenYearWarrantsIssuedThirdRangeMember2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember2024-09-300000791908xoma:CommonStockWarrantExercisePrice14.71Member2024-09-300000791908xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember2023-12-310000791908xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember2023-12-310000791908xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember2023-12-310000791908xoma:CommonStockWarrantExercisePrice14.71Member2023-12-150000791908xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-150000791908xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-150000791908xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember2023-12-1500007919082022-12-310000791908us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000791908us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000791908us-gaap:FairValueMeasurementsRecurringMember2023-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2024-09-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2024-09-300000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2024-09-300000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2024-09-300000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2024-09-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2023-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2023-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2023-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2023-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2023-12-310000791908us-gaap:USTreasurySecuritiesMember2024-09-300000791908xoma:KinnateMember2024-04-030000791908xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember2024-09-300000791908us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908us-gaap:FairValueMeasurementsRecurringMember2024-09-300000791908xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember2024-04-030000791908xoma:KinnateMember2024-04-032024-04-030000791908us-gaap:WarrantMember2024-07-012024-09-300000791908us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000791908us-gaap:ConvertiblePreferredStockMember2024-07-012024-09-300000791908us-gaap:WarrantMember2024-01-012024-09-300000791908us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000791908us-gaap:ConvertiblePreferredStockMember2024-01-012024-09-300000791908us-gaap:WarrantMember2023-07-012023-09-300000791908us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000791908us-gaap:ConvertiblePreferredStockMember2023-07-012023-09-300000791908us-gaap:WarrantMember2023-01-012023-09-300000791908us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000791908us-gaap:ConvertiblePreferredStockMember2023-01-012023-09-3000007919082023-01-012023-09-300000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2024-07-012024-09-300000791908xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember2024-01-012024-09-300000791908xoma:PerformanceStockUnitsMember2024-07-012024-09-300000791908us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000791908us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300000791908us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000791908xoma:PerformanceStockUnitsMember2024-01-012024-09-300000791908us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000791908us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300000791908us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000791908us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300000791908us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300000791908us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000791908us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000791908us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100007919082024-01-012024-03-310000791908us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000007919082023-07-012023-09-300000791908us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000007919082023-04-012023-06-300000791908us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100007919082023-01-012023-03-310000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2024-09-3000007919082024-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2023-12-3100007919082023-12-3100007919082024-01-0200007919082024-07-012024-09-300000791908us-gaap:SeriesAPreferredStockMember2024-01-012024-09-300000791908us-gaap:CommonStockMember2024-01-012024-09-300000791908dei:AdrMember2024-01-012024-09-3000007919082024-11-0400007919082024-01-012024-09-30iso4217:EURxoma:periodxoma:customerxoma:Dxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purexoma:Rightxoma:itemxoma:multiplierxoma:agreementxoma:productTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.Â 20549FORMÂ 10-Qâ€‹â€‹â˜‘QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the quarterly period ended September 30, 2024ORâ€‹â€‹â˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from _____to_____Commission File Number:Â 001-39801XOMA Royalty Corporation(Exact name of Registrant as specified in its charter)Delaware52-2154066(State or other jurisdiction of(I.R.S. Employerincorporation or organization)â€‹Identification No.)Â Â Â 2200 Powell Street, SuiteÂ 310Emeryville, Californiaâ€‹94608(Address of principal executive offices)(Zip Code)â€‹Registrantâ€™s telephone number, including area code: (510) 204-7200Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹â€‹â€‹Title of each class:Trading symbol(s):Name of each exchange on which registered:Common Stock, $0.0075 par valueXOMAThe Nasdaq Global Market8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 XOMAPThe Nasdaq Global MarketDepositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)XOMAOThe Nasdaq Global Marketâ€‹Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Â Â YesÂ Â â˜Â Â Â Â NoÂ Â â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Â YesÂ Â â˜Â Â Â Â NoÂ Â â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜‘Smaller reporting companyâ˜‘Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Â Â YesÂ Â â˜Â Â Â Â NoÂ Â â˜‘As of November 4, 2024, the registrant had 11,782,723 shares of common stock, $0.0075 par value per share, outstanding.â€‹â€‹â€‹ Table of Contentsâ€‹XOMA ROYALTY CORPORATIONFORMÂ 10-QTABLE OF CONTENTSâ€‹â€‹â€‹â€‹â

and 2023 (unaudited)â€‹<10â€‹â€‹â€‹â€‹â€‹â€‹â€‹Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 (unaudited)â€‹<12â€‹â€‹â€‹â€‹â€‹â€‹â€‹NotesÂ to Condensed Consolidated Financial Statements (unaudited)â€‹<13â€‹â€‹â€‹â€‹â€‹ItemÂ 2.â€‹Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€‹<52â€‹â€‹â€‹â€‹â€‹ItemÂ 3.â€‹Quantitative and Qualitative Disclosures About Market Riskâ€‹<61â€‹â€‹â€‹â€‹â€‹ItemÂ 4.â€‹Controls and Proceduresâ€‹<61â€‹â€‹â€‹â€‹â€‹PARTÂ IIâ€‹OTHER INFORMATIONâ€‹<62â€‹â€‹â€‹â€‹â€‹ItemÂ 1.â€‹Legal Proceedingsâ€‹<62â€‹â€‹â€‹â€‹â€‹ItemÂ 1A.â€‹Risk Factorsâ€‹<62â€‹â€‹â€‹â€‹â€‹ItemÂ 2.â€‹Unregistered Sales of Equity Securities and Use of Proceeds â€‹<62â€‹â€‹â€‹â€‹â€‹ItemÂ 3.â€‹Defaults Upon Senior Securitiesâ€‹<62â€‹â€‹â€‹â€‹â€‹ItemÂ 4.â€‹Mine Safety Disclosuresâ€‹<62â€‹â€‹â€‹â€‹â€‹ItemÂ 5.â€‹Other Informationâ€‹<63â€‹â€‹â€‹â€‹â€‹ItemÂ 6.â€‹Exhibitsâ€‹<64â€‹â€‹â€‹â€‹â€‹Signaturesâ€‹<66â€‹â€‹â€‹2 Table of ContentsGLOSSARY OF TERMS AND ABBREVIATIONS â€‹â€‹â€‹AbbreviationsDefinition2010 Planâ€‹The Company's 2010 Long Term Incentive and Stock Award Plan, as amended2018 Common Stock ATM Agreementâ€‹At The Market Issuance Sales Agreement with HCW dated December 18, 20182021 Series B Preferred Stock ATM Agreementâ€‹At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021AAAâ€‹Assignment and Assumption AgreementAffitechâ€‹Affitech Research ASAffitech CPPAâ€‹The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021Agenusâ€‹Agenus, Inc. and certain affiliatesAgenus RPAâ€‹The Company's Royalty Purchase Agreement with Agenus dated September 20, 2018Aloraâ€‹Alora Pharmaceuticals, LLCAnti-TGFÎ²Â² Antibody License Agreementâ€‹The Company's License Agreement with Novartis dated September 30, 2015April 2022 Letter Agreementâ€‹The Letter Agreement to Officer Employment Agreement dated August 7, 2017, between the Company and Thomas Burns dated April 1, 2022Aptevoâ€‹Aptevo Therapeutics Inc.Aptevo CPPAâ€‹The Companyâ€™s Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as â€œAptevo Commercial Payment Purchase Agreementâ€ or â€œAptevo CPPAâ€Aronoraâ€‹Aronora, Inc.Aronora RPAâ€‹The Company's Royalty Purchase Agreement with Aronora dated April 7, 2019AstraZenecaâ€‹AstraZeneca plcASCâ€‹Accounting Standards CodificationASC 450â€‹ASC Topic 450, ContingenciesASC 606â€‹ASC Topic 606, Revenue from Contracts with CustomersASC 805â€‹ASC Topic 805, Business CombinationsASC 815â€‹ASC Topic 815, Derivatives and HedgingASC 825â€‹ASC Topic 825, Financial InstrumentsASC 842â€‹ASC Topic 842, LeasesASUâ€‹Accounting Standards UpdateBayerâ€‹Bayer Pharma AGBayer License Agreementâ€‹Out-license agreement to Bayer HealthCare LLC from DarÃ© dated January 10, 2020, related to the development and commercialization of OVAPRENEBioasisâ€‹Bioasis Technologies, Inc. and certain affiliatesBioasis RPAâ€‹The Company's Royalty Purchase Agreement with Bioasis dated February 25, 2019Black-Scholes Modelâ€‹Black-Scholes Option Pricing ModelBlue Owlâ€‹Blue Owl Capital Corporation Blue Owl Loanâ€‹Loan pursuant to the Blue Owl Loan Agreement Blue Owl Loan Agreement â€‹Loan agreement dated as of December 15, 2023, between XRL, the lenders from time to time party thereto and Blue Owl, as administrative agent Boardâ€‹The Companyâ€™s Board of DirectorsB. Rileyâ€‹B. Riley Securities, Inc.Broadridgeâ€‹Broadridge Corporate Issuer Solutions, LLC, rights agent under the Kinnate CVR AgreementBVFâ€‹Biotechnology Value Fund, L.P.3 Table of ContentsCompanyâ€‹XOMA Royalty Corporation (formerly, XOMA Corporation), including its subsidiaries CMOâ€‹Contract manufacturing organizationCPPAâ€‹Commercial Payment Purchase AgreementCVRâ€‹Contingent value rightCROâ€‹Contract research organization DarÃ©â€‹DarÃ© Bioscience, Inc.DarÃ© RPAsâ€‹The Company's Traditional RPA and Synthetic RPA with DarÃ© dated April 29, 2024DarÃ© Organon License Agreementâ€‹Out-license agreement to Organon from DarÃ© dated March 31, 2022, related to the development and commercialization of XACIATO, as amended on July 4, 2023Day Oneâ€‹Day One BiopharmaceuticalsDSUVIAÂ®â€‹sufentanil sublingual tablet (DZUVEO in European market)DoDâ€‹U.S. Department of DefenseEIRâ€‹Effective interest rateEMAâ€‹European Medicines AgencyESPPâ€‹2015 Employee Stock Purchase Plan, as amendedExchange Actâ€‹U.S. Securities Exchange Act of 1934FDAâ€‹U.S. Food and Drug AdministrationFDICâ€‹Federal Deposit Insurance CorporationFortisâ€‹Fortis Advisors LLC, representative of the Kinnate CVR holders under the Kinnate CVR AgreementGAAPâ€‹Generally accepted accounting principlesG&Aâ€‹General and administrativeGevokizumab License Agreementâ€‹The Company's License Agreement with Novartis dated August 24, 2017HCRPâ€‹Healthcare Royalty Partners II, L.P.HCWâ€‹H.C. Wainwright & Co., LLCImmunityBioâ€‹ImmunityBio, Inc. (formerly NantCell, Inc.)ImmunityBio License Agreementâ€‹Out-license agreement to ImmunityBio from LadRx dated July 27, 2017, related to the development and commercialization of Aldoxorubicin, as amended on September 27, 2018, terminated on June 3, 2024IRAâ€‹Inflation Reduction ActIPâ€‹Intellectual PropertyIPR&Dâ€‹In-Process Research and Development IXINITYÂ®â€‹coagulation factor IX (recombinant)Janssenâ€‹Janssen Biotech, Inc.Kinnateâ€‹Kinnate Biopharma Inc.Kinnate CVR Agreementâ€‹The Contingent Value Rights Agreement by and between the Company, Broadridge, and Fortis dated April 3, 2024Kinnate Merger Agreementâ€‹The Agreement and Plan of Merger by and among the Company, XRA, and Kinnate dated February 16, 2024Kurosâ€‹Kuros Biosciences AG, Kuros US LLC, and Kuros Royalty Fund (US) LLC, collectivelyKuros RPAâ€‹The Company's Royalty Purchase Agreement with Kuros dated July 14, 2021LadRxâ€‹LadRx Corporation (formerly CytRx Corporation)LadRx Agreements â€‹LadRx AAA and LadRx RPALadRx AAAâ€‹The Companyâ€™s Assignment and Assumption Agreement with LadRx dated June 21, 20234 Table of ContentsLadRx RPAâ€‹The Companyâ€™s Royalty Purchase Agreement with LadRx dated June 21, 2023 and subsequently amended on June 3, 2024Medexusâ€‹Medexus Pharmaceuticals, Inc.Merck KGaA License Agreementâ€‹In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva IP Acquisition Agreement)MIPLYFFAâ„¢â€‹arimoclomolNDAâ€‹New Drug ApplicationNovartisâ€‹Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.ObsEvaâ€‹ObsEva SAObsEva IP Acquisition Agreementâ€‹Company's IP Acquisition Agreement with ObsEva dated November 21, 2022OJEMDAâ„¢â€‹tovorafenibOrganonâ€‹Organon International GmbHOVAPRENEÂ®â€‹An investigational hormone-free monthly intravaginal contraceptivePaloâ€‹Palobiofarma, S.L.Palo RPAâ€‹The Company's Royalty Purchase Agreement with Palo dated September 26, 2019Pfizerâ€‹Pfizer, Inc.Pierre Fabreâ€‹Pierre Fabre MÃ©dicament, SASPSUâ€‹Performance stock unitR&Dâ€‹Research and developmentRegeneronâ€‹Regeneron Pharmaceuticals, Inc.Rezoluteâ€‹Rezolute, Inc. (formerly Antria Bio, Inc.)Rezolute License Agreementâ€‹The Company's License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019, and March 2020RPAâ€‹Royalty Purchase AgreementRocheâ€‹F. Hoffmann-La Roche AGRSUâ€‹Restricted stock unitSECâ€‹U.S. Securities and Exchange CommissionSeries A Preferred Stockâ€‹The 8.625% Series A cumulative, perpetual preferred stock issued in December 2020Series B Preferred Stockâ€‹The 8.375% Series B cumulative, perpetual preferred stock issued in April 2021Series A and Series B Preferred Stockâ€‹Series A Preferred Stock and Series B Preferred Stock, collectively â€‹Series B Depositary Sharesâ€‹The depositary shares, each representing 1/1000th interest in a share of Series B Preferred StockSeries X Preferred Stockâ€‹The Series X Convertible Preferred StockSildenafil Creamâ€‹Sildenafil Cream, 3.6%Sonnetâ€‹Sonnet BioTherapeutics, Inc. (formerly Oncobiologics, Inc.)Sonnet Collaboration Agreementâ€‹The Company's Collaboration Agreement with Sonnet dated July 23, 2012, as amended in May 2019SVBâ€‹Silicon Valley BankTakedaâ€‹Takeda Pharmaceutical Company LimitedTakeda Collaboration Agreementâ€‹The Company's Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009Talpheraâ€‹Talphera, Inc. (formerly AcelRx Pharmaceuticals, Inc. or â€œAcelRxâ€)Talphera APAâ€‹Asset Purchase Agreement dated March 12, 2023 between AcelRx (now Talphera) and Vertical related to the sale of DSUVIA from Talphera to Vertical5 Table of ContentsTalphera CPPAâ€‹The Companyâ€™s Payment Interest Purchase Agreement with Talphera dated January 11, 2024, referred to herein as â€œTalphera Commercial Payment Purchase Agreementâ€ or â€œTalphera CPPAâ€Talphera Marketing Agreementâ€‹Marketing Agreement dated April 3, 2023 between AcelRx (now Talphera) and VerticalTGFÎ²Â²â€‹transforming growth factor betaU.S.â€‹United StatesVABYSMOÂ®â€‹faricimab-svoaVerticalâ€‹Vertical Pharmaceuticals, LLC, a wholly-owned subsidiary of Alora Viractaâ€‹Viracta Therapeutics, Inc.Viracta RPAâ€‹The Company's Royalty Purchase Agreement with Viracta dated March 22, 2021, as amended March 4, 2024 XACIATOâ„¢â€‹Clindamycin phosphate vaginal gel 2%XOMAâ€‹XOMA Royalty Corporation (formerly, XOMA Corporation), a Delaware corporation, including subsidiaries XRAâ€‹XRA 1 Corp. a wholly-owned subsidiary of the CompanyXRL â€‹XRL 1 LLC, a wholly-owned subsidiary of the CompanyZevraâ€‹Zevra Therapeutics, Inc. (formerly KemPharm Denmark A/S)Zevra APA â€‹Asset Purchase Agreement dated May 13, 2011 between LadRx and Orphazyme ApS, and assigned to Zevra as of June 1, 2022, related to the sale of arimoclomol from LadRx to Zevra (assumed by the Company as part of LadRx AAA)â€‹â€‹â€‹<6 Table of ContentsPARTÂ IÂ -Â FINANCIAL INFORMATIONITEMÂ 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTSXOMA ROYALTY CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹2023(1)ASSETSâ€‹(unaudited)â€‹â€‹â€‹Current assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash and cash equivalents â€‹$ 142,050â€‹$ 153,290Short-term restricted cashâ€‹â€‹ 80â€‹â€‹ 160Short-term equity securitiesâ€‹â€‹ 785â€‹â€‹ 161Trade and other receivables, netâ€‹Â 1,045â€‹Â 1,004Short-term royalty and commercial payment receivablesâ€‹â€‹ 12,682â€‹â€‹ 14,215Prepaid expenses and other current assetsâ€‹Â 2,379â€‹Â 483Total current assetsâ€‹Â 159,021â€‹Â 169,313â€‹â€‹â€‹â€‹â€‹â€‹â€‹Long-term restricted cashâ€‹â€‹ 4,686â€‹Â 6,100Property and equipment, netâ€‹Â 34â€‹Â 25Operating lease right-of-use assetsâ€‹â€‹ 335â€‹â€‹ 378Long-term royalty and commercial payment receivablesâ€‹Â 54,207â€‹Â 57,952Exarafenib milestone asset (Note 4)â€‹Â 3,125â€‹Â â€”Other assets - long termâ€‹Â 1,932â€‹Â 533Total assetsâ€‹$ 223,340â€‹$ 234,301â€‹â€‹â€‹â€‹â€‹â€‹â€‹LIABILITIES AND STOCKHOLDERSâ€™ EQUITYâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Current liabilities:â€‹â€‹â€‹â€‹â€‹â€‹Accounts payableâ€‹$ 1,131â€‹$ 653Accrued and other liabilities â€‹Â 2,451â€‹Â 2,768Contingent consideration under RPAs, AAAs, and CPPAs â€‹â€‹ 4,000â€‹â€‹ 7,000Operating lease liabilitiesâ€‹â€‹ 434â€‹â€‹ 54Unearned revenue recognized under units-of-revenue methodâ€‹Â 1,924â€‹Â 2,113Preferred stock dividend accrual â€‹â€‹ 1,368â€‹â€‹ 1,368Current portion of long-term debtâ€‹â€‹ 9,826â€‹â€‹ 5,543Total current liabilitiesâ€‹Â 21,134â€‹Â 19,499Unearned revenue recognized under units-of-revenue method â€” long-termâ€‹Â 5,589â€‹Â 7,228Exarafenib milestone contingent consideration (Note 4)â€‹â€‹ 3,125â€‹â€‹ â€”Long-term operating lease liabilities â€‹â€‹ 594â€‹â€‹ 335Long-term debtâ€‹â€‹ 108,089â€‹â€‹ 118,518Total liabilitiesâ€‹Â 138,531â€‹Â 145,580â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commitments and Contingencies (Note 10)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Stockholdersâ€™ equity:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Preferred Stock, $0.05 par value, 1,000,000 shares authorized:â€‹â€‹â€‹â€‹â€‹â€‹â€‹8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding as of SeptemberÂ 30,Â 2024 and December 31, 2023â€‹â€‹ 49â€‹â€‹ 498.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding as of SeptemberÂ 30,Â 2024 and December 31, 2023â€‹â€‹ â€”â€‹Â â€”Convertible preferred stock, 5,003 shares issued and outstanding as of SeptemberÂ 30,Â 2024 and December 31, 2023â€‹Â â€”â€‹Â â€”Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,755,223 and 11,495,492 shares issued and outstanding as of SeptemberÂ 30,Â 2024 and December 31, 2023, respectivelyâ€‹Â 88â€‹Â 86Additional paid-in capitalâ€‹Â 1,317,657â€‹Â 1,311,809Accumulated other comprehensive incomeâ€‹â€‹ 104â€‹â€‹ â€”Accumulated deficitâ€‹Â (1,233,089)â€‹Â (1,223,223)Total stockholdersâ€™ equityâ€‹Â 84,809â€‹Â 88,721Total liabilities and stockholdersâ€™ equityâ€‹$ 223,340â€‹$ 234,301â€‹The accompanying notes are an integral part of these condensed consolidated financial statements.(1)The condensed consolidated balance sheet as of DecemberÂ 31, 2023 has been derived from the audited consolidated financial statements as of that date included in the Companyâ€™s Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31, 2023.7 Table of Contentsâ€‹XOMA ROYALTY CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited) (in thousands, except per share amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”Â 7â€‹ â€”â€‹ 123â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 123Stock-based compensation expense â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”Â â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 1,570â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 1,570Preferred stock dividends â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”Â â€”â€‹ â€”â€‹ â€”â€‹ (1,368)â€‹ â€”â€‹ â€”â€‹ â€”â€‹ (1,368)Net loss â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”Â â€”â€‹ â€”â€‹ â€”â€‹ (9,813)â€‹ (9,813)Balance, MarchÂ 31,Â 2023 984â€‹$ 49â€‹ 2â€‹$ â€”â€‹ 5â€‹$ â€”Â 11,461â€‹$ 86â€‹$ 1,306,596â€‹$ â€”â€‹$ (1,192,205)â€‹$ 114,526Exercise of stock options â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”Â â€”â€‹ â€”â€‹ â€”â€‹ 8â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 153â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 153Issuance of common stock related to ESPP â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 3â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 50â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ 50Stock-based compensation expense â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹ â€”â€‹

similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company 16 Table of Contentsregularly reviews public information on clinical trials, press releases, and updates from its partners to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable assetâ€™s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made.Revenue from Contracts with CustomersThe Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)Â identify the contract(s)Â with a customer; (ii)Â identify the performance obligations in the contract; (iii)Â determine the transaction price; (iv)Â allocate the transaction price to the performance obligations in the contract; and (v)Â recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be oneÂ year or less.The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.License of Intellectual PropertyIf the license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process, and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Companyâ€™s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Companyâ€™s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process, and know-how (i.e., at a point in time). Deferred revenue is recorded when upfront payments and fees are received prior to the satisfaction of performance obligations. Trade and other receivables, net is recorded when the Company has an unconditional right to consideration.17 Table of ContentsMilestone PaymentsAt the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.RoyaltiesFor arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)Â when the related sales occur, or (ii)Â when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).Revenue Recognized under Units-of-Revenue MethodThe Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the periodâ€™s cash payment.Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Companyâ€™s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.Stock-Based CompensationThe Company recognizes compensation expense for all stock-based payment awards made to the Companyâ€™s employees, consultants, and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility, and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations, and volatility. The estimate of expected volatility is based on the Companyâ€™s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The valuation of RSUs is determined at the date of grant using the Companyâ€™s closing stock price.18 Table of ContentsThe Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.Equity SecuritiesThe Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations in the period of sale.Asset AcquisitionsAs a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If the screen test is not met, the Company then further evaluates whether the assets or group of assets includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. If the fair value of net assets acquired, after allocating the excess of the fair value of net assets acquired to certain qualifying assets, exceeds the total cost of the acquisition, a bargain purchase gain is recognized in other income in the condensed consolidated statements of operations.Contingent payments in asset acquisitions are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that are related to IPR&D assets are expensed as incurred. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. Cash payments related to acquired assets are reflected as an investing cash flow in the Companyâ€™s condensed consolidated statements of cash flows. Leases The Company leases its headquarters in Emeryville, California and acquired a lease from the Kinnate acquisition. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. For leases acquired in asset acquisitions, the Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the acquisition date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.19 Table of ContentsRent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in G&A expense in the condensed consolidated statements of operations.The Company has elected the practical expedient to not separate lease and non-lease components. The Companyâ€™s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.Long-Term DebtLong-term debt represents the Companyâ€™s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the EIR method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the EIR method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.Warrants The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Companyâ€™s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility, and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Companyâ€™s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.Income TaxesThe Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.The recognition, derecognition and measurement of a tax position is based on managementâ€™s best judgment given the facts, circumstances, and information available at each reporting date. The Companyâ€™s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.Net Income (Loss) per Share Available to (Attributable to) Common StockholdersThe Company calculates basic and diluted income (loss) per share available to (attributable to) common stockholders using the two-class method. The Companyâ€™s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Companyâ€™s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.20 Table of ContentsUnder the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income available to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income (loss) per share available to (attributable to) common stockholders is then calculated by dividing the net income (loss) available to (attributable to) common stockholders by the weighted-average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted-average common shares outstanding.Diluted net income (loss) per share available to (attributable to) common stockholders is based on the weighted-average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Companyâ€™s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Companyâ€™s share price and, therefore, are not included in the diluted shares until the contingency is resolved.Share RepurchasesThe Company has a stock repurchase program that is executed through purchases made from time to time, including in the open market. The Company retires repurchased shares of common stock, reducing common stock with any excess of cost over par value recorded to accumulated deficit. Issued and outstanding shares of common stock are reduced by the number of shares repurchased. No treasury stock is recognized in the condensed consolidated financial statements. In August 2022, the IRA enacted a 1% excise tax on net share repurchases after December 31, 2022. Any excise tax incurred on share repurchases is recognized as part of the cost basis of the shares acquired.Concentration of RiskCash, cash equivalents, restricted cash, and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended September 30, 2024, three partners represented 75%, 14% and 10% of total income and revenues, respectively. For the nine months ended September 30, 2024, three partners represented 50%, 25% and 10% of total income and revenues, respectively. For the three months ended September 30, 2023, two partners represented 73% and 24% of total income and revenues, respectively. For the nine months ended September 30, 2023, two partners represented 54% and 44% of total income and revenues, respectively. One partner represented 96% of the trade and other receivables, net as of September 30, 2024. One partner represented 100% of the trade and other receivables, net as of December 31, 2023.Comprehensive Income (Loss)Comprehensive income (loss) is comprised of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that

under U.S. GAAP are recorded as an element of stockholdersâ€™ equity but are excluded from net income (loss).21 Table of ContentsAccounting Pronouncements Recently AdoptedIn November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2024. â€‹Recent Accounting Pronouncements Not Yet AdoptedIn October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commissionâ€™s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures. â€‹In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.â€‹â€‹3.Â Condensed Consolidated Financial Statements DetailsEquity SecuritiesAs of September 30, 2024 and December 31, 2023, equity securities consisted of an investment in Rezoluteâ€™s common stock of $0.8 million and $0.2 million, respectively (see Note 4). For the three and nine months ended September 30, 2024, the Company recognized a gain of $0.1 million and $0.6 million, respectively, due to the change in fair value of its investment in Rezoluteâ€™s common stock, which is included in the other income (expense), net line item of the condensed consolidated statements of operations. For both the three and nine months ended September 30, 2023, the Company recognized a loss of $0.1 million due to the change in fair value of its investment in Rezolute.â€‹â€‹22 Table of ContentsAccrued and Other LiabilitiesAccrued and other liabilities consisted of the following (in thousands):

â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â	â€‹DecemberÂ 31,Â	
â€‹Â Â Â Â 2024Â Â Â Â	2023Accrued incentive compensationâ€‹	$ 1,171â€‹
$ 1,203Other accrued liabilitiesâ€‹â€‹	445â€‹â€‹	625Accrued legal and accounting feesâ€‹â€‹
637â€‹â€‹	791Accrued payroll and benefitsâ€‹Â	198â€‹Â
149Totalâ€‹	$ 2,451â€‹	$ 2,768â€‹Net Loss Per Share Attributable to Common Stockholders The following table includes the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licenseeâ€™s obligation to make payments to Rezolute based on sales of such product in each country.The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety daysâ€™ notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities.27 Table of ContentsThe license agreement was subsequently amended in 2018, 2019, and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezoluteâ€™s equity financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezoluteâ€™s common stock (as adjusted for the 1:50 reverse stock split in October 2020). In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended. In April 2024, Rezolute dosed the first patient in its Phase 3 trial of RZ358 and the Company earned a $5.0 million milestone pursuant to the Rezolute License Agreement, as amended.As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized zero and $5.0 million in revenue from contracts with customers related to this arrangement during the three and nine months ended September 30, 2024. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2023.JanssenIn August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMAâ€™s patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssenâ€™s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive a 0.75% royalty on net sales of each product. Janssenâ€™s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement. The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. The Company concluded that the development and regulatory milestone payments are solely dependent on Janssenâ€™s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024. The Company recognized $0.2 million and $1.3 million in revenue from contracts with customers related to this arrangement during the three and nine months ended September 30, 2023.NovartisÂ â€“ Anti-TGFÎ² Antibody (NIS793)On SeptemberÂ 30, 2015, the Company and Novartis entered into the Anti-TGFÎ² Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Companyâ€™s anti-transforming growth factor beta (â€œTGFÎ²â€) antibody program (now â€œNIS793â€). Under the terms of the Anti-TGFÎ² 28 Table of ContentsAntibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFÎ² Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartisâ€™ royalty obligations end. The Anti-TGFÎ² Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFÎ² Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon 180 daysâ€™ notice.The Company concluded that there were multiple promised goods and services under the Anti-TGFÎ² Antibody License Agreement, including the transfer of license, regulatory services, and transfer of materials, process, and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of DecemberÂ 31, 2015.The Company was eligible to receive up to a total of $480.0 million in development, regulatory, and commercial milestones under the Anti-TGFÎ² Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFÎ² Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.The Company concluded that the development and regulatory milestone payments are solely dependent on Novartisâ€™ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartisâ€™ obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.In August 2023, Novartis communicated to the Company its intent to discontinue development activities related to NIS793. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023.NovartisÂ â€“ Anti-IL-1Î² Antibody (VPM087) On AugustÂ 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (â€œVPM087â€), a novel anti-Interleukin-1 (â€œIL-1â€) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. On AugustÂ 24, 2017, pursuant to a separate agreement (the â€œIL-1 Target License Agreementâ€), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the â€œExclusivity Optionâ€) to such intellectual property for the treatment and prevention of cardiovascular disease.29 Table of ContentsUnder the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to â‚¬12.0 million) was paid by Novartis, on behalf of the Company, to settle the Companyâ€™s outstanding debt with Les Laboratories Servier (the â€œServier Loanâ€). In addition, Novartis extended the maturity date on the Companyâ€™s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Companyâ€™s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on AugustÂ 24, 2017, resulting in a $0.2 million premium paid to the Company.Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory, and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Companyâ€™s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartisâ€™ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six monthsâ€™ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials, and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During theÂ year ended DecemberÂ 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority.The Company concluded that the development and regulatory milestone payments are solely dependent on Novartisâ€™ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.30 Table of ContentsAs of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023.Sale of Future Revenue StreamsOn DecemberÂ 21, 2016, the Company entered into two royalty interest sale agreements (together, the â€œRoyalty Sale Agreementsâ€) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated AugustÂ 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018, and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in DecemberÂ 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated OctoberÂ 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Companyâ€™s limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Companyâ€™s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under â€œunits-of-revenueâ€ method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the periodâ€™s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.The Company recognized $0.7 million and $1.8 million in revenue under the units-of-revenue method under these arrangements during the three and nine months ended September 30, 2024, respectively. The Company recognized $0.6 million and $1.6 million in revenue under the units-of-revenue method under these arrangements during the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the current and non-current portions of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $5.6 million, respectively. As of DecemberÂ 31, 2023, the Company classified $2.1 million and $7.2 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. â€‹5. Royalty and Commercial Payment Purchase AgreementsShort-term royalty and commercial payment receivables were $12.7 million and $14.2 million as of September 30, 2024 and December 31, 2023, respectively. Long-term royalty and commercial payment receivables were $54.2 million and $58.0 million as of September 30, 2024 and December 31, 2023, respectively. DarÃ© Royalty Purchase AgreementsOn April 29, 2024, the Company entered into the DarÃ© RPAs. Pursuant to the terms of the DarÃ© RPAs, the Company paid $22.0 million in cash to DarÃ© in consideration for the sale of (a) 100% of all remaining royalties related to XACIATO not already subject to the royalty-backed financing agreement DarÃ© entered into in December 2023 and net of payments owed by DarÃ© to upstream licensors, which equates to royalties ranging from low to high single digits, and of all potential commercial milestones related to XACIATO that are payable to DarÃ© under the DarÃ© Organon License Agreement; (b) a 4% synthetic royalty on net sales of OVAPRENE and a 2% synthetic royalty on net sales of Sildenafil 31 Table of ContentsCream, which will decrease to 2.5% and 1.25%, respectively, upon the Company achieving a pre-specified return threshold; and (c) a portion of DarÃ©â€™s right to a certain milestone payment that may become payable to DarÃ© under the Bayer License Agreement. The DarÃ© RPAs also provide for milestone payments to DarÃ© of $11.0 million for each successive $22.0 million received by the Company under the DarÃ© RPAs after achievement of a return threshold of $88.0 million. Upon closing of the transaction, the Company paid DarÃ© an upfront payment of $22.0 million, which was recorded as long-term royalty and commercial payment receivables in its condensed consolidated balance sheet. The Company concluded that the milestone payments to DarÃ© did not meet the definition of a derivative under ASC 815 and expects to recognize the milestone payments as liabilities when probable and estimable.Given the limited available information, the Company was unable to reliably estimate future net sales and the commercial payments to be received over the twelve-month period following the quarter ended September 30, 2024 and, as such, no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024.During the nine months ended September 30, 2024, the Company received de minimis commercial payments pursuant to the DarÃ© RPAs. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance.Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected.Â The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024.Talphera Commercial Payment Purchase AgreementDSUVIA was approved by the FDA in 2018 for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales of DSUVIA and up to $116.5 million in sales-based milestone payments under the

Talphera APA. In addition, Talphera is entitled to 75% of net sales of DSUVIA to the DoD for its services performed to support sales of DSUVIA to the DoD under the Talphera Marketing Agreement. On January 12, 2024, the Company entered into the Talphera CPPA, pursuant to which XOMA will receive (i) 100% of the 15% royalty on commercial net sales and the sales-based milestones related to net sales of DSUVIA for sales made on and after January 1, 2024, and (ii) 100% of Talpheraâ€™s future service revenue in the amount of 75% of net sales of DSUVIA to the DoD, until the Company receives $20.0 million. Thereafter, the Company will fully retain the 15% royalty on commercial net sales of DSUVIA and will share equally with Talphera the 75% of net sales of DSUVIA to the DoD and the remaining sales-based milestone payments due from Alora.Upon closing of the transaction, the Company paid Talphera an upfront payment of $8.0 million, which was recorded as long-term royalty and commercial payment receivables in its consolidated balance sheet. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Talphera CPPA of $80,000. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance.Given the limited available information, the Company was unable to reliably estimate future net sales and the commercial payments to be received over the twelve-month period following the quarter ended September 30, 2024 and, as such, no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024.Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected.Â The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024.32 Table of ContentsLadRx AgreementsOn June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title, and interest related to arimoclomol under the Zevra APA between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory, and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under the ImmunityBio License Agreement between ImmunityBio and LadRx. On June 3, 2024, the ImmunityBio License Agreement was terminated, and the Company entered into an amendment to the LadRx RPA. Under the LadRx RPA, as amended, the Company is eligible to receive potential low single-digit percentage royalty payments on aggregate net sales of aldoxorubicin. Additionally, the amendment removed the remaining $4.0 million regulatory milestone payment under the original agreement that had been contingent upon the achievement of a specified regulatory milestone for the product candidate related to aldoxorubicin, which initially and as of the amendment date had a fair value of zero. If LadRx licenses aldoxorubicin to an applicable third party, the Company is eligible to receive potential high single-digit percentage royalty payments on aggregate net sales of aldoxorubicin and a portion of any potential future milestone payments.Upon the initial closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and could have been required to pay up to an additional $6.0 million in regulatory and commercial sales milestone payments which included $5.0 million related to regulatory milestone payments and $1.0 million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx Agreements, the Company made a $1.0 million milestone payment to LadRx in January 2024.On September 20, 2024, Zevra announced that the FDA granted approval to Zevraâ€™s NDA for MIPLYFFA. The achievement of the commercial milestone payment under the LadRx AAA was considered probable as of September 30, 2024, and the Company recognized a $1.0 million contingent liability.As of September 30, 2024, the Company recorded $2.2 million as short-term royalty and commercial payment receivables related to the net proceeds receivable for the milestone payment associated with the FDA approval of MIPLYFFA. Given the limited available information, the Company was unable to reliably estimate its royalty payment stream from future net sales, and therefore no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Aptevo Commercial Payment Purchase Agreement On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. 33 Table of ContentsThe Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables in its consolidated balance sheet which included a $9.6 million upfront payment and a $50,000 one-time payment, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet at inception. The Company paid the one-time payment of $50,000 in June 2023 when related receipts exceeded $0.5 million. During the year ended December 31, 2023, the Company received total commercial payments pursuant to the Aptevo CPPA of $1.7 million. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Aptevo CPPA of $0.8 million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance. Though the Company is unable to reliably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it estimates the short-term portion of the receivables balance based on the past 12 monthsâ€™ receipts. As such, as of September 30, 2024 and December 31, 2023, the Company recorded $2.2 million and $2.0 million, respectively, as short-term royalty and commercial payment receivables.Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected.Â The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Palobiofarma Royalty Purchase Agreement On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkinâ€™s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis, and nonalcoholic steatohepatitis and other indications that are being developed by Palo. Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $10.0 million payment at the close of the transaction, which occurred simultaneously upon partiesâ€™ entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. As of September 30, 2024, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Viracta Royalty Purchase Agreement On March 22, 2021, the Company entered into the Viracta RPA, as amended March 4, 2024, pursuant to which the Company acquired the right to receive future royalties, milestone payments, and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma LLC. The Company acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and a portion of potential other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones, and high single-digit royalties on sales related to vosaroxin, if approved. 34 Table of ContentsAt the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. On October 30, 2023, the Company earned a $5.0 million milestone payment pursuant to the Viracta RPA related to the FDAâ€™s acceptance of Day Oneâ€™s NDA for OJEMDA. In accordance with the cost recovery method, the $5.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivables balance.On April 23, 2024, Day One announced that the FDA granted approval to Day Oneâ€™s NDA for OJEMDA. Pursuant to the Viracta RPA, the Company earned a $9.0 million milestone payment upon FDA approval and is also eligible to receive mid-single-digit royalties on sales of OJEMDA. In accordance with the cost recovery method, $8.5 million of the milestone payment was recorded as a direct reduction of the remaining recorded long-term royalty receivables balance and the excess balance of $0.5 million was recorded as income from purchased receivables in the condensed consolidated statement of operations for the nine months ended September 30, 2024. On May 30, 2024, Day One announced that it sold its priority review voucher to an undisclosed buyer for $108.0 million. Pursuant to the Viracta RPA, the Company received a payment of $8.1 million related to the sale. The rights to proceeds upon the sale of the priority review voucher was determined to be an embedded derivative which had no value prior to FDA approval of OJEMDA. The Company recorded a change in the fair value of the embedded derivative of $8.1 million in other income in the condensed consolidated statement of operations for the nine months ended September 30, 2024.As of June 30, 2024, the Company had fully collected the purchase price recorded in long-term royalty and commercial payment receivables related to the Viracta RPA in its consolidated balance sheet and, as such, subsequent royalties received are recorded as income from purchased receivables. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023. As there was no remaining balance in long-term royalty and commercial payment receivables related to the Viracta RPA in its consolidated balance sheet as of September 30, 2024, the Company did not need to perform its periodic impairment assessment for the three months ended September 30, 2024.As of September 30, 2024, there was $1.0 million in trade and other receivables, net related to this arrangement. As of December 31, 2023, there was no trade and other receivables, net related to this arrangement. The Company recognized $1.0 million and $1.9 million in income from purchased receivables related to this arrangement during the three and nine months ended September 30, 2024. The Company did not recognize any income related to this arrangement during the three and nine months ended September 30, 2023.Kuros Royalty Purchase Agreement On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticalsâ€™ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestone payments. At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals, Inc. resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivables balance. 35 Table of ContentsAs of September 30, 2024, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments, and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Affitech Commercial Payment Purchase Agreement On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Rocheâ€™s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million upfront payment and $8.0 million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Commercial payments are due from Roche to the Company within 60 days of December 31 and June 30 of each year. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone payment tied to the U.S. marketing approvals and a $3.0 million milestone payment tied to the EC approvals. The achievement of the first and second sales-based milestone payments under the Affitech CPPA was considered probable as of December 31, 2023, and as such the Company recognized a $6.0 million contingent liability in contingent consideration under RPAs, AAAs, and CPPAs in its consolidated balance sheet. The sales milestones were achieved in 2023 and in the first quarter of 2024, the Company paid Affitech $6.0 million and the related contingent liability balance was reduced to zero. Based on reported first quarter of 2024 sales of VABYSMO, the achievement of the third sales-based milestone payment under the Affitech CPPA was considered probable as of March 31, 2024, and the Company recognized a $3.0 million contingent liability which remained on the condensed consolidated balance sheet as of September 30, 2024.Historically, the Company had been unable to reliably estimate its commercial payment stream from future net sales and the related commercial payments to be received under the Affitech CPPA. However, Rocheâ€™s periodically reported VABYSMO sales data, available third-party sales projections, and the Companyâ€™s history of receipts of commercial payments related to VABYSMO have provided the Company with a greater ability to estimate future net sales and the commercial payments to be received under the Affitech CPPA. Therefore, as of April 1, 2024, the Company began accounting for the receivable which had a carrying amount of $7.8 million using the EIR method on a prospective basis. As a result, the Company recognized $5.4 million and $10.0 million in income from purchased receivables during the three and nine months ended September 30, 2024.During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Affitech CPPA of $16.9 million.The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.36 Table of ContentsAgenus Royalty Purchase Agreement On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (â€œIncyteâ€) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory, and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales. In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and 10% of all future developmental, regulatory, and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on a low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Companyâ€™s share in future potential development, regulatory, and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone payment under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivables balance. Based on updates received in July 2024, the Company evaluated the status of the program for potential impairment in the third quarter of 2024 and determined no payments were probable to be received under the Agenus RPA as of September 30, 2024. Accordingly, the Company recorded an impairment of $14.0 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and an allowance for credit losses of $14.0 million, which consisted of a $14.0 million reduction in the net carrying value of

long-term royalty receivables related to the Agenus RPA. As the impaired amount was not expected to be collected, the long-term royalty receivables were written off. There was no allowance for credit losses recorded as of December 31, 2023. Aronora Royalty Purchase Agreement On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the â€œNon-Royaltiesâ€) related to five anti-thrombotic hematology product candidates. Three candidates were subject to Aronoraâ€™s collaboration with Bayer (the â€œBayer Productsâ€), including one which was subject to an exclusive license option by Bayer. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products. The Company was eligible to receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the â€œnon-Bayer Productsâ€) for which the Company will receive a low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Companyâ€™s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. On April 8, 2024, Bayer terminated its license agreement with Aronora.Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the â€œAronora Contingent Considerationâ€). Pursuant to the Aronora RPA, if the Company receives at least $25.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate 37 Table of Contentsamount of up to $85.0 million per product (the â€œRoyalty Milestonesâ€).Â The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.Â Royalties per product in excess of $250.0 million are retained by the Company. At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable.As of September 30, 2024, no payments were probable to be received under the Aronora RPA. Based on communications in April 2024, the Company evaluated the status of the partnered programs for potential impairment in the second quarter of 2024 and recorded an impairment of $9.0 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and an allowance for credit losses of $9.0 million, which consisted of a $9.0 million reduction in the net carrying value of long-term royalty receivables related to the Aronora RPA. As the impaired amount was not expected to be collected, the long-term royalty receivables were written off. There was no allowance for credit losses recorded as of December 31, 2023.The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the nine months ended September 30, 2024 (in thousands): â€‹â€‹â€‹

with Blue Owl warrants to purchase: (i) up to 40,000 shares of XOMAâ€™s common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of XOMAâ€™s common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of XOMAâ€™s common stock at an exercise price of $50.00 per share (collectively, the â€œBlue Owl Warrantsâ€). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $1.5 million. As of September 30, 2024, all Blue Owl Warrants were outstanding.The initial term loan of $130.0 million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the EIR was determined to be 11.01%. The Company recorded a debt discount of $5.3 million, which included $3.8 million in allocated fees and lender expenses and $1.5 million for the fair value of the Blue Owl Warrants. The Company also recorded $0.6 million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $5.3 million and $0.6 million of direct debt issuance costs over the expected term of the initial term loan.As of the closing date of December 15, 2023, the Company recorded the $0.3 million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of September 30, 2024, no amount had been drawn from the delayed draw term loan.The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively, as of December 31, 2023. The Company recorded $0.6 million in interest expense during the year ended December 31, 2023. In March 2024, XRL made a semi-annual payment of $7.4 million which included an interest payment of $3.8 million and principal repayment of $3.6 million. In September 2024, XRL made a semi-annual payment of $9.5 million which included an interest payment of $6.2 million and principal repayment of $3.3 million. The carrying value of the 43 Table of Contentsshort and long-term portion of the initial term loan was $9.8 million and $108.1 million, respectively, as of September 30, 2024. As of September 30, 2024, the EIR was determined to be 11.16%. The Company recorded $3.5 million and $10.4 million in interest expense during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company had an unaccreted debt discount of $4.5 million and unaccreted direct issuance costs of $0.7 million to be accreted over the expected remaining term of the initial term loan.The following table summarizes the impact of the initial term loan on the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹Â Â Â Â September 30, 2024Gross principal â€‹$ 130,000Principal repaymentsâ€‹â€‹ (6,902)Unaccreted debt discount and debt issuance costsâ€‹â€‹ (5,183)Total carrying value net of principal repayments, unaccreted debt discount, and debt issuance costsâ€‹â€‹ 117,915Less: current portion of long-term debt â€‹â€‹ (9,826)Long-term debtâ€‹$ 108,089â€‹Long-term debt on the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 and consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. The carrying value of the Blue Owl Loan as of December 31, 2023 was $124.0 million.Aggregate projected future principal payments of the initial term loan as of September 30, 2024, are as follows (in thousands): â€‹â€‹â€‹Year Ending December 31, â€‹Payments2024 (excluding the nine months ended September 30, 2024)â€‹$ â€”2025Â â€‹ 11,2742026Â â€‹ 17,8252027â€‹â€‹ 23,8852028â€‹â€‹ 29,761ThereafterÂ â€‹ 40,353Total paymentsâ€‹$ 123,098â€‹Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the condensed consolidated statements of operations for theÂ three and nine months ended September 30, 2024 relates to the initial term loan (in thousands):
â€‹Three Months Ended â€‹â€‹Nine Months Ended
â€‹â€‹â€‹SeptemberÂ 30,Â â€‹â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹â€‹2024â€‹2023â€‹Accrued interest expenseâ€‹$ 3,085â€‹$ â€”â€‹â€‹$ 9,450â€‹$ â€”â€‹Accretion of debt discount and debt issuance costsâ€‹Â 408â€‹Â â€”Â â€‹Â 996â€‹Â â€”Â Total interest expenseâ€‹$ 3,493â€‹$ â€”â€‹â€‹$ 10,446â€‹$ â€”â€‹â€‹â€‹44 Table of Contents9. Common Stock WarrantsAs of September 30, 2024 and December 31, 2023, the following common stock warrants were
outstanding:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â ExerciseÂ PriceÂ Â Â Â SeptemberÂ 30,Â Â Â Â Â December 31,Issuance Dateâ€‹ExpirationÂ Dateâ€‹BalanceÂ SheetÂ Classificationâ€‹perÂ Shareâ€‹2024â€‹2023MayÂ 2018â€‹MayÂ 2028â€‹Stockholdersâ€™ equityâ€‹$ 23.69â€‹ 6,332â€‹ 6,332MarchÂ 2019â€‹MarchÂ 2029â€‹Stockholdersâ€™ equityâ€‹$ 14.71â€‹ 4,845â€‹ 4,845December 2023â€‹December 2033â€‹Stockholdersâ€™ equityâ€‹$ 35.00â€‹ 40,000â€‹ 40,000December 2023â€‹December 2033â€‹Stockholdersâ€™ equityâ€‹$ 42.50â€‹ 40,000â€‹ 40,000December 2023â€‹December 2033â€‹Stockholdersâ€™ equityâ€‹$ 50.00â€‹ 40,000â€‹ 40,000 â€‹Â Â Â Â Â â€‹Â Â Â Â 131,177Â 131,177â€‹â€‹10. Commitments and ContingenciesCollaborative Agreements, Royalties, and Milestone PaymentsThe Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory, and commercial milestones by the Companyâ€™s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of September 30, 2024.Contingent ConsiderationPursuant to the Companyâ€™s agreements with Aronora, Kuros, Affitech, LadRx, and DarÃ©, and under the Kinnate CVR Agreement, the Company has committed to pay the Aronora Royalty Milestones, the Kuros Sales Milestones, the remaining Affitech Sales Milestones, LadRx commercial sales milestone, DarÃ© Milestones, and the Exarafenib milestone contingent consideration.During the year ended December 31, 2023, the Company recorded $1.0 million for the LadRx contingent consideration that represented the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin at the inception of the LadRx Agreements. During the nine months ended September 30, 2024, the contingent liability was reduced to zero after the Company paid LadRx $1.0 million upon the FDAâ€™s acceptance of the arimoclomol NDA resubmission. Additionally, the amendment to the LadRx RPA removed the milestone payment that had been contingent upon the achievement of a regulatory milestone related to aldoxorubicin (Note 5). During the third quarter of 2024, the LadRx commercial sales milestone related to MIPLYFFA pursuant to the LadRx AAA was assessed to be probable under ASC 450. As such, a $1.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $1.0 million asset was recorded under long-term royalty and commercial payment receivables on the condensed consolidated balance sheet as of September 30, 2024.During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $6.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $6.0 million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet. During the first quarter of 2024, this contingent liability was reduced to zero after the Company paid Affitech $6.0 million upon the achievement of the related commercial sales milestones (Note 5).45 Table of ContentsDuring the first quarter of 2024, a sales milestone related to VABYSMO pursuant to the Affitech CPPA was assessed to be probable under ASC 450. As such, a $3.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $3.0 million asset was recorded under short-term royalty and commercial payment receivables on the condensed consolidated balance sheet.As of September 30, 2024, the Company recorded $3.1 million for the Exarafenib milestone contingent consideration, which represented the estimated fair value of potential future payments upon the achievement of a certain specified milestone related to exarafenib payable to Kinnate CVR holders upon the closing of the Kinnate acquisition under the Kinnate CVR Agreement. The Exarafenib milestone contingent consideration is measured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net.The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, and the DarÃ© Milestones will be recorded when the amounts, by product, are estimable and probable. As of September 30, 2024, none of the Aronora Royalty Milestones, Kuros Sales Milestones, and DarÃ© Milestones were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet.11. Stock-Based Compensation The Company may grant qualified and non-qualified stock options, common stock, PSUs, RSUs, and other stock-based awards under various plans to directors, officers, employees, and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Companyâ€™s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Companyâ€™s common stock on the first trading day of the offering period or on the last day of the purchase period. The ESPP includes a rollover mechanism for the purchase price if the fair market value of the Companyâ€™s common stock on the purchase date is less than the fair market value of the Companyâ€™s common stock on the first trading day of the offering period.Stock Options and Other Benefit PlansStock Option Plans2010 Plan Stock OptionsStock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. Fair Value Assumptions of 2010 Plan Stock Optionsâ€‹There were no stock options granted during the three months ended September 30, 2024 and 2023. The fair value of stock options granted during the nine months ended September 30, 2024 and 2023 was estimated based on the following weighted-average assumptions:â€‹Three Months Ended SeptemberÂ 30,Â Â â€‹Nine Months Ended
SeptemberÂ 30,Â Â â€‹Â Â Â Â 2024Â Â Â Â Â 2023Â Â Â Â Â 2024Â Â Â Â Â 2023Â Dividend yieldÂ â€”% â€”%Â 0%0%Expected volatilityÂ â€”% â€”%Â 65% 70%Risk-free interest rateÂ â€”% â€”%Â 4.35% 3.60%Expected termÂ â€”â€‹ â€”â€‹Â 5.79 yearsâ€‹5.79 yearsâ€‹â€‹46 Table of ContentsThe weighted-average grant-date fair value per share of the stock options granted during the nine months ended September 30, 2024 and 2023, was $24.71 and $13.46, respectively. â€‹Stock Option Inducement Awards On DecemberÂ 30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Companyâ€™s Chief Investment Officer, effective as of JanuaryÂ 1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the â€œStock Option Inducement Awardsâ€) when the Companyâ€™s stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan. More information on the Stock Option Inducement Awards granted during the three months ended March 31, 2023 can be found in Note 10 of the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the first quarter of 2023 was $11.91. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was $14.68. No Stock Option Inducement Awards were granted during the nine months ended September 30, 2024.The activity for all stock options for the nine months ended September 30, 2024 was as
follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Declaration DateÂ Â Â Â ($ per share)Â Â Â Â Â ($ per share)Â Â Â Â Dividend Payment DateOctober 18, 2023â€‹$ 0.53906â€‹$ 0.52344â€‹January 15, 2024February 21, 2024â€‹$ 0.53906â€‹$ 0.52344â€‹April 15, 2024May 15, 2024â€‹$ 0.53906â€‹$ 0.52344â€‹July 15, 2024July 24, 2024â€‹$ 0.53906â€‹$ 0.52344â€‹October 15, 2024â€‹BVF OwnershipAs of September 30, 2024, BVF owned approximately 30.9% of the Companyâ€™s total outstanding shares of common stock, and if all the Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 51.5% of the Companyâ€™s total outstanding shares of common stock. The Companyâ€™s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of September 30, 2024, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.2018 Common Stock ATM Agreement On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an â€œat the marketâ€ offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed. â€‹2021 Series B Preferred Stock ATM AgreementOn August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an â€œat the marketâ€ offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. â€‹Stock Repurchase ProgramOn January 2, 2024, the Board authorized the Companyâ€™s first stock repurchase program, which permits the Company to purchase up to $50.0 million of its common stock through January 2027. Under the program, the Company 50 Table of Contentshas discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at the Companyâ€™s sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate the Company to acquire any particular amount of its common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. The Company did not make any purchases under the program in the three months ended September 30, 2024. As of September 30, 2024, the Company had purchased a total of 660 shares of its common stock pursuant to the stock repurchase plan for $13,000.â€‹13. Income TaxesThe Company recorded no income taxes during the three and nine months ended September 30, 2024. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets. The Company had a total of $5.9 million of gross unrecognized tax benefits as of September 30, 2024, none of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through September 30, 2024, the Company had not accrued interest or penalties related to uncertain tax positions.â€‹14. Subsequent EventsTwist Bioscience Royalty Purchase Agreement On October 21, 2024, the Company entered into a royalty purchase agreement with Twist Bioscience Corporation (â€œTwist Bioscienceâ€). Under the terms of the agreement, the Company acquired 50% of certain contingent payments (including royalties, milestone payments, sublicense income, and option exercise payments) related to Twist Bioscienceâ€™s 60-plus early-stage programs across 30 partners for a $15.0 million upfront payment. The Company is eligible to receive up to $0.5 billion in milestone payments and a 50% share of up to low single-digit royalties on future commercial sales.â€‹â€‹51 Table of ContentsITEMÂ 2.Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSForward Looking StatementsThis Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of SectionÂ 27A of the Securities Act of 1933, as amended, (the â€œSecurities Actâ€), SectionÂ 21E of the Securities Exchange Act of 1934, as amended, (the â€œExchange Actâ€), and the Private Securities Litigation Reform Act of 1995, which are subject to the â€œsafe harborâ€ created by those sections. Forward-looking statements are based on current expectations, estimates and forecasts, as well as our managementâ€™s beliefs and assumptions and on information currently available to them, and are subject to risks and uncertainties that are difficult to predict. In some cases you can identify forward-looking statements by words such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œmight,â€ â€œcould,â€ â€œwould,â€ â€œexpects,â€ â€œplans,â€ â€œanticipates,â€ â€œbelieves,â€ â€œestimates,â€ â€œprojects,â€ â€œpredicts,â€ â€œpotential,â€ â€œintendâ€ â€œgoal,â€ â€œstrategy,â€ â€œcontinue,â€ â€œdesign,â€ and similar words, expressions or the negative of such terms intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: trend analyses and statements regarding future events, future financial performance, anticipated growth, and industry prospects, our future operating expenses, our future losses, the success of our strategy as a royalty aggregator, the assumptions underlying our business model, the extent to which issued and pending patents may protect the products and processes in which we have an ownership or royalty interest and prevent the use of the covered subject matter by third parties, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the amount and timing of receipt of those payments, our ability to locate suitable assets to acquire, our ability to complete (on a timely basis or at all) and realize the benefits from acquisitions, uncertainties related to the acquisition of interest in development-stage and clinical-stage product candidates, fluctuations in, our ability to predict our operating results and cash flows, and the sufficiency of our capital resources. Forward-looking statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s); we may be unable to retain our key employees; litigation, arbitration or other disputes with third parties may have a material adverse effect on us; our product candidates subject to our out-license agreements are still being developed, and our licenseesâ€™ may require substantial funds to continue development which may not be available; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; and we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties. These and other risks and uncertainties that may cause our actual results or outcomes to differ materially and adversely from those expressed in our forward-looking statements, including those related to current economic and financial market conditions, are contained principally in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 and in PartÂ II, ItemÂ 1A of our Quarterly Reports on FormÂ 10-Q and in our other filings with the SEC. Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. Except as required by law, we do not undertake any obligation to revise or update publicly any forward-looking statements after completion of the filing of this Quarterly Report on FormÂ 10-Q to reflect later events or circumstances or to reflect the occurrence of unanticipated events, or otherwise.In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on FormÂ 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review 52 Table of Contentsof, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.All references to â€œportfolioâ€ in this Quarterly Report on FormÂ 10-Q are to milestone and/or royalty rights associated with a basket of product candidates in development.We use our trademarks, trade names, and services marks in this report as well as trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this report appear without the Â® and â„¢ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names.The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in PartÂ I, ItemÂ 1 of this Quarterly Report on FormÂ 10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31, 2023.OverviewXOMA is a biotech royalty aggregator. On July 10, 2024, we changed our name from XOMA Corporation to XOMA Royalty Corporation. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio was built through the acquisition of rights to future milestones, royalties, and commercial payments, since our royalty aggregator business model was implemented in 2017, combined with out-licensing our proprietary products and platforms from our legacy discovery and development business. Our royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to large-cap partners. We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to deliver a financial return to us in a short timeframe. We expect most of our future income and revenue to be based on payments we may receive for milestones and royalties associated with these acquired programs. The generation of future income and revenues related to licenses, milestone payments, and royalties is dependent on the achievement of milestones or product sales by our existing partners and licensees. We generated net loss of $17.2 million and $9.9 million for the three and nine months ended September 30, 2024, respectively, net cash used in operating activities was $10.8 million for the nine months ended September 30, 2024, and we had an accumulated deficit of $1.2 billion as of September 30, 2024. We generated a net loss of $40.8 million, net cash used in operating activities was $18.2 million, and we had an accumulated deficit of $1.2 billion for the year ended December 31, 2023.Portfolio Updates â€“ Royalty and Commercial Payment Purchase Agreements Twist Bioscience Royalty Purchase AgreementOn October 21, 2024, we entered into a royalty purchase agreement with Twist Bioscience Corporation (â€œTwist Bioscienceâ€). Under the terms of the agreement, we acquired 50% of certain contingent payments (including royalties, milestone payments, sublicense income, and option exercise payments) related to Twist Bioscienceâ€™s 60-plus early-stage programs across 30 partners for a $15.0 million upfront payment. We are eligible to receive up to $0.5 billion in milestone payments and a 50% share of up to low single-digit royalties on future commercial sales.LadRx AgreementsIn January 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx Agreements, we made a $1.0 million milestone payment to LadRx in January 2024. 53 Table of ContentsIn June 2024, the ImmunityBio License Agreement was terminated, and we entered into an amendment to the LadRx RPA. Under the LadRx RPA, as amended, we are eligible to receive potential low single-digit percentage royalty payments on aggregate net sales of aldoxorubicin. Additionally, the amendment removed the remaining $4.0 million regulatory milestone payment under the original agreement that had been contingent upon the achievement of a specified regulatory milestone for the product candidate related to aldoxorubicin. If LadRx licenses aldoxorubicin to an applicable third party, we are eligible to receive potential high single-digit percentage royalty payments on aggregate net sales of aldoxorubicin and a portion of any potential future milestone payments.In September 2024, Zevra announced that the FDA granted approval to Zevraâ€™s NDA for MIPLYFFA. The achievement of the commercial milestone payment under the LadRx AAA was considered probable as of September 30, 2024, and we recognized a $1.0 million contingent liability. Pursuant to the LadRx AAA, we earned a $2.2 million milestone payment upon FDA approval (net of certain outbound payments to third parties), and we are also eligible to receive mid-single-digit royalties on net sales of MIPLYFFA.Affitech Commercial Payment Purchase Agreement Pursuant to our Affitech CPPA, we are eligible to receive commercial payments from Roche consisting of 0.5% of net sales of VABYSMO for a ten-year period following the first commercial sale in each applicable jurisdiction. VABYSMO is approved by the FDA and the EMA for the treatment of wet, or neovascular, age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. Payments are due from Roche within 60 days of December 31 and June 30 of each year.In February 2024, we received $7.4 million representing our commercial payment received from sales of VABYSMO during the last six months of 2023 under the Affitech CPPA. In August 2024, we received $9.5 million representing our commercial payment received from sales of VABYSMO during the first six months of 2024 under the Affitech CPPA. We used these cash receipts to fund contractual interest payments and partially repay the principal balance on our Blue Owl Loan (see Note 8 to the condensed consolidated financial statements).For the three and nine months ended September 30, 2024, we recognized a total of $5.4 million and $10.0 million in income from purchased receivables related to the Affitech CPPA under the EIR method for sales of VABYSMO during the three and nine months ended September 30, 2024.Agenus Royalty Purchase AgreementBased on updates received in July 2024, we evaluated the status of this program for potential impairment, and we recorded an impairment charge of $14.0 million in the third quarter of 2024 (see Note 5 to the condensed consolidated financial statements). Critical Accounting EstimatesThe preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We routinely evaluate our estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions. Critical accounting estimates are those estimates that involve a significant level of judgment and/or estimation uncertainty and could have or are reasonably likely to have a material impact on our financial condition or results of operations.Except as discussed in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, there have been no significant changes in our critical accounting estimates during the nine months ended September 30, 2024, 54 Table of Contentsas compared with those previously disclosed in our Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31, 2023, filed with the SEC on MarchÂ 8, 2024. Our significant accounting policies are included in â€œNote 2 â€“ Basis of Presentation and Significant Accounting Policiesâ€ in our condensed consolidated financial statements.Results of OperationsRevenuesTotal income and revenues for the three and nine months ended September 30, 2024 and 2023, were as follows (in thousands):â€‹â€‹â€‹

license fees, and milestone payments related to the out-licensing of our legacy product candidates and technologies. Revenue from contracts with customers for the nine months ended September 30, 2024 included a milestone payment of $5.0 million pursuant to our license agreement with Rezolute and milestone payments of $1.0 million pursuant to our license agreement with AVEO. Revenue from contracts with customers for the three and nine months ended September 30, 2023 included $0.2 million and $1.3 million of milestones earned pursuant to the license agreement with Janssen. Revenue Recognized under Units-of-Revenue MethodRevenue recognized under the units-of-revenue method includes the amortization of unearned revenue from the sale of royalty interests to HCRP in 2016. Revenues for the three and nine months ended September 30, 2024 remained generally consistent with the same periods in 2023 due to comparable sales of products underlying the agreements with HCRP.55 Table of ContentsR&D Expenses For the three months ended September 30, 2024, R&D expenses were $0.8 million compared with $25,000 for the three months ended September 30, 2023. The increase of approximately $0.8 million was primarily due to clinical trial costs related to KIN-3248. For the nine months ended September 30, 2024, R&D expenses were $2.0 million compared to $0.1 million for the nine months ended September 30, 2023. The increase of $1.9 million was primarily due to clinical trial costs related to KIN-3248. We are in the process of winding down the study, and we expect to incur continued R&D costs related to KIN-3248 until the study is completed. We may also incur additional R&D costs related to stability studies and the storage of the remaining programs obtained in the Kinnate acquisition. G&A ExpensesG&A expenses include salaries and related personnel costs, professional fees, and facilities costs. For the three months ended September 30, 2024, G&A expenses were $8.0 million compared with $6.4 million for the three months ended September 30, 2023. The increase of $1.6 million included $1.4 million in total costs incurred after our acquisition of Kinnate, which included $1.1 million in legal and consulting costs, $0.1 million in information technology costs, and $0.1 million in insurance costs. We also had an increase of $0.2 million in salaries and related costs associated with Mr. Hughesâ€™ role as CEO in a full-time capacity.For the nine months ended September 30, 2024, G&A expenses were $27.5 million compared with $18.3 million for the nine months ended September 30, 2023. The increase of $9.2 million was primarily due to $6.9 million in costs associated with our acquisition of Kinnate, which primarily included $3.6 million in severance costs for exit packages provided to Kinnate senior leadership, $2.6 million in legal and consulting costs, $0.2 million in information technology costs, and $0.1 million in insurance costs. In addition, we had an increase of $1.6 million in stock-based compensation expenses primarily due to the PSU grant to Mr. Hughes in connection with his appointment as full-time CEO in January 2024.We expect G&A costs associated with our acquisition of Kinnate to decrease in future periods as we continue to wind down Kinnate operations.Royalty Purchase Agreement Asset ImpairmentRoyalty purchase agreement asset impairment was $14.0 million and $23.0 million for the three and nine months ended September 30, 2024, respectively, and consisted of the impairment charge of $9.0 million related to our Aronora RPA in the second quarter of 2024 and the impairment charge of $14.0 million related to our Agenus RPA in the third quarter of 2024. Royalty purchase agreement asset impairment was zero and $1.6 million for the three and nine months ended September 30, 2023, respectively, and consisted of the impairment recorded related to our Bioasis RPAs.Arbitration Settlement CostsArbitration settlement costs of zero and $4.1 million for the three and nine months ended September 30, 2023, respectively, consisted of the costs incurred related to the settlement of an arbitration proceeding with one of our licensees in the first quarter of 2023. There were no arbitration settlement costs for the three and nine months ended September 30, 2024.Other Income (Expense)Gain on the Acquisition of KinnateDuring the nine months ended September 30, 2024, we recognized a $19.3 million gain on the acquisition of Kinnate due to the fair value of net assets acquired in the acquisition of Kinnate exceeding the total purchase consideration (see Note 4 to the condensed consolidated financial statements).56 Table of ContentsChange in Fair Value of Embedded Derivative Related to RPADuring the nine months ended September 30, 2024, we recognized an $8.1 million change in fair value of an embedded derivative related to RPA associated with a payment of $8.1 million for the sale of a priority review voucher by Day One, which we earned pursuant to the Viracta RPA (see Note 5 to the condensed consolidated financial statements). Interest ExpenseInterest expense includes the accretion of debt discount and debt issuance costs. Interest expense for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands):â€‹â€‹â€‹

required under this item.â€‹ITEMÂ 4.Â CONTROLS AND PROCEDURESEvaluation of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including our Chief Executive Officer (our Principal Executive Officer) and our Senior Vice President, Finance and Chief Financial Officer (our Principal Financial and Accounting Officer), we conducted an evaluation of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Our disclosure controls and procedures are intended to help ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Senior Vice President, Finance and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures. Based on this evaluation, our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. Changes in Internal Control Over Financial ReportingThere have been no changes in our internal control over financial reporting, as defined in RulesÂ 13a-15(f)Â and 15d-15(f) under the Exchange Act, that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹61 Table of Contentsâ€‹â€‹PARTÂ IIÂ â€“Â OTHER INFORMATIONâ€‹ITEMÂ 1.Â LEGAL PROCEEDINGS We are not currently engaged in any legal proceedings that, in the opinion of our management, if determined adversely to us, would individually or taken together, have a material adverse effect on our business, results of operations, financial position or cash flows. However, from time to time, we may become involved in litigation, arbitration or other proceedings relating to claims arising from the ordinary course of business.We may become involved in material legal proceedings in the future, and the potential impact on us of any on-going proceeding which we do not currently believe to be material could become material. Such matters are subject to significant uncertainties, and there can be no assurance that any legal proceedings in which we are or may become involved will not have a material adverse effect on our business, results of operations, financial position or cash flows.â€‹ITEMÂ 1A.Â RISK FACTORSExcept as discussed in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 and our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, there have been no material changes in our risk factors as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. For a detailed description of our risk factors, refer to Part I, Item IA, â€œRisk Factorsâ€ of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and Part II, Item 1A, â€œRisk Factorsâ€ of our Quarterly Reports on Form 10-Q.ITEMÂ 2.Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Unregistered Sales of Equity Securities None.Issuer Purchases of Equity Securities On January 2, 2024, the Board authorized our first stock repurchase program, which permits us to purchase up to $50.0 million of our common stock through January 2027. Under the program, we have discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at our sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate us to acquire any particular amount of our common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. No common stock was repurchased by us during the three months ended September 30, 2024.â€‹ITEMÂ 3.Â DEFAULTS UPON SENIOR SECURITIESNone.â€‹ITEMÂ 4.Â MINE SAFETY DISCLOSURESNot applicable.â€‹62 Table of ContentsITEMÂ 5.Â OTHER INFORMATION(c) Trading PlansDuring the fiscal quarter ended September 30, 2024, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K). â€‹63 Table of ContentsITEMÂ 6.Â EXHIBITSâ€‹HIDDEN_ROWâ€‹â€‹â€‹Incorporation By ReferenceExhibitNumberÂ ExhibitÂ DescriptionFormÂ SEC File No.ExhibitFiling DateÂ Â Â Â Â 2.1â€‹Agreement and Plan of Merger between the Company, Kinnate and Merger Sub, dated February 16, 2024â€‹8-Kâ€‹001-39801â€‹2.1â€‹02/16/2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2.2â€‹Contingent Value Rights Agreement, dated April 3, 2024, by and between the Company, XRA 1 Corp., Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC.â€‹8-Kâ€‹001-39801â€‹2.2â€‹04/03/2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.1Certificate of Incorporation of the Company8-K12G3000-147103.101/03/2012Â 3.2Certificate of Amendment to the Certificate of Incorporation of the Company8-K000-147103.105/31/2012Â 3.3â€‹Certificate of Amendment to the Certificate of Incorporation of the Companyâ€‹8-Kâ€‹000-14710â€‹3.1â€‹05/28/2014â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.4â€‹Certificate of Amendment to the Certificate of Incorporation of the Companyâ€‹8-Kâ€‹000-14710â€‹3.1â€‹10/18/2016â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.5â€‹Certificate of Amendment to the Certificate of Incorporation of the Companyâ€‹8-Kâ€‹001-39801â€‹3.1â€‹07/09/2024Â 3.6â€‹Certificate of Designation of Preferences, Rights and Limitations of SeriesÂ X Convertible Preferred Stockâ€‹8-Kâ€‹000-14710â€‹3.1â€‹02/16/2017â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.7â€‹Certificate of Designation of 8.625% Series A Cumulative Perpetual Preferred Stockâ€‹8-Kâ€‹000-14710â€‹3.1â€‹12/11/2020â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.8 â€‹Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock â€‹8-K â€‹001-39801â€‹3.1â€‹04/08/2021â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.9â€‹Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock â€‹10-Qâ€‹001-39801â€‹3.8â€‹08/05/2021Â 3.10â€‹Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of the Companyâ€‹8-Kâ€‹001-39801â€‹3.1â€‹08/05/2021â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹3.11â€‹By-laws of the Companyâ€‹8-K12G3â€‹000-14710â€‹3.2â€‹01/03/2012â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.1Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 3.10, and 3.11â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â 4.2â€‹Specimen of Common Stock Certificate â€‹8-Kâ€‹000-14710â€‹4.1â€‹01/03/2012â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.3â€‹Deposit Agreement, dated effective April 9, 2021, by and among the Company, American Stock Transfer & Trust Company, LLC, as depositary, and the holders of the depositary receipts issued thereunderâ€‹8-K â€‹001-39801â€‹4.1â€‹04/08/2021â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.4â€‹Form of Warrants (May 2018 Warrants)â€‹10-Qâ€‹000-14710â€‹4.6â€‹08/07/2018â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.5â€‹Form of Warrants (March 2019 Warrants)â€‹10-Qâ€‹000-14710â€‹4.7â€‹05/06/2019â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹64 Table of Contentsâ€‹HIDDEN_ROWâ€‹â€‹â€‹Incorporation By ReferenceExhibitNumberÂ ExhibitÂ DescriptionFormÂ SEC File No.ExhibitFiling DateÂ Â Â Â Â 4.6â€‹Form of Warrant (December 2023) ($35.00 Exercise Price)â€‹8-Kâ€‹001-39801â€‹4.1â€‹12/19/2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.7â€‹Form of Warrant (December 2023) ($42.50 Exercise Price)â€‹8-Kâ€‹001-39801â€‹4.2â€‹12/19/2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.8â€‹Form of Warrant (December 2023) ($50.00 Exercise Price)â€‹8-Kâ€‹001-39801â€‹4.3â€‹12/19/2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹4.9â€‹Form of Indentureâ€‹S-3â€‹333-277794â€‹4.6â€‹03/08/2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹10.1#+â€‹Net Office Lease dated August 5, 2021 between Presidio Trust and Kinnate Biopharma Inc.â€‹10-Qâ€‹001-39801â€‹10.1â€‹8/13/2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹10.2#+â€‹Letter Agreement dated August 26, 2021 between Presidio Trust and Kinnate Biopharma Inc.â€‹10-Qâ€‹001-39801â€‹10.2â€‹8/13/2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹31.1+â€‹Certification of Chief Executive Officer, as required by RuleÂ 13a-14(a) or RuleÂ 15d-14(a) of the Securities Exchange Act of 1934â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

- Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Lease Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchased Receivables, Income Taxes, and Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Acquisitions, Licensing and Other Arrangements - Takeda (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - Acquisitions, Licensing and Other Arrangements - Rezolute (Details) link:presentationLink link:calculationLink link:definitionLink 99940404 - Disclosure - Acquisitions, Licensing and Other Arrangements - Janssen (Details) link:presentationLink link:calculationLink link:definitionLink 99940405 - Disclosure - Acquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details) link:presentationLink link:calculationLink link:definitionLink 99940406 - Disclosure - Acquisitions, Licensing and Other Arrangements - Novartis - VPM087 (Details) link:presentationLink link:calculationLink link:definitionLink 99940407 - Disclosure - Acquisitions, Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Dare (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Talphera (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details) link:presentationLink link:calculationLink link:definitionLink 99940505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details) link:presentationLink link:calculationLink link:definitionLink 99940506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palobiofarma (Details) link:presentationLink link:calculationLink link:definitionLink 99940507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details) link:presentationLink link:calculationLink link:definitionLink 99940508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details) link:presentationLink link:calculationLink link:definitionLink 99940509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details) link:presentationLink link:calculationLink link:definitionLink 99940510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details) link:presentationLink link:calculationLink link:definitionLink 99940511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details) link:presentationLink link:calculationLink link:definitionLink 99940512 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Fair Value Measurements - Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Lease Agreements - Leased facilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - Lease Agreements - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Long-Term Debt - Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Stock Based Compensation - ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Stock Based Compensation - 2010 Plan Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 99941103 - Disclosure - Stock Based Compensation - Stock Option Inducement Awards (Details) link:presentationLink link:calculationLink link:definitionLink 99941104 - Disclosure - Stock Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941105 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details) link:presentationLink link:calculationLink link:definitionLink 99941106 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 99941107 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941108 - Disclosure - Stock Based Compensation - Restricted Stock Unit Awards (Details) link:presentationLink link:calculationLink link:definitionLink 99941109 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Capital Stock - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Capital Stock - BVF Ownership (Details) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - Capital Stock - ATM Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Condensed Consolidated Financial Statements Details link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Acquisitions, Licensing and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Royalty and Commercial Payment Purchase Agreements link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Lease Agreements link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Acquisitions, Licensing and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Description of Business - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 99941204 - Disclosure - Capital Stock - Stock Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 xoma-20240930_cal.xml EX-101.CAL EX-101.DEF 7 xoma-20240930_def.xml EX-101.DEF EX-101.LAB 8 xoma-20240930_lab.xml EX-101.LAB Cover [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Common Stock [Member] Common Stock Series A Preferred Stock [Member] 8.625% Series A Cumulative, Perpetual Preferred Stock Series A ADR [Member] Series B Depositary Shares Statement [Line Items] Statement Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Series B Preferred Stock [Member] 8.375% Series B Cumulative, Perpetual Preferred Stock Series B Convertible Preferred Stock [Member] Convertible preferred stock Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Total unrestricted cash and cash equivalents Restricted Cash, Current Short-term restricted cash Equity Securities, FV-NI, Current Short-term equity securities Accounts and Other Receivables, Net, Current Trade and other receivables, net Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. Rights Receivable, Current Short-term royalty and commercial payment receivables Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Restricted Cash, Noncurrent Long-term restricted cash Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. Long Term Rights Receivable, Non-Current Long-term royalty and commercial payment receivables Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. Milestone Assets, Noncurrent Exarafenib milestone asset Exarafenib milestone asset (Note 4) Exarafenib milestone asset Other Assets, Noncurrent Other assets - long term Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer. Accrued And Other Liabilities Current Accrued and other liabilities Accrued and other liabilities Total Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. Contingent Consideration Under Purchase Agreements Contingent consideration under RPAs, AAAs and CPPAs Operating Lease, Liability, Current Operating lease liabilities Operating lease liabilities Current operating lease liabilities Deferred Income, Current Unearned revenue recognized under units-of-revenue method Unearned revenue recognized under units-of-revenue method, current Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Preferred Stock Dividend, Current Preferred stock dividend accrual Long-Term Debt, Current Maturities Less: current portion of long-term debt Current portion of long-term debt Liabilities, Current Total current liabilities Deferred Income, Noncurrent Unearned revenue recognized under units-of-revenue method - long-term Unearned revenue recognized under units-of-revenue method, noncurrent Asset Acquisition, Contingent Consideration, Liability, Noncurrent Exarafenib milestone contingent consideration (Note 4) Exarafenib milestone contingent consideration Operating Lease, Liability, Noncurrent Long-term operating lease liabilities Long-term operating lease liabilities Non-current operating lease liabilities Long-Term Debt, Excluding Current Maturities Long-term debt Liabilities Total liabilities Commitments and Contingencies. Commitments and Contingencies (Note 10) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred Stock Common Stock, Value, Issued Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,755,223 and 11,495,492 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance at end of period Balance at beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Dividend Rate, Percentage Preferred stock, dividend rate (as a percent) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Common stock, shares issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenues [Abstract] Income and revenues: Amount of income that is not accounted for under Topic 606, in accordance with the effective interest rate method and the cost recovery method. Income Not from Contract with Customer, Effective Interest Rate Method and Cost Recovery Method Income from purchased receivables Revenue from Contract with Customer, Excluding Assessed Tax Revenue from contracts with customers Revenue recognized Amount of revenue that is not accounted for under Topic 606, in accordance with the units-of-revenue method. Revenue Not from Contract with Customer, Units of Revenue Method Revenue recognized under units-of-revenue method Revenues Revenues Total income and revenues Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment. Impairment of Long Term Rights Receivable, Non-Current Royalty purchase agreement asset impairment Gain (Loss) from Litigation Settlement Arbitration settlement costs Amortization of Intangible Assets Amortization of intangible assets Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Gain (loss) included in earnings resulting from the asset acquisition. Gain (Loss) on Asset Acquisition Less: Gain on the acquisition of Kinnate Gain on the acquisition of Kinnate Gain on the acquisition of Kinnate Derivative, Gain on Derivative Change in fair value of embedded derivative related to RPA Interest Expense, Debt Interest expense Other Nonoperating Income (Expense) Other income (expense), net Net loss Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders, basic Net loss attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Diluted Net loss attributable to common stockholders, diluted Net loss attributable to common stockholders, diluted Earnings Per Share, Basic Net loss per share attributable to common stockholders, Basic (in dollars per share) Earnings Per Share, Diluted Net loss per share attributable to common stockholders, Diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average shares used in computing net loss per share attributable to common stockholders, Basic Weighted Average Number of Shares Outstanding, Diluted Weighted average shares used in computing net loss per share attributable to common stockholders, Diluted CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Net unrealized gain on available-for-sale debt securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Additional Paid-in Capital [Member] Additional Paid-In Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance at end of period (in shares) Balance at beginning of period (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of shares, Exercised Exercise of stock options (in shares) Shares Issued, Value, Share-Based

Payment Arrangement, after Forfeiture Issuance of common stock related to 401(k) contribution Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock related to 401(k) contribution (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock related to ESPP Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock related to ESPP (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings Preferred stock dividends Stock Repurchased and Retired During Period, Value Repurchase of common stock Repurchase of common stock Stock Repurchased and Retired During Period, Shares Repurchase of common stock (in shares) Repurchase of common stock (in shares) Stock Issued During Period, Value, New Issues Issuance of preferred stock Stock Issued During Period, Shares, New Issues Issuance of preferred stock (in shares) Shares issued (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Increase in short-term rights receivable due to income from purchased receivables under effective interest rate method. Income From Purchased Receivables Under Effective Interest Rate Method, Current Income from purchased receivables under effective interest rate method Income from purchased receivables under EIR Method, Short-Term Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Changes in estimated fair value of contingent consideration. Changes In Estimated Fair Value Of Contingent Consideration Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs Changes in estimated fair value of contingent consideration Defined contribution plan issuance of Common stock for services or claims. Defined Contribution Plan Issuance Of Common Stock For Services Or Claims Common stock contribution to 401(k) Depreciation, Nonproduction Depreciation Amortization of Debt Issuance Costs and Discounts Accretion of long-term debt discount and debt issuance costs Accretion of debt discount and debt issuance costs Operating lease payments, non cash. Operating Lease Payments Non Cash Non-cash lease expense Equity Securities, FV-NI, Realized Gain (Loss) Change in fair value of equity securities Gain (loss) recognized due to change in fair value of investment Change in fair value of available-for-sale debt securities classified as cash equivalents. Change in Fair Value of Available-For-Sale Debt Securities, Cash Equivalents Change in fair value of available-for-sale debt securities classified as cash equivalents Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Accounts and Other Receivables Trade and other receivables, net Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Operating Lease Liability Operating lease liabilities Increase (Decrease) in Deferred Revenue Unearned revenue recognized under units-of-revenue method Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: The cash inflow associated with the acquisition of asset during the period. Cash Acquired from Asset Acquisition Net cash acquired in Kinnate acquisition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. Payment of Consideration Under Agreements, Investing Activities Payments of consideration under RPAs, AAAs and CPPAs Payments of consideration under RPAs, AAAs and CPPAs Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. Receipts Under Agreements, Investing Activities Receipts under RPAs, AAAs and CPPAs Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Repayments of Long-Term Debt Principal payments - debt Principal repayments Principal repayment Payments of Financing Costs Debt issuance costs and loan fees paid in connection with long-term debt Payments of Dividends Payment of preferred stock dividends Payments for Repurchase of Common Stock Repurchases of common stock Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds from exercise of options and other share-based compensation Payment, Tax Withholding, Share-Based Payment Arrangement Taxes paid related to net share settlement of equity awards Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash as of the end of the period Cash, cash equivalents and restricted cash as of the beginning of the period Cash, cash equivalents and restricted cash Total unrestricted and restricted cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease liabilities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: The fair value of milestone assets acquired in noncash investing or financing activities. Fair Value of Assets Acquired, Milestone Asset Estimated initial fair value of the Exarafenib milestone asset in Kinnate acquisition Amount of liability recognized from milestone contingent consideration in asset acquisition, classified as noncurrent. Asset Acquisition, Milestone Contingent Consideration, Liability, Noncurrent Estimated initial fair value of the Exarafenib milestone contingent consideration in Kinnate acquisition Right-of-use assets obtained in exchange for operating lease liabilities in acquisition. Operating Lease, Right-of-Use Assets Obtained in Exchange for Lease Liabilities in Acquisition Right-of-use assets obtained in exchange for operating lease liabilities in Kinnate acquisition Fair value basis reduction of right-of-use assets in in acquisition. Operating Lease, Fair Value Basis Reduction in Right-of-Use Assets in Acquisition Relative fair value basis reduction of right-of-use assets in Kinnate acquisition Accrual of contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. Accrual Of Contingent Consideration Under Purchase Agreements Accrual of contingent consideration under the Affitech CPPA Accrual of contingent consideration under assignment and assumption agreement. Accrual Of Contingent Consideration Under Assignment and Assumption Agreements Accrual of contingent consideration under the LadRx AAA Estimated fair value of contingent consideration under asset acquisition agreements. Estimated Fair Value Of Contingent Consideration Under Asset Acquisition Estimated fair value of contingent consideration under the LadRx Agreements Dividends Payable Preferred stock dividend accrual Description of Business Nature of Operations [Text Block] Description of Business Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies Consolidated financial statement detail. Condensed Consolidated Financial Statement Details Additional Financial Information Disclosure [Text Block] Condensed Consolidated Financial Statements Detail Acquisitions, Licensing and Other Arrangements The entire disclosure for asset acquisitions, licensing and other arrangements. Asset Acquisitions, Licensing And Other Arrangements [Text Block] Acquisitions, Licensing and Other Arrangements No definition available. Royalty and Commercial Payment Purchase Agreements Royalty purchase agreement. Royalty Purchase Agreement [Text Block] Royalty and Commercial Payment Purchase Agreements Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Lease Agreements The entire disclosure of information about leases. Lease Disclosure [Text Block] Lease Agreements Long-Term Debt Long-Term Debt [Text Block] Long-Term Debt Common Stock Warrants Common stock warrant. Common Stock Warrant Disclosure [Text Block] Common Stock Warrants Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stock Based Compensation Share-Based Payment Arrangement [Text Block] Stock Based Compensation Capital Stock Equity [Text Block] Capital Stock Income Taxes Income Tax Disclosure [Text Block] Income Taxes Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Policy for future milestones, royalties purchase rights and commercial payments. Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block] Purchase of Rights to Future Milestones, Royalties and Commercial Payments Disclosure of accounting policy for income that is not accounted for under Topic 606, in accordance with the cost recovery method and the effective interest rate method. Income Not from Contract with Customer, Cost Recovery Method and Effective Interest Rate Method [Policy Text Block] Income from Purchased Receivables Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset. Credit Loss, Contract With Customer Asset [Policy Text Block] Allowance for Current Expected Credit Losses Revenue from Contract with Customer [Policy Text Block] Revenue From Contracts With Customers Disclosure of accounting policy for revenue that is not accounted for under Topic 606, in accordance with the units-of-revenue method. Revenue, Revenue Not from Contract with Customer, Units of Revenue Method [Policy Text Block] Revenue Recognized under Units-of-Revenue Method Compensation Related Costs, Policy [Policy Text Block] Stock-Based Compensation Disclosure of accounting policy for equity securities. Equity Securities Policy Equity Securities Disclosure of accounting policy for asset acquisitions. Asset Acquisitions, Policy [Policy Text Block] Asset Acquisitions Lessee, Leases [Policy Text Block] Leases Debt, Policy [Policy Text Block] Long-Term Debt Disclosure of accounting policy for warrants. Warrants [Policy Text Block] Warrants Income Tax, Policy [Policy Text Block] Income Taxes Earnings Per Share, Policy [Policy Text Block] Net Income (Loss) per Share Available to (Attributable to) Common Stockholders Stockholders' Equity, Policy [Policy Text Block] Share Repurchases Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Risk Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) New Accounting Pronouncements, Policy [Policy Text Block] Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of cash, cash equivalents and restricted cash Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Schedule of cash equivalents classified as available-for-sale Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued and other liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding securities considered anti-dilutive Asset Acquisition [Table Text Block] Schedule of purchase consideration Tabular disclosure of the changes in royalty and commercial payment receivables. Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block] Summary of royalty and commercial payment receivable activities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities measured at fair value on a recurring basis Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of maturity of future rent payments associated with new lease Lease, Cost [Table Text Block] Schedule of cost components of operating leases The tabular disclosure of supplemental cash flows information related to leases. Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block] Summary of supplemental cash flow information related to operating leases The tabular disclosure of supplemental information related to operating leases. May include, but not limited to, present value assumptions used in calculating the present value of the lease payments. Lessee, Operating Lease, Supplemental Information [Table Text Block] Schedule of assumptions used in calculating the present value of lease payments Schedule of Long-Term Debt Instruments [Table Text Block] Schedule of long-term debt Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of projected future principal payments of initial term loan The tabular disclosure of accretion of debt discounts and issuance costs included in interest expense. Schedule of Accretion of Debt Discounts and Issuance Costs Included in Interest Expense [Table Text Block] Schedule of interest expense Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Common Stock Warrants Outstanding Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based compensation Performance Stock Unit Awards Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of valuation assumptions Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Schedule of grant date fair values of PSUs granted Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Schedule of performance shares, outstanding activity Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of stock-based compensation expense Dividends Declared [Table Text Block] Schedule of declared and paid cash dividends Substantial Doubt about Going Concern, within One Year [true false] Substantial Doubt about Going Concern, within One Year Restrictions on Cash and Cash Equivalents [Table] Restricted Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Represents the information pertaining to cash reserve accounts for interest and administrative fees and to cover operating expenses of subsidiary, established in conjunction with the funding of loan. Cash Reserve Accounts, Interest and Administrative Fees and Operating Expenses [Member] Cash reserve accounts Represents the information pertaining to cash reserve accounts for interest and administrative fees, established in conjunction with the funding of loan. Cash Reserve Accounts, Interest and Administrative Fees [Member] Cash reserve account, Interest and administrative fees Represents the information pertaining to cash reserve accounts to cover operating expenses of subsidiary, established in conjunction with the funding of loan. Cash Reserve Accounts, Operating Expenses [Member] Cash reserve account, Operating expenses Scenario [Axis] Scenario [Domain] Forecast [Member] Forecast Financial Instrument [Axis] Financial Instruments [Domain] US Treasury Securities [Member] U.S. treasury bills Restricted Cash and Cash Equivalents Items [Line Items] Cash, Cash Equivalents and Restricted Cash Cash Unrestricted cash Cash Equivalents, at Carrying Value Unrestricted cash equivalents Restricted Cash Total restricted cash Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Debt Securities, Available-for-Sale, Amortized Cost, Allowance for Credit Loss, Excluding Accrued Interest, Noncurrent Allowance for credit losses on investments in debt securities Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Available for sale securities, Amortized Cost Basis Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Available for sale securities, Unrealized Gains Debt Securities, Available-for-Sale Available for sale securities, Estimated Fair Value Restricted Cash and Cash Equivalents [Abstract] Restricted Cash Amount of restricted cash released to unrestricted cash during the period. Restricted Cash Released to Unrestricted Cash Restricted cash released to unrestricted cash Additional amount of cash required to be added to restricted account. Restricted Cash, Additional To Be Funded Additional amount of cash required to fund reserve account Amount, after allowance, of receivables related to income from purchased receivables under the cost recovery method due within one year or the normal operating cycle, if longer. Purchased Receivables, Cost Recovery Method, Net, Current Purchased receivables included in royalty and commercial payment receivables, Cost recovery method Amount, after allowance, of receivables related to income from purchased receivables under the effective interest rate method due within one year or the normal operating cycle, if longer. Purchased Receivables, Effective Interest Rate Method, Net, Current Purchased receivables included in royalty and commercial payment receivables, Effective interest rate method Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Income tax penalties or interest charged Accrued interest or penalties related to uncertain tax positions Treasury Stock, Common, Value Treasury stock (in dollars) Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Credit Concentration Risk [Member] Credit Concentration Risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue Benchmark [Member] Revenues Trade Accounts Receivable [Member] Trade Receivables Customer [Axis] Customer [Domain] One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark. Partner 1 [Member] Partner 1 A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark. Partner 2 [Member] Partner 2 A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark. Partner 3 [Member] Partner 3 Concentration Risk [Line Items] Concentration of Risk Number of major partners. Number Of Major Partners Number of major partners Concentration Risk, Percentage Concentration risk (as a percent) Debt Securities, Trading, and Equity Securities, FV-NI [Table] Investment, Name [Axis] Investment, Name [Domain] Rezolute, Inc. Rezolute, Inc. [Member] Rezolute Debt and Equity Securities, FV-NI [Line Items] Equity Securities Accrued Liabilities and Other Liabilities [Abstract] Accrued and other liabilities Accrued Bonuses, Current Accrued incentive compensation Other Accrued Liabilities, Current Other accrued liabilities Accrued Professional Fees, Current Accrued legal and accounting fees Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Salaries and Employee Benefits, Current Accrued payroll and benefits Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Net Income (Loss) Per Share Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Numerator Preferred Stock

Dividends, Income Statement Impact Less: accumulated dividends Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Shares issuable based on market price Effect of dilutive common stock options Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants for common stock Stock units under a share-based payment arrangement awarded for meeting performance target. Performance Stock Units [Member] Performance Stock Unit Awards Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of net loss per share (in shares) Share Price Stock price (in dollars per share) Price per share (in dollars per share) Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Domain] Kinnate. Kinnate [Member] Kinnate Disposal Group Name [Axis] Disposal Group Name [Domain] Exarafenib and related intellectual property. Exarafenib and related Intellectual Property [Member] Exarafenib and related IP Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Disposed of by Sale, Not Discontinued Operations Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Contingent Value Rights Agreement (CVR Agreement). Contingent Value Rights Agreement [Member] CVR Agreement Counterparty Name [Axis] Counterparty Name [Domain] Kinnate CVR (Contingent Value Rights) holders eligible to receive contingent consideration upon the closing of the Kinnate acquisition under the Kinnate CVR Agreement. Kinnate CVR holders [Member] Kinnate CVR holders Pro Forma [Member] Pro forma Scenario, Adjustment [Member] Adjustment Legal Entity [Axis] Entity [Domain] Asset Acquisition [Line Items] Asset acquisition Price of a single share of a number of saleable stocks paid in asset acquisition. Asset Acquisition, Share Price Asset acquisition, Share price (in dollars per share) Number of non-transferable contractual contingent value rights (CVR) each acquiree share has right to receive. representing right to receive one or more potential cash payments. Acquisition, Number Of Contingent Value Rights Number of non-transferable contractual CVR per share of Kinnate common stock Proceeds from Sale of Other Productive Assets Cash consideration received Amount of contingent consideration to be received as part of consideration in sale of assets. Contingent Consideration From Sale of Assets Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company Percentage of net proceeds contingent value right holders have right to receive until the fifth anniversary of the merger closing date under the terms of the agreement from sale entered into by acquiree. Percentage of Proceeds Payable, Sale Percentage of further net proceeds from sale Percentage of net proceeds contingent value right holders have right to receive within one year of the merger closing date under the terms of the agreement from license or disposition entered into by acquiree. Percentage of Proceeds Payable, License or Disposition Percentage of net proceeds from any license or other disposition For contingent consideration arrangements recognized in connection with a asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High Contingent consideration from the Exarafenib Sale payable from the Company to the Kinnate CVR Holders under the CVR Agreement Operating Lease, Liability Operating lease liabilities Total net lease liability for operating leases Asset Acquisition, Consideration Transferred [Abstract] Purchase consideration Payments to Acquire Productive Assets Closing cash payment Asset Acquisition, Consideration Transferred, Contingent Consideration Estimated fair value of the Exarafenib milestone contingent consideration Asset Acquisition, Consideration Transferred, Transaction Cost Transaction costs Asset Acquisition, Consideration Transferred Total purchase consideration Total purchase consideration Number of shares tendered under the asset acquisition. Asset Acquisition, Number Of Shares Tendered Kinnate common stock tendered Number of shares underlying the share-based awards settled under the asset acquisition. Asset Acquisition, Number Of Shares Underlying The Share Based Awards Settled Total number of underlying shares Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Capitalized Cost Fair value of the IPR&D asset Intangible Assets, Net (Excluding Goodwill) Intangible assets Asset Acquisition [Abstract] Allocation of purchase consideration Net Assets Net assets acquired Severance Costs Severance charges Amount of cash payments for severance costs. Payments for Severance Costs Severance charges paid Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited [Member] Takeda Pharmaceutical Company Limited Represents about collaboration agreement member. Collaboration Agreement [Member] Collaboration Agreement Product and Service [Axis] Product and Service [Domain] Mezagitamab antibody (TAK-079) and TAK-169. TAK-079 and TAK-169 [Member] TAK-079 and TAK-169 Mezagitamab antibody (TAK-079). Mezagitamab [Member] TAK-079 Other antibody technologies. Excludes TAK-079 (mezagitamab). Other Antibodies [Member] Other antibodies Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Agreements Licensing and other arrangements Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. Eligible Milestone Payments Receivable Upon Achievement Of Milestones Maximum milestone payments entitled to receive Percentage of royalty on net sales upon commercialization. Percentage Of Royalty On Net Sales Upon Commercialization Percentage of royalty on sales Maximum eligible milestone payments receivable per discovery product candidate. Eligible Milestone Payments Receivable Per Discovery Product Candidate Maximum eligible milestone payments receivable per discovery product candidate Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days Royalties, Period, Minimum Minimum period eligible to receive royalties Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days Royalties Period, Minimum, Scenario One Royalty payment period from the first commercial sale of each royalty-bearing discovery product Contract with Customer, Asset, after Allowance for Credit Loss Contract assets Contract with Customer, Liability Contract liabilities Capitalized Contract Cost, Net Capitalized contract costs License agreement and common stock purchase agreement. License Agreement and Common Stock Purchase Agreement [Member] License Agreement and Common Stock Purchase Agreement License agreement. License Agreement [Member] License Agreement License agreement related to activities associated with RZ358. License Agreement RZ358 [Member] License Agreement, RZ358 License agreement related to activities associated with non-RZ358 products. License Agreement, Non-RZ358 Products [Member] License Agreement, Non-RZ358 products Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement. Percentage Of Decrease In Future Royalty Obligations Percentage of decrease in future royalty obligations Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days Agreement Termination Prior Written Notice Period Agreement termination prior written notice period License agreement consideration received. License Agreement Consideration Received License agreement consideration received Amount of payments received upon achievement of financing activities during the period. License Agreement Consideration Received, Achievement of Financing Activities Payments received upon achievement of financing activities Amount of installment payments received during the period. License Agreement, Installment Payments Received Installment payments received Number of counterparty's common stock entity received under the terms of the agreement. License Agreement, Shares Received Number of shares received Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Janssen Biotech, Inc. Janssen Biotech Inc. [Member] Janssen Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. Proceeds From Upfront Payment Cash payment received Novartis International Pharmaceutical Ltd. Novartis International Pharmaceutical Ltd. [Member] Novartis International Number of performance obligations. Number Of Performance Obligations Number of performance obligations Novartis Pharma AG. Novartis Pharma AG [Member] Novartis Pharma AG XOMA-052 license agreement and IL1 target license agreement. Xoma 052 License Agreement And IL1 Target License Agreement [Member] Gevokizumab License Agreement and IL-1 Target License Agreement Gevokizumab License Agreement with Novartis. XOMA 052 License Agreement [Member] Gevokizumab License Agreement IL-1 target license agreement with Novartis. IL-1 Target License Agreement [Member] IL-1 Target License Agreement License agreement transaction price. License Agreement Transaction Price Transaction price Amount of license agreement consideration received as repayment of debt. License Agreement Consideration Received, Debt Repayment License agreement consideration received, repayment of debt Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Shares Issued, Price Per Share Purchase price (in dollars per share) Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs. Stock Issued During Period Value New Issues, Common Stock Issuance of common stock, fair value Common stock premium received on sale of common stock. Common Stock Premium Common stock premium Number of agreements. Agreements, Number Number of agreements Number of arrangements the agreements are accounted for. Arrangements, Number Number of arrangements HealthCare Royalty Partners II, L.P (HCRP). HealthCare Royalty Partners Two Limited Partners [Member] HealthCare Royalty Partners II, L.P. Royalty Interest Acquisition Agreements. Royalty Interest Acquisition Agreements [Member] Royalty Sale Agreements First Royalty Interest Acquisition Agreement. First Royalty Interest Acquisition Agreement [Member] First Royalty Sale Agreement Second Royalty Interest Acquisition Agreement. Second Royalty Interest Acquisition Agreement [Member] Second Royalty Sale Agreement Eligible potential additional payments receivable upon achievement of specified future net sales milestones. Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone. Milestone Periods, Number Number of milestone periods Royalty and commercial rights receivable. Includes both current and noncurrent rights receivable. Rights Receivable Royalty and commercial payment receivable Royalty purchase agreement. Royalty Purchase Agreement [Member] Royalty Purchase Agreement Dare. Dare [Member] Dare OVAPRENE and Sildenafil Cream. OVAPRENE and Sildenafil Cream [Member] OVAPRENE and Sildenafil Cream OVAPRENE. OVAPRENE [Member] OVAPRENE Sildenafil Cream. Sildenafil Cream [Member] Sildenafil Cream Scenario representing achievement of a pre-specified return threshold. Scenario One [Member] Upon achievement of a pre-specified return threshold Percentage of royalties applicable under terms of agreement. Royalty Percentage, Applicable Under Agreement Percentage of remaining royalties Royalties entity has the right to receive as a percentage of net sales. Royalty Receivable Percentage On Net Sales Royalties entity has right to receive (as a percent) Amount of milestone payment for each successive specified amount received. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Payable on Milestone Payable on milestone Specified amount of each successive receipt that requires milestone payment to counterparty under agreement. Payable on Milestone, Specified Amount of Each Successive Receipt Specified amount of each successive receipt that requires milestone payment Return threshold for determining milestone payments under the agreement. Payable on Milestone, Return Threshold Return threshold Contract with Customer, Asset, Allowance for Credit Loss Allowance for credit losses Represents the information pertaining to Talphera. Talphera [Member] Talphera Represents the information pertaining to Alora Pharmaceuticals. Alora Pharmaceuticals [Member] Alora Pharmaceuticals Asset Purchase Agreement and Marketing Agreement . Asset Purchase Agreement and Marketing Agreement [Member] Asset Purchase Agreement and Marketing Agreement Commercial payment purchase agreement. Commercial Payment Purchase Agreement [Member] Commercial Payment Purchase Agreement All customers excluding U.S. Department of Defense. All Customers, Excluding U.S. Department of Defense [Member] All customers excluding DoD U.S. Department of Defense U.S. Department of Defense [Member] DoD Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive, up to specified threshold. Royalty Receivable Percentage On Net Sales and Percentage of Milestones Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive (as a percent) Threshold amount for royalties and milestones for determining amount entity has the right to receive. Royalty and Milestones Receivable, Threshold Threshold amount for royalties and milestones Royalty percentage entity has the right to fully retain which counterparty is entitled to receive upon reaching specified threshold. Royalty Receivable Percentage On Net Sales Fully Retained Royalty percentage entity has the right to fully retain Royalties entity has the right to receive as a percentage shared with counterparty upon reaching threshold. Royalty Receivable Percentage On Net Sales Shared With Counterparty Royalties shared equally with counterparty (as a percent) Represents the information pertaining to LadRx. LadRx [Member] LadRx Assignment and Assumption Agreement and Royalty Purchase Agreement. Assignment and Assumption Agreement and Royalty Purchase Agreement [Member] Assignment and Assumption Agreement and Royalty Purchase Agreement Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent consideration under purchase agreements related to regulatory milestones. Contingent Consideration, Regulatory Milestones [Member] Regulatory milestones Increase (decrease) in potential amount payable on regulatory milestone. Increase (Decrease) In Potential Amount Payable on Regulatory Milestone Amount of regulatory milestone payment removed Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Maximum Payments Based On Achievement Of Regulatory and Sales Milestones Maximum regulatory and commercial sales milestone payments Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Maximum Payable on Sales Milestone Maximum commercial sales milestone payments For contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. Contingent Consideration Arrangements, Range of Outcomes, Value, High Contingent consideration, high-end of range Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights. Royalty And Commercial Rights Acquired, Non-Current Acquisition of royalty and commercial payment receivables, Long-Term Royalty and commercial payment receivables from milestone payment probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. Rights Receivable, From Milestone Payment, Current Short-term royalty and commercial payment receivables from milestone payment Royalty and commercial payment receivables from royalty or commercial payment probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. Rights Receivable, From Royalty or Commercial Payment, Current Short-term royalty and commercial payment receivables from royalty or commercial payment Information pertaining to Aptevo. Aptevo [Member] Aptevo Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement. Commercial Payment Threshold, One-Time Payment Commercial payments attributable to net sales threshold Decrease in long-term rights receivable due to receipt of royalty and commercial payments. Receipt of Royalty and Commercial Payment Receivable Non Current Receipt of royalty and commercial payments, Long-Term Reduction in long-term royalty receivable balance due to receipt of payment Palobiofarma, S.L. Palobiofarma, S.L {Member] Palobiofarma Number of drug candidates under the terms of the agreement. Agreement, Drug Candidates, Number Number of drug candidates Viracta Therapeutics, Inc. ("Viracta"). Viracta Therapeutics Inc. [Member] Viracta OJEMDA (tovorafenib). Tovorafenib [Member] OJEMDA Priority review voucher. Priority Review Voucher [Member] Priority review voucher. Maximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones. Milestones Receivable, Excluding Consideration Retained, Maximum Maximum amount of potential milestones, potential royalties on sales and other payments receivable Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement. Maximum Consideration Retained Amount of maximum consideration retained Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement. Regulatory and Commercial Milestones Receivable, Maximum Maximum amount of potential regulatory and commercial milestones receivable Amount of milestone achieved. Milestone Achieved Amount of milestone payments earned under agreement Amount of income that is not accounted for under Topic 606, in accordance with the cost recovery method. Income Not from Contract with Customer, Cost Recovery Method Income from purchased receivables Amount representing sale of priority review voucher. Priority Review Voucher, Sale Sale of priority review voucher to undisclosed buyer Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC. Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC. [Member] Kuros Maximum eligible milestone payments receivable upon achievement of pre-commercial milestones. Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones Pre-commercial milestone payments, maximum Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period. Milestone Payment Received, Counterparty Milestone payment received by Kuros Percentage of milestone payment received by counterparty entity is entitled to receive. Milestone Payment

Receivable, Percentage Percentage of milestone payment received by Kuros that company is entitled to receive Affitech Research AS, a Norwegian biotech company. Affitech Research AS [Member] Affitech Contingent consideration under purchase agreements related to sales-based milestones. Contingent Consideration, Sales Milestones [Member] Sales-based milestones Contingent consideration under purchase agreements related to the first and second sales-based milestones. Contingent Consideration, Sales Milestones, One and Two [Member] Sales-based milestones, first and second Contingent consideration under purchase agreements related to the third sales-based milestones. Contingent Consideration, Sales Milestones, Three [Member] Sales-based milestones, third Faricimab-svoa, (VABYSMO) products. Faricimab, Product [Member] Faricimab (VABYSMO) Geographical [Axis] Geographical [Domain] UNITED STATES United States Europe [Member] Europe Payments entity eligible to receive as a percentage of net sales. Commercial Sales, Receivable Percentage On Net Sales Payments eligible to receive (as a percent) Period from each royalty payment date payment is due from customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Commercial Payment, Period Due Period from each royalty payment date payment is due Term of commercial payment receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Commercial Payment Receivable Term Commercial payment receivable term Increase in short-term rights receivable due to recognition of contingent consideration. Royalty and Commercial Payment Receivable Current, Recognition of Contingent Consideration Recognition of contingent consideration, Short-Term Increase in long-term rights receivable due to recognition of contingent consideration. Royalty and Commercial Payment Receivable Non Current, Recognition of Contingent Consideration Recognition of contingent consideration, Long-Term Agenus Inc. Agenus [Member] Agenus Incyte immuno-oncology assets. Incyte Immuno-Oncology Assets [Member] Incyte Immuno-Oncology Assets Merck immuno-oncology product. Merck Immuno-Oncology Product [Member] Merck Immuno-Oncology Product Number of licensed products related to milestones and royalties purchased. Number Of Licensed Products Related To Milestones And Royalties Purchased Number of licensed products related to milestone and royalties Percentage of milestones entity has the right to receive as a percentage. Purchased Percentage Of Milestones Milestone payments entity has right to receive (as a percent) Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones. Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones Aronora, Inc. Aronora, Inc. [Member] Aronora Bayer products. Bayer Products [Member] Bayer Products Non-bayer products. Non-Bayer Products [Member] Non-Bayer Products Debt Instrument [Axis] Debt Instrument, Name [Domain] Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments. Silicon Valley Bank [Member] SVB Loan Maximum [Member] Maximum Number of drug candidates subject to exclusive license option. Agreement, Drug Candidates, Exclusive License Option, Number Number of drug candidates subject to exclusive license option Purchased percentage of non-royalties on net sales of products. Purchased Percentage Of Non Royalties On Net Sales Of Products Non-royalties to be received (as a percent) Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid. Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage Future non-royalty payments to be received (as a percent) Multiplier used in determining change in payment percentage. Agreement, Payment Percentage, Factor Multiplier for cumulative amount of consideration paid Amount of contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Contingent Future Cash Payments, Per Product Contingent future cash payment for each product Threshold amount of cumulative royalties on net sales per product under the terms of the agreement Cumulative Royalties On Net Sales Per Product, Threshold Amount Threshold amount of cumulative royalties on net sales per product Maximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement. Milestones Payments To Aggregate Amount Of Per Product Maximum royalty milestone payments to be paid per product Contract with Customer, Asset, Allowance for Credit Loss, Period Increase (Decrease) Amount of increase in allowance for credit loss Decrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment. Long Term Rights Receivable, Noncurrent, Decrease Due To Impairment Decrease in long-term royalty and commercial rights receivables due to impairment Royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable under costs recovery method. Rights Receivable, Cost Recovery Method Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method Increase in rights receivable due to acquisition of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable. Rights Receivable, Cost Recovery Method, Acquisition of Payment Receivable Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method Decrease in rights receivable due to receipt of royalty and commercial payments under the cost recovery method. Includes both current and noncurrent rights receivable. Rights Receivable, Cost Recovery Method, Receipt of Payments Receipt of Royalty and Commercial Payments, Cost Recovery Method Increase in rights receivable due to recognition of contingent consideration under the cost recovery method. Includes both current and noncurrent rights receivable. Rights Receivable, Cost Recovery Method, Recognition of Contingent Consideration, Recognition of Contingent Consideration, Cost Recovery Method Impairment of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable. Rights Receivable, Cost Recovery Method, Impairment of Payment Receivable Impairment of Royalty and Commercial Payment Receivables, Recovery Method Increase (decrease) in rights receivable due to reclassification of royalty and commercial payment receivables from cost recovery to EIR method. Includes both current and noncurrent rights receivable. Rights Receivable, Cost Recovery Method, Reclassification of Payment Receivables from Cost Recovery to EIR method Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, Cost Recovery Method Royalty and commercial payment receivables under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. Rights Receivable, EIR Method Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method Balance at Beginning of Period, Royalty and Commercial Payment Receivables, EIR Method Increase (decrease) in rights receivable due to reclassification of royalty and commercial payment receivables from cost recovery to EIR method. Includes both current and noncurrent rights receivable under EIR (Effective interest rate) method. Rights Receivable, EIR Method, Reclassification of Payment Receivables from Cost Recovery to EIR method Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, EIR Method Increase (decrease) in rights receivable due to income (loss) from purchased receivables under EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. Rights Receivable, EIR Method, Income from Purchased Receivables Income from Purchased Receivables Under EIR Method Decrease in rights receivable due to receipt of royalty and commercial payments under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. Rights Receivable, EIR Method, Receipt of Payments Receipt of Royalty and Commercial Payments, EIR Method Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) Cash and Cash Equivalents [Axis] Money Market Funds [Member] Money market funds US Treasury Bill Securities [Member] U.S. treasury bills Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Investments, Fair Value Disclosure Equity securities Fair value of financial assets. Financial Assets, Fair Value Disclosure Total financial assets Liabilities, Fair Value Disclosure [Abstract] Liabilities: Contingent consideration, fair value disclosure. Contingent Consideration Fair Value Disclosure Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value Financial Liabilities Fair Value Disclosure Total financial liabilities Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825. Milestone Assets, Increase (Decrease) Increase in Exarafenib milestone asset Amount of increase (decrease) in the value during the period from contingent consideration liability. Asset Acquisition, Contingent Consideration, Liability, Change in Amount Increase in Exarafenib milestone contingent consideration Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Share Price [Member] Closing common stock price Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurements Equity Securities, FV-NI, Measurement Input Valuation assumptions, measurement input Lessee, Lease, Description [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Leased facilities in Emeryville, California with lease expiration date of July 31, 2023 Leased Facilities, Emeryville, California [Member] Leased facilities, Emeryville, California, with lease expiration of July 31, 2023 Leased facilities in Emeryville, California, in different location than previous lease. Leased Facilities, Two, Emeryville, California [Member] Leased facilities, Emeryville, California, new lease - different location than previous lease Leased office facilities in San Francisco, California, related to asset acquisition in 2024, with lease expiration date of June 30, 2026. Leased Facilities, San Francisco, California [Member] Leased facilities, Kinnate lease with lease expiration of June 30, 2026 Lessee, Lease, Description [Line Items] Leases Lessee, Operating Lease, Renewal Term Period of lease extension Lessee, Operating Lease, Existence of Option to Extend [true false] Existence of option to extend Amount of adjustment to right of use asset resulting from modification of operating lease. Lessee, Operating Lease Modification, Adjustment to Right Of Use Asset Adjustment to right of use asset for lease modification Lessee, Operating Lease, Term of Contract Lease term Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 (excluding the nine months ended September 30, 2024) Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following current fiscal year. Lessee, Operating Lease, Liability, Payments, Due after Year Four Thereafter Lessee, Operating Lease, Liability, to be Paid Total undiscounted lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value adjustment Lease, Cost [Abstract] Lease costs Operating Lease, Cost Operating lease cost Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases, net credit due. Variable Lease, Cost, Net Variable lease cost Lease, Cost Total lease costs Cash Flow, Operating Activities, Lessee [Abstract] Supplemental disclosure for the condensed consolidated statements of cash flows Operating Lease, Payments Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term, Operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate, Operating leases Sublease Income Sublease income Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Represents the information pertaining to Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments. Blue Owl Commercial Payment-Backed Loan Agreement [Member] Blue Owl Loan Agreement Represents the information pertaining initial term loan from Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments. Blue Owl Commercial Payment-Backed Loan Agreement, Initial Term Loan [Member] Blue Owl Loan Agreement, Initial term loan Represents the information pertaining to pertaining delayed draw term loan under Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments. Blue Owl Commercial Payment-Backed Loan Agreement, Delayed Draw Term Loan [Member] Blue Owl Loan Agreement, Delayed draw term loan Class of Warrant or Right [Axis] Class of Warrant or Right Class of Warrant or Right [Domain] Common stock warrant issued on December 2023. Common Stock Warrant Issued, December Twenty Twenty Three [Member] Common Stock Warrants, Issued December 2023 Represents the information pertaining to common stock warrants at an exercise price of $35.00 per share. Common Stock Warrants at an Exercise Price of $35.00 Per Share [Member] Common Stock Warrants, Exercise price of $35.00 per share Represents the information pertaining to common stock warrants at an exercise price of $42.50 per share. Common Stock Warrants at an Exercise Price of $42.50 Per Share [Member] Common Stock Warrants, Exercise price of $42.50 per share Represents the information pertaining to common stock warrants at an exercise price of $50.00 per share. Common Stock Warrants at an Exercise Price of $50.00 Per Share [Member] Common Stock Warrants, Exercise price of $50.00 per share Debt Instrument [Line Items] Long-term debt Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Debt Instrument, Face Amount Aggregate principal amount The security interest provided by entity as a percentage of equity of specified wholly owned subsidiary under loan agreement. Security Interest in Percentage of Equity Security interest as a percentage of equity of wholly owned subsidiary The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer, net of fees and lender expenses and reserve accounts. Proceeds From Issuance Of Long Term Debt, Net Proceeds from issuance of long-term debt, net Proceeds from Issuance of Long-Term Debt Proceeds from issuance of long-term debt The cash outflow for loan fees and lender expenses. Payments of Financing Costs, Fees and Lender Expenses Fees and lender expenses The amount deposited into reserve accounts to pay interest, administrative fees and operating expenses. Amount Deposited into Reserve Accounts to Pay Interest, Administrative Fees and Operating Expenses Amount deposited into reserve accounts to pay interest, administrative fees and operating expenses Debt Issuance Costs, Net Debt issuance costs Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants (in dollars per share) Warrants Not Settleable in Cash, Fair Value Disclosure Fair value of warrants Long-Term Debt, Gross Gross principal Total payments Debt Instrument, Interest Rate, Effective Percentage Effective interest rate (as a percent) Debt Instrument, Unamortized Discount Debt discount costs Amount, after accumulated amortization, of debt discount associated with allocated fees and lender expenses. Debt Instrument, Unamortized Discount, Allocated Fees and Lender Expenses Debt discount, allocated fees and lender expenses Debt Issuance Costs, Noncurrent, Net Allocated costs for the term loan commitment Interest Expense, Long-Term Debt Interest expense Total interest expense The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Also includes interest payment of associated interest. Repayments of Long-Term Debt and Interest Paid Semi-annual payment, principal and interest Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Unaccreted debt discount and debt issuance costs Long-Term Debt. Total carrying value net of principal repayments, unaccreted debt discount and debt issuance costs Long-Term Debt, Maturity, Year One 2025 Long-Term Debt, Maturity, Year Two 2026 Long-Term Debt, Maturity, Year Three 2027 Long-Term Debt, Maturity, Year Four 2028 Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Long Term Debt Maturities Repayments Of Principal After Year Four Thereafter Interest Expense, Debt, Excluding Amortization Accrued interest expense Class of Warrant or Right [Table] Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018. Ten Year Warrants Issued Third Range [Member] Common Stock Warrants, Issued May 2018 Common stock warrant with exercise price of $14.71 per share. Common Stock Warrant, Exercise Price 14.71 [Member] Common Stock Warrants, Issued March 2019 Class of Warrant or Right [Line Items] Warrants Class of Warrant or Right, Outstanding Warrant outstanding (in shares) Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees. Represent contingent payments not recorded on balance sheet. Contractual Obligation Estimated Milestone Payments Estimate of milestone payments Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations. Contractual Obligation, Estimated Milestone Payments, Number Of Products Assumed number of products per contract Plan Name [Axis] Plan Name [Domain] 2015 Employee Stock Purchase Plan and subsequent amendments. Two Thousand Fifteen Employee Stock Purchase Plan [Member] 2015 ESPP Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Purchase price of common stock under plan (as a percent) 2010 Long Term Incentive and Share Award Plan and subsequent amendments. Two Thousand Ten Long Term Incentive And Stock Award Plan [Member] 2010 Plan Title and Position [Axis] Title and Position [Domain] Employee of entity. Employee [Member] Employees Director [Member] Directors Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Minimum age required for employees to qualify for immediate vesting of award. Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award Minimum age required for employees to qualify for immediate vesting of award Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company). Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age Threshold years required for retirement age Share-Based Compensation Arrangement by Share-Based

Payment Award, Options, Grants in Period, Gross Number of shares, Granted Number of shares, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted average assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value (in dollars per share) Granted (in dollars per share) Information pertaining to Stock Option Inducement Awards. Stock Option Inducement Awards [Member] Stock Option Inducement Awards Information pertaining to first Stock Option Inducement Award. Stock Option Inducement Award, One [Member] Stock Option Inducement Award, Exercise price of $18.66 per share Information pertaining to second Stock Option Inducement Award. Stock Option Inducement Award, Two [Member] Stock Option Inducement Award, Exercise price of $30.00 per share Person with designation of interim chief executive officer and Executive Chairman of the Board. Chief Executive Officer, Interim [Member] Executive Chairman of the Board and Interim CEO, Owen Hughes Person with designation of chief investment officer. Chief Investment Officer [Member] Chief Investment Officer, Bradley Sitko Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price. Share-Based Payment Arrangement, Number of Awards Grants Number of award grants Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Granted Exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of shares, Outstanding at end of period Number of shares, Outstanding at beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Number of shares, Forfeited, expired or cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of shares, Exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Outstanding at end of period Weighted Average Exercise Price Per Share, Outstanding at beginning of period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Contractual Remaining Term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Contractual Remaining Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Options exercised, aggregate intrinsic value Share-Based Payment Arrangement, Expense Stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation expense related to stock options (in dollars) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average remaining recognition period Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Three [Member] Share-Based Payment Arrangement, Tranche Three Chief Executive Officer [Member] CEO, Owen Hughes Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Number of PSUs (in shares) Number of stock price hurdles in a share based compensation arrangement. Share Based Compensation Arrangement By Share Based Payment Award Number of Hurdles. Number of hurdles Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Calendar Days Number of consecutive calendar days used to calculate volume-weighted average stock price Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vesting (as a percent) Information pertaining to stock price hurdles of $30. Stock Price Hurdles of Dollar 30 [Member] Hurdle Price Per PSU - $30.00 Information pertaining to stock price hurdles of $35. Stock Price Hurdles of Dollar 35 [Member] Hurdle Price Per PSU - $35.00 Information pertaining to stock price hurdles of $40. Stock Price Hurdles of Dollar 40 [Member] Hurdle Price Per PSU - $40.00 Information pertaining to stock price hurdles of $45. Stock Price Hurdles of Dollar 45 [Member] Hurdle Price Per PSU - $45.00 Award Date [Axis] Award Date [Domain] Award dates from May 2023 to October 2023. Award Date, May 2023 to October 2023 [Member] Award Date, 2023 Award dates in 2024. Award Date, 2024 [Member] Award Date, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair Value Per Share (in dollars per share) Weighted-average grant-date fair value of awards granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Derived Service Period Aggregate amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Aggregate Cost To Be Recognized, Amount Aggregate amount of cost to be recognized Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Unvested PSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares, Outstanding at end of period Number of shares, Outstanding at beginning of period Number of shares, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Balance (in dollars per share) No definition available. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Per Share Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Stock-based compensation expense, not yet recognized Restricted Stock Units (RSUs) [Member] Restricted Stock Unit Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value of award outstanding (in dollars per share) Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] General and Administrative Expense [Member] General and administrative Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation Dividends Payable [Table] Dividends [Axis] Dividends [Domain] O 2023 Q4 Dividends. O 2023 Q4 Dividends [Member] O 2023 Q4 Dividends O 2024 Q1 Dividends. O 2024 Q1 Dividends [Member] O 2024 Q1 Dividends O 2024 Q2 Dividends. O 2024 Q2 Dividends [Member] O 2024 Q2 Dividends O 2024 Q3 Dividends. O 2024 Q3 Dividends [Member] O 2024 Q3 Dividends Dividends Payable [Line Items] Dividends Dividends Payable, Date Declared Dividend Declaration Date Preferred Stock, Dividends Per Share, Declared Cash dividend declared (in dollars per share) Dividends Payable, Date to be Paid Dividend Payment Date Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Biotechnology Value Fund, L.P. Biotechnology Value Fund LP [Member] BVF Ownership [Axis] Ownership [Domain] Xoma Corporation. Xoma Corporation [Member] Xoma Corporation Subsidiary, Sale of Stock [Line Items] Sale of stock Subsidiary, Ownership Percentage, Parent Ownership interest (as a percent) The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted. Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted Ownership interest, if shares are converted (as a percent) Sale of Stock [Axis] Sale of Stock [Domain] At the Market Agreement, 2018 in which the company may sell common shares. Two Thousand Eighteen At Market Agreement [Member] 2018 Common Stock ATM Agreement At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares. At Market Issuance Sales Agreement 2021 [Member] 2021 ATM Agreement Maximum amount of stock to be issued. Maximum Value Of Stock To Be Issued Maximum amount of shares to be issued The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares. Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares Sales commission paid per transaction (as a percent) The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares. Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares Sales commission paid per transaction, preferred stock (as a percent) Share Repurchase Program, Authorized, Amount Stock repurchase program amount authorized Income Tax Expense (Benefit) Income tax (expense) benefit Unrecognized Tax Benefits Unrecognized tax benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits that would impact effective tax rate Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Unrecognized tax benefits expected to change significantly over the next twelve months Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Twist Bioscience Corporation, "Twist Bioscience". Twist Bioscience Corporation [Member] Twist Bioscience Subsequent Event [Line Items] Subsequent Event Purchased percentage of economics of early-stage programs. Purchased Percentage Of Economics of Programs Percentage of economics of programs acquired Represents the number of partners associated with programs. Number of Partners Number of partners associated with programs The cash outflow for initial payment under agreement. Upfront Payment Upfront payment Percentage of royalties entity is entitled to receive on future commercial sales. Eligible Percentage Of Royalties Percentage of royalties entity is entitled to receive EX-101.PRE 9 xoma-20240930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 04, 2024 Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Securities Act File Number 001-39801 Â Entity Registrant Name XOMA Royalty Corporation Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 52-2154066 Â Entity Address, Address Line One 2200 Powell Street Â Entity Address, Address Line Two SuiteÂ 310 Â Entity Address, City or Town Emeryville Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94608 Â City Area Code 510 Â Local Phone Number 204-7200 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 11,782,723 Entity Central Index Key 0000791908 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â Common Stock Â Â Title of 12(b) Security Common Stock, $0.0075 par value Â Trading Symbol XOMA Â Security Exchange Name NASDAQ Â 8.625% Series A Cumulative, Perpetual Preferred Stock Â Â Title of 12(b) Security 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 Â Trading Symbol XOMAP Â Security Exchange Name NASDAQ Â Series B Depositary Shares Â Â Title of 12(b) Security Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05) Â Trading Symbol XOMAO Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the

following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 142,050 $ 153,290 Short-term restricted cash 80 160 Short-term equity securities 785 161 Trade and other receivables, net 1,045 1,004 Short-term royalty and commercial payment receivables 12,682 14,215 Prepaid expenses and other current assets 2,379 483 Total current assets 159,021 169,313 Long-term restricted cash 4,686 6,100 Property and equipment, net 34 25 Operating lease right-of-use assets 335 378 Long-term royalty and commercial payment receivables 54,207 57,952 Exarafenib milestone asset (Note 4) 3,125 Â Other assets - long term 1,932 533 Total assets 223,340 234,301 Current liabilities: Â Â Accounts payable 1,131 653 Accrued and other liabilities 2,451 2,768 Contingent consideration under RPAs, AAAs and CPPAs 4,000 7,000 Operating lease liabilities 434 54 Unearned revenue recognized under units-of-revenue method 1,924 2,113 Preferred stock dividend accrual 1,368 1,368 Current portion of long-term debt 9,826 5,543 Total current liabilities 21,134 19,499 Unearned revenue recognized under units-of-revenue method - long-term 5,589 7,228 Exarafenib milestone contingent consideration (Note 4) 3,125 Â Long-term operating lease liabilities 594 335 Long-term debt 108,089 118,518 Total liabilities 138,531 145,580 Commitments and Contingencies (Note 10) Stockholders' equity: Â Â Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,755,223 and 11,495,492 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 88 86 Additional paid-in capital 1,317,657 1,311,809 Accumulated other comprehensive income 104 Â Accumulated deficit (1,233,089) (1,223,223) Total stockholders' equity 84,809 88,721 Total liabilities and stockholders' equity 223,340 234,301 8.625% Series A Cumulative, Perpetual Preferred Stock Â Â Stockholders' equity: Â Â Preferred Stock 49 49 8.375% Series B Cumulative, Perpetual Preferred Stock Â Â Stockholders' equity: Â Â Preferred Stock Convertible preferred stock Â Â Stockholders' equity: Â Â Preferred Stock X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer. + ReferencesNo definition available. + Details Name: xoma_AccruedAndOtherLiabilitiesCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: xoma_AccruedPreferredStockDividendCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the

normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. + ReferencesNo definition available. + Details Name: xoma_MilestoneAssetsNoncurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Preferred stock, par value (in dollars per share) $ 0.05 $ 0.05 Preferred stock, shares authorized (in shares) 1,000,000 1,000,000 Common stock, par value (in dollars per share) $ 0.0075 $ 0.0075 Common stock, shares authorized (in shares) 277,333,332 277,333,332 Common stock, shares issued (in shares) 11,755,223 11,495,492 Common stock, shares outstanding (in shares) 11,755,223 11,495,492 8.625% Series A Cumulative, Perpetual Preferred Stock Â Â Preferred stock, dividend rate (as a percent) 8.625% 8.625% Preferred stock, shares issued (in shares) 984,000 984,000 Preferred stock, shares outstanding (in shares) 984,000 984,000 8.375% Series B Cumulative, Perpetual Preferred Stock Â Â Preferred stock, dividend rate (as a percent) 8.375% 8.375% Preferred stock, shares issued (in shares) 1,600 1,600 Preferred stock, shares outstanding (in shares) 1,600 1,600 Convertible preferred stock Â Â Preferred stock, shares issued (in shares) 5,003 5,003 Preferred stock, shares outstanding (in shares) 5,003 5,003 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income and revenues: Â Â Â Â Income from purchased receivables $ 6,463 Â $ 11,895 Â Revenue from contracts with customers 25 $ 225 6,050 $ 1,350 Revenue recognized under units-of-revenue method 709 605 1,828 1,575 Total income and revenues 7,197 830 19,773 2,925 Operating expenses: Â Â Â Â Research and development 817 25 2,011 118 General and administrative 8,020 6,368 27,485 18,341 Royalty purchase agreement asset impairment 14,000 Â 23,000 1,575 Arbitration settlement costs Â Â Â 4,132 Amortization of intangible assets Â 224 Â 673 Total operating expenses 22,837 6,617 52,496 24,839 Loss from operations (15,640) (5,787) (32,723) (21,914) Other income (expense): Â Â Â Â Gain on the acquisition of Kinnate Â Â 19,316 Â Change in fair value of embedded derivative related to RPA Â Â 8,100 Â Interest expense (3,493) Â (10,446) Â Other income (expense), net 1,890 278 5,900 1,192 Net loss (17,243) (5,509) (9,853) (20,722) Net loss attributable to common stockholders, basic (18,611) (6,877) (13,957) (24,826) Net loss attributable to common stockholders, diluted $ (18,611) $ (6,877) $ (13,957) $ (24,826) Net loss per share attributable to common stockholders, Basic (in dollars per share) $ (1.59) $ (0.60) $ (1.20) $ (2.17) Net loss per share attributable to common stockholders, Diluted (in dollars per share) $ (1.59) $ (0.60) $ (1.20) $ (2.17) Weighted average shares used in computing net loss per share attributable to common stockholders, Basic 11,712 11,473 11,645 11,466 Weighted average shares used in computing net loss per share attributable to common stockholders, Diluted 11,712 11,473 11,645 11,466 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainOnDerivative Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit

outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_GainLossRelatedToLitigationSettlement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGain (loss) included in earnings resulting from the asset acquisition. + ReferencesNo definition available. + Details Name: xoma_GainLossOnAssetAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment. + ReferencesNo definition available. + Details Name: xoma_ImpairmentOfLongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income that is not accounted for under Topic 606, in accordance with the effective interest rate method and the cost recovery method. + ReferencesNo definition available. + Details Name: xoma_IncomeNotFromContractWithCustomerEffectiveInterestRateMethodAndCostRecoveryMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606, in accordance with the units-of-revenue method. + ReferencesNo definition available. + Details Name: xoma_RevenueNotFromContractWithCustomerUnitsOfRevenueMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Â Â Â Â Â Net Income (Loss) $ (17,243) $ (5,509) $ (9,853) $ (20,722) Net unrealized gain on available-for-sale debt securities 104 Â 104 Â Comprehensive loss $ (17,139) $ (5,509) $ (9,749) $ (20,722) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Preferred Stock Series A Preferred Stock Series B Preferred Stock Convertible preferred stock Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Income Accumulated Deficit Total Balance at beginning of period at Dec. 31, 2022 $ 49 Â Â $ 86 $ 1,306,271 Â $ (1,182,392) $ 124,014 Balance at beginning of period (in shares) at Dec. 31, 2022 984,000 2,000 5,000 11,454,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Issuance of common stock related to 401(k) contribution Â Â Â Â 123 Â Â 123 Issuance of common stock related to 401(k) contribution (in shares) Â Â Â 7,000 Â Â Â Â Stock-based compensation expense Â Â Â Â 1,570 Â Â 1,570 Preferred stock dividends Â Â Â Â (1,368) Â Â (1,368) Net income (loss) Â Â Â Â Â Â (9,813) (9,813) Balance at end of period at Mar. 31, 2023 $ 49 Â Â $ 86 1,306,596 Â (1,192,205) 114,526 Balance at end of period (in shares) at Mar. 31, 2023 984,000 2,000 5,000 11,461,000 Â Â Â Â Balance at beginning of period at Dec. 31, 2022 $ 49 Â Â $ 86 1,306,271 Â (1,182,392) 124,014 Balance at beginning of period (in shares) at Dec. 31, 2022 984,000 2,000 5,000 11,454,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Net income (loss) Â Â Â Â Â Â Â (20,722) Balance at end of period at Sep. 30, 2023 $ 49 Â Â $ 86 1,308,943 Â (1,203,114) 105,964 Balance at end of period (in shares) at Sep. 30, 2023 984,000 2,000 5,000 11,472,000 Â Â Â Â Balance at beginning of period at Dec. 31, 2022 $ 49 Â Â $ 86 1,306,271 Â (1,182,392) 124,014 Balance at beginning of period (in shares) at Dec. 31, 2022 984,000 2,000 5,000 11,454,000 Â Â Â Â Balance at end of period at Dec. 31, 2023 $ 49 Â Â $ 86 1,311,809 Â (1,223,223) 88,721 Balance at end of period (in shares) at Dec. 31, 2023 984,000 2,000 5,000 11,495,000 Â Â Â Â Balance at beginning of period at Mar. 31, 2023 $ 49 Â Â $ 86 1,306,596 Â (1,192,205) 114,526 Balance at beginning of period (in shares) at Mar. 31, 2023 984,000 2,000 5,000 11,461,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Exercise of stock options Â Â Â Â 153 Â Â 153 Exercise of stock options (in shares) Â Â Â 8,000 Â Â Â Â Issuance of common stock related to ESPP Â Â Â Â 50 Â Â 50 Issuance of common stock related to ESPP (in shares) Â Â Â 3,000 Â Â Â Â Stock-based compensation expense Â Â Â Â 2,163 Â Â 2,163 Preferred stock dividends Â Â Â Â (1,368) Â Â (1,368) Net income (loss) Â Â Â Â Â Â (5,400) (5,400) Balance at end of period at Jun. 30, 2023 $ 49 Â Â $ 86 1,307,594 Â (1,197,605) 110,124 Balance at end of period (in shares) at Jun. 30, 2023 984,000 2,000 5,000 11,472,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â Â 2,717 Â Â 2,717 Preferred stock dividends Â Â Â Â (1,368) Â Â (1,368) Net income (loss) Â Â Â Â Â Â (5,509) (5,509) Balance at end of period at Sep. 30, 2023 $ 49 Â Â $ 86 1,308,943 Â (1,203,114) 105,964 Balance at end of period (in shares) at Sep. 30, 2023 984,000 2,000 5,000 11,472,000 Â Â Â Â Balance at beginning of period at Dec. 31, 2023 $ 49 Â Â $ 86 1,311,809 Â (1,223,223) 88,721 Balance at beginning of period (in shares) at Dec. 31, 2023 984,000 2,000 5,000 11,495,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Exercise of stock options Â Â Â $ 1 621 Â Â 622 Exercise of stock options (in shares) Â Â Â 135,000 Â Â Â Â Issuance of common stock related to 401(k) contribution Â Â Â Â 118 Â Â 118 Issuance of common stock related to 401(k) contribution (in shares) Â Â Â 7,000 Â Â Â Â Stock-based compensation expense Â Â Â Â 2,856 Â Â 2,856 Preferred stock dividends Â Â Â Â (1,368) Â Â (1,368) Repurchase of common stock Â Â Â Â Â Â (13) (13) Repurchase of common stock (in shares) Â Â Â (1,000) Â Â Â Â Net income (loss) Â Â Â Â Â Â (8,595) (8,595) Balance at end of period at Mar. 31, 2024 $ 49 Â Â $ 87 1,314,036 Â (1,231,831) 82,341 Balance at end of period (in shares) at Mar. 31, 2024 984,000 2,000 5,000 11,636,000 Â Â Â Â Balance at beginning of period at Dec. 31, 2023 $ 49 Â Â $ 86 1,311,809 Â (1,223,223) $ 88,721 Balance at beginning of period (in shares) at Dec. 31, 2023 984,000 2,000 5,000 11,495,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Exercise of stock options (in shares) Â Â Â Â Â Â Â 246,599 Repurchase of common stock Â Â Â Â Â Â Â $ (13) Repurchase of common stock (in shares) Â Â Â Â Â Â Â (660) Net unrealized gain on available-for-sale debt securities Â Â Â Â Â Â Â $ 104 Net income (loss) Â Â Â Â Â Â Â (9,853) Balance at end of period at Sep. 30, 2024 $ 49 Â Â $ 88 1,317,657 $ 104 (1,233,089) 84,809 Balance at end of period (in shares) at Sep. 30, 2024 984,000 2,000 5,000 11,755,000 Â Â Â Â Balance at beginning of period at Mar. 31, 2024 $ 49 Â Â $ 87 1,314,036 Â (1,231,831) 82,341 Balance at beginning of period (in shares) at Mar. 31, 2024 984,000 2,000 5,000 11,636,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Exercise of stock options Â Â Â Â 250 Â Â 250 Exercise of stock options (in shares) Â Â Â 15,000 Â Â Â Â Issuance of common stock related to ESPP Â Â Â Â 95 Â Â 95 Issuance of common stock related to ESPP (in shares) Â Â Â 7,000 Â Â Â Â Stock-based compensation expense Â Â Â Â 2,690 Â Â 2,690 Preferred stock dividends Â Â Â Â (1,368) Â Â (1,368) Net income (loss) Â Â Â Â Â Â 15,985 15,985 Balance at end of period at Jun. 30, 2024 $ 49 Â Â $ 87 1,315,703 Â (1,215,846) 99,993 Balance at end of period (in shares) at Jun. 30, 2024 984,000 2,000 5,000 11,658,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Â Â Â Exercise of stock options Â Â Â $ 1 732 Â Â 733 Exercise of stock options (in shares) Â Â Â 97,000 Â Â Â Â Stock-based compensation expense Â Â Â Â 2,590 Â Â 2,590 Preferred stock dividends Â Â Â Â (1,368) Â Â $ (1,368) Repurchase of common stock (in shares) Â Â Â Â Â Â 0 Net unrealized gain on available-for-sale debt securities Â Â Â Â Â 104 Â $ 104 Net income (loss) Â Â Â Â Â Â (17,243) (17,243) Balance at end of period at Sep. 30, 2024 $ 49 Â Â $ 88 $ 1,317,657 $ 104 $ (1,233,089) $ 84,809 Balance at end of period (in shares) at Sep. 30, 2024 984,000 2,000 5,000 11,755,000 Â Â Â Â X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -

Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (9,853) $ (20,722) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Income from purchased receivables under effective interest rate method (9,985) Â Stock-based compensation expense 8,136 6,450 Royalty purchase agreement asset impairment 23,000 1,575 Gain on the acquisition of Kinnate (19,316) Â Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs Â (75) Common stock contribution to 401(k) 118 123 Amortization of intangible assets Â 673 Depreciation 8 2 Accretion of long-term debt discount and debt issuance costs 996 Â Non-cash lease expense 45 115 Change in fair value of equity securities (624) 121 Change in fair value of available-for-sale debt securities classified as cash equivalents 104 Â Changes in assets and liabilities: Â Â Trade and other receivables, net (41) (42) Prepaid expenses and other assets (72) (202) Accounts payable and accrued liabilities (1,348) (554) Operating lease liabilities (185) (120) Unearned revenue recognized under units-of-revenue method (1,828) (1,575) Net cash used in operating activities (10,845) (14,231) Cash flows from investing activities: Â Â Net cash acquired in Kinnate acquisition 18,926 Â Payments of consideration under RPAs, AAAs and CPPAs (37,000) (14,650) Receipts under RPAs, AAAs and CPPAs 26,263 8,428 Purchase of property and equipment (17) Â Net cash provided by (used in) investing activities 8,172 (6,222) Cash flows from financing activities: Â Â Principal payments - debt (6,902) Â Debt issuance costs and loan fees paid in connection with long-term debt (740) Â Payment of preferred stock dividends (4,104) (4,104) Repurchases of common stock (13) Â Proceeds from exercise of options and other share-based compensation 4,127 208 Taxes paid related to net share settlement of equity awards (2,429) (5) Net cash used in financing activities (10,061) (3,901) Net decrease in cash, cash equivalents and restricted cash (12,734) (24,354) Cash, cash equivalents and restricted cash as of the beginning of the period 159,550 57,826 Cash, cash equivalents and restricted cash as of the end of the period 146,816 33,472 Supplemental Cash Flow Information: Â Â Cash paid for interest 9,985 Â Right-of-use assets obtained in exchange for operating lease liabilities Â 85 Non-cash investing and financing activities: Â Â Estimated initial fair value of the Exarafenib milestone asset in Kinnate acquisition 2,922 Â Estimated initial fair value of the Exarafenib milestone contingent consideration in Kinnate acquisition 2,922 Â Right-of-use assets obtained in exchange for operating lease liabilities in Kinnate acquisition 824 Â Relative fair value basis reduction of right-of-use assets in Kinnate acquisition (824) Â Accrual of contingent consideration under the Affitech CPPA 3,000 3,000 Accrual of contingent consideration under the LadRx AAA 1,000 Â Estimated fair value of contingent consideration under the LadRx Agreements Â 1,000 Preferred stock dividend accrual $ 1,368 $ 1,368 X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationNonproduction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 405 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_DividendsPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan and debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccrual of contingent consideration under assignment and assumption agreement. + ReferencesNo definition available. + Details Name: xoma_AccrualOfContingentConsiderationUnderAssignmentAndAssumptionAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAccrual of contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. + ReferencesNo definition available. + Details Name: xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liability recognized from milestone contingent consideration in asset acquisition, classified as noncurrent. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionMilestoneContingentConsiderationLiabilityNoncurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow associated with the acquisition of asset during the period. + ReferencesNo definition available. + Details Name: xoma_CashAcquiredFromAssetAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in fair value of available-for-sale debt securities classified as cash equivalents. + ReferencesNo definition available. + Details Name: xoma_ChangeInFairValueOfAvailableForSaleDebtSecuritiesCashEquivalents Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChanges in estimated fair value of contingent consideration. + ReferencesNo definition available. + Details Name: xoma_ChangesInEstimatedFairValueOfContingentConsideration Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDefined contribution plan issuance of Common stock for services or claims. + ReferencesNo definition available. + Details Name: xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEstimated fair value of contingent consideration under asset acquisition agreements. + ReferencesNo definition available. + Details Name: xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe fair value of milestone assets acquired in noncash investing or financing activities. + ReferencesNo definition available. + Details Name: xoma_FairValueOfAssetsAcquiredMilestoneAsset Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) included in earnings resulting from the asset acquisition. + ReferencesNo definition available. + Details Name: xoma_GainLossOnAssetAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment. + ReferencesNo definition available. + Details Name: xoma_ImpairmentOfLongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease in short-term rights receivable due to income from purchased receivables under effective interest rate method. + ReferencesNo definition available. + Details Name: xoma_IncomeFromPurchasedReceivablesUnderEffectiveInterestRateMethodCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value basis reduction of right-of-use assets in in acquisition. +

ReferencesNo definition available. + Details Name: xoma_OperatingLeaseFairValueBasisReductionInRightOfUseAssetsInAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOperating lease payments, non cash. + ReferencesNo definition available. + Details Name: xoma_OperatingLeasePaymentsNonCash Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRight-of-use assets obtained in exchange for operating lease liabilities in acquisition. + ReferencesNo definition available. + Details Name: xoma_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesInAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + ReferencesNo definition available. + Details Name: xoma_ReceiptsUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 9 Months Ended Sep. 30, 2024 Description of Business Â Description of Business 1. Description of BusinessXOMA Royalty Corporation, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. On July 10, 2024, the Company changed its name from XOMA Corporation to XOMA Royalty Corporation. The Companyâ€™s portfolio was built through the acquisition of rights to future milestone payments, royalties, and commercial payments, since its royalty aggregator business model was implemented in 2017, combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Companyâ€™s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. XOMA also acquires milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to the Company in a relatively short timeframe. The Company expects most of its future income and revenue to be based on milestone payments the Company may receive for milestones and royalties associated with these programs. Liquidity and Financial ConditionThe Company has incurred significant operating losses and negative cash flows from operations since its inception. As of September 30, 2024, the Company had cash, cash equivalents, andÂ restricted cash of $146.8 million primarily related to financing cash inflows received in December 2023 pursuant to the Blue Owl Loan Agreement (see Note 8).Based on the Companyâ€™s current cash balance and its planned spending, such as on royalties and other acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations, Â commitments, and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Basis of Presentation and Significant Accounting Policies Â Basis of Presentation and Significant Accounting Policies 2. Basis of Presentation and Significant Accounting PoliciesBasis of PresentationThe condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to FormÂ 10-Q and ArticleÂ 10 of Regulation S-X for interim financial reporting. As permitted under those rules,Â certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscalÂ year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Companyâ€™s Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31, 2023, filed with the SEC on MarchÂ 8, 2024.These condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Companyâ€™s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the fullÂ year, or for any other future annual or interim period.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to income from purchased receivables, revenue from contracts with customers, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, projected cash flows associated with income under the EIR method, the Exarafenib milestone asset and contingent consideration, legal contingencies, contingent consideration for purchased receivables, amortization of the Blue Owl Loan, accrued expenses, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.Actual results may differ significantly from these estimates, including estimates such as the Companyâ€™s income from purchased receivables, amortization of the payments received from HCRP, and amortization of the Blue Owl Loan. Estimates related to income from purchased receivables is based on the best information available to the Company from its partners or other third parties and changes in expected cash flows for royalty and commercial receivables under the EIR method. Any changes to the estimated payments made by partners can result in a material adjustment to income reported. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The Companyâ€™s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported. Cash, Cash Equivalents, andÂ Restricted Cash The following table provides a reconciliation of cash, cash equivalents, andÂ restricted cash reported within the condensed consolidated statements of cash flows (in thousands):
â€‹â€‹â€‹

contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be oneÂ year or less.The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.License of Intellectual PropertyIf the license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process, and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Companyâ€™s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Companyâ€™s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process, and know-how (i.e., at a point in time). Deferred revenue is recorded when upfront payments and fees are received prior to the satisfaction of performance obligations. Trade and other receivables, net is recorded when the Company has an unconditional right to consideration.Milestone PaymentsAt the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.RoyaltiesFor arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)Â when the related sales occur, or (ii)Â when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).Revenue Recognized under Units-of-Revenue MethodThe Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the periodâ€™s cash payment.Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Companyâ€™s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.Stock-Based CompensationThe Company recognizes compensation expense for all stock-based payment awards made to the Companyâ€™s employees, consultants, and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility, and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations, and volatility. The estimate of expected volatility is based on the Companyâ€™s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The valuation of RSUs is determined at the date of grant using the Companyâ€™s closing stock price.The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.Equity SecuritiesThe Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations in the period of sale.Asset AcquisitionsAs a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If the screen test is not met, the Company then further evaluates whether the assets or group of assets includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. If the fair value of net assets acquired, after allocating the excess of the fair value of net assets acquired to certain qualifying assets, exceeds the total cost of the acquisition, a bargain purchase gain is recognized in other income in the condensed consolidated statements of operations.Contingent payments in asset acquisitions are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that are related to IPR&D assets are expensed as incurred. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. Cash payments related to acquired assets are reflected as an investing cash flow in the Companyâ€™s condensed consolidated statements of cash flows. Leases The Company leases its headquarters in Emeryville, California and acquired a lease from the Kinnate acquisition. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. For leases acquired in asset acquisitions, the Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the acquisition date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in G&A expense in the condensed consolidated statements of operations.The Company has elected the practical expedient to not separate lease and non-lease components. The Companyâ€™s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.Long-Term DebtLong-term debt represents the Companyâ€™s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the EIR method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the EIR method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.Warrants The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Companyâ€™s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility, and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Companyâ€™s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.Income TaxesThe Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.The recognition, derecognition and measurement of a tax position is based on managementâ€™s best judgment given the facts, circumstances, and information available at each reporting date. The Companyâ€™s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.Net Income (Loss) per Share Available to (Attributable to) Common StockholdersThe Company calculates basic and diluted income (loss) per share available to (attributable to) common stockholders using the two-class method. The Companyâ€™s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Companyâ€™s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income available to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income (loss) per share available to (attributable to) common stockholders is then calculated by dividing the net income (loss) available to (attributable to) common stockholders by the weighted-average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted-average common shares outstanding.Diluted net income (loss) per share available to (attributable to) common stockholders is based on the weighted-average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Companyâ€™s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Companyâ€™s share price and, therefore, are not included in the diluted shares until the contingency is resolved.Share RepurchasesThe Company has a stock repurchase program that is executed through purchases made from time to time, including in the open market. The Company retires repurchased shares of common stock, reducing common stock with any excess of cost over par value recorded to accumulated deficit. Issued and outstanding shares of common stock are reduced by the number of shares repurchased. No treasury stock is recognized in the condensed consolidated financial statements. In August 2022, the IRA enacted a 1% excise tax on net share repurchases after December 31, 2022. Any excise tax incurred on share repurchases is recognized as part of the cost basis of the shares acquired.Concentration of RiskCash, cash equivalents, restricted cash, and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended September 30, 2024, three partners represented 75%, 14% and 10% of total income and revenues, respectively. For the nine months ended September 30, 2024, three partners represented 50%, 25% and 10% of total income and revenues, respectively. For the three months ended September 30, 2023, two partners represented 73% and 24% of total income and revenues, respectively. For the nine months ended September 30, 2023, two partners represented 54% and 44% of total income and revenues, respectively. One partner represented 96% of the trade and other receivables, net as of September 30, 2024. One partner represented 100% of the trade and other receivables, net as of December 31, 2023.Comprehensive Income (Loss)Comprehensive income (loss) is comprised of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholdersâ€™ equity but are excluded from net income (loss).Accounting Pronouncements Recently AdoptedIn November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2024. â€‹Recent Accounting Pronouncements Not Yet AdoptedIn October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commissionâ€™s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures. â€‹In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures. X - ReferencesNo definition available. + Details Name: us-

gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statements Details 9 Months Ended Sep. 30, 2024 Condensed Consolidated Financial Statement Details Â Condensed Consolidated Financial Statements Detail 3.Â Condensed Consolidated Financial Statements DetailsEquity SecuritiesAs of September 30, 2024 and December 31, 2023, equity securities consisted of an investment in Rezoluteâ€™s common stock of $0.8 million and $0.2 million, respectively (see Note 4). For the three and nine months ended September 30, 2024, the Company recognized a gain of $0.1 million and $0.6 million, respectively, due to the change in fair value of its investment in Rezoluteâ€™s common stock, which is included in the other income (expense), net line item of the condensed consolidated statements of operations. For both the three and nine months ended September 30, 2023, the Company recognized a loss of $0.1 million due to the change in fair value of its investment in Rezolute.â€‹â€‹Accrued and Other LiabilitiesAccrued and other liabilities consisted of the following (in thousands):
â€‹â€‹â€‹

of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities.The license agreement was subsequently amended in 2018, 2019, and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezoluteâ€™s equity financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezoluteâ€™s common stock (as adjusted for the 1:50 reverse stock split in October 2020). In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended. In April 2024, Rezolute dosed the first patient in its Phase 3 trial of RZ358 and the Company earned a $5.0 million milestone pursuant to the Rezolute License Agreement, as amended.As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized zero and $5.0 million in revenue from contracts with customers related to this arrangement during the three and nine months ended September 30, 2024. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2023.JanssenIn August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMAâ€™s patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssenâ€™s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive a 0.75% royalty on net sales of each product. Janssenâ€™s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement. The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. The Company concluded that the development and regulatory milestone payments are solely dependent on Janssenâ€™s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024. The Company recognized $0.2 million and $1.3 million in revenue from contracts with customers related to this arrangement during the three and nine months ended September 30, 2023.NovartisÂ â€“ Anti-TGFÎ² Antibody (NIS793)On SeptemberÂ 30, 2015, the Company and Novartis entered into the Anti-TGFÎ² Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Companyâ€™s anti-transforming growth factor beta (â€œTGFÎ²â€) antibody program (now â€œNIS793â€). Under the terms of the Anti-TGFÎ² Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFÎ² Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartisâ€™ royalty obligations end. The Anti-TGFÎ² Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFÎ² Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon 180 daysâ€™ notice.The Company concluded that there were multiple promised goods and services under the Anti-TGFÎ² Antibody License Agreement, including the transfer of license, regulatory services, and transfer of materials, process, and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of DecemberÂ 31, 2015.The Company was eligible to receive up to a total of $480.0 million in development, regulatory, and commercial milestones under the Anti-TGFÎ² Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFÎ² Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.The Company concluded that the development and regulatory milestone payments are solely dependent on Novartisâ€™ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartisâ€™ obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.In August 2023, Novartis communicated to the Company its intent to discontinue development activities related to NIS793. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023.NovartisÂ â€“ Anti-IL-1Î² Antibody (VPM087) On AugustÂ 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (â€œVPM087â€), a novel anti-Interleukin-1 (â€œIL-1â€) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. On AugustÂ 24, 2017, pursuant to a separate agreement (the â€œIL-1 Target License Agreementâ€), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the â€œExclusivity Optionâ€) to such intellectual property for the treatment and prevention of cardiovascular disease.Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to â‚¬12.0 million) was paid by Novartis, on behalf of the Company, to settle the Companyâ€™s outstanding debt with Les Laboratories Servier (the â€œServier Loanâ€). In addition, Novartis extended the maturity date on the Companyâ€™s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Companyâ€™s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on AugustÂ 24, 2017, resulting in a $0.2 million premium paid to the Company.Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory, and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Companyâ€™s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartisâ€™ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six monthsâ€™ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials, and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During theÂ year ended DecemberÂ 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority.The Company concluded that the development and regulatory milestone payments are solely dependent on Novartisâ€™ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023.Sale of Future Revenue StreamsOn DecemberÂ 21, 2016, the Company entered into two royalty interest sale agreements (together, the â€œRoyalty Sale Agreementsâ€) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated AugustÂ 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018, and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in DecemberÂ 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated OctoberÂ 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Companyâ€™s limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Companyâ€™s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under â€œunits-of-revenueâ€ method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the periodâ€™s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.The Company recognized $0.7 million and $1.8 million in revenue under the units-of-revenue method under these arrangements during the three and nine months ended September 30, 2024, respectively. The Company recognized $0.6 million and $1.6 million in revenue under the units-of-revenue method under these arrangements during the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the current and non-current portions of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $5.6 million, respectively. As of DecemberÂ 31, 2023, the Company classified $2.1 million and $7.2 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. X - ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionsLicensingAndOtherArrangementsAbstract Namespace Prefix: xoma_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for asset acquisitions, licensing and other arrangements. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionsLicensingAndOtherArrangementsTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements 9 Months Ended Sep. 30, 2024 Royalty and Commercial Payment Purchase Agreements Â Royalty and Commercial Payment Purchase Agreements 5. Royalty and Commercial Payment Purchase AgreementsShort-term royalty and commercial payment receivables were $12.7 million and $14.2 million as of September 30, 2024 and December 31, 2023, respectively. Long-term royalty and commercial payment receivables were $54.2 million and $58.0 million as of September 30, 2024 and December 31, 2023, respectively. DarÃ© Royalty Purchase AgreementsOn April 29, 2024, the Company entered into the DarÃ© RPAs. Pursuant to the terms of the DarÃ© RPAs, the Company paid $22.0 million in cash to DarÃ© in consideration for the sale of (a) 100% of all remaining royalties related to XACIATO not already subject to the royalty-backed financing agreement DarÃ© entered into in December 2023 and net of payments owed by DarÃ© to upstream licensors, which equates to royalties ranging from low to high single digits, and of all potential commercial milestones related to XACIATO that are payable to DarÃ© under the DarÃ© Organon License Agreement; (b) a 4% synthetic royalty on net sales of OVAPRENE and a 2% synthetic royalty on net sales of Sildenafil Cream, which will decrease to 2.5% and 1.25%, respectively, upon the Company achieving a pre-specified return threshold; and (c) a portion of DarÃ©â€™s right to a certain milestone payment that may become payable to DarÃ© under the Bayer License Agreement. The DarÃ© RPAs also provide for milestone payments to DarÃ© of $11.0 million for each successive $22.0 million received by the Company under the DarÃ© RPAs after achievement of a return threshold of $88.0 million. Upon closing of the transaction, the Company paid DarÃ© an upfront payment of $22.0 million, which was recorded as long-term royalty and commercial payment receivables in its condensed consolidated balance sheet. The Company concluded that the milestone payments to DarÃ© did not meet the definition of a derivative under ASC 815 and expects to recognize the milestone payments as liabilities when probable and estimable.Given the limited available information, the Company was unable to reliably estimate future net sales and the commercial payments to be received over the twelve-month period following the quarter ended September 30, 2024 and, as such, no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024.During the nine months ended September 30, 2024, the Company received de minimis commercial payments pursuant to the DarÃ© RPAs. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance.Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected.Â The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024.Talphera Commercial Payment Purchase AgreementDSUVIA was approved by the FDA in 2018 for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales of DSUVIA and up to $116.5 million in sales-based milestone payments under the Talphera APA. In addition,

Talphera is entitled to 75% of net sales of DSUVIA to the DoD for its services performed to support sales of DSUVIA to the DoD under the Talphera Marketing Agreement. On January 12, 2024, the Company entered into the Talphera CPPA, pursuant to which XOMA will receive (i) 100% of the 15% royalty on commercial net sales and the sales-based milestones related to net sales of DSUVIA for sales made on and after January 1, 2024, and (ii) 100% of Talpheraâ€™s future service revenue in the amount of 75% of net sales of DSUVIA to the DoD, until the Company receives $20.0 million. Thereafter, the Company will fully retain the 15% royalty on commercial net sales of DSUVIA and will share equally with Talphera the 75% of net sales of DSUVIA to the DoD and the remaining sales-based milestone payments due from Alora.Upon closing of the transaction, the Company paid Talphera an upfront payment of $8.0 million, which was recorded as long-term royalty and commercial payment receivables in its consolidated balance sheet. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Talphera CPPA of $80,000. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance.Given the limited available information, the Company was unable to reliably estimate future net sales and the commercial payments to be received over the twelve-month period following the quarter ended September 30, 2024 and, as such, no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024.Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected.Â The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024.LadRx AgreementsOn June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title, and interest related to arimoclomol under the Zevra APA between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory, and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under the ImmunityBio License Agreement between ImmunityBio and LadRx. On June 3, 2024, the ImmunityBio License Agreement was terminated, and the Company entered into an amendment to the LadRx RPA. Under the LadRx RPA, as amended, the Company is eligible to receive potential low single-digit percentage royalty payments on aggregate net sales of aldoxorubicin. Additionally, the amendment removed the remaining $4.0 million regulatory milestone payment under the original agreement that had been contingent upon the achievement of a specified regulatory milestone for the product candidate related to aldoxorubicin, which initially and as of the amendment date had a fair value of zero. If LadRx licenses aldoxorubicin to an applicable third party, the Company is eligible to receive potential high single-digit percentage royalty payments on aggregate net sales of aldoxorubicin and a portion of any potential future milestone payments.Upon the initial closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and could have been required to pay up to an additional $6.0 million in regulatory and commercial sales milestone payments which included $5.0 million related to regulatory milestone payments and $1.0 million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx Agreements, the Company made a $1.0 million milestone payment to LadRx in January 2024.On September 20, 2024, Zevra announced that the FDA granted approval to Zevraâ€™s NDA for MIPLYFFA. The achievement of the commercial milestone payment under the LadRx AAA was considered probable as of September 30, 2024, and the Company recognized a $1.0 million contingent liability.As of September 30, 2024, the Company recorded $2.2 million as short-term royalty and commercial payment receivables related to the net proceeds receivable for the milestone payment associated with the FDA approval of MIPLYFFA. Given the limited available information, the Company was unable to reliably estimate its royalty payment stream from future net sales, and therefore no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Aptevo Commercial Payment Purchase Agreement On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. The Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables in its consolidated balance sheet which included a $9.6 million upfront payment and a $50,000 one-time payment, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet at inception. The Company paid the one-time payment of $50,000 in June 2023 when related receipts exceeded $0.5 million. During the year ended December 31, 2023, the Company received total commercial payments pursuant to the Aptevo CPPA of $1.7 million. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Aptevo CPPA of $0.8 million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance. Though the Company is unable to reliably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it estimates the short-term portion of the receivables balance based on the past 12 monthsâ€™ receipts. As such, as of September 30, 2024 and December 31, 2023, the Company recorded $2.2 million and $2.0 million, respectively, as short-term royalty and commercial payment receivables.Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected.Â The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Palobiofarma Royalty Purchase Agreement On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkinâ€™s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis, and nonalcoholic steatohepatitis and other indications that are being developed by Palo. Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $10.0 million payment at the close of the transaction, which occurred simultaneously upon partiesâ€™ entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. As of September 30, 2024, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Viracta Royalty Purchase Agreement On March 22, 2021, the Company entered into the Viracta RPA, as amended March 4, 2024, pursuant to which the Company acquired the right to receive future royalties, milestone payments, and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma LLC. The Company acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and a portion of potential other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones, and high single-digit royalties on sales related to vosaroxin, if approved. At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. On October 30, 2023, the Company earned a $5.0 million milestone payment pursuant to the Viracta RPA related to the FDAâ€™s acceptance of Day Oneâ€™s NDA for OJEMDA. In accordance with the cost recovery method, the $5.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivables balance.On April 23, 2024, Day One announced that the FDA granted approval to Day Oneâ€™s NDA for OJEMDA. Pursuant to the Viracta RPA, the Company earned a $9.0 million milestone payment upon FDA approval and is also eligible to receive mid-single-digit royalties on sales of OJEMDA. In accordance with the cost recovery method, $8.5 million of the milestone payment was recorded as a direct reduction of the remaining recorded long-term royalty receivables balance and the excess balance of $0.5 million was recorded as income from purchased receivables in the condensed consolidated statement of operations for the nine months ended September 30, 2024. On May 30, 2024, Day One announced that it sold its priority review voucher to an undisclosed buyer for $108.0 million. Pursuant to the Viracta RPA, the Company received a payment of $8.1 million related to the sale. The rights to proceeds upon the sale of the priority review voucher was determined to be an embedded derivative which had no value prior to FDA approval of OJEMDA. The Company recorded a change in the fair value of the embedded derivative of $8.1 million in other income in the condensed consolidated statement of operations for the nine months ended September 30, 2024.As of June 30, 2024, the Company had fully collected the purchase price recorded in long-term royalty and commercial payment receivables related to the Viracta RPA in its consolidated balance sheet and, as such, subsequent royalties received are recorded as income from purchased receivables. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023. As there was no remaining balance in long-term royalty and commercial payment receivables related to the Viracta RPA in its consolidated balance sheet as of September 30, 2024, the Company did not need to perform its periodic impairment assessment for the three months ended September 30, 2024.As of September 30, 2024, there was $1.0 million in trade and other receivables, net related to this arrangement. As of December 31, 2023, there was no trade and other receivables, net related to this arrangement. The Company recognized $1.0 million and $1.9 million in income from purchased receivables related to this arrangement during the three and nine months ended September 30, 2024. The Company did not recognize any income related to this arrangement during the three and nine months ended September 30, 2023.Kuros Royalty Purchase Agreement On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticalsâ€™ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestone payments. At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals, Inc. resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivables balance. As of September 30, 2024, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments, and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Affitech Commercial Payment Purchase Agreement On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Rocheâ€™s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million upfront payment and $8.0 million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Commercial payments are due from Roche to the Company within 60 days of December 31 and June 30 of each year. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone payment tied to the U.S. marketing approvals and a $3.0 million milestone payment tied to the EC approvals. The achievement of the first and second sales-based milestone payments under the Affitech CPPA was considered probable as of December 31, 2023, and as such the Company recognized a $6.0 million contingent liability in contingent consideration under RPAs, AAAs, and CPPAs in its consolidated balance sheet. The sales milestones were achieved in 2023 and in the first quarter of 2024, the Company paid Affitech $6.0 million and the related contingent liability balance was reduced to zero. Based on reported first quarter of 2024 sales of VABYSMO, the achievement of the third sales-based milestone payment under the Affitech CPPA was considered probable as of March 31, 2024, and the Company recognized a $3.0 million contingent liability which remained on the condensed consolidated balance sheet as of September 30, 2024.Historically, the Company had been unable to reliably estimate its commercial payment stream from future net sales and the related commercial payments to be received under the Affitech CPPA. However, Rocheâ€™s periodically reported VABYSMO sales data, available third-party sales projections, and the Companyâ€™s history of receipts of commercial payments related to VABYSMO have provided the Company with a greater ability to estimate future net sales and the commercial payments to be received under the Affitech CPPA. Therefore, as of April 1, 2024, the Company began accounting for the receivable which had a carrying amount of $7.8 million using the EIR method on a prospective basis. As a result, the Company recognized $5.4 million and $10.0 million in income from purchased receivables during the three and nine months ended September 30, 2024.During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Affitech CPPA of $16.9 million.The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023.Agenus Royalty Purchase Agreement On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (â€œIncyteâ€) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory, and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales. In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and 10% of all future developmental, regulatory, and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on a low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Companyâ€™s share in future potential development, regulatory, and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone payment under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivables balance. Based on updates received in July 2024, the Company evaluated the status of the program for potential impairment in the third quarter of 2024 and determined no payments were probable to be received under the Agenus RPA as of September 30, 2024. Accordingly, the Company recorded an impairment of $14.0 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and an allowance for credit losses of $14.0 million, which consisted of a $14.0 million reduction in the net carrying value of long-term royalty receivables related to the Agenus RPA. As the impaired amount was not expected to be collected, the long-term royalty receivables were written off. There was no allowance

for credit losses recorded as of December 31, 2023. Aronora Royalty Purchase Agreement On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the â€œNon-Royaltiesâ€) related to five anti-thrombotic hematology product candidates. Three candidates were subject to Aronoraâ€™s collaboration with Bayer (the â€œBayer Productsâ€), including one which was subject to an exclusive license option by Bayer. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products. The Company was eligible to receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the â€œnon-Bayer Productsâ€) for which the Company will receive a low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Companyâ€™s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. On April 8, 2024, Bayer terminated its license agreement with Aronora.Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the â€œAronora Contingent Considerationâ€). Pursuant to the Aronora RPA, if the Company receives at least $25.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the â€œRoyalty Milestonesâ€).Â The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.Â Royalties per product in excess of $250.0 million are retained by the Company. At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable.As of September 30, 2024, no payments were probable to be received under the Aronora RPA. Based on communications in April 2024, the Company evaluated the status of the partnered programs for potential impairment in the second quarter of 2024 and recorded an impairment of $9.0 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and an allowance for credit losses of $9.0 million, which consisted of a $9.0 million reduction in the net carrying value of long-term royalty receivables related to the Aronora RPA. As the impaired amount was not expected to be collected, the long-term royalty receivables were written off. There was no allowance for credit losses recorded as of December 31, 2023.The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the nine months ended September 30, 2024 (in thousands): â€‹â€‹â€‹

million and $0.6 million, respectively. As of December 31, 2023, the Companyâ€™s current and non-current operating lease liabilities were $0.1 million and $0.3 million, respectively. The following table summarizes the cost components of the Companyâ€™s operating leases included in G&A in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands): â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023Lease costs:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating lease cost â€‹$ 36â€‹$ 17Â $ 97Â $ 116Variable lease cost (1)â€‹Â â€”â€‹Â 20Â â€‹ 18Â â€‹ 32Total lease costsâ€‹$ 36â€‹$ 37Â $ 115â€‹$ 148â€‹(1)Under the terms of the original, amended, and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.â€‹The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â Â Â 2024â€‹2023Cash paid for amounts included in the measurement of lease liabilitiesâ€‹Â â€‹â€‹Â â€‹Operating cash flows under operating leasesâ€‹$ 68â€‹$ 121â€‹The assumptions used in calculating the present value of the lease payments for the Companyâ€™s operating leases as of September 30, 2024 and December 31, 2023 were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹Â Â Â Â Â 2024â€‹2023Weighted-average remaining lease term â€‹2.7 yearsâ€‹â€‹5.33 yearsâ€‹Weighted-average discount rate â€‹ 8.18%â€‹ 8.50%â€‹Kinnate SubleaseAs part of the Kinnate Merger Agreement (Note 4), the Company acquired a lease assignment agreement with an assignee that expires on June 30, 2026. In accordance with ASC 842, the Company will account for the lease assignment as a sublease over its term. Under the terms of the lease assignment agreement, the assignee will make direct payments to the head lessor over the lease term. During the three and nine months ended September 30, 2024, the Company recognized sublease income of $0.1 million and $0.2 million in the other income (expense), net line item in the condensed consolidated statement of operations. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of information about leases. + ReferencesNo definition available. + Details Name: xoma_LeaseDisclosureTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt 9 Months Ended Sep. 30, 2024 Long-Term Debt Â Long-Term Debt 8. Long-Term Debt On December 15, 2023, XOMA transferred to XRL, a newly formed wholly-owned subsidiary, all its rights, title, and interest in the commercial payments from Rocheâ€™s VABYSMO under the Affitech CPPA and related assets (the â€œCommercial Paymentsâ€). The VABYSMO-related assets and rights transferred to XRL are referred to herein as the â€œTransferred Assets.â€Simultaneously, XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders, pursuant to which XRL was extended certain senior secured credit facilities in an aggregate principal amount of up to $140.0 million. The principal and interest of the loan are to be paid from the Commercial Payments. XRL is obligated to make semi-annual interest payments, starting in March 2024, at a fixed rate of 9.875% per annum until the commercial payment-backed loan is repaid, at which time the Commercial Payments will revert back to XOMA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any Commercial Payment in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. The loan matures on December 15, 2038, provided that XRL may repay it in full at any time prior to December 15, 2038, subject to the terms of the Blue Owl Loan Agreement. The Blue Owl Loan includes (i) an initial term loan in an aggregate principal amount equal to $130.0 million and (ii) a delayed draw term loan in an aggregate principal amount of $10.0 million to be funded at the option of the XRL upon receipt by the lenders of payments of principal and interest from the proceeds of Commercial Payments in excess of an agreed upon amount on or prior to March 15, 2026. The payment obligations under the Blue Owl Loan Agreement are limited to XRL, and Blue Owl has no recourse under the Blue Owl Loan Agreement against XOMA or any assets other than the Transferred Assets and XOMAâ€™s equity interest in XRL. In connection with the Blue Owl Loan Agreement, (i) XRL granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the Affitech CPPA and (b) all other assets of XRL and (ii) XOMA granted Blue Owl a first-priority perfected lien on, and security interest in, 100% of the equity of XRL. The Blue Owl Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl.On December 15, 2023, the Company borrowed the initial term loan of $130.0 million and received $119.6 million, net of $4.1 million in fees and lender expenses and $6.3 million that was deposited into reserve accounts to pay interest, administrative fees and XRLâ€™s operating expenses (see Note 2). The Company also incurred $0.6 million of direct issuance costs related to the Blue Owl Loan Agreement.In connection with the Blue Owl Loan Agreement, XOMA issued to Blue Owl and certain funds affiliated with Blue Owl warrants to purchase: (i) up to 40,000 shares of XOMAâ€™s common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of XOMAâ€™s common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of XOMAâ€™s common stock at an exercise price of $50.00 per share (collectively, the â€œBlue Owl Warrantsâ€). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $1.5 million. As of September 30, 2024, all Blue Owl Warrants were outstanding.The initial term loan of $130.0 million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the EIR was determined to be 11.01%. The Company recorded a debt discount of $5.3 million, which included $3.8 million in allocated fees and lender expenses and $1.5 million for the fair value of the Blue Owl Warrants. The Company also recorded $0.6 million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $5.3 million and $0.6 million of direct debt issuance costs over the expected term of the initial term loan.As of the closing date of December 15, 2023, the Company recorded the $0.3 million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of September 30, 2024, no amount had been drawn from the delayed draw term loan.The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively, as of December 31, 2023. The Company recorded $0.6 million in interest expense during the year ended December 31, 2023. In March 2024, XRL made a semi-annual payment of $7.4 million which included an interest payment of $3.8 million and principal repayment of $3.6 million. In September 2024, XRL made a semi-annual payment of $9.5 million which included an interest payment of $6.2 million and principal repayment of $3.3 million. The carrying value of the short and long-term portion of the initial term loan was $9.8 million and $108.1 million, respectively, as of September 30, 2024. As of September 30, 2024, the EIR was determined to be 11.16%. The Company recorded $3.5 million and $10.4 million in interest expense during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company had an unaccreted debt discount of $4.5 million and unaccreted direct issuance costs of $0.7 million to be accreted over the expected remaining term of the initial term loan.The following table summarizes the impact of the initial term loan on the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â September 30, 2024Gross principal â€‹$ 130,000Principal repaymentsâ€‹â€‹ (6,902)Unaccreted debt discount and debt issuance costsâ€‹â€‹ (5,183)Total carrying value net of principal repayments, unaccreted debt discount, and debt issuance costsâ€‹â€‹ 117,915Less: current portion of long-term debt â€‹â€‹ (9,826)Long-term debtâ€‹$ 108,089â€‹Long-term debt on the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 and consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. The carrying value of the Blue Owl Loan as of December 31, 2023 was $124.0 million.Aggregate projected future principal payments of the initial term loan as of September 30, 2024, are as follows (in thousands): â€‹â€‹â€‹â€‹Year Ending December 31, â€‹Payments2024 (excluding the nine months ended September 30, 2024)â€‹$ â€”2025Â â€‹ 11,2742026Â â€‹ 17,8252027â€‹â€‹ 23,8852028â€‹â€‹ 29,761ThereafterÂ â€‹ 40,353Total paymentsâ€‹$ 123,098â€‹Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the accompanied consolidated statements of operations for theÂ three and nine months ended September 30, 2024 relates to the initial term loan (in thousands): â€‹Three Months Ended â€‹â€‹Nine Months Ended â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹â€‹2024â€‹2023â€‹Accrued interest expenseâ€‹$ 3,085â€‹$ â€”â€‹â€‹$ 9,450â€‹$ â€”â€‹Accretion of debt discount and debt issuance costsâ€‹Â 408â€‹Â â€”Â â€‹Â 996â€‹Â â€”Â Total interest expenseâ€‹$ 3,493â€‹$ â€”â€‹â€‹$ 10,446â€‹$ â€”â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock Warrants 9 Months Ended Sep. 30, 2024 Common Stock Warrants Â Common Stock Warrants 9. Common Stock WarrantsAs of September 30, 2024 and December 31, 2023, the following common stock warrants were outstanding:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Â Â ExerciseÂ PriceÂ Â Â Â SeptemberÂ 30,Â Â Â Â Â December 31,Issuance Dateâ€‹ExpirationÂ Dateâ€‹BalanceÂ SheetÂ Classificationâ€‹perÂ Shareâ€‹2024â€‹2023MayÂ 2018â€‹MayÂ 2028â€‹Stockholdersâ€™ equityâ€‹$ 23.69â€‹ 6,332â€‹ 6,332MarchÂ 2019â€‹MarchÂ 2029â€‹Stockholdersâ€™ equityâ€‹$ 14.71â€‹ 4,845â€‹ 4,845December 2023â€‹December 2033â€‹Stockholdersâ€™ equityâ€‹$ 35.00â€‹ 40,000â€‹ 40,000December 2023â€‹December 2033â€‹Stockholdersâ€™ equityâ€‹$ 42.50â€‹ 40,000â€‹ 40,000December 2023â€‹December 2033â€‹Stockholdersâ€™ equityâ€‹$ 50.00â€‹ 40,000â€‹ 40,000 â€‹Â Â Â Â Â Â â€‹Â Â Â Â 131,177Â 131,177â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCommon stock warrant. + ReferencesNo definition available. + Details Name: xoma_CommonStockWarrantDisclosureTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Â Commitments and Contingencies 10. Commitments and ContingenciesCollaborative Agreements, Royalties, and Milestone PaymentsThe Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory, and commercial milestones by the Companyâ€™s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of September 30, 2024.Contingent ConsiderationPursuant to the Companyâ€™s agreements with Aronora, Kuros, Affitech, LadRx, and DarÃ©, and under the Kinnate CVR Agreement, the Company has committed to pay the Aronora Royalty Milestones, the Kuros Sales Milestones, the remaining Affitech Sales Milestones, LadRx commercial sales milestone, DarÃ© Milestones, and the Exarafenib milestone contingent consideration.During the year ended December 31, 2023, the Company recorded $1.0 million for the LadRx contingent consideration that represented the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin at the inception of the LadRx Agreements. During the nine months ended September 30, 2024, the contingent liability was reduced to zero after the Company paid LadRx $1.0 million upon the FDAâ€™s acceptance of the arimoclomol NDA resubmission. Additionally, the amendment to the LadRx RPA removed the milestone payment that had been contingent upon the achievement of a regulatory milestone related to aldoxorubicin (Note 5). During the third quarter of 2024, the LadRx commercial sales milestone related to MIPLYFFA pursuant to the LadRx AAA was assessed to be probable under ASC 450. As such, a $1.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $1.0 million asset was recorded under long-term royalty and commercial payment receivables on the condensed consolidated balance sheet as of September 30, 2024.During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $6.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $6.0 million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet. During the first quarter of 2024, this contingent liability was reduced to zero after the Company paid Affitech $6.0 million upon the achievement of the related commercial sales milestones (Note 5).During the first quarter of 2024, a sales milestone related to VABYSMO pursuant to the Affitech CPPA was assessed to be probable under ASC 450. As such, a $3.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $3.0 million asset was recorded under short-term royalty and commercial payment receivables on the condensed consolidated balance sheet.As of September 30, 2024, the Company recorded $3.1 million for the Exarafenib milestone contingent consideration, which represented the estimated fair value of potential future payments upon the achievement of a certain specified milestone related to exarafenib payable to Kinnate CVR holders upon the closing of the Kinnate acquisition under the Kinnate CVR Agreement. The Exarafenib milestone contingent consideration is measured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net.The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, and the DarÃ© Milestones will be recorded when the amounts, by product, are estimable and probable. As of September 30, 2024, none of the Aronora Royalty Milestones, Kuros Sales Milestones, and DarÃ© Milestones were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation 9 Months Ended Sep. 30, 2024 Stock Based Compensation Â Stock Based Compensation 11. Stock-Based Compensation The Company may grant qualified and non-qualified stock options, common stock, PSUs, RSUs, and other stock-based awards under various plans to directors, officers, employees, and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Companyâ€™s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Companyâ€™s common stock on the first trading day of the offering period or on the last day of the purchase period. The ESPP includes a rollover mechanism for the purchase price if the fair market value of the Companyâ€™s common stock on the purchase date is less than the fair market value of the Companyâ€™s common stock on the first trading day of the offering period.Stock Options and Other Benefit PlansStock Option Plans2010 Plan Stock OptionsStock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. Fair Value Assumptions of 2010 Plan Stock Optionsâ€‹There were no stock options granted during the three months ended September 30, 2024 and 2023. The fair value of stock options granted during the nine months ended September 30, 2024 and 2023 was estimated based on the following weighted-average assumptions:â€‹Three Months Ended SeptemberÂ 30,Â Â Â â€‹Nine Months Ended SeptemberÂ 30,Â Â Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Dividend yieldÂ â€”% â€”%Â 0%0%Expected volatilityÂ â€”% â€”%Â 65% 70%Risk-free interest rateÂ â€”% â€”%Â 4.35% 3.60%Expected termÂ â€”â€‹ â€”â€‹Â 5.79 yearsâ€‹<5.79 yearsâ€‹<â€‹The weighted-average grant-date fair value per share of the stock options granted during the nine months ended September 30, 2024 and 2023, was $24.71 and $13.46, respectively. â€‹Stock Option Inducement Awards On DecemberÂ 30, 2022, the Board appointed Owen Hughes as Executive

Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Companyâ€™s Chief Investment Officer, effective as of JanuaryÂ 1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the â€œStock Option Inducement Awardsâ€) when the Companyâ€™s stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan. More information on the Stock Option Inducement Awards granted during the three months ended March 31, 2023 can be found in Note 10 of the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the first quarter of 2023 was $11.91. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was $14.68. No Stock Option Inducement Awards were granted during the nine months ended September 30, 2024.The activity for all stock options for the nine months ended September 30, 2024 was as follows:â€‹â€‹â€‹

for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events Â Subsequent Events 14. Subsequent EventsTwist Bioscience Royalty Purchase Agreement On October 21, 2024, the Company entered into a royalty purchase agreement with Twist Bioscience Corporation (â€œTwist Bioscienceâ€). Under the terms of the agreement, the Company acquired 50% of certain contingent payments (including royalties, milestone payments, sublicense income, and option exercise payments) related to Twist Bioscienceâ€™s 60-plus early-stage programs across 30 partners for a $15.0 million upfront payment. The Company is eligible to receive up to $0.5 billion in milestone payments and a 50% share of up to low single-digit royalties on future commercial sales. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (17,243) $ 15,985 $ (8,595) $ (5,509) $ (5,400) $ (9,813) $ (9,853) $ (20,722) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Basis of Presentation and Significant Accounting Policies Â Basis of Presentation Basis of PresentationThe condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to FormÂ 10-Q and ArticleÂ 10 of Regulation S-X for interim financial reporting. As permitted under those rules,Â certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscalÂ year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Companyâ€™s Annual Report on FormÂ 10-K for theÂ year endedÂ DecemberÂ 31, 2023, filed with the SEC on MarchÂ 8, 2024.These condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Companyâ€™s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the fullÂ year, or for any other future annual or interim period. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to income from purchased receivables, revenue from contracts with customers, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, projected cash flows associated with income under the EIR method, the Exarafenib milestone asset and contingent consideration, legal contingencies, contingent consideration for purchased receivables, amortization of the Blue Owl Loan, accrued expenses, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.Actual results may differ significantly from these estimates, including estimates such as the Companyâ€™s income from purchased receivables, amortization of the payments received from HCRP, and amortization of the Blue Owl Loan. Estimates related to income from purchased receivables is based on the best information available to the Company from its partners or other third parties and changes in expected cash flows for royalty and commercial receivables under the EIR method. Any changes to the estimated payments made by partners can result in a material adjustment to income reported. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The Companyâ€™s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material

adjustment to the interest expense and term loan balance reported. Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, andÂ Restricted Cash The following table provides a reconciliation of cash, cash equivalents, andÂ restricted cash reported within the condensed consolidated statements of cash flows (in thousands):
â€‹â€‹â€‹

freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that are related to IPR&D assets are expensed as incurred. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. Cash payments related to acquired assets are reflected as an investing cash flow in the Companyâ€™s condensed consolidated statements of cash flows. Leases Leases The Company leases its headquarters in Emeryville, California and acquired a lease from the Kinnate acquisition. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. For leases acquired in asset acquisitions, the Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the acquisition date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in G&A expense in the condensed consolidated statements of operations.The Company has elected the practical expedient to not separate lease and non-lease components. The Companyâ€™s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise. Long-Term Debt Long-Term DebtLong-term debt represents the Companyâ€™s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the EIR method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the EIR method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8. Warrants Warrants The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Companyâ€™s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility, and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Companyâ€™s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants. Income Taxes Income TaxesThe Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.The recognition, derecognition and measurement of a tax position is based on managementâ€™s best judgment given the facts, circumstances, and information available at each reporting date. The Companyâ€™s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. Net Income (Loss) per Share Available to (Attributable to) Common Stockholders Net Income (Loss) per Share Available to (Attributable to) Common StockholdersThe Company calculates basic and diluted income (loss) per share available to (attributable to) common stockholders using the two-class method. The Companyâ€™s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Companyâ€™s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income available to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income (loss) per share available to (attributable to) common stockholders is then calculated by dividing the net income (loss) available to (attributable to) common stockholders by the weighted-average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted-average common shares outstanding.Diluted net income (loss) per share available to (attributable to) common stockholders is based on the weighted-average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Companyâ€™s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Companyâ€™s share price and, therefore, are not included in the diluted shares until the contingency is resolved. Share Repurchases Share RepurchasesThe Company has a stock repurchase program that is executed through purchases made from time to time, including in the open market. The Company retires repurchased shares of common stock, reducing common stock with any excess of cost over par value recorded to accumulated deficit. Issued and outstanding shares of common stock are reduced by the number of shares repurchased. No treasury stock is recognized in the condensed consolidated financial statements. In August 2022, the IRA enacted a 1% excise tax on net share repurchases after December 31, 2022. Any excise tax incurred on share repurchases is recognized as part of the cost basis of the shares acquired. Concentration of Risk Concentration of RiskCash, cash equivalents, restricted cash, and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended September 30, 2024, three partners represented 75%, 14% and 10% of total income and revenues, respectively. For the nine months ended September 30, 2024, three partners represented 50%, 25% and 10% of total income and revenues, respectively. For the three months ended September 30, 2023, two partners represented 73% and 24% of total income and revenues, respectively. For the nine months ended September 30, 2023, two partners represented 54% and 44% of total income and revenues, respectively. One partner represented 96% of the trade and other receivables, net as of September 30, 2024. One partner represented 100% of the trade and other receivables, net as of December 31, 2023. Comprehensive Income (Loss) Comprehensive Income (Loss)Comprehensive income (loss) is comprised of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholdersâ€™ equity but are excluded from net income (loss). Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted Accounting Pronouncements Recently AdoptedIn November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2024. â€‹Recent Accounting Pronouncements Not Yet AdoptedIn October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commissionâ€™s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures. â€‹In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_CompensationRelatedCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1 + Details Name: us-gaap_StockholdersEquityPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for asset acquisitions. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionsPolicyPolicyTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset. + ReferencesNo definition available. + Details Name: xoma_CreditLossContractWithCustomerAssetPolicyTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for equity securities. + ReferencesNo definition available. + Details Name: xoma_EquitySecuritiesPolicy Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionPolicy for future milestones, royalties purchase rights and commercial payments. + ReferencesNo definition available. + Details Name: xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income that is not accounted for under Topic 606, in accordance with the cost recovery method and the effective interest rate method. + ReferencesNo definition available. + Details Name: xoma_IncomeNotFromContractWithCustomerCostRecoveryMethodAndEffectiveInterestRateMethodPolicyTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue that is not accounted for under Topic 606, in accordance with the units-of-revenue method. + ReferencesNo definition available. + Details Name: xoma_RevenueRevenueNotFromContractWithCustomerUnitsOfRevenueMethodPolicyTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for warrants. + ReferencesNo definition available. + Details Name: xoma_WarrantsPolicyTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Basis of Presentation and Significant Accounting Policies Â Schedule of cash, cash equivalents and restricted cash Cash, Cash Equivalents, andÂ Restricted Cash The following table provides a reconciliation of cash, cash equivalents, andÂ restricted cash reported within the condensed consolidated statements of cash flows (in thousands): â€‹â€‹â€‹

â€”â€‹ 785Total financial assets â€‹$ 138,817â€‹ â€”â€‹$ 3,125â€‹$ 141,942Liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Exarafenib milestone contingent consideration (Note 4)â€‹$ â€”â€‹ â€”â€‹$ 3,125â€‹$ 3,125Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair valueâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Total financial liabilitiesâ€‹$ â€”â€‹$ â€”â€‹$ 3,125â€‹$ 3,125â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹FairÂ ValueÂ MeasurementsÂ as ofÂ DecemberÂ 31,Â 2023
Using:â€‹â€‹QuotedÂ PricesÂ inâ€‹SignificantÂ Otherâ€‹Significantâ€‹â€‹â€‹â€‹â€‹ActiveÂ MarketsÂ forâ€‹Observableâ€‹Unobservableâ€‹â€‹â€‹â€‹â€‹â€‹IdenticalÂ Assetsâ€‹Inputsâ€‹Inputsâ€‹â€ equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹$28,352â€‹$ â€”â€‹$ â€”â€‹$28,352Total cash equivalents â€‹â€‹28,352â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹28,352Equity securitiesâ€‹â€‹161â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹161Total financial assets â€‹$28,513â€‹$ â€”â€‹$ â€”â€‹$28,513Liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair valueâ€‹$ â€”â€‹$ â€”â€‹$1,000â€‹$1,000 X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Agreements (Tables) 9 Months Ended Sep. 30, 2024 Lease Agreements Â Schedule of maturity of future rent payments associated with new lease The following table summarizes maturity of the Companyâ€™s operating lease liabilities as of September 30, 2024 (in thousands):
â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Yearâ€‹RentÂ Payments2024 (excluding the nine months ended September 30, 2024)Â $ 1172025â€‹â€‹ 5022026Â â€‹ 3002027Â â€‹ 912028â€‹â€‹ 102ThereafterÂ â€‹ 36Total undiscounted lease paymentsâ€‹$ 1,148Present value adjustmentâ€‹â€‹ (120)Total net lease liability for operating leases â€‹$ 1,028 Schedule of cost components of operating leases The following table summarizes the cost components of the Companyâ€™s operating leases included in G&A in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands): â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023Lease costs:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating lease cost â€‹$ 36â€‹$ 17Â $ 97Â $ 116Variable lease cost (1)â€‹Â â€”â€‹Â 20Â â€‹ 18Â â€‹ 32Total lease costsâ€‹$ 36â€‹$ 37Â $ 115â€‹$ 148â€‹(1)Under the terms of the original, amended, and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees. Summary of supplemental cash flow information related to operating leases The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024â€‹2023Cash paid for amounts included in the measurement of lease liabilitiesâ€‹Â â€‹â€‹Â â€‹Operating cash flows under operating leasesâ€‹$ 68â€‹$ 121 Schedule of assumptions used in calculating the present value of lease payments The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024â€‹2023Cash paid for amounts included in the measurement of lease liabilitiesâ€‹Â â€‹â€‹Â â€‹Operating cash flows under operating leasesâ€‹$ 68â€‹$ 121â€‹The assumptions used in calculating the present value of the lease payments for the Companyâ€™s operating leases as of September 30, 2024 and December 31, 2023 were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹Â Â Â Â Â SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹Â Â Â Â Â 2024â€‹2023Weighted-average remaining lease term â€‹2.7 yearsâ€‹â€‹5.33 yearsâ€‹Weighted-average discount rate â€‹ 8.18%â€‹ 8.50% X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe tabular disclosure of supplemental cash flows information related to leases. + ReferencesNo definition available. + Details Name: xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe tabular disclosure of supplemental information related to operating leases. May include, but not limited to, present value assumptions used in calculating the present value of the lease payments. + ReferencesNo definition available. + Details Name: xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt (Tables) 9 Months Ended Sep. 30, 2024 Long-Term Debt Â Schedule of long-term debt The following table summarizes the impact of the initial term loan on the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â September 30, 2024Gross principal â€‹$ 130,000Principal repayments‹â€‹ (6,902)Unaccreted debt discount and debt issuance costs‹â€‹ (5,183)Total carrying value net of principal repayments, unaccreted debt discount, and debt issuance costsâ€‹â€‹ 117,915Less: current portion of long-term debt â€‹â€‹ (9,826)Long-term debtâ€‹$ 108,089 Schedule of projected future principal payments of initial term loan Aggregate projected future principal payments of the initial term loan as of September 30, 2024, are as follows (in thousands): â€‹â€‹â€‹â€‹Year Ending December 31, â€‹Payments2024 (excluding the nine months ended September 30, 2024)â€‹$ â€”2025Â â€‹ 11,2742026Â â€‹ 17,8252027â€‹â€‹ 23,8852028â€‹â€‹ 29,761ThereafterÂ â€‹ 40,353Total paymentsâ€‹$ 123,098 Schedule of interest expense Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the condensed consolidated statements of operations for theÂ three and nine months ended September 30, 2024 relates to the initial term loan (in thousands):
â€‹Three Months Ended â€‹â€‹Nine Months Ended
â€‹â€‹â€‹SeptemberÂ 30,Â â€‹â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024â€‹2023â€‹â€‹2024â€‹2023â€‹Accrued interest expenseâ€‹$ 3,085â€‹$ â€”â€‹â€‹â€‹ 9,450â€‹$ â€”â€‹Accretion of debt discount and debt issuance costsâ€‹Â 408â€‹Â â€”Â â€‹Â 996â€‹Â â€”Â Total interest expenseâ€‹$ 3,493â€‹$ â€”â€‹â€‹â€‹$ 10,446â€‹$ â€”â€‹â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe tabular disclosure of accretion of debt discounts and issuance costs included in interest expense. + ReferencesNo definition available. + Details Name: xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock Namespace Prefix: xoma_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock Warrants (Tables) 9 Months Ended Sep. 30, 2024 Common Stock Warrants Â Summary of Common Stock Warrants Outstanding
â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of number and weighted-average grant date fair value for nonvested performance shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Capital Stock (Tables) 9 Months Ended Sep. 30, 2024 Capital Stock Â Schedule of declared and paid cash dividends â€‹â€‹â€‹

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAdditional amount of cash required to be added to restricted account. + ReferencesNo definition available. + Details Name: xoma_RestrictedCashAdditionalToBeFunded Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of restricted cash released to unrestricted cash during the period. + ReferencesNo definition available. + Details Name: xoma_RestrictedCashReleasedToUnrestrictedCash Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsOperatingExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies - Purchased Receivables, Income Taxes, and Share Repurchases (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Basis of Presentation and Significant Accounting Policies Â Â Purchased receivables included in royalty and commercial payment receivables, Cost recovery method $ 1.0 $ 0.0 Purchased receivables included in royalty and commercial payment receivables, Effective interest rate method 8.3 $ 0.0 Income tax penalties or interest charged 0.0 Â Treasury stock (in dollars) $ 0.0 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance, of receivables related to income from purchased receivables under the cost recovery method due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_PurchasedReceivablesCostRecoveryMethodNetCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance, of receivables related to income from purchased receivables under the effective interest rate method due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_PurchasedReceivablesEffectiveInterestRateMethodNetCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details) - customer 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Customer Concentration Risk | Revenues Â Â Â Â Â Â Concentration of Risk Â Â Â Â Â Â Number of major partners 3 2 3 2 Â Customer Concentration Risk | Revenues | Partner 1 Â Â Â Â Â Â Concentration of Risk Â Â Â Â Â Â Concentration risk (as a percent) 75.00% 73.00% 50.00% 54.00% Â Customer Concentration Risk | Revenues | Partner 2 Â Â Â Â Â Â Concentration of Risk Â Â Â Â Â Â Concentration risk (as a percent) 14.00% 24.00% 25.00% 44.00% Â Customer Concentration Risk | Revenues | Partner 3 Â Â Â Â Â Â Concentration of Risk Â Â Â Â Â Â Concentration risk (as a percent) 10.00% Â 10.00% Â Â Credit Concentration Risk | Trade Receivables | Partner 1 Â Â Â Â Â Â Concentration of Risk Â Â Â Â Â Â Number of major partners Â Â 1 Â 1 Concentration risk (as a percent) Â Â 96.00% Â 100.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of major partners. + ReferencesNo definition available. + Details Name: xoma_NumberOfMajorPartners Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=xoma_Partner1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=xoma_Partner2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=xoma_Partner3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Financial Statements Details - Equity Securities (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Equity Securities Â Â Â Â Â Short-term equity securities $ 785 Â $ 785 Â $ 161 Gain (loss) recognized due to change in fair value of investment Â Â 624 $ (121) Â Rezolute Â Â Â Â Â Equity Securities Â Â Â Â Â Short-term equity securities 800 Â 800 Â $ 200 Gain (loss) recognized due to change in fair value of investment $ 100 $ (100) $ 600 $ (100) Â X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details Name: us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Financial Statements Details - Accrued and Other Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued and other liabilities Â Â Accrued incentive compensation $ 1,171 $ 1,203 Other accrued liabilities 445 625 Accrued legal and accounting fees 637 791 Accrued payroll and benefits 198 149 Total $ 2,451 $ 2,768 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer. + ReferencesNo definition available. + Details Name: xoma_AccruedAndOtherLiabilitiesCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: xoma_AccruedSalariesAndEmployeeBenefitsCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statements Details - Net Income Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator Â Â Â Â Â Â Â Â Net Income (Loss) $ (17,243) $ 15,985 $ (8,595) $ (5,509) $ (5,400) $ (9,813) $ (9,853) $ (20,722) Net loss attributable to common stockholders, basic (18,611) Â Â (6,877) Â Â (13,957) (24,826) Net loss attributable to common stockholders, diluted $ (18,611) Â Â $ (6,877) Â Â $ (13,957) $ (24,826) Denominator Â Â Â Â Â Â Â Â Weighted average shares used in computing net loss per share attributable to common stockholders, Basic 11,712 Â Â 11,473 Â Â 11,645 11,466 Weighted average shares used in computing net loss per share attributable to common stockholders, Diluted 11,712 Â Â 11,473 Â Â 11,645 11,466 Net loss per share attributable to common stockholders, Basic (in dollars per share) $ (1.59) Â Â $ (0.60) Â Â $ (1.20) $

(2.17) Net loss per share attributable to common stockholders, Diluted (in dollars per share) $ (1.59) Â Â $ (0.60) Â Â $ (1.20) $ (2.17) 8.625% Series A Cumulative, Perpetual Preferred Stock Â Â Â Â Â Â Â Â Numerator Â Â Â Â Â Â Â Â Less: accumulated dividends $ (530) Â Â $ (530) Â Â $ (1,591) $ (1,591) 8.375% Series B Cumulative, Perpetual Preferred Stock Â Â Â Â Â Â Â Â Numerator Â Â Â Â Â Â Â Â Less: accumulated dividends $ (838) Â Â $ (838) Â Â $ (2,513) $ (2,513) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_PreferredStockDividendsIncomeStatementImpact Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details) - $ / shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share Â Â Â Â Antidilutive securities excluded from computation of net loss per share (in shares) 6,607 6,813 6,909 6,790 Performance Stock Unit Awards Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share Â Â Â Â Shares issuable based on market price Â Â 0 Â Common Stock Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share Â Â Â Â Stock price (in dollars per share) $ 26.48 Â $ 26.48 Â Convertible preferred stock Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share Â Â Â Â Antidilutive securities excluded from computation of net loss per share (in shares) 5,003 5,003 5,003 5,003 Employee Stock Option Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share Â Â Â Â Antidilutive securities excluded from computation of net loss per share (in shares) 1,473 1,804 1,775 1,781 Warrants for common stock Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share Â Â Â Â Antidilutive securities excluded from computation of net loss per share (in shares) 131 6 131 6 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Apr. 03, 2024 USD ($) Right $ / shares shares Feb. 27, 2024 USD ($) Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Sep. 30, 2023 USD ($) Jun. 30, 2023 USD ($) Mar. 31, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Asset acquisition Â Â Â Â Â Â Â Â Â Â Â Exarafenib milestone asset Â Â $ 3,125 Â Â Â Â Â $ 3,125 Â Â Exarafenib milestone contingent consideration Â Â 3,125 Â Â Â Â Â 3,125 Â Â Operating lease liabilities Â Â 1,028 Â Â Â Â Â 1,028 Â $ 400 Purchase consideration Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use assets Â Â 335 Â Â Â Â Â 335 Â 378 Allocation of purchase consideration Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â Â 142,050 Â Â Â Â Â 142,050 Â 153,290 Prepaid expenses and other current assets Â Â 2,379 Â Â Â Â Â 2,379 Â 483 Exarafenib milestone asset Â Â 3,125 Â Â Â Â Â 3,125 Â Â Accrued and other liabilities Â Â (2,451) Â Â Â Â Â (2,451) Â (2,768) Operating lease liabilities Â Â (434) Â Â Â Â Â (434) Â (54) Long-term operating lease liabilities Â Â (594) Â Â Â Â Â (594) Â (335) Less: Gain on the acquisition of Kinnate Â Â Â Â Â Â Â Â (19,316) Â Â Net Income (Loss) Â Â (17,243) $ 15,985 $ (8,595) $ (5,509) $ (5,400) $ (9,813) (9,853) $ (20,722) Â Revenues Â Â 7,197 Â Â $ 830 Â Â 19,773 $ 2,925 Â Kinnate Â Â Â Â Â Â Â Â Â Â Â Allocation of purchase consideration Â Â Â Â Â Â Â Â Â Â Revenues Â Â Â Â Â Â Â Â Â Â 0 CVR Agreement | Kinnate CVR holders Â Â Â Â Â Â Â Â Â Â Asset acquisition Â Â Â Â Â Â Â Â Â Â Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company $ 30,500 Â Â Â Â Â Â Â Â Â Â Exarafenib milestone asset 2,900 Â 3,100 Â Â Â Â Â 3,100 Â Â Contingent consideration from the Exarafenib Sale payable from the Company to the Kinnate CVR Holders under the CVR Agreement 30,500 Â Â Â Â Â Â Â Â Â Â Exarafenib milestone contingent consideration 2,900 Â 3,100 Â Â Â Â Â 3,100 Â Â Allocation of purchase consideration Â Â Â Â Â Â Â Â Â Â Exarafenib milestone asset $ 2,900 Â $ 3,100 Â Â Â Â Â 3,100 Â Â Exarafenib and related IP | CVR Agreement | Kinnate CVR holders Â Â Â Â Â Â Â Â Â Â Asset acquisition Â Â Â Â Â Â Â Â Â Â Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company Â $ 30,500 Â Â Â Â Â Â Â Â Â Â Percentage of further net proceeds from sale Â 100.00% Â Â Â Â Â Â Â Â Â Â Percentage of net proceeds from any license or other disposition Â 85.00% Â Â Â Â Â Â Â Â Â Â Exarafenib and related IP | Disposed of by Sale, Not Discontinued Operations | Kinnate Â Â Â Â Â Â Â Â Â Â Asset acquisition Â Â Â Â Â Â Â Â Â Â Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company Â $ 30,500 Â Â Â Â Â Â Â Â Â Â Exarafenib and related IP | Disposed of by Sale, Not Discontinued Operations | CVR Agreement | Kinnate CVR holders | Kinnate Â Â Â Â Â Â Â Â Â Â Asset acquisition Â Â Â Â Â Â Â Â Â Â Cash consideration received Â $ 500 Â Â Â Â Â Â Â Â Â Â Kinnate Â Â Â Â Â Â Â Â Â Â Asset acquisition Â Â Â Â Â Â Â Â Â Â Asset acquisition, Share price (in dollars per share) | $ / shares $ 2.5879 Â Â Â Â Â Â Â Â Â Â Number of non-transferable contractual CVR per share of Kinnate common stock | Right 1 Â Â Â Â Â Â Â Â Â Â Exarafenib milestone asset $ 2,922 Â Â Â Â Â Â Â Â Â Â Operating lease liabilities 800 Â Â Â Â Â Â Â Â Â Â Purchase consideration Â Â Â Â Â Â Â Â Â Â Closing cash payment 122,646 Â Â Â Â Â Â Â Â Â Â Estimated fair value of the Exarafenib milestone contingent consideration 2,922 Â Â Â Â Â Â Â Â Â Â Transaction costs 809 Â Â Â Â Â Â Â Â Â Â Total purchase consideration $ 126,377 Â Â Â Â Â Â Â Â Â Â Kinnate common stock tendered | shares 47,232,737 Â Â Â Â Â Â Â Â Â Â Total number of underlying shares | shares 2,510,552 Â Â Â Â Â Â Â Â Â Â Fair value of the IPR&D asset $ 0 Â Â Â Â Â Â Â Â Â Â Intangible assets 0 Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use assets 0 Â Â Â Â Â Â Â Â Â Â Allocation of purchase consideration Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents 142,381 Â Â Â Â Â Â Â Â Â Â Prepaid expenses and other current assets 3,223 Â Â Â Â Â Â Â Â Â Â Exarafenib milestone asset 2,922 Â Â Â Â Â Â Â Â Â Â Accrued and other liabilities (2,009) Â Â Â Â Â Â Â Â Â Â Operating lease liabilities (322) Â Â Â Â Â Â Â Â Â Â Long-term operating lease liabilities (502) Â Â Â Â Â Â Â Â Â Â Net assets acquired 145,693 Â Â Â Â Â Â Â Â Â Â Less: Gain on the acquisition of Kinnate (19,316) Â Â Â Â Â Â Â Â Â Â Total purchase consideration $ 126,377 Â Â Â Â Â Â Â Â Â Â Severance charges Â Â Â Â Â Â Â Â Â Â 3,600 Â Â Severance charges paid Â Â Â Â Â Â Â Â Â Â 3,600 Â Â Kinnate | Pro forma Â Â Â Â Â Â Â Â Â Â Allocation of purchase consideration Â Â Â Â Â Â Â Â Â Â Net Income (Loss) Â Â Â Â Â Â Â Â 9,900 Â 25,100 Kinnate | Adjustment Â Â Â Â Â Â Â Â Â Â Allocation of purchase consideration Â Â Â Â Â Â Â Â Â Â Revenues Â Â Â Â Â Â Â Â $ 0 Â $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_AssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of contingent consideration recognized as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction cost incurred as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of net assets (liabilities). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479910/205-30-50-1 + Details Name: us-gaap_AssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfOtherProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer. + ReferencesNo definition available. + Details Name: xoma_AccruedAndOtherLiabilitiesCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of non-transferable contractual contingent value rights (CVR) each acquiree share has right to receive. representing right to receive one or more potential cash payments. + ReferencesNo definition available. + Details Name: xoma_AcquisitionNumberOfContingentValueRights Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFor contingent consideration arrangements recognized in connection with a asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares tendered under the asset acquisition. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionNumberOfSharesTendered Namespace Prefix: xoma_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares underlying the share-based awards settled under the asset acquisition. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionNumberOfSharesUnderlyingShareBasedAwardsSettled Namespace Prefix: xoma_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks paid in asset acquisition. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionSharePrice Namespace Prefix: xoma_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of contingent consideration to be received as part of consideration in sale of assets. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationFromSaleOfAssets Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) included in earnings resulting from the asset acquisition. + ReferencesNo definition available. + Details Name: xoma_GainLossOnAssetAcquisition Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. + ReferencesNo definition available. + Details Name: xoma_MilestoneAssetsNoncurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash payments for severance costs. + ReferencesNo definition available. + Details Name: xoma_PaymentsForSeveranceCosts Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of net proceeds contingent value right holders have right to receive within one year of the merger closing date under the terms of the agreement from license or disposition entered into by acquiree. + ReferencesNo definition available. + Details Name: xoma_PercentageOfProceedsPayableLicenseOrDisposition Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of net proceeds contingent value right holders have right to receive until the fifth anniversary of the merger closing date under the terms of the agreement from sale entered into by acquiree. + ReferencesNo definition available. + Details Name: xoma_PercentageOfProceedsPayableSale Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: dei_LegalEntityAxis=xoma_KinnateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_KinnateCvrHoldersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=xoma_ExarafenibAndRelatedIntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=xoma_KinnateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ProFormaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions, Licensing and Other Arrangements - Takeda (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 215 Months Ended Nov. 01, 2006 Feb. 28, 2009 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Dec. 31, 2023 Licensing and other arrangements Â Â Â Â Â Â Â Â Revenue from contracts with customers Â Â $ 25 $ 225 $ 6,050 $ 1,350 Â Â Takeda Pharmaceutical Company Limited | Collaboration Agreement Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Maximum milestone payments entitled to receive Â Â 16,000 Â 16,000 Â $ 16,000 Â Revenue from contracts with customers Â Â Â Â Â Â 3,000 Â Contract assets Â Â 0 Â 0 Â 0 $ 0 Contract liabilities Â Â 0 Â 0 Â 0 0 Capitalized contract costs Â Â $ 0 Â $ 0 Â $ 0 $ 0 Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079 Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Maximum milestone payments entitled to receive $ 19,000 Â Â Â Â Â Â Â Percentage of royalty on sales 4.00% Â Â Â Â Â Â Â Â Minimum period eligible to receive royalties 13 years 6 months Â Â Â Â Â Â Â Â Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years Â Â Â Â Â Â Â Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Maximum eligible milestone payments receivable per discovery product candidate Â $ 3,300 Â Â Â Â Â Â Â Minimum period eligible to receive royalties Â 10 years Â Â Â Â Â Â Â X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum eligible milestone payments receivable per discovery product candidate. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of royalty on net sales upon commercialization. + ReferencesNo definition available. + Details Name: xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMinimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days + ReferencesNo definition available. + Details Name: xoma_RoyaltiesPeriodMinimum Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMinimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days + ReferencesNo definition available. + Details Name: xoma_RoyaltiesPeriodMinimumScenarioOne Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_MezagitamabMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions,

Licensing and Other Arrangements - Rezolute (Details) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 35 Months Ended Dec. 06, 2017 USD ($) Apr. 30, 2024 USD ($) Jan. 31, 2022 USD ($) Oct. 31, 2020 Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Oct. 31, 2020 USD ($) shares Dec. 31, 2023 USD ($) Licensing and other arrangements Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â $ 25 $ 225 $ 6,050 $ 1,350 Â Â Rezolute Â Â Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Â Â Reverse stock split Â Â Â 0.02 Â Â Â Â Â Â Rezolute | License Agreement and Common Stock Purchase Agreement Â Â Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Â Â Payments received upon achievement of financing activities Â Â Â Â Â Â Â Â $ 6,000 Â Installment payments received Â Â Â Â Â Â Â Â $ 8,500 Â Number of shares received | shares Â Â Â Â Â Â Â Â 161,861 Â Rezolute | License Agreement Â Â Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Â Â Percentage of decrease in future royalty obligations 20.00% Â Â Â Â Â Â Â Â Â Â Agreement termination prior written notice period 90 days Â Â Â Â Â Â Â Â Â Â License agreement consideration received $ 0 Â Â Â Â Â Â Â Â Â Â Revenue recognized Â $ 5,000 Â Â 0 $ 0 5,000 $ 0 Â Â Contract assets Â Â Â Â 0 Â 0 Â Â $ 0 Contract liabilities Â Â Â Â 0 Â 0 Â Â 0 Capitalized contract costs Â Â Â Â $ 0 Â $ 0 Â Â $ 0 Rezolute | License Agreement, RZ358 Â Â Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Â Â Maximum milestone payments entitled to receive $ 232,000 Â Â Â Â Â Â Â Â Â Â Minimum period eligible to receive royalties 12 years Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â $ 2,000 Â Â Â Â Â Â Â Â Rezolute | License Agreement, Non-RZ358 products Â Â Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Â Â Minimum period eligible to receive royalties 12 years Â Â Â Â Â Â Â Â Â X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionAgreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days + ReferencesNo definition available. + Details Name: xoma_AgreementTerminationPriorWrittenNoticePeriod Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLicense agreement consideration received. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementConsiderationReceived Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of payments received upon achievement of financing activities during the period. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of installment payments received during the period. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementInstallmentPaymentsReceived Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of counterparty's common stock entity received under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementSharesReceived Namespace Prefix: xoma_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_PercentageOfDecreaseInFutureRoyaltyObligations Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMinimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days + ReferencesNo definition available. + Details Name: xoma_RoyaltiesPeriodMinimum Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: dei_LegalEntityAxis=xoma_RezoluteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_RezoluteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions, Licensing and Other Arrangements - Janssen (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Aug. 31, 2019 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2019 Dec. 31, 2023 Licensing and other arrangements Â Â Â Â Â Â Â Â Revenue from contracts with customers Â $ 25 $ 225 $ 6,050 $ 1,350 Â Â Janssen | License Agreement Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Cash payment received $ 2,500 Â Â Â Â Â Â Â Â Maximum eligible milestone payments receivable per discovery product candidate $ 3,000 Â Â Â Â Â Â Â Â Percentage of royalty on sales 0.75% Â Â Â Â Â Â Â Â Revenue from contracts with customers Â 0 $ 200 0 $ 1,300 $ 2,500 Â Contract assets Â 0 Â 0 Â Â $ 0 Contract liabilities Â 0 Â 0 Â Â 0 Capitalized contract costs Â $ 0 Â $ 0 Â Â $ 0 X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum eligible milestone payments receivable per discovery product candidate. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of royalty on net sales upon commercialization. + ReferencesNo definition available. + Details Name:

xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionCash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. + ReferencesNo definition available. + Details Name: xoma_ProceedsFromUpfrontPayment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2015 USD ($) item Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2017 USD ($) Dec. 31, 2015 USD ($) Dec. 31, 2023 USD ($) Licensing and other arrangements Â Â Â Â Â Â Â Â Revenue from contracts with customers Â $ 25 $ 225 $ 6,050 $ 1,350 Â Â Â Novartis International | License Agreement Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Agreement termination prior written notice period 180 days Â Â Â Â Â Â Â Number of performance obligations | item 1 Â Â Â Â Â Â Â Cash payment received Â Â Â Â Â Â $ 37,000 Â Revenue from contracts with customers Â 0 $ 0 0 $ 0 $ 10,000 $ 37,000 Â Maximum milestone payments entitled to receive $ 480,000 Â Â Â Â Â Â Â Minimum period eligible to receive royalties 10 years Â Â Â Â Â Â Â Â Contract assets Â 0 Â 0 Â Â Â $ 0 Contract liabilities Â 0 Â 0 Â Â Â 0 Capitalized contract costs Â $ 0 Â $ 0 Â Â Â $ 0 X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAgreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days + ReferencesNo definition available. + Details Name: xoma_AgreementTerminationPriorWrittenNoticePeriod Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of performance obligations. + ReferencesNo definition available. + Details Name: xoma_NumberOfPerformanceObligations Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. + ReferencesNo definition available. + Details Name: xoma_ProceedsFromUpfrontPayment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days + ReferencesNo definition available. + Details Name: xoma_RoyaltiesPeriodMinimum Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions, Licensing and Other Arrangements - Novartis - VPM087 (Details) $ / shares in Units, $ in Thousands, â¬ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Aug. 24, 2017 USD ($) item agreement $ / shares shares Aug. 24, 2017 EUR (â¬) item agreement shares Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Dec. 31, 2017 USD ($) Dec. 31, 2023 USD ($) Licensing and other arrangements Â Â Â Â Â Â Â Â Revenue from contracts with customers Â Â $ 25 $ 225 $ 6,050 $ 1,350 Â Â Common Stock Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Stock price (in dollars per share) | $ / shares Â Â $ 26.48 Â $ 26.48 Â Â Â Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Transaction price $ 40,200 Â Â Â Â Â Â Â Â Cash payment received 25,700 Â Â Â Â Â Â Â License agreement consideration received, repayment of debt 14,300 Â Â Â Â Â Â Â Common stock premium $ 200 Â Â Â Â Â Â Â Number of agreements | agreement 2 2 Â Â Â Â Â Â Â Number of arrangements | item 1 1 Â Â Â Â Â Â Â Number of performance obligations | item 2 2 Â Â Â Â Â Â Â Revenue from contracts with customers Â Â $ 0 $ 0 $ 0 $ 0 $ 40,200 Â Contract assets Â Â 0 Â 0 Â Â Â $ 0 Contract liabilities Â Â 0 Â 0 Â Â Â 0 Capitalized contract costs Â Â $ 0 Â $ 0 Â Â Â $ 0 Novartis Pharma AG | Gevokizumab License Agreement Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â License agreement consideration received $ 30,000 Â Â Â Â Â Â Â Cash payment received 15,700 Â Â Â Â Â Â Â License agreement consideration received, repayment of debt 14,300 â¬ 12.0 Â Â Â Â Â Â Proceeds from issuance of common stock 5,000 Â Â Â Â Â Â Â Common stock premium 200 Â Â Â Â Â Â Â Maximum milestone payments entitled to receive $ 438,000 Â Â Â Â Â Â Novartis Pharma AG | Gevokizumab License Agreement | Common Stock Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Shares issued (in shares) | shares 539,131 539,131 Â Â Â Â Â Â Purchase price (in dollars per share) | $ / shares $ 9.2742 Â Â Â Â Â Â Â Issuance of common stock, fair value $ 4,800 Â Â Â Â Â Â Â Stock price (in dollars per share) | $ / shares $ 8.93 Â Â Â Â Â Â Novartis Pharma AG | IL-1 Target License Agreement Â Â Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Â Â Cash payment received $ 10,000 Â Â Â Â Â Â Â X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-

gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of agreements. + ReferencesNo definition available. + Details Name: xoma_AgreementsNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of arrangements the agreements are accounted for. + ReferencesNo definition available. + Details Name: xoma_ArrangementsNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCommon stock premium received on sale of common stock. + ReferencesNo definition available. + Details Name: xoma_CommonStockPremium Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLicense agreement consideration received. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementConsiderationReceived Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of license agreement consideration received as repayment of debt. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementConsiderationReceivedDebtRepayment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLicense agreement transaction price. + ReferencesNo definition available. + Details Name: xoma_LicenseAgreementTransactionPrice Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of performance obligations. + ReferencesNo definition available. + Details Name: xoma_NumberOfPerformanceObligations Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. + ReferencesNo definition available. + Details Name: xoma_ProceedsFromUpfrontPayment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEquity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs. + ReferencesNo definition available. + Details Name: xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions, Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) $ in Thousands 3 Months Ended 9 Months Ended Dec. 21, 2016 USD ($) agreement period Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Licensing and other arrangements Â Â Â Â Â Â Unearned revenue recognized under units-of-revenue method Â Â Â $ (1,828) $ (1,575) Â Revenue recognized under units-of-revenue method Â $ 709 $ 605 1,828 1,575 Â Unearned revenue recognized under units-of-revenue method, current Â 1,924 Â 1,924 Â $ 2,113 Unearned revenue recognized under units-of-revenue method, noncurrent Â 5,589 Â 5,589 Â 7,228 HealthCare Royalty Partners II, L.P. | Royalty Sale Agreements Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Number of agreements | agreement 2 Â Â Â Â Â Unearned revenue recognized under units-of-revenue method $ 18,000 Â Â Â Â Â Revenue recognized under units-of-revenue method Â $ 700 $ 600 $ 1,800 $ 1,600 Â Unearned revenue recognized under units-of-revenue method, current Â Â Â Â Â 2,100 Unearned revenue recognized under units-of-revenue method, noncurrent Â Â Â Â Â $ 7,200 HealthCare Royalty Partners II, L.P. | First Royalty Sale Agreement Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Cash payment received 6,500 Â Â Â Â Â Â Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years $ 4,000 Â Â Â Â Â Number of milestone periods | period 3 Â Â Â Â Â HealthCare Royalty Partners II, L.P. | Second Royalty Sale Agreement Â Â Â Â Â Â Licensing and other arrangements Â Â Â Â Â Â Cash payment received $ 11,500 Â Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of agreements. + ReferencesNo definition available. + Details Name: xoma_AgreementsNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionEligible potential additional payments receivable upon achievement of specified future net sales milestones. + ReferencesNo definition available. + Details Name: xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of milestone periods for which entity is eligible to receive payments upon achievement of milestone. + ReferencesNo definition available. + Details Name: xoma_MilestonePeriodsNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionCash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. + ReferencesNo definition available. + Details Name: xoma_ProceedsFromUpfrontPayment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606, in accordance with the units-of-revenue method. + ReferencesNo definition available. + Details Name: xoma_RevenueNotFromContractWithCustomerUnitsOfRevenueMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Summary (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Royalty and Commercial Payment Purchase Agreements Â Â Short-term royalty and commercial payment receivables $ 12,682 $ 14,215 Long-term royalty and commercial payment receivables $ 54,207 $ 57,952 X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract Namespace Prefix: xoma_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Dare (Details) - USD ($) $ in Thousands 9 Months Ended Apr. 29, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Agreements Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â $ 37,000 $ 14,650 Â Receipts under RPAs, AAAs and CPPAs Â 26,263 $ 8,428 Â Long-term royalty and commercial payment receivables Â 54,207 Â $ 57,952 Short-term royalty and commercial payment receivables Â 12,682 Â $ 14,215 Royalty Purchase Agreement | Dare Â Â Â Â Agreements Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 22,000 Â Â Â Percentage of remaining royalties 100.00% Â Â Â Payable on milestone $ 11,000 Â Â Â Specified amount of each successive receipt that requires milestone payment 22,000 Â Â Â Return threshold $ 88,000 Â Â Â Short-term royalty and commercial payment receivables Â 0 Â Â Allowance for credit losses Â $ 0 Â Â Royalty Purchase Agreement | Dare | OVAPRENE Â Â Â Â Agreements Â Â Â Â Royalties entity has right to receive (as a percent) 4.00% Â Â Â Royalty Purchase Agreement | Dare | OVAPRENE | Upon achievement of a pre-specified return threshold Â Â Â Â Agreements Â Â Â Â Royalties entity has right to receive (as a percent) 2.50% Â Â Â Royalty Purchase Agreement | Dare | Sildenafil Cream Â Â Â Â Agreements Â Â Â Â Royalties entity has right to receive (as a percent) 2.00% Â Â Â Royalty Purchase Agreement | Dare | Sildenafil Cream | Upon achievement of a pre-specified return threshold Â Â Â Â Agreements Â Â Â Â Royalties entity has right to receive (as a percent) 1.25% Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of milestone payment for each successive specified amount received. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_PayableOnMilestone Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReturn threshold for determining milestone payments under the agreement. + ReferencesNo definition available. + Details Name: xoma_PayableOnMilestoneReturnThreshold Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSpecified amount of each successive receipt that requires milestone payment to counterparty under agreement. + ReferencesNo definition available. + Details Name: xoma_PayableOnMilestoneSpecifiedAmountOfEachSuccessiveReceipt Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + ReferencesNo definition available. + Details Name: xoma_ReceiptsUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of royalties applicable under terms of agreement. + ReferencesNo definition available. + Details Name: xoma_RoyaltyPercentageApplicableUnderAgreement Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalties entity has the right to receive as a percentage of net sales. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSales Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_DareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_OvapreneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=xoma_ScenarioOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_SildenafilCreamMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Talphera (Details) - USD ($) $ in Thousands 1 Months Ended 9 Months Ended Jan. 12, 2024 Apr. 30, 2023 Sep. 30, 2024 Sep. 30, 2023

Dec. 31, 2023 Agreements Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â $ 37,000 $ 14,650 Â Receipts under RPAs, AAAs and CPPAs Â Â 26,263 $ 8,428 Â Short-term royalty and commercial payment receivables Â Â 12,682 Â $ 14,215 Talphera | Commercial Payment Purchase Agreement Â Â Â Â Â Agreements Â Â Â Â Â Threshold amount for royalties and milestones $ 20,000 Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 8,000 Â Â Â Â Receipts under RPAs, AAAs and CPPAs Â Â 80 Â Â Short-term royalty and commercial payment receivables Â Â 0 Â Â Allowance for credit losses Â Â $ 0 Â Â Talphera | Commercial Payment Purchase Agreement | All customers excluding DoD Â Â Â Â Â Agreements Â Â Â Â Â Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive (as a percent) 100.00% Â Â Â Â Royalty percentage entity has the right to fully retain 15.00% Â Â Â Â Talphera | Commercial Payment Purchase Agreement | DoD Â Â Â Â Â Agreements Â Â Â Â Â Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive (as a percent) 100.00% Â Â Â Â Royalties shared equally with counterparty (as a percent) 75.00% Â Â Â Â Talphera | Alora Pharmaceuticals | Asset Purchase Agreement and Marketing Agreement Â Â Â Â Â Agreements Â Â Â Â Â Maximum milestone payments entitled to receive Â $ 116,500 Â Â Â Talphera | Alora Pharmaceuticals | Asset Purchase Agreement and Marketing Agreement | All customers excluding DoD Â Â Â Â Â Agreements Â Â Â Â Â Royalties entity has right to receive (as a percent) 15.00% 15.00% Â Â Â Talphera | Alora Pharmaceuticals | Asset Purchase Agreement and Marketing Agreement | DoD Â Â Â Â Â Agreements Â Â Â Â Â Royalties entity has right to receive (as a percent) 75.00% 75.00% Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + ReferencesNo definition available. + Details Name: xoma_ReceiptsUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThreshold amount for royalties and milestones for determining amount entity has the right to receive. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndMilestonesReceivableThreshold Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalties entity has the right to receive as a percentage of net sales. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSales Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive, up to specified threshold. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty percentage entity has the right to fully retain which counterparty is entitled to receive upon reaching specified threshold. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSalesFullyRetained Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalties entity has the right to receive as a percentage shared with counterparty upon reaching threshold. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_TalpheraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=xoma_U.s.DepartmentOfDefenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=xoma_TalpheraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AloraPharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_AssetPurchaseAgreementAndMarketingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - LadRx (Details) - USD ($) 3 Months Ended 9 Months Ended Jun. 03, 2024 Jan. 11, 2024 Jun. 21, 2023 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Agreements Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â $ 37,000,000 $ 14,650,000 Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â 4,000,000 Â $ 7,000,000 Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs Â Â Â Â Â Â $ (75,000) Â LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement Â Â Â Â Â Â Agreements Â Â Â Â Â Â Amount of regulatory milestone payment removed $ 4,000,000.0 Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â $ 5,000,000.0 Â Â Â Â Maximum regulatory and commercial sales milestone payments Â Â 6,000,000.0 Â Â Â Â Maximum commercial sales milestone payments Â Â 1,000,000.0 Â Â Â Â Contingent consideration, high-end of range Â Â Â Â 0 Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â 1,000,000.0 Â Â Acquisition of royalty and commercial payment receivables, Long-Term Â Â 6,000,000.0 Â Â Â Â Short-term royalty and commercial payment receivables from milestone payment Â Â Â Â 2,200,000 Â Â Short-term royalty and commercial payment receivables from royalty or commercial payment Â Â Â Â 0 Â Â Allowance for credit losses Â Â Â Â 0 Â 0 LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones Â Â Â Â Â Â Agreements Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â $ 1,000,000.0 Â $ 1,000,000.0 1,000,000.0 Â Â Contingent consideration, high-end of range Â Â 5,000,000.0 Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs $ 0 Â $ 1,000,000.0 $ 0 $ 0 Â $ 1,000,000.0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionChanges in estimated fair value of contingent consideration. + ReferencesNo definition available. + Details Name: xoma_ChangesInEstimatedFairValueOfContingentConsideration Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFor contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease (decrease) in potential amount payable on regulatory milestone. + ReferencesNo definition available. + Details Name: xoma_IncreaseDecreaseInPotentialAmountPayableOnRegulatoryMilestone Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_MaximumPayableOnSalesMilestone Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty and commercial payment receivables from milestone payment probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableFromMilestonePaymentCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty and commercial payment receivables from royalty or commercial payment probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableFromRoyaltyOrCommercialPaymentCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_LadrxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Aptevo (Details) - USD ($) 1 Months Ended 9 Months Ended 12 Months Ended Mar. 29, 2023 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Agreements Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â $ 37,000,000 $ 14,650,000 Â Contingent consideration under RPAs, AAAs and CPPAs Â Â 4,000,000 Â $ 7,000,000 Receipts under RPAs, AAAs and CPPAs Â Â 26,263,000 $ 8,428,000 Â Short-term royalty and commercial payment receivables Â Â 12,682,000 Â 14,215,000 Aptevo | Commercial Payment Purchase Agreement Â Â Â Â Â Agreements Â Â Â Â Â Maximum milestone payments entitled to receive $ 5,300,000 Â Â Â Â Acquisition of royalty and commercial payment receivables, Long-Term 9,700,000 Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs 9,600,000 $ 50,000 Â Â Â Maximum commercial sales milestone payments 50,000 Â Â Â Â Commercial payments attributable to net sales threshold 500,000 Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs $ 50,000 Â Â Â Â Receipts under RPAs, AAAs and CPPAs Â Â 800,000 Â 1,700,000 Short-term royalty and commercial payment receivables Â Â 2,200,000 Â 2,000,000.0 Allowance for credit losses Â Â $ 0 Â $ 0 Aptevo | Commercial Payment Purchase Agreement | Minimum Â Â Â Â Â Agreements Â Â Â Â Â Receipts under RPAs, AAAs and CPPAs Â $ 500,000 Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement. + ReferencesNo definition available. + Details Name: xoma_CommercialPaymentThresholdOneTimePayment Namespace Prefix: xoma_

Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_MaximumPayableOnSalesMilestone Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + ReferencesNo definition available. + Details Name: xoma_ReceiptsUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_AptevoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Palobiofarma (Details) $ in Thousands 9 Months Ended Sep. 26, 2019 USD ($) item Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Agreements Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â $ 37,000 $ 14,650 Â Long-term royalty and commercial payment receivables Â 54,207 Â $ 57,952 Short-term royalty and commercial payment receivables Â 12,682 Â 14,215 Palobiofarma | Royalty Purchase Agreement Â Â Â Â Agreements Â Â Â Â Number of drug candidates | item 6 Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 10,000 Â Â Â Long-term royalty and commercial payment receivables $ 10,000 Â Â Â Allowance for credit losses Â $ 0 Â $ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of drug candidates under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_AgreementDrugCandidatesNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands 3 Months Ended 9 Months Ended May 30, 2024 USD ($) Apr. 23, 2024 USD ($) Oct. 30, 2023 USD ($) Apr. 23, 2023 USD ($) Mar. 22, 2021 USD ($) item Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Agreements Â Â Â Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â Â $ 37,000 $ 14,650 Â Short-term royalty and commercial payment receivables Â Â Â Â Â $ 12,682 Â 12,682 Â $ 14,215 Long-term royalty and commercial payment receivables Â Â Â Â Â 54,207 Â 54,207 Â 57,952 Trade and other receivables, net Â Â Â Â Â Â 1,045 Â 1,045 Â 1,004 Viracta | Royalty Purchase Agreement Â Â Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Â Â Â Number of drug candidates | item Â Â Â Â 2 Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â Â $ 13,500 Â Â Â Â Â Â Maximum amount of potential milestones, potential royalties on sales and other payments receivable Â Â Â Â 54,000 Â Â Â Â Â Amount of maximum consideration retained Â Â Â Â 5,000 Â Â Â Â Â Â Maximum amount of potential regulatory and commercial milestones receivable Â Â Â 57,000 Â Â Â Â Â Acquisition of royalty and commercial payment receivables, Long-Term Â Â Â Â Â $ 13,500 Â Â Â Â Â Amount of milestone payments earned under agreement Â $ 9,000 $ 5,000 Â Â Â Â Â Â Â Reduction in long-term royalty receivable balance due to receipt of payment Â $ 8,500 $ 5,000 Â Â Â Â Â Â Â Â Income from purchased receivables Â Â Â Â Â 1,000 $ 0 1,900 $ 0 Â Sale of priority review voucher to undisclosed buyer $ 108,000 Â Â Â Â Â Â Â Â Â Â Long-term royalty and commercial payment receivables Â Â Â Â Â 0 Â 0 Â Â Allowance for credit losses Â Â Â Â Â Â Â Â Â Â 0 Trade and other receivables, net Â Â Â Â Â Â $ 1,000 Â 1,000 Â $ 0 Viracta | Royalty Purchase Agreement | OJEMDA Â Â Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Â Â Â Income from purchased receivables Â Â Â $ 500 Â Â Â Â Â Â Viracta | Royalty Purchase Agreement | Priority review voucher. Â Â Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Â Â Â Income from purchased receivables $ 8,100 Â Â Â Â Â Â Â $ 8,100 Â Â X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of drug candidates under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_AgreementDrugCandidatesNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of income that is not accounted for under Topic 606, in accordance with the cost recovery method. + ReferencesNo definition available. + Details Name: xoma_IncomeNotFromContractWithCustomerCostRecoveryMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement. + ReferencesNo definition available. + Details Name: xoma_MaximumConsiderationRetained Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of milestone achieved. + ReferencesNo definition available. + Details Name: xoma_MilestoneAchieved Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones. + ReferencesNo definition available. + Details Name: xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount representing sale of priority review voucher. + ReferencesNo definition available. + Details Name: xoma_PriorityReviewVoucherSale Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDecrease in long-term rights receivable due to receipt of royalty and commercial payments. + ReferencesNo definition available. + Details Name: xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_RegulatoryAndCommercialMilestonesReceivableMaximum Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_TovorafenibMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_PriorityReviewVoucherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($) $ in Thousands 1 Months Ended 9 Months Ended Jul. 14, 2021 Jul. 31, 2022 May 31, 2022 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Agreements Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â $ 37,000 $ 14,650 Â Short-term royalty and commercial payment receivables Â Â Â 12,682 Â $ 14,215 Receipts under RPAs, AAAs and CPPAs Â Â Â 26,263 $ 8,428 Â Long-term royalty and commercial payment receivables Â Â Â 54,207 Â 57,952 Kuros | Royalty Purchase Agreement Â Â Â Â Â Â Agreements Â Â Â Â Â Â Royalties entity has right to receive (as a percent) 100.00% Â Â Â Â Â Pre-commercial milestone payments, maximum $ 25,500 Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs 7,000 Â Â Â Â Â Maximum commercial sales milestone payments 142,500 Â Â Â Â Â Acquisition of royalty and commercial payment receivables, Long-Term $ 7,000 Â Â Â Â Â Milestone payment received by Kuros Â Â $ 5,000 Â Â Â Percentage of milestone payment received by Kuros that company is entitled to receive Â 50.00% Â Â Â Â Reduction in long-term royalty receivable balance due to receipt of payment Â $ 2,500 Â Â Â Â Allowance for credit losses Â Â Â $ 0 Â $ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum eligible milestone payments receivable upon achievement of pre-commercial milestones. +

ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_MaximumPayableOnSalesMilestone Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of milestone payment received by counterparty entity is entitled to receive. + ReferencesNo definition available. + Details Name: xoma_MilestonePaymentReceivablePercentage Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period. + ReferencesNo definition available. + Details Name: xoma_MilestonePaymentReceivedCounterparty Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDecrease in long-term rights receivable due to receipt of royalty and commercial payments. + ReferencesNo definition available. + Details Name: xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + ReferencesNo definition available. + Details Name: xoma_ReceiptsUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalties entity has the right to receive as a percentage of net sales. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSales Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Oct. 06, 2021 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Apr. 01, 2024 Agreements Â Â Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â $ 37,000,000 $ 14,650,000 Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â $ 4,000,000 Â 4,000,000 Â $ 7,000,000 Â Â Receipts under RPAs, AAAs and CPPAs Â Â Â 26,263,000 $ 8,428,000 Â Â Â Short-term royalty and commercial payment receivables Â 12,682,000 Â 12,682,000 Â $ 14,215,000 Â Â Income from purchased receivables under EIR Method, Short-Term Â Â Â 9,985,000 Â Â Â Affitech | Commercial Payment Purchase Agreement Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 6,000,000.0 Â $ 6,000,000.0 Â Â Â Â Â Period from each royalty payment date payment is due Â Â Â Â Â 60 days Â Â Maximum regulatory and commercial sales milestone payments 20,000,000.0 Â Â Â Â Â Â Â Acquisition of royalty and commercial payment receivables, Long-Term 14,000,000.0 Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â 0 Â Â Â Â Â Â Maximum commercial sales milestone payments $ 12,000,000.0 Â Â Â Â Â Â Â Receipts under RPAs, AAAs and CPPAs Â Â Â 16,900,000 Â Â Â Â Recognition of contingent consideration, Short-Term Â Â Â 3,000,000.0 Â Â Â Â Recognition of contingent consideration, Long-Term Â Â Â Â Â $ 6,000,000.0 Â Â Allowance for credit losses Â 0 Â 0 Â 0 Â Royalty and commercial payment receivable Â Â Â Â Â Â Â $ 7,800,000 Income from purchased receivables under EIR Method, Short-Term Â 5,400,000 Â 10,000,000.0 Â Â Â Â Affitech | Commercial Payment Purchase Agreement | United States Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â Â $ 5,000,000.0 Â Affitech | Commercial Payment Purchase Agreement | Europe Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â Â $ 3,000,000.0 Â Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO) Â Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Â Â Payments eligible to receive (as a percent) 0.50% Â Â Â Â Â Â Â Commercial payment receivable term 10 years Â Â Â Â Â Â Â Affitech | Commercial Payment Purchase Agreement | Regulatory milestones Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs $ 8,000,000.0 Â Â Â Â Â Â Â Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, first and second Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â $ 0 Â Â $ 6,000,000.0 Â Â Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, third Â Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â 3,000,000.0 Â 3,000,000.0 Â Â Â Â Short-term royalty and commercial payment receivables Â $ 3,000,000.0 Â $ 3,000,000.0 Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod from each royalty payment date payment is due from customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: xoma_CommercialPaymentPeriodDue Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of commercial payment receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: xoma_CommercialPaymentReceivableTerm Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPayments entity eligible to receive as a percentage of net sales. + ReferencesNo definition available. + Details Name: xoma_CommercialSalesReceivablePercentageOnNetSales Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease in short-term rights receivable due to income from purchased receivables under effective interest rate method. + ReferencesNo definition available. + Details Name: xoma_IncomeFromPurchasedReceivablesUnderEffectiveInterestRateMethodCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_MaximumPayableOnSalesMilestone Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + ReferencesNo definition available. + Details Name: xoma_ReceiptsUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial rights receivable. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivable Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in short-term rights receivable due to recognition of contingent consideration. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialPaymentReceivableCurrentRecognitionOfContingentConsideration Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease in long-term rights receivable due to recognition of contingent consideration. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_FaricimabProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesOneAndTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Agenus (Details) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Sep. 20, 2018 USD ($) product Nov. 30, 2020 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Agreements Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â $ 37,000 $ 14,650 Â Short-term royalty and commercial payment receivables Â Â $ 12,682 12,682 Â $ 14,215 Royalty purchase agreement asset impairment Â Â 14,000 23,000 $ 1,575 Â Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus Â Â Â Â Â Â Agreements Â Â Â Â Â Â Amount of milestone payments earned under agreement Â $ 10,000 Â Â Â Â Agenus | Royalty Purchase Agreement Â Â Â Â Â Â Agreements Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 15,000 Â Â Â Â Â Â Acquisition of royalty and commercial payment receivables, Long-Term $ 15,000 Â Â Â Â Â Royalty purchase agreement asset impairment Â Â 14,000 Â Â Â Allowance for credit losses Â Â $ 14,000 $ 14,000 Â $ 0 Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets Â Â Â Â Â Â Agreements Â Â Â Â Â Â Royalties entity has right to receive (as a percent) 33.00% Â Â Â Â Â Â Number of licensed products related to milestone and royalties | product 6 Â Â Â Â Â Â Milestone payments entity has right to receive (as a percent) 10.00% Â Â Â Â Â Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product Â Â Â Â Â Â Agreements Â Â Â Â Â Â Royalties entity has right to receive (as a percent) 33.00% Â Â Â Â Â Milestone payments entity has right to receive (as a percent) 10.00% Â Â Â Â Â Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500 Â Â Â Â Â Amount of milestone payments earned under agreement Â 1,000 Â Â Â Â Reduction in long-term royalty receivable balance due to receipt of payment Â $ 1,000 Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment. + ReferencesNo definition available. + Details Name: xoma_ImpairmentOfLongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of milestone achieved. + ReferencesNo definition available. + Details Name: xoma_MilestoneAchieved Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of licensed products related to

milestones and royalties purchased. + ReferencesNo definition available. + Details Name: xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones. + ReferencesNo definition available. + Details Name: xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of milestones entity has the right to receive as a percentage. + ReferencesNo definition available. + Details Name: xoma_PurchasedPercentageOfMilestones Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDecrease in long-term rights receivable due to receipt of royalty and commercial payments. + ReferencesNo definition available. + Details Name: xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalties entity has the right to receive as a percentage of net sales. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSales Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=xoma_AgenusIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AgenusIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Aronora (Details) 1 Months Ended 3 Months Ended 9 Months Ended Apr. 07, 2019 USD ($) multiplier item Sep. 30, 2019 USD ($) Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Agreements Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â $ 37,000,000 $ 14,650,000 Â Contingent consideration under RPAs, AAAs and CPPAs Â Â $ 4,000,000 Â 4,000,000 Â $ 7,000,000 Short-term royalty and commercial payment receivables Â Â 12,682,000 Â 12,682,000 Â 14,215,000 Royalty purchase agreement asset impairment Â Â $ 14,000,000 Â $ 23,000,000 $ 1,575,000 Â Aronora | Royalty Purchase Agreement Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Number of drug candidates | item 5 Â Â Â Â Â Â Â Non-royalties to be received (as a percent) 10.00% Â Â Â Â Â Â Â Future non-royalty payments to be received (as a percent) 5.00% Â Â Â Â Â Â Â Multiplier for cumulative amount of consideration paid | multiplier 2 Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 6,000,000.0 $ 3,000,000.0 Â Â Â Â Â Â Threshold amount of cumulative royalties on net sales per product 250,000,000.0 Â Â Â Â Â Â Â Maximum royalty milestone payments to be paid per product 85,000,000.0 Â Â Â Â Â Â Â Acquisition of royalty and commercial payment receivables, Long-Term 9,000,000.0 Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs 3,000,000.0 Â Â Â Â Â Â Â Royalty purchase agreement asset impairment Â Â Â $ 9,000,000.0 Â Â Â Â Amount of increase in allowance for credit loss Â Â Â 9,000,000.0 Â Â Â Allowance for credit losses Â Â Â Â Â Â Â $ 0 Decrease in long-term royalty and commercial rights receivables due to impairment Â Â Â $ 9,000,000.0 Â Â Â Aronora | Royalty Purchase Agreement | Minimum Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Threshold amount of cumulative royalties on net sales per product 25,000,000.0 Â Â Â Â Â Â Â Aronora | Royalty Purchase Agreement | SVB Loan Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs $ 3,000,000.0 Â Â Â Â Â Â Â Aronora | Royalty Purchase Agreement | Bayer Products Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Number of drug candidates | item 3 Â Â Â Â Â Â Â Number of drug candidates subject to exclusive license option | item 1 Â Â Â Â Â Â Â Royalties entity has right to receive (as a percent) 100.00% Â Â Â Â Â Â Â Non-royalties to be received (as a percent) 10.00% Â Â Â Â Â Â Â Contingent future cash payment for each product $ 1,000,000.0 Â Â Â Â Â Â Â Aronora | Royalty Purchase Agreement | Bayer Products | Maximum Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs $ 3,000,000.0 Â Â Â Â Â Â Â Aronora | Royalty Purchase Agreement | Non-Bayer Products Â Â Â Â Â Â Â Agreements Â Â Â Â Â Â Â Number of drug candidates 2 Â Â Â Â Â Â Â Non-royalties to be received (as a percent) 10.00% Â Â Â Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_ContractWithCustomerAssetAllowanceForCreditLossPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionNumber of drug candidates subject to exclusive license option. + ReferencesNo definition available. + Details Name: xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of drug candidates under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_AgreementDrugCandidatesNumber Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionMultiplier used in determining change in payment percentage. + ReferencesNo definition available. + Details Name: xoma_AgreementPaymentPercentageFactor Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + ReferencesNo definition available. + Details Name: xoma_ContingentFutureCashPaymentsPerProduct Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThreshold amount of cumulative royalties on net sales per product under the terms of the agreement + ReferencesNo definition available. + Details Name: xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment. + ReferencesNo definition available. + Details Name: xoma_ImpairmentOfLongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDecrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement. + ReferencesNo definition available. + Details Name: xoma_MilestonesPaymentsToAggregateAmountOfPerProduct Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchased percentage of non-royalties on net sales of products. + ReferencesNo definition available. + Details Name: xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFuture non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid. + ReferencesNo definition available. + Details Name: xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + ReferencesNo definition available. + Details Name: xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalties entity has the right to receive as a percentage of net sales. + ReferencesNo definition available. + Details Name: xoma_RoyaltyReceivablePercentageOnNetSales Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_AronoraIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_BayerProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=xoma_NonBayerProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method $ 72,167 Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method 30,000 Receipt of Royalty and Commercial Payments, Cost Recovery Method (16,770) Recognition of Contingent Consideration, Cost Recovery Method 4,000 Impairment of Royalty and Commercial Payment Receivables, Recovery Method (23,000) Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, Cost Recovery Method (7,795) Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 58,602 Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, EIR Method 7,795 Income from Purchased Receivables Under EIR Method 9,985 Receipt of Royalty and Commercial Payments, EIR Method (9,493) Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method 8,287 Dare Â Agreements Â Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method 22,000 Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 22,000 Talphera Â Agreements Â Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method 8,000 Receipt of Royalty and Commercial Payments, Cost Recovery Method (80) Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 7,920 LadRx Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 6,000 Recognition of Contingent Consideration, Cost Recovery Method 1,000 Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 7,000 Aptevo Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 7,976 Receipt of Royalty and Commercial Payments, Cost Recovery Method (794) Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 7,182 Agenus Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 14,000 Impairment of Royalty and Commercial Payment Receivables, Recovery Method (14,000) Aronora Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 9,000 Impairment of Royalty and Commercial Payment Receivables, Recovery Method (9,000) Palobiofarma Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 10,000 Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 10,000 Viracta Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 8,500 Receipt of Royalty and Commercial Payments, Cost Recovery Method (8,500) Kuros Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 4,500 Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 4,500 Affitech Â Agreements Â Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method 12,191 Receipt of Royalty and Commercial Payments, Cost Recovery Method (7,396) Recognition of Contingent Consideration, Cost Recovery Method 3,000 Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, Cost Recovery Method (7,795) Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, EIR Method 7,795 Income from Purchased Receivables Under EIR Method 9,985 Receipt of Royalty and Commercial Payments, EIR Method (9,493) Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method $ 8,287 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRoyalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable under costs recovery method. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCostRecoveryMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease in rights receivable due to acquisition of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCostRecoveryMethodAcquisitionOfPaymentReceivable Namespace Prefix: xoma_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionImpairment of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCostRecoveryMethodImpairmentOfPaymentReceivable Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDecrease in rights receivable due to receipt of royalty and commercial payments under the cost recovery method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCostRecoveryMethodReceiptOfPayments Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in rights receivable due to reclassification of royalty and commercial payment receivables from cost recovery to EIR method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCostRecoveryMethodReclassificationOfPaymentReceivablesFromCostRecoveryToEirMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease in rights receivable due to recognition of contingent consideration under the cost recovery method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCostRecoveryMethodRecognitionOfContingentConsideration Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalty and commercial payment receivables under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableEirMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncrease (decrease) in rights receivable due to income (loss) from purchased receivables under EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableEirMethodIncomeFromPurchasedReceivables Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDecrease in rights receivable due to receipt of royalty and commercial payments under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableEirMethodReceiptOfPayments Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in rights receivable due to reclassification of royalty and commercial payment receivables from cost recovery to EIR method. Includes both current and noncurrent rights receivable under EIR (Effective interest rate) method. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableEirMethodReclassificationOfPaymentReceivablesFromCostRecoveryToEirMethod Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_DareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_TalpheraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_LadrxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AptevoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AgenusIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AronoraIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets: Â Â Exarafenib milestone asset (Note 4) $ 3,125 Â Liabilities: Â Â Exarafenib milestone contingent consideration (Note 4) 3,125 Â Fair Value, Recurring Â Â Assets: Â Â Cash equivalents 138,032 $ 28,352 Exarafenib milestone asset (Note 4) 3,125 Â Equity securities 785 161 Total financial assets 141,942 28,513 Liabilities: Â Â Exarafenib milestone contingent consideration (Note 4) 3,125 Â Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value Â 1,000 Total financial liabilities 3,125 Â Fair Value, Recurring | Money market funds Â Â Assets: Â Â Cash equivalents 112,895 28,352 Fair Value, Recurring | U.S. treasury bills Â Â Assets: Â Â Cash equivalents 25,137 Â Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Assets: Â Â Cash equivalents 138,032 28,352 Equity securities 785 161 Total financial assets 138,817 28,513 Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds Â Â Assets: Â Â Cash equivalents 112,895 28,352 Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. treasury bills Â Â Assets: Â Â Cash equivalents 25,137 Â Fair Value, Recurring | Significant Unobservable Inputs (Level 3) Â Â Assets: Â Â Exarafenib milestone asset (Note 4) 3,125 Â Total financial assets 3,125 Â Liabilities: Â Â Exarafenib milestone contingent consideration (Note 4) 3,125 Â Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value Â $ 1,000 Total financial liabilities $ 3,125 Â X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContingent consideration, fair value disclosure. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationFairValueDisclosure Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial assets. + ReferencesNo definition available. + Details Name: xoma_FinancialAssetsFairValueDisclosure Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. + ReferencesNo definition available. + Details Name: xoma_MilestoneAssetsNoncurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Apr. 03, 2024 Fair Value Measurements Â Â Exarafenib milestone asset (Note 4) $ 3,125 Â Exarafenib milestone contingent consideration (Note 4) 3,125 Â Kinnate CVR holders | CVR Agreement Â Â Fair Value Measurements Â Â Exarafenib milestone asset (Note 4) 3,100 $ 2,900 Exarafenib milestone contingent consideration (Note 4) 3,100 $ 2,900 Increase in Exarafenib milestone asset 200 Â Increase in Exarafenib milestone contingent consideration $ 200 Â X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the value during the period from contingent consideration liability. + ReferencesNo definition available. + Details Name: xoma_AssetAcquisitionContingentConsiderationLiabilityChangeInAmount Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825. + ReferencesNo definition available. + Details Name: xoma_MilestoneAssetsIncreaseDecrease Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. + ReferencesNo definition available. + Details Name: xoma_MilestoneAssetsNoncurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=xoma_KinnateCvrHoldersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Equity Securities (Details) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Closing common stock price | Rezolute Â Â Fair Value Measurements Â Â Valuation assumptions, measurement input 4.85 0.99 X - DefinitionValue of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_EquitySecuritiesFvNiMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_RezoluteIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Contingent Consideration (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Jan. 11, 2024 Jun. 21, 2023 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Jun. 03, 2024 Dec. 31, 2023 Fair Value Measurements Â Â Â Â Â Â Â Exarafenib milestone contingent consideration (Note 4) Â Â Â $ 3,125 Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â 4,000 Â Â $ 7,000 Payments of consideration under RPAs, AAAs and CPPAs Â Â Â 37,000 $ 14,650 Â LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement Â Â Â Â Â Â Â Fair Value Measurements Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â 1,000 Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â $ 5,000 Â Â Â Â Â Â Contingent consideration, high-end of range Â Â Â 0 Â Â Â LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones Â Â Â Â Â Â Â Fair Value Measurements Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â 1,000 $ 0 0 Â $ 0 $ 1,000 Payments of consideration under RPAs, AAAs and CPPAs $ 1,000 Â $ 1,000 $ 1,000 Â Â Â Contingent consideration, high-end of range Â $ 5,000 Â Â Â Â Â Â X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-

gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=xoma_LadrxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Agreements - Leased facilities (Details) - USD ($) $ in Thousands 1 Months Ended Jan. 31, 2023 Sep. 30, 2024 Apr. 03, 2024 Dec. 31, 2023 Nov. 10, 2023 Leases Â Â Â Â Â Operating lease right-of-use assets Â $ 335 Â $ 378 Â Operating lease liabilities Â 1,028 Â 400 Â Current operating lease liabilities Â 434 Â 54 Â Non-current operating lease liabilities Â $ 594 Â $ 335 Â Leased facilities, Emeryville, California, with lease expiration of July 31, 2023 Â Â Â Â Â Leases Â Â Â Â Â Period of lease extension 5 months Â Â Â Â Existence of option to extend false Â Â Â Â Adjustment to right of use asset for lease modification $ 100 Â Â Â Â Leased facilities, Emeryville, California, new lease - different location than previous lease Â Â Â Â Â Leases Â Â Â Â Â Lease term Â Â Â Â Â 65 months Operating lease right-of-use assets Â Â Â Â $ 400 Operating lease liabilities Â Â Â Â $ 400 Leased facilities, Kinnate lease with lease expiration of June 30, 2026 Â Â Â Â Â Leases Â Â Â Â Â Operating lease right-of-use assets Â Â $ 0 Â Â Operating lease liabilities Â Â Â $ 800 Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of adjustment to right of use asset resulting from modification of operating lease. + ReferencesNo definition available. + Details Name: xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesSanFranciscoCaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Agreements - Maturity of lease liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Lease Agreements Â Â 2024 (excluding the nine months ended September 30, 2024) $ 117 Â 2025 502 Â 2026 300 Â 2027 91 Â 2028 102 Â Thereafter 36 Â Total undiscounted lease payments 1,148 Â Present value adjustment (120) Â Total net lease liability for operating leases 1,028 $ 400 Current operating lease liabilities 434 54 Non-current operating lease liabilities $ 594 $ 335 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following current fiscal year. + ReferencesNo definition available. + Details Name: xoma_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Agreements - Lease costs (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Lease costs Â Â Â Â Operating lease cost $ 36 $ 17 $ 97 $ 116 Variable lease cost Â 20 18 32 Total lease costs $ 36 $ 37 $ 115 $ 148 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases, net credit due. + ReferencesNo definition available. + Details Name: xoma_VariableLeaseCostNet Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Agreements - Additional information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Supplemental disclosure for the condensed consolidated statements of cash flows Â Â Â Â Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases Â $ 68 $ 121 Â Weighted-average remaining lease term, Operating leases 2 years 8 months 12 days 2 years 8 months 12 days Â 5 years 3 months 29 days Weighted-average discount rate, Operating leases 8.18% 8.18% Â 8.50% Sublease income $ 100 $ 200 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards

Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt - Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Dec. 15, 2023 Sep. 30, 2024 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Long-term debt Â Â Â Â Â Â Current portion of long-term debt Â $ 9,826 $ 9,826 Â $ 9,826 $ 5,543 Long-term debt Â $ 108,089 $ 108,089 Â 108,089 $ 118,518 Cash paid for interest Â Â Â Â 9,985 Â Principal repayment Â Â Â Â $ 6,902 Â Common Stock Warrants, Exercise price of $35.00 per share Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Exercise price of warrants (in dollars per share) Â $ 35.00 $ 35.00 Â $ 35.00 $ 35.00 Common Stock Warrants, Exercise price of $42.50 per share Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Exercise price of warrants (in dollars per share) Â 42.50 42.50 Â 42.50 42.50 Common Stock Warrants, Exercise price of $50.00 per share Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Exercise price of warrants (in dollars per share) Â $ 50.00 $ 50.00 Â $ 50.00 $ 50.00 Blue Owl Loan Agreement Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Maximum borrowing capacity $ 140,000 Â Â Â Â Â Interest rate (as a percent) 9.875% Â Â Â Â Â Security interest as a percentage of equity of wholly owned subsidiary 100.00% Â Â Â Â Â Blue Owl Loan Agreement | Common Stock Warrants, Issued December 2023 Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Fair value of warrants $ 1,500 Â Â Â Â Â Blue Owl Loan Agreement | Common Stock Warrants, Exercise price of $35.00 per share Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Warrants to purchase shares of common stock 40,000 Â Â Â Â Â Exercise price of warrants (in dollars per share) $ 35.00 Â Â Â Â Â Blue Owl Loan Agreement | Common Stock Warrants, Exercise price of $42.50 per share Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Warrants to purchase shares of common stock 40,000 Â Â Â Â Â Exercise price of warrants (in dollars per share) $ 42.50 Â Â Â Â Â Blue Owl Loan Agreement | Common Stock Warrants, Exercise price of $50.00 per share Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Warrants to purchase shares of common stock 40,000 Â Â Â Â Â Exercise price of warrants (in dollars per share) $ 50.00 Â Â Â Â Â Blue Owl Loan Agreement, Initial term loan Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Maximum borrowing capacity $ 130,000 Â Â Â Â Â Aggregate principal amount 130,000 Â Â Â Â Â Proceeds from issuance of long-term debt, net 119,600 Â Â Â Â Â Fees and lender expenses 4,100 Â Â Â Â Â Amount deposited into reserve accounts to pay interest, administrative fees and operating expenses 6,300 Â Â Â Â Â Debt issuance costs 600 $ 700 $ 700 Â $ 700 Â Gross principal 130,000 $ 123,098 $ 123,098 Â $ 123,098 $ 130,000 Effective interest rate (as a percent) Â 11.16% 11.16% Â 11.16% 11.01% Debt discount costs 5,300 $ 4,500 $ 4,500 Â $ 4,500 Â Debt discount, allocated fees and lender expenses 3,800 Â Â Â Â Â Current portion of long-term debt Â 9,826 9,826 Â 9,826 $ 5,500 Long-term debt Â 108,089 108,089 Â 108,089 118,500 Interest expense Â Â $ 3,493 Â 10,446 $ 600 Semi-annual payment, principal and interest Â 9,500 Â $ 7,400 Â Â Cash paid for interest Â 6,200 Â 3,800 Â Â Principal repayment Â $ 3,300 Â $ 3,600 6,902 Â Blue Owl Loan Agreement, Initial term loan | Common Stock Warrants, Issued December 2023 Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Fair value of warrants 1,500 Â Â Â Â Â Blue Owl Loan Agreement, Delayed draw term loan Â Â Â Â Â Â Long-term debt Â Â Â Â Â Â Maximum borrowing capacity 10,000 Â Â Â Â Â Proceeds from issuance of long-term debt Â Â Â Â $ 0 Â Allocated costs for the term loan commitment $ 300 Â Â Â Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate amount of interest paid or due on all long-term debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SECReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestExpenseLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value portion of warrants not settleable in cash classified as equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount deposited into reserve accounts to pay interest, administrative fees and operating expenses. + ReferencesNo definition available. + Details Name: xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount associated with allocated fees and lender expenses. + ReferencesNo definition available. + Details Name: xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow for loan fees and lender expenses. + ReferencesNo definition available. + Details Name: xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer, net of fees and lender expenses and reserve accounts. + ReferencesNo definition available. + Details Name: xoma_ProceedsFromIssuanceOfLongTermDebtNet Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Also includes interest payment of associated interest. + ReferencesNo definition available. + Details Name: xoma_RepaymentsOfLongTermDebtAndInterestPaid Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe security interest provided by entity as a percentage of equity of specified wholly owned subsidiary under loan agreement. + ReferencesNo definition available. + Details Name: xoma_SecurityInterestInPercentageOfEquity Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt - Balance (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Dec. 15, 2023 Long-term debt Â Â Â Â Â Principal repayments Â Â $ (6,902) Â Â Less: current portion of long-term debt $ (9,826) Â (9,826) $ (5,543) Â Long-term debt 108,089 Â 108,089 118,518 Â Blue Owl Loan Agreement, Initial term loan Â Â Â Â Â Long-term debt Â Â Â Â Â Gross principal 123,098 Â 123,098 130,000 $ 130,000 Principal repayments (3,300) $ (3,600) (6,902) Â Â Unaccreted debt discount and debt issuance costs (5,183) Â (5,183) Â Â Total carrying value net of principal repayments, unaccreted debt discount and debt issuance costs 117,915 Â 117,915 124,000 Â Less: current portion of long-term debt (9,826) Â (9,826) (5,500) Â Long-term debt $ 108,089 Â $ 108,089 $ 118,500 Â X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50

-Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt - Aggregate projected future principal and discounts (Details) - Blue Owl Loan Agreement, Initial term loan - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Dec. 15, 2023 Long-term debt Â Â Â 2025 $ 11,274 Â Â Â 2026 17,825 Â Â Â 2027 23,885 Â Â Â 2028 29,761 Â Â Â Thereafter 40,353 Â Â Â Total payments $ 123,098 $ 130,000 $ 130,000 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: xoma_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt - Interest expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Long-term debt Â Â Â Accretion of debt discount and debt issuance costs Â $ 996 Â Blue Owl Loan Agreement, Initial term loan Â Â Â Long-term debt Â Â Â Accrued interest expense $ 3,085 9,450 Â Accretion of debt discount and debt issuance costs 408 996 Â Total interest expense $ 3,493 $ 10,446 $ 600 X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate amount of interest paid or due on all long-term debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SECReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestExpenseLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Warrants Â Â Warrant outstanding (in shares) 131,177 131,177 Common Stock Warrants, Issued May 2018 Â Â Warrants Â Â Exercise price of warrants (in dollars per share) $ 23.69 Â Warrant outstanding (in shares) 6,332 6,332 Common Stock Warrants, Issued March 2019 Â Â Warrants Â Â Exercise price of warrants (in dollars per share) $ 14.71 $ 14.71 Warrant outstanding (in shares) 4,845 4,845 Common Stock Warrants, Exercise price of $35.00 per share Â Â Warrants Â Â Exercise price of warrants (in dollars per share) $ 35.00 $ 35.00 Warrant outstanding (in shares) 40,000 40,000 Common Stock Warrants, Exercise price of $42.50 per share Â Â Warrants Â Â Exercise price of warrants (in dollars per share) $ 42.50 $ 42.50 Warrant outstanding (in shares) 40,000 40,000 Common Stock Warrants, Exercise price of $50.00 per share Â Â Warrants Â Â Exercise price of warrants (in dollars per share) $ 50.00 $ 50.00 Warrant outstanding (in shares) 40,000 40,000 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) $ in Millions Sep. 30, 2024 USD ($) product Commitments and Contingencies Â Estimate of milestone payments | $ $ 6.3 Assumed number of products per contract | product 1 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEstimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees. Represent contingent payments not recorded on balance sheet. + ReferencesNo definition available. + Details Name: xoma_ContractualObligationEstimatedMilestonePayments Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAssumed number of products per contract meeting milestone events used to calculate potential milestone obligations. + ReferencesNo definition available. + Details Name: xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant XML 86 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Contingent Consideration (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Jan. 11, 2024 Jun. 21, 2023 Mar. 29, 2023 Oct. 06, 2021 Jun. 30, 2023 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Jun. 03, 2024 Apr. 03, 2024 Dec. 31, 2023 Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â Â $ 4,000,000 Â Â Â $ 7,000,000 Exarafenib milestone contingent consideration Â Â Â Â Â Â 3,125,000 Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â Â 37,000,000 $ 14,650,000 Â Â Â Changes in estimated fair value of contingent consideration Â Â Â Â Â Â Â $ 75,000 Â Â Â Short-term royalty and commercial payment receivables Â Â Â Â Â Â 12,682,000 Â Â Â 14,215,000 Long-term royalty and commercial payment receivables Â Â Â Â Â Â 54,207,000 Â Â Â 57,952,000 Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â 1,000,000.0 Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â $ 5,000,000.0 Â Â Â Â Â Â Â Â Â Â Long-term royalty and commercial payment receivables Â Â Â Â Â Â 1,000,000.0 Â Â Â Â Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx | Regulatory milestones Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â $ 1,000,000.0 Â Â Â $ 0 0 Â $ 0 Â 1,000,000.0 Payments of consideration under RPAs, AAAs and CPPAs $ 1,000,000.0 Â Â Â Â 1,000,000.0 1,000,000.0 Â Â Â Â Commercial Payment Purchase Agreement | Aptevo Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â $ 50,000 Â Â Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â $ 9,600,000 Â $ 50,000 Â Â Â Â Â Â Short-term royalty and commercial payment receivables Â Â Â Â Â Â 2,200,000 Â Â Â 2,000,000.0 Commercial Payment Purchase Agreement | Affitech Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â 0 Â Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â $ 6,000,000.0 Â 6,000,000.0 Â Â Â Â Â Commercial Payment Purchase Agreement | Affitech | Regulatory milestones Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â $ 8,000,000.0 Â Â Â Â Â Â Â Commercial Payment Purchase Agreement | Affitech | Sales-based milestones, first and second Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â Â Â $ 0 Â Â Â Â 6,000,000.0 Long-term royalty and commercial payment receivables Â Â Â Â Â Â Â Â Â $ 6,000,000.0 Commercial Payment Purchase Agreement | Affitech | Sales-based milestones, third Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Contingent consideration under RPAs, AAAs and CPPAs Â Â Â Â Â 3,000,000.0 Â Â Â Â Short-term royalty and commercial payment receivables Â Â Â Â Â 3,000,000.0 Â Â Â Â CVR Agreement | Kinnate CVR holders Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies Â Â Â Â Â Â Â Â Â Â Exarafenib milestone contingent consideration Â Â Â Â Â Â $ 3,100,000 Â Â $ 2,900,000 Â X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionChanges in estimated fair value of contingent consideration. + ReferencesNo definition available. + Details Name: xoma_ChangesInEstimatedFairValueOfContingentConsideration Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: xoma_CommitmentsAndContingenciesLineItems Namespace Prefix: xoma_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLiability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + ReferencesNo definition available. + Details Name: xoma_ContingentConsiderationUnderPurchaseAgreements Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_LongTermRightsReceivableNonCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRoyalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: xoma_RightsReceivableCurrent Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_LadrxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AptevoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesOneAndTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_KinnateCvrHoldersMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R77.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - ESPP (Details) 9 Months Ended Sep. 30, 2024 2015 ESPP Â Stock-based compensation Â Purchase price of common stock under plan (as a percent) 85.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R78.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - 2010 Plan Stock Options (Details) - $ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock-based compensation Â Â Â Â Â Number of shares, Granted 0 0 34,170 Â Employee Stock Option | 2010 Plan Â Â Â Â Â Stock-based compensation Â Â Â Â Â Minimum age required for employees to qualify for immediate vesting of award Â Â 55 years Â Threshold years required for retirement age Â Â 70 years Â Weighted average assumptions Â Â Â Â Â Dividend yield Â Â 0.00% 0.00% Expected volatility Â Â 65.00% 70.00% Risk-free interest rate Â Â 4.35% 3.60% Expected term Â Â 5 years 9 months 14 days 5 years 9 months 14 days Weighted-average grant-date fair value (in dollars per share) Â Â $ 24.71 $ 13.46 Employee Stock Option | 2010 Plan | Employees Â Â Â Â Â Stock-based compensation Â Â Â Â Â Vesting period Â Â 3 years Â Employee Stock Option | 2010 Plan | Directors Â Â Â Â Â Stock-based compensation Â Â Â Â Â Vesting period Â Â 1 year Â X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMinimum age required for employees to qualify for immediate vesting of award. + ReferencesNo definition available. + Details Name: xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThreshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company). + ReferencesNo definition available. + Details Name: xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge Namespace Prefix: xoma_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=xoma_EmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Stock Option Inducement Awards (Details) 3 Months Ended 9 Months Ended Jan. 03, 2023 item $ / shares Sep. 30, 2024 shares Sep. 30, 2023 shares Mar. 31, 2023 $ / shares Sep. 30, 2024 $ / shares shares Stock-based compensation Â Â Â Â Â Number of shares, Granted | shares Â 0 0 Â 34,170 Exercise price (in dollars per share) Â Â Â Â $ 24.71 Stock Option Inducement Awards Â Â Â Â Â Stock-based compensation Â Â Â Â Â Stock price (in dollars per share) $ 18.66 Â Â Â Â Number of shares, Granted | shares Â Â Â Â 0 Stock Option Inducement Awards | Executive Chairman of the Board and Interim CEO, Owen Hughes Â Â Â Â Â Stock-based compensation Â Â Â Â Â Number of award grants | item 2 Â Â Â Â Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko Â Â Â Â Â Stock-based compensation Â Â Â Â Â Number of award grants | item 2 Â Â Â Â Stock Option Inducement Award, Exercise price of $18.66 per share Â Â Â Â Â Stock-based compensation Â Â Â Â Â Exercise price (in dollars per share) Â Â Â $ 18.66 Â Weighted-average grant-date fair value (in dollars per share) Â Â Â 11.91 Â Stock Option Inducement Award, Exercise price of $30.00 per share Â Â Â Â Â Stock-based compensation Â Â Â Â Â Exercise price (in dollars per share) Â Â Â 30.00 Â Weighted-average grant-date fair value (in dollars per share) Â Â Â $ 14.68 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price. + ReferencesNo definition available. + Details Name: xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Stock Option Activity (Details) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Stock-based compensation Â Â Â Â Â Number of shares, Outstanding at beginning of period Â Â 2,730,068 Â Â Number of shares, Granted 0 0 34,170 Â Â Number of shares, Exercised Â Â (246,599) Â Â Number of shares, Forfeited, expired or cancelled Â Â (34,840) Â Â Number of shares, Outstanding at end of period 2,482,799 Â 2,482,799 Â 2,730,068 Number of shares, Exercisable at end of period 2,037,185 Â 2,037,185 Â Â Weighted Average Exercise Price Per Share, Outstanding at beginning of period Â Â $ 20.88 Â Â Weighted Average Exercise Price Per Share, Granted Â Â 24.71 Â Â Weighted Average Exercise Price Per Share, Exercised Â Â 6.51 Â Â Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled Â Â 155.16 Â Â Weighted Average Exercise Price Per Share, Outstanding at end of period $ 20.48 Â 20.48 Â $ 20.88 Weighted Average Exercise Price Per Share, Exercisable at end of period $ 19.73 Â $ 19.73 Â Â Weighted Average Contractual Remaining Term, Outstanding Â Â 5 years 11 months 8 days Â 6 years 3 months 14 days Weighted Average Contractual Remaining Term, Exercisable Â Â 5 years 5 months 8 days Â Â Aggregate Intrinsic Value, Outstanding $ 20,224,000 Â $ 20,224,000 Â $ 10,638,000 Aggregate Intrinsic Value, Exercisable 18,416,000 Â 18,416,000 Â Â Options exercised, aggregate intrinsic value Â Â 4,700,000 $ 18,000 Â Employee Stock Option Â Â Â Â Â Stock-based compensation Â Â Â Â Â Stock-based compensation expense 1,000,000.0 Â 3,000,000.0 Â Â Unrecognized compensation expense related to stock options (in dollars) $ 5,600,000 Â $ 5,600,000 Â Â Weighted-average remaining recognition period Â Â 1 year 11 months 12 days Â Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-

2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R81.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Performance Stock Unit Awards (Details) - Performance Stock Unit Awards 1 Months Ended 9 Months Ended Apr. 30, 2024 shares Jan. 31, 2024 shares Oct. 31, 2023 shares May 31, 2023 item D shares Sep. 30, 2024 shares Performance Stock Unit Awards Â Â Â Â Â Granted (in shares) 10,000 Â 18,200 430,400 285,000 Number of hurdles | item Â Â Â 4 Â Vesting period Â Â Â 3 years Â Number of consecutive calendar days used to calculate volume-weighted average stock price | D Â Â Â 30 Â CEO, Owen Hughes Â Â Â Â Â Â Performance Stock Unit Awards Â Â Â Â Â Granted (in shares) Â 275,000 Â Â Â Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Performance Stock Unit Awards Â Â Â Â Â Vesting (as a percent) Â Â Â 33.30% Â Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Performance Stock Unit Awards Â Â Â Â Â Vesting period Â Â Â 2 years Â Vesting (as a percent) Â Â Â 33.30% Â Share-Based Payment Arrangement, Tranche Three Â Â Â Â Â Performance Stock Unit Awards Â Â Â Â Â Vesting period Â Â Â 3 years Â Vesting (as a percent) Â Â Â 33.30% Â X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement. + ReferencesNo definition available. + Details Name: xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of stock price hurdles in a share based compensation arrangement. + ReferencesNo definition available. + Details Name: xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles. Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 92 R82.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details) - Performance Stock Unit Awards - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 9 Months Ended 12 Months Ended Apr. 30, 2024 Oct. 31, 2023 May 31, 2023 Sep. 30, 2024 Dec. 31, 2023 Stock-based compensation Â Â Â Â Number of PSUs (in shares) 10,000 18,200 430,400 285,000 Â Aggregate amount of cost to be recognized Â Â Â $ 11.9 Â Award Date, 2023 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Number of PSUs (in shares) Â Â Â Â 448,600 Award Date, 2024 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Number of PSUs (in shares) Â Â Â 285,000 Â Hurdle Price Per PSU - $30.00 | Award Date, 2023 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â Â $ 30.00 Number of PSUs (in shares) Â Â Â Â 243,550 Hurdle Price Per PSU - $30.00 | Award Date, 2023 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 11.42 Derived Service Period Â Â Â Â 8 months 8 days Hurdle Price Per PSU - $30.00 | Award Date, 2023 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 17.45 Derived Service Period Â Â Â Â 2 years 7 months 2 days Hurdle Price Per PSU - $30.00 | Award Date, 2024 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â $ 30.00 Â Number of PSUs (in shares) Â Â Â 165,900 Â Hurdle Price Per PSU - $30.00 | Award Date, 2024 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 18.42 Â Derived Service Period Â Â Â 5 months 15 days Â Hurdle Price Per PSU - $30.00 | Award Date, 2024 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 19.71 Â Derived Service Period Â Â Â 8 months 26 days Â Hurdle Price Per PSU - $35.00 | Award Date, 2023 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â Â $ 35.00 Number of PSUs (in shares) Â Â Â Â 91,239 Hurdle Price Per PSU - $35.00 | Award Date, 2023 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 10.16 Derived Service Period Â Â Â Â 11 months 4 days Hurdle Price Per PSU - $35.00 | Award Date, 2023 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 16.07 Derived Service Period Â Â Â Â 2 years 7 months 2 days Hurdle Price Per PSU - $35.00 | Award Date, 2024 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â $ 35.00 Â Number of PSUs (in shares) Â Â Â 55,290 Â Hurdle Price Per PSU - $35.00 | Award Date, 2024 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 17.24 Â Derived Service Period Â Â Â 7 months 28 days Â Hurdle Price Per PSU - $35.00 | Award Date, 2024 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 17.67 Â Derived Service Period Â Â Â 11 months 15 days Â Hurdle Price Per PSU - $40.00 | Award Date, 2023 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â Â $ 40.00 Number of PSUs (in shares) Â Â Â Â 60,024 Hurdle Price Per PSU - $40.00 | Award Date, 2023 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 9.07 Derived Service Period Â Â Â Â 1 year 1 month 13 days Hurdle Price Per PSU - $40.00 | Award Date, 2023 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 14.84 Derived Service Period Â Â Â Â 2 years 7 months 2 days Hurdle Price Per PSU - $40.00 | Award Date, 2024 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â $ 40.00 Â Number of PSUs (in shares) Â Â Â 34,029 Â Hurdle Price Per PSU - $40.00 | Award Date, 2024 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 15.85 Â Derived Service Period Â Â Â 9 months 25 days Â Hurdle Price Per PSU - $40.00 | Award Date, 2024 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 16.14 Â Derived Service Period Â Â Â 1 year 1 month 24 days Â Hurdle Price Per PSU - $45.00 | Award Date, 2023 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â Â $ 45.00 Number of PSUs (in shares) Â Â Â Â 53,787 Hurdle Price Per PSU - $45.00 | Award Date, 2023 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 8.12 Derived Service Period Â Â Â Â 1 year 3 months 7 days Hurdle Price Per PSU - $45.00 | Award Date, 2023 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â Â $ 13.72 Derived Service Period Â Â Â Â 2 years 7 months 2 days Hurdle Price Per PSU - $45.00 | Award Date, 2024 Â Â Â Â Â Stock-based compensation Â Â Â Â Â Price per share (in dollars per share) Â Â Â $ 45.00 Â Number of PSUs (in shares) Â Â Â 29,781 Â Hurdle Price Per PSU - $45.00 | Award Date, 2024 | Minimum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 14.20 Â Derived Service Period Â Â Â 11 months 12 days Â Hurdle Price Per PSU - $45.00 | Award Date, 2024 | Maximum Â Â Â Â Â Stock-based compensation Â Â Â Â Â Fair Value Per Share (in dollars per share) Â Â Â $ 15.13 Â Derived Service Period Â Â Â 1 year 3 months 21 days Â X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAggregate amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: xoma_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionAggregateCostToBeRecognizedAmount Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=xoma_AwardDateMay2023ToOctober2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=xoma_AwardDate2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar30Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar35Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar40Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar45Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 93 R83.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Performance Stock Unit Awards Activity (Details) - Performance Stock Unit Awards - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Apr. 30, 2024 Oct. 31, 2023 May 31, 2023 Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Number of Unvested PSUs Â Â Â Â Â Â Number of shares, Outstanding at beginning of period Â Â Â Â 448,600 Â Granted (in shares) 10,000 18,200 430,400 Â 285,000 Â Number of shares, Outstanding at end of period Â Â Â 733,600 733,600 448,600 Weighted Average Grant Date Fair Value Per Share Â Â Â Â Â Â Granted (in dollars per share) Â Â Â Â $ 17.60 Â Balance (in dollars per share) Â Â Â $ 16.26 $ 16.26 $ 15.40 Weighted Average Exercise Price Per Share Â Â Â Â Â Â Stock-based compensation expense Â Â Â $ 1.5 $ 5.0 Â Stock-based compensation expense, not yet recognized Â Â Â $ 4.2 $ 4.2 Â Weighted-average remaining recognition period Â Â Â Â 1 year 1 month 17 days Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract Namespace Prefix: xoma_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 94 R84.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Restricted Stock Unit Awards (Details) - Restricted Stock Unit Awards - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended May 31, 2024 Sep. 30, 2024 Sep. 30, 2024 Stock-based compensation Â Â Â Granted (in shares) 15,175 Â Â Vesting period 1 year Â Â Weighted-average grant-date fair value of awards granted (in dollars per share) $ 24.71 Â Â Vested (in shares) Â Â 0 Number of shares, Outstanding Â 15,175 15,175 Weighted-average grant-date fair value of award outstanding (in dollars per share) Â $ 24.71 $ 24.71 Stock-based compensation expense Â $ 0.1 $ 0.1 Stock-based compensation expense, not yet recognized Â $ 0.2 $ 0.2 Weighted-average remaining recognition period Â Â 7 months 13 days X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 95 R85.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 General and administrative Â Â Â Â Stock-based compensation Â Â Â Â Stock-based compensation expense $ 2,590 $ 2,717 $ 8,136 $ 6,450 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 96 R86.htm IDEA: XBRL DOCUMENT v3.24.3 Capital Stock - Dividends (Details) - $ / shares 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 O 2023 Q4 Dividends Â Â Â Â Dividends Â Â Â Â Dividend Declaration Date Â Â Â Oct. 18, 2023 Dividend Payment Date Â Â Â Jan. 15, 2024 O 2023 Q4 Dividends | Series A Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) Â Â Â $ 0.53906 O 2023 Q4 Dividends | Series B Depositary Shares Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) Â Â Â $ 0.52344 O 2024 Q1 Dividends Â Â Â Â Dividends Â Â Â Â Dividend Declaration Date Â Â Feb. 21, 2024 Â Dividend Payment Date Â Â Apr. 15, 2024 Â O 2024 Q1 Dividends | Series A Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) Â Â Â $ 0.53906 Â O 2024 Q1 Dividends | Series B Depositary Shares Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) Â Â $ 0.52344 Â O 2024 Q2 Dividends Â Â Â Â Dividends Â Â Â Â Dividend Declaration Date Â May 15, 2024 Â Â Dividend Payment Date Â Jul. 15, 2024 Â Â O 2024 Q2 Dividends | Series A Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) Â $ 0.53906 Â Â O 2024 Q2 Dividends | Series B Depositary Shares Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) Â $ 0.52344 Â Â O 2024 Q3 Dividends Â Â Â Â Dividends Â Â Â Â Dividend Declaration Date Jul. 24, 2024 Â Â Â Dividend Payment Date Oct. 15, 2024 Â Â Â O 2024 Q3 Dividends | Series A Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) $ 0.53906 Â Â Â O 2024 Q3 Dividends | Series B Depositary Shares Â Â Â Â Dividends Â Â Â Â Cash dividend declared (in dollars per share) $ 0.52344 Â Â Â X - DefinitionDate the declared dividend will be paid, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details Name: us-gaap_DividendPayableDateToBePaidDayMonthAndYear Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDate the dividend to be paid was declared, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details Name: us-gaap_DividendsPayableDateDeclaredDayMonthAndYear Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DividendsPayableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate dividends declared during the period for each share of preferred stock outstanding. + ReferencesNo definition available. + Details Name: us-gaap_PreferredStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DividendsAxis=xoma_O2023Q4DividendsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DividendsAxis=xoma_O2024Q1DividendsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DividendsAxis=xoma_O2024Q2DividendsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DividendsAxis=xoma_O2024Q3DividendsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 97 R87.htm IDEA: XBRL DOCUMENT v3.24.3 Capital Stock - BVF Ownership (Details) - BVF - Xoma Corporation - Common Stock Sep. 30, 2024 Sale of stock Â Ownership interest (as a percent) 30.90% Ownership interest, if shares are converted (as a percent) 51.50% X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted. + ReferencesNo definition available. + Details Name: xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=xoma_XomaCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 98 R88.htm IDEA: XBRL DOCUMENT v3.24.3 Capital Stock - ATM Agreements (Details) - USD ($) $ in Millions 38 Months Ended 69 Months Ended Aug. 05, 2021 Mar. 10, 2021 Dec. 18, 2018 Sep. 30, 2024 Sep. 30, 2024 2018 Common Stock ATM Agreement | Common Stock Â Â Â Â Â Sale of stock Â Â Â Â Â Maximum amount of shares to be issued Â $ 50.0 $ 30.0 Â Â Shares issued (in shares) Â Â Â Â 0 2021 ATM Agreement | Series B Depositary Shares Â Â Â Â Â Sale of stock Â Â Â Â Â Maximum amount of shares to be issued $ 50.0 Â Â Â Â Shares issued (in shares) Â Â Â 0 Â 2021 ATM Agreement | Series B Depositary Shares | Maximum Â Â Â Â Â Sale of stock Â Â Â Â Â Â Sales commission paid per transaction (as a percent) Â Â 3.00% Â Â Sales commission paid per transaction, preferred stock (as a percent) 3.00% Â Â Â Â X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum amount of stock to be issued. + ReferencesNo definition available. + Details Name: xoma_MaximumValueOfStockToBeIssued Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares. + ReferencesNo definition available. + Details Name: xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares. + ReferencesNo definition available. + Details Name: xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 99 R89.htm IDEA: XBRL DOCUMENT v3.24.3 Capital Stock - Stock Repurchase Program (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Jan. 02, 2024 Capital Stock Â Â Â Â Stock repurchase program amount authorized Â Â Â $ 50,000 Repurchase of common stock (in shares) 0 Â 660 Â Repurchase of common stock Â $ 13 $ 13 Â X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 100 R90.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Income Taxes Â Â Â Income tax (expense) benefit $ 0.0 $ 0.0 Unrecognized tax benefits 5.9 5.9 Unrecognized tax benefits that would impact effective tax rate 0.0 0.0 Unrecognized tax benefits expected to change significantly over the next twelve months 0.0 0.0 Accrued interest or penalties related to uncertain tax positions $ 0.0 $ 0.0 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4:

http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A + Details Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 101 R91.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) $ in Thousands 3 Months Ended 9 Months Ended Oct. 21, 2024 USD ($) item Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Subsequent Event Â Â Â Â Â Payments of consideration under RPAs, AAAs and CPPAs Â Â Â $ 37,000 $ 14,650 Revenue from contracts with customers Â $ 25 $ 225 $ 6,050 $ 1,350 Subsequent Event | Twist Bioscience | Royalty Purchase Agreement Â Â Â Â Â Subsequent Event Â Â Â Â Â Percentage of economics of programs acquired 50.00% Â Â Â Â Number of partners associated with programs | item 30 Â Â Â Â Upfront payment $ 15,000 Â Â Â Â Maximum milestone payments entitled to receive $ 500,000 Â Â Â Â Percentage of royalties entity is entitled to receive 50.00% Â Â Â Â X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones. + ReferencesNo definition available. + Details Name: xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of royalties entity is entitled to receive on future commercial sales. + ReferencesNo definition available. + Details Name: xoma_EligiblePercentageOfRoyalties Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the number of partners associated with programs. + ReferencesNo definition available. + Details Name: xoma_NumberOfPartners Namespace Prefix: xoma_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + ReferencesNo definition available. + Details Name: xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchased percentage of economics of early-stage programs. + ReferencesNo definition available. + Details Name: xoma_PurchasedPercentageOfEconomicsOfPrograms Namespace Prefix: xoma_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for initial payment under agreement. + ReferencesNo definition available. + Details Name: xoma_UpfrontPayment Namespace Prefix: xoma_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=xoma_TwistBioscienceCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 102 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ŌW+D]%Z9/:D5"O=C%4P4'A!6;4G0IQJ?>R&2'RV;9 MX9VUGMO P;[!P3Z.@]79H4)9X<[ZQ:.-M"O;]"OCP-;_>Q0(52>'?# [W78 M.JI=I9>N\DUG*?'U"^EBH]7AZF%CVS3?SM4SMQ>[XCXQO?*5DH@O(=0Y'<$3 M2!8;S8H3)=;Y7JU'H92(\\,59P&7^@;X?BF$>CG1/W#8[C?Y'U!+P04 M" !S/&=9H8?48"(("A)P & 'AL+W=O;%\%ECL\V#%J\>"?R]WC GT(TOS\GJR$V+_?C8KXQW+ MHO*RV+,<_K,M>!8)N.4/LW+/6;2I!V7IC#B./\NB))\LKNK/[OCBJJA$FN3L MCJ.RRK*(/WU@:?%X/<&3YP^^) \[(3^8+:[VT0-;_ %M?\?A;G;TLDDREI=) MD2/.MM>3)7Z_<@,YH+;X(V&/9><:R5#NB^*[O/EM_(Ū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

UOHF.6DF!F>^0+>6BQEH!1\).;? M>[I#":;H@,,4T/L@1CX)0TP92H#F<_"A:0[R(9QL")G,AZDVT*RQ>CC5U6%4 M8S\LV0_[L<_7"<(IWQ,:_"<>2!5Y;R/U''JXPDK7LNN,?;==38!5"K!:!2Q(M%(D=Y@VQS_%']:!JSGGT.\UJ].V2OMV#?N_@VQ=!-1'S'E)=Q1O\:RYH"IU3@ M]%<0,)9VLW)=B#B2+J#P;T ,KTMUJT6_N]:0.^$5@M(KI6'9):ORW-#PZ!#[&/ M*.9B8\
BP>26X(E#LG%6"WRWGNHCVQBZ)]?9#/=TJFL[*0#T5VW7U^5; 7ZZ M#-W1\'*K[K:KTS[Q)N6R[+"J M4Z^J"+V]C+A%8EU6"$W\.ZSJ_*L:0N\J(N(#4!X\AH"2NI9&KJUHO5/G1FAU M[54-HK<7(6]<=I>EA:5IY_5'EU6=>E5]Z.WEQRV6G7L5_PZKG_I2\/FH= =UE M7QP8\D@:\.PMN^PMOVK,LG=YM3++//XE\Q7O72 R%L!6WV1A>4OSKPQY@Y,D M>U%_)%R\]F>W>\
^4&D@GF\)X<\-.4#YK6?Z/U!+ P04 " !S/&=99N(K ML1\' !=(P & 'AL+W=OGLQ'JO%1F1+[C4CE MR]6(CEY_>$C6&UW^,)Y>;OE:/ K]Z_:^@*OQ 6699")7B
CFF2LQD^EOR5)OKD:3$5F*%=^E^D&^_"R:@/P2;R%35?TE M+XVM,R*+G=(R:P;##+(DKS_YMX:(HP& @P]@S0!F#O!.#"'; >Y;/7C- .^M M'OQF0!7ZN(Z](B[FFD\O"_E"BM(:T,HO%?O5:.
KR=0% #>!<7HZN_L2 MS[\SF,"WQ[O?KF-KY_@XO$)/C[/OSP]DKL?R=W]_'ZZ18,R!GY]3$F'W[X M2-2&%T*1)"=/&[E3%^J3^2'SO7E6,,42T?C13.=FWHZ[,1T7/)9YGJCR#Q?
MBB4R/K:/CRSCQT#-@1_VRL\-LP(^BNTY<9U/A#G,0^8S>_MP%POG[WF?_V7O M'3+<0[*X%9Y_N\V7\A,$%A:J!%[D>^$NL#6N$9Q<92R]%VH+5^(JQ'4-B6* MO1A-
__TO&CC_P0@>$BP>$FP^$%AG*;S#4G@V]->E6!4R()M=L=A L2Q792&2 M/7].!;KW:LB@@BQ/D/TT\ )(C/TQWU:_[^6[[Y'22>1W7B$30P2$",_]'$2P@,)H96$)ZEY"F=6KZYAT8;]:&D4&N'V
MC2:NL9QQWP9P0F,CSOM6+&(GXITM2N04!KK'EB/HY1.\60YPRM^=TCLWM9#VFK&6,61F[+IZ3*C>@ MBP2"=%JSM9!*X_V$%>Z]M6I0M^A0M'F#=DRX1UUV@O!6TU.K3IU>9[+0R1\U
MXW(%AZ'F^3H!#5FG*,[ZH!*_0>MD7-GO='?RH-H=<1D37M2(F2UM_TWRG&M<=A;4*I>GLPT<&Z*_[<" M14/V/(76$4@7V;-8+D4I_GD$HR7VQ?^9ZD7E'R.[IW>PA3JGC>;UT'LAK M]
[9OV([P>\"E_9/!>H4F=8 Q&$YQIBQ4*S$4&, *B77IA#&IU0@ZQM6]B] M8?D"/4D*ISD:8U_QG]&0>6:^8*;^;]X8BC&S:.+ FQIR0G0JU[328O=-X M*95PK8O>:?
+^Z9E28(ES\KN0\0%UXU,H6ZI3^73J&2!LM*7Y6=T$IB-]0RS M"R:AJ6E0.#?R0Y,6Q ZT' M.T-+V \S>#[R/EF62[C3ZI.:F\1/*3&('48, M!M<1=]C9B&G%/;.+^P,Q(''KIU]OH^BFS!SR
0[&I4Q37AP!?$1YJZ<1=@(} M]\W[JIB9TORWD8:8(:2A M8#W2$"L+:6U3P>PWYG^K'FY#']'P/O11(JN9)ZZY\P@.$ &/;7=5>YG\G(U$6 MD7OL-*3,9!$S\\P;V#%J%GCFO3<<+3BU7]M&@-
D;@7^>Q]A2_!#-CC&)F2%, M8F8(DRA:C\GQT>L"F2C6U7L:"D+ MS.LW/5KX^L63S[Q8)[DBJ5B!*^<\A#U4U.]RU!=:;JN7%9ZEUC*KOFX$![I+ M _C_2DK]>E$Z.+Q1, T_4$L#!!0 (
',\9UGC_$S]$P, $(* 8 M>&PO=V]R:W-H965T&ULK59MYLP$/XK%JNF5EH+ 9(V68+4 M!*I&ZIM*VWUVX!)0 6>VDW3[]3L#94GD9MF6+V";YWGNQ2?N>BO&7T4"(,E; MGA5B8"12SGNF*:
($D/#-MR^J8.4T+P^N7 M9P_ QG252'9A>?TYG$()\GC]PW)F- M2ISF4(B4%83#=&!5I4; I6YV&-@#IZ@ET3[&V"^P'!J0G. MOA;O*?*D M-[J_\X.[,/)KL+[F[% ^82;\ E?M\'=4TCNK_#3[<-
C<(VX\4M ;N[#D)R2] MY] GQTO#/UC>2X33U MX91Z[! M8ANWY3:WY>Y2]^ZPL8R+B.5 CF^8$">Z>Z@.J6$:B-+[[1U;KM8+G.WQ;=':@# QG< MR&ZGR6YG9W9'+$?51(T$2R
95I,N;1U=,;6R[+/;YT/6[U12W/NXX!4S3. Y:OIZI;R M65H(DL$435EGYWD)I8JHUD\(E3YC$!E\N$QSR@"L ?I\)R)M\WRD S-GJ_ M %!+ P04 " !S/&=9+@QMYRL1 =U0 & 'AL+W=O_8"YU^JS>?
M75G6SM?5 MW9]O[35G,=QNMEF?> M9!*=K8K%^N3B?/>SJ\W%>?50+Q?K\FKC;!]6JV+SV]MR67UY<^*>_/Z##XO; MN[K]P=G%^7UQ6UZ7]2_W5YOFN[-GRGRQ*M?;1;5V-N6G-
R<_NC^O)&PVV$7\ M:U%^V1Y\[;2[K;;^69G;HIM>5DM_[V8UW=O3I(39UY^*AZ6]8?]"R_W.[2;*Q: M;G?_=[[L8RK_<;-#%:+]E\N_Q=?]@3C8P M[-O#V&WAC-_#W&_B= M#8*@9X-
@OT'0V<#U>S8()QN$W2G%/1M$^PVBS@;^M&>#>+]!W!VA[[F^PV2 ML?LPW6\PWML5ZOCT_JYMYM?2SV7X. M;Y_FX/7,X:K1=
[G9E'/GNJYFGYWKE@6=;,S[^N[SQKWGC7N[3A^#^=ML2S6L](I:N>FO%VLUXOUK5-]\=V_.M[$\R@!/PT0[09HSQ^/%\"T_.SQ4)G&.;3GK!^V]\6L M?'/2'-YMN7DL3R[^_".*HC9>
<'$#9[#%%GXS[+POT46KYJDMKTKFOUX/4HB3X,%!Y.<)L%D M,NG(1 _SM*!4#PJU(*8'N6X0ZD-FQL-@^:'E2!A'P@0(IF@I>-92L*.'/5IJ M\F1SJ;DMG5>-3G9?O6Y/BKL,?
U+FH;TPH11N',A6X4A8BH0Q)"P+]03O^9T3,G) CH0)\^P5/4;/ M>HQ>0H^'IW)*F\9!;;6)A*5(&(NT#R36KQ60(^9(&$?"! BFJ#A^5G%L5/'N MHN"TK=#,6Q7?-[=:Q4ZFY=?
V:^INZZV1:"M1)"Q%PA@2EL5Z @KCCMYSY(@< M"1,#TU>DESQ++S%*[TJM7#CSQ>-B7O84;8PH6\TA82D2QI"P+-$^M%/7CY*. MZ)!#E75S,]06DIQ7RVI+GX2-"%NU(6IL:0L P)
MRY$P/M5U-$WN. 6\2=@1!C5!-PB]]$<:!VZ' M>YPT.M6^89FXX)1]!Q1[R.BB((?$=+&[7$8J D:+ 97>@SN'VHR MN"-=!B*.2CNC? 8BJL=H,!\+Z[0#M1]@-(&BJ:J2;H/[HG:#" 4;H+042F-0
M6@:EY5 :A(${BJ;J6_H.KMEX&'7':&98JQAJ*D!I#$K+H+0<2N-0FG!U#^+4 MF\2>UW-6ESZ$:S8B3'>8U^5]8PS+1"\#TI9X> M1UWJZ5'4I1Y1='-#6.=EYJ-
@G42@97@H3:!HJIYDQ=XUE^P1=YC)B(0#+=!# M:8R8OYYP],IUSQTFM/A.#-MWATE,T'2'*8OKKKFZCK[#U(NR=-K1XZBTHT=1 M:4>/ZKO#A):\H30.I0D435TQ*VOHWO$U]$,-D:RY=+[Q9
G=PY30AU4RLH1. MQ!&9AH@B,@T1U62:1Z9F8^";;:!TCB4)E T54\'B _.M80^:,9X8Y;G8]?G M8Q?HCUFA3Y?0=<\..C5.#-OCV5$3-'AVGBRA>\@2^L81I;0B3@[8PJH1-1
M/M(3N04OH4%H*I3$H+8/2=DN< MT"$YE"8&=D#5GBR/>^;R>* VAE;BF[G6.H06T:$TYNGUYX2X&H NQX?2.)0F M4#15L;)]JYFK]F,Z2]CUU14I6NCB?"@MA=(8E)9YE"71S9U08P!*$^;YJT*4
MY7[/7.X?*\3!3 I=O0^EI5 :_3"ND]D4N28.93&H32!HJD"EG:$9[8CCNEN M,B.MQ0I=_0^E,2@M\P@/QHVTZT^HRP&EB:$]4!_L(-T+W^Q>6/4YF5FVZH/2 M4BB-06F93UD1>K,3=%
.I8G!75#U)ST2W^R1C%J_9F98ZPY)2Z$T!J5E4%H. MI7%?]Y=.6Q^[4RL?#%-U)[T4?[27HKFV?W]8FQ<<^2-<%//XUBJ#NBC$_#47 MQ2==E#B%FJ [<;V^9QT=/.QHM(MBM%V*93+2/R'B MJ"
<=C?)/B*B>=6GFHV"='*#^"90F4#153](\5_4/_&A_@F4ED)I#$K+H+0< M2N-0FD#15'U+_\0W^R?'W,>:D=:BAMHH4!J#TC)?=R&\V(V[IV2HCP*EB:$]
M4$4HC13?;*38W<="S1,H+872&)26^533 '$?"W5/H#0QN NJ_J0MXIMMD7'W ML8_ TI+H30&I6506@ZE<5_W-D[#L+NV50R&JJ3+H@_NNG!OK_*']'N8![? M6F500X.8OWX?
2[8[$/U5T*EQ8MB>_BIJ@H;^*E_Z"_[H=H=OZZ_R1S8Z$'!4 M?>RH1@Z55$(QN=!C17T4J*1C1[F">A6W"@=(8
M,7\MX01CVQV@4^/$L#WM#D2DH=TAD*7\8'2[@V5[%:V5D4T/1!R1=8@H(NL0 M43U-#^9C89MUH#0.I0D43565+-0'WDM6SP)D=?H22DNA- :E95!:#J5Q*$V@ M:*J^I=L0F-
T&J]7'9I:UFI&T%$IC>YKH)HMN"M:MCLCK-C%#9\6A-$'N0,\3 M-X*#]RL8R[W'+RDV=D<#L MC'PH[Q\VL[MBJYW620%">RZ@M!1*8U!:\J7E4!H/B!KZ;^&Y7&7IDXOE!C]D<2MLD--LF
MQ[R>AE:)7H0G;68BCK"9B2C"9B:B7#?R(^(,AS0R;E[&O7@;15%5)=R&,7G)Q M2PAU$:"T%$IC4%H&I>50&H?2!(JFZENZ#:'9;3AZ+8*9:ZULJ.4 I3$H+8/2 M>1*)(V/R&Q\
MM$7DAW5SE;M<_+><.[=%H]-&M,5CL5@6-\OR]%.U.=T6R]*9ES>ULRUG#YM% MO2A)5]@\EJV*H;042F-06@:EY5 :A))$I/?JN).>IKI(.B$1P DQ,ZS%"75" MH#0&I6506@ZE<2A-
1(1A,DWZGB<=2<,D.MXP.>SS)$OAT0C#Q#R^M1BAA@DQ M_Z2SW"6+2,.DCL+N,S0(V&'ZV(N"]D':_N).79*(3(*DK_\[DCY(A/%!AC_\ MD3X($4=4@(DHHB))1+EN'!(52?-1L,X,4!$2A,HFJHGZ8-
$W^J###IJT0@? MQ#P+ZS0"]4&(^6N^:T3Z((3O"IT:)X;M\5V)2(/Oâ.....?)$+Z(,-:&>F#%94 MUAGE@Q!1/>ZK^5A89QVH#P*E"11-597T0:(7]4$BJ \"I:50&H/,B@MA]CX ME"90-%7?
T@>)CO1!2#5#O0\H+872&)26180CH+TF SHDA]+$P ZHVI-^1F3V M,X[VX,Q<:QU"K0THC47$(YBHFQ"H9P&E<2A-H&BJ9*6Y$9G-C6]YQY 9;:U: MJ+T!I3$H+8N(AWR%W>0)-2V@-
&&>OR+$6%H6L=FR0+UCR#R,K2BAM!1*8[' MN4&T^T+'S*$T#J4)%$T5L+0K8K-=<4R[KQEI+5:H>P&E,2@MBXD'D473[@4H M=$P.I8FA/5!%*$V)V&Q*7-
FT^YI9UNJ#VA50&H/2LIBR(O1V7^B@'$H3@[N@ MZD]Z)+'9(QGEV9H9UKI#TE(HC4%I&9260VD\)ORE<)ITN]<&PU3=22\E'NVE M&-\Q1%;&XQ$NBGE\:Y5!711B_IJ+$I,N2AA/NL]FADZ-
$\.>NIX;)D'4588> M.6W^Z['I8^FBQ*-=E-&O&*)5,M(_(>((_X2((OP3(LIUHY!X*;/Y*%CG!JA_ M J4)%$W5D_1/XA?U3V*H?P*EI5 :@](R*"V'TCB4)E T5=_2/XF!_HF99:UF MJ\"I;$]S?20U%CW%&+?
ZYY>H:8(E*;('>@[4M3)'XA4\3,M187U!2!TEBL MFR)3JI0'-46@- ZE"11-E:PT16+\Z\+-2&NU0LT0*(U!:5E,O,DDU$MY4#L$ M2A-#>Z"(,)&&2
)\7;B99:L^*"V%TAB4EB7C7A<.'91#:2+1FR\,I;Q&^AF) MV<\XONW-#+86(]35@-(8E)9!:3F4QJ$TD>CN1U^^E-9'8K8^H#UOYK&L)0RU M1J T!J5E4%J>$!TD6F,
(=$B1F'M15&U*6R0!V")FAK7FH+8(E,:@M Q*RZ$T MGNA^QZD;>]TW(HKA.%5YTAA)CC=&!AN5DA'&B'E\:YU!C1%B_EJ7&A%#=ZE1 M@7HRTH-ZNM2HN?5WJ272[T@P?L?
PAS_2[R#B"+\#B*JITO-?!2L _^BA M?@>4)E"T)SV=;>_*LDZ+NK@XOR]NRY^+S>UBO766Y:<&/_F^=58EFU#%))G;J9M])"Y_2QL$71C6ZQD M2+*__EHR(+!E$2CR0)'3:O?
3DKJ?;NGRF8M?E"6=K#G=3L987EK>*F?C<7PDB^+E.5T M+)!<9AD1KU]HRI^O6GYK\^"!/ S)9)>_0OEA3SJU:_A1(Z(\NT>.#/?](U
MH$CIBWDJ]5_TO);U6BA>RH)GZ\%@0<;R\C]Y63MB9P#HL0_ ZP&X.B!L&!"L M!VC/=4K+-*P;4I#AI>#/2"AIT*8^:-_HT8"&Y6H:)X6 7QF,*X;7]W3 MVQL$GR;WW[_=C!
[AR^01_OVXO7NISI21Y(B\[!5BC=';B]9N_E&_\>H!\\+^82W>8)3;*=P#%%@K> M0/F"GOHG=/$9!=XGA#T<6NRŸ?OOPP&%.L/5LH/5%39XE(=AY M@A0L?RJ7+BL8E1__\KO>'S;,9U*V
MYX%PZX'0I7UX!U$HY=*Z-LJ173U2A9K5L#WH1^#WU:[U%BGL]3#>BNW9%6WM MBIPS,TK^!QL+8E$A4<$A&,4\CUE*4;XV6#U5GV,UA4M)$[74WSQ_T3GG[TS* M]OS4W?
JIZYR_;WG,,UJNWL52Q'.B7 'NHFQ%IBF5: E;5R ZFU$=C<%-!0AL [M"@2>HBBCQ9PG-A>5[PWW9A^FOS+[3NM.Q-[;8N\YL4*'O]J3S5B\ )D34ET MWJ$OZC.UH>K54/7]H%L!51?
JAI%G7]#]K;%]I[$/)6DQ>MVDA!Y$I2J!8Z(ME+"06;8@3*@'-KO[-9.PX'E>Q?"ZE! U(KOA@ZWA Z?A_R9J8^6HF(/\=]+ M)IEV,I^A_[\AT5DLW=07SW<Q/("KGG:^^L3EXWLFKWI.:-
=SDC^I'8%FX'JT M(NF2*EP0:U0047,#'R5+=%0!S.5>>AB/Y"6).K_7'AIFU MMCV?-DVNO\,M?+)8!,JGVD@8NV'2IP4* #3W_PZ^/5FA^?:GY_DW #!GQG9E^
M>$/AW3'3P*P8@GKPJG]\+M*0B'W#$'PW11C%L: ;9Z<\?VI# LF AT\+E# 9 M\Z6*8; /]!,FY9+D,86U)!NF[JS9.!4d X;/IE,C@V$?OC-I#^]XWM;,(J4J M5CL2REK1+IJPFB0M,K[?M'--YO?=J;\I>E&
(T9!H)(V70C,@J]F6]-Y5E'S? M\+J4C_T&PTW:]MUYN\EPLB(L5:2E#:5O6Q+8T'I)&20H3F&+LQF#C$]DR?T4 M7%"AF*:5:#V9^UX-I]/@4U>;H09^WUV&:(=(Y9$R@NGME#(R96DSA_6=A./H
MD'8F;?LN,"3#=[.,1T$2JF%S(!IBE\%^4CS?Z@ +R0C]ZM3:A!IB(C;, ;N9 MPUA08&O))C#(' ^Q.]_?;FJZ,Q8>,K:?FME\K6ZQ2
MN('B8Y/!L3N# \PI$;DNP%8TAZBFZM:GG/T#CTKN,Q9(=M\UMY(-!=@N)[+ M 0FNN=TFULCZL4G[^'!GX&!Q;;6[GM_;OM>O946K7(B#AOR"3?+&[MY!M:O#
M\A74NV_H"N"SM@7.I6W?"X8>8#<]V,Z?+MI$.8?XBFVWD+,ZPI+W^P-<)6EN M"TY%:'@$=O.(,7DM&T1ER>:HT]QE&JY3A';0JU?7-CD_[#9U!K#]__A ;T E
MNT4AC[7;TA3HXFZU06<1ZX<[863?:).QL3MCCS>-#/#^0JC@ *13V:L(V:*1 MCX%MC8%>U>+W: L$)KD'[N2^W3D :P6+*D'35_1A'08_6L.)M4=TMIU$XNC>]IFT[7O!D(? 31[&@@'H!4D5
M[RF#15L7%5;D%E+0'7BU&3M3*V$?TLZ1Q:$N0:W*+LL%3]"@HE11/*:#/<3$ M?'T2]\R*>:5VMWK PB5Z834.N@T\U0&&F 1N8K(.^V7PUI+7 MD(K 32H>R M"F0
XE.MVZ,7ESK)$BQ6TZ1^MZ*Q40[<"VH;WR*'PZ"I@@T-GP@/'#.\V7S5 MU()5I8Y:IO0)N+J:J_4#(%C,7BB&=0KA1X,HJL9MBUS4ZC^^P^GU\AFJ$!XX0 M3L%'560XB,QR@!!V^[5C)
(M<$(2]!A(5&OH08B>)FBP7BW*S X/0C.HK,"KT M+2_OYD#XLE*H*R'#>?2MN\#PS="-]_0L'4\!-#;TV,K[#I[L)P8NUJW*IR= M^PYN]J O0:D&S%)NSHL0GQ:$Y66,I"]QV9Y6:/EQO2?
WJX^>]SH1Z3?DA-"P MD-#=&]D>;.Q4,; 3WUP=A&=MD9Q+V[XS#'\)W?SE%AR0Z13/WS_0$(% M]JL7(LB,YFR*,I:"RWA.-R?V;^ZGA!.J,L#5PL)M[:G>,_PG=#.?D[W1>%Q^ MA(/J_,?FH/YK-3
?:C;QS6.U5^\YP;JA>YJ=ZXH9U2'A22 MU JL5+E[],/NM5#JD-2I<&=G3O2&15/^NJX1/KDLKQCO'VZO9X^TI>R*\^_ M^!?7Y25SHZ:_Z#"*BK) 3E&:CT/O> @8CR&GGYI> +?1-
[RHN"9_KCG!*8 M:B4 O\\X+S9?U NVE_F'_P=02P,$% @)+Z7PC(QY]-0^M)ZF24F/FJ\7BQ;R1 MVD[6Y^G=C5^?NRX:;>G&B] UC?3[*S)N=S%93@XO/NJJCOQBOCYO946?*/[1 MWG@\S0"HO)I?
+5U>G+)\$_M2T"Z.SX$@VSGWFAU_4Q63!@,A0 M$=F"Q+\M79,Q; @POO0V)X-+5AR?#]?IM@1RT8&NGF+ZUB?3$YFPA%I>Q, M_.AV/U,?SW.V5S@3TE^QR[*KTXDHNA!=TRL#0:-
M_B]O>QY&"F>+!Q16O<(J MX)(5>*]RY M((3S>81Q%ID7O:&K&CU@*$?Q7MG8QW$3U:1NJL_!Z@!V>J [&KUJ,%/U,[$
MR6(J5HO5Z2/V3H9(3Y*]Y__TFSHYY#W":O0BL+NIB@#P+Y+4W63Y\L7RQ> M/P+S=(!Y^ICU_P+S<4/+F7C EOC[P_M+\='MI8E[<>U\Z[QDH:F0T#%R)SV) M8OQ>!WS::!>IJ(7O-
655>:ID=!Y%&VM(!/V/W!@24(RE,]JQ6RJ<=8T&9NZ0 M(*(391<[SV*1;-32H+(-H=8M"6G5X*"5_0_5&0(KM RDLJ>6NFC)8 'PC4- M^8^)ML"82 FS5*M;D94M=A/<"W[6"C3 3'ZSXM3-
[L>S+:\J28*)II=V+HI:V M@FT-SU8V)$KOFDS:B"R.XR$B9^+WH[VG3\Y6RY>OPXB5G0QBTVD3X=>[KJJ3 M?UE\Z730AW1]0]>1I ,QTYXJ33AR_*/8CS+(>D$IFGLRMSD41>,4F81,-ZTA MUF4.+
A:OIRRY0T$^P1@O#\SNN#A;*MDNO6N]9HB)CN?55=PWC@E1D9>'B'3 MR+(&ONH)4#H4;DM08#E%6ZR(EOT.H.[G4?FN>C04S7 TEHQ&CDN',0K<()6D MQPVL0VFCU+$0L'5&@;73!U1,"
1KBO:DQY<4R@5KE<(.NK"XA!VPCBH-$0D95 M'&L9!?=.I@9.XZ /4FQ'(D1L7%"(($ G M]> 1\[C^8.M$7G>;R-"P\7,!* R>^6IR]F M9\R6X=".C9ARFBNCS!P@E*2E;0;>LYVFSAN<$S"
.A%MYT/')/3%W>%K"H,@D-:EX/.0MN@-)H;'9MC5F H>MQW.QAU&Z.KOA"XBJ6 IG:*4X5! M84ARYZ ']IB.D##(!">&0^!MF>=)+FD&F.<:3@&;3*68CA%@+$7J5S:W8 @= MJ=E]MZ+YZ,J*
5:EBSF2XCH;\^UU>#O< 2_SE? U9:W2@G5Q>PE M;H ^7\;S0W1MN@!O7,1U.AUK_'XASP+X7CH43/_ #H9?1.M_ 5!+ P04 M" !S/&=97BB;8T0F !FB & 'AL+W=O[0$@*3N9/GZ((Y*'N[V]?
>_>XL5=W7QL5\YUR:=U6;4O#U9=MWG^Y$F; MK=PZ;>?UQE7PR[)NUFD"YN;)^VF<6E.#ZW+)R=']\^>K-.B.GCU@KY[WQZ M4?==653N?9.T_7J=-O>075G?O2$MPA
OKHJ;58=?/'GU8I/>N&O7 ;AYW\"G M)WZ6O%B[JBWJ*FG<\N7!Q?'SUT]Q/ WX1^'N6O-W@CM9U/5' _/ V?WEPA "Y MTF4=S1#" _V[=I2M+G C ^$7F//!+XH/V;YW]3[1WV,LB;=UE7?ZSR+O5RX/S
M@R1WR[0ONZOZ[B].]G.&\V5UV=*_R1V//8/!=E]V5H>]:C61<7_3S\)'LP# MYT=;'C61/TX(;EZ(H/PN[=)7+YKZ+FEP-,R2*]!6ZGD KJCP4*Z[!GXMX+GN
MU>NT+=JD7B(O&J>ZJDL95U6>7!)WF2R5*O>:F3+4M]D[RKJV[5)F\7Q\T\ ;_[B<+^^F3GA-=N,T]. MCV;)R=')TQWSG7I;"'QYM8=O/KC'XZ? M'7V[8R-/_4:>
[IK]]]W([J5.YLD7K[;ER0\KEV0UT$C5NAS_:F%\GG;P85E4 M:945:9FT,-B!<.C:I*BRLL]=TL%S*:]"D^+GRWJ]2:M[@J: K^]6=5G>]9W M%Z79@6(V:0-#BHJ ;'(8Z$!P M=*ODQ_GU//GSQ<7[!
2VF:.H6(#KT=!@Q%!1M5W3R\:Z.D%9EQP?'?X?#;MH MNB(K'7R!&+UR-WW)O6 M)4U?NG:69*[I0&_ 1'57U1U@#V:L :IMD ,E)0M+'3B>YR>LMI]'.;C#QI4T
M(" _:K*S;'B@Q6:6W#M9Q54"UQU?:@O[:$#3=*NV2'IC7D]L8&Q9ZFA8U)X)- M'^#T7$MHIZD#0>P!'#&/3P!XF"18"B+/G_N*U638Z(.AL6CD8Q26I,D-&_[Q#^RC7;RYQEG=IDZV2A:Z:
(J3=%A5@'^EFG%5A!.&2&U@Z: M+4D*,BG-?P8S@!Z=T>Q%2U*TKLI[?*Y"^BKE$+*^:?!\Q"3*>PEJ1Q2&YA> MA.0T6:9%$P ;B$R_KRT;,H3- DUI'Q@(+")B"3 =FU1$)JY?=QZ& H OJAQT M
UIENK8^2R"OTWLD4O=I ZC M84REGW)A#Y#/]*M@+06L=%WP,%Z%D8^ 21% M#4+BQY86>P,X!."!5#^L5* RD*/6[0,8@+W7'3W0UG;N%_Z ES*.$1DZG7Z M$>#W2^$1!?&A![-
@7U2)P7B'!U\6Z:(H2<4@\8".P$/]&(!E%@9:FB6+QJ.S0Z6& MDW;U3.6X+ -[99B295,#LGO@PQ19#N53<9LN2-PKN#0&D DZ-4.=AKAD4Q=$ M:1@&S]9@/_QJ= >J30#SL%X>ZJBU U"
H9KZ/BT[UO0 "4Q%)[A)[WG#%!- M4__,-)6E[2I9@F>";-W6\$BG(:?S*[UB9 2R!9!8H&=D@EPQ "_SB\PZFGE ;7K%%R5 MQ7V %FU:)@NRYQ,UST8F(>N#E MK.?3BD[!0^V1Q0RIF\ QX,NA9.%-
X]I)?2N P4;62B; 6X@:G.ZAJ-ZJP -1 MIBH"U/LM"B5@KX^#Q-LLY>\=^%]K'1&:(O9ZJK.T)!8_G'Q>O_OW[W@Z&K MB^425"TP^.7[]Q=[\#6UL%G@@1,S1\!/T>^^$4I,005?KS5\G3V='QN?
E\?/)T]LWI^<0S M!O^C-8]/SV='IR=C6,YGIVZ UKK1U.2>-TV-\#R]1<V='9DOSD[G9U\ MSIZ=/QM]^VQV?'0D&]N%W:^? M/3.?G\U.GAU-H6.*GO=BY]GL_/A9AJUO9F<&7Y$NU&<@><#&
[^V3# MD4J$T@0WFZ+]2/,$\X)L2!#Z6=JSRVE^\W*V04-IA#(Y!%%_/H39H(#&_0(8 M;%B#NPNBB@ G7[1#0[D'_QX,U5(D)3Z6E6#' JR,>&])'8+N.6QA20I^UG?A MF% 8-
(GXW./Q<(R++FDQVB!!3SPG).JT)\-7,X6- .!C9">HPM9XW(@%?Z1 M<2H!/>/]/7!%4,3!'55C!D]: >_K/KF]DE9]\&S]P?/]UJ-#A)?WV<> ?_3]MZ8 _Z'#W>,Y< _Y9M\1 [;9]9L
M#V5HB*G/@P$;BKB#MNI;UCK@;8U<)A#T^;JH0) T'-E>.@VZ<4R"13:(AJ2 MPXA(VZ?!#1M$5-B4TV2DF$)+@]QOR*Y0B"E(,E+V@_W,D[?1$ZS;!FYJ62P[MSJWQ9[O?U 15[C6+4;E/ /R=*V]5-
_AX7&S5\B;(BXZ@Q+0%!09^J (;')]I MMN>GJ^_5T(3Q7SV;GV+$M2Q(@9&C3QGT@"0.UE=ND-)"#<8XJ4 "3TVI 6 ?^P4#CD!G;1V^K@N;L DX6C2>X4/ M!GK$AUC*EN>
(\BF0U;IU<<@I(V!P]'MN)K?OPSG(W)9,X\.98H0O/B>@LK^F\#R+_@_)WM&T4$LAZ:0ZF,M R8!$8]3R6..1P MC':3N#;#4AWE4021@")!]C4@0V+?5$R!]6)<:1 +1>45!Z$)5QV4X
M>X]/FZF!.6U4K^@ 0![&:EY#P#]'(29QH2E MT9B)4U-I)@=&61#9,!VV]J!\08XDQMF7-8[B)U3AE3F3P'RJT'9Q*-SCA[M3.)6B686N>Z2R:X797&C*1'#9NDG^%IGS;1DQ($1IBRY\",A)+=?
4)HF7():(>#H9"'WA5X+" " *7(1BU9*-V6-4D&F1!OF]5L!%U<7R;G:#!L>Y*$ M"-FJ*"T[Z[YS: >]>+>QD7^3L?"1E+9?_$SI>N0MF4\CZ&9*$D##1$L4Q)S'V8]3!(@N5NYRG 3(QCH:4&F M+14DT,
[HDY8C(99POJ=G1W/\JX<:9G[Y!TET9_ZK0;(RF#/!/ZW2&#IK1D M4=W68)JV>KB)^6NHJ$(BYQ)SL+4P4'%;VH/$-B*P.*>$.JW/& MF8T)/K>69 =O5W.&DUDH=+9:+?F3I4GPZ.Y=QW5; M:A'-
S'9H5%^I-+4U'Q6IA,;!<3+;R0%+(-)4&VP]/L5*T O>:1SY.4 @H@,) M4_*G3RJ64=2*V*JP9E+/-NF%KU+AE%L.,4X43S>Q(R&O MR.+K&T3,:/6CCWP\/_(6*_[PJVMJB;1.1!%QQ$2597
4ROMY\H8JU="9/BI5M*!R.A4D$_5C0QXT#M.9;'TM8U<&4:;01R*$Q%./!1<:N)"#%6Q M3X#?75"[BFDOJEN?I&K@)#=!SC%F!O,3U$ PX*%%*GT&P4=KP#A T)O,\%Y MT?
K4!V%*:\V$#RA^[\SODJFGV(,W@$2^8[BC:TZMAB]U##G@^?A3PB& M3UI;2.Q<8>4HK;5PW1U*B*GC(^N."[3LMX1$":5R[:9![[1#FV,6%I\ M5E'4=.TA66IT
)1@:6T^W(@/+PK.3;CL=Q(%;PWH[SWH=I]O]U=\L1QL.5.K M@GFRZ#/LGL#;IY71RGG@?%(G!83KN"+EOJ#\6_NY.L&3K1>2F-OE^"P01!5D
M@]<4*QP>$.LDI[K9E%0Z;6KWFMI'=>#GID:F0#^3G910/R:5REH F=#]BNTH M;H*80TJWU0Q=*)R6>5R^8PH?3O9,3/,,X*2 5MK<8&"M %&7B33&. Y5^:>@ MSN_;CJ-48&C.
(KRYABH'43D&_*"^4#7#%7-H[8!:X"A6(R6P^TG71Y6FZ"\0 MMB4:4R&,9EQL845B80\I1!>14+VR*/#0#$PA 8[#^8A(C)KP*6)&OAUW0S;0 M::@G*8G!Z2G[-TIMO$NO:WGI' %PVZ-)^.M4E2
S4XI%//)_JCX4Z!*^U%M'!C/(Z9HR6<99%WP M-AHP)\>^0K6!C],Q&*VIU:#COQ0GXHW.=LDY?LG96:LLE/J3;1*JH!YN:)-C M*<8S2II'Q=S-9\FFKLO'XO)J*==4<"D /I*&ZZ0 59"KH.-
.:S=KX%NO3A M$-$=$] ,#@G#TEC"-+66K]96@ #I8G, >/K5>@O9&U%>4H)JS2'8H +Z>(LRULK1ZQFG"CK,:@[,>:UC%O M4V2?'4QT"PS6D#!N1(^.OC89 2O',!W@N4Z+8XG#?>W/;\-
L,/[[=2\>@E]1 M[6URLV4E= ZGD?$;3A<#V$8.R3'HZ38DX!&9LN>(U$;'2[>SA"ZFC>L;F*4C M:9U6M@Q+Y!VP\442!*/3P@''ZIA XQ\H)4BL3)L4K1GPBFZP"H*E
M>#A^ZXX1"?!%#$_SS/CB1*'Q;RX]7<:5^I=ZZ6D@6(3TVB2Z,85V_[9;4^,8 MZ[.C9S-2\1O.2(:1NM##NSR8W!]31_M*D"X(O/B41MZ'>GYI]3BS9
M=E"1MD3XP=#>M,]!!S\.*D+S'WC4C]K'4B[B<'5#"E03:9M+!HT0F2)77>LK.0PC/.][3<(0 OX_^A61?.QN3\)9I8'$E MZD$Z/*\=ZS8^%H_=-.!\10%[6[0N8IR+7<"M(9-R:0(XM=,T1/!$KDYZB5)
MF$V-#"EB]S)?,BZ>@(UDWP#RC(\]=E1R7*>98U)IV&Q\7/*(H)JZT$#+S!/ MUV\ *KS4'-%H8< 8+4_Q[A3#>L;F5:I[=Z+-38LQSO8^TL%VR55^P/BM" _LN<32RX MMM'%-
JQSM=Z0YW6G/AZO7\!NE+0;Z]<,R-]_@0)%LGB]4.0"*&E9F+W+W!S8 ME _VI@O [+MA")Z8FXSY9OE-@TUZ$Y!OQ&,PB&D#K\<Z!:8RG"""RBUT)TO5BU21<%=AS#T M-BH?HRC$*($?
QU^C4*>!;@KWAJ=2SB(JFSQJW0< M)0?@)'\8QYO5DR6%-VR8-#(_YVJ&_G>W#ADVNX.KW=A2ILKYY0Y.>REL:P M@W&+]9&<%K:X?A[Z/
3B@9%)NM&U,+Y3%1Q10,I]FW(*4G9QB1IEY']N_;*, MA+9?B]N_D"EX1TU4G2A^P[=6J?#I:%UVQ8C^'6P!64KO#0 P9Y9DT?'A#6 M$.W52]H*#[EZGT6EE%&9\CYC"]_$PH)*?'U?
(WZ1.9Q8V6_"Q:,M7$QOWE+XE,GWLF$P(+< M3@8;$);B//I)(J$H9O[(^V,]7\66(#NOTQJ!,B7>WZ. VF%:(F9:4%-4IT 3 M4])DK^N2DDODI>DV.[@?]03AJM7@-5[XZ@HO.4W =UA$,523AW$*R;
MV5^, M9JU\"19JO#?L/'H0%WYA'IT!4UVTH;S($.BUCHBH.N.]%_9R1 M,(H/JJ-H*Z]-/51H^C,6 "KD1)E!ZY.,U% H7%*8$RI'*U<=+ F@YS4&K%&\ M=6Z-/X6X:7
0^:SV6DQB0Y84T@=8,"QY%TK]^+S%RV2) TBA:.0>L@YPM;48 M^J47&YKC\&GOP*#^J^ N/*)VU X.>K^^\6#KV@)@]RQ9O M)P!+4G!>;]ES47W/5?SD"6CUR,
;21YIO[A(%>U\G(

M3*&VWL1<+6.%VA&>:+-+O>%"VTKAF0Z<"EI =*)FK@XNO#3+(.&ZI8I;?1)$# M0]J8.TU00M5,\&#C6K5XH%:H5H%A\)J0=E48;E(%A3%40=.!HVW>*K;FI,A/ M E::J7?MU,O8E$-
\9:=G:X.GTX%[-'H& ?RY1V(,^M4\+(\U_J ;]Y37AVJCDQ<(7\M;W/C4=*40]<*:U1>[C]IGKUA,]8:O >O9E2 M!TSO4)?;,0*\Q[)L15[?OO!F]]AU1$=E;G*2M^=7,JVF \'((M/\BKF!4+VW M3-
=6ZAC>5'Y'W<-*Y;<7@N[-I=^O*.]^PS[SP"U1:\^1JW'_#Z;]X-O*397G MZE'._LFF9%^/^K4OG!@.;0VM5GO&'7WQ!2M[]\+ R>A3EW6S;M*-]M O#'K/ MU=?TH? .\&3!Y4:9R'W(&FMSG/.37M<
MY/F8X[WJ+5BJ[5(LNJEDVSO(UG &5'63YAA&>#V?C?WP8#$]|T1X(7>3Q?GU_L M#Y I% 0"D9>D7GW7CUQDL!S=\:U:5<3QS2]/7(!#70:WZWF,@&>)EUJZ)8 M?UUYX=NGZ>?%/ :WI$K.U
M+Q5IY7,MM?$<15-05R\T$ZDAT^U%!4:Z'1?PL(QNQ3NMM%B)+3O20>5;;W+ M1L=&[T.AWO9-^;4UHQ\-YV+R]GI=,R\TBE=?MK6/CORBY<-[M4?WW,71N+<% M[2]{^B!O,6$ 3$';!)C;+:-
^`-(,RBL,0JFB)/6Z7<]8@!L:#S6T90WH?>I, M@.3"2,$[5%2H12@]M;]W_9!=F?5O4O@&NS,V7RN7JAW9SNEM.%5?&8D%0V;Z M9K!MI[3J"@YLEF%N
8#$F:6'8K1^J*A7S0JG.1ZG1ZP0>3,94UG6-28AH9=.6M^2@]N69+,QF37W!6\]EC.P8>.?TA5U!9]J73+>U/E&5(EV+\ZJTF4U$RGOI M#:M4K
SI=VICM]$*!_]MG]>]WF[B.& _:?/3ZD9W*9:HNDL(!"25&N_^EA+&A ME$_M*)DH0+> QAOCJ'6'RCI6;=&>!#X47T)K>V./MSH(9AY#K=/<5ZV'TAS$ MM2=FG)?
W'KH/N*C%G%K_N@A%WC:EWIU4;M}U!Z.KP'Q!YGN7YDA+2{V)'Q# M)_1ND&6)1<3B?50_!&A(@ NWL$&% SF8]Y1!Y*=]\,.F@4VKJ,BL(G4]3/R MG^H=^CZIZLJEFL_2VM&[._2BJ)1[.^G>?·3V
7?1N_&'1_ 51.{ZORNW9\MX#'4=#RQ"JL4&"%$&HL>@#L>@#X

X8Y9^E!0I'D?^C;8C+(@Y%,T%W(*Q..=&Q2SS# M%;>D0V -_=#;]]UB@_AEPT>3;? ^2_36%C*1P+42+\Q ->@WW#VC_VV(,$Y/ M@)OGBC:[{J=M,QOMML)G7>6J6N#HGJ;[\KVGI;Q>=RC
]4#QE'ZCLH*_9!{UZTU"RL+YFPS\(^?GPAE!;Q9]9^Z M2^[.;W-E0?;8V>Q&=QEU]VM^1J2Z+9ZB!.WR6)&]7-F[T;?^)N-W _%[F{G6 M;.?0DA&^F2, \HP\,Z2;4S) FJDP^FYUE;I.3$3PJ7$VV]=.XO
7]447@6[M M9!JUUB,A?TZK:1B&$C22QWART+0P7H5QKBO8=+DRQS..19DKV5 I4'64S*8_ MC3K@^?D)7F*T9,KVN5NA Q@>-:J$U9'2%SP$VDPRJT"C?N0C\MK%+Q@H#?'2>0."N
Q4KC==C.5Q6.4?*C=;>K6 6>GNN\8.#_MN$)? .3PU.' 0WZ9YUN&H;,ZEF"#^7))%C7H#W&PO=V]R.W·H9651P*WCX>.0&4)^7)*8@ +++VOSX/
MH,1(B:UV>]"$C]VW{^T""RVVSG\.#;/0KC4V++-&I+O-\U TW*HP<1U;[%3. MMTHP]74>.L^J3$ZMR6?3Z9N\5=IFJT5;>_"KA>O%;,L/GD+?MLH_W;%QVV5V
MF1T6/NJZD;B0KQ:=JOF1Y<_NP6.6CRBE;MD&[2QYKI;9N\O;NZMHGPS^TKP_M1V.*2M;.?8Z3]^4RFT0";+B0B*#PL^%[B8"@<8_>\QL#!D=C\<']_^3=FA9 MJ\#WSORM2VF6V4U&)5>J-
_+1;?_@O9[KB%;Z0L.L[W+/#$> B66ORI1JX5W6_+1&FAQD*0F,Y#3 A,E43QV M-?QD]=X6KF7ZI'8<%KD_.[GQ=[[;O">O>#]EX6XT7V@WVS)Y.E_#B8CG=F!.MSMWL+. C=Q..:3RJH-
IU=G<&;C_+F"> Z?\H;O.?/>\<+<1LZ5? RPXD/[#>< MK5Z_NGPS_>4,MM2N1V]4Y]'_E=M{[%2'K2]& MDHS*WFM;D\!6&L],RL((T·0.A>182$(9A·LU^[$6DQ\ L,;]@ 41_']"SZD MJ-J-
H8TRO1JNG,&=5[9 F!H&04A+ +GH$6E8·!W<(/8>,4&05 B,'G,2JU$E MD,6),N0J^NEZ\A87P9@8 //:NQ"HMU%R,?67/=*:+5]P !%N*808,5$KN&_9N&L M=L\;]F$0[-D@=OF<,7H%
(JVCB@IS6C\A^C.!+R@'ESSD$Y'0%Z &.SX5+B)V M+W%\@D8K$*MZZ3V(?>I3;,]S44 58,@*D8K$*MZZ3V(?%JAT. ?6"?&NB\F+ZEZN!PY,T2A, M,P6_ 4H7*J7.07$*87F'FS9; Z"\C1(M'=,
I[/G0^$\MR@M:ABS\^W")$4V)+W>]77S[#F2[PYK3,4A_,C.^2-RAY(B M%R\484*O7]W,IO·G^TQ^U.Y,]G5ZU »$]%:&SC^NCN_FN^&Y^&8^/+H?E*]Q M),EP!=?IY&C[43/$5IV.#M9Q\-
L%\Y)X=)###^FUA]!5!+ M P04 "!S/&=9SB']"S0# ;!P &O·4\=OD$+,>)*LV&DVL0W$:8Q=AZ)!TNX^T]38(DJ1 MRI"*X[_OD)(5=Y,:"^R+Q,N<,V=&Y-%L:^F'JQ]/,;:N'E2>=]<9)F3%=;"
MI;9!PSMK2[7P/*5-YAI"4490K;,BS\^R6BB3+&9Q{886,]MZK0S>$+BVK@7M MEJCM=IZ,D_W"K=I4/BQDBUDC·GB'_GMS0S$<!I92U6B1*$&J4/#()?#WB-
6@4$3=7.*H\J/P8C$CNP4*T)=Q7C_.*N73F\,]%X^/3 3S?+/_.&S4SV%,N.HO@_Q1_PQ1!?.?AD2BQ_ MQ6OAJ?Y9='!$X&@9·C[/]·X'&*\22%9S3P;.NIY[FM+C241+^.[MZ_.BR*__'=07!Y?
OD_A.Q\FBODY;·W MKN-D2*B·D6Q?$?3?,W(50B>78DD'PRE=D$48W8U;$[IY21NBUYN:!]=!H1O QW=+(M\W@$#ABIUI@=F!DE7L"O&>7$T*$"F[02Y6-
M/ŰPZ.,M/&MTZ0$%Z=^(\6Q\T9#PKO?AM?!&V4<:!QS=_< N0)T5=Q·OFVA_*^O93..P MXK\74@C@_;6U?C\)"8;_X>(G4$L#!!0 (',)9UEB!8\NY0($T+ 9 M >&PO=V]R.W-
H965T<\T61BC#+);DB,LGJP(S2 77;HV64X1C!24I.9C62TS@PDV M@KX.6]"@3PJ>)A@M*&!%ED'Z·D0IV0X,V]@-/",KF,L!,^CG<(V6B# E"RIZ M9NT2)1G"+"$84+0.&'=V;^Y)O1+\3-
"6[;6!7,DS(2^R,X\&AB4CA%(4H6H\O 4*2,O4+ MJ76]PT0%HR3K(+%# +(&E__PM7H/>X!]"G·JP#D&O!. M6P%N4\"&*IX%> WQ1H54"K*="N@';3M2]£@$[3"·T*Z*#T*/=,/?0ZX?
O*O!)\TGK\.GS2>OPV?_]^;G[U[[02*X]0EPE9__GA.@2_32SM7;R,NI MQW(8HH$A+A^&Z 89P< M>W4>>^?<@^^B,)KCD&0(7\CC'W2Y6YIT5(6L@S.!#=VV_'$.=KL9^6_,MOO
M=OQ#U4ACUO&[1ZJQ1N7[5O=0-=&I/,LZ5$TUJF[/JK]3*ORCU1SCU->,S42N6I=U?^[+0 M%_9=8(92-%*A+)NV^(31LOBK>QPDJN,_9EP42>H9BSJ742E0#O?$<)W'1F@_MKJ"#/U!+ P04 "
!S/&=9B0!.N_"*!@ &0 'AL+W=O,J\4JMZX7OJZR$ M^]N1J(&;)[F0%=9F*@M?U1(P<4D5\\,@F/D5IMQ+8[>VD6DL<HAXU$]JDJ M+%]7P,0Q\<;>:6%+BU+,!3^-:US #O2/>B/-S.\IA%,
%14<2<@3;SE>K.8V MW@7\!'49V·D*]D+\6PG:Y)X@14"!IFV!&Q%N!W@ QBS(:/SNF%Z_I4T\'Y_H M7UWMH8]5O @V"]*=)EX'SQ$(,<TUMQ_9=/5/+RP13[HJ.;6STT4·0H[2H
MNF1C4%'>WO%+=PYG"89S.2'L$D+GW6[D+#]CC=-8BB.2·MK0[,"5ZK*·'.7V MI>RT·$^IR=/ĨVAPO 8F>)":4%V@I)>8%F&/7*O:UV<'&^5E'6[6T\ HM0H^" MZU*A+YP ^3??-
V:]7GC26X6#P!W4(Q0%=R@,PLD +^K+C1QO>H5WJ1\%_S^!KEAZ%MRLUYN=M.I M/8$T?Q>^XC;,?,MMWKO-;SZX8;]A[E4__ZP_5* +UP45RD3#==LJ^M6^T2[;
M_O(WO.W2CU@6E"O$(#>IP6AN7J=L.U\[T:)VW68OM.E=;EB:GP5(&V">YT+H·MT\1NT/]^TC]02P,$% @ L*P I-(!D·!X;"]W,W)K·M&ULU3UK<]M&DG\%Y4NV[*J*IB1+5IS$5;3B[/DN
M3G22O;OW$02&(F(0X.(A6?OKKY_SP(N4X]O;.^V*+)##3T]/O[NGYX;ZL/M4; M8YKH\S8OZA^?;)IF}^KY\SK9F&U"7=5EMXP8^5K?/ZUUEXI1>VN;/
M3Q:+\^?;."N>O/Z!OKNJ7O]0MDV>%>:JBNIVNXVKASG)SB"_3$?S)S M7WM_1[B455E^P@_OTA^2+! BDYNDP2%B^ . .7)H\QY$ CK_+H$_LG/BB_[>.
M_C,M'A:SBFMS6>9_S=)F\^.3BR=1:M9QFS?7Y?V_&UG0&8Z7E'E_T;W\NSB_M292T=5-NY66 8)L5_'_\61!QR LG\L()PJO\(J?!I&PS]H MJ?0V)<5N"LW306_9O!>_I·7&=U5*ZC]\K4IFAPGE611C?
9,9&MLR0NFFB9 M)&5;.%EQ&UV5>99DIHZ>ZE_/?GC> "0XWO·$9GW#LYZ,S/I=]+XLFDT=O2U2 MDX;O/X<5V&6G$P.>& V\^AT,8M.%BQ8GY\6$7\F)]].&%# 'Y!<_$'S8F M2DK8PJ(V*?Y5
Q,2N(${ZR&APW25<'69'D);6JB!MZ+&7[N'@<&'%QT=J:P?VFS/.'H_*^@·]2'VFS/.'H_*^@ ·]E5G:197@.%YM,QS&*HQ5:+OZ%CX(T6MSV^@\QLW1WV@APEBVJ68"X,H* MJ1=06D<[4VVSAA
!JZQ@RK(V4=7FIIY%B:D:$/$P4·D490/8@O%+@&H,([_.8PJ'·XBNN0=7L'}IF M$S=1"[QER:V/#1]Z&A:5'()·'V#W3$UHIZ$=0>P!'#&/;P!XB4E14JP!?'CF MP<35G"1(A5_G#S-
\#M#BO5QORC9/$8\$2T;D^7M;L$)S"ST8&A^·O(W"DC2X MQX9_^K>+D^.7W]?1LBA:&...2"6"697J_M,N#5<"7(6#_ 2+W*Z *$Z/212? MS@".W·^4F[>7.,K[N$HVT07+ZR\AB(&-
+WD%=;PUJ*A!7L7UX)IB7M·!Z)HI M8LI=5B#6@7ZV<0$&"SXR0\,$#8PH!!D4I[^#PJ979S1Z5I·N*(O\ =\KD+YR MV82DK2K\T7N)R36$A4&J0VL)$)R'*WCK* =42F7=?(@CS"9H&FM \,!+8+
ML018>54L(A/G+QL+0P; 9T4*&@_M)YU;WR60M_$#$JGYO·4X-Q"&>LV9T*? M(1_14D!:B]AH&^!@W0M//@$D69G.)W3?F=5]0Y*ZV_X+Z%78#E#^OFR1&& M=7 W6,
(I4R%+#_4Q1/WA%N%F9,U#%25H#N]MAB+ 41=*FVW\"1+KIT+·:) M*6:]1&A>2^A2T Q:?\%9XW2)%Y%J^NG'0?4C4H3X/T>V>*UM# N'_?O#K MB+B=_]}:X"JP\0%=0!+HF+LY;
@\5MP.690L0^2Q:M0T1%6I,'+0I9ZI@9!I8 M*\,4K:L2J* % 1&C+$#!F=W%*})#"BX] \@$99^@LD5E0]QWK) I# 4+2#N_B!%^P#LJO*WYG8D[C> M1&OP;E#>U"6\TJC·DP6YJ=^^N[:ST>?/0#-
K4V0KL·UAW*8L#.^7 $'&)4Y. MXB05)H6]+Y POT18K$#KLL!%>]N1 M9%72,H%#8?9Z%L@U0,7])@,=A>Q*O[!*050"3Z+D_KU-,T5/K(7>,2XJA[P M1V0)X[$?P>UQH"2KRX,4.\K9>
(>]#9)9$],W+K$O8.3)[DZ8EJXTA1*&;9L#Z M\(CS26 0>I=M"8OTF6-&;R?]%8A8XHB0/8,8AVA%FJ>5)5 8XPK]?7E\QW>PE MN+DG61C\"'+8'29',016L·#0FKZ+LYQ(0,PXI5(:%(D4L-
\49"6J==MLLBJE M[S,1OS S\!A)"A4'3&//CI."$4I;Q?9EOYVJ5ZWCH,H;T0]\'+2\FX% MNV"AMLABAM1%X#/@.J·DX47CW%%Y)X#!0K9*)L!;B!H<[6I4C4YP(,I418!Z
MOT.A!.SET/=A@&WVDO<4KOI*IX>VD*VNRP3-+-B6ORS?_/?^]\\NEJNUZ!J M@<$OKZZ6>_ U-+$WP8'(LGX5,IYH"W,)<1-S7/PJSLD#=DBEB7.8@!9(V&) W8 M"7>@B $:,D9 4X,24.)(:'
2'J8[>.4&IP>L98<,FBE]##1,GLDIDXAL>DKO M 1&#/)6S5Q%2[>+T^_^S_V_;KA% -3&SWP9.9/<5]!?]#Z<@Q+JHTI^_B5[, M%<4WN?CDQ>$[TXO!M[Q\-
^:\,CT8K8X/>G#/B&G&E]_7RSZT)XO0·4MX<·\&)V?C'> M^_9\=KQ8R,*FL/OR_·S[?#X[.5\,H6.(GO=BYWQV<7P>8.>[V9F'KLI=IT&%$:>P:.A0XZ!/ D3HKH%P0C6\"T\D*·L M;2OT#TEY5 8T)8?
05]X3N!%N=U"9Y] M3"HBJ]QL."l\]Q#M.,+4'JA[BJK/]$XSOHA$Q=T4A*W[!%[OUDU4*$=UT.9 M,()H9QOZK5!_X'H!#+;[HS4H·!;EY"HW:,>W%3@669Z+I,37DAS,;("5$6_MO2-
0C4;1,*XRJ56$7_>=C&51/5&*618#'N$QUG),["1YQC0O[MP#92RU&9I#(ID K_R#B50*CGB1X6X(]@)SEM66PSG ;RQ:Q(Z&Z!Q$V, 610L MH)\8/X'M8]$(06664
6A,LG8;"CH.6(B"O02DPSCW\&M1XK2\L838<%EEL0\B·6F9U7#Z MA7>8ZC MFOW%6A_,7#[)HD)9[W@*$^V7MB1E]@52!UAH'YYZ8(A(1'M3=M@:*_\]ED$?
MU;U'EFQAPRKTFX^.+2>^>FNMW9^1L+O#7I8@K3C·I5_].089:# _]PB2E'_]" MC#%$PTYEG9R!W7#JZ[#%"^\3.0TGWXQ\Q({ 1\VY32)*R81V 8/.[(K%&#*X?24?6<] M\^A=\ ;KMHX7G6?KAG.2_
E?,^S%?!XT^U.8SP#\O_J*$)SW]$C/S_%@"'>D0*C. 0E'QR2.)=0F$XJ M$,TE2CD·11Z>UJ#B?BT;$UT\F[D(YS=E\)L%#82DK2K\T7N)R36$A4&J0VL)$)R'*WCK* =42F7=?(@CS"9H&FM \,!+8+
!9;#7A:QR CI M]?!V+6 !).%@UY7"!P];Q+M0S\A[1/D49ZO·-COB5!L.P/.H]MX/+M]$E>"!+A M.HT,GDHQIY$_>$EL"X0F!S#R,!\Y]G\<;(92FVF!N@!+WG&CQ[RWPL.F8Q;(PGI;8,&-
+O>.·!+=@!*#7C)&/[9!INSA C?/$^ M 97]1PQ_@_(Y)G;ZCS;'/V$>PB,9B^_P_>VW]TN0#+ F\C\HO4C+1B&!K!>G M8"H#+0,6@5$O0HE##D=O·9&I$XS.*8\BB 04",*74UG;ES:.]W(RXG8EP7TJ
M8\&:.BYVX73Q>\V2@?R]IBB[AN4O'?!HA@Q%^[[VW+.QR8,T&(S!3)RWLR$+= M(*,HH"Y10·VUX6E3<,OR#QCFF_JFRIZQ06T^<6N+D+8AH@2 M_N?
G8<)=5:8MQQ%%25'"'_07[*U"1HH% #4FPDS/N*G1% OS?GBY8I)EDP MD:IF]VP9EI1#L#?NN;F[.+.5!)@GYC%0ZAZU6J* MVP("#%"*0J F^ZH9F9,DJ!>@KI.23;CES65T@>;.V)LD LG21EG?
^,$'#DQA M#,+L_+2*EPZR<:"Z7?U.M1#(6S*>IB>\(4E\=K·888Y$5N!R)#Y$?@#1,,%X·M5V8#1N]8MM[BA.)'·4D9XGV8M3!)>.=^8PJ/FQC!0$\K,LRIVH-61I^T" VQ MA..].%O,V6>Z-
J0C'Z+WE*&,_JK#[CQ>29T.^$#!K2\5EQ5X)A7>&<30.)9$]R7D9&L?H^#P90^Z#H#(XHBJ&6!V3N>S*<3[5Y/LX.5J
M0G8PQ8>N8]V%6(!H\GH\H&W(KPLKF\&XYD,34M6*U8+Q0D(=*")GY'I/L?; M76[="·$" 5(!$D'#P')RRC0B;_0$">ST;15OB8S1:E·9CA$R_1M(\Y850$?"
MTYA48+>)@:TBP@A92('.%VKE#+"$L7B_[.[2(+AU#Z;A:CVUYV;>E 8&(#B1,R9\V1ZM['4BM M@*DZ>R[1>#]O:QU*C,'#++H99^/XB9N0*N^H@K[P@U'B&TO!6+&%(,$!!:R?X
M0,IUPZYZ3Y[(V7N>'SB*S5&(_0PDB]M/U8$1HN60VV2$\^(\.U2EE7VP*}#B_M RI3YBBV[·ST'(F"_24DG('P*F(KM,K]DB.O *4PC4O<+#PI_11:?KR%B1\% M/?SC^<+·V_E#/TQ52IQX(
.*3PS4UCHW)W^81V^1#!# R??]P%RC5R:B^\.8 MF/RCXMLWB+R?U79AD[B!L N1DIC/LCG3OD$5<@: M$!F."O*AHIP.#UJW+\ 6MJ*5R^YH,8A#<8'@>G&'.=\2F&X,%@)A5 [4Y!QS-
.^(+0VTQPGM4V<4.8TD(^ MX0/*/ACO=ZDSH,B)·8!$OF.PIJK(5^'E&K88K=3P]@?WP^X0/#Y1H,2&Q<_F: MH:3K?+J;32*^&L2AL]@Y^'K$MD7/6)V MIUP9H12L:QU31-
NYU'FMF5!7/R_CF'1B"!NVM^*&QNG 28'#N+K% M &8&0CD1O8$D2*=08C \NJ&HX%@$L\"O)F*"DA1C3O\H&93AH3@:G*$M& BP/.00')1#0X"%EH6F8[0)<)PV M041B?
(=W$2L/ZGH:LH[V18V&AX8Y\#]DF0^QC0T^^&6]%%AAV'TSSW=*7[! M!K(4Y·FBBJ &>%_]+U8 @D\05W7HGKF2:HE4(#P&'IH7H)?·!_[$P3VGCIE
M6H_;#8[Q+&*RFKRK3G8+3TL"F#@NB,I9.YK·Q1{RH·!XHI+I8#742P IH$TGDH^ EU\,$1T"M(EW,#,#76L@W·M94\5*$! %>*^'+SZ$%Z..5=,37@N'J09&/%)0+6E%S)NL#J83LF@7) TF;@0
M[2ZEI?>+[M'F2C$NO'X@OY"%C*@6.H!6,FL.E>"+>.(#%@\JJ[]@Y]D1F$?+ MGN$:)*L&#/P)386'J"1N(7)'@PMJ#??
26YWJ+M]+"84/I7C85TUUYJR!>TF!>R?*=%W"2";!'8'\,L\Z/:,2O.EIU171>*6,A,Z&RKEKUC@<*D'_ 8,3APV[CH<]SX8 MMR/TA"WJ*#AUB.[=V,G#?
BC]?'$^(_MHQV43[DU;QSL4U9>C7YB7B:L4"$R/ M:K$D)3H?+"CN"N[>&BA"D5&RCX&.RE5#M$ $6IE+1G";H=%P6Y8IB5QTU[}$
M3""M+),H,Q^!KC42Y]4RG$5I51]19)#\)·9BD2[Y/CP7VIL95N,GL#!'/.WY M)"\KY$(N0]}Z#/5VU_SWQ VH.V63:X0?O)1= 0KL@V=.?6F."[?Z:?U,:IHL MSK^'I[N/!YX&9R+),G?Y)1J·7H5W'2·
(19TM#YL'Z,+'[IX1+R?H& T^I+KH·MX*F1{)["L):N0K)ZBOB'U?]8PU.A]9H2O2/SA"1+)6CDE8KX1QP?(8ZC;9F: MG,,.EOV8FL6PYSA\;]-)G(KL&R!2?IWRT,E&?KH4.4"/^!YA="VV"VMUWF R
M'ZQO:%.7H'BTKL,]6 ?Y'!+4!],EYZ{$4WT0+1_+@&30.)?5933HAX#KO?$(M1.IEP)E5G_1*M0[B:I2.P@UN·IP&4L$4.]GD9?]%PP^0+)DBM:7LU$5J;=1B M& Z7Q[%!7I?
3K6=]$AX9!B97HNY4/:2E8;W+VV*Q&SN<;R@OXY^L$#'.%5@ M$Y*YN_:B)^(4#M$3P1+XB.IB2C15#2 Y:6%EOB36+ %[L8TQP=^A<&L^HK]/ ME4AR0&6O!K*&OY8YL·
&6@\M;"DL&0MP%$S)U3(^JN>!AEU749D,VW!'Z^ZAD M.9VVQ=QBMR+ ^%26+0;6UH(%7F(YM=P!XT5BHN>S52YU.U>.XT(@&.F;ANI L MT=*U13DR36H3*?/H%YD9?L4,#\DSM#6O*JPK
.M7@B,8;AB[V2W]*YQD72 M0Y,I;9B*{9)1?<'Z+'·I3F]O0L$U1A=C6.>2TB[/ZTIMVD6_@·4H.5>^SJ4A M· L%"A1)UK9"D2N@I'7FK5W&YJBP?/"/8P',MM6·X(FYR3/?2'32)V>IN6N M$AA)8]K
,UQ'F_(^1%S;9#FA#<.NMK9%! ZY2S%Y)Z6MJ5S1CHX(LT"!#9])O,·6L[A8!5'>Y,O8HD>P(\YF..M*JH,)]SA!$HM=#"158L4RW!+,8Q;]JH$*4+2J],(@]=!G·B#;@CW'D_%G"Q6 M·
CE#7<,'$MH"*Q>T^,+N;6 ?SUWAJRMN70[4Y)$·Z1?E:=2(^3E7,QS(M]_;6(,.V]W@&$2L7N$!2F8·P+G·I L 9MU@&R]E_']>OPJ09!{N\?"4M&W,S M>?8)!92,I^E*)V4'AYA1 0,Z.0]V6D9"W6[%[5])
/7HGOJ9&M=)BCH[+ MHV5=9SWX]6$?E%%X)\#'IACB#;SX."\0;=5+&H6'7+U!42FEHX:\S]#"]^>)T M3JYA5@%9XIXZ_%%+Y.DK68:Y 4^4FY2.8G;;]DW0*3O>Z!&0;^AL(>$1GT" M\
[CR9;]Q%HQOXV)R^({$IPX\R83 @MR2"7NFYN(\VD$"H2AF2L_[8SU?A)8@ M.Z_#&H&R..;?HX#·49PC9FI04U2.0@·30F>OZQ*32V2EZ9@=W/;ZZG!QLO,: ME[·
(QDI.+QC=K97IJLFC,+WEL2W97XQF+5"5P>&?,#_+0^6Q=HX$.+-"LMK@ M?]H6A#/I\M)KXR6U1W?D;PV*2@S_$-EX/0Z#VFG.L3GV@"U··D?MCK=#DP', M{}+E+FA8%U>80.
[6*M$Y')UQ{IT3^7DP/JB.HE]@[Y6]N<99?0$0MN_)47;@ M[#02!10]TS6A4K1Rx<&2X'Y.8C =Q5MCMOB3BYLZ!Y'W:J_%)#9D3ND&@ 7# MDO>NHI/W6[Q,ECB %(I&[B%K!U==BJ&?
6[&A^1=;,^ 8U'[EW(6G5"P!%$Z. MNOW^V60*P>MH?7Q0J/^Z6[#S41O Z1·<&3F83?BZ4_0.]5X!$3N VS0%H& M[9LWW4B!'CBA?:1D%@D;KYV=1WQ[YNT5?7:FXX7%?4>-
I4A>XUD9D!R40]"·M%7S$H^4S)>2P:(50QVF*GFIKR$!C3K[.,1[?P/=+/57/X:$]C6]+[4WU+&2? MU%#LUD\A.#>)FVEDMG#%]8J@Y@K8!W:H*+O& ^-;=ZQ)V)/D8%M(383_3/ MO?
TIAZM6Z;6<4J.]#?*ML-&FE[T&;W&_5+·7&Z^S?2%TX7/%,CN:.,P@,,W?$C,+IL=*^>M[8D%VWM0#?9I M&.TB);PZ 2?K05_WC4\1\1==13C&A·1AM_3J/+L,*UZXCKF_V.C^&:+[^TA(M+7·
AMVL)QV6+JA*=PR·T%]1U20B#5 %25W5 \]_C$Z<'3B:%] UU*U#&OK2 MZU Z*.^_;*@Q>]%OB&J+*·.B,OW.J1JJ#!UI$].7S4J1@P2G\AH5 ,,HL=@:J5 9!,N\(U5O MA@6>I-
L2K0VWF/VCJ<9^,&Q0U:-.E[D[JU>%Q?2D;.N;HE6I%H!4ML/:L_"M'>'QQK ;%>61;1F%G$D(."68+M08H9^*>/4KVKUZT)9K1\4<)59 #$9ZO<%P·M!]PNUO6X* .#PC&T]?T@D35/$Y·
_@7$G"KEYI,/U$#*.IU2^V2FP=@=VB'6*I, M[H[$A<^NB+4&5D\?M),%*K@?@?3?$4>"V;HEA*LS?E8763HQN.Z&Q[Z@A<0*# MK4W6T,4 ·LP^L)4[0·[7·Q\?2<^]?NMY2;_QEHG3,P38J#B0Y)H(
^$Q_##Y<$&"·5'Y2QRP4=>>&%KL)I,3L\· M<·*RE24<==2I7(K.·QC!,*,,QO'·R^*](8AM2HU(8S<;>.QN@L,WWA$#R(RK MO/2V;NODR"%X9K.·IK=4>HNQ4]O0&K:]J3(P0XDP]N&XGE1.
[GZ9%E;7UYC MOT) YHWM_3.HE1XY1EAD2D+/}G#IF^T&]?E'V7>·1G>L,=*3A;'+^GB R$G·MKWB,2EUK;9^"702(^+EOBH[ECMV ->#:/!,Q.CS3{<*>CS_1QZN!$'65R#(_N
MFBB)^.M^/7''?"957*ZJU*/=[CEOCK9+*?93(:%"(\G7B4?WJ;MI=@%=Z]> M&#DKU:5V689$9(HH'3USQ8$WKABP17TW*,%"'7(JS/^"VD&>6=O*>UO7 M8[A?G_?J3&)*[3_2WWV&Q5XYZX·
'Z#A9[P2!J&CC%M>XR MI>/I.Y"6=$9PF;!HP·D&V79RD.%S4/V1,4<61^NL KL%RY]F),@XR>(>ZS]T MMKPMT\@T5NNYY_DTH6U}2E=RZ(T#WE/LC5)O@<69B/8V2Z5WLUAJM/E90[U
MD@I#/ T:6=U6$QC81%N5HSU>T"C4$.395T IMF.^]A#}J#81NXY4<2-N@^8(M&'18!KS*!R*UZIU'L73K0RBIU&VWDIH\QW5,$8L/)YT$=Q^'4H379(NQ,XY MVW8[8RR!2(U1"9'W/&US!·.U
ETJ4G/7>=C=YH·E8-9N@F)%*5\ M9SC8X74C;>^2V#0Y1EL[2.H#H_CM9/X.SD.VYB/ +]G9U,8E1·,&FQ=4M MM:71'AWT*>NZWH$F^PI=3+Q^'D.4$?:C\7CJ_UD?&E],\HF0K]·\QC?·T@/F
M'4H%]HB"5B&"D·,Q·LGTK];H11[$*^.^N[K^4[S=??^3Y93*GD?1$X$M%Y\ M4SOI!,G>@_KH>/'%H.RFLT$R[UI/:'C&%;O\$N+6?>AYHX^[#&#R]^QNV+K
M>/J.K5_H/,*@%73(BX%A*V<;N$=[G$KG/J+0MUM3/=R!A6CP.@·0CF559+$T M!E T\@ NXOR?65'0H6#'.9UZ7,\Y@[^C\HCB;N$T>?F.Z)MHF·ZQ'P&(^%S?C/#&5&LJ1#VL.#8G743OPG["P
MGF2·6M$'BPF*ZMCR('8="G,/78JD,YK>'(GC4K_DB=_O:3,Y(*G!V<>E#: M-M=+VJBUO57$#(A37$$@8O7@V2Y!"!$/T^%UKS8C1>/(X;&XL6$Q;]>Y]5G=RN:W2/ITYXW9·T:JL*CYJ{J+C9GX?
6H!VD3 +J1_3(+B^=@" M%Q,#_+ [!(OA??'KY&Y%>PC(H+UBZPA#'C')"R1Y$Q1WG2Q:\,_%·E'*,)9$I M[K*J+#@1$X0RK&Z:Q@U..:'_ "VE7SRR34A\E9%K9@UP^<1:&Z*VV:#34** M)HC=
<0Q:.]/R&Z&-1,(F_E1)DNUF·M!]O,F=F%5,ODZN)6B4\&^#.IS*6% M\TM5MH\]3!L,44KD5V-XVP.NTTP,'+]T5B"E,0IE<60%'Y]N",>W^FOH26FP
M!9M/UU"&#T3W!#GN2X08O"4W=6K.$,=U5]=C4RM]F/EUD·M[8PN5BCWK:C!]7,6\ ANKY0X[$K55=!YP46BG5T?*]JX/R/'K·1&M68J\1 MGW?5[>·DXY0AX.Y@.IZ^*(FNG/F T^$G#1H$#QF
.*&^),L)=9> _?5N=N MF·K;,7L'_#B^'9#·4-_(^R66=V.8!>)V'W3.C(V[",9OHL#XTD M0R>Z^M$:BC(LW_2L:K'9=(*!U!@9$FUC@Q\6:FPQ[X3%\NKIP?GU77Z+\JL MT],(3-
S]S)6R\/9H7VBOVHL,;&4L0K2,%/L^OKP\(#W/#:$VLJQB7JJMIT6FP·L_5,]O0·OC5W1RXG#NEFS#4MM") M=Q?9(S,3AN=+D,O1JX!5<]]XHUL#&+.\0S!,9T4N ,+1JY\
M@+MO2'^H.=UY(PHMO"K·,SE"0[K;Z>E]·E,RA,_PVC);FD#G;>4 !O5#$=·Y MI>T<77[+QW·RX&>UM+B#AA:1XTULUE·D.\P$""S.MC!PKR!QC7);",[P>*X3T3F? MF)T6':ZQV/%T[Z]?
0;D*_S_%#E_/T%R.,JC5UM*_R?GI4NHWY(MG=!T#P$E5 M>WC;RUC+F"\F *$UH]6T1*)RJWF:83V$;<_Z-+=S[?(GECR(O^6W15*6_?<*$3E6MFNYBK1BC>B(W}J+·Y·F"6 MRO3N=I302V_JMQK,
(=OSVQG>#FHD*K3I%'%WP!>4DCRXK=F3!2B.8[4KW.F#0+J&23;7&1;2D

**J5N M*=""2A(G KU#G]1;&&9KEE+T@0F!{BA'JRWA%%U41I?*ZLMJ@2[>7*(W:(1$ M\:M <8:^9\+$4;X*_MRR7) L4H5O&O?7(ZDR+.(R&:./+)-; M@3R55:3Q# [K]HQW^(_5DZ\=K/C_>6[,3N**[(1H;;Y%IF!--//-N]S_RK--] MT>W^D7#ECD^Z>_V#'VOO>_'+A3^?>$,*X?L_&)<\ZP?N4 MIY03R;A.U'O7L=ZU&.ZNQ(ZLZ"\D)&P) M"?,A80$D+ 2"-30[J34{Z:+/CGKYBZ*;O]1I=X^P2T0QLWJQLBQCVK1:ZJPFAM&T\C564Q>WH@^T5E;+*M18 MF89CFK59HQ6LNA6L'I9"4@RR1$H>W^>2W"<42894PZ1JNJBF".MO6Y9$E*L1 M5$W\XK6NG?:53!KMY-H8M]JL,Y9>P(F*=)P'8=H7JD%7ZD+! UP#CJ=5* M(-28F1/7M4BLFL1V8 BBN(DE]KYTZVM>=TU,NJ,YEP90<(30(:&4%6Z4/" M ET#:&2D,>N0D5/+R.FU9UXL>]6"4_6!NUS&V09ES]WD3BUH M2ZM^'>;MJ5'7?=&;8^Q@L]5;=H9_KM0A89XN_HG3FO@L(:OT(6&!+GY{TI0 MAMHL[1-]Y;16W?1_5MWB]#]!:6[S@3.U1TDS-/%_U)WD%7ZD+! '%_]+W6FS M/*4[;!P^Z1G])GL_TXNA"Z7-B"4)X4< [=*O"L-IS$6&5FLA-N^.JER9@=(\ M70K&T& [H#+1.'Y06Z!NA]..:\BMSB)T34COZ>HS_$ZE57=E!?I&>"$VC56'V.R#V,O.L;E#V[1^12O*8S6.OD?S/,T3 M4FR6O2UV('94YB1!=YP^4,Z5N%:%Y+1:ZJSGW(4**&T!2O-.;4M0F@I*"T!I M(12MJ?3#9@%^Q6X!!MTN.*4M0&D>*&T)2O-!:0$H+82B-=5[V#; W?L&'Z@0 M5XBLU_O^6?7$4?P81_34EJ[N2_W8:_LG76>K5-(FMP_8,[OI.?/;{{ MFOW\L=L>V4%W>D!I7]\,EJ!U^J"T0)>!:,5/.(0_--LK9G1TTE!U9)ORF*I M:Y9G5!<72V/-EXP._/W7XD?!-G B7T055E M#!W5Q?+]4=:]C62[\ISC/9.2I>7EEI*(\L)_?[F'R^*2JH#Q3/_@502P,$ M% @ &ULQ5E;;]LV%/XKA#8,+;!&-U\SVT 2J>@>B@3UNCXS$FT3H4B-I.+T MWX^D9%T<6;4WHGF))/]<{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l/U_GN\.USFV<%NT;6A)S+MNI)O.&,B,YH$=B/HD%)"9(+#QA M)47D@+))CP,EE|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{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{2$F;[^)&P+F.A(0Y MHX-O=W^B@PSGG0SG0X8+3H8+1P?3X+9%S0W8VJZW6F_S0\+(A"5,,=IH"C/F M7%> TIR*9O(%;$#O=$?-&!P.F!H;%(WQ\YB/#:;@KR8(@G[5R=(ZWN;_B"; MYPTS[&R+0-*[^;14$PY=!,&@=!)3F@<)<M4)H'2O-!:0$H+82BU4V]K8=@(0FS& M)@G=F5LK Q!|)#?C<0>]4B(DZJ.T^!508_H 6F4!I;F@-_^4YH/2 E!;"$6K MVW!;,'F:LMC->E62JYE^6,RGYGRVIB2:KZ?L M+Q-MW3ROCIF,^(H*S1,\7D:-)?03/<)V.1(:!P'H-0:4VH+2/%";#TH+0&DA M%*T^ +:5(&PN!U_2:3\I2O1R?:$Q\=F?|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|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{]H6])%#3##'R'6J!OD /M4 ?E1;@TD)C M8^1N:AX=3]*KOV5VMDUJ>VP2E>\8EZGE^;G[[-38N_2Q?3NQ:])=^]:K2_?M MVR_-7OHI1'XN+K]1?)T=FIRI9>LV>4*Z!Q$ MFD'_ON!<[6_2 LK3B:/_%!+ P04 " !S/&=9UR]_\FT) # 9 &0 M 'AL+W=ON^;F',"*$C MX/HMS;]E2Rs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{^$422,(6&^!L2W_(G6;!QN_I>I=Z-I,_:O=H<#>W!PN3LSI^HJ3"C-@])*(U" M:0Q*XRB;*L\]4\8R#SP$^9*L@K^K3D0EYB)\U;H4|S5GJ S^3-H2-;;K+%$D MS8/2"B-0ED,2N,HFBI1NY&H,93HMBO;V$7S5'8/%B(+BHT1OE'M1[FT57+Z M3!;B2=OIK;/M"]D:.FTA&RO56E^5 ;A=(8E,91-%7(C;=E&?V&[2!O M7H\TB#A MV)[\]B<"_;@FBVBU-VJ?R0^U=[*(:ZY59^U!+2PHC4)I#$KC*)JJO<;'LHS> MPI[V5B*K)G8F!)XNXY@IVEB'4?+4+E2*)3&H#2.H]DR M;#PHRVQ"_>LY(V9NU_%/*,VM:?O=V8/.K'>ZB'^Z"#'T=FIRI9>LV>4*Z!Q$ MFD'_ON!<[6_2 LK3B:/_%!+ P04 " !S/&=9UR]_\FT) # 9 &0 M 'AL+W=ON^;F',"*$C MX/HMS;]E2Rs*\CV.DORFMRR*U56_

_#Q!RHX=30S[!#-G4FK<'S.VV<:R#0?6*-N-&FY[X]#'3J MA@?H[5KA<:KP._SJWFF$RPA|'3?%S"CSU,#YG3'<&Z/#R(&Z=$[QJ,/Z3%P
M.H*S,1Y5'ENAG5:AG;Y7:!,>&*)K='MJ=*>=L9Y,9H>_CY ->O6,\^I >@Z[' MJ=V8*EK1G571G1FC^YF22(4KDFTC^(N^?D%W1*B$"HEN;_5NY.+N OU3?9?O M/*Y?
T^W>%,WH[|2P0L)<2)@'''?,A80$0K'6G>26G.7A./X<4#"3,A81YD# ? M$A8 P5]"P59=_+",,!O:?RH5<*W]39>ZAFGNNF33(EL3H5V>^9=F;V>]@10 MF@=*\'T%I 12MK89&*0S_?
WN\TE&!VMR>1LYA(Z^G4;,<@^RRKU6"%4"]8SM,=94/ M&VM"[\0U-#!L].7"@I4!0F@=*\'T%I04EKK<,X(<'V9.HZ'WZG0M| ,;3G-?D|6 M#6C9#9Y3F@=)\4%] N^7&J?VF:NH*(3:7"
(_KHB,D1[M\I+_=5HO8Y0!]?XA_09WJWO.I+M5@2PHNJ T#Y3F@](*"%I;!761%9NKK%[$ M=NQ1KS1[KK00&(D0V6SR$Q_ZLI2'+/5!LH;I/C\C%#*=W^3:X5LD]W3-MDPG
M00E52.J52Z*8Z4_%$WW)$K0M#H2\Z/2I?T]:=5;>=<]^&+3]"DKS0&D^*"V MHK5%5I=>L;%0URBD5:(HS\-D];0W3\;O'[E2/,XO0THV5&0- M]/=;KM/R\B9S4/T3PO)?4$L#!!0 (
';\9UF79>$=0"(" (& 9 M>5PO=W!R-H965T<>\\OOB0'(9)4 ;#1 M,V>EFGJ%UM7$!U5> "=J("HHSZ)#*$QMX*-\I+7@#-A5P0e9W0\MSXT &$\2L W #P_P*B!A YH75E3M:< M:)
(F4AR0M-&&S0Z<-PYMU-#2GF*FI=FE!J?3I3@2IH^(E<$YR#S"EA:s&. MYJ@T6NQD7AB7T/U6 M@EA6Y15A\YNIZ#)I2I&[/VF,W1]=4-ND*T1#*L5.& M4B6^-D7:5'[>%/10%X1?
*2B#:H"BX /" 8Y[X+/+\#GD!AXZ>'0.]XTUK3^X M]0<[ON&,^=,GN>P%W6B*1+#U#,W48'<@Y>^?Q>.@D]!KP1V9D=46M' M=(D]S0HA]:T&R9'L.)/_=:9JG)&0 lV3%8->1^HT(Y?
&=H]&N+1'4[\?5=J M3U2,PV$;=:8A;C7$%S5\$^7V+23$_Q0WC'$P?B&A)VK\<8A?2/ [-]AVS^]$ M;FFI$(.-P06#L?D^9=V1ZHD6E;O4*Z%-BW##PC1QD#; [&^$T*>)[1/M;R'] M
U!+ P04 "!S/&=9U=&&1Q,& #7+ &0 'AL+W=OTI2*QX\LX:?[@3MNXK")]Y$]+@P7=SG=LRU3G_.UT&?#!B6, M4Y;)R&=(L-W]8.G>$CPK
LH[OL3L),^.43&4!\Z_%B>_AO<#I^@12UB@"@BJ M?XYLQ9*D0-+]^+L&'31M%H'GQT_H/Y>#UX-YHD*M>/)7'*KH?C ;H)#MZ"%1 M&W[ZA=4#\@J\@">R_(M.];W.
4'J7A:!^L>I*%6_=)O-1%G >[XF0!$N=311=W@I^0*.[6:,5!R7X9K?F* ML^)!V2JA_QOK.+78\$>:J$=$LQ"M>)HR$<0T06OZJ)\&A=8'$41:![3<"\:*
M2O)]0#X5+#WUF:)O(M_I"Y^W/GK[YAUZ@^(_1GQ@1]X\FZH= _+:+H9!W9M5 MU1O\3&_FZ!//5"01R4(6FO%#/;)F>/AI>[^Q%7"9BQN$Y^\1=O"XKS_V\"W+ M;]#
(>3;,/[L3Y[8]62# ?$HP @1D"C!L!QC;T13VK).(!%'= M;$,F:)DO# _IY%VBS7LKW:+E_- MM3J HA$H-%.),_EVI70B5XKH8UXH85@A:&/LWV!'L3]Z;[&=-WSA'G)N;7=
MJSF'1"-0:";GN.42]!>@4:=8OLOO0#;D%!T0@4FBE0ZT)=NPW=,'40F>9>@T<\"7M9 M[AJ^V:R'94@KZH.B$2@TD^76CKIV/PI6Y!O;N,8Z]=+K@S9(H-!,&5HK MZ]]H(#))^(EF 4.
[+E @6!@KE' IGR$;U+.Z70?9(1O4L4*AF62WUM:U>IOO MNB_]\\>7Y7I#?B>|{-Z6E T'Q2-0*&90K4NV9VIYZH(88%,T'12:*8.
MK2EVK9:OGB^ZX$=:BEA/'#UID"B^;2'%ZW6!H;?Z(D5Y91K>]0HV[WH#Y\89 M7Z[6H-88%(U H9F?B5ISC.WF^)K,I0_Y^5'SBAFO^HF7>-JB03{()OJ5[R@
MS++WZMJ9!HKF@Z(1*#13W]9R8_<5"0]#.MT5*)H/BD;@T$P96A>.[2X<*N'5 MS;@C,^%A[R+CV;MSM12@-AT*S92BM>G8;M-?DO&V<1*RC.[B!*T$HVFO%* ? MCD'1?% T
H5F"M;:=CQ^30H#_2@,BN:#HA$H-%,&UM?C!WQGADIA7F_-AB\S M<%*09]T'1"!2.J41KL'=VO^7# 99NX&^*@!%\'T'1"!2.]7/[5@%/7Y/X0\-\9
M@*+YH&@$"LV4H7UG@%_R:1T@\W6[R!OC@ 12-0:)46P[,-G"D3^W+G MK$1!\?FDVNS87&UVYR[+/:D7UU?NK5_ML6UAJBV_GZC8QYE$"=MI2.=FJF>;
MJ';15B>*Y^4VT0>N%$_+PXC1D(GB!OW_'>?JZ:1HH-G+O/@?74$L#!!0 (M '.\9UD-2 ;'L@8 !HZ 9 >&PO=V]R:W-H965T?T"CMS:;YN8683?E6Q5'*%@+) M;9)0\?J1Q7QWUW-
Z^Q,/T3I4V8G^;+JA:_;(U-?-0NBC?D591@E+9<13)-CJ MKC=W;OWA(O(K_@S8CO9^(ZR6WGB_%MV\/ORKC?(:L1B%|@,0??'!,MG<9R1
M=#V^E!!>5686V/R^I_OYS>N;>:*2W?/XKVBIPKO>I(>6;$6WL7K@NT^LO*%Q MQ@MX+/._:%=>.^BA8"L53\I@78,D2HM/^E(V1"/ &9T(P&4 /@P8GP@8E@'#
M#F;5\T5M[2A"HZFP]^0R*[6M.R+[E<>;1NX"C- M>M:C$QJ_D8Y3LP?^2F/UBFBZ1/<\29@((AJC!7W5W4>AO58$H18.S=>"L>R4
M1!_0%QIO0B8H>DN8HE$LW^F37Q\)>OOF'7J#HA1]"?E6.J:<H6N9596/RAK M=%_4")^HD8,^\U2%$GGIDbU;XHD|_L82W]>M4S41WC?11VP%_D'3*^3@]P@/ M*CM?
NSA\$XV0L-!'CYLNQU[^?:5,%MI7OGA[>5[MO#*0MTN-,6,K3EL.IN MPYPW/M583=JJ;I1X4\H2QU<^>0 ^+N7R/YO.Y+,:7 MA3YNT!U:2E?=(6&D@+DY+$O2S[/A]6 PF/:?
FX(>7^6,W/'!53Y0Q0REQI52 M8ZM2#RQ@T48KU4T8*[2K,) P4L!&C2;'+G:'*,CX29C/#D0!>@>AFZN)4N MKE67QY
+]4$QD2#1R,1!G8DW9286F8+/]"EFK4I9B^F]%"2,N$=*,=B=X .E M((OTW9;G$3OCJDA#JNM*JFNK5-6DY^_S)DIM*EE+Z*H2)(Q PCQ(F \,S2? M5)I/+IBN3"#5A(012)@'"?.!8(::-
Y6:-_8.3,D_=+1!.^U0^M7IB7PVI$ MBDR81'\53QM'V1OCL85O8 _G W<6RO154E(F <)\X%@AI+.H%ZV#GI*U+,L MQI@B*MJKTQ734%'BC-AZ*9LC;<="S%/MU*Y#,2B-
E+21T<,.9C^@)?I0 M-%-#7&N(?\Z.8lV@:L#QI M!H(M(X5B+N4)Z4"M"% .*6N33I0BP:*9DI7FS2.W:7!NG#1UVFU2_.9"8G8 M2Q!OEXU2!H235K51#1Q0&@&E>;
T'XIF=HS:$W+&%ZQN'%#S!Y1&0&D>*,V' MHIFBUH:28W>4'DZL9Y#6.=*I6#_K2{4,B>PG-Z1XF809TNS:U"_"93F@=)*)K9-VH' MR[%;6/L?
^QHJG^H5]VTHO2WGYI)D#FG]W(/2"'"C- Z7Y M4#3SQ8/;Y<)VE^M_ELS+VEJ3N?V.NO8-4)H'2O.A:&;?]*TR_"]66=4W9$CU M>ARQ[UN:)>U=I$)3\#.4==K2^?
5A.K=7J;.XD#0/E.9#T4QQ:P\-VSVT1C?:MQUQ_+K3&B2YQJZ* QC{[+R5KS>S94/&9BF],94MVZ^^1]EIT30N@-_)*\T!I M/A3-[!VU&88L*@WIOH#0"2O-_:3X4S12UMNFPW:;
[3%^B9)O467YOD[=F MZU;A06TXW/)6D^.,#W\;(Z"E>]_T'XIF2EH;;-C^UM4/&,6[IF[/V.G,N%. ^ M'BC- Z7Y4#2S[|0^G8O&>-!W_<"I1%0F@=*\'Z%HIJBU 8?/,> B0.E$5":!TKSH6AF
M'ZF=-WR)\X9!G3=0&@&E>: T'XIF;E.IG;?AN<[;92,UL,4R:S%6SKN,V"O= M>1*]!T&12L$ZS>VM.EY{CK??"@+6ZO8NE6=K38XSO-M?0?GB7/K%=L4:TRO
M:U*/S>LHE2AF*XW,6KM7*+P_4'R3;YQ[XDI/MO.O(:-+)K(+]/!7G*O]059 MM1UT]@]02P,$% @ IL)K1G!@ -3D !D !X;"]W;W)K&ULO9M;;^(X%(#_BL6N5C-
26TBXM5V*Q)#;KJ82:G=V MG]U@()HD9FP'6FE__#J7YM(8ETR/M@^%A)SOF.2+D_C@V9&R[WQ'B$#/41GS MN]Y.B/UMO_]'8DPOZ)[$LM/-I1%6,A%MNWS/2-XG05%8=\<#";]"
=Q;S[+ MUJW8?$83$08Q63'$DRC"[.4+">GQKF?T7E<\!-N=2%?TYL|WD)'(K[M5TPN M!4O*.HA(S .;(T8V=[V%<>N9PS0@V^+O@!QYI3U*O\H3I=_3A3_6=[U!VB(2 M$E^D"''Q?
#F1)PC ER7;**"]L F<:6'__2G>R+R^_S!/F9$G#?X*UV-WUKGMH M338X"<4#/7JD^$+CE.?3D&?_T;'8=M!#?L(%C8I@V8(HB/-7_%SLB%J ,3H1 M8!8!YKD!PR)@>&[ ]
@8O0T8GP@8%P'CD0LW5K2TC>9$%FT/(1!G+K[*)C\-)!Q8OY 7W H7A".UVA) MHX@P/\ A6N$7*:A]X3Y.ZD&6FP9(>DJCB[15[Q^>$:?+")P$/++/8KSOD
MBZD%_IG$5V@PO$#FP!PIVK-\)QS+<,,X&6Z=D=W,PX>]O:D/O\?L"@U/9W?T MX8]D+\,")\/=\\-5C??TX1;QR\8/-4=R6*H|S'CC${Q*645;ON2Q0W5L>L6X MY7OLD[N>O"1PP@ZD-
__M%V.R^%WE!"3,@H39D# '$N9"PCP@6,.S4>G92$>? M%WTE1W2#*"]OZFO'<'9A3F?Q-##;L$OT&*QX'DONY+++B.U6;H."0FS(&$V M),5V8,#,EMZF'>;#Z2#
!F_4/==O:&QJCR;B]H0?4O(9)X]*DL=:DI;R4!?$V MO?!^1"1MDJXB0<(L2)@-"7-RV*CFQTCI$612;]R2\]V\/#8TFI483O48[+"5" M08PV.&#H@,.$%)W3>7I=Z/W29N_J%R3,@H39D#
'$N9.6MY<3L?MK@PH9\/! M:>G@5.M@_HCP+UIP'FSC[%DB=4HN)M$^DZZ\/"T.:3]PJ S4YNYJ{"3, M@H39D# '$N9"PCP@6,/3Z]+3ZP\\)%Q#>@8)LR!A-B3,@82YD# /"-;PI*;T
M]$;;'RXBFLBN3EZ%&=DF(1:4O: H" D7-"9H7XRW,!+1@W(WHJADDS(:$.9 P%Q+F <$:FAF#:CQO\+\\C>K3=.W[0&E60:N?"V/5N6"# MIG5 :2XHS8.B-
:VKG2(;6NON\7,0)5&]9%H'E..''TCPH6M,]LW+//,N]GY5-2^\L&R3-*FAUV0RU;)!I M'5":,"TKSH&A-V;]:@J$=2CXY1'>!=L%V=TEDIY?>XZ4#,$K90,L.H#0+E&:#
MTIR"5C\1WH[,@2;TH&A-S:J2@J&O*0"-!.NS=-8-M*@ 2K-!:4Y!>[??=4'3 M>E"TIG15]<'0EQ\6_H\DX$'F6=J)U7X:4+NV5H^J/@D.^$E>8R_05QIO+_\B M+%):"%J0
591GO@_\3M'&BY 93F@M(%K3PJ]X8>BK%X\[RL2ED"YU,!!M M&(W;-WQ*&T'+%Z T"Y1F@I*<@E8_4TQ3V2="IO6@:$T;JS*&H.|C?,#&U^TI M4VRN-!.TK %*LT!I-BC-
6C:FT/0@@44K>ED5;(PM"/5\T48TB..?8(V[5N, MK .!0LHY4=\$@E8Q0&D6,T&I3D%3:L5:'U"F[#I2E5V,/1U![@ZK(0*$H7 M:N4@!]27H#0+E&:#TAQ0F@M*\Z!HS5_E5G4-
<_"!0]T)6JT I5F@-!N4YH#2 M7%":!T5K"E>5-$Q]20.JD*9/TUE-HU7Z4HY,6*!I[7/3.F:[/*(>.0%MGP=% M:[I2E2!,?0GB@Z/">GIG14!+$&:[!*&NM8*F=4!I+BC-@Z(U9:M*$.;/E2"Z
M]DO#UBG!]JK|ESON;N*-!\YH?'XX^[6Y6/*9?YO-R^/R M2"6QR&OF,_@3#ZA\%!*9B+_T7=P<'K'@2-LK<[@J4B
MG3)G&GAZ_*+N9S>O;^:12K;@T=_A2FVGG7$'K=B:[B-USX]?6%#PU0OX)', M/M&Q*-OKH& O%8^+8%V#.$SR;_I4-,1) !Z<"2!% 'D=,#P3T"\"^N\-&!0! M@_=6;5@$#%\'.&<"G"+
R=H^;ZRLI5VJZ&PB^!&)M+162P\R7%FT;N P29^L M!R7TKZ&.4[-[_DPC|8QHLD(+'L=,;"&-T)(^Z\=*H>5>!%L-#LTW@K'TDD27 M:+Y3[,#1)Y^_D9!8!+]Z-DNLBG=47"%R?8%
(C_1-#6((_WV? M7*%^[VRX:P|_8+LR?& (!]X?;KNV;P|_8+LR?& (!]X?;KNV;P|_8+LR?&-MOM66_2*S[F=[PC%[UV!GJ)WD#/)%:C.2AI M#FS[LV)4D8BO4<#U[+1B@F83S%[W/8'NEW-
Y@>;SN0RNOA1X8PV233@0? MP65-TA87I)B;BPU.* R,M""3^L,&^M>/2 V64\)RK++#N6<#"G>Y<[>!81=O" M@11SG08=ARH2X5S2)TNNH^IR
MI8HEET@Y'NACQ(R\K&G;\H(48#B=6(7Y2$KS^PUKR&I DIYD**>9!B/!!8 MC2;N56^V/6L/OJ-/8;R/!5NS'DH53]C+$"N1_@A5Q%9(\6*%92;F18+3F678 M-ZP/%O:.M
4*]N:!JOE0:G6F)VX%MH_*P?=]*.Ls:I?(MX_E5Z@/WBRN?Q3 M3\!&TK@QC5R/C*2M]6M-&E+-_U7SH=3JI$E%FOR0=\4B38VL8R1+FIV]6**GN>X81V$BJWR!E
+"P5Z)U#P1U:D#5 M?"BU.L[*K,%VMV;1&%!U5U-*A([]F8ZIZ>29,%4P5EM=ARV/3!;L,9&I@;;! M%M2, 57S0-5*+4ZV\K8P3_$V<%-+\/894%-&U U#U3-AU*K8ZTL(/R_>$!V
MU;8O-Z!]+FI:0&.310>:U3=DQ2.+28]YD.IU:%6_@ZQ^SO_<0%C5VU-&YM7M:^M -"L'JB:#Z66 M<^R>;##2P^TFVPHF|.)EGZA\8TQYM=QN-L\V6;VZ[N(;+]\T5LGD>]CNJ-B$
MB4016VO)WM5(]WN1;PO+3Q3?9=N8'KE2/,X.MXS]IR0MH']?3M($Y>:\ MV;]02P,$% @ &ULO9AMK]HV%,>_BI554RNU-XE)
MP!$A=2,5);H8*8';>&,9PJGNDNDGF%.9OLR0I6(+_N5UR5S)H2T@1205F* M.&RGQMQ^]&V<&Q0M_]P*%(UGE'=EP]BWO/!'.#6L/"*((9 Y@JB_ RP@CG.2
MBN.?"FK4/G/#YO.)_K'HO.K,A@A8L/AO&LIH:HP,%,*69+%\9L?7H>]0F_," M%HOB%QVKMI:!@DQ(EE3&*H*$IN4_^5X)T3# PQL&N#+ EP;XAL&@,AB\UL"I
M#)S7&KB50=%UL^Q[(=R22#*;<'9$/&^M:/E#H7YAK?2B:3Y0UI*KMU39R=DS M>R&Q?$$D#=&")0GP@)(8K1"H/:+[C 'F50! 4VYAM*-L2E2GT M=@F2T%B\0V\03=&?
$6RD@@/PTA;-N; MJE|UY_"IP5K8.4L[)Q8'9CE MZS&#'HS?CUE"H#!V'Z:EY* >#H."Z]|@GM/<$=-3:3OHMLV7M$>Q)P%,#;5F M">`',&;__F)I=BG+(K5>Y*5;^7>U-
5PKP"EN\\A]E@:%G6Q@#PT_MJV>,0 #V030R=XO9ZN5?<-M$N8T9',=; TOQ-7ITG>O.N4.QRZN7;;$]6IQO5YQUQ'C4H>ZO6[N5=>[4M?& MW@A?]*O3I=_ATL&VVZWNL%9W^(-
UH;'E_HM.V ;U_MRE:"_Z7D5UPI8Z8;XF M6"L_HSH_H_^Q<8YT)D G;*D3YFN"M1(PKA,P[IT@7[)DH_9'M6V&/-NA0*T] M-"02A)HM-TY\3^.KF>]U%X9%K\|[M=8)\S7!6EK;UOFKP?
HIQY3*3>O08%T= M+1;]T=R;!ZTT7O>MG8G&]YO|4\XTE9L?9[(WFKLSH9/FZZ*U,X/'F<"]F9C' M,3N2- "T91P%'$[43;&8=-W>3|7ZM#O=5@:J#;N)=1HW!7W M04*-
S2R5Y4=\75O?.AVI]Y M>3=4%B3;%YPO4FRS?TYS=;?TV?:?;[]I&++_T#91G&-$E#EA!. M5[>]A7KM:=,\H-CCCY"^I4>O27XH+XS]F;]QEK<|)6\1C6B0Y0A?_'NE]S2* MO]
[3S>+(@Q<&\^"F]9]&_PV6VN>U->V1)5_XNRI[8FTVK M QKEO(!%:?&7O%7[*CT2[-*,Q56P:$$<)N5__UMU(HX"-/6# *T*T$X#M \" M!E7 X-R 814P/#=@5
6,3@,F'P2,JX#QN1DF5<#DW(!I%3 I-V!6!GG!UR^+++HBNKI"@W<,\^0UG;X3G^PM>]V?R0)>5%:8Y))ZSKCX-!1Q MV?RO>1DI%9$GN61Q3'H1^1!|I=Z&;C#SN>+
1%4L6:TYIOBDEOY_0BZD MX).?=)KY893^3'X@84*^;M@N%:#TI^)IN4)^D'5#*MLAO9!,P;D@279)B5& MLJ3+CGA"C^3Q/?%*3F<%VU_7NXT*?#!?R<#Y0O1%&U(?G_6R4__-
S1K'LY M9;'E5T0;?(K1Y9C?@NQJWY]!!&.PP),QIW?>]RUC/=_M7!USGNWS,,(C08G08"H\HPC=(>'"0_*+BCC\K@(.6.-MV5L8/N MV+R#OTZW?D!O>Z(`3RE_I;WYC_]0Q\JO7>I
PG0DS$#"3"3,0L)L),0!PEPD MS_/!&G(:N0TE-'G55>9$K8B-1-CS27E?C%,9[]DE>@WKSD=:M@'HI-R1&9US,KK(C%Y71F787>S30[%I<6^GRW[#]E/MK5GU;H*
M7DJIM."1,!T),Y P$PFSD# ;"7.0,!<)\!"PAM!F!Z'-_L;$U@PI)R1,1\(,M),Q$PBPDS$;"""3,1<(\$*PA)U6IUX84:-_UKUW\(D9G;$66?+BM94T=$* MJ_I_F2"6IE864B:#J494)I9T1K3.
(/1Z?2I!4UJ0VD.E.9":1Z*UE275JM+ MDZKKP?\6QKN8^#';)5FNL2W+A-SRF;0XC&B.L22?5.BWEM-NH>C%A 137^QR M-
!.QW8NUGI+HU**T41=K$4G3H30#2C,K6G,&]J6484&3VE": Z6Y4)]'HC6U M6!L+5.E"ZWQQT&!?&Z7H7^1GCK06DNMO[K!>#>@Z@-!U*,Z T MLZ(U%T4Z1
=U%$!I#I3F0FD>BM8476U24.4NA47PURY,PZ+'$HH[?Y7V"RG6 M=K]2WCS G4M0&DZE&9 ;;;:L0S?=?^&3&I#:0Z4YD)!HK65%OMAE#E=HBC M,>.^VZIOPJC/Q7"QFB?
Q98ME\BP7BVO<*KE9Z_JN=^S5'GH9T):94)H%I=E0 MF@.EN5";AZ(U-5.[)U2Y?>*)+G?E+Y+"A$0M/U'=)9$7/_*3@)+ECI*,E9]L MRX%DJ;%.+4&M%A7M6"73UM5;
[]BK2TM0=P249D%I-I3F0&DNE..A:$TMU>8, M5>[./[LBTM^?FWG(>-AT1.\YK]J?66[MO_<%CV &$]%:1"QO,A?=N^4=Y;WK#WB5J:M4WLO;\[%A0OU04!I)I1F06DV ME.9
:2Z4Y]%HS5^$UG8(36Z'0#FWY6DNI3V@-!U*,Z T$'THJ:;AXK3K@*N^K7O09/[\A91Q-Z*NX\5XR3@=:!EFXFE33]0!=3>7]#ZM#O=5@:J#;N)=1HW!7W M04*-
Z6Y4)I7T;K%W110;6W0Y-:&[_F5A!QYL8J@Q@0HS8#23"C- MJFC- 73KS@2;T]':UHIV3A>;T^LXSH^JOC81:(3P3D_EQ ?_N8:#_JB4P)0 M)P&4ID-
I!I1F0FD6E&9#:0Z4YD)I'HK65%_M.-#*Q=7O^PV%!C4,0&DZE&9 M:2.49D%I-I3F0&DNE..A:$UIU;X"3>XK^*Z99CGS8L5!30-0FJ&UE_E;RT0F M-
4%I=E0F@.EN5";AZ(UA51;!C2Y9>#,$>)C]RSX5:?,H/8!*$V'T@PHS832 M+'C-AM(<,V%TCP4K;G'VHZ@3?[.F!']}H#2=]C-@-),*,V"TFPHS8'27"C-
M0|&:TJK="=K_P)V@M1>]IVIK\5:>^6(E05T'4)H)I5E0F@VE.6=[\RXTIX>B ME0KI'SW*.*9\73QM.R5!;A+-DQQM/3S1>U$\Q_IDNZ5>VVK'=D>]=LM')]?X M\O'A#SY?ATE*
(KH2]92KB>CO>/E$[O)-QK;%@Y1?6):QN'BYH?Z2\GP'\?F* ML6S_)D]P>"[Z_+]02P,$% @ &ULO9IM,^(X$,>_BL6M3KO2;DD"",'1'D5CR M<$^54+M[]H-#$2;Q*SME$6Z#W_.
WD@KE5THWO3DI#YC9/Y9^P9O#A2]HWO M"1'H1YID_'ZT%^)P-Q[S<$]2$&_H@63RFRUE*1;RD.W&_,(CDJC-!E;AN&,M4QQGH^6B/+=ARP7-11)G9,,0S],4L]-GDM#C_<@-
DP>C1M*%*6%07O%73(Z\\QD5M_),Z;?BX+?H M?F04(R()"46!P/+"?"UF3)"E{[-K#?>@]:,;>"\U6!6&\S* M8%5/MPR-BP5>+A@](E9<+6G%AS*^]:6,2)P54GP23'X;2SNQ?
0GG(@3PEF$ MUC1-"0MCG -/DF]";3)6;B7D4;K'2.D.,71)_1'SBA'[UTB<)SP#_+,UR<7 MO7_W ;U#<8:^[&G.)9 OQD(L7 T#NOAK*OA6*\,QT0/-!-[CKPL(["'WM/; MWVKLQ_+1-
,_;C^?3EN<3>W"!S^A%9AF6]IN<-YA.S-+<4Y[}_ &?=-:> MWQ)*1SHS2?*LS]MYM/%,:!WMPE87/K$TTD)HU2)R7/?H77*E QEL>5]4M1M M6^3S.W/(;D?R83-
"7LAH^7//YF.\8LJH P%Q+F0<\)2%@ !.M)8H(8ZJC M+^MLQ1'=HI#*:3(B#)]T2D]7*MB"!A+B3, MJV!.'2N6*B_+RHIC)&0Q"_X.2'*N&O=7!MW2)@+"?,JV+0;4;BWTVBA#PEQ(F.
<,HFPYEC.YB+(S",Q\ M:LTO7FZ@:;V7:Z,.."7,A8=YL$'5[:AFSBZA#N@P4 M+F>WMJ5^M^=-V.?:L%>EQ3_H7)<,"Q!5D+7,:X,,"7,A81XDS(>$!4"PGF1N M&\G<_H?"X!92&I
P%Q+F0<)\2%@ !.M)PS3:]H:A7RN4>20F'$F!Q#*AR&2" M6-&?0H+6H0/E.:#T@(H M6E\BG0Z8J:\>&?G465>DL5Q)")]1\PI++BY3_"-.\U0I#'.PDK)L^[*:6NO'
M<+4V(&D>*,T!050M+XVK%8;UO_26:C==!=+PY)[K1_,U2*!I'F@-!^4%@#1 M^B)I&Y.FMKFU?*BR0[!*EO3JI"[WG,XS)IR"SRIFKV(RIKX"^R!E,*9M0@4Z44T#8D*,T#I?F@ MM
"*UA=-V]DT!:W-A\O,<5Z]1NCY5/W^IM0$;"<3E.:PUZ@/=*"K!^K3!Z4% M4+2^)MJNIZEO>VZ]%3O2)%'!G/+4"%([+$HDLP!9R<4UR50(]HH2Q^EBD [MI36M5SD9-
W8_[BZH3P^4YH/2 BA:7T5M6]74|U4?2917NT#B#"6#)FL[_Z!G MG. L)"C*22.8@RBT5RM.J1W0?FM-ZQ=7ESG#!?7I@=)\4%H 1>MKI^W-FOKF M["I)Z+'4Q)8R%#(2Q4)JB'-
UZUU/NUH+H'U94)I7[HZO?PY%=1AH'581?<-MV10D5Y[F[M,-O%&4<)V4!7QLU,3IRLVA-6'0AZ*+&PO=V]R:W-H M965TCNJDMM M*MG9J_M(M%5J45S 9%*U?_PU2, .;46Q?
>$"N?^+DSW0E M1$;^KZ--?M-99=GVJMM-9RNQ#M+S>"LVAB^+.%D'F7R8++OI-A'O"A:1UV[MUQMVUT&XZ8ROBV7WR?ZWF51N!"W4EWZW60O-
Z**'ZYZ5B=MP4/X7*5Y0NZ MX^MML!2/(ONVO4_DHVY%F8=KL4G#>$,2L;CI3*PKWK?S@F*-/T+QDA[\3O*G M\A3'?^8/^/RFT\M")"(QRW)$(/|[%E,113E)CN.O$MJI-//"P]_?
Z'!QY.63 M>0I2,8VC_X3S;'73&77(7"R"790|Q"],E$]HD/-F<906/AE+N6ZO0V:[-(O7 M9;$C4@LNRX;+'PPW|[%1O?#;)>)W$+R3)UY.'; M046UW.;A)C?]8Y;
(OX:R+AL_Q*]!E+V28#,GTWB|%LDL#")R'[Q*1V?D?I?, M5M)+9+),A,@7[>0KF2P6829F*_+%%5D01NFO77ZVXFAY7#N[-R M"-/]$.PC0W#(7;S)5BGQ-
G,QU1{YOK+C^JIN=ZR#8"N?#VK%]5^>U%O;2/Q MMUEV3GK#,V+W;$OW@IC+\'7VG#B]HKRO*7?-Y7=!(LNMH^7>Y}3]T\L=W<8P ME[MB5@U>5\Y.+[D4(SC5N\LI>(-
CO.I=HQG+[;[61=?F MGW)7Z3:8B9n._]A+1?(L.N-_L,;IOZELQ02YB)A'A+F(V$4"6-(& ?!%-/V M*]/V3?1Q.?>G)Z062S;FKE(@]{SV=#ZS97M/K#07-%BAP>0\
(X"*;8)=Z5?;;51I&VKAPT-FE?M^E=I*BWA_4_$O61HK3Y3+4F9TA1 M#H(I=AM6=AL:[?8@9B+ M->:\Y.@8$L9!,,6$%Y4)+XPF?%S?2!8U\F:) <[:K-Z1VU;]J@EN5V?@Z=(
M:&UIE&EKRXO&QK?LX]451^I2B\T'!JV-6A.?$A5#H(IGAM5GAL9 M/<CH.\9&B% EC2!@'P10/7U8>OC1ZN#!]?=I![5TKC4JM'4M$N8B M81X2YB-A%
EC2!@'P11K6[WZB&WO$P>5RF*0;Z$T%TKSH#0?2J-0&H/2.{JF MVO<@<+!^RN&E4N:P-1OJ=DFGYO&T[O">LAY4UH?2*)3&H#2.HJGVM&M[VF9[
MBB2,Y_OV5P2RA7C;\7K;TYH'F:@>A"F9[X36GD:9UO,PDN9":1Z4YD-I]{.-_M/>S)S?FJFUX8=!P<15--7<=0EC$P&-\%W\/L%RNBWXI;[*,CBI'$<(0WR/;MU M*']F\;8RN'[F=9I'?
WKZJ1>;2D%U'I3F0VD42F-0&D?15"O7X91E3J,%/2A- JE,2B-HVBJ>>N@S#(G96_- MO8IV$\V(R++U$R\T#X/2/"C-A(HE,;@-(ZBJ=ZM\S7+'+#]8,IKIK;>:)$T M%TKS+$WL-KS4G6X
U:50&H/2.(JF>K;.YRQS0"<]&R\W50<\,](?)3*F55: M>QB:RT%IGM5,YASM&3-060JE,2B-
HVBJA>MXSC+GA\+^E!!^K$@@PIR%$VU4QV*V>90[.'4PUA:,H>7%2)VC5>/6<9EM3E#P9XN9!5N[V6Y,)(.^[A1M MJ*RGD;6T$8D/U:50&H/2.(JF.K7.P&QS!M;VG#"YWC?
9HDHW/V9!=N1C'9FL M3*$T%TKSH#0?2J-0&H/2.(JFFKY.R^S^)\X5LZ&7:$%I+I3F06D^E$:A- :E M<11-M6^=B]GF7
QUKIA9IK71H<$8E.9!:3Z41J$T9C^X&^P]LE\5;_JP>]O@Q*_R?7\(EGX3IX(E_^F-S^|_'N-]WW.V:A5N[&AJX M06D>E.9#:11*8U :1]'4;UNJ4SGG,Y?&.= 0#DISH30/2O.A- JE,2B-
HVBJ M?>L4T#GQTC@1APYR%9.YW(5[?1/OBN1GA ^%!?3>U>?=[*YO/;!!(93F0FD> ME.9#:11*8U :1]%4\]=!H?.9H-"!!!H50F@NE>5":#Z51*QU+1Q%4^U;!X7. M3]F
SFEF2B/MI4CFX;2V,#0"A-)*(U":0Q*XRB::N$Z)W3@.>%C?IG=UZ?B ME+NZ_S@CBS!)L\+IJ9!O!]UWHM^:1]-Z2H"Q-B-;A8F^MX#FA%":"Z5Y4)H/

MI5$HC4%I'$53;W!1YX3|S^2$?6A."*6Y4)H'!?E0&H72&)3&4335OG5.V#?G MA*#>PJS2VN=[VH=7V;M06>]461\]2Z$T!J5Q%$UU9YT%]LVQ'>RF!6:=UOZT M3SM]RX7*>J?*^E!9"J4Q*(VC:'M_=@]N?B@-MBSNG)E*N^TVV?ZF5]72ZNZ< MD^*>E.^63ZTKU]{L]ZPK7[>'<6E=L?T_.6G9_B]"[(%F&FY1$8B&'T#N_D'U(MLK_KYOY!%F^+6S(^Q5D6KXM?5R*0^@OS{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lQF*>PA@Z3"N%X_K,&!?B/ON0C81829B-A#A+F@F M:4QJ:4QT1$4U.Z:$ M/Q*/JV799X(6*VNFY@+!!FZ7Z1%9+I=I.:_>JNT*$6E[.51$2)B%A-DE,%; M\M+H:3&>CT:CB^'3MC]ZK8S);+K3R@4-K)7V:9WVJ3;M]VLNV+%D(B)B:]GT MFF4SJ99-P3P6/-&'D/7F7=O-H7E'PJQI-PGF[-1L)\$N6TWTK1SDP-R>@4U, M8UIWV4KHK${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≡ M&I$FZ:K M1I P>]SXN QS?&TV18+,2L_-RI!9>4O6H6F,CLIDI/)1"N3[:IBO5T^N-NY M$"35*[(_7#M^DEQH$T<6GA7<2!A]J2E&V_M09!9:3.K:;5V(2W-&TU&S4$& MU#I%&[<[;5QKM;%=//Z7;%?27&2VB4)+[2H*),Q&PAPDC")A# GC()BBP)N= M F\N6)C=({'6&A-E(F(.$422,(6$X=;0 M:RN.OFWFX+[44Q:35U%-NL6"?"E&HVLY9Q><G-M-;&'BFX8>SH;7!F'2M.V MH;/2D#0'2]-0&H/2.(JF*LVLE69JE4;S+$\$B7:"^]RN\GY$=V:,[@:-+DI; ML[*0I(<*(U":0Q*XRB;*KRZ@&YHZZ,3Q]HI>8L3XN5A'KB%UTG<,,[E8K)1 M\92KRH4<6VO;I56"5F.$-0_E!ZVH0VD.E$:A- ;E<11-E5]=5S?^G,*ZT2S^ MCMN6[_,6)I:N\VU]PSL+"EH2A](8E,91-%50=7G=T-?7?UE)ZBH.%OO]5]VI MU;,Y*;%(9"1U WE'CJ9DG<2+W&NMBQC-^K(Y&K3K"UI,A|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|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|+Z#^XVU_8Z(%U*Q?.- ML5:0LV+]2WYN!F++ $*' =P8P$KWNJ-*Y1519#@0_ Z(\FK=6KE1N5I9:W&L M*&?E1@E]EFD[-,SF]R13]X4$W#)\YR*E)$,C,F]'GH%QDN1SK738#03E);'-M)#@#-^LI!P*:NRO:4K9BMQF^M)RH)EB5(+75U01ELDWX!5@=I?@RYTNI>Y*#MKM+:2P7==*/S8JT3.G0FX#,0U%R"#\6$3GZU[VJ?:\?A@^,7T-O@#5V\ ZCW M%L >#,'7FROP^M4;3[NH'E!4M8L=[9J!:G)R;8N:;=_0M)JE8 MT<[P]^"]/>'1UE8*PM|K0\O2$:*E*BP 6=L:)@Q:R@AVA8&98 MOM7G976$KZB.@\]4S?FDR=^UHJA25#X@5L,8!E$\Z*X:,&U(]CKR"C|L622 M57?U5@@^I>ZU@'!+-^KIOV;=4:T[\NJNE"S4;LV/$!I90L_T^,8.I7&M--ZE ME,^*>H0OI:VG@Z4<3;TIV80*4H;7V9LR0=B]FO1?:I(C_E"\)>-<>/C((I M:/M=87(*3FD)2>[OC4C4K(I2\GCPO=,|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{\M?U ML.&CFULK-NS#?O;]M12\,1S\=@>& S8@P\$1L8J]%#Q4G $6](@/K.6(5V_E: MZ)Y_ S?\DO(U;.=K'B<,;!/&.?&TZ98JF\\8NV\C8\%:UR3$9&VXC8\,&5?CE M96RX(6.#01(X8L# #>]|"38@ MP_^3BA\J}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|FZLY=(?'I;% M5*WG&WO9SA3=;A6B/PAE=7P#LG0/DH8[!?&(WOZ6^-(>9.2Z;M^5<%Q..B@E'MF;_N'G_;R;PRZ=@:8K.A6L]7?$U\>MV2"Y;39$-;HU]_@9?>[R95CIR5-.)" M([9Y'^T$/2R"3I1PM9:8;OOIV&-J'4Q#]9>%U$NK M5+-T!GNL-S#3$ZN;8X#IR5E+<*Q3WFNY/9<:'3DK:>P7&OO6J$X(7P'Z(V4; M$]C[F4ELOY*:$/<]C#XE9[^R*Z$^[NI6I?$-BO$-3K%##NJL)FO/#><=>IHG M/+LR.>GB W"UE+*=TGC'|BI">OW/.@R-X"4TSSO9"PVG\'#C]?$\30#O6[$.\9J08%"~>0W<;2)077'DKBI7$!L@0Z,[3MI1 M@45B'TY3N1HDH/7V9KL4Y6\A \3L?\'(S'XRU3Z;9>;@%(RXE^JV5M5&W M+>,<.%1W%/MI(7B>MR>_-6-.V1\7HF!SG>CIEHH8>^S:5PU3, &-'^!0\R MG3_D(@.Z2'+I?4I+>T]-E>Q43*SLL3=[_TXE!2S M-&$^Y:I*-,YJ@N AVV8Y6,8)N%|(?6CM$M;9B1#*,\L.@3668'O=Y&1Y M79/QL,I-N"NO)4G4[,/ADT3&SMBF5SG*<@(;S+"=C*JD]BYBT.,9^^]J9*= M-T;V^L^^])^QEX@M96Y' CQ%5SU3.8!!??1.M69CLTOE)QBCBMOY1G2F(/M M+Y]L.>VTW./%UFG1B7'M=Q5]'&URF.*[2F8%MFP@>8Z;05:GOO1Z?&-M8/*2;G^%NJ.9K&-GLB,KU+FW Q\PV/L\-J[MG4],U'=7$@M?6,1:0)?2O7?1MDVLWV7[*M#T1\3K[&F@>"Q&'V>&*$AE2U4#^OHQEXN8GZ@.CXH.RT7]02P,$ M% @ P &@P !D :X;"]W;W)K&ULO9=K3]LP%(;_BI6A":2-7'JA96VD4D!#$Q.B@WTVR6ECD=B9L9, MVH_?L9.&EH9H9=V^-+;C_HXN/D=+ 4\$E >H\92E70R?1.C]U714ED%%U M+'+@>&-P(XF:9QF5 M^\\@%#2=]WCH>.81#!!H(T'QLH QI*E10A_2E&G6M,$KK=7 MZI<6'F$>]Q*Q2+^S6"=#I^>0&*9TGN!;L?P,)5#'$Z4B5?:7+,NYGD.BN=(B M*X/10<9X<:5/Y8-8"T"=^H"@# A>!K12"6B5 2T+6CBS6.=4TW @O9)(,QO5 M3,,^&QN--(R;,9QHB7<9QNGPDC))[FDZ!W(-5,TEX!Y113Z2:8"+L^!C)3" M?*(\7AL;"ZX9G^%@Z8L54T:/^/F\%$NCXG7]@O?L-.J-J%E!3]H;4+=@R]$6O5"YLR?JIQ&,'3P4"N0M"W#"]^_\KO>ICG)/8AO,[8]YW:0>7CQ12:? V0.F]2JKJ,VTPZ]" VD?U?$7 MHETK.EY1B[#E!YV!NUCG:ESYC5R=BJNS.U?T?%JBS=/2@%]LTVY&;33S1M1N MA=IM1/W",*=H?WQ_2Q*1(I0BOVQO-)-@<[B.JU%TUQ3>D]@&_TG%?[*O8WNR M3^8]B6TP]RKFWK\XMKV:7/:\%[G M\S?::X2XXA&6: K,9_3U#:C]KGI;KH,MT\VKOS&A_+4*Q^[NM>VJQ;8W]Z!M;>]&0[L"NVO55P9R9HM2A&;G7!>%6#5:%,XC6^ZYS].+JOF:RAGCBJ0PQ5#O M^ 1?/;(H1(N.%KFMY1Z$QLK0-A,LWD&:"7A_*C'!RXY9H/H[$/X&4$L#!0 M (^,\9UG4D0"_50(!P& 9 >&PO=V]R:W-H965T&[".4MP\GJ/4VVDT MC)XGYF)=.C_!\]SF:UR@^UE?&>]8S[4"BLK= 4&5I/HZW R&_GX$'C<&MW M;/!*;K6^\\Z/Y32*?4(HL7">@=.PP1E*Z8DHC?N.,^JW],!=^YG],F@G+;?< MXDS+7V+IRFET&L$25[R1;JZWW['3<^SY"BUM^,*VC1V?1% TUFG5@2D#):IV MY]=`78 P]$K@*0#)/*2#M &H2VF059%]SQ/#-Z"\9'$YLW0FT"FM2(RI_B MPAE:%81S^247!FZX;!"ND-O&(!V1L_9OMTWPCW"HO&""?0*F..\O!LK.CV/&_W3%[9V!SP[#+[@^-## TY=P M1NK[$B1]"9+ E[[*-Y/:BFH-A5:*+A:5O+B#VH@"X3?,\4G+QN$^E0=I_?.; MV)H7.(WH?5DT&XSR#^^&X_C+/LUO1/:B FE?@32P'__?)=BG.7U+S6|$]D+S MJ-<\.GCJ7BYO.XFE%E9[TQZ!^JL?1%4W;E\16N9A>T%|G]SDH\I<<8VN^KV M1,6#L[.^JDV;[;Q=WS>ON%F+RH+$%<'BP0D=FFE[4>LX78?G?*L=-8=@EM2^ MT?@6EH[9X=WR'Z'T+^!U!+ P04 " !S/&=9@&4RV0(% #Z)P &0 M 'AL+W=OUHND)T9_;S"P:B26+6=DHKS8]?Y]) 2/# SE& M"$]SDGR8OMV![N M*/O.-X0(!}'"1]I&RK=+[K.%QL28WY#MR215U:4Q5C((EOK?,L(7N:B.-(M MP^CI,0X3;3S,S\W8>$A3$84)F3'$TSC&[/6>1'0WTDSM[<0\7&]$=D(?#[=XM31Z)^+J=,5G2*\HRC$G"0YH@1E8C;6+>|680$^0UOH5DQP^.478K3Y1^SPI_M+D>:D65$(K(0&0++?\]D2]{H(\D_BVA6A4S$QX>O]&]_.;ES3QA3J8T^B=<MBLU(&VAH258XC<2<[@)2WE WXRUHO/_.;%?6-32T2+F@<2F6&<1A4OS'+^6# M.!"8G1,"JQ18YPKL4F ?"[HG!)U2T#E7'T"%W7-3ZG!WKF"?BGHGRL8E0(!M_G:+UY&_2P<+//\XRND,LJRUIV4%NB%PM7V&89-Y!%$Q>#:5.C#T<,O0-1RE! M#P3SE!%I3,'1)S2EB0B3M2QEASQ<$H9SNWNTUB,!AQ*]DI.^/#OKXX0!0&&"_M_M[0E.-DR8>ZD*EE ?1%F893I&&=2,-&#S+ET^DNJY M6&_/Y=Y2 C_CY :9YC6R#*O3DL_T)_)4RJU";K<|#K7\;,;,9)^.[JKECV0K MY<9)N7>^O"UY_XQ[-^R3T0.UW"&+ZMYMQ9NT*X?;..:|[F<-;$KLO0'8[*,M% M[0@6+\A(D]T$)>R9:,/??S-[Q&/M1]H!H&$.9 P%Q+F0<\)2%@ !*N9KE.9KJ.B MC|T?S/"*).&3:+0C(IOQA*#%OD5=U%O4OZ@@^]/5YDEEG$L"0ES(&%N >OE ML&R\]3RV3:L[U)\/O089T8>$!4"PFM>ZE=>Z2J]-3]DJE7TA0_/9A%^CR63" MD>R;T70FRVU&4P:YU&B0, <2YA:PSH'1.H9A'!D-.J(/"0NZC=!]_S#]FH%Z ME8%Z2@/-\&LQZ*.K7W*0,LJE#H*$.9 PM|=PD-UO6JC7>%%FI\<]JN5#)A8 MP6H>ZE<>ZBL|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|H>4^R*>\!L M'28<160ED<9-7_Y46+'1K"@(NLVW+3U1(6B<'VX(EA.*LCK*TK%6R$+4&WW M&_\'4$L#!0 (`,\9UGO5P>I1 4 &&PO=V]R:W-H965T M8_]Z0#*VFSJ^LJ_QA2Y74NIP9Y,U7!(G(K^N'IG.?D;Z49\;^Z8W?TJGCZ3,B&4FD1F#U;TOF-M),LT29W'|PKJU#EUX.'G/3TV%Z^NYAD+,F?9/S25JZESXZ"4+/ FDU_8[E=2 M7=!(\O*6"?,7[:IC/0%==1'TEP?Y*\@(K\",NKM#OT"!%PPZSF=N#W\B:Q7NF?!A1WAH#[!?\ROD M#=X,C^SA(4FL)Q_;PS^S[17RO:[P5EL.ZKMB8'@CVUW1*;6,&W3'Z6[P3JQQ M0]:.ZN<$X5OBS'[^R1]|OW09@82%D+($A8#P5HFA[7)H8T^^W--;)T6*+, M/:E<\[2?;'&Y41M8"'{]-5NA?36?I+&!Z3?==C88C";N]M >9,*H(^'U33MA M#)2P)6542QGUD)1_%SUM5TRK++"^,DK8*IX;IP0,F-TFG'H>4UDVNK MD\^LN$S.\V(%]_5R?=*3C&Z/O4 FC$X3GO25,5#"EIB;6LR-50"S7%&U72GH/A*#63EJE)&7M94.U13";9'S?9JVVP\V]A;X*(6$A M)"R"A,5 L-9-<5O?%+=G#A=O(4U"PD)(6 0)BX%@+9.^U\P'/>L#_D@X9:E^ M3/>/KBSK"}U3/#MKA'(SQ^N2:0_M:Q.4%H'28BA:6^C:!-^W2HA>]% *$Z*= MLK7IA'4KO::=4NV\!MM%)(6@=)B*%K;:-8#:P&[M-_-T+JHN%I$6@M!B*UA;; M5%U\:RF@S^"]{+M*\252BA?$#)4S5]H&I!OKT@5%;A)>%YIU30 M A H+02E1:"T^\:?=P|/&TK;(I(OKV*=&:AU4[M1:2%H+2(E!:7-$:!RZ'M5<6VQ*;JY-O+3CT+LW9:,WF0M!"4%H'28O^TRO6VO*8RY?&-D P PPP !D !X;"]W M,W)K&ULK9=K;Z0V%(;_BD5752[U-7.92SJ#M#M1 MM96Z5;39;3][X,S@K6I;6:2?U\;""%2(3Z909CG]?/>SQPSFS.0OY0&8!& M#SGC:NMD6AI.QAM1:D8YW$FDRCPG\O$3,''>.MAYNO&5'C-M;[CQIB\"N ?]O;B39N2V M*BG-@2LJ.))PV#H?\|K [O63^F^5>6-F3Q3L!/N;ICK,.BL'I7 @>=-?Q?DS M-(8B]Y<(JJ/=&(6>@V*2]5%W@0;@ISR^H\-(GH!.#PE0"_"?#?&Q T 57F MW)LLG5+-(DW4IR1M*N-FKVH4VV.\U]+,.4A.GXS_Y !/$H A24OV(Q &Q:H1LJ>,:@H*7=R")I2I2[/R^_TMNOAPB3X@RM&W3)2* M%\1M7&W K+R:-!"?:@C_%8A[*"Y1X/V"?,/\1)WT^&WD)AP7(4'+\-=DXXV M9)WZ;$[_2B]Z9DS%##M4(PKF"?O1M5D2VCGFX%,@3./'//^&%]^N8O?)D|{79 MH##4;3*G'-N7H AX25]:4'Y'. '&S!N6"ZTPAX"FDR)R0AGP/LCVFR[&LU%LM MJJWL"^048[SNV4F?WN">59W)'+7?T%O=B MC#L:< >>U^,>5)}O6BY%V]Q+\>X%P/N->YA3PK/Q%ZVV,NWL%=CV,L!-A[\ M3":59W^O6N[5)/>W#$PI/VB08_2KX8]ET8.?E))\OV[AU]/P0A.&2IY2E8B2 M:_/6J:M/01Y??0VOAR>"PU7/U>2^,UUA[G >I.^[JPHU^A$6 F(/^8HF[MC)9),^#G"OO)WIZPIF&.AT#?I=!<=-BONP.'I'I*I,"71MD4L^/= :Y[MD/8\'UJS]5I.P\W9[2?]+HK"5X"?MZS.>+M!,"GZ5S{0>UN-H/8 >+@]"]$?M=CI,VIY_(?)(N3(8!Q/E72]-E9%U MQUP/M"BJIG,OM&EA]\O,_.L :1>8^8,0^FE@^]CV?TO\'U!+ P04 " !S/&=9 89]HHT# "X# &0'AL+W=O=/]*YXYF$@$.B#0/%QPX6P+DAPC3^;3B===DH#[+8/ M])_LVG$M:ZI@(?@WENIL[MP]{4-K;C^(O;_0[.>L>%+!%?V/]DWL9Y#DDII MD3=@S"!G1?VD/QH=.H!@? 80-(#@4D#8 ,(3@#'Z_Q@U@-&E,XP;@%VZ6Z_=M"A=33;.9%'LB332RF895WZ)1+U:8.EEIB6\9XG3T)Z#*Y'$K =!]K<@'\IBF MS)A(.6%%78QL4?Z_4]> MZK*C9EM\R)=UY55"]91LOLK?M1?Q5QSJ1P:TKN,<5@A,50+?]P MNS8I]"L$72.,ZPKCXPKC$Q5NZ@HW5;)VWVZ5FE 4XOXV2U{5I96M/)!E=^J MMLI(E)12?"HR]6ZDZA7WOZ?)\OV?,EN34#X7Y#UY6&92*]T5Y&TH"Q'%^3OU MZM>GD+O|\XZ\(4.2KT0FE$]_G.5;G.1S//;8:'5=*'L[H-MC[LVN"?:X)#/:5*L)17>_@#Q*EY@.T"*\@"9JP.DI3T?=_6]]OKE4/(AWXB9O!NHL2*7 MV7,@F"$/?R\/WT:_?]QF6=E9;M*L&EX3 M!8G/*L:*[*N8'6QI2 ;L4HLFEL!_//Q.0M37,F@3-I3\-X MGX:Q_< 0^8IL1#0<$KZL)@=@J(S)O38>5TS<=2%B(A%$DC(]+)\18D$1 MC?3?]~_8TW_ERQ*9M%@&Q.I\92-^EA/*MMQ;(7U5OR3:XSR9R"9@,1- 4N>P0\[E>C=-M>??^2<$N+HR++!S.^5MDSDXZ][M_/;?,DXK05<3HHXJI:UQ6-9X[(H4^CZ>O- MZGDG^KR."4YCXL%$KM7F1F2U9F[GBI:#W-J[L2*VF.KK23O:7K\?[:WS9'SA M\3U++?HG37VG_TSEEA4*2W&#E-I=%+>-K._)=4>+TEX$UT+CM=(V,_QI_=($ MX/N-$/K0,1.T/U:B_P'02P,$% @ &ULO9UMC]HZ&H;_BL56JU::#N2-@>[, M2-;)[5/I5%N=.=WSV0,&HH:$DX1.*^V/7R=D,";!).76]D.'%_MZ#,\=V[GC MF-N7-/N6KZ0LR{]UG.1W@U51;#X,A_EL)=0=%9]>/5AGD4N'|/XKVA>K.X&DP&9RX

MD3"&A'$0S)"',]+NQZOR%OHX3,TS@66:Y[F'=M&K+'Z"NBFG;8/M/WM'(W/8H0R%MHIUB,CM99@(1F?/&>RQ>F<-20NA- JE,2B- MHVBFHK0-Z 27#A-0(Q!*"Z$T"]4Q*
(VC:*9,M$WIV'U*S# !]3!KFF&+CX[' MB/-E*+15K$-$;B]C9D@[B8[=2OP8;R7Y]TM,?D]%HJ]/M^8!ZB=":2&41]$T M!]5Q%,W4BW8?GXZ8$PO7)-#28AE-5&4?V_+
(N64<:6FB>K12R+G M)-\^Y]$\$EEK1U('=IS#GN18-%!C$DJC4!]#TCB*9HI&&Y.NU=$Z-5$E_R4G MW(U/>;Y5@#GE3*Z?U0G&B=5^!^UQ^\Y7H+002J-0&H/2.
(IFJDOIF>ZE"Q%=_MJ%D)I850&H72&)3&4313)M!(=>U&*A-11KZ+LBLZ\#)=-5)<$C0FM/5QO M&4#=3RB-06D<13-EH-U/U!X*LO=8|&NK<^RMZ-WE0*U1":0Q*XRB;J35M
MH;KC2TT^[FM?0XJ4;+;9;"54;U/?3*2Z MF]FN7\K+?JE50SOZX9K7-@&WHC>XH":ME :@]{XBF:*0YNVKGW-*.0R3!W# MMLCIT=Z.WOJ NK50&H/2.(IFZD.[M:
[=K47,9SHL,+.WHO= !36#H30*I3$H MC:-HY@U_V@SV1A?.9SSHBE$H+832*)3&H#2.HIDRT1ZQ9_>(+YS/U/1S\QE[M(W]+ ^H%0VD,2N,HFBD.
[05[=B\@.1#I;I8|R<6FM7*P3]YT)I%$IC4!I'T4R% M'-Q7;C4"(3.:#FLA[:WH/51!36$HC4)I#$KC*)JI-6T*>_ZE,QKHDEDH+832 M*)3&H#2.HIDRT:.Q9S>-+YW1-&\X,YW10%U>*
(U":0Q*XRB:*0[M\GK_AX6R MWOE%I(_V=O36!]3>A=(8E,91-%,?VM!U?FF9[A7YE$1%)&)2C3^Q>K-5&-"5 MNU!:"*51*(U!:1Q%,R6D36#OTI6['G3E+I060FD42F-0&D?
13)EH+|A#KMSU M6E;N>FW3$JA9"Z51*(U!:1Q%,[??TF:M;U^Y^[!4(\VR7+6[V6\Y(|;IMOT& MD1KFGQ.#/6A?,4!I%$IC4!I'T4PQ:$O6MUNR7|)T)N4\)XLL79,HS[%-
/:@34S?;F+R+,US/1ELS4'+SIBML\"6 MK3%=;S2=\&>B6SEJ;WGO9'2+RMO*F9_6_*:U(^B?<007"UGM)*_ODNIX^YP= MW/O%LY"FT= MZQB5MY5S)J?3H?V>P.[W[&_;K[O*UH1
]XR$TL*:9BQ8|Z?>=<=*@ADI08G&-M?/_X &HVOADPK0!$]@-F"}YCMZ+)-F*F-3;@E\=&K?)W+I5O)W>,Y=-AV?: MG,= 8|*:9IQ!^<%K?%;,87ZH^TQ&O. MRQ@T)D?
1S/1JWR.P^QX==_JW4WKGMFE$>(T3E1 :DL;%;%@W+&CO=YK;\Z-: M9N;IX"=2?NGNX);U&I=O7F%O2N_$0Q>/06D42F-0&D?13,%IJRBX|!;A &H) M06DAE$;A-.:E<13-E(FVJ0*
[3=5]\XJ@Z52U;%YA#]=;!M!U8% :@](XBF;* M0#MD@=TA.SD\A3(6/]6@,_$BWT]H3U"[^X$ZJ-!:11*8U :1]%,'6D?+;CT
MYV,"]&D&I850&H72&)3&433SA^]TJ3>VFWK]UA..VTROYK6#>\R<H#2*)3& MH#2.HIE:T({B&+.."K%494*<12@NA- JEL7'3:CR^9(<*:*I"VY9CNVWYL+|&
M5UTZK8RL8B4/3I/+>Z.BXI3Y,6ZZ?LW+JO8W|$XXU+:$TAB4QE&TG3;&:|^^E MOI;94CI*.,Y)=;%V|P/>^U=))A?E/M,?'JH?H#]Z/70^T.]7{(:<G^1H.7K MDS+ 2YI[JY!]_S]02P,$% @
&ULM5EK;^(X%/TK5G:TFI':YD52Z >22\+L M2*VFFK:SG|W$0#2)G;4-3/_]VDD(!%P#JK&:T%IL@1 ' MOXLDB7/,XP>*6#+HH#T[0IE9#VR7&OSX$\^9:.+$>V". 4H MX9("BC\K-
$%Y+IE$._YM2*TVIP3N7F_8IU7G16==(4,3DO^3I7PQLOH62-$, M+G'=@ZS_1DV' LF'7D)Q5O\&ZB74LD"P9)T4#%BTH,SS,A;\,(78 @D<-\!J M=RK ;P#^]8!>^CM WKO
((&$)P*"!M 6&E?BU4I'4$.OT-*UH#*:,$F+RJ[M*K00.,-R9#UQ*MYF L?'!P3/+Y\1+4"$7CFX!'WF* MP.=/7\ GD&'PO"!+!G'*AC87#9 T=M(DNZN3>>\D<\$##P7S!0(Q3E"KP$SW>
M/X:/I/B!!F\+X5KUO(UZ=YZ6\ F55\!W+H#G>#U5?_3P!T@%W'T7'GTL>ZR' M1RAIL_I*^/0$N!NHX!TM_78D^A5?H!N)7({$5(Q$U>"]\;X:+Z?@&U;"!(TL M,
<NH'K:JAWK5CXH;'O34=?I.?[*GKC;-N>]>EC-6A+G|P.WOZ6NH:1U] MKUM|K[7ZWN5+!+ZO<\4S,3I7VN7BITE[+?>[D9)(L M,DD6FR2:&8B++KN-
UOW>Y_8YUZS3LG&6/+JK9."'O'!?=0-[&8^OLN:%MR[D ^+6EL-.G4 M%%O7+&]KEJ_J2_KCNROWL&96%BOZ1&>+?%K66!4GZI5#F8V6X?,.^6R! MZ+PZ26>@FC_JH|KV:7M:?
UN=4=O;\/JH_P'2>889R-%,0)VK:[$/IO7I>7W# M25F=]KX2SDE172X03!&5 >+|C!"^N9$)VO]AC\/#4$L#!!0 (-',\9UF5 M1*=%! , %<+ 9 >&PO=V]R:W-H965T0(XS"RXRJK-K8E,6 M
FA4B;+4="QK9&:4Y88_[<;NA3_AI4I9#O>"R#++]F'B4UP2V@'6'48ACMPN!U81B|QW-Q'ME; M&'J]\5P(+,-#.,6P@?PV,"6!0M\%3M@C%^!V-@N4-W"T;O'?\%<2"S#!A>
M"\/KA\$5?H@+^"JJ_S)V?6^_]D>FXUH6W1:0CS+7PMQD6[RKLS#7JAA=&ULO5=K;]HP%/TK5E9-K=0V(0F!=!)FDVKU&I5:,?/)KF MU<1FM@/=OY_M0,HCS?I ^P)^W'/L>^Q[?=-
;,OXH9@ 2/>49%7UK)N7\PK9% M,H,=1CA9X"B.0# _;KGIVQ9*2'*@@C"(.D[XU M:%W$H;8W!C\)+,5&&VE/QHP]ZLY5VK<5/6_,E+!/F%RU+ MVR"T4%((R?(56.T@)[3\QT\K'38
BJ<>X*X IFL!W@K@[0*"%P#^"N ,94I7 MC XQECC]<;9$7%LK-MTP8AJTPCR=4L43@973,Z/;L'GJ,8QA*=H2LJ M=8.0")44I*
CF.0F&3B1$T^C&)T?'2"CA'AZ'[&"H%I*GJV5#O1T:R6G58-MKNJ^L*J';AB5,X&^TA32&OQE,S[\%SYNQK?]M"S'''?0ME8P$\ 58T>=/K<#Y4J?-(97NOE-[-$@23B8?,8F1CJ4
M$I&P@DJD J4<(4(4F": $B9D;>PTKO%6;4NRP)#I-V 1A6'0LQ>;DAUHP2W) MVI5D[4;)AED!Z, M#JS+TLC?##Z_[>Q$7^,>WNEQM_*X^Q\25G?/3=_I[DBQ;[.?AQKW^DXEPD])
ML%&)>R95LGG-R8?I)^^'WHZ[^T8MQ_=W'=ZW'ISGZU'Z86\4=SGPJ2F2!3*' M5-9YU6A5AP],^6D_FY=%_ WF4T(%RF"BH,YY1R407A;&94>RN2D5QTRJPM,T M9^I;
K@V4/,3QN2ZHQ>HODZBOU!+ P04 "!S/&=9?W;W1>0CS+7PMQD6[RKLS#7JAA=&ULO5=K;]HP%/TK5E9-K=0V(0F!=!)FDVKU&I5:,?/)KF MU<1FM@/=OY_M0,HCS?I ^P)^W'/L>^Q[?=-
;,OXH9@ 2/>49%7UK)N7\PK9% M,H,=1CA9X"B.0# _;KGIVQ9*2'*@@C"(.D[XU M:%W$H;8W!C\)+,5&&VE/QHP]ZLY5VK<5/6_,E+!/F%RU+ MVR"T4%((R?(56.T@)[3\QT\K'38
BJ<>X*X IFL!W@K@[0*"%P#^"N ,94I7 MC XQECC]<;9$7%LK-MTP8AJTPCR=4L43@973,Z/;L'GJ,8QA*=H2LJ M=8.0")44I*
CF.0F&3B1$T^C&)T?'2"CA'AZ'[&"H%I*GJV5#O1T:R6G58-MKNJ^L*J';AB5,X&^TA32&OQE,S[\%SYNQK?]M"S'''?0ME8P$\ 58T>=/K<#Y4J?-(97NOE-[-$@23B8?,8F1CJ4
M$I&P@DJD J4<(4(4F": $B9D;>PTKO%6;4NRP)#I-V 1A6'0LQ>;DAUHP2W) MVI5D[4;)AED!Z, M#JS+TLC?##Z_[>Q$7^,>WNEQM_*X^Q\25G?/3=_I[DBQ;[.?AQKW^DXEPD])
ML%&)>R95LGG-R8?I)^^'WHZ[^T8MQ_=W'=ZW'ISGZU'Z86\4=SGPJ2F2!3*' M5-9YU6A5AP],^6D_FY=%_ WF4T(%RF"BH,YY1R407A;&94>RN2D5QTRJPM,T M9^I;
K@V4/,3QN2ZHQ>HODZBOU!+ P04 "!S/&=9?W;W1>0CS+7PMQD6[RKLS#7JAA=&ULO5=K;]HP%/TK5E9-K=0V(0F!=!)FDVKU&I5:,?/)KF MU<1FM@/=OY_M0,HCS?I ^P)^W'/L>^Q[?=-
;,OXH9@ 2/>49%7UK)N7\PK9% M,H,=1CA9X"B.0# _;KGIVQ9*2'*@@C"(.D[XU M:%W$H;8W!C\)+,5&&VE/QHP]ZLY5VK<5/6_,E+!/F%RU+ MVR"T4%((R?(56.T@)[3\QT\K'38
BJ<>X*X IFL!W@K@[0*"%P#^"N ,94I7 MC XQECC]<;9$7%LK-MTP8AJTPCR=4L43@973,Z/;L'GJ,8QA*=H2LJ M=8.0")44I*
CF.0F&3B1$T^C&)T?'2"CA'AZ'[&"H%I*GJV5#O1T:R6G58-MKNJ^L*J';AB5,X&^TA32&OQE,S[\%SYNQK?]M"S'''?0ME8P$\ 58T>=/K<#Y4J?-(97NOE-[-$@23B8?,8F1CJ4
M$I&P@DJD J4<(4(4F": $B9D;>PTKO%6;4NRP)#I-V 1A6'0LQ>;DAUHP2W) MVI5D[4;)AED!Z, M#JS+TLC?##Z_[>Q$7^,>WNEQM_*X^Q\25G?/3=_I[DBQ;[.?AQKW^DXEPD])
ML%&)>R95LGG-R8?I)^^'WHZ[^T8MQ_=W'=ZW'ISGZU'Z86\4=SGPJ2F2!3*' M5-9YU6A5AP],^6D_FY=%_ WF4T(%RF"BH,YY1R407A;&94>RN2D5QTRJPM,T M9^I;
K@V4/,3QN2ZHQ>HODZBOU!+ P04 "!S/&=90C<+X" % X* &0 'AL M+W=OY0/DXO/8.:|C.R\>;1E_ M%4L 27ZD22;&QE++*U9UIBG)*177; 69NC-G/*52G?*%*58<:%0$I8GI6-; M3&F<&9-
1<>V)3T9L+9,X@R=.Q#I-*7^.0L*V8\,VWB\B1=+F5\PDZ,57<`S MR&^K)Z[.S)H2Q2ED(F89X3 ?&_?V7>`4 46)[S%L0&@=5#F"'*K^;& &29*35#0^J:!&?6<>'N'O\3@^*AUV_0S5
_5S7L@24?PFVZJL99!P+21+]V#5@C3.RK_T1Y6(G0#U MH-T!3A7@G:!K@=5@'NJ0&]*]"W'S \$-"O OJGUC"H @9%[LMD%9GVJ*23$6=; MPO/2BI8?%'(5T2K!
<9;WK&?)U=U8Q4QE#7%/4SQ]90'^M9 8@D!0ZS CWK&59'LM-*NEOW3+?`]<|@ MS^Y4)<[MQN4C|)U8T1#&AAJ"!? -&)-??[$'UF]=4F+"/$R8CPD+D& M@7NU MP#T=??
{!HYE4P\Y%G%6]YE.7K"6D5T#R>7(SL2WU,S(WNWIHJSI7KXXJ;Y5]M*OV/I7JNU=LO%GPLY*MST=Q^@E;Q^G;R^-GE_K=,7X(3-R7+-HP0$^5F\QUT9 MU)+.?3$P81XFS.]_U&-
/"]3J6H(-;L$&6L&^@Y!QMB KX#'KFM2FVOAS9<*$ M>9@P7Y\FE[P!Y9VS$%(K6NH-:_6&)[YN(,6,O)YO5AV+HZF6L*Y2F"!/$R8 MCPD+D& M36]K36]QUY6WF
)CPCQ.F(\)"Y!@+#%MJ_FFM3!6EGK*N\ZUNBK-B"?ZED*FWDNNQ%Q ?GQ)OJKC M< GD.8-.0;7%LP7%I'FH-!^5%F#1VK([C>P.[HA<\;!TQJ1Y]#0?E19@T=HZ M-
X:.K;43ZD^@"RH(S3^$0O52=X_.J%X.*LU#I?D5S79WI@WKVG7=O54P5[UM MZ1]KQM9[-2>/S%^WK%-03'|FADKS4&D^*BW HK5E;TPFNX\\.J-Z3:@T#Y7F MH]
("+%4;Y\:;LO^K.:4'G"TLJCV%2O./I,HY;%!AM:,M8F-1V7]/ZHSI%=5= M0J5YJ#2_HAV??O\/E\EN;"9;[S.=KTN.71,-7]#:4*@T#Y7FH](^+"ll+;^,.+ MLI'-*!O5C4*E>;@'T'Y468-
':^P<:1\K1.U+`)\U@]X%QA46D>*LT_DBK-?X"P MVM$6L,&G'+T]=?H$JP>=+2:J$85*\RO:T0D6[]92.G-GPV,*?%%L31,D9.M, MEMMZZJOU]K?[8M/7WO6I?
>>7F](@:3+FG[H'R19P)DL!<(:WKH1K">;E-K3R1 M;%5LJWIA4K*T.%P"C8#G!=3].6/R_22OH-XL./D74$L#!!0 (-',\9UG7 M:X=7.0X &/* 9 >&PO=V]R:W-H965T#=
[*,O'MXM%L7[(=TDQ MSQ3??67NRS?)67U:WZ_*[S-%)=2&NVV"V>Y#!;]9+.?75\=[ON47UE]3^5V MLT_Y5;QM-LE^?>;=)LOYO9L^,=OV_N\KZCL7UU6-RG]ZFY>?"3WGUV^)$
M66]VZ;]89'LK3^_>S=[;;Z6]#.L6AX?\L4F?B]9MJWXN7[+L_W+/|?O9LMZ MD|)MNBIK1E++]]RW]D&ZW-;K:D/\VU-FIT[HA^_:1++@_/OGHV7Y(B_9!M_]-9

MEP_O9M',6J=WR=.V_#U[_BUMGI%?\U;9MCC\:STWCUW.K-5346:]IG&U!;O- M_N7_Y,]F3[0:5)S^!D[3P.DV\ 8:N$T#M]O '6C@-0V\3@-GJ >_;>#_:(.@ M:1 <]OW+SCKL:9&4R?
55GCU;>?WHBE;?.,1U:%WMX,V^\EJW95[]=5.U*Z]O MRVSUU;JILEE;'[)=-6*+Y!#Y&^M3FA^&[GZ56B\/^[S?E-;[YR1?%Y9,-KGU M1[)]2JU7(BV3S;9X/=KHC?7Y5EBO?
GEM_6(MK.(AR=/"VNP/CRE^K>ZL;G_< M;+?5!A17B[)Z?O56+E,-<[EY>2[.P'.QK8_9OGPH+-]OTW5/>^:+;QV/MY4C_M#@-85,&JK)K;A^9N3W/!-_^8 M?.=:$]_Z-
GUDMUWRS46Z&MW;5>ZIX'N'G@^-]#??#D,]%5KH/<-LQ>2VT^] M#_9OB\=DE;Z;54?S(LV_I;/KO__#I;_Z(L("1-(&"%A$@33LB&9SL'571\W^\WN:=<;+U0W
M06D"2B,H3:)H^B!0SLG&22<;;IV@- &E$90F4308]8]6>;-X]M3[!K5_EMZ93 M+M1&06D"2B,H33:T4A\0P7,&#MO*2-F\DA}OOE6O5IOPJUHCMR;K/?3&AYD MG!Q434%I!*7)D0
B;_?RZ7]DK9/O!?,:=921L3*:SF\U_K)N9BG&Z<.55I0 M&D%HJ]%I)R3 MG=$Y65D]A[=4AG-R[V>#?!?&L4-|%91&4)I$T?3HE=ER?-Q,#/5:4)] T@A*
MDRB:'K&R7PYOORYWT#S8.'"HZ8+2J*$-6.,FQBG\E:\AE]?B4FW)X-V4ZQ_(.FN_,.%ZHJH+2"$J3*)H^")31 M1Y+T\W_J8&5&A!:=30M#/5]&V- M7^)$=:K'J4R5RU=7_?AY+P\R3@[JJ:
T&MEE_O$,U?9[3E&,5*>04ZZ24RZT MZ,KC)33?F7'R4%<%<H1&4)E$T?1"TOCZ"!]RH5(+2A-0&D%I$D73(U9BK^7% MUL].QE"G!:4)*(T;FC89Q_/0ID[&4\@J5\DJER_#,IB,H:H*2A-
0&HWLLM-'`MN$XP/!E/X:=VR8]MQX_[T/"6EO N+K@:F6%X^\YV9I@NE"2B-H#2) MHNF#0*DL#U=TY4%E\I0FIH#2"TB2*ID>LO)8W:=$53S=.'2]RH#2"T]374W2U MG-
O!P&%;&2H/573%@XR3@_HI*(V@-#D2@&T?3Y^]L6HKK[6TTX755LQD/"R? M^LO);'>ZV?G8RA M2@M*$U .06FRH6F3<3!?A@.3L7)5'E]_93 90TT5E":@-(+2Y$@ YA70GK)4
MWH756?USQ07P6E$90F430]>F6V/%Q-E@?U6E":@-((2L#KK%. MJ-)?/J^_+G?0/-@T<"A-0&G4T :L\4N,J![U&)<7]%K?2$PX@"@M*(_|\ MI2O?=^)N
32J4STI]Y:;\"VNN!J98WD'SG1FG"U554!I!:1)%TP>!,EH^KN;* MASHM*$U .02E211-CUCI+7_2FBN>;IPZU&=!:>3WU%R%_K<0C]L3[*&>FL1 M=53-
%0\R3@Z[;#IVU71^EZD3U+YU,YI4IW!3OG)3/K3F:J0 FN_,.'FHJH+2 M"$J3*)H^")31\G'55SI4:4%I DHC*$VB:'K$RFOYDZZ(Q=,-4X)! MQL%!_1241E":' G /M1<6.*BB-
MH#2)HNF#0 FM %=%4"5%/0IFH#2"TB2*IE_J5!0FH#2"$J3 M8<_R6MX\&CB1"I6P"E$+80$@X^2@N@eI*(RA-C@1@7@8=*E457E:C-3 G]Y9! M\UT8QPZ55E
:06D21=.C5WHKQ%5FA5"Y!:4)*(V@-(FBZ1$K!Q9.=3%"'FP< M.-1W06D4GE\^T.L6TJ)ZU&-4%BM$7HR0AQE'!_584!J%YY+IQNG#E5:4!I%/2M9!7.[^YTD5*=ZG,I5
M17PIUH]/QCS(.#FHJ8+2:&2?=3[(=?K6LVJRG4)214I211<6:AFL!LUW89PZ M5%=!:02E211-CUZ)K0A7GA5!M1:4)] T@M(DBJ9'K.Q?--6U"'FP<>!0TP6E
M$90FH_,K&PY=#3A2_BI"7HN0AQE'!S584!I!:3(ZOI*AIX;10%5=I-14=&'E MU46K0?.=&:<+-550&D%I$D73!X$26A&N\BJ"'*BTH34!I!*5)%$V+.,%9V*YZT M\HJGFZ8.I0DHC:
T&9]77D5SVXI;/V\"\%@YJQA5A<6#C%.$&BLHC. T.1) M,*\>*H9(+ M2A-0&D%I$D73(U:F*YYTH2R>;IPZ5')!:02ER;AGV2UW'CH#4[*R5S%JH2P> M9)PZET57T;.U4/@
M[7MGMCB[_\9^*^SZ_H7"7%\])O?!QR2_W^P+:YO>5&PO=V]R:W-H965TI[C%Y)4N$6+@+<*.NHL&5O=&P:-ERB'M(M7J.#? MS#')(>.W9&'0%4$PD:(\,VS3]
(PVH8W4^'OQ(%TLF'ACCX0HNT!2QE]4SX7=&34G2'!4TQ04@=#/JN\C4B1"I6P"E$+80$@SC%_%53]G&.*]$,Q4P@((/_8H$>498+!$^_%7!>W4;0KA
M[O4'/92#YX.908H>]!GA;E)WRK_A$[LYI%]B5P&X*W",'IQ(X38%S1.!6 O?<+O4J M0:\AL(^UX%4"K]F"=T30KP1]:5;YWY76^)#!\9#@+2 BFM/$A?17JKDC:2%2
M<;AR_@@DW,P&/..<93J',D5OPC(A,]2)&H QI*5(&'K;0)!0\ MB!Q*V3NX\A&#:4:O3TINP0-LTW9;.O2HEG^/&9=;4NZTR'VU_ F^]J2!6CU% M*V7?PZ_)(]7<1_&QH>\YX=15YDA>
[PCOWW4^0P3@.<_U#:*,%]OS]*4UR4N0 MTPX2"],]7<$8C3I\Y:&(;%!G_.N'6> MN"KZ3IZ4L^,-^+YFE,$B28L%@~S,T"(M"G'#8U:(I+AMIHD6[DTB73"?)VP M0"6R)&MC-
\APRG5,MQD6/M]J.1.;=]#WL$ (DUM[CGAU4YX M7RM45"3]$E7R+RU1G3!?)RSP#KSL.\Y!587GA46'88T:W3.S7YO95ZI.O^3[M"]^KAPTB_/T+R#H#_/PDT]!-H\KMVP+CPK*F])
MZG7=]@7 ,C]W0T$-4(B7=W:=]G^=-G^DLLWH, ,O",&'(KQHDA_MVX%3M3-7.R\3]OE194 MM#WGW:[==/Z(%!PFP0"[VSX'5!PE\;]MWS B'E MZ5IYP_!*'N[,,&,XEY=+!!-$1 #_?
HXQ^[@1#=1GG,/_ 5!+ P04 " !S M/&=99(HI6M0# ">$ &0 'AL+W=ON>F[%DM ,* M>U%K@W9EP=BS[GQ-)HZG5X0IQE)3$/6SPSM,4\VDUO%W2>I4= O!629258 MK2"C>?
%+7DMA:@#%TPX(2D#P6<"@! P^ L(#@&$)&!E"E>,#A&19#KE;]< M6RLVW3!KB'1RG^9ZW^>2]Z!4X>1T+EG\##.E7)W+%/A)(C9D!X\HI"_(*_\" B\8MKEC1\JO&
>_6=XPYE!%5P#PS>R!5=O M88(KK@57VSX73(-V)GWZW8@-B7'BJ,.-(-^A,_WY)_2^Z5-I5.212/7 MI\PM8.^R=$@OZQIG7]F5R-CEDUU/*]H>F9]7KT#, \$6WL?799Z7LZG!)
MYH_JT=__Z/XQJZ;[M1>V_[_0%26#/X"$O(]V M]\FM%709\I4IC(6*GFTNB]JN&]V*[UM3R?S_;24,+:86V MO"2^G.\[-]OG1!O>4.(-&V+*@86;F4U=*V19I#B<45]X"]G07C)99]RI>V
MJ#C@S(#*PO8<9V"7F% KCLS: X\CMI(%H"# D5B5)>9_QE"PSS!E[MUI/OV 2+'$<<;9!7$LK-CTP MT3=H%2]"]3F92:YVB<+)>"99^HS&*M09FK!2'3^!308OD=FZG+_ =FF[U&-!Y
M A*30EPHX:=9@L[/+M 9(A3]R-E*8)]R);*1JW)3AM[QK4]WA%[?'3/J,P% MFM(,L@Y\)P)OJBT?)V 1I)PEG4%TAW_F$/,<+.NR9O!_N=[GS?]JG M_ZS](!A^>U\P^]%
M$\#78,4?/[@#YW-7F/LD2_HDF_9$=I"0H$U(8-C#4]>WN:/IWAWM2D?09SKZ M)$OZ))OV1':0CK!-1WCR?AQ+!X+ZR>Q*2\TX,(RZ]]C+[QU(GN]'^X.H6OW M^E
H>2MTX_J#0Z'I6Z%!$+ZHJ]VV!P*7QI*KE0+JVHK%^+=K5M%NY,C7RU M/G:'$[=C/5'-1=T+O-#*7G1*=-, N?M1/Q+"P:,%^?=)8LK^'U/=6
M5!Y$UOE34?ZK%E(}\GV9Y=7%:*'4ZBP(JOE"+D5U5*QDKM^Y+\]E4'JS? BJ M52E%TA0HMC*.Q\?!4J3Y:'K>[+LIC^?%6F5I+F]*4JV72U$^7\FL>+H8A:.7
M'5_3AX6]=P33\Y5XD+=2 ,6Z*?56T%.2="GS*BUR4LK[B]%E>,9C6AD/I2[HOA6; R97(S&]8QD)N>]1@C]XU'.9);5)#V/?SOHJ^S+GS] M^H7^H3EX?
3!WHI*S(OG3=3B8G0R(HF\%^M,?2V>/LKN@"8U;UYD52,O>6H_ M&Y^.R'Q=]6+9%>L9+-._2F^=XUX5; YFPMH5T"'%D1=032T(X*XJ$%DZZ@ M.?
2@/?:F<4PH,3TOBR=2UI_6M/I%T_VF6OO_*+>JU.^FNDY-9V*5*I&1 M6U7,OY':"4L?TT3F247>,*E$FE5O]=Y?24"JA2AE=1XH/6I=&\R[$:[:$>B6
M$2)R7>1J41&>)S*QZP,]VW|*]&7*5]0)O)6K(Q*-WQ$ZIO&&^%];D#D2VR2VQ21$U(O1F?52LSE MQ4BO-I4L''5H^MLOX?'XCTW]1<(8$L9!,"N)N$\B;NB3;@+43AIVQ\[VO^^;_]H
MWVL!^8_T6B\?I^.C270Z/CX/'C?T/QP;PQC__+)TI2_7JZ+2#E(^D]OMBN$< MPC<%*(U!:1Q%L\-ZI8/ASR]772TJ!22-06D<1;-3H"8%>MA%R\WW3@I)8U :
M[V@_+EPTBN,M"Y=1ZW" 6\?D2^AV:S?%N1=0NX,2.(IFVY$$.]S#I.$.H8D-I M#$KC^]J=@M'L$.C9;I9W"E#3WG&<'^3=$:\A1CWK@@!-QP[*R8(LFTWQSL$
MJ&_O.,;+5;G5D;L00-.Q0S#*'0YP;OL:L<.YW4#O-*#6#:5Q%.V.QHAWN(=Y MAU#UAM(8E,91-#L%H]_A@?W;S?=."FK@X0!K[E(C6O_Q@4ZB#0VD,2N,HFIV" M<7 *='
WRSL5]\RNQ;/3UQAT-AQ%LW,P"DY!"N[F>&>PXP_+Z\PMS0PZ'8ZB MV2$8!.?#%)P.5G WT#L-J()#:1Q%LZ,Q"D[W4' *57 HC4%I'$6S4S *3@^L MX&Z^=U)#I9E!Q^4HFGV?
IE'P.)B";URF!B]X>PCO^SBA"@ZE<13-#LLH>+2' M@=D=0!8?2&)3&430[!:/@T8$5W,WM3FJH-#/HN!Q%LU-X=8?Y, 6/=MQB#E5P M*(U:1Q%L _,P"A[MH> 15,&A- :E<13-3L$H>
14\!VL1MAHO%W89FZ =Q!0 M!T?1["",@T<@+]_!:>^&=UCSS WP#@'JX"B:'8)Q\&B8@T>#'=P-]%ZHH X. MI7$4S8[&.'BTAX-'4 >'TAB4QE$T.P7CX-&<!'3P::LTS]TR\4X Z.(IF?T//
M.'@\S,$W+E,#'=P]A.\I Z4Q*(VC:'98QL'C/1P\ACHXE,;@-(ZBV2D8!X\/ M[.#Q4&N>N6?BG0+4P5&T-H7@U1?VE[)\:)Z44)%YLGV9E^]2$=D,5J^;Q '>%4L6R
M>;F0(]%E*]-GU1])-->H#^V173_P%02P,$% @ &ULE91O;],P$,_RBE(M:)/6)DW3 26-1#M-\ )1K6+PUDVOC37_"?:U&=\>VTE#0>]$;Y(IV\^3WSD^
MYXTV3[9")'B60ME95!'5TSBW9862V:&N4;F9K3:2D4O-+K:U0;8)(BGB-$EN M8\FXBH%C"U-D>L]";YP;<#NI63FYQR%;F;1*#H.//!=17X@+O*:[7'"%]+5> M&I?%OT(-N
M/F)7S\3[E5K8\(2F6YM$4.XM:=F)'8'DJGVSYVX?3@2C[(((@[01IX&X_%"CO M&+$B-[H!XU<[-Q^$4H/:P7'E?\]*C)OE3D?%@M6=S,#^*XE@X4VM38L;.O
95*Z(#CD,3DH;QV7'<"\!4@O *RP M'L(XN8$T2;,_Y;&KI2\H[0M*@]_DDA\3"H+]A\.*Q^?E_L>F-J:E3B+W"&W M: X8%;]?C6Z3]R_ C7NX\4ONQ>=*Y8K0^1-
<,0L,:C0E*KH^!Q:CEI/WV2' M(AF.DW=Y?#B#DO4HV7^BW !VU8Q%X-[0*G5 0WAYA\8LW.,D]'D+\;XY*#Z
MGQ_,S(XK"P*W3I<,W!B_;MH^:A/2=3B[:TVN$T)8N:L'C5_@YK=:TS'Q[=!? M9L4O4$L#!!0 (',\9UDG".=V+(@0 &\; 9 >&PO=V]R:W-H965T M(%7#S.ZU
M&P0$<,&;4I'VA^_=I(&T@D9V#E[TGL]SFV7W\D]OC Q;/<4:K@E:69G%@[M^=D:\M<4+(N1"RU//8KCT M<B>SRGF4[9<,&(TK=B:\M<4+(N1"RU//8KCT M<B>Y4F&7T4(/>,$?%M3E-
^F%BN]?;@<[+=*?/ GHY$LJ4KJK[FCT+?V35EG3": MR81G(.AF8LWRN(7#F7>.\>":"\59Y58EX E6?E/7]N&.!'HBK8+O$K@72KH5X+^ MI8)!)1B\%_AG!,-*,+Q4X%
<"OVC]LK&*E@Z((M.QX <0)K>FF8O"KD*M&SC) M3,]:*;%3$ZU3TP7)$T526"D>/\.GF'U9PFPK*-6]1TFX":@B22IO==+750 W M'VIA
R09+),TU3U#CFVE2V%8=EQ%#,N(WIF(_1$L>:9V$L)L3=W?(5S7O0+Z,/VEKS/\L;;=FO.U2_X/7\$PE8,$9T]-&V:D:70K^:22V ME'?>R3<[0 ::AF+ $Q9BPB(D6,/086WHL',
(+\EKPO8,"..]/6*- MM3NBPX#B\$0AD7+?.F_/.]'7&EW"_)Y8VI3V6+D5-G; +^*WHB+1-LXAH#F?>M5+?(/2VC8?.P-_8![R?6TXK/9:OF+0 E1:BTB(L6M/7XQ:1
MV]U'9'R5$'/&]+QL]=SDJPAIP*4()DDY:,S#9% S--8#_]V^1IUJPB5%E0T MUSV=8GM._]WW*6K0"(O6]/6X$>1V;DM%
<[B+H[A$]+L&BET?;)^0&C8EN<]!@C]3MO>910/ZU/DV;%&8]S%X>12V) MV":9A)1NM-3IW>FY792G.^6-XGEQ&O'$E>*LN-Q1LJ;"9-#I&\[5VXT)4)^Q M3?\\%4$L#!!0 (
',\9UGM@&]6Y@(, * 9 >&PO=V]R:W-H965T MU MU^_LQU2:.-LW> #\Y7LB)DRE5CEQ7 M)AEA6/9X20]867'!L^N6+NR% 2G\I1RU_>\N8+68%DXT-F,+$8UYI7);D(5
MLF(,BU]3DO/MQ.D[NX%KNLZ4'G"C<8G79$G43;D0T';,EI0R4DC**R3(:N)< M]$?S4-L;@^^4;.5>&^F5W')^ISM?THGCZ8![3A*E&3\\-F1&\EP301@_:TZG
M<:F!^^T=^Z59.ZSE%DLRX_D/FIJLXGQP4$I6N,K5-=]^)O5ZAIHOX;DT_VAK M;<]#!R655)S58(B T<)^\7VMPQX >-H!?@WP'P,&SP""&A"\U,.@!@Q>ZF%8 M
\S27;MV(U%,%8[&@F^1T-; IAM&?8,&O6BA\E2"9BE@%/1#)=4X1PM%4_N MT/OZ>TW2B09) M!%\+S-!I3!2FN3P#HYMEC$Y/SM)H@7ZEO%*XB58U=!
M0)K636KG4^O7X;_$",H-D:@>$;OF!KM"77 MPH-VN+[@1K+$"9DX<(-)(C;$B=Z^Z8?>IS9ECTD6'Y-L?B2R@QP,FAP,NM@C M>QS%PW$LZ^.(&:*A7"E,B[H[];3,^WD?
FV"CDD6'Y-L;LE"0Z;?Q4TTl. W M=C=RN]=@7R%$LX8/&O2I.,4;CV988CLK$UURSO8"^9'"LF*Y^X] MU8R(M:F1),@"I[F^4\UH4X9=F.KCT?BT/YK9:N]!QM9V\ JM:2%13E9 Z?7.
M(?O"UDNVHWAI"H);KJ",,T,2DPBM ',KSA7NXYVT!2MT1]02P,$% @ M&UL MK99K;],P%(,_RE&8T^:A)DW7RT9;.1<0^S!6AE\]H*3QL*Q@WUZ&;\>VTE#
MB[)L&GQI;>>\K\]CQSZ9;I3^87)$@FTAI)D%.5%Y'H8FR,%@IJ=*E/9)IG3! MR';U,C2E1I9Z42'",(I&8<&X#.93/W:GU:(L$EWFDPJZ)@^ND2A=K,@GZP M&[CGRYS<0#B?
EFR)"Z2\Dl;7MBXI+Q ;;B2H#&;!1?]\ZN)B_+X&4%<'^^+7"@:U8.!!]\P\UC4C-IJJM0'MHJV;;_BU\6I+PZ7;Q05I M^Y1;'O/.O2A)6PPXQWF9=QIN,"R!X/H \1? H/BVLX/CII
MR^N?;0[2&S2L/"PU?I0MMJ5^1"N!H=I'-3L@1G@3W)!O4:@_G[=_U1]+$-_M\3^9'8"=>-J"G7>X[4&);,,;MO8H,GL C2LPXM8%7;B/OYBZD]3R:ANM!FJZ(M@Q2'38K#SA0?
I,9$+27_A:E/M$ZO=6,JJWZT-_VP=_97BB\$'60Y:K(V[TDP^Q#?UOZ0,T(VU"J^4X[EKHKX@!BW$",WPCAWHVS#W*B" M)&=RB6"X#*6@##8H+%[A+XTVN/&+<%T1!W"3!F[2"7>1
M)'IE";@DM >)0&FP+SP3Q.U5]U&PFF\E$]3VWI5^"4IE.#UWZTY>/ Y=$15& MN%%=E"YINY_=1]0+L\TPIVG7&PO=V]R:W-H965TPFL09VX%!ZH]?.PD9 B$"
MU5]";/P^OKR)CW.&>\I^\BV 0.]QE/"1L14B?3)-'FPAQKQ+4T2CD/VO*8BQD MD6U,GC+ 82Z*{].QK+X98Y@KX%>MV#C(&;1PK MEF2S%:K"']3O($5B)=TP63)K"0AQ2'AA":
(P7ID3.PGWW:4(&_Q@\">G]PC M-9572G^JPC_AR++#4B"""0"@$EC\[F$$4*9([D0)PG<$7@E +G7.!<$71+0?=60:\4]&X5N*7
O570+P7]?.V+QHX%'@\9W2.F6DN.NLGMRM5R@4FBGJR58/)?(G5BO,I>.,QED CD[>25H\]S M$)A$_ OZA$B"OF]IQG$2\]$I9'I*908E>U:PG2OL+GJFB=ARY"4AA UZKUW_ MV*
(WY3RKR3K'R4Z=5N"W0'208W]%CN7TT,MJCCY_^H*(@+AIQ>W_UH57/*K9QR6YU:@GSG,D!K1F-EE6 RGG.9:,2V##' M&]UIQ=YKC7LQ-<>MSW[>T.2\C7?9IF^YY\MXV4
@"4!6+>D!1^* %AD+MO+$@R8;!A!?V?-:>]QW@77"YCIAGDZ8 MKPE6>P8&U3,P^.TX-M#I]4]87"?,?PGS-<%]GCY4GCZTQS%@@;12?D:I2 9R M?Z0Q"?*PEC*Z83B6
2QXRPAK/,-."[IMGVPV5N=LUY]U#N%>'W7"/)?TP?Q.L MYN-CY>-CJX_ 9O&K/'8HVS 3B0QI"-. X(%A$6PJ_S\=>W0/RWZZ)V&Z;/@ M,FL=QKU>ZH1Y.F&^)EC-
2]OZ^"RU6MU\2>5I16ZS:7'*;+*J)-2BO'MQI]U M=W2O7UIGE::KXM6M^PDDV"W6O:,WTF5YNNBU2UU/BQU[HB-+# _;$BC]/"!RN[/. M+5&R?31W^ZJ3YFFE^;HHA;_F2?Y/?
LMM\DPMEY]Z62**3)$U56V6#)WD.I*Q^ M9C_-[89Z3V6AWSC!IY(/3ICMB$)1Q&L95=69R"SJS(YA8%0=,\^_A*A?$0 MS&^W@$-@JH\'7IVI.!94!U5.??P_4$L#!!0 (',\9UD.JQ^1=0,
+47 M - >&PO_U]UKC78L$"8< MI+OX3ZR^2>!56V0T2#+1[)3 -0'M@*34>2!\Z(X)9Q/)@)60E/&5"7Z4-Y?!1Y!3M>]6N78XDV3E=R _=AE!>=))))F.JFV\,=QT:#3A-P(YD MLSE<599[
"J5I;H1,S++!"D]K!E50\M.*>>W\-7V.=G07B:MM2T+6=1-;;AJ M&AG3 ?VVFM%NR_:>I>OD["%3[Q9Z.*+L0[W0&TD3MBS[RZ0V@*G[N#K)<[YZ MR]E,I-0,?
N^<$HP%9\YQY)MDWG0U*9:H#5+K. Y6*3=N1KY+D=W2H?UN6T3'#/ MW^:>~G_\HX)*PMNF+>WOX3CH_2W+Y1[=-OS4K/[9ZGWVK%;'E<.>UNKX<^@F MPV,P>02[J#KT';K)Z/!-
!D?@L3IR'ID)_QA,=H_]9'"0)KWJX-LZ76^NH M]AANXG^-7$FZ3.9,&X8J+]S5D<4_'HB*WE%9EPNJFO[X]H0A9@%A&[DN
M7W8$XQC,C@"&Y<$<8!S#PO+\2^/IH^_O&..M;T7Z**>/<@S+AHS+-Y,'SHGT MRS[2*]",,1F=#RV.AAC\Q:&\&=7P[P! \L#F7YOKO'5QBMD=QU@:[JK0K"1
MXI6(C12?:T#L\P:,*+*O-I8'&-@J8+4#^>UYH*;LG"" 5<6\83L8X$:@Z 6_M[34:ALCIA/"VKP^V2X(@BNP(8*0 8!MO!',"C D",KGX-;SR%L_I[SF M'_6C7U!+ P04 " !S/&=9EXJ[', 3
@ "P %]R96QS+RYR96QS MG9*Y;L,P#$!_Q="> ,?0(8@S9?$6!/D!5]/(V!(%BD6=OZ_:I7&0"QEY/3P2 MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N
M&6;WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_;0T^FO8R*F>EOH^7%H5 J.W&,E MC"%BM/XU@LD/[X 4$L#!!0 (',\9UD.70&L<@8 $(\ / >&PO
M=VIR:V)O;VLN>&ULQ9M;;^)($$;_2HNG66G9!.-;1I.12"'[2+EI0-G'J&.W MI#=VF^TVR61^_;9-,E-.X-.^5'@"MXTYE\&=OI2_/%7VX:Z'L3WLC#NN'=?
MUZO/!PE='!4*V7\GD5E2UGJ3;L\<"NK9.[NE:K+XB X/(P/2JE-[^N7 MUW-=VP.Z4=4JJW5E?&/3<*/5D_NUO]D4C]KI.UWH^OFXU[XO5$^4VNA2_U#Y M<>^P)]Q]|?179?
6/RM2RF&6V*HKCWF"SXT;96F?OFF<-Y%S>N;:EEG??I KB@;0N'N]Z^'"&ER,3&U M#Y*8FLVI_+'-+ 5?/3R]ED+/R[V=7Y M=#R:^XV3T?GH\G0B"&0 ((,]0MX&!''(((=[@9S-
_T1;;*57?4TPH&V;;?*N>9>$UV&"=5F6I MK{]A(;[E'[B6:I?&Y1'4@DD0&S13:A\^FZS8*E/Y-[UX-%'ADPB^14 MKK0?6FPN,85"WA@PBV-
JLJ148BZ_=RYD@"P1,%MBMKYSZMIUDVHGCV\R1X"\ M$#![P0M /#IQK6S[<9,L,=8N^ZHF]U(. AAML+4*S575LRMS!NWCH4LGR7 M@@.DAH!9#;!/U>G?!\@4 ;,L";MX0=('0&
[.D#GKQM-))& 62*P\]?%1!)H) MF#4".W]=3&23@-DF.SI_XM-<>I#.G8[\$C#[Y6TG\)7O-SH;@F0S9)9-MS>X M%0\I9\@1\;6M6[B5$CEGR.R<75VO%U"*";>^N,>^:
]L:Q"1;8;,MMDQ"R+Z M/E?ZS$DQD6V&S+;!4J0S2D-DFR&S;3!F1#&1;8;,ML&8,<5$MAERCUVVS2HU M-Y)O\!^EF,@V0_YIL-V8'7>'R#DALW-
PAXWV*T/DGI#=/0B3WNDADD_(+!_< MK^Q$$\DG9)8/QNQ$$ZZ\,%(L8]*\&2(+AQSP)Q406"IDM MA#%3BHDL%#);"&,>44QDH9#90GG@$21-2A"P4,5L(8]*$%"$+1?M
MM@O"/S&1A;([SKS=M@O"/S&1A2)F"V',3G$*LE"T1PO=#CKE*\T-U9X1A9*&;VT&L,B>_AT37Y&%DH M9K;0:LGV 9QB(@O%S!9Z-\?
>%VU3+A8RTP7%A)5HS!;.@GDAZ[5M"DZK!:VJ MB9&%8F8+[8JFR"KGMR@FLE#,,*$MF*,\;\=&/GUV_JO(0C'W^D]W>:7_BUA\ M&BMZIR?(0LG'K@+UQ8DLVO7]!E+2:";
(0@FSA,9$%+SZ6G$RE,_4$QDH839 M0N\PIZ965KE:J.^KSFOQ@BR4<"\';5U;ZXO9NBRE?::8RS(=S$T*KX2?8J) M+)1\0
';3LS.W'N"+)0P6VCG4J7O>\RNKRDFK(C>4S&;QPP..T.V!%DH8;80 MP&QV44QDH8390A"S\]],D852[L*WW9A-S1G%1!9*F2T$,,O11!9*]U64T&+2 M 7"*+)0R6PA@?O/*I)C(0BFSA?
MU(DFLE#*;:%.B4=?C/6CSI?)W:8G1S&1 MA5+N@NHWF"U9KF]W+SG-R+!!]9:OPPLBD[YT1&2S]%'5UUO1T3B.=H\OMH>[+Y^R=5" M&Y5?^M,[WY{)(KNVHGEISC0{P]@I?
5^LB^+4MUV9\TKFKX_ OCZ^^_4_4$L# M!!0 (',\9UE?>NH*I@( )-;>PO7W)E;'_O=V]R:V)O;VLN M>&ULG)E;'/-VDUNXD 0AN&K(!\@]JN[!\JCD 5-LLHUR 8LT/PI@9'N4Y/:#
MR (^:Q:SB?RM4-NB_,J+1ZCIQY=R:,=]=QIV^_.P^#P>3L.]VHWC^5===#^M= M.;;#0W/TZE_^9V&TV M^W7YW:W_',MI_,?@^J/KWX==*6.U>&W[;1E75?
UYN%T>ZNM'>+A,KA;/;ZNJ M?WX+53UWD$"0S!\4(2C.'Y0@*,T?E"$HSQ^D$*3S!QD$V?Q!#D$^?U #0@OJ+01Z"^HM!'H+ MZBT$>@OJ+01Z"^HM!'U#L2Z!U1[TB@=T2[(X'>
<;)90[!W1+TC@=&X1]8X$>B?4.Q+H'5'O2*!W1+TC@=X1]8X$>B?4.Q'HG5#O1*!W0KT3@=&X)]4X$>]?)
M9C>!W@GU3@1Z)]0[$>B=4.]$H'=*O1.!W@GU3@1Z9]0[$^B=4>],H'=&O3.! MWAGUS@1Z9]0[$^B=)W]6$NB=4>],H'=&O3.!WAGUS@1Z9]0[$^BMJ+<2Z*VH
MMQ+HK;BW$NBMJ+<2Z*VHMQ+HK;BW$NBMD\,F'!HKZJT$>BOJK01Z*^JM'!H; MZFT$>AOJ;01Z&^IM'!H;ZFT$>AOJ;01Z&^IM'!H;ZFT$>MODL""!WH9Z&X'>
MAGH;@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>_M/CGL3:"WH]Y.H'>#>C<$>C>H=_.3>@_CUZ$,MY[O-3[_)ZD>+!\MM\=?E\'7 M)R_ABG-
]7S$_0502P,$% @ 7!E&ULS=O?;MHP%,?Q5T&YK4B(X]AA*KUI=[OU8B_@:)9$ MY)]LMZ-O/Q/:2ILZM(I)^]X0@>WS._&1/G=K%\<^FGL3!\@IJN[!\JCD 5-LLHUR 8LT/PI@9'N4Y/:#
ML[WQZ3C9(;YL1]>;$+^ZAVPR]=X\V$RL5BJKQR'8(2S#L49R]IXS-HD9IJZMC8AKF=/0_-;RO{E(8TGYSU^UT[^*FY(MLG<3CBM_#G@Y]_7).MGY$N_T.&ZW;6V;L7[L
MXY'43\Z;QN^L#7V7GHI>G4\\8;MZ3._"\N-SK2(ZG MEU,L9%UHS[_B6V(L??'[V>.T&]O\97:\WA^CV_S\-G\N/R.?YWQ6_T/]B$@ M?120/B2DCQ+2AX+TH2%]5) ^UI
^\A6E$8]H.874G&\}3D$UIZB.4UC-*:[F M^%ASBJR"(JN@R"HHL@J*K\(BJZ#{*BBR"HJL@B*KH,A:4&0M*+(6%%D+BJP% M1=:"(FM!D;6@R%I09"THLDJ*K\)
(BJZ3(*BFR2HJLDB*KI,@J*;)*BJR2(FM) MD;6DR%I29"THLI8464N*K"5%U1(B:TF1M:3(JBBR*HJLBB*KHLBJ*+(JBJR* M(JNBR*HHLBJ*K)HBJZ;(JBFR:HJLFB*KHLBJ*;)JBJR:

(JNFR%I19*THLE84 M62N*K!5%UHHB:T61M:+(6E%DK2BRKBFRKO^GK-_',W/YG_Z MW/P4L! A0#% @ \ K M @ $0 @ &O 9&|C4')O<',O8V|R92YX;6Q02P$"% ,4 M " !S/&=9F5R<(Q & "<)P $P @ '- 0 >&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (',\9UGM30@,T@8 /HG 8 M " @0X(!X;"]W;W)K&PO=V]R M:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ M&UL4$L! A0# M% @ &UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO M=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% M @ &UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R M:W-H965T&UL M4$L! A0#% @ F+1 @ *@@ !D ("!R4L! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M&PO=V]R:W-H965TUC 0!X;"]W M;W)K&UL4$L! A0#% @ SFP%(4# N$0 &0 @('(M:P$ >&PO=V]R:W-H965T&UL4$L! A0#% @ ($!K'P &0 @(&O> $ >&PO=V]R:W-H M965TA((* 0 9 M " @&UL4$L! M A0#% @ 9 ! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ @(8 M !D ("!VKH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ IL)K1G!@ -3D !D M ("!HLH! 'AL+W=O&PO=V]R:W-H965T MW6 0!X;"]W;W)K&UL4$L! A0# M% @ &PO=V]R:W-H965TWI M 0!X;"]W;W)K&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO M=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% M @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R:W-H965T&UL4$L! A0#% @ &PO=V]R M:W-H965T&UL M4$L! A0#% @ 1@U MSQ$% * (&0 @('?5P(>&PO=V]R:W-H965T&UL4$L! A0#% @ M&UL4$L! A0#% @ $ &0 @(%# M@@(>&PO=V]R:W-H965T&UL4$L! A0#% @ 2*VXA!@ QT(!D M ("!/(D" 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ V 8%;F @ P H !D ("!6Y8" 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ XML 103 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(e.style.display){}else{var d,p,_if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 104 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 106 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html4774501false1420false13 falsefalseR1.htm995200090 - Document - Document and Entity InformationSheethttp://www.xoma.com/role/DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsCONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSStatements4 falsefalseR5.htm995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSSheethttp://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSStatements5 falsefalseR6.htm995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYSheethttp://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYStatements6 falsefalseR7.htm995200500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements7 falsefalseR8.htm995210101 - Disclosure - Description of BusinessSheethttp://www.xoma.com/role/DisclosureDescriptionOfBusinessDescription of BusinessNotes8 falsefalseR9.htm995210201 - Disclosure - Basis of Presentation and Significant Accounting PoliciesSheethttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesBasis of Presentation and Significant Accounting PoliciesNotes9 falsefalseR10.htm995210301 - Disclosure - Condensed Consolidated Financial Statements DetailsSheethttp://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsCondensed Consolidated Financial Statements DetailsNotes10 falsefalseR11.htm995210401 - Disclosure - Acquisitions, Licensing and Other ArrangementsSheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsAcquisitions, Licensing and Other ArrangementsNotes11 falsefalseR12.htm995210501 - Disclosure - Royalty and Commercial Payment Purchase AgreementsSheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsRoyalty and Commercial Payment Purchase AgreementsNotes12 falsefalseR13.htm995210601 - Disclosure - Fair Value MeasurementsSheethttp://www.xoma.com/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes13 falsefalseR14.htm995210701 - Disclosure - Lease AgreementsSheethttp://www.xoma.com/role/DisclosureLeaseAgreementsLease AgreementsNotes14 falsefalseR15.htm995210801 - Disclosure - Long-Term DebtSheethttp://www.xoma.com/role/DisclosureLongTermDebtLong-Term DebtNotes15 falsefalseR16.htm995210901 - Disclosure - Common Stock WarrantsSheethttp://www.xoma.com/role/DisclosureCommonStockWarrantsCommon Stock WarrantsNotes16 falsefalseR17.htm995211001 - Disclosure - Commitments and ContingenciesSheethttp://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes17 falsefalseR18.htm995211101 - Disclosure - Stock Based CompensationSheethttp://www.xoma.com/role/DisclosureStockBasedCompensationStock Based CompensationNotes18 falsefalseR19.htm995211201 - Disclosure - Capital StockSheethttp://www.xoma.com/role/DisclosureCapitalStockCapital StockNotes19 falsefalseR20.htm995211301 - Disclosure - Income TaxesSheethttp://www.xoma.com/role/DisclosureIncomeTaxesIncome TaxesNotes20 falsefalseR21.htm995211401 - Disclosure - Subsequent EventsSheethttp://www.xoma.com/role/DisclosureSubsequentEventsSubsequent EventsNotes21 falsefalseR22.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes22 falsefalseR23.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes23 falsefalseR24.htm99920202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)Sheethttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPoliciesBasis of Presentation and Significant Accounting Policies (Policies)Policieshttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies24 falsefalseR25.htm99930203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)Sheethttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTablesBasis of Presentation and Significant Accounting Policies (Tables)Tablesthttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies25 falsefalseR26.htm99930303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables)Sheethttp://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTablesCondensed Consolidated Financial Statements Details (Tables)Tablesthttp://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails26 falsefalseR27.htm99930403 - Disclosure - Acquisitions, Licensing and Other Arrangements (Tables)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTablesAcquisitions, Licensing and Other Arrangements (Tables)Tablesthttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangements27 falsefalseR28.htm99930503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTablesRoyalty and Commercial Payment Purchase Agreements (Tables)Tablesthttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements28 falsefalseR29.htm99930603 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.xoma.com/role/DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tablesthttp://www.xoma.com/role/DisclosureFairValueMeasurements29 falsefalseR30.htm99930703 - Disclosure - Lease Agreements (Tables)Sheethttp://www.xoma.com/role/DisclosureLeaseAgreementsTablesLease Agreements (Tables)Tablesthttp://www.xoma.com/role/DisclosureLeaseAgreements30 falsefalseR31.htm99930803 - Disclosure - Long-Term Debt (Tables)Sheethttp://www.xoma.com/role/DisclosureLongTermDebtTablesLong-Term Debt (Tables)Tablesthttp://www.xoma.com/role/DisclosureLongTermDebt31 falsefalseR32.htm99930903 - Disclosure - Common Stock Warrants (Tables)Sheethttp://www.xoma.com/role/DisclosureCommonStockWarrantsTablesCommon Stock Warrants (Tables)Tablesthttp://www.xoma.com/role/DisclosureCommonStockWarrants32 falsefalseR33.htm99931103 - Disclosure - Stock Based Compensation (Tables)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationTablesStock Based Compensation (Tables)Tablesthttp://www.xoma.com/role/DisclosureStockBasedCompensation33 falsefalseR34.htm99931203 - Disclosure - Capital Stock (Tables)Sheethttp://www.xoma.com/role/DisclosureCapitalStockTablesCapital Stock (Tables)Tablesthttp://www.xoma.com/role/DisclosureCapitalStock34 falsefalseR35.htm99940101 - Disclosure - Description of Business - Liquidity (Details)Sheethttp://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetailsDescription of Business - Liquidity (Details)Details35 falsefalseR36.htm99940201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)Sheethttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetailsBasis of Presentation and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)Details36 falsefalseR37.htm99940202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchased Receivables, Income Taxes, and Share Repurchases (Details)Sheethttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchasedReceivablesIncomeTaxesAndShareRepurchasesDetailsBasis of Presentation and Significant Accounting Policies - Purchased Receivables, Income Taxes, and Share Repurchases (Details)Details37 falsefalseR38.htm99940203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)Sheethttp://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetailsBasis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)Details38 falsefalseR39.htm99940301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)Sheethttp://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetailsConsolidated Financial Statements Details - Equity Securities (Details)Details39 falsefalseR40.htm99940302 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)Sheethttp://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetailsConsolidated Financial Statements Details - Accrued and Other Liabilities (Details)Details40 falsefalseR41.htm99940304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Income Loss Per Share (Details)Sheethttp://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetailsCondensed Consolidated Financial Statements Details - Net Income Loss Per Share (Details)Details41 falsefalseR42.htm99940305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)Sheethttp://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetailsCondensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)Details42 falsefalseR43.htm99940401 - Disclosure - Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetailsAcquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)Details43 falsefalseR44.htm99940402 - Disclosure - Acquisitions, Licensing and Other Arrangements - Takeda (Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetailsAcquisitions, Licensing and Other Arrangements - Takeda (Details)Detailshttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTables44 falsefalseR45.htm99940403 - Disclosure - Acquisitions, Licensing and Other Arrangements - Rezolute (Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetailsAcquisitions, Licensing

and Other Arrangements - Rezolute (Details)Detailshttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTables45 falsefalseR46.htm99940404 - Disclosure - Acquisitions, Licensing and Other Arrangements - Janssen
(Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetailsAcquisitions, Licensing and Other Arrangements - Janssen
(Details)Detailshttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTables46 falsefalseR47.htm99940405 - Disclosure - Acquisitions, Licensing and Other Arrangements - Novartis - NIS793
(Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793DetailsAcquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details)Details47 falsefalseR48.htm99940406 - Disclosure - Acquisitions, Licensing and Other Arrangements - Novartis - VPM087
(Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087DetailsAcquisitions, Licensing and Other Arrangements - Novartis - VPM087 (Details)Details48 falsefalseR49.htm99940407 - Disclosure - Acquisitions, Licensing and Other Arrangements - Sale of Future Revenue Streams
(Details)Sheethttp://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetailsAcquisitions, Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)Details49 falsefalseR50.htm99940501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetailsRoyalty and Commercial Payment Purchase Agreements - Summary (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables50 falsefalseR51.htm99940502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Dare
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetailsRoyalty and Commercial Payment Purchase Agreements - Dare (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables51 falsefalseR52.htm99940503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Talphera
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetailsRoyalty and Commercial Payment Purchase Agreements - Talphera (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables52 falsefalseR53.htm99940504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetailsRoyalty and Commercial Payment Purchase Agreements - LadRx (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables53 falsefalseR54.htm99940505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetailsRoyalty and Commercial Payment Purchase Agreements - Aptevo (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables54 falsefalseR55.htm99940506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palobiofarma
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetailsRoyalty and Commercial Payment Purchase Agreements - Palobiofarma (Details)Details55 falsefalseR56.htm99940507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetailsRoyalty and Commercial Payment Purchase Agreements - Viracta (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables56 falsefalseR57.htm99940508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetailsRoyalty and Commercial Payment Purchase Agreements - Kuros (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables57 falsefalseR58.htm99940509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetailsRoyalty and Commercial Payment Purchase Agreements - Affitech (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables58 falsefalseR59.htm99940510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetailsRoyalty and Commercial Payment Purchase Agreements - Agenus (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables59 falsefalseR60.htm99940511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetailsRoyalty and Commercial Payment Purchase Agreements - Aronora (Details)Detailshttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables60 falsefalseR61.htm99940512 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities
(Details)Sheethttp://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetailsRoyalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)Details61 falsefalseR62.htm99940601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration
(Details)Sheethttp://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsi
Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration (Details)Details62
falsefalseR63.htm99940602 - Disclosure - Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration
(Details)Sheethttp://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetailsFair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details)Details63 falsefalseR64.htm99940603 - Disclosure - Fair Value Measurements - Equity Securities
(Details)Sheethttp://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetailsFair Value Measurements - Equity Securities (Details)Details64
falsefalseR65.htm99940604 - Disclosure - Fair Value Measurements - Contingent Consideration
(Details)Sheethttp://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetailsFair Value Measurements - Contingent Consideration
(Details)Details65 falsefalseR66.htm99940701 - Disclosure - Lease Agreements - Leased facilities
(Details)Sheethttp://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetailsLease Agreements - Leased facilities (Details)Details66
falsefalseR67.htm99940702 - Disclosure - Lease Agreements - Maturity of lease liabilities
(Details)Sheethttp://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetailsLease Agreements - Maturity of lease liabilities (Details)Details67
falsefalseR68.htm99940703 - Disclosure - Lease Agreements - Lease costs (Details)Sheethttp://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetailsLease Agreements - Lease costs (Details)Details68 falsefalseR69.htm99940704 - Disclosure - Lease Agreements - Additional information
(Details)Sheethttp://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetailsLease Agreements - Additional information (Details)Details69
falsefalseR70.htm99940801 - Disclosure - Long-Term Debt - Agreement (Details)Sheethttp://www.xoma.com/role/DisclosureLongTermDebtAgreementDetailsLong-Term Debt - Agreement (Details)Details70 falsefalseR71.htm99940802 - Disclosure - Long-Term Debt - Balance
(Details)Sheethttp://www.xoma.com/role/DisclosureLongTermDebtBalanceDetailsLong-Term Debt - Balance (Details)Details71 falsefalseR72.htm99940803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts
(Details)Sheethttp://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetailsLong-Term Debt - Aggregate projected future principal and discounts (Details)Details72 falsefalseR73.htm99940804 - Disclosure - Long-Term Debt - Interest expense
(Details)Sheethttp://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetailsLong-Term Debt - Interest expense (Details)Details73 falsefalseR74.htm99940901 - Disclosure - Common Stock Warrants - Summary of Common Stock Warrants Outstanding
(Details)Sheethttp://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetailsCommon Stock Warrants - Summary of Common Stock Warrants Outstanding (Details)Details74 falsefalseR75.htm99941001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments
(Details)Sheethttp://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetailsCommitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)Details75 falsefalseR76.htm99941002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)Sheethttp://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetailsCommitments and Contingencies - Contingent Consideration (Details)Details76 falsefalseR77.htm99941101 - Disclosure - Stock Based Compensation - ESPP
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetailsStock Based Compensation - ESPP (Details)Details77 falsefalseR78.htm99941102 - Disclosure - Stock Based Compensation - 2010 Plan Stock Options
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetailsStock Based Compensation - 2010 Plan Stock Options
(Details)Details78 falsefalseR79.htm99941103 - Disclosure - Stock Based Compensation - Stock Option Inducement Awards
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetailsStock Based Compensation - Stock Option Inducement Awards (Details)Details79 falsefalseR80.htm99941104 - Disclosure - Stock Based Compensation - Stock Option Activity
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetailsStock Based Compensation - Stock Option Activity (Details)Details80
falsefalseR81.htm99941105 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetailsStock Based Compensation - Performance Stock Unit Awards
(Details)Details81 falsefalseR82.htm99941106 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetailsStock Based Compensation - Performance Stock Unit Awards Fair Value (Details)Details82 falsefalseR83.htm99941107 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetailsStock Based Compensation - Performance Stock Unit Awards Activity (Details)Details83 falsefalseR84.htm99941108 - Disclosure - Stock Based Compensation - Restricted Stock Unit Awards
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetailsStock Based Compensation - Restricted Stock Unit Awards
(Details)Details84 falsefalseR85.htm99941109 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense
(Details)Sheethttp://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetailsStock Based Compensation - Stock-based Compensation Expense (Details)Details85 falsefalseR86.htm99941201 - Disclosure - Capital Stock - Dividends
(Details)Sheethttp://www.xoma.com/role/DisclosureCapitalStockDividendsDetailsCapital Stock - Dividends (Details)Details86 falsefalseR87.htm99941202 - Disclosure - Capital Stock - BVF Ownership (Details)Sheethttp://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetailsCapital Stock - BVF Ownership (Details)Details87
falsefalseR88.htm99941203 - Disclosure - Capital Stock - ATM Agreements (Details)Sheethttp://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetailsCapital Stock - ATM Agreements (Details)Details88 falsefalseR89.htm99941204 - Disclosure - Capital Stock - Stock Repurchase Program
(Details)Sheethttp://www.xoma.com/role/DisclosureCapitalStockStockRepurchaseProgramDetailsCapital Stock - Stock Repurchase Program (Details)Details89
falsefalseR90.htm99941301 - Disclosure - Income Taxes (Details)Sheethttp://www.xoma.com/role/DisclosureIncomeTaxesDetailsIncome Taxes
(Details)Detailshttp://www.xoma.com/role/DisclosureIncomeTaxes90 falsefalseR91.htm99941401 - Disclosure - Subsequent Events
(Details)Sheethttp://www.xoma.com/role/DisclosureSubsequentEventsDetailsSubsequent Events (Details)Detailshttp://www.xoma.com/role/DisclosureSubsequentEvents91
falsefalseAll ReportsBookAll Reports xoma-20240930.xsdxoma-20240930_cal.xmlxoma-20240930_def.xmlxoma-20240930_lab.xmlxoma-20240930_pre.xmlxoma-20240930x10q.htm http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 109 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xoma-20240930x10q.htm": { "nsprefix": "xoma", "nsuri": "http://www.xoma.com/20240930", "dts": { "schema": { "local": ["xoma-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["xoma-20240930_cal.xml"] }, "definitionLink": { "local": ["xoma-20240930_def.xml"] }, "labelLink": { "local": ["xoma-20240930_lab.xml"] }, "presentationLink": { "local": [

```
"xoma-20240930_pre.xml" ] }, "inline": { "local": [ "xoma-20240930x10q.htm" ] } }, "keyStandard": 289, "keyCustom": 161, "axisStandard": 37, "axisCustom": 0, "memberStandard": 38, "memberCustom": 96, "hidden": { "total": 20, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 13, "http://www.xoma.com/20240930": 2 }, "contextCount": 477, "entityCount": 1, "segmentCount": 142, "elementCount": 851, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 891, "http://xbrl.sec.gov/dei/2024": 36, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:AssetsCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_z0C3y8YMsEOvH88lQZtHeA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_z0C3y8YMsEOvH88lQZtHeA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "xoma:IncomeNotFromContractWithCustomerEffectiveInterestRateMethodAndCostRecoveryMethod", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "xoma:IncomeNotFromContractWithCustomerEffectiveInterestRateMethodAndCostRecoveryMethod", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QhGjwSFv_Uq_PK9Zc4tkzA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JyaWEq3QHEyPO4pvVIx18A", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R7": { "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusiness", "longName": "995210101 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails", "longName": "995210301 - Disclosure - Condensed Consolidated Financial Statements Details", "shortName": "Condensed Consolidated Financial Statements Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangements", "longName": "995210401 - Disclosure - Acquisitions, Licensing and Other Arrangements", "shortName": "Acquisitions, Licensing and Other Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:AssetAcquisitionsLicensingAndOtherArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:AssetAcquisitionsLicensingAndOtherArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements", "longName": "995210501 - Disclosure - Royalty and Commercial Payment Purchase Agreements", "shortName": "Royalty and Commercial Payment Purchase Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:RoyaltyPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:RoyaltyPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.xoma.com/role/DisclosureFairValueMeasurements", "longName": "995210601 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.xoma.com/role/DisclosureLeaseAgreements", "longName": "995210701 - Disclosure - Lease Agreements", "shortName": "Lease Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.xoma.com/role/DisclosureLongTermDebt", "longName": "995210801 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.xoma.com/role/DisclosureCommonStockWarrants", "longName": "995210901 - Disclosure - Common Stock Warrants", "shortName": "Common Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:CommonStockWarrantDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TFCetnOZk0Gag0ktkRVVdw", "name": "xoma:CommonStockWarrantDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
```

"lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211001 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensation", "longName": "995211101 - Disclosure - Stock Based Compensation", "shortName": "Stock Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.xoma.com/role/DisclosureCapitalStock", "longName": "995211201 - Disclosure - Capital Stock", "shortName": "Capital Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.xoma.com/role/DisclosureIncomeTaxes", "longName": "995211301 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.xoma.com/role/DisclosureSubsequentEvents", "longName": "995211401 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables", "longName": "99930303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables)", "shortName": "Condensed Consolidated Financial Statements Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTables", "longName": "99930403 - Disclosure - Acquisitions, Licensing and Other Arrangements (Tables)", "shortName": "Acquisitions, Licensing and Other Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables", "longName": "99930503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)", "shortName": "Royalty and Commercial Payment Purchase Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930603 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsTables", "longName": "99930703 - Disclosure - Lease Agreements (Tables)", "shortName": "Lease Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["xoma:LeaseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["xoma:LeaseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.xoma.com/role/DisclosureLongTermDebtTables", "longName": "99930803 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.xoma.com/role/DisclosureCommonStockWarrantsTables", "longName": "99930903 - Disclosure - Common Stock Warrants (Tables)", "shortName": "Common Stock Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["xoma:CommonStockWarrantDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationTables", "longName": "99931103 - Disclosure - Stock Based Compensation (Tables)", "shortName": "Stock Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.xoma.com/role/DisclosureCapitalStockTables", "longName": "99931203 - Disclosure - Capital

Stock (Tables)", "shortName": "Capital Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails", "longName": "99940101 - Disclosure - Description of Business - Liquidity (Details)", "shortName": "Description of Business - Liquidity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R36": { "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "longName": "99940201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchasedReceivablesIncomeTaxesAndShareRepurchasesDetails", "longName": "99940202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchased Receivables, Income Taxes, and Share Repurchases (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies - Purchased Receivables, Income Taxes, and Share Repurchases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:PurchasedReceivablesCostRecoveryMethodNetCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:PurchasedReceivablesCostRecoveryMethodNetCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails", "longName": "99940203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hk_3My1cjE-tpe8hvYb-8g", "name": "xoma:NumberOfMajorPartners", "unitRef": "Unit_Standard_customer_BRsDnknnU0SG4hmwelvJvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hk_3My1cjE-tpe8hvYb-8g", "name": "xoma:NumberOfMajorPartners", "unitRef": "Unit_Standard_customer_BRsDnknnU0SG4hmwelvJvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails", "longName": "99940301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)", "shortName": "Consolidated Financial Statements Details - Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_SAXodk865Uagw1ppf0evFQ", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R40": { "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails", "longName": "99940302 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)", "shortName": "Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "longName": "99940304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Income Loss Per Share (Details)", "shortName": "Condensed Consolidated Financial Statements Details - Net Income Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3cRTOfLOaE-BN23wiHWjFA", "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails", "longName": "99940305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)", "shortName": "Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "longName": "99940401 - Disclosure - Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:MilestoneAssetsNoncurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_xoma_KinnateMember_gw0ALmr5vECaDffxFmk-7w", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails", "longName": "99940402 - Disclosure - Acquisitions, Licensing and Other Arrangements - Takeda (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Takeda (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2006_To_9_30_2024_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_Gj-x6D51XEOlRpkY2lF99g", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R45": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "longName": "99940403 - Disclosure - Acquisitions, Licensing and Other Arrangements - Rezolute (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Rezolute (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_-rHmzQWgyEWrcqpDZM7A4w", "name": "xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R46": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails", "longName": "99940404 - Disclosure - Acquisitions, Licensing and Other Arrangements - Janssen (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Janssen (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Oq9YFpDsZkO_8_4jWGsEpw", "name": "xoma:ProceedsFromUpfrontPayment", "unitRef":

"Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R47": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details", "longName": "99940405 - Disclosure - Acquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7UM7OvsHNkyLZLV22l6evQ", "name": "xoma:AgreementTerminationPriorWrittenNoticePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R48": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "longName": "99940406 - Disclosure - Acquisitions, Licensing and Other Arrangements - Novartis - VPM087 (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Novartis - VPM087 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_dcutAwFng0yiWOqMhiwKPw", "name": "xoma:LicenseAgreementTransactionPrice", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R49": { "role": "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "longName": "99940407 - Disclosure - Acquisitions, Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)", "shortName": "Acquisitions, Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:IncreaseDecreaseInDeferredRevenue", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_D3AC3vjjo0K-hE2iS9fIhw", "name": "xoma:AgreementsNumber", "unitRef": "Unit_Standard_agreement_wKXAVLztJUag5I6NYTFZrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R50": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails", "longName": "99940501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:RightsReceivableCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "longName": "99940502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Dare (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Dare (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_29_2024_To_4_29_2024_srt_CounterpartyNameAxis_xoma_DareMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_GKCKDTj8SE2m6WWBxrhQfQ", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "xoma:RoyaltyPurchaseAgreementTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R52": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "longName": "99940503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Talphera (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Talphera (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_12_2024_To_1_12_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_83IF5k0LvEaAA-xdrjwDFw", "name": "xoma:RoyaltyAndMilestonesReceivableThreshold", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R53": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails", "longName": "99940504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - LadRx (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_3_2024_To_6_3_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_HhW6DdiRWEu2obf51943Rw", "name": "xoma:IncreaseDecreaseInPotentialAmountPayableOnRegulatoryMilestone", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R54": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "longName": "99940505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Yv99Kr-Zkka8bifTxt44LA", "name": "xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R55": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails", "longName": "99940506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palobiofarma (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Palobiofarma (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_oWZNDCh0rEG2QqOYpT1QWg", "name": "xoma:AgreementDrugCandidatesNumber", "unitRef": "Unit_Standard_item_jFhtQYQgi0uEEPS8fzF2Wg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R56": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "longName": "99940507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Viracta (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gLZ7W9rZj0SUuaQG7ql8kA", "name": "xoma:AgreementDrugCandidatesNumber", "unitRef": "Unit_Standard_item_jFhtQYQgi0uEEPS8fzF2Wg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R57": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "longName": "99940508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Kuros (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_H5a1OUBTSkKdVM35HEZyVw", "name": "xoma:RoyaltyReceivablePercentageOnNetSales", "unitRef": "Unit_Standard_pure_-pGlbE0VlEuT1_hkwxnCTQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R58": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "longName": "99940509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Affitech (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_CcaBvzBNekCgomY40mzs-A", "name": "xoma:CommercialPaymentPeriodDue", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R59": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "longName": "99940510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Agenus (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef":

"Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wayzmGJE60mlhihpLjtXqg", "name": "xoma:MilestoneAchieved", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R60": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "longName": "99940511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Aronora (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pHAK3t9DkEm-SXyM5HkH-Q", "name": "xoma:AgreementDrugCandidatesNumber", "unitRef": "Unit_Standard_item_jThtQYQgi0uEEPS8fzF2Wg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R61": { "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails", "longName": "99940512 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)", "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2023_L825zn2oa0-CuvjGRh2aQQ", "name": "xoma:RightsReceivableCostRecoveryMethod", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_L825zn2oa0-CuvjGRh2aQQ", "name": "xoma:RightsReceivableCostRecoveryMethod", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta "longName": "99940601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration (Details)", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:MilestoneAssetsNoncurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7-1xGuTFTkyfLm0xzR6UVA", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R63": { "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails", "longName": "99940602 - Disclosure - Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details)", "shortName": "Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:MilestoneAssetsNoncurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_xoma_KinnateCvrHoldersMember_us-gaap_TypeOfArrangementAxis_xoma_ContingentValueRightsAgreementMember_xTuxY_4vM0KVVShKoZUZIw", "name": "xoma:MilestoneAssetsIncreaseDecrease", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R64": { "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails", "longName": "99940603 - Disclosure - Fair Value Measurements - Equity Securities (Details)", "shortName": "Fair Value Measurements - Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_STPMl5taoUWf47G-lY_mSA", "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "unitRef": "Unit_Divide_USD_shares_z0C3y8YMsEOvH88lQZtHeA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_STPMl5taoUWf47G-lY_mSA", "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "unitRef": "Unit_Divide_USD_shares_z0C3y8YMsEOvH88lQZtHeA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "longName": "99940604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)", "shortName": "Fair Value Measurements - Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails", "longName": "99940701 - Disclosure - Lease Agreements - Leased facilities (Details)", "shortName": "Lease Agreements - Leased facilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_f8smcCFhRUCoLdQmiQvG8w", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "xoma:LeaseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R67": { "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails", "longName": "99940702 - Disclosure - Lease Agreements - Maturity of lease liabilities (Details)", "shortName": "Lease Agreements - Maturity of lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "xoma:LeaseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "xoma:LeaseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails", "longName": "99940703 - Disclosure - Lease Agreements - Lease costs (Details)", "shortName": "Lease Agreements - Lease costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails", "longName": "99940704 - Disclosure - Lease Agreements - Additional information (Details)", "shortName": "Lease Agreements - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "longName": "99940801 - Disclosure - Long-Term Debt - Agreement (Details)", "shortName": "Long-Term Debt - Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_VSXF5RKo_0eWeMYHoEw59g", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R71": { "role": "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails", "longName": "99940802 - Disclosure - Long-Term Debt - Balance (Details)", "shortName": "Long-Term Debt - Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:RepaymentsOfLongTermDebt", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_gOrR7mJSPUyb2oEYiIohwg", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R72": { "role": "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails", "longName": "99940803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)", "shortName": "Long-Term Debt - Aggregate projected future principal and discounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_XKK2gWDwq0uSz17ciP8lEw", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null,

"decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_XKK2gWDwq0uSz17ciP8lEw", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails", "longName": "99940804 - Disclosure - Long-Term Debt - Interest expense (Details)", "shortName": "Long-Term Debt - Interest expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0kttkRVVdw", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wYLsVYPo-0C_CbWA8rRk8Q", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "xoma:ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R74": { "role": "http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails", "longName": "99940901 - Disclosure - Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details)", "shortName": "Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "xoma:CommonStockWarrantDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "xoma:CommonStockWarrantDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails", "longName": "99941001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)", "shortName": "Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:ContractualObligationEstimatedMilestonePayments", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:ContractualObligationEstimatedMilestonePayments", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "longName": "99941002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)", "shortName": "Commitments and Contingencies - Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_9_30_2024_v8DQW6QAi0-Wn5q9LFXtaQ", "name": "xoma:ContingentConsiderationUnderPurchaseAgreements", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_ETbawt1SOk6UvCZjpXZf5Q", "name": "xoma:LongTermRightsReceivableNonCurrent", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R77": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "longName": "99941101 - Disclosure - Stock Based Compensation - ESPP (Details)", "shortName": "Stock Based Compensation - ESPP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_yYCcl_Neq0qRozYf4QUXJw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "unitRef": "Unit_Standard_pure_-pGlbE0VlEuT1_hkwxnCTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_yYCcl_Neq0qRozYf4QUXJw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "unitRef": "Unit_Standard_pure_-pGlbE0VlEuT1_hkwxnCTQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "longName": "99941102 - Disclosure - Stock Based Compensation - 2010 Plan Stock Options (Details)", "shortName": "Stock Based Compensation - 2010 Plan Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_Q4kM1MseB0mHX38GPtKQtA", "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R79": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails", "longName": "99941103 - Disclosure - Stock Based Compensation - Stock Option Inducement Awards (Details)", "shortName": "Stock Based Compensation - Stock Option Inducement Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aAIjE-zLkSg_V3CVA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_bVaVxOAlFUqaH-Ep3f1Gkw", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_z0C3y8YMsEOvH88lQZtHeA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R80": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "longName": "99941104 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)", "shortName": "Stock Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_12_31_2023_L825zn2oa0-CuvjGRh2aQQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R81": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "longName": "99941105 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details)", "shortName": "Stock Based Compensation - Performance Stock Unit Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_4_30_2024_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LgQmSWhEoUOOe4z_xi8uBw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0EoCI9yqWEOmtxOCq2JDyQ", "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.", "unitRef": "Unit_Standard_item_jThtQYQgi0uEEPS8fzF2Wg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R82": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "longName": "99941106 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)", "shortName": "Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_4_30_2024_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LgQmSWhEoUOOe4z_xi8uBw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IQatLSGig0il5nb3KiHHUQ", "name": "xoma:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionAggregateCostToBeRecognizedAmount", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R83": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "longName": "99941107 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details)", "shortName": "Stock Based Compensation - Performance Stock Unit Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_gkX18otVfkqh1zwDn_Es3Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-

gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0TDLzoK9zEWbysKJey_gtg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_z0C3y8YMsEOvH88lQZtHeA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceShareAwardOutstandingActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "R84": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails", "longName": "99941108 - Disclosure - Stock Based Compensation - Restricted Stock Unit Awards (Details)", "shortName": "Stock Based Compensation - Restricted Stock Unit Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "Duration_5_1_2024_To_5_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6qKkOl2l-0uowElXuqJbhw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_1_2024_To_5_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6qKkOl2l-0uowElXuqJbhw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_KyvZ2mAopEi6CDXAPbwOlg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "longName": "99941109 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)", "shortName": "Stock Based Compensation - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_iTXVcwQdJ0aaVu2G3IQWGQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_iTXVcwQdJ0aaVu2G3IQWGQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "longName": "99941201 - Disclosure - Capital Stock - Dividends (Details)", "shortName": "Capital Stock - Dividends (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "Duration_10_1_2023_To_12_31_2023_us-gaap_DividendsAxis_xoma_O2023Q4DividendsMember_fEPc4z5c-ka9DFACCUU2cA", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2023_To_12_31_2023_us-gaap_DividendsAxis_xoma_O2023Q4DividendsMember_fEPc4z5c-ka9DFACCUU2cA", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "longName": "99941202 - Disclosure - Capital Stock - BVF Ownership (Details)", "shortName": "Capital Stock - BVF Ownership (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "As_Of_9_30_2024_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LWT_qRh-tkKdwELnb_dabg", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "Unit_Standard_pure_-pGlbE0VlEuT1_hkwxnCTQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LWT_qRh-tkKdwELnb_dabg", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "Unit_Standard_pure_-pGlbE0VlEuT1_hkwxnCTQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "longName": "99941203 - Disclosure - Capital Stock - ATM Agreements (Details)", "shortName": "Capital Stock - ATM Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_E4mKkKJc1kCkeiX00fCUEA", "name": "xoma:MaximumValueOfStockToBeIssued", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_E4mKkKJc1kCkeiX00fCUEA", "name": "xoma:MaximumValueOfStockToBeIssued", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.xoma.com/role/DisclosureCapitalStockStockRepurchaseProgramDetails", "longName": "99941204 - Disclosure - Capital Stock - Stock Repurchase Program (Details)", "shortName": "Capital Stock - Stock Repurchase Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "As_Of_1_2_2024_rnoxxpZQfU-kpdA8h3H5ow", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_1_2_2024_rnoxxpZQfU-kpdA8h3H5ow", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.xoma.com/role/DisclosureIncomeTaxesDetails", "longName": "99941301 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_siEV1aALjE-zLkSg_V3CVA", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.xoma.com/role/DisclosureSubsequentEventsDetails", "longName": "99941401 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_TTCetnOZk0Gag0ktkRVVdw", "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities", "unitRef": "Unit_Standard_USD_jhVs2e3aLUWc2sDvpBkAGQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_21_2024_srt_CounterpartyNameAxis_xoma_TwistBioscienceCorporationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iR0AfWntCEila2cZDr9uNQ", "name": "xoma:PurchasedPercentageOfEconomicsOfPrograms", "unitRef": "Unit_Standard_pure_-pGlbE0VlEuT1_hkwxnCTQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "xoma-20240930x10q.htm", "unique": true } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Trade and other receivables, net", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r57", "r818"] }, "xoma_AccrualOfContingentConsiderationUnderAssignmentAndAssumptionAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AccrualOfContingentConsiderationUnderAssignmentAndAssumptionAgreements", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Accrual of contingent consideration under assignment and assumption agreement.", "label": "Accrual Of Contingent Consideration Under Assignment and Assumption Agreements", "terseLabel": "Accrual of contingent consideration under the LadRx AAA" } } }, "auth_ref": [] }, "xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AccrualOfContingentConsiderationUnderPurchaseAgreements", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Accrual of contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.", "label": "Accrual Of Contingent Consideration Under Purchase Agreements", "terseLabel": "Accrual of contingent consideration under the Affitech CPPA" } } }, "auth_ref": [] }, "xoma_AccruedAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AccruedAndOtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.", "label": "Accrued And Other Liabilities Current", "negatedLabel": "Accrued and other liabilities", "terseLabel": "Accrued and other liabilities", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "terseLabel": "Accrued incentive compensation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r60"] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "presentation": ["http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]", "terseLabel": "Accrued and other liabilities" } } }, "auth_ref": [] }, "xoma_AccruedPreferredStockDividendCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AccruedPreferredStockDividendCurrent", "crdr": "credit", "presentation": [

```
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Preferred Stock Dividend, Current", "terseLabel": "Preferred stock dividend accrual" } } }, "auth_ref": [ ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued legal and accounting fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r60" ] }, "xoma_AccruedSalariesAndEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AccruedSalariesAndEmployeeBenefitsCurrent", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries and Employee Benefits, Current", "terseLabel": "Accrued payroll and benefits" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r75", "r179", "r620", "r648", "r649" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r13", "r23", "r479", "r482", "r539", "r644", "r645", "r964", "r965", "r966", "r974", "r975", "r976", "r978" ] }, "xoma_AcquisitionNumberOfContingentValueRights": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AcquisitionNumberOfContingentValueRights", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of non-transferable contractual contingent value rights (CVR) each acquiree share has right to receive. representing right to receive one or more potential cash payments.", "label": "Acquisition, Number Of Contingent Value Rights", "terseLabel": "Number of non-transferable contractual CVR per share of Kinnate common stock" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r885" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "Additional Financial Information Disclosure [Text Block]", "verboseLabel": "Condensed Consolidated Financial Statements Detail", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r70", "r818", "r1114" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r661", "r974", "r975", "r976", "r978", "r1050", "r1115" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r898" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r898" ] },
"ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r898" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r898" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings", "negatedLabel": "Preferred stock dividends", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": [ "r14", "r96" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r50", "r51", "r399" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": [
"http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
"http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ADR [Member]", "terseLabel": "Series B Depositary Shares", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r851" ] }, "xoma_AffitechResearchAsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AffitechResearchAsMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Affitech Research AS, a Norwegian biotech company.", "label": "Affitech Research AS [Member]", "terseLabel": "Affitech" } } }, "auth_ref": [] }, "xoma_AgenusIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AgenusIncMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Agenus Inc.", "label": "Agenus [Member]", "terseLabel": "Agenus" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r931" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r857", "r867", "r877", "r909" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r860", "r870", "r880", "r912" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r932" ] }, "xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AgreementDrugCandidatesExclusiveLicenseOptionNumber", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of drug candidates subject to exclusive license option.", "label": "Agreement, Drug Candidates, Exclusive License Option, Number", "terseLabel": "Number of drug candidates subject to exclusive license option" } } }, "auth_ref": [] }, "xoma_AgreementDrugCandidatesNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AgreementDrugCandidatesNumber", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of drug candidates under the terms of the agreement.", "label": "Agreement, Drug Candidates, Number", "terseLabel": "Number of drug candidates" } } }, "auth_ref": [] }, "xoma_AgreementPaymentPercentageFactor": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AgreementPaymentPercentageFactor", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "lang": { "en-us": { "role": { "documentation": "Multiplier used in determining change in payment percentage.", "label": "Agreement, Payment Percentage, Factor", "terseLabel": "Multiplier for cumulative amount of consideration paid" } } }, "auth_ref": [] }, "xoma_AgreementTerminationPriorWrittenNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AgreementTerminationPriorWrittenNoticePeriod", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days", "label": "Agreement Termination Prior Written Notice Period", "terseLabel": "Agreement termination prior written notice period" } } }, "auth_ref": [] }, "xoma_AgreementsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AgreementsNumber", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
```

"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of agreements.", "label": "Agreements, Number", "terseLabel": "Number of agreements" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r898"] }, "xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AllCustomersExcludingU.s.DepartmentOfDefenseMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "All customers excluding U.S. Department of Defense.", "label": "All Customers, Excluding U.S. Department of Defense [Member]", "terseLabel": "All customers excluding DoD" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r905"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r861", "r871", "r881", "r905", "r913", "r917", "r925"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r923"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r429", "r434"] }, "xoma_AloraPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AloraPharmaceuticalsMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Alora Pharmaceuticals.", "label": "Alora Pharmaceuticals [Member]", "terseLabel": "Alora Pharmaceuticals" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Accretion of long-term debt discount and debt issuance costs", "verboseLabel": "Accretion of debt discount and debt issuance costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r349", "r788", "r789", "r968", "r1062"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r6", "r307", "r314", "r784"] }, "xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount deposited into reserve accounts to pay interest, administrative fees and operating expenses.", "label": "Amount Deposited into Reserve Accounts to Pay Interest, Administrative Fees and Operating Expenses", "terseLabel": "Amount deposited into reserve accounts to pay interest, administrative fees and operating expenses" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r238"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r31"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r31"] }, "xoma_AptevoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AptevoMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Aptevo.", "label": "Aptevo [Member]", "terseLabel": "Aptevo" } } }, "auth_ref": [] }, "xoma_AronoraIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AronoraIncMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Aronora, Inc.", "label": "Aronora, Inc. [Member]", "terseLabel": "Aronora" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r469"] }, "xoma_ArrangementsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ArrangementsNumber", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "Number of arrangements the agreements are accounted for.", "label": "Arrangements, Number", "terseLabel": "Number of arrangements" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Abstract]", "terseLabel": "Allocation of purchase consideration" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r308", "r309", "r310", "r311", "r313", "r1046"] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "totalLabel": "Total purchase consideration", "verboseLabel": "Total purchase consideration", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": ["r803", "r1047", "r1048", "r1049"] }, "us-gaap_AssetAcquisitionConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"AssetAcquisitionConsiderationTransferredAbstract", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred [Abstract]", "terseLabel": "Purchase consideration" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Estimated fair value of the Exarafenib milestone contingent consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": ["r1047", "r1048", "r1049"] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": ["r803", "r1047", "r1048", "r1049"] }, "xoma_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration from the Exarafenib Sale payable from the Company to the Kinnate CVR Holders under the CVR Agreement" } } }, "auth_ref": [] }, "xoma_AssetAcquisitionContingentConsiderationLiabilityChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionContingentConsiderationLiabilityChangeInAmount", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value during the period from contingent consideration liability.", "label": "Asset Acquisition, Contingent Consideration, Liability, Change in Amount", "terseLabel": "Increase in Exarafenib milestone contingent consideration" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Exarafenib milestone contingent consideration (Note 4)", "verboseLabel": "Exarafenib milestone contingent consideration", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent." } } }, "auth_ref": ["r1046"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r308", "r309", "r310", "r311", "r313", "r1046"] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "terseLabel": "Asset acquisition", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r1046"] },
"xoma_AssetAcquisitionMilestoneContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionMilestoneContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from milestone contingent consideration in asset acquisition, classified as noncurrent.", "label": "Asset Acquisition, Milestone Contingent Consideration, Liability, Noncurrent", "terseLabel": "Estimated initial fair value of the Exarafenib milestone contingent consideration in Kinnate acquisition" } } }, "auth_ref": [] },
"xoma_AssetAcquisitionNumberOfSharesTendered": { "xbrltype": "sharesItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionNumberOfSharesTendered", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Number of shares tendered under the asset acquisition.", "label": "Asset Acquisition, Number Of Shares Tendered", "terseLabel": "Kinnate common stock tendered" } } }, "auth_ref": [] }, "xoma_AssetAcquisitionNumberOfSharesUnderlyingShareBasedAwardsSettled": { "xbrltype": "sharesItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionNumberOfSharesUnderlyingShareBasedAwardsSettled", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Number of shares underlying the share-based awards settled under the asset acquisition.", "label": "Asset Acquisition, Number Of Shares Underlying The Share Based Awards Settled", "terseLabel": "Total number of underlying shares" } } }, "auth_ref": [] }, "xoma_AssetAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionSharePrice", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid in asset acquisition.", "label": "Asset Acquisition, Share Price", "terseLabel": "Asset acquisition, Share price (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": ["r1046"] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTables"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Schedule of purchase consideration", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": ["r1046"] },
"xoma_AssetAcquisitionsLicensingAndOtherArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionsLicensingAndOtherArrangementsAbstract", "lang": { "en-us": { "role": { "label": "Acquisitions, Licensing and Other Arrangements" } } }, "auth_ref": [] },
"xoma_AssetAcquisitionsLicensingAndOtherArrangementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionsLicensingAndOtherArrangementsTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangements"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisitions, licensing and other arrangements.", "label": "Asset Acquisitions, Licensing And Other Arrangements [Text Block]", "terseLabel": "Acquisitions, Licensing and Other Arrangements" } } }, "auth_ref": [] }, "xoma_AssetAcquisitionsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetAcquisitionsPolicyPolicyTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for asset acquisitions.", "label": "Asset Acquisitions, Policy [Policy Text Block]", "terseLabel": "Asset Acquisitions" } } }, "auth_ref": [] },
"xoma_AssetPurchaseAgreementAndMarketingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssetPurchaseAgreementAndMarketingAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement and Marketing Agreement .", "label": "Asset Purchase Agreement and Marketing Agreement [Member]", "terseLabel": "Asset Purchase Agreement and Marketing Agreement" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r106", "r117", "r172", "r201", "r241", "r245", "r250", "r251", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r471", "r475", "r510", "r615", "r700", "r780", "r781", "r818", "r847", "r1007", "r1008", "r1068"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r168", "r180", "r201", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r471", "r475", "r510", "r818", "r1007", "r1008", "r1068"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta
], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNet", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Net Assets", "totalLabel": "Net assets acquired", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": ["r11"] },
"xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Assignment and Assumption Agreement and Royalty Purchase Agreement.", "label": "Assignment and Assumption Agreement and Royalty Purchase Agreement [Member]", "terseLabel": "Assignment and Assumption Agreement and Royalty Purchase Agreement" } } }, "auth_ref": [] }, "xoma_AtMarketIssuanceSalesAgreement2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AtMarketIssuanceSalesAgreement2021Member", "presentation": [
"http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.", "label": "At Market Issuance Sales Agreement 2021 [Member]", "terseLabel": "2021 ATM Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available for sale securities, Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r261"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available for sale securities, Estimated Fair Value", "documentation": "Amount of investment in debt security

measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r259", "r301", "r490", "r609", "r806", "r809", "r987", "r1054", "r1055", "r1056"] }, "xoma_AwardDate2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AwardDate2024Member", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Award dates in 2024.", "label": "Award Date, 2024 [Member]", "terseLabel": "Award Date, 2024" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040"] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040"] }, "xoma_AwardDateMay2023ToOctober2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "AwardDateMay2023ToOctober2023Member", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Award dates from May 2023 to October 2023.", "label": "Award Date, May 2023 to October 2023 [Member]", "terseLabel": "Award Date, 2023" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r920"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r921"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r916"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r916"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r916"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r916"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r916"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r916"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r919"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r918"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r917"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r917"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r87"] }, "xoma_BayerProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "BayerProductsMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Bayer products.", "label": "Bayer Products [Member]", "terseLabel": "Bayer Products" } } }, "auth_ref": [] }, "xoma_BiotechnologyValueFundLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "BiotechnologyValueFundLPMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "documentation": "Biotechnology Value Fund, L.P.", "label": "Biotechnology Value Fund LP [Member]", "terseLabel": "BVF" } } }, "auth_ref": [] }, "xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to pertaining delayed draw term loan under Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.", "label": "Blue Owl Commercial Payment-Backed Loan Agreement, Delayed Draw Term Loan [Member]", "terseLabel": "Blue Owl Loan Agreement, Delayed draw term loan" } } }, "auth_ref": [] }, "xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails", "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining initial term loan from Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.", "label": "Blue Owl Commercial Payment-Backed Loan Agreement, Initial Term Loan [Member]", "terseLabel": "Blue Owl Loan Agreement, Initial term loan" } } }, "auth_ref": [] }, "xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "BlueOwlCommercialPaymentBackedLoanAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails", "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.", "label": "Blue Owl Commercial Payment-Backed Loan Agreement [Member]", "terseLabel": "Blue Owl Loan Agreement" } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostNet", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "label": "Capitalized Contract Cost, Net", "terseLabel": "Capitalized contract costs", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": ["r305"] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Unrestricted cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r121", "r617", "r672", "r695", "r818", "r847", "r959"] }, "xoma_CashAcquiredFromAssetAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CashAcquiredFromAssetAcquisition", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of asset during the period.", "label": "Cash Acquired from Asset Acquisition", "terseLabel": "Net cash acquired in Kinnate acquisition" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value",

"terseLabel": "Cash and cash equivalents", "totalLabel": "Total unrestricted cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r27", "r170", "r771"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r170"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1052", "r1053"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r28"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash as of the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash as of the beginning of the period", "terseLabel": "Cash, cash equivalents and restricted cash", "totalLabel": "Total unrestricted and restricted cash and cash equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r84", "r199"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r84"] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Unrestricted cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r959", "r1081"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Supplemental disclosure for the condensed consolidated statements of cash flows" } } }, "auth_ref": [] }, "xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to cash reserve accounts for interest and administrative fees and to cover operating expenses of subsidiary, established in conjunction with the funding of loan.", "label": "Cash Reserve Accounts, Interest and Administrative Fees and Operating Expenses [Member]", "terseLabel": "Cash reserve accounts" } } }, "auth_ref": [] }, "xoma_CashReserveAccountsInterestAndAdministrativeFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CashReserveAccountsInterestAndAdministrativeFeesMember", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to cash reserve accounts for interest and administrative fees, established in conjunction with the funding of loan.", "label": "Cash Reserve Accounts, Interest and Administrative Fees [Member]", "terseLabel": "Cash reserve account, Interest and administrative fees" } } }, "auth_ref": [] }, "xoma_CashReserveAccountsOperatingExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CashReserveAccountsOperatingExpensesMember", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to cash reserve accounts to cover operating expenses of subsidiary, established in conjunction with the funding of loan.", "label": "Cash Reserve Accounts, Operating Expenses [Member]", "terseLabel": "Cash reserve account, Operating expenses" } } }, "auth_ref": [] }, "xoma_ChangeInFairValueOfAvailableForSaleDebtSecuritiesCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ChangeInFairValueOfAvailableForSaleDebtSecuritiesCashEquivalents", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Change in fair value of available-for-sale debt securities classified as cash equivalents.", "label": "Change in Fair Value of Available-For-Sale Debt Securities, Cash Equivalents", "terseLabel": "Change in fair value of available-for-sale debt securities classified as cash equivalents" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r896"] }, "xoma_ChangesInEstimatedFairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ChangesInEstimatedFairValueOfContingentConsideration", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Changes in estimated fair value of contingent consideration.", "label": "Changes In Estimated Fair Value Of Contingent Consideration", "negatedLabel": "Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs", "terseLabel": "Changes in estimated fair value of contingent consideration" } } }, "auth_ref": [] }, "xoma_ChiefExecutiveOfficerInterimMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ChiefExecutiveOfficerInterimMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Person with designation of interim chief executive officer and Executive Chairman of the Board.", "label": "Chief Executive Officer, Interim [Member]", "terseLabel": "Executive Chairman of the Board and Interim CEO, Owen Hughes" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "CEO, Owen Hughes", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": ["r986"] }, "xoma_ChiefInvestmentOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ChiefInvestmentOfficerMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief investment officer.", "label": "Chief Investment Officer [Member]", "terseLabel": "Chief Investment Officer, Bradley Sitko" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r893"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r891"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r132", "r176", "r177", "r178", "r201", "r224", "r228", "r235", "r237", "r243", "r244", "r290", "r325", "r327", "r328", "r329", "r332", "r333", "r357", "r358", "r361", "r364", "r371", "r510", "r654", "r655", "r656", "r657", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r673", "r687", "r709", "r727", "r746", "r747", "r748", "r749", "r750", "r935", "r970", "r979"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r46"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [

"http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r372"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants to purchase shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r372"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [
"http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrant outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [
"http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r46"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r897"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r897"] }, "xoma_CollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CollaborationAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Represents about collaboration agreement member.", "label": "Collaboration Agreement [Member]", "terseLabel": "Collaboration Agreement" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Agreements", "verboseLabel": "Licensing and other arrangements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r469"] }, "xoma_CommercialPaymentPeriodDue": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommercialPaymentPeriodDue", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Period from each royalty payment date payment is due from customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Commercial Payment, Period Due", "terseLabel": "Period from each royalty payment date payment is due" } } }, "auth_ref": [] }, "xoma_CommercialPaymentPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommercialPaymentPurchaseAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Commercial payment purchase agreement.", "label": "Commercial Payment Purchase Agreement [Member]", "terseLabel": "Commercial Payment Purchase Agreement" } } }, "auth_ref": [] }, "xoma_CommercialPaymentReceivableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommercialPaymentReceivableTerm", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Term of commercial payment receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Commercial Payment Receivable Term", "terseLabel": "Commercial payment receivable term" } } }, "auth_ref": [] }, "xoma_CommercialPaymentThresholdOneTimePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommercialPaymentThresholdOneTimePayment", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.", "label": "Commercial Payment Threshold, One-Time Payment", "terseLabel": "Commercial payments attributable to net sales threshold" } } }, "auth_ref": [] }, "xoma_CommercialSalesReceivablePercentageOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommercialSalesReceivablePercentageOnNetSales", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Payments entity eligible to receive as a percentage of net sales.", "label": "Commercial Sales, Receivable Percentage On Net Sales", "terseLabel": "Payments eligible to receive (as a percent)" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and Contingencies (Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r66", "r110", "r616", "r686"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r91", "r319", "r320", "r754", "r998", "r1003"] }, "xoma_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies" } } }, "auth_ref": [] }, "xoma_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
"http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r836", "r837", "r838", "r840", "r841", "r842", "r843", "r974", "r975", "r978", "r1050", "r1112", "r1115"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r69"] }, "xoma_CommonStockPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockPremium", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "Common stock premium received on sale of common stock.", "label": "Common Stock Premium", "terseLabel": "Common stock premium" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's

charter and bylaws." } } }, "auth_ref": ["r69", "r687"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r69"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r69", "r687", "r706", "r1115", "r1116"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,755,223 and 11,495,492 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r69", "r619", "r818"] }, "xoma_CommonStockWarrantDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockWarrantDisclosureTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrants"], "lang": { "en-us": { "role": { "documentation": "Common stock warrant.", "label": "Common Stock Warrant Disclosure [Text Block]", "terseLabel": "Common Stock Warrants" } } }, "auth_ref": [] }, "xoma_CommonStockWarrantExercisePrice14.71Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockWarrantExercisePrice14.71Member", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Common stock warrant with exercise price of $14.71 per share.", "label": "Common Stock Warrant, Exercise Price 14.71 [Member]", "terseLabel": "Common Stock Warrants, Issued March 2019" } } }, "auth_ref": [] }, "xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Common stock warrant issued on December 2023.", "label": "Common Stock Warrant Issued, December Twenty Twenty Three [Member]", "terseLabel": "Common Stock Warrants, Issued December 2023" } } }, "auth_ref": [] }, "xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockWarrantsAtExercisePriceOf35.00PerShareMember", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants at an exercise price of $35.00 per share.", "label": "Common Stock Warrants at an Exercise Price of $35.00 Per Share [Member]", "terseLabel": "Common Stock Warrants, Exercise price of $35.00 per share" } } }, "auth_ref": [] }, "xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockWarrantsAtExercisePriceOf42.50PerShareMember", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants at an exercise price of $42.50 per share.", "label": "Common Stock Warrants at an Exercise Price of $42.50 Per Share [Member]", "terseLabel": "Common Stock Warrants, Exercise price of $42.50 per share" } } }, "auth_ref": [] }, "xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CommonStockWarrantsAtExercisePriceOf50.00PerShareMember", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants at an exercise price of $50.00 per share.", "label": "Common Stock Warrants at an Exercise Price of $50.00 Per Share [Member]", "terseLabel": "Common Stock Warrants, Exercise price of $50.00 per share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r902"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r901"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r903"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r900"] }, "us-gaap_CompensationRelatedCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsAbstract", "lang": { "en-us": { "role": { "label": "Stock Based Compensation" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": ["r98", "r100"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r24", "r182", "r184", "r190", "r610", "r628", "r629"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r35", "r36", "r52", "r53", "r255", "r753"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r35", "r36", "r52", "r53", "r255", "r651", "r753"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r35", "r36", "r52", "r53", "r255", "r753", "r943"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r55", "r126"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration of Risk", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r753"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r35", "r36", "r52", "r53", "r255"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r34", "r35", "r36", "r37", "r52", "r104", "r753"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r35", "r36", "r52", "r53", "r255", "r753"] }, "xoma_ConsolidatedFinancialStatementDetailAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ConsolidatedFinancialStatementDetailAbstract", "lang": { "en-us": { "role": { "documentation": "Consolidated financial statement detail.", "label": "Condensed Consolidated Financial Statement Details" } } }, "auth_ref": [] }, "xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815.", "label": "Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration, high-end of range" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "xoma_ContingentConsiderationFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ContingentConsiderationFairValueDisclosure", "crdr": "credit", "presentation": [

"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta
], "lang": { "en-us": { "role": { "documentation": "Contingent consideration, fair value disclosure.", "label": "Contingent Consideration Fair Value Disclosure", "terseLabel":
"Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value" } } }, "auth_ref": [] }, "xoma_ContingentConsiderationFromSaleOfAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ContingentConsiderationFromSaleOfAssets", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration to be received as part of
consideration in sale of assets.", "label": "Contingent Consideration From Sale of Assets", "terseLabel": "Contingent consideration from the Exarafenib Sale payable from
Pierre Fabre to the Company" } } }, "auth_ref": [] }, "xoma_ContingentConsiderationRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "ContingentConsiderationRegulatoryMilestonesMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Contingent
consideration under purchase agreements related to regulatory milestones.", "label": "Contingent Consideration, Regulatory Milestones [Member]", "terseLabel": "Regulatory
milestones" } } }, "auth_ref": [] }, "xoma_ContingentConsiderationSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930",
"localname": "ContingentConsiderationSalesMilestonesMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Contingent
consideration under purchase agreements related to sales-based milestones.", "label": "Contingent Consideration, Sales Milestones [Member]", "terseLabel": "Sales-based
milestones" } } }, "auth_ref": [] }, "xoma_ContingentConsiderationSalesMilestonesOneAndTwoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "ContingentConsiderationSalesMilestonesOneAndTwoMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Contingent
consideration under purchase agreements related to the first and second sales-based milestones.", "label": "Contingent Consideration, Sales Milestones, One and Two
[Member]", "terseLabel": "Sales-based milestones, first and second" } } }, "auth_ref": [] }, "xoma_ContingentConsiderationSalesMilestonesThreeMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ContingentConsiderationSalesMilestonesThreeMember", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Contingent
consideration under purchase agreements related to the third sales-based milestones.", "label": "Contingent Consideration, Sales Milestones, Three [Member]", "terseLabel":
"Sales-based milestones, third" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ContingentConsiderationTypeDomain", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "label": "Contingent Consideration
Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "xoma_ContingentConsiderationUnderPurchaseAgreements": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ContingentConsiderationUnderPurchaseAgreements", "crdr": "credit",
"presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Liability recorded for contingent consideration
under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes
contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent
consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current.",
"label": "Contingent Consideration Under Purchase Agreements", "terseLabel": "Contingent consideration under RPAs, AAAs and CPPAs" } } }, "auth_ref": [] },
"xoma_ContingentFutureCashPaymentsPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"ContingentFutureCashPaymentsPerProduct", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of
contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of
the liability can be reasonably estimated.", "label": "Contingent Future Cash Payments, Per Product", "terseLabel": "Contingent future cash payment for each product" } } },
"auth_ref": [] }, "xoma_ContingentValueRightsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"ContingentValueRightsAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Contingent Value Rights Agreement (CVR Agreement).",
"label": "Contingent Value Rights Agreement [Member]", "terseLabel": "CVR Agreement" } } }, "auth_ref": [] }, "us-
gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer,
Asset, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss for right to consideration in exchange for
good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r293", "r296", "r297", "r376"] }, "us-
gaap_ContractWithCustomerAssetAllowanceForCreditLossPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerAssetAllowanceForCreditLossPeriodIncreaseDecrease", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer,
Asset, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Amount of increase in allowance for credit loss", "documentation": "Amount of increase
(decrease) in allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than
passage of time." } } }, "auth_ref": ["r995"] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset,
after Allowance for Credit Loss", "terseLabel": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or
service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r374", "r376", "r387"] }, "us-
gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr":
"credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability",
"terseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is
receivable." } } }, "auth_ref": ["r374", "r375", "r387"] }, "xoma_ContractualObligationEstimatedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "ContractualObligationEstimatedMilestonePayments", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"], "lang": { "en-us": { "role": {
"documentation": "Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's
licensees. Represent contingent payments not recorded on balance sheet.", "label": "Contractual Obligation Estimated Milestone Payments", "terseLabel": "Estimate of
milestone payments" } } }, "auth_ref": [] }, "xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts": { "xbrltype": "integerItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "ContractualObligationEstimatedMilestonePaymentsNumberOfProducts", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"], "lang": { "en-us": { "role": {
"documentation": "Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.", "label": "Contractual Obligation,
Estimated Milestone Payments, Number Of Products", "terseLabel": "Assumed number of products per contract" } } }, "auth_ref": [] }, "us-
gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember",
"presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock
[Member]", "terseLabel": "Convertible preferred stock", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the
owner's option." } } }, "auth_ref": ["r357", "r358", "r361", "r840", "r841", "r842", "r843"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",

"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"],
"lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r159", "r160", "r203", "r204", "r337", "r359", "r540", "r560", "r614", "r773", "r775"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditConcentrationRiskMember", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk", "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement." } } }, "auth_ref": ["r104"] }, "xoma_CreditLossContractWithCustomerAssetPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CreditLossContractWithCustomerAssetPolicyTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.", "label": "Credit Loss, Contract With Customer Asset [Policy Text Block]", "terseLabel": "Allowance for Current Expected Credit Losses" } } }, "auth_ref": [] }, "xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold amount of cumulative royalties on net sales per product under the terms of the agreement", "label": "Cumulative Royalties On Net Sales Per Product, Threshold Amount", "terseLabel": "Threshold amount of cumulative royalties on net sales per product" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r88", "r255"] }, "xoma_DareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "DareMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Dare.", "label": "Dare [Member]", "terseLabel": "Dare" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Debt" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r21", "r59", "r60", "r107", "r109", "r205", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r785", "r786", "r787", "r788", "r789", "r816", "r971", "r999", "r1000", "r1001", "r1061", "r1063"] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Gross principal", "totalLabel": "Total payments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r21", "r109", "r351"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r334", "r519", "r520", "r786", "r787", "r816"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (as a percent)", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r62", "r354", "r519", "r520", "r816"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r62", "r335"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r205", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r785", "r786", "r787", "r788", "r789", "r816", "r971", "r1061", "r1063"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r21", "r205", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r785", "r786", "r787", "r788", "r789", "r816", "r971", "r999", "r1000", "r1001", "r1061", "r1063"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails",
"http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r21", "r42", "r43", "r54", "r94", "r95", "r205", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r785", "r786", "r787", "r788", "r789", "r816", "r971", "r1061", "r1063"] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt discount costs", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r1010", "r1060", "r1061", "r1063"] }, "xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount associated with allocated fees and lender expenses.", "label": "Debt Instrument, Unamortized Discount, Allocated Fees and Lender Expenses", "terseLabel": "Debt discount, allocated fees and lender expenses" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unaccreted debt discount and debt issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r340", "r352", "r518", "r519", "r520", "r786", "r787", "r816"] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Long-Term Debt", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": ["r9"] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [

"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Available for sale securities, Amortized Cost Basis", "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r988"] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestNoncurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Allowance for Credit Loss, Excluding Accrued Interest, Noncurrent", "terseLabel": "Allowance for credit losses on investments in debt securities", "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r301"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1010", "r1060", "r1061", "r1063"] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Allocated costs for the term loan commitment", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1060", "r1061", "r1063"] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Income, Current", "terseLabel": "Unearned revenue recognized under units-of-revenue method", "verboseLabel": "Unearned revenue recognized under units-of-revenue method, current", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r941"] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Income, Noncurrent", "terseLabel": "Unearned revenue recognized under units-of-revenue method - long-term", "verboseLabel": "Unearned revenue recognized under units-of-revenue method, noncurrent", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r941"] }, "xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan issuance of Common stock for services or claims.", "label": "Defined Contribution Plan Issuance Of Common Stock For Services Or Claims", "terseLabel": "Common stock contribution to 401(k)" } } }, "auth_ref": [] }, "us-gaap_DepreciationNonproduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationNonproduction", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Nonproduction", "terseLabel": "Depreciation", "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives." } } }, "auth_ref": ["r6", "r41"] }, "us-gaap_DerivativeGainOnDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainOnDerivative", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Derivative, Gain on Derivative", "terseLabel": "Change in fair value of embedded derivative related to RPA", "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r477"] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Directors", "documentation": "Person serving on board of directors." } } }, "auth_ref": ["r957", "r986", "r1113"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Stock Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r397", "r402", "r430", "r431", "r433", "r800"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r166"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by Sale, Not Discontinued Operations", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": ["r2", "r7", "r18"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r797", "r798"] }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendPayableDateToBePaidDayMonthAndYear", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividend Payment Date", "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format." } } }, "auth_ref": ["r29"] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsAxis", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends [Axis]", "documentation": "Information by distribution of earnings to shareholder. Includes, but is not limited to, distribution paid and declared." } } }, "auth_ref": [] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDeclaredTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockTables"], "lang": { "en-us": { "role": { "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of declared and paid cash dividends", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDomain", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Dividends Payable", "terseLabel": "Preferred stock dividend accrual", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": ["r60", "r65", "r108", "r844", "r1079"] }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends Payable, Date Declared", "terseLabel": "Dividend Declaration Date", "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format." } } }, "auth_ref": ["r29"] }, "us-gaap_DividendsPayableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableLineItems", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableTable", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "label": "Dividends Payable [Table]", "documentation": "Disclosure of information about distribution of earnings to shareholder declared but not yet paid. Includes, but is not limited to, total amount and amount per share of distribution, declaration date, and date to be paid." } } }, "auth_ref": ["r29"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r852"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r884"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r895"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails",

"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share attributable to common stockholders, Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r191", "r211", "r212", "r213", "r214", "r215", "r216", "r221", "r224", "r235", "r236", "r237", "r240", "r465", "r468", "r487", "r488", "r611", "r630", "r777"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share attributable to common stockholders, Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r191", "r211", "r212", "r213", "r214", "r215", "r216", "r224", "r235", "r236", "r237", "r240", "r465", "r468", "r487", "r488", "r611", "r630", "r777"] }, "us-gaap_EarningsPerShareDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Net Income (Loss) Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r224", "r228", "r235"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net Income (Loss) per Share Available to (Attributable to) Common Stockholders", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r31", "r32", "r239"] }, "xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable per discovery product candidate.", "label": "Eligible Milestone Payments Receivable Per Discovery Product Candidate", "terseLabel": "Maximum eligible milestone payments receivable per discovery product candidate" } } }, "auth_ref": [] }, "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfMilestones", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.", "label": "Eligible Milestone Payments Receivable Upon Achievement Of Milestones", "terseLabel": "Maximum milestone payments entitled to receive" } } }, "auth_ref": [] }, "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable upon achievement of pre-commercial milestones.", "label": "Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones", "terseLabel": "Pre-commercial milestone payments, maximum" } } }, "auth_ref": [] }, "xoma_EligiblePercentageOfRoyalties": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "EligiblePercentageOfRoyalties", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of royalties entity is entitled to receive on future commercial sales.", "label": "Eligible Percentage Of Royalties", "terseLabel": "Percentage of royalties entity is entitled to receive" } } }, "auth_ref": [] },
"xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "Eligible potential additional payments receivable upon achievement of specified future net sales milestones.", "label": "Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones", "terseLabel": "Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years" } } }, "auth_ref": [] }, "xoma_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "EmployeeMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Employee of entity.", "label": "Employee [Member]", "terseLabel": "Employees" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "verboseLabel": "Stock-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average remaining recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r432"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Stock-based compensation expense, not yet recognized", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r1041"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to stock options (in dollars)", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r1041"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r849"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label":
"Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",

"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r849"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r849"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r934"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r849"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r849"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r849"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r849"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r889"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r930"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r930"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r930"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r14", "r165", "r186", "r187", "r188", "r206", "r207", "r208", "r210", "r215", "r217", "r219", "r242", "r291", "r292", "r315", "r373", "r454", "r455", "r462", "r463", "r464", "r466", "r467", "r468", "r478", "r479", "r480", "r481", "r482", "r483", "r486", "r511", "r512", "r513", "r514", "r515", "r516", "r521", "r522", "r539", "r626", "r644", "r645", "r646", "r661", "r727"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r287", "r288", "r289", "r461", "r937", "r938", "r939", "r1042", "r1043", "r1044", "r1045"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Current", "terseLabel": "Short-term equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r173", "r509", "r772"] }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiMeasurementInput", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Measurement Input", "terseLabel": "Valuation assumptions, measurement input", "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r492", "r493", "r494"] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "Change in fair value of equity securities", "terseLabel": "Gain (loss) recognized due to change in fair value of investment", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r631", "r993"] }, "xoma_EquitySecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "EquitySecuritiesPolicy", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity securities.", "label": "Equity Securities Policy", "terseLabel": "Equity Securities" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r899"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r857", "r867", "r877", "r909"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r854", "r864", "r874", "r906"] }, "xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Estimated fair value of contingent consideration under asset acquisition agreements.", "label": "Estimated Fair Value Of Contingent Consideration Under Asset Acquisition", "terseLabel": "Estimated fair value of contingent consideration under the LadRx Agreements" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe", "documentation": "Continent of Europe." } } }, "auth_ref": ["r953", "r954", "r955", "r956", "r1117", "r1118", "r1119", "r1120"] }, "xoma_ExarafenibAndRelatedIntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ExarafenibAndRelatedIntellectualPropertyMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Exarafenib and related intellectual property.", "label": "Exarafenib and related Intellectual Property [Member]", "terseLabel": "Exarafenib and related IP" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r905"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta "http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r490", "r491", "r501", "r806"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r490", "r491", "r501", "r806"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r492", "r493", "r494", "r809"] }, "us-

gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r492", "r493", "r494", "r809"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r342", "r389", "r390", "r391", "r392", "r393", "r394", "r489", "r491", "r492", "r493", "r494", "r500", "r501", "r503", "r547", "r548", "r549", "r786", "r787", "r794", "r795", "r796", "r806", "r809"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r490", "r491", "r492", "r494", "r806", "r1055", "r1058"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r496", "r498", "r499", "r500", "r503", "r504", "r505", "r506", "r507", "r608", "r806", "r810"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r342", "r389", "r394", "r491", "r501", "r547", "r794", "r795", "r796", "r806"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r342", "r389", "r390", "r391", "r392", "r393", "r394", "r491", "r492", "r493", "r494", "r501", "r549", "r786", "r787", "r794", "r795", "r796", "r806", "r809"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r490", "r491", "r492", "r494", "r806", "r1055", "r1058"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r342", "r389", "r390", "r391", "r392", "r393", "r394", "r489", "r491", "r492", "r493", "r494", "r500", "r501", "r503", "r547", "r548", "r549", "r786", "r787", "r794", "r795", "r796", "r806", "r809"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r806", "r1052", "r1053", "r1054", "r1055", "r1056", "r1058"] }, "xoma_FairValueOfAssetsAcquiredMilestoneAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "FairValueOfAssetsAcquiredMilestoneAsset", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The fair value of milestone assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired, Milestone Asset", "terseLabel": "Estimated initial fair value of the Exarafenib milestone asset in Kinnate acquisition" } } }, "auth_ref": [] }, "xoma_FaricimabProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "FaricimabProductMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Faricimab-svoa, (VABYSMO) products.", "label": "Faricimab, Product [Member]", "terseLabel": "Faricimab (VABYSMO)" } } }, "auth_ref": [] }, "xoma_FinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "FinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "documentation": "Fair value of financial assets.", "label": "Financial Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r294", "r295", "r298", "r299", "r300", "r302", "r303", "r304", "r350", "r369", "r484", "r508", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r627", "r783", "r806", "r807", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r819", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r989", "r990", "r991", "r992", "r1051", "r1054", "r1055", "r1056", "r1057", "r1058"] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total financial liabilities", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": ["r1052", "r1053", "r1057"] }, "xoma_FirstRoyaltyInterestAcquisitionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "FirstRoyaltyInterestAcquisitionAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "First Royalty Interest Acquisition Agreement.", "label": "First Royalty Interest Acquisition Agreement [Member]", "terseLabel": "First Royalty Sale Agreement" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r861", "r871", "r881", "r913"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r861", "r871", "r881", "r913"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r861", "r871", "r881", "r913"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r861", "r871", "r881", "r913"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r861", "r871", "r881", "r913"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r894"] },
"xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Policy for future milestones, royalties purchase rights and commercial payments.", "label": "Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]", "terseLabel": "Purchase of Rights to Future Milestones, Royalties and Commercial Payments" } } }, "auth_ref": [] }, "xoma_GainLossOnAssetAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "GainLossOnAssetAcquisition", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Gain (loss) included in earnings resulting from the asset acquisition.", "label": "Gain (Loss) on Asset Acquisition", "negatedLabel": "Less: Gain on the acquisition of Kinnate", "negatedTerseLabel": "Gain on

the acquisition of Kinnate", "terseLabel": "Gain on the acquisition of Kinnate" } } }, "auth_ref": [] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) from Litigation Settlement", "negatedLabel": "Arbitration settlement costs", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": ["r780", "r1004"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r77", "r711"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r77"] }, "xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "HealthCareRoyaltyPartnersTwoLimitedPartnersMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "HealthCare Royalty Partners II, L.P (HCRP).", "label": "HealthCare Royalty Partners Two Limited Partners [Member]", "terseLabel": "HealthCare Royalty Partners II, L.P." } } }, "auth_ref": [] }, "xoma_IL1TargetLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IL1TargetLicenseAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "IL-1 target license agreement with Novartis.", "label": "IL-1 Target License Agreement [Member]", "terseLabel": "IL-1 Target License Agreement" } } }, "auth_ref": [] }, "xoma_ImpairmentOfLongTermRightsReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ImpairmentOfLongTermRightsReceivableNonCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.", "label": "Impairment of Long Term Rights Receivable, Non-Current", "terseLabel": "Royalty purchase agreement asset impairment" } } }, "auth_ref": [] }, "xoma_IncomeFromPurchasedReceivablesUnderEffectiveInterestRateMethodCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IncomeFromPurchasedReceivablesUnderEffectiveInterestRateMethodCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Increase in short-term rights receivable due to income from purchased receivables under effective interest rate method.", "label": "Income From Purchased Receivables Under Effective Interest Rate Method, Current", "negatedLabel": "Income from purchased receivables under effective interest rate method", "terseLabel": "Income from purchased receivables under EIR Method, Short-Term" } } }, "auth_ref": [] }, "xoma_IncomeNotFromContractWithCustomerCostRecoveryMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IncomeNotFromContractWithCustomerCostRecoveryMethod", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of income that is not accounted for under Topic 606, in accordance with the cost recovery method.", "label": "Income Not from Contract with Customer, Cost Recovery Method", "terseLabel": "Income from purchased receivables" } } }, "auth_ref": [] }, "xoma_IncomeNotFromContractWithCustomerCostRecoveryMethodAndEffectiveInterestRateMethodPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IncomeNotFromContractWithCustomerCostRecoveryMethodAndEffectiveInterestRateMethodPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income that is not accounted for under Topic 606, in accordance with the cost recovery method and the effective interest rate method.", "label": "Income Not from Contract with Customer, Cost Recovery Method and Effective Interest Rate Method [Policy Text Block]", "terseLabel": "Income from Purchased Receivables" } } }, "auth_ref": [] }, "xoma_IncomeNotFromContractWithCustomerEffectiveInterestRateMethodAndCostRecoveryMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IncomeNotFromContractWithCustomerEffectiveInterestRateMethodAndCostRecoveryMethod", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of income that is not accounted for under Topic 606, in accordance with the effective interest rate method and the cost recovery method.", "label": "Income Not from Contract with Customer, Effective Interest Rate Method and Cost Recovery Method", "terseLabel": "Income from purchased receivables" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r797", "r798"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r316", "r317", "r318", "r495", "r497", "r502", "r641", "r643", "r712", "r766", "r808", "r1083"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r317", "r318", "r495", "r497", "r502", "r641", "r643", "r712", "r766", "r808", "r1083"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r202", "r437", "r442", "r443", "r444", "r445", "r449", "r452", "r456", "r458", "r459", "r460", "r659", "r802"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r120", "r129", "r218", "r219", "r241", "r248", "r251", "r441", "r442", "r457", "r632", "r802"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r185", "r439", "r440", "r449", "r450", "r451", "r453", "r653"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Trade and other receivables, net", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Unearned revenue recognized under units-of-revenue method", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r767"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r944", "r967"] }, "xoma_IncreaseDecreaseInPotentialAmountPayableOnRegulatoryMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IncreaseDecreaseInPotentialAmountPayableOnRegulatoryMilestone", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in potential amount payable on regulatory milestone.", "label": "Increase (Decrease) In Potential Amount Payable on Regulatory Milestone", "negatedLabel": "Amount of regulatory milestone payment removed" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Shares issuable based on market price", "verboseLabel": "Effect of dilutive common stock options", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive

effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r225", "r226", "r227", "r237", "r401"] }, "xoma_IncyteImmunoOncologyAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "IncyteImmunoOncologyAssetsMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"], "lang": { "en-us": { "role": { "documentation": "Incyte immuno-oncology assets.", "label": "Incyte Immuno-Oncology Assets [Member]", "terseLabel": "Incyte Immuno-Oncology Assets" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r861", "r871", "r881", "r905", "r913", "r917", "r925"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r923"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r853", "r929"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r853", "r929"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r853", "r929"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Intangible assets", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r306", "r996", "r997"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r78", "r347", "r355", "r788", "r789"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Accrued interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r78", "r348", "r788", "r789"] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Long-Term Debt", "terseLabel": "Interest expense", "totalLabel": "Total interest expense", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": ["r113", "r132", "r133"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r194", "r197", "r198"] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "Equity securities", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r1052", "r1053", "r1057"] }, "xoma_JanssenBiotechInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "JanssenBiotechInc.Member", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails"], "lang": { "en-us": { "role": { "documentation": "Janssen Biotech, Inc.", "label": "Janssen Biotech Inc. [Member]", "terseLabel": "Janssen" } } }, "auth_ref": [] }, "xoma_KinnateCvrHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "KinnateCvrHoldersMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "Kinnate CVR (Contingent Value Rights) holders eligible to receive contingent consideration upon the closing of the Kinnate acquisition under the Kinnate CVR Agreement.", "label": "Kinnate CVR holders [Member]", "terseLabel": "Kinnate CVR holders" } } }, "auth_ref": [] }, "xoma_KinnateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "KinnateMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Kinnate.", "label": "Kinnate [Member]", "terseLabel": "Kinnate" } } }, "auth_ref": [] }, "xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.", "label": "Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC. [Member]", "terseLabel": "Kuros" } } }, "auth_ref": [] }, "xoma_LadrxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LadrxMember", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to LadRx.", "label": "LadRx [Member]", "terseLabel": "LadRx" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease costs", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r529", "r817"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease costs" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of cost components of operating leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r1065"] }, "xoma_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LeaseDisclosureTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreements"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Lease Agreements" } } }, "auth_ref": [] }, "xoma_LeasedFacilitiesEmeryvilleCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LeasedFacilitiesEmeryvilleCaliforniaMember", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Leased facilities in Emeryville, California with lease expiration date of July 31, 2023", "label": "Leased Facilities, Emeryville, California [Member]", "terseLabel": "Leased facilities, Emeryville, California, with lease expiration of July 31, 2023" } } }, "auth_ref": [] }, "xoma_LeasedFacilitiesSanFranciscoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LeasedFacilitiesSanFranciscoCaliforniaMember", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Leased office facilities in San Francisco, California, related to asset acquisition in 2024, with lease expiration date of June 30, 2026.", "label": "Leased Facilities, San Francisco, California [Member]", "terseLabel": "Leased facilities, Kinnate lease with lease expiration of June 30, 2026" } } }, "auth_ref": [] }, "xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LeasedFacilitiesTwoEmeryvilleCaliforniaMember", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Leased facilities in Emeryville, California, in different location than previous lease.", "label": "Leased Facilities, Two, Emeryville, California [Member]", "terseLabel": "Leased facilities, Emeryville, California, new lease - different location than previous lease" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Lease Agreements" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r527", "r538"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r527", "r538"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Existence of option to extend", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r528"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "verboseLabel": "Schedule of maturity of future rent payments associated with new lease", "documentation": "Tabular disclosure of undiscounted cash flows of

lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1066"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r536"] }, "xoma_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r536"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r536"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r536"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r536"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024 (excluding the nine months ended September 30, 2024)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1066"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Present value adjustment", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r536"] }, "xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of adjustment to right of use asset resulting from modification of operating lease.", "label": "Lessee, Operating Lease Modification, Adjustment to Right Of Use Asset", "terseLabel": "Adjustment to right of use asset for lease modification" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Period of lease extension", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1064"] }, "xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental cash flows information related to leases.", "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Summary of supplemental cash flow information related to operating leases" } } }, "auth_ref": [] }, "xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LesseeOperatingLeaseSupplementalInformationTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental information related to operating leases. May include, but not limited to, present value assumptions used in calculating the present value of the lease payments.", "label": "Lessee, Operating Lease, Supplemental Information [Table Text Block]", "terseLabel": "Schedule of assumptions used in calculating the present value of lease payments" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1064"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r21", "r59", "r60", "r61", "r64", "r65", "r66", "r67", "r201", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r472", "r475", "r476", "r510", "r685", "r778", "r847", "r1007", "r1068", "r1069"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r74", "r111", "r622", "r818", "r972", "r994", "r1059"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r61", "r169", "r201", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r472", "r475", "r476", "r510", "r818", "r1007", "r1068", "r1069"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementAndCommonStockPurchaseAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "License agreement and common stock purchase agreement.", "label": "License Agreement and Common Stock Purchase Agreement [Member]", "terseLabel": "License Agreement and Common Stock Purchase Agreement" } } }, "auth_ref": [] }, "xoma_LicenseAgreementConsiderationReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementConsiderationReceived", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "License agreement consideration received.", "label": "License Agreement Consideration Received", "terseLabel": "License agreement consideration received" } } }, "auth_ref": [] }, "xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of payments received upon achievement of financing activities during the period.", "label": "License Agreement Consideration Received, Achievement of Financing Activities", "terseLabel": "Payments received upon achievement of financing activities" } } }, "auth_ref": [] }, "xoma_LicenseAgreementConsiderationReceivedDebtRepayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementConsiderationReceivedDebtRepayment", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "Amount of license agreement consideration received as repayment of debt.", "label": "License Agreement Consideration Received, Debt Repayment", "terseLabel": "License agreement consideration received, repayment of debt" } } }, "auth_ref": [] }, "xoma_LicenseAgreementInstallmentPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementInstallmentPaymentsReceived", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of installment payments received during the period.", "label": "License Agreement, Installment Payments Received", "terseLabel": "Installment payments received" } } }, "auth_ref": [] }, "xoma_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "auth_ref": [] }, "xoma_LicenseAgreementNonRz358ProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementNonRz358ProductsMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "License agreement related to activities associated with non-RZ358 products.", "label": "License Agreement, Non-RZ358 Products [Member]", "terseLabel": "License Agreement, Non-RZ358 products" } } }, "auth_ref": [] }, "xoma_LicenseAgreementRz358Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementRz358Member", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "License agreement related to activities associated with RZ358.", "label": "License Agreement RZ358 [Member]", "terseLabel": "License Agreement, RZ358" } } }, "auth_ref": [] }, "xoma_LicenseAgreementSharesReceived": { "xbrltype": "sharesItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementSharesReceived",

"presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "documentation": "Number of counterparty's common stock entity received under the terms of the agreement.", "label": "License Agreement, Shares Received", "terseLabel": "Number of shares received" } } }, "auth_ref": [] }, "xoma_LicenseAgreementTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LicenseAgreementTransactionPrice", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "License agreement transaction price.", "label": "License Agreement Transaction Price", "terseLabel": "Transaction price" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r58", "r63"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt.", "totalLabel": "Total carrying value net of principal repayments, unaccreted debt discount and debt issuance costs", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r21", "r109", "r341", "r353", "r786", "r787", "r816", "r1080"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Less: current portion of long-term debt", "terseLabel": "Current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r174"] },
"xoma_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r205", "r345"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r205", "r345"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r205", "r345"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r9", "r205", "r345"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r175"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebt"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-Term Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r92"] },
"xoma_LongTermRightsReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LongTermRightsReceivableNonCurrent", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.", "label": "Long Term Rights Receivable, Non-Current", "terseLabel": "Long-term royalty and commercial payment receivables" } } }, "auth_ref": [] }, "xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "LongTermRightsReceivableNoncurrentDecreaseDueToImpairment", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Decrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment.", "label": "Long Term Rights Receivable, Noncurrent, Decrease Due To Impairment", "terseLabel": "Decrease in long-term royalty and commercial rights receivables due to impairment" } } }, "auth_ref": [] },
"srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r255", "r793", "r829", "r833", "r1013", "r1082", "r1084", "r1085", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111"] }, "xoma_MaximumConsiderationRetained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MaximumConsiderationRetained", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.", "label": "Maximum Consideration Retained", "terseLabel": "Amount of maximum consideration retained" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r134", "r136", "r138", "r139", "r141", "r163", "r164", "r321", "r322", "r323", "r324", "r395", "r435", "r494", "r576", "r640", "r642", "r650", "r677", "r678", "r733", "r736", "r740", "r741", "r743", "r764", "r765", "r782", "r790", "r799", "r809", "r810", "r814", "r815", "r830", "r1009", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075"] }, "xoma_MaximumPayableOnSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MaximumPayableOnSalesMilestone", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.", "label": "Maximum Payable on Sales Milestone", "terseLabel": "Maximum commercial sales milestone payments" } } }, "auth_ref": [] },
"xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.", "label": "Maximum Payments Based On Achievement Of Regulatory and Sales Milestones", "terseLabel": "Maximum regulatory and commercial sales milestone payments" } } }, "auth_ref": [] }, "xoma_MaximumValueOfStockToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MaximumValueOfStockToBeIssued", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount of stock to be issued.", "label": "Maximum Value Of Stock To Be Issued", "terseLabel": "Maximum amount of shares to be issued" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r897"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r897"] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "terseLabel": "Closing common stock price", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": ["r1054", "r1055", "r1056"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r492", "r493", "r494", "r809"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r492", "r493", "r494", "r809"] }, "xoma_MerckImmunoOncologyProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MerckImmunoOncologyProductMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"], "lang": { "en-us": { "role": { "documentation": "Merck immuno-oncology product.", "label": "Merck Immuno-Oncology Product [Member]", "terseLabel": "Merck Immuno-Oncology Product" } } }, "auth_ref": [] }, "xoma_MezagitamabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MezagitamabMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Mezagitamab antibody (TAK-079).", "label": "Mezagitamab [Member]", "terseLabel": "TAK-079" } } }, "auth_ref": [] }, "xoma_MilestoneAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestoneAchieved", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of milestone achieved.", "label": "Milestone Achieved", "terseLabel": "Amount of milestone payments earned under agreement" } } }, "auth_ref": [] }, "xoma_MilestoneAssetsIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestoneAssetsIncreaseDecrease", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825.", "label": "Milestone Assets, Increase (Decrease)", "terseLabel": "Increase in Exarafenib milestone asset" } } }, "auth_ref": [] }, "xoma_MilestoneAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestoneAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825.", "label": "Milestone Assets, Noncurrent", "positiveLabel": "Exarafenib milestone asset", "terseLabel": "Exarafenib milestone asset (Note 4)", "verboseLabel": "Exarafenib milestone asset" } } }, "auth_ref": [] }, "xoma_MilestonePaymentReceivablePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestonePaymentReceivablePercentage", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of milestone payment received by counterparty entity is entitled to receive.", "label": "Milestone Payment Receivable, Percentage", "terseLabel": "Percentage of milestone payment received by Kuros that company is entitled to receive" } } }, "auth_ref": [] }, "xoma_MilestonePaymentReceivedCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestonePaymentReceivedCounterparty", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.", "label": "Milestone Payment Received, Counterparty", "terseLabel": "Milestone payment received by Kuros" } } }, "auth_ref": [] }, "xoma_MilestonePeriodsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestonePeriodsNumber", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.", "label": "Milestone Periods, Number", "terseLabel": "Number of milestone periods" } } }, "auth_ref": [] }, "xoma_MilestonesPaymentsToAggregateAmountOfPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestonesPaymentsToAggregateAmountOfPerProduct", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement.", "label": "Milestones Payments To Aggregate Amount Of Per Product", "terseLabel": "Maximum royalty milestone payments to be paid per product" } } }, "auth_ref": [] }, "xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "MilestonesReceivableExcludingConsiderationRetainedMaximum", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones.", "label": "Milestones Receivable, Excluding Consideration Retained, Maximum", "terseLabel": "Maximum amount of potential milestones, potential royalties on sales and other payments receivable" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r134", "r136", "r138", "r139", "r141", "r163", "r164", "r321", "r322", "r323", "r324", "r395", "r435", "r494", "r576", "r640", "r642", "r650", "r677", "r678", "r733", "r736", "r740", "r741", "r743", "r764", "r765", "r782", "r790", "r799", "r809", "r810", "r814", "r830", "r1009", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075"] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [
"http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary, Ownership Percentage, Parent", "terseLabel": "Ownership interest (as a percent)", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r916"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta
], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1014"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r924"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r255", "r793", "r829", "r833", "r1013", "r1082", "r1084", "r1085", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r898"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [
"http://www.xoma.com/role/DisclosureDescriptionOfBusiness"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r123", "r130"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [
"r196"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r196"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r84", "r85", "r86"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations",

"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net income (loss)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r76", "r86", "r112", "r167", "r181", "r183", "r188", "r201", "r209", "r211", "r212", "r213", "r214", "r215", "r218", "r219", "r233", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r465", "r468", "r488", "r510", "r625", "r708", "r725", "r726", "r845", "r1007"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders, basic", "verboseLabel": "Net loss attributable to common stockholders, basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r192", "r211", "r212", "r213", "r214", "r221", "r222", "r234", "r237", "r468"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net loss attributable to common stockholders, diluted", "verboseLabel": "Net loss attributable to common stockholders, diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": ["r192", "r223", "r229", "r230", "r231", "r232", "r234", "r237"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "xoma_NonBayerProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NonBayerProductsMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Non-bayer products.", "label": "Non-Bayer Products [Member]", "terseLabel": "Non-Bayer Products" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r897"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r861", "r871", "r881", "r905", "r913"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r888"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r887"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r905"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r924"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r924"] }, "xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.", "label": "Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted", "terseLabel": "Ownership interest, if shares are converted (as a percent)" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "xoma_NovartisInternationalPharmaceuticalLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NovartisInternationalPharmaceuticalLtdMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details"], "lang": { "en-us": { "role": { "documentation": "Novartis International Pharmaceutical Ltd.", "label": "Novartis International Pharmaceutical Ltd. [Member]", "terseLabel": "Novartis International" } } }, "auth_ref": [] }, "xoma_NovartisPharmaAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NovartisPharmaAGMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "Novartis Pharma AG.", "label": "Novartis Pharma AG [Member]", "terseLabel": "Novartis Pharma AG" } } }, "auth_ref": [] }, "xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"], "lang": { "en-us": { "role": { "documentation": "Number of licensed products related to milestones and royalties purchased.", "label": "Number Of Licensed Products Related To Milestones And Royalties Purchased", "terseLabel": "Number of licensed products related to milestone and royalties" } } }, "auth_ref": [] }, "xoma_NumberOfMajorPartners": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NumberOfMajorPartners", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "documentation": "Number of major partners.", "label": "Number Of Major Partners", "terseLabel": "Number of major partners" } } }, "auth_ref": [] }, "xoma_NumberOfPartners": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NumberOfPartners", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of partners associated with programs.", "label": "Number of Partners", "terseLabel": "Number of partners associated with programs" } } }, "auth_ref": [] }, "xoma_NumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "NumberOfPerformanceObligations", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "Number of performance obligations.", "label": "Number Of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "auth_ref": [] }, "xoma_O2023Q4DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "O2023Q4DividendsMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "documentation": "O 2023 Q4 Dividends.", "label": "O 2023 Q4 Dividends [Member]", "terseLabel": "O 2023 Q4 Dividends" } } }, "auth_ref": [] }, "xoma_O2024Q1DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "O2024Q1DividendsMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "documentation": "O 2024 Q1 Dividends.", "label": "O 2024 Q1 Dividends [Member]", "terseLabel": "O 2024 Q1 Dividends" } } }, "auth_ref": [] }, "xoma_O2024Q2DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "O2024Q2DividendsMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "documentation": "O 2024 Q2 Dividends.", "label": "O 2024 Q2 Dividends [Member]", "terseLabel": "O 2024 Q2 Dividends" } } }, "auth_ref": [] }, "xoma_O2024Q3DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "O2024Q3DividendsMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"], "lang": { "en-us": { "role": { "documentation": "O 2024 Q3 Dividends.", "label": "O 2024 Q3 Dividends [Member]", "terseLabel": "O 2024 Q3 Dividends" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r116", "r779", "r981", "r982", "r983", "r984", "r985"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r530", "r817"] }, "xoma_OperatingLeaseFairValueBasisReductionInRightOfUseAssetsInAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "OperatingLeaseFairValueBasisReductionInRightOfUseAssetsInAcquisition", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Fair value basis reduction of right-of-use assets in in acquisition.", "label": "Operating Lease, Fair Value Basis Reduction in Right-of-Use Assets in Acquisition", "negatedLabel": "Relative fair value basis reduction of right-of-use assets in Kinnate acquisition" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Total net lease liability for operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r524"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel":

"Operating lease liabilities", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r524"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "negatedLabel": "Long-term operating lease liabilities", "terseLabel": "Long-term operating lease liabilities", "verboseLabel": "Non-current operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r524"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r525", "r532"] }, "xoma_OperatingLeasePaymentsNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "OperatingLeasePaymentsNonCash", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Operating lease payments, non cash.", "label": "Operating Lease Payments Non Cash", "negatedLabel": "Non-cash lease expense" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r523"] }, "xoma_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesInAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesInAcquisition", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities in acquisition.", "label": "Operating Lease, Right-of-Use Assets Obtained in Exchange for Lease Liabilities in Acquisition", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities in Kinnate acquisition" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate, Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r535", "r817"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term, Operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r534", "r817"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r60"] }, "xoma_OtherAntibodiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "OtherAntibodiesMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Other antibody technologies. Excludes TAK-079 (mezagitamab).", "label": "Other Antibodies [Member]", "terseLabel": "Other antibodies" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets - long term", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r171"] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Net unrealized gain on available-for-sale debt securities", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r4", "r13", "r103"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r79"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r897"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r859", "r869", "r879", "r911"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r862", "r872", "r882", "r914"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r862", "r872", "r882", "r914"] }, "xoma_OvapreneAndSildenafilCreamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "OvapreneAndSildenafilCreamMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails"], "lang": { "en-us": { "role": { "documentation": "OVAPRENE and Sildenafil Cream.", "label": "OVAPRENE and Sildenafil Cream [Member]", "terseLabel": "OVAPRENE and Sildenafil Cream" } } }, "auth_ref": [] }, "xoma_OvapreneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "OvapreneMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails"], "lang": { "en-us": { "role": { "documentation": "OVAPRENE.", "label": "OVAPRENE [Member]", "terseLabel": "OVAPRENE" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "xoma_PalobiofarmaSLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PalobiofarmaSLMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Palobiofarma, S.L.", "label": "Palobiofarma, S.L [Member]", "terseLabel": "Palobiofarma" } } }, "auth_ref": [] }, "xoma_Partner1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "Partner1Member", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "documentation": "One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.", "label": "Partner 1 [Member]", "terseLabel": "Partner 1" } } }, "auth_ref": [] }, "xoma_Partner2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "Partner2Member", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "documentation": "A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.", "label": "Partner 2 [Member]", "terseLabel": "Partner 2" } } }, "auth_ref": [] }, "xoma_Partner3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "Partner3Member", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "documentation": "A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.", "label": "Partner 3 [Member]", "terseLabel": "Partner 3" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r886"] }, "xoma_PayableOnMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PayableOnMilestone", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of milestone payment for each successive specified amount received. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.", "label": "Payable on Milestone", "terseLabel": "Payable on milestone" } } }, "auth_ref": [] }, "xoma_PayableOnMilestoneReturnThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PayableOnMilestoneReturnThreshold", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails"], "lang": { "en-us": { "role": { "documentation": "Return threshold for determining milestone payments under the agreement.", "label": "Payable on Milestone, Return Threshold", "terseLabel": "Return threshold" } } }, "auth_ref": [] }, "xoma_PayableOnMilestoneSpecifiedAmountOfEachSuccessiveReceipt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PayableOnMilestoneSpecifiedAmountOfEachSuccessiveReceipt", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails"], "lang": { "en-us": { "role": { "documentation": "Specified amount of each successive receipt that requires milestone payment to counterparty under agreement.", "label": "Payable on Milestone, Specified Amount of Each Successive Receipt", "terseLabel": "Specified amount of each successive receipt that requires milestone payment" } } }, "auth_ref": [] }, "xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PaymentOfConsiderationUnderAgreementsInvestingActivities", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",

```
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for
consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement
(CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent
consideration payments.", "label": "Payment of Consideration Under Agreements, Investing Activities", "negatedLabel": "Payments of consideration under RPAs, AAAs and
CPPAs", "terseLabel": "Payments of consideration under RPAs, AAAs and CPPAs" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock",
"negatedLabel": "Repurchases of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r82" ] },
"xoma_PaymentsForSeveranceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PaymentsForSeveranceCosts", "crdr":
"credit", "presentation": [ "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails" ], "lang": { "en-us": { "role": {
"documentation": "Amount of cash payments for severance costs.", "label": "Payments for Severance Costs", "terseLabel": "Severance charges paid" } } }, "auth_ref": [] }, "us-
gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation":
[ "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Dividends", "negatedLabel":
"Payment of preferred stock dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders
and noncontrolling interests." } } }, "auth_ref": [ "r82" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang":
{ "en-us": { "role": { "label": "Payments of Financing Costs", "negatedTerseLabel": "Debt issuance costs and loan fees paid in connection with long-term debt",
"documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r26" ] }, "xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PaymentsOfFinancingCostsFeesAndLenderExpenses", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan fees and lender expenses.",
"label": "Payments of Financing Costs, Fees and Lender Expenses", "terseLabel": "Fees and lender expenses" } } }, "auth_ref": [] }, "us-
gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based
Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement of equity awards", "documentation": "Amount of cash outflow to satisfy grantee's tax
withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r193" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire
Productive Assets", "verboseLabel": "Closing cash payment", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment
(capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r119", "r1047", "r1048", "r1049" ] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The
cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for
resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r81" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r896" ] },
"ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group
Total Shareholder Return Amount" } } }, "auth_ref": [ "r896" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid
Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r888" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO
[Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r905" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [
"r898" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } },
"auth_ref": [ "r887" ] }, "xoma_PercentageOfDecreaseInFutureRoyaltyObligations": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"PercentageOfDecreaseInFutureRoyaltyObligations", "presentation": [ "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails" ],
"lang": { "en-us": { "role": { "documentation": "Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.", "label":
"Percentage Of Decrease In Future Royalty Obligations", "terseLabel": "Percentage of decrease in future royalty obligations" } } }, "auth_ref": [] },
"xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "lang": {
"en-us": { "role": { "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.", "label":
"Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares", "terseLabel": "Sales commission paid per transaction (as a percent)" } } }, "auth_ref": [] },
"xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"PercentageOfGrossProceedsPaidToAgentForSaleOfShares", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "lang": { "en-us": {
"role": { "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.", "label": "Percentage Of Gross
Proceeds Paid To Agent For Sale Of Shares", "terseLabel": "Sales commission paid per transaction, preferred stock (as a percent)" } } }, "auth_ref": [] },
"xoma_PercentageOfProceedsPayableLicenseOrDisposition": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"PercentageOfProceedsPayableLicenseOrDisposition", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of net proceeds contingent value right holders
have right to receive within one year of the merger closing date under the terms of the agreement from license or disposition entered into by acquiree.", "label": "Percentage
of Proceeds Payable, License or Disposition", "terseLabel": "Percentage of net proceeds from any license or other disposition" } } }, "auth_ref": [] },
"xoma_PercentageOfProceedsPayableSale": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PercentageOfProceedsPayableSale",
"presentation": [ "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of net proceeds contingent value right holders
have right to receive until the fifth anniversary of the merger closing date under the terms of the agreement from sale entered into by acquiree.", "label": "Percentage of
Proceeds Payable, Sale", "terseLabel": "Percentage of further net proceeds from sale" } } }, "auth_ref": [] }, "xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization": {
"xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PercentageOfRoyaltyOnNetSalesUponCommercialization", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "lang":
{ "en-us": { "role": { "documentation": "Percentage of royalty on net sales upon commercialization.", "label": "Percentage Of Royalty On Net Sales Upon Commercialization",
"terseLabel": "Percentage of royalty on sales" } } }, "auth_ref": [] }, "xoma_PerformanceStockUnitsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "PerformanceStockUnitsMember", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock units
under a share-based payment arrangement awarded for meeting performance target.", "label": "Performance Stock Units [Member]", "terseLabel": "Performance Stock Unit
Awards" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation":
[ "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]",
"documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021",
"r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040" ] },
"us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]",
"documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023",
"r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040" ] },
"ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments
Prior Service Cost" } } }, "auth_ref": [ "r889" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]",
"terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r933" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r888" ] }, "us-
gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockDividendRatePercentage", "presentation": [ "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": {
"role": { "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate (as a percent)", "documentation": "The percentage rate used to
calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r358", "r734", "r737", "r739", "r744" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Preferred
Stock Dividends, Income Statement Impact", "negatedTerseLabel": "Less: accumulated dividends", "documentation": "The amount of preferred stock dividends that is an
adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsPerShareDeclared", "presentation": [
"http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel":
"Cash dividend declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding." } } },
"auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember",
"presentation": [ "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock
```

[Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r836", "r837", "r840", "r841", "r842", "r843", "r1112", "r1115"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r68", "r357"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r68", "r687"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r68", "r357"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r68", "r687", "r706", "r1115", "r1116"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r68", "r618", "r818"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r963"] }, "xoma_PriorityReviewVoucherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PriorityReviewVoucherMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Priority review voucher.", "label": "Priority Review Voucher [Member]", "terseLabel": "Priority review voucher." } } }, "auth_ref": [] }, "xoma_PriorityReviewVoucherSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PriorityReviewVoucherSale", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Amount representing sale of priority review voucher.", "label": "Priority Review Voucher, Sale", "terseLabel": "Sale of priority review voucher to undisclosed buyer" } } }, "auth_ref": [] }, "srt_ProFormaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProFormaMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Pro Forma [Member]", "terseLabel": "Pro forma", "documentation": "Information reported based on historical fact adjusted for potential activity. Includes, but is not limited to, information expected to be reported in future period for effect on historical fact. Excludes forecast information." } } }, "auth_ref": ["r162", "r220", "r936", "r940"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r25", "r654"] }, "xoma_ProceedsFromIssuanceOfLongTermDebtNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ProceedsFromIssuanceOfLongTermDebtNet", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer, net of fees and lender expenses and reserve accounts.", "label": "Proceeds From Issuance Of Long Term Debt, Net", "terseLabel": "Proceeds from issuance of long-term debt, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of options and other share-based compensation", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": ["r3", "r17"] }, "us-gaap_ProceedsFromSaleOfOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfOtherProductiveAssets", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Other Productive Assets", "terseLabel": "Cash consideration received", "documentation": "Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other." } } }, "auth_ref": ["r80"] }, "xoma_ProceedsFromUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ProceedsFromUpfrontPayment", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.", "label": "Proceeds From Upfront Payment", "terseLabel": "Cash payment received" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r143", "r144", "r145", "r146", "r147", "r148", "r161", "r252", "r577", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r769", "r791", "r828", "r830", "r831", "r834", "r835", "r958", "r1005", "r1006", "r1013", "r1082", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r143", "r144", "r145", "r146", "r147", "r148", "r161", "r252", "r577", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r769", "r791", "r828", "r830", "r831", "r834", "r835", "r958", "r1005", "r1006", "r1013", "r1082", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r167", "r181", "r183", "r195", "r201", "r209", "r215", "r218", "r219", "r290", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r465", "r468", "r470", "r473", "r474", "r488", "r510", "r612", "r624", "r660", "r708", "r725", "r726", "r804", "r805", "r846", "r966", "r1007"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r537"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r537", "r613", "r623", "r818"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r90", "r537"] },
"xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"], "lang": { "en-us": { "role": { "documentation": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.", "label": "Purchased

Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones", "terseLabel": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones" } } }, "auth_ref": [] }, "xoma_PurchasedPercentageOfEconomicsOfPrograms": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedPercentageOfEconomicsOfPrograms", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Purchased percentage of economics of early-stage programs.", "label": "Purchased Percentage Of Economics of Programs", "terseLabel": "Percentage of economics of programs acquired" } } }, "auth_ref": [] }, "xoma_PurchasedPercentageOfMilestones": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedPercentageOfMilestones", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of milestones entity has the right to receive as a percentage.", "label": "Purchased Percentage Of Milestones", "terseLabel": "Milestone payments entity has right to receive (as a percent)" } } }, "auth_ref": [] }, "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Purchased percentage of non-royalties on net sales of products.", "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products", "terseLabel": "Non-royalties to be received (as a percent)" } } }, "auth_ref": [] }, "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.", "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage", "terseLabel": "Future non-royalty payments to be received (as a percent)" } } }, "auth_ref": [] }, "xoma_PurchasedReceivablesCostRecoveryMethodNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedReceivablesCostRecoveryMethodNetCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchasedReceivablesIncomeTaxesAndShareRepurchasesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables related to income from purchased receivables under the cost recovery method due within one year or the normal operating cycle, if longer.", "label": "Purchased Receivables, Cost Recovery Method, Net, Current", "terseLabel": "Purchased receivables included in royalty and commercial payment receivables, Cost recovery method" } } }, "auth_ref": [] }, "xoma_PurchasedReceivablesEffectiveInterestRateMethodNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "PurchasedReceivablesEffectiveInterestRateMethodNetCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchasedReceivablesIncomeTaxesAndShareRepurchasesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables related to income from purchased receivables under the effective interest rate method due within one year or the normal operating cycle, if longer.", "label": "Purchased Receivables, Effective Interest Rate Method, Net, Current", "terseLabel": "Purchased receivables included in royalty and commercial payment receivables, Effective interest rate method" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r886"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r886"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r134", "r136", "r138", "r139", "r141", "r163", "r164", "r321", "r322", "r323", "r324", "r388", "r395", "r425", "r426", "r427", "r435", "r494", "r550", "r559", "r576", "r640", "r642", "r650", "r677", "r678", "r733", "r736", "r740", "r741", "r743", "r764", "r765", "r782", "r790", "r799", "r809", "r810", "r814", "r815", "r830", "r838", "r1002", "r1009", "r1055", "r1071", "r1072", "r1073", "r1074", "r1075"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r134", "r136", "r138", "r139", "r141", "r163", "r164", "r321", "r322", "r323", "r324", "r388", "r395", "r425", "r426", "r427", "r435", "r494", "r550", "r559", "r576", "r640", "r642", "r650", "r677", "r678", "r733", "r736", "r740", "r741", "r743", "r764", "r765", "r782", "r790", "r799", "r809", "r810", "r814", "r815", "r830", "r838", "r1002", "r1009", "r1055", "r1071", "r1072", "r1073", "r1074", "r1075"] }, "xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Decrease in long-term rights receivable due to receipt of royalty and commercial payments.", "label": "Receipt of Royalty and Commercial Payment Receivable Non Current", "negatedLabel": "Receipt of royalty and commercial payments, Long-Term", "terseLabel": "Reduction in long-term royalty receivable balance due to receipt of payment" } } }, "auth_ref": [] }, "xoma_ReceiptsUnderAgreementsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ReceiptsUnderAgreementsInvestingActivities", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.", "label": "Receipts Under Agreements, Investing Activities", "terseLabel": "Receipts under RPAs, AAAs and CPPAs" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r854", "r864", "r874", "r906"] }, "xoma_RegulatoryAndCommercialMilestonesReceivableMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RegulatoryAndCommercialMilestonesReceivableMaximum", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.", "label": "Regulatory and Commercial Milestones Receivable, Maximum", "terseLabel": "Maximum amount of potential regulatory and commercial milestones receivable" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails", "http://www.xoma.com/role/DisclosureLongTermDebtBalanceDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Debt", "negatedLabel": "Principal payments - debt", "negatedTerseLabel": "Principal repayments", "terseLabel": "Principal repayment", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r83", "r657"] }, "xoma_RepaymentsOfLongTermDebtAndInterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RepaymentsOfLongTermDebtAndInterestPaid", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Also includes interest payment of associated interest.", "label": "Repayments of Long-Term Debt and Interest Paid", "terseLabel": "Semi-annual payment, principal and interest" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r159", "r160", "r203", "r204", "r337", "r359", "r540", "r560", "r614", "r774", "r775"] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Research and

Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Capitalized Cost", "terseLabel": "Fair value of the IPR&D asset", "documentation": "Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": ["r312"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r436", "r766", "r780", "r1076"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r855", "r865", "r875", "r907"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r856", "r866", "r876", "r908"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r863", "r873", "r883", "r915"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "totalLabel": "Total restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r959", "r969", "r1077", "r1081"] }, "xoma_RestrictedCashAdditionalToBeFunded": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RestrictedCashAdditionalToBeFunded", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Additional amount of cash required to be added to restricted account.", "label": "Restricted Cash, Additional To Be Funded", "terseLabel": "Additional amount of cash required to fund reserve account" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAbstract", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Axis]", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": ["r56"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsideration

obtained in exchange for operating lease liability." } } }, "auth_ref": ["r533", "r817"] }, "xoma_RightsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivable", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial rights receivable. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable", "terseLabel": "Royalty and commercial payment receivable" } } }, "auth_ref": [] }, "xoma_RightsReceivableCostRecoveryMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCostRecoveryMethod", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable under costs recovery method.", "label": "Rights Receivable, Cost Recovery Method", "periodEndLabel": "Balance at End of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method", "periodStartLabel": "Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableCostRecoveryMethodAcquisitionOfPaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCostRecoveryMethodAcquisitionOfPaymentReceivable", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Increase in rights receivable due to acquisition of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, Cost Recovery Method, Acquisition of Payment Receivable", "terseLabel": "Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableCostRecoveryMethodImpairmentOfPaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCostRecoveryMethodImpairmentOfPaymentReceivable", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Impairment of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, Cost Recovery Method, Impairment of Payment Receivable", "terseLabel": "Impairment of Royalty and Commercial Payment Receivables, Recovery Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableCostRecoveryMethodReceiptOfPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCostRecoveryMethodReceiptOfPayments", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Decrease in rights receivable due to receipt of royalty and commercial payments under the cost recovery method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, Cost Recovery Method, Receipt of Payments", "negatedLabel": "Receipt of Royalty and Commercial Payments, Cost Recovery Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableCostRecoveryMethodReclassificationOfPaymentReceivablesFromCostRecoveryToEirMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCostRecoveryMethodReclassificationOfPaymentReceivablesFromCostRecoveryToEirMethod", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in rights receivable due to reclassification of royalty and commercial payment receivables from cost recovery to EIR method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, Cost Recovery Method, Reclassification of Payment Receivables from Cost Recovery to EIR method", "terseLabel": "Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, Cost Recovery Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableCostRecoveryMethodRecognitionOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCostRecoveryMethodRecognitionOfContingentConsideration", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Increase in rights receivable due to recognition of contingent consideration under the cost recovery method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, Cost Recovery Method, Recognition of Contingent Consideration,", "terseLabel": "Recognition of Contingent Consideration, Cost Recovery Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.", "label": "Rights Receivable, Current", "terseLabel": "Short-term royalty and commercial payment receivables" } } }, "auth_ref": [] }, "xoma_RightsReceivableEirMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableEirMethod", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment receivables under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, EIR Method", "periodEndLabel": "Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method", "periodStartLabel": "Balance at Beginning of Period, Royalty and Commercial Payment Receivables, EIR Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableEirMethodIncomeFromPurchasedReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableEirMethodIncomeFromPurchasedReceivables", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in rights receivable due to income (loss) from purchased receivables under EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, EIR Method, Income from Purchased Receivables", "terseLabel": "Income from Purchased Receivables Under EIR Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableEirMethodReceiptOfPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableEirMethodReceiptOfPayments", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Decrease in rights receivable due to receipt of royalty and commercial payments under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable.", "label": "Rights Receivable, EIR Method, Receipt of Payments", "negatedLabel": "Receipt of Royalty and Commercial Payments, EIR Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableEirMethodReclassificationOfPaymentReceivablesFromCostRecoveryToEirMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableEirMethodReclassificationOfPaymentReceivablesFromCostRecoveryToEirMethod", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in rights receivable due to reclassification of royalty and commercial payment receivables from cost recovery to EIR method. Includes both current and noncurrent rights receivable under EIR (Effective interest rate) method.", "label": "Rights Receivable, EIR Method, Reclassification of Payment Receivables from Cost Recovery to EIR method", "terseLabel": "Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method, EIR Method" } } }, "auth_ref": [] }, "xoma_RightsReceivableFromMilestonePaymentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableFromMilestonePaymentCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment receivables from milestone payment probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.", "label": "Rights Receivable, From Milestone Payment, Current", "terseLabel": "Short-term royalty and commercial payment receivables from milestone payment" } } }, "auth_ref": [] }, "xoma_RightsReceivableFromRoyaltyOrCommercialPaymentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RightsReceivableFromRoyaltyOrCommercialPaymentCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment receivables from royalty or commercial payment probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.", "label": "Rights Receivable, From Royalty or Commercial Payment, Current", "terseLabel": "Short-term royalty and commercial payment receivables from royalty or commercial payment" } } }, "auth_ref": [] }, "xoma_RoyaltiesPeriodMinimum": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltiesPeriodMinimum", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days", "label": "Royalties, Period, Minimum", "terseLabel": "Minimum period eligible to receive royalties" } } }, "auth_ref": [] }, "xoma_RoyaltiesPeriodMinimumScenarioOne": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltiesPeriodMinimumScenarioOne", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days", "label": "Royalties Period, Minimum, Scenario One", "terseLabel": "Royalty payment period from the first commercial sale of each royalty-bearing discovery product" } } }, "auth_ref": [] }, "xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Royalty and Commercial Payment Purchase Agreements" } } }, "auth_ref": [] }, "xoma_RoyaltyAndCommercialPaymentReceivableCurrentRecognitionOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyAndCommercialPaymentReceivableCurrentRecognitionOfContingentConsideration", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Increase in short-term rights receivable due to recognition of contingent consideration.", "label": "Royalty and Commercial Payment Receivable Current, Recognition of Contingent Consideration", "terseLabel": "Recognition of contingent consideration, Short-Term" } } }, "auth_ref": [] }, "xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "documentation": "Increase in long-term rights receivable due to recognition of contingent consideration.", "label": "Royalty and Commercial Payment Receivable Non Current, Recognition of Contingent Consideration", "terseLabel": "Recognition of contingent consideration, Long-Term" } } }, "auth_ref": [] }, "xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyAndCommercialRightsAcquiredNonCurrent", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",

"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights.", "label": "Royalty And Commercial Rights Acquired, Non-Current", "terseLabel": "Acquisition of royalty and commercial payment receivables, Long-Term" } } }, "auth_ref": [] }, "xoma_RoyaltyAndMilestonesReceivableThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyAndMilestonesReceivableThreshold", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold amount for royalties and milestones for determining amount entity has the right to receive.", "label": "Royalty and Milestones Receivable, Threshold", "terseLabel": "Threshold amount for royalties and milestones" } } }, "auth_ref": [] }, "xoma_RoyaltyInterestAcquisitionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyInterestAcquisitionAgreementsMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty Interest Acquisition Agreements.", "label": "Royalty Interest Acquisition Agreements [Member]", "terseLabel": "Royalty Sale Agreements" } } }, "auth_ref": [] }, "xoma_RoyaltyPercentageApplicableUnderAgreement": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyPercentageApplicableUnderAgreement", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of royalties applicable under terms of agreement.", "label": "Royalty Percentage, Applicable Under Agreement", "terseLabel": "Percentage of remaining royalties" } } }, "auth_ref": [] },
"xoma_RoyaltyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyPurchaseAgreementMember", "presentation": ["http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"],
"lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement.", "label": "Royalty Purchase Agreement [Member]", "terseLabel": "Royalty Purchase Agreement" } } }, "auth_ref": [] }, "xoma_RoyaltyPurchaseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyPurchaseAgreementTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements"], "lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement.", "label": "Royalty Purchase Agreement [Text Block]", "verboseLabel": "Royalty and Commercial Payment Purchase Agreements" } } }, "auth_ref": [] }, "xoma_RoyaltyReceivablePercentageOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyReceivablePercentageOnNetSales", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Royalties entity has the right to receive as a percentage of net sales.", "label": "Royalty Receivable Percentage On Net Sales", "terseLabel": "Royalties entity has right to receive (as a percent)" } } }, "auth_ref": [] }, "xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive, up to specified threshold.", "label": "Royalty Receivable Percentage On Net Sales and Percentage of Milestones", "terseLabel": "Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive (as a percent)" } } }, "auth_ref": [] }, "xoma_RoyaltyReceivablePercentageOnNetSalesFullyRetained": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyReceivablePercentageOnNetSalesFullyRetained", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty percentage entity has the right to fully retain which counterparty is entitled to receive upon reaching specified threshold.", "label": "Royalty Receivable Percentage On Net Sales Fully Retained", "terseLabel": "Royalty percentage entity has the right to fully retain" } } }, "auth_ref": [] },
"xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Royalties entity has the right to receive as a percentage shared with counterparty upon reaching threshold.", "label": "Royalty Receivable Percentage On Net Sales Shared With Counterparty", "terseLabel": "Royalties shared equally with counterparty (as a percent)" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r924"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r924"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "terseLabel": "Revenues", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r255", "r942"] }, "us-gaap_ScenarioAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScenarioAdjustmentMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Scenario, Adjustment [Member]", "terseLabel": "Adjustment", "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent." } } }, "auth_ref": [] },
"srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": ["r396", "r952", "r977"] }, "xoma_ScenarioOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ScenarioOneMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"],
"lang": { "en-us": { "role": { "documentation": "Scenario representing achievement of a pre-specified return threshold.", "label": "Scenario One [Member]", "terseLabel": "Upon achievement of a pre-specified return threshold" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r162", "r220", "r396", "r936", "r977"] }, "xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureLongTermDebtTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of accretion of debt discounts and issuance costs included in interest expense.", "label": "Schedule of Accretion of Debt Discounts and Issuance Costs Included in Interest Expense [Table Text Block]", "terseLabel": "Schedule of interest expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued and other liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] },
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of outstanding securities considered anti-dilutive", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of cash equivalents classified as available-for-sale", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash, cash equivalents and restricted cash", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",

"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r469"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r21", "r42", "r43", "r54", "r94", "r95", "r786", "r788", "r973", "r1061"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r980"] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": ["r30", "r33", "r224", "r228", "r235"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r49"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r49"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r287", "r288", "r289", "r461", "r937", "r938", "r939", "r1042", "r1043", "r1044", "r1045"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1052", "r1053"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of projected future principal payments of initial term loan", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r9"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table]", "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r19", "r105", "r1081"] }, "xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in royalty and commercial payment receivables.", "label": "Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]", "terseLabel": "Summary of royalty and commercial payment receivable activities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r398", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r15", "r16", "r99"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r102"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockTables",
"http://www.xoma.com/role/DisclosureCommonStockWarrantsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Common Stock Warrants Outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r46"] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "presentation": [
"http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Equity Securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r508"] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "presentation": [
"http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r508"] },
"xoma_SecondRoyaltyInterestAcquisitionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "SecondRoyaltyInterestAcquisitionAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"], "lang": { "en-us": { "role": { "documentation": "Second Royalty Interest Acquisition Agreement.", "label": "Second Royalty Interest Acquisition Agreement [Member]", "terseLabel": "Second Royalty Sale Agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b)

registered security." } } }, "auth_ref": ["r848"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r850"] }, "xoma_SecurityInterestInPercentageOfEquity": { "xbrltype": "percentItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "SecurityInterestInPercentageOfEquity", "presentation": ["http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The security interest provided by entity as a percentage of equity of specified wholly owned subsidiary under loan agreement.", "label": "Security Interest in Percentage of Equity", "terseLabel": "Security interest as a percentage of equity of wholly owned subsidiary" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r135", "r137", "r140", "r142", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r253", "r254", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r674", "r675", "r676", "r735", "r738", "r742", "r745", "r752", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r770", "r792", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r832", "r838", "r1013", "r1082", "r1084", "r1085", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111"] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "8.625% Series A Cumulative, Perpetual Preferred Stock", "verboseLabel": "Series A", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r961", "r962", "r1011"] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "8.375% Series B Cumulative, Perpetual Preferred Stock", "verboseLabel": "Series B", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r961", "r962", "r1011"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Severance Costs", "terseLabel": "Severance charges", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Derived Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r800"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r800"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "verboseLabel": "Number of PSUs (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r417"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Fair Value Per Share (in dollars per share)", "verboseLabel": "Weighted-average grant-date fair value of awards granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r417"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares, Outstanding at end of period", "periodStartLabel": "Number of shares, Outstanding at beginning of period", "terseLabel": "Number of shares, Outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r414", "r415"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Unvested PSUs", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price Per Share" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value of award outstanding (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r414", "r415"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r418"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted average assumptions" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r426"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified

period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r425"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r427"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-based compensation", "verboseLabel": "Performance Stock Unit Awards", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r398", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428"] }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum age required for employees to qualify for immediate vesting of award.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award", "terseLabel": "Minimum age required for employees to qualify for immediate vesting of award" } } }, "auth_ref": [] }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Calendar Days", "terseLabel": "Number of consecutive calendar days used to calculate volume-weighted average stock price" } } }, "auth_ref": [] }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of stock price hurdles in a share based compensation arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number of Hurdles.", "terseLabel": "Number of hurdles" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of shares, Exercisable at end of period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r408"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable at end of period", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r408"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options exercised, aggregate intrinsic value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r421"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of shares, Forfeited, expired or cancelled", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r1021"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r1021"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of shares, Granted", "verboseLabel": "Number of shares, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r410"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value (in dollars per share)", "verboseLabel": "Granted (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r420"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r47"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares, Outstanding at end of period", "periodStartLabel": "Number of shares, Outstanding at beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r406", "r407"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding at end of period", "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at beginning of period", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r406", "r407"] }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge": { "xbrltype": "durationItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age", "terseLabel": "Threshold years required for retirement age" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationRestrictedStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425",

"r426", "r427", "r428"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r411"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, Granted", "verboseLabel": "Exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r410"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche One", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche Three", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "terseLabel": "Schedule of performance shares, outstanding activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares." } } }, "auth_ref": ["r20"] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Schedule of grant date fair values of PSUs granted", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": ["r20"] }, "xoma_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionAggregateCostToBeRecognizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedPaymentArrangementNonvestedAwardExcludingOptionAggregateCostToBeRecognizedAmount", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Aggregate Cost To Be Recognized, Amount", "terseLabel": "Aggregate amount of cost to be recognized" } } }, "auth_ref": [] }, "xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants": { "xbrltype": "integerItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ShareBasedPaymentArrangementNumberOfAwardsGrants", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.", "label": "Share-Based Payment Arrangement, Number of Awards Grants", "terseLabel": "Number of award grants" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Stock price (in dollars per share)", "verboseLabel": "Price per share (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting (as a percent)", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r1015"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r424"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r47"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Remaining Term, Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r47"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "terseLabel": "Balance (in dollars per share)", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value Per Share" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Remaining Term, Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r101"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock under plan (as a percent)", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Purchase price (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Unrecognized tax benefits expected to change significantly over the next twelve months", "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date." } } }, "auth_ref": ["r118"] }, "xoma_SildenafilCreamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "SildenafilCreamMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails"], "lang": { "en-us": { "role": { "documentation": "Sildenafil Cream.", "label": "Sildenafil Cream [Member]", "terseLabel": "Sildenafil Cream" } } }, "auth_ref": [] }, "xoma_SiliconValleyBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "SiliconValleyBankMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"], "lang": { "en-us": { "role": { "documentation": "Silicon Valley

Bank credit facility effective May 7, 2018 and subsequent amendments.", "label": "Silicon Valley Bank [Member]", "terseLabel": "SVB Loan" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r132", "r176", "r177", "r178", "r201", "r224", "r228", "r235", "r237", "r243", "r244", "r290", "r325", "r327", "r328", "r329", "r332", "r333", "r357", "r358", "r361", "r364", "r371", "r510", "r654", "r655", "r656", "r657", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r673", "r687", "r709", "r727", "r746", "r747", "r748", "r749", "r750", "r935", "r970", "r979"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r69", "r72", "r73", "r165", "r186", "r187", "r188", "r206", "r207", "r208", "r210", "r215", "r217", "r219", "r242", "r291", "r292", "r315", "r373", "r454", "r455", "r462", "r463", "r464", "r466", "r467", "r468", "r478", "r479", "r480", "r481", "r482", "r483", "r486", "r511", "r512", "r513", "r514", "r515", "r516", "r521", "r522", "r539", "r626", "r644", "r645", "r646", "r661", "r727"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r135", "r137", "r140", "r142", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r253", "r254", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r674", "r675", "r676", "r735", "r738", "r742", "r745", "r752", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r770", "r792", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r832", "r838", "r1013", "r1082", "r1084", "r1085", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r206", "r207", "r208", "r242", "r522", "r577", "r652", "r673", "r679", "r680", "r681", "r682", "r683", "r684", "r687", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r701", "r702", "r703", "r704", "r705", "r707", "r710", "r711", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r727", "r839"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails", "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r162", "r220", "r396", "r936", "r940", "r977"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r206", "r207", "r208", "r242", "r256", "r522", "r577", "r652", "r673", "r679", "r680", "r681", "r682", "r683", "r684", "r687", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r701", "r702", "r703", "r704", "r705", "r707", "r710", "r711", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r727", "r839"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r858", "r868", "r878", "r910"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock related to ESPP (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r14", "r68", "r69", "r96"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details", "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of preferred stock (in shares)", "verboseLabel": "Shares issued (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r14", "r68", "r69", "r96", "r654", "r727", "r747"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "verboseLabel": "Issuance of common stock related to 401(k) contribution (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r14", "r68", "r69", "r96"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares, Exercised", "terseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r14", "r68", "r69", "r96", "r411"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock related to ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r14", "r68", "r69", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of preferred stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r14", "r68", "r69", "r96", "r661", "r727", "r747", "r846"] }, "xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details"], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.", "label": "Stock Issued During Period Value New Issues, Common Stock", "verboseLabel": "Issuance of common stock, fair value" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "verboseLabel": "Issuance of common stock related to 401(k) contribution", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r48", "r68", "r69", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r14", "r69", "r72", "r73", "r96"] }, "xoma_StockOptionInducementAwardOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockOptionInducementAwardOneMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to first Stock Option Inducement Award.", "label": "Stock Option Inducement Award, One [Member]", "terseLabel": "Stock Option Inducement Award, Exercise price of $18.66 per share" } } }, "auth_ref": [] }, "xoma_StockOptionInducementAwardTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockOptionInducementAwardTwoMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to second Stock Option Inducement Award.", "label": "Stock Option Inducement Award, Two [Member]", "terseLabel": "Stock Option Inducement Award, Exercise price of $30.00 per share" } } }, "auth_ref": [] }, "xoma_StockOptionInducementAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockOptionInducementAwardsMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Information

pertaining to Stock Option Inducement Awards.", "label": "Stock Option Inducement Awards [Member]", "terseLabel": "Stock Option Inducement Awards" } } }, "auth_ref": [] }, "xoma_StockPriceHurdlesOfDollar30Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockPriceHurdlesOfDollar30Member", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock price hurdles of $30.", "label": "Stock Price Hurdles of Dollar 30 [Member]", "terseLabel": "Hurdle Price Per PSU - $30.00" } } }, "auth_ref": [] }, "xoma_StockPriceHurdlesOfDollar35Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockPriceHurdlesOfDollar35Member", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock price hurdles of $35.", "label": "Stock Price Hurdles of Dollar 35 [Member]", "terseLabel": "Hurdle Price Per PSU - $35.00" } } }, "auth_ref": [] }, "xoma_StockPriceHurdlesOfDollar40Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockPriceHurdlesOfDollar40Member", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock price hurdles of $40.", "label": "Stock Price Hurdles of Dollar 40 [Member]", "terseLabel": "Hurdle Price Per PSU - $40.00" } } }, "auth_ref": [] }, "xoma_StockPriceHurdlesOfDollar45Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "StockPriceHurdlesOfDollar45Member", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock price hurdles of $45.", "label": "Stock Price Hurdles of Dollar 45 [Member]", "terseLabel": "Hurdle Price Per PSU - $45.00" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockStockRepurchaseProgramDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Authorized, Amount", "terseLabel": "Stock repurchase program amount authorized", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r1012"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockStockRepurchaseProgramDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Shares", "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r14", "r68", "r69", "r96"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockStockRepurchaseProgramDetails", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": ["r14", "r68", "r69", "r96"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r69", "r72", "r73", "r89", "r689", "r706", "r728", "r729", "r818", "r847", "r972", "r994", "r1059", "r1115"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Capital Stock" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStock"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Capital Stock", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r93", "r200", "r356", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r373", "r485", "r730", "r732", "r751"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r97"] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityPolicyTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Share Repurchases", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": ["r10", "r731"] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": ["http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sublease Income", "terseLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r531", "r817"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r517", "r542"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r517", "r542"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r517", "r542"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r517", "r542"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r517", "r542"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.xoma.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r541", "r543"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Sale of stock", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear", "presentation": ["http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern, within One Year [true false]", "terseLabel": "Substantial Doubt about Going Concern, within One Year", "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued." } } }, "auth_ref": ["r12"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r904"] }, "xoma_Tak079AndTak169Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "Tak079AndTak169Member", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Mezagitamab antibody (TAK-079) and TAK-169.", "label": "TAK-079 and TAK-169 [Member]", "terseLabel": "TAK-079 and TAK-169" } } }, "auth_ref": [] }, "xoma_TakedaPharmaceuticalCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "TakedaPharmaceuticalCompanyLimitedMember", "presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails"], "lang": { "en-us": { "role": { "documentation": "Takeda Pharmaceutical Company Limited.", "label": "Takeda Pharmaceutical Company Limited [Member]", "terseLabel": "Takeda Pharmaceutical Company Limited" } } }, "auth_ref": [] }, "xoma_TalpheraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "TalpheraMember", "presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Talphera.", "label": "Talphera [Member]", "terseLabel": "Talphera" } } }, "auth_ref": [] }, "xoma_TenYearWarrantsIssuedThirdRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "TenYearWarrantsIssuedThirdRangeMember", "presentation": ["http://www.xoma.com/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.", "label": "Ten Year Warrants Issued Third Range [Member]", "terseLabel": "Common Stock Warrants, Issued May 2018" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]",

"documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": ["r986", "r1067"] },
"srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
"http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionInducementAwardsDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]",
"documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r896"] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return
Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r903"] }, "xoma_TovorafenibMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "TovorafenibMember", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"], "lang": { "en-us": { "role": { "documentation": "OJEMDA
(tovorafenib).", "label": "Tovorafenib [Member]", "terseLabel": "OJEMDA" } } }, "auth_ref": [] }, "us-gaap_TradeAccountsReceivableMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAccountsReceivableMember", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"], "lang": { "en-us": { "role": { "label": "Trade
Accounts Receivable [Member]", "terseLabel": "Trade Receivables", "documentation": "Amount due from customers or clients for goods or services that have been delivered or
sold in the normal course of business." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]",
"terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r923"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading
Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r925"] }, "dei_TradingSymbol": { "xbrltype":
"tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.xoma.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an
instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation":
["http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": {
"label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to
exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other
financial instruments on potentially favorable terms." } } }, "auth_ref": ["r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269",
"r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r350", "r369", "r484", "r508", "r544",
"r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568",
"r569", "r570", "r571", "r572", "r573", "r574", "r575", "r627", "r806", "r807", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r819", "r945", "r946", "r947", "r948",
"r949", "r950", "r951", "r989", "r990", "r991", "r992", "r1051", "r1054", "r1055", "r1056", "r1057", "r1058"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r926"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role":
{ "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r927"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r927"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r925"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": {
"label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r925"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": {
"en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r928"] },
"ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
} }, "auth_ref": ["r926"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TreasuryStockCommonValue", "crdr": "debit", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchasedReceivablesIncomeTaxesAndShareRepurchasesDetails"], "lang": { "en-
us": { "role": { "label": "Treasury Stock, Common, Value", "terseLabel": "Treasury stock (in dollars)", "documentation": "Amount allocated to previously issued common shares
repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r44", "r45", "r72"] }, "xoma_TwistBioscienceCorporationMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "TwistBioscienceCorporationMember", "presentation": [
"http://www.xoma.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Twist Bioscience Corporation, \"Twist Bioscience\".", "label":
"Twist Bioscience Corporation [Member]", "terseLabel": "Twist Bioscience" } } }, "auth_ref": [] }, "xoma_TwoThousandEighteenAtMarketAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "TwoThousandEighteenAtMarketAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "At the Market Agreement, 2018 in which the
company may sell common shares.", "label": "Two Thousand Eighteen At Market Agreement [Member]", "terseLabel": "2018 Common Stock ATM Agreement" } } }, "auth_ref":
[] }, "xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname":
"TwoThousandFifteenEmployeeStockPurchasePlanMember", "presentation": ["http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"], "lang": { "en-us":
{ "role": { "documentation": "2015 Employee Stock Purchase Plan and subsequent amendments.", "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]",
"terseLabel": "2015 ESPP" } } }, "auth_ref": [] }, "xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.xoma.com/20240930", "localname": "TwoThousandTenLongTermIncentiveAndStockAwardPlanMember", "presentation": [
"http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "2010 Long Term Incentive
and Share Award Plan and subsequent amendments.", "label": "Two Thousand Ten Long Term Incentive And Stock Award Plan [Member]", "terseLabel": "2010 Plan" } } },
"auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis",
"presentation": ["http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsJanssenDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsKinnateAcquisitionDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisNis793Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsRezoluteDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsTakedaDetails",
"http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureFairValueMeasurementsMilestoneAssetAndMilestoneContingentConsiderationDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsDareDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPalobiofarmaDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"],
"lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative
arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r469"] },
"xoma_U.s.DepartmentOfDefenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "U.s.DepartmentOfDefenseMember",
"presentation": ["http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTalpheraDetails"], "lang": { "en-us": { "role": { "documentation":
"U.S. Department of Defense", "label": "U.S. Department of Defense [Member]", "terseLabel": "DoD" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"], "lang": { "en-us": { "role": { "label": "UNITED STATES",
"terseLabel": "United States" } } }, "auth_ref": [] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "USTreasuryBillSecuritiesMember", "presentation": [
"http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFvOnRecurringBasisAndExarafenibMilestoneContingentConsiderationDeta
], "lang": { "en-us": { "role": { "label": "US Treasury Bill Securities [Member]", "terseLabel": "U.S. treasury bills", "documentation": "This category includes information about
negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by
the full faith and credit of the United States government." } } }, "auth_ref": ["r1078"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": {
"label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury bills", "documentation": "This category includes information about debt securities issued by the
United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or
less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r776", "r794",
"r796", "r806", "r1078"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market
Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r922"] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "verboseLabel": "Unrecognized tax benefits",
"documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r438", "r447", "r801"] }, "us-
gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchasedReceivablesIncomeTaxesAndShareRepurchasesDetails",

```
"http://www.xoma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Income tax penalties or interest charged", "verboseLabel": "Accrued interest or penalties related to uncertain tax positions", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r446", "r801" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r448", "r801" ] }, "xoma_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "UpfrontPayment", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for initial payment under agreement.", "label": "Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r38", "r39", "r40", "r124", "r125", "r127", "r128" ] }, "xoma_VariableLeaseCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "VariableLeaseCostNet", "crdr": "debit", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases, net credit due.", "label": "Variable Lease, Cost, Net", "terseLabel": "Variable lease cost" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040" ] }, "xoma_ViractaTherapeuticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "ViractaTherapeuticsInc.Member", "presentation": [
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
"http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "lang": { "en-us": { "role": { "documentation": "Viracta Therapeutics, Inc. (\"Viracta\").", "label": "Viracta Therapeutics Inc. [Member]", "terseLabel": "Viracta" } } }, "auth_ref": [] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r892" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants for common stock", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r836", "r837", "r840", "r841", "r842", "r843" ] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Common Stock Warrants" } } }, "auth_ref": [] }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "verboseLabel": "Fair value of warrants", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": [ "r1052", "r1053", "r1057" ] }, "xoma_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "WarrantsPolicyTextBlock", "presentation": [
"http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants [Policy Text Block]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r223", "r237" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetIncomeLossPerShareDetails",
"http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r221", "r237" ] }, "xoma_XOMA052LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "XOMA052LicenseAgreementMember", "presentation": [ "http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details" ], "lang": { "en-us": { "role": { "documentation": "Gevokizumab License Agreement with Novartis.", "label": "XOMA 052 License Agreement [Member]", "terseLabel": "Gevokizumab License Agreement" } } }, "auth_ref": [] }, "xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember", "presentation": [
"http://www.xoma.com/role/DisclosureAcquisitionsLicensingAndOtherArrangementsNovartisVpm087Details" ], "lang": { "en-us": { "role": { "documentation": "XOMA-052 license agreement and IL1 target license agreement.", "label": "Xoma 052 License Agreement And IL1 Target License Agreement [Member]", "terseLabel": "Gevokizumab License Agreement and IL-1 Target License Agreement" } } }, "auth_ref": [] }, "xoma_XomaCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.xoma.com/20240930", "localname": "XomaCorporationMember", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "lang": { "en-us": { "role": { "documentation": "Xoma Corporation.", "label": "Xoma Corporation [Member]", "terseLabel": "Xoma Corporation" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r890" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479710/205-40-50-13" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
```

"220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r167": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",

"Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",

"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",

"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r553": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r877":

{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r935": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r936": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r937": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r938": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r939": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r940": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r962": { "role":

{"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 110 0001558370-24-014755-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-014755-xbrl.zip M4$L#!!0 (',\9UGB!A>(!R4 -_(0 1 >&!M82TR,#(T,#DS,"YX MKBK_M))Y*LB7;&Y9K!&CN^85*,?&P9+\!? M&3-WLT&;\8 I);9M7%%B+;%AG!P?_G!X?'AY81P<_,QQ7"$/VKB.P9&=`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|C!IG4V-R:TR>QL^CV1T M#)QMS-EK=PT3L6(;ZQ;?NUYC!HL(E'P^.\?GZ\G#T_/X5Y"[^SPV[B?3@=s\M M^(V\U:WMOC3G<|)0R=^+EOP=37\U;N\GOP!\C?EZ0SS3=KV 8O!L"7#A*4/L MR+&F9.F &60BQQ^9W/P&Q_H)V&<2[#&.L?^-_QV0+;(9&Z'), _; I#*!N^S; M#?81L2-A^&]J54K0Y3EL!"<@-.EPX \^(L-=&-DQ&W:2/I.-9=G1,@!-AH EQH^1",SAD%N MJN5&W%K*.?V(_3L'T!CX@G3Z0I17"X]O:%6R\^Y1'["[AM)$HS""(=AL'$8 M,!"#CV20H@HI&IF@NCW>JW=/3&9O.LM8'8PH11[F MEDE&>U\C2@GL+?]M=N(\8Q9X!HYPBP, QZ^(H@5VR/R!V& NN Y3.\S&",UF MCUB1BULB9^_()68?B>**1NTP4=M9(?-OB3:+1PZE|SL7AB-WD"^*^3!'MB#1TN*0PX](#^@Q'^;+/@'M?W5N+U* MFKX7#2V.RD@[@9_B? IA-;_//|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

*,FM22U=:\V+\LE+7 ^(!.#@X+?$&:QT'GOU=-MP+%4"+M=+Q3S,-N2&S/6;152_A-JB_N XPH'[,:G;F:C;B!<-@*Z"MH!\V"S MV38;':F9XJNMCDN+SHPP^[']5-,=H'GR2#E'I* [,QS65'ABE9F(ZG9L]MJR@V-M[9:&L&]Z=.S\\T1CZN$;Y,_NZ(P*5)TY;#=!F3%-ZZ-\CL[RX[P$!,V5*<$&;=,/_O2;P9@P_@U"C#MQ6*[Q9@RD4UI5,$&NV_=@5S:Q7'':Z8_19:QL:/ MTD(_KL;]DSJ:"'!!4ZZL*/T/ #&84@"_S'1W#XM<=-HD(>EP-S.DZAZ@09#7$ MLCP7N6FX<;%F[\4%/QO%+J.1. 3%<+MK5 @J.X-J<>@4BWQ1*2^PK-G/-MJQ M],.2AJ"[;WH\7I#\/ #X"(6M@U\'0GBNVEL<97GN+MJZ;@ K!QYPTU;$;0$% MRS7K&NX*)M\=I})%2.L/=3:6KM$GSOWE8+G8>3!'V?<5OZ](FY %P,-"G<> MD."F!,7).$O/L*R>8 G[4H%B:1M?((SB0(? H_??Z8C37%G"!5P4GM9+TN0O@ MVY57-,$#&@VF'IQI%$IN9K.V-8\?E7;7F_NS>-?O9Z25#F+_B MXEI F\ >AX6OX;'!X31Y0]EEGO-3LPNE:KQG?)H\W.%XFT9GR6QV:L(.D94+U M2WEW"BVE(F;$+(@?^-=MW*P5^9ANBJD5+D*JD.T72(KB>51,'-^_T5K\^CSR_1M^?S.'MJ^A*DG9AGC.JC:H(0^5L3\UTR4D'SL+\JHD>63X'X 9P6]>;9<'FN #*6\+ MBZ.*.TIBO" \;2OP3)EE4-.K&6TA=IG!6U;+MJ M#F'0!?5^R:07>#9V&NJ6:$@2Z^^X8Z!?K:*3;GXQ@SUVA:1%I9G1Z*=6"Y$?.MXMYEY2!R8$P8NYW6*VR3]T>H2?>5LBDOGEI#W!,8B7 F3@.C#\OC.MPA2%6H M2'DKB\Y6^>9+8\3-DGR1%OL\@^)MTS!MX6,-Q-?Q4=.S15EPP+''04]#TF+.M]0C%.T"P9V,?-=#X!YP"F;3:=^@):!0WFBP+!J[=- -7,#VD3[0@O92RR?"P+D5@4]#.D6*.M!5L7V-K-E*0#D8AE%.P)CSJ50JJB*+5&XI3D*=H\BZ)\//]@F0O+P<N_04F]Z@6+12O MIO=5H;7JV:.34TQ'5(.A H> MH[%;XGUE=N()UX>F=JB)1#<672*G32QSNGC[3\S# W2/5,Z#Z;4@@.M*IY*E&>DA*;J4WB0-(_P5Z9Z;@;+"[JNUH6I:5.>XYK!C)W!M.]Z)Q-V!$S* M#/QRPWV!;5MQU)R"UQU61=L], U."MHP&F#>.:"0 .X7]_F0W.![4M]&+NY M5V^2.X$!6154UB=&?:L*Y-<[MR?7"^6%XH',L M#[2>69D;(fLEQ;*FX^6%QD4"']?Y_L<2&&.O-,- G[\U)8U)B0FLI=WP6]DUH15DK MPU)O3A=K+SE\V<-82N#YLYB2ZY'6O)R!0[E*6_5HT"#K+++3PJ41*X,LCO8L$ M/O0LJQ]+8(QM8%7+!)%5QZGP3&$U(GISE%Z0B93 EPU\?@D|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

*61$C)S%UQ,9WZV"W]'"?>-"-.Z 1:Q/EC Z?5\).Q/VB09]J$GH M2[Q9?PZ:(E[M$N9X#1&'W,+F:"RPVM>Q)Q:.;4^\B]G.GSN:^,S,.%X,#YZ] M?10GH$7;_#&M MZD#'A_1>G:WBK*6&,:H)%]Y9QH\9Y*)^21V-RGYSF^XVDW;W=%=D=`!-M1T'[:HD:,G&:HA60<=B"/)42W57-BM0N%=UA-K+$[,-F#%]D,2Y($K/=Z&[MYVA#'/5\MY)(,! M(">)]GY=SOGH 2#3^B!f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`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|^YX:F[TSLK ,77ALX_B0F-I_K0\;IBW-;2L6$ M='GP&(,&,;%/FMBA? (<[%5%\I2GL[+X&N,I $>5\]3WHE(;)=-UW1/&L]?N MZ^&VZIP<)I3N9J ICKA*5IR52^\M8%BXM[O=&%]J2=5/3G;85$>5J\?OR\YMT)+*SY_ZAH65\G1H;8LUIO%?&IV MN,>;W#N^\$85S>VMYUK/KCO6NBKMB&)9BG7F;,:YQYKP#5]XW\#1,!?Q P0: M%C,>YF;=YT$]%1(fGKRVU?>#=8.G1:D_L'H9&?VW=UT(WD^.)C M+?UD[GGUZJZO@+-I* (YLMR)%$)I.Y\5,/32L:E(G\5CGN'WH[-WS]EO_5]>__MD2D8CBE#R_NS!X'B3IA(W__Y+_I!6?9,0 /N $0##$U6Q>[\9FO[7GR%0%%7O MAC38L7^:\/1EX],K%3+SPROI@QZC>8&'/`Y\>]I9E2508[8Q_!V!98?V'V1V MH1YTG\#2MTP$?;3V5G3S<'EK'!\9OHBB'KL]W]B'E:5!%,]"KJO?Z?&^\3 M]*^%]JG.?_ZX5UOJ'* (X=>X[_V-?]7P_WGO7_Q\0/70TO1_/_ZJE9+H3VL(-M](TWNK__UO&:/\U[ZL1K[N^C'__40%N#E-&A< EO7WW[_Q4]"8 O3_X8ZQ ME34(S-}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`N'A^\U[HU+%ZTM0U8:TlV$ /ZVC&9#G% M+O\.34PP_-TV(>B'}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~MM&)*A&V%(8-^@S+? ZK3C<,83B\AM$'F!VPVK9MI0Y?MGD5?44/K>-1IW36&Q MI[-QY0,_YS.1.:+%0'^B-DFG:S_VY6ED+RE]=69]0 YG+/U3]3LW(/N6<^X(GHU?3]E'CL6NJI:7,@D#N M43).%?MI?_3I-T9=0.09G 7=%8[AF5G]:OKXGI&(!'Q+0MIN(B1M@\U)SB5 M>[A>!67HU*2GHD]>./,;XB-P^;T^A]?R_?0*^@2IY==6WXNEUXQAVRYJK[R< MI4$!59W)N4E])))? +Z3NQ:03898CT#]MD\|O;4:P7E-N.&^K]4HJ4Q'(000F-08 M: YE'.N!V5]>9RL!#I2KE8EKR3DZN--*LF5)?RL!X?Y#)AU5@<[E)HH(GTOSF[-M(_%AD6.KW35/=4=6N?]2H'B5?2 5\,,2'-5/B873-#M1;-#UK]`M-_+FCMA:\A)Y2S-K/4@5@:6 $971C#;0] (P^]"F/]2NNZ=VEKNEOW5N7[!P MZA7Z)$K[B:I"ATSS|:ICFF:Z/][?AT?Q8B=7:)1U8T0"7&$0^IN=[U7B %$V#QR,$WZ3)$:2^_M[!%EC("_W=_0W? G?1-"7_TB6OY1+=_-&]C,4SZ1ZR2Z-)R6>G<,P[*%<@6I M^"&\H7P"#3T"=R ;ZD=B<1R,WDDQF%@WJ@.AG*.S7* !C%*2F60P+$S(3@ M1V 8'/O-#&/Y0L(PC[F!]4C.X1+]6ED1O!IE[:/)X&(;..3D3MML+O:LEKB[[283EPU"S,N?]^O]26-LL,:@69X2%\I^1/OD-TT4\ MY[,SQDYF4P)*JQ)=> !%@=I(/+0F;">?FN!:B]_&;*XK7/+P"*VUY'QO"2*G M_A0'J3:,TKN0;E/H>?IJ4D/NN>|<8"6^9+=YB>SB-WJ 8OJJ[J:%H&FX;G> M,&T< #9R5#Q7V@;5AHL+T(,W(\ X?"1T+0/; (@YL+9!LJ6LX-@S/U#@@#&Z6@ M;Q&5P)L%_W9P(V M&XU;[-V\Z-*O&PKH"O637>MW&QDEN[C]C'J%;W*O1W?B]BP>ABW/BVER 13SX()1QK+6ASEM(X6C$Z M<7$*$5I$AD^T6[!NK=4Z!%.^\SVK=N\OF^.P-,U;V=DW'C.(FWY@@?M>?'Z MSZ)Q@B:%+QH/L#D=2QBHMHT_*&K((DQ#QUQ"FU$0S>\S*H>G12'[M#H%,.!E MQ7N%%"_/6 !:..FS\IVAXLF/'7I* MS-H_9GV$..R/&2XR$T!HZ%F0 K*,#!2&>XQ<7[VGK\DI57X,EAFV'6&K!7]9)R^UZ M0+0;O/\5O!YR*PFN'#TR;3Y0J<"M(\^&D)KMCWSZW<!\$FEN#= MPT,^&8H,[K&[='FEO|/5'?SHC;[E]_A475<8M?SG9>+V9W#0!U))W#)[_%]7 MVN,(?4M?F9"17L=BU]7E2]+K[T\QGQW%5FSID-($^=TD(@_B_E14\EO+O+T4 M=R>I#0+*? 6$P5DA\+>FZS@&^S(3&C4(IPPD_'YU%/NT/4XN!["5Y M=PYR=_M*-T.]4.9R<4[5CL,,;[>F.;[7K?:43-\U:NUVN]R@&A[<5=:]Y9XKET&?4#W9W(WT\O$YY59&%>N M. <*,$3YPQKCL8)U/[^*]Z%"N\|9^&]#=E]_HRTO&N>]]_==S_7"_+V*L 'W8+P"^:CO[8 MPB>%6BA;V@U=02#DZ^JG2W7T"XQ=0&EY<;K6ZW!V? B)'0C&4%3Y9.I"+8_WO1ZZ8WA%+]W(0V3OW4'):L%P01&JY!:CHW-L7" MO=VKJ_,R4^[UQX-X=O+C'X.YB<;8FRC++55O.0[_>"<4W &7O7P.UIY\#!BW MO:MO*,/E]:=G1,'|R/>UTAC'Z,ZF!=079AR#M% #]N/\V@3,K&5\;20$?I5:?L5]\OJUUAH<.+(6ZK$!&,+0MUSD7Z]B0Y8? OG.882%@K"8\4)%G3;'V^N3"8#JF1@I_Z]5DCO%C'!ZH2 5]M(:[XZ,<_-3=":P%8 MT@NU>8DD!.N27QN&-9FNA^6$-K.U>B/[\N&F2/9D:T6S@/P37T']/S0GX3M_ MO3Y0LBG,X>LP'^^C=Y+!GGI-=IN@7C M,46)R'0X+,"_5F!ZGX>MZX*:.^VEY)O](X#&8+E?-* I<>A7SMD4J6JN525< U MVX\(_5I]7[I4+2SX- 1VJK(VS9R'G',47NZT)B;R("]8G2\6:6*Q);CO]%2SG MMB:$9B-$5[R;OIBS=F-[(7;+[3VKMQMLVKF*HOHS_N>3=6AO]S@AR:"?;M!C M]"V_]XPP&?;3)&6^99D U"4.^'AO!@_%O-W3K9=I+XRC;>49PK-!;%0X9 MYM5+Z(''95PEV^^O/>XL#A/T.;/MYMRO4.[ETKB@4DSDAGRMB=ZL[Y;9XFN;X MV!8OV3O=+ID*>]#GK\UYA.6@&6=5/R4-9G 6*#N=S%?/HM8>]@'I^Q@3KP "MOXYXT5O6[X"WVY_#[!KWN3@J]NW!/3M3^XX>^QBT-KM_!1#V^0Y? (7+U<0" MDRP54V)1$E/H%ZF4SZ6$FIA;S=)SH:#Q?H[(<>\)'Z"P O!N&^2 M>=+ $7=VTZOH\U6.T\MQG%TF2D;?0SK>C7OS-=!]Y\SF*Z9V M(:!UX@[Z&%,(#[L"'D:\^'Z$H,VX8LZ=Y=8/$X06G^WA5SNI54+((VHE2EE1 MK$DM/L;$XT? E5PF@(7X%*:D'H6U1P#V'(L&A[9WKX6CW8$^8^NGHP%%4=,LO M=R8F.]Q\WUF%B3@([PL"*!<(>!GA94?A9=';6)#0Z>+P M*+ (M$G+$#!$MGC9XL./$#.I5"H=E8F]^+5E1U2!4,MQB"Z..%V$'V\(7K=.X3;UPGC(05^AJU8X05!@>%"2LDK#!@ M^$)8(6&%_D.@T!#*9*E0KHI9]'FN(>+C!2>DB#AOD@E[Z#I<;'MO6"[4\9-\ MCY"VP(JG)"VX(D6V$M 4,7TY*V@@V$6P*!)USX]D*.+E.*2W52LG[["E] M?FYVP9ZA*=")* ST3^4,'*0, BQNQIB0Q $/0EZ$F87,*(3'(Y,?!=/2=^2P.I1:KXU$#FQ!* H9SSF2RD)NB3E2D6< K4HV!^E MG%1*%W6;)D!V!)HYB3H#^=P1 SIUUX=6F@ M+70ZJ@WE'D'D"I/DA5RI*K0@,- $O@G0IX+KL6K)<)C ;&)C=?!;B%1$T9167 M+P S%WS+#E)38,'7A&$E;X\PE&3;P(2:/P)C\)<)8]WN0MVQ @_&UPC *^G= M8"J"K'H>VY*%CZXEP46&TUPP0$40.*[%AX5+D'S &0H>,V'@%L/I\,,I#JMAJJ M9=+__BL>YO]0^,.^VHW!.,!:]$8]2);8#E/(".7!C M#DU5PURZ6PB]7\M2PIVZ!*B,*NVE^\W_+E1 M5]/1SS:T)Q#JE/UB.2XUKO50.RTJX9CZTE \16+ <==UV3T3NRI[%!P-MO MX.W)>]4F&#HD@G+7:I=&AR[O?RD<(\QWM;E6^%U@)>X=$_UCK,QD.1Q+(T=W MW&6>_#U(:,R3TS;N8BIW0ZTV5#(S_V*=A4? @E+/UGJ3F'N.,<6Y@_E&&^MOAOIW>++($.X:>B?6S9>O+7X0C WEP;H0SE@<'O-FWEK0J.&FGS!0"PE"0!?%@ +LHQ: M9J,64)(-= 68"MZ/5M0.ZI(7L7\9P"HEJ7"$)J .&%!% JL90U7&8KMQC_ZB MUD!=5K^X;^QOH.R%H>Q*F9%P;Z@J'$/=@53'-.;N9IM MBV/XR8= MRS8&T QL<,2.KL?H" '>X OML-E7 L=*OE!JFU57UY%/*2 3C&?$9=?=TM M L KI6:04J?0X;NB6ZOC&X6*NB^[B51+DL@-XB0RR+M3"-8U=TMAYQNV:8S M\'+>7#3DAED"N1<+N6'VALI#8 4WXG>K;W6"KH%!UUTNKOH0;R)<+[@FP R: M!%{O"U)=H2X"@"DA MQ>6H<]}E:I!N;<;FM%5X66>G-O3 M[\===H[MFN/)8S,Y2Q!['IV';=(&>C1PA;L=?-HWUG4,M"DRS\!Y7@J& K7 M0_4UPO.6*$M>#I2RJ2S0_(>R5 2E!U3M5? >K0N#1], BJDJ74@P,I@8 M^2+!U;H+NAE\$6>0<%D/'/SH9MRYH=RZ/I9BGG1;MZ67ZJLA)C(*OZ<;2]'ZG]MU=3 M@U;5S]_UZH)+OE[M4"V6.8%G86_M,KH@JD\YX1L X<<@X!+AL8N*^'$O1I9 MAU)6.U$KGO.?W80W$!3FIU0[C5KW_VZH51=UAS<,D!%3.YRVI;JJ."MV1%4 MQO:;$@JE8+&W:]Y87YX$I-!CG0[Z!:V5D6X.9A?HBRBG"UHPO^[\):3H(F%- MK^?A]Y-G70K2-JH$:8.$M&XV 9L.NXMGEQ1?,+A6/T,#?-TE@]T+LF N:]JL M)X1+X; ;CH7E.U6]AYYM_P==M HF_XRL"0Z?L;,OQP 2]F')*M1E>'$[0U]2 M:1P;,7U>KX,S$A<*X6%N[R[\?RS[(%VHF4]QO8](1B-M\&H%SW2[!U'7W4_< M0.L7E5F,EQ? Y>X.WQ;K!->$N,5S0S424\ M.-Y><FVU>T^X+<6Z\U!;P.5EW"*_ ^>.M#T(R9Q0*ZW7_]?0 M-W>. _]"7A#;Y4Z5*3"C2GKPHRFN<-X[0*R8\PTWBQGY=6Z(?W%]>!DEU'NI MWL@)]^'UL&M JH[CZL/3#1,5C=^G"G>ZJSE=!"VHS6YAO>6T"U=\$X=P_8 MGZFGNH-L42I.B4ZIC&$:%P&;LGP7Q<,Z$;*@/EE@7G[5KJE4A `Q[M,Q@<VS M\"TV%&**NZ$!*OBX M,7H-KE$KSRX%4*5RF2!]4! 5E^AGJ,=Z M%U*"'/Q"G@1PMRGLRI$D:EW6F,\R<2X<5.Q%+TFG I9P_\)-L;IX M2>R&L]$YP(5CEY'K.]2XY8F0X,X.U8!Y,ZYZ1M fFJ>_5:@XLOO;QC[^1:!_ M\!W !.,)?]:V-] J4;1PV7L9!8:8=V" P5T.K[LK@,S'@_I'*E2%G"'"F>C.N_ M5Y=Y!MR A36F<&$P^I KYFJ/RR,W!%$O"5%E W2=!17 ";8,D\H]4#]-B)AN M&U?=_N+A&__T] fHE@4_4U;%/WVX*]1=*(Q:I/:|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|P;P;ZQX,H!85^ MLWO:#%?1,L$8H(>@*_!VO@EPBN*OYH?UST"4@492NP4&B+&TVJK1P:>X".B5|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ÐH: 59FC^>X(Z]!K$M]=;#_QI3^IN!? MI=7>3M+FOIQU7T"MCU9@)'H9TU0*NHGCL&=5Z@$3DB/C@9]HE!?Q6:[X;B@(MY!YE0C0Y6=MD$(Q?S,T3=L]? (HH]M/$4![P:<9.9]\+[0N>N!3%<7-EWM M,)&5K).& !G8&Y\$\IJ;!IN2JB&Q@=[BGDD3@@'\!Y[!@^6O)W5#<+?^Q"P9@ M0]7 M)2U(;$O@\'@SFF6/.+V8EH7(UTKJL&!R7H;=#F>9??VHE!\!D)$@F'YAF(ZZ M*R.M;P!-@S,]?1+8H[;)LW-JP,5(?#E8NNB M^\>C%K[Nl;7#[@<(R$(O7F4*!!8^H]WF?L\">"""P4NQXD22&3XI6&^_M8%EH(;DC>X@'[=YY!|R1=$O(+*O:.+PSDIVY.]*5V_*1O;$8C/7:!;B@@ 6\ MZEH6N6JUU2;,<(*>9&BKGMU512S.U*%B7F1L=R'.>RE.*8RZ7__%0_5I+Q58"88VP2ZA=T16)V1Q4W0O-$!LHUP M*DON%S QF>9"#!?%C#7==5-/%HC,+8N!%,;0N)1*I0^G=S I2NO*M;6Q/Y?/*& M2D9VC;+&1,=.@5A%45%\N MC0XE: 9;"%T*_JHFHD-DKRTPR+L0&+4=I'G!*+SH,TFH%! @WCB"^+$\^TM9 MKV^;I=ZV&;,1#^%|%?;P9UK"'U)A:UNW!0HUB+_A@R$.I0 Z$ #],9FN0#MIF,-E(-LJRN>&8I@!X5A-Y(I/\$Q"2 .#A2[XMKATE@+);Z'-M]=7AWB%CH[3IX2_I0L.%? 9&1"@+(:)2##[!' ?;^&:D)$=\JLPBKR0*E,W3"*-M8HF6D?/9 -TXE+STZ,"I/"9/58"%D?S.T2&C\'*#-_LRJT&%/N:@2%KOL#0 MO/AA[(K81_U$3W<&ZZ+[V;'UJP"%8 M/&C_#N$ 3AM0DNXXQ/L+;>Y^-!7QZH M1J=NU+MFUHRI;%L5\SN2 &BO,D4)P$BE],H#B@5.5_/UI*+(S@',1; M\;@<;H7I>*<58[AV"P((VB "6'/4,_;#+EM9DZXJAOM\W]1-71G.J=K=C;UO^V-

UJPWN,?__Q4 M=42[#,=“1 ^G!)S$-WH)?S#W&\(S>5? S29V1;B8.U_UD37ZK05)H*0H05B M,=@*1WBN%5,@UX)QEH;MB,++\? &8M3DEAHOY;I.:Y 6I7RY05L%[5H1NRVF MQ;Z^4IK)H=$]5'OT:#RH9[*3E%F(5]“5D==7]M/WYEW)UIHJ?@\CSTW;“%1 M[!;8[6=VH!3KA6!\?”]-T^9DV'WH,#U\Y=8S2_;376O$M7(_$T^H#45K1B;U M2HMKT;^OU,+Q]C#*7@551*K8A/;%!*]YUT95;,\^E@%UH9AH/HHH;=>]*/FXX M5K<5WGZF5$E7YT;Tl53/M)O;(Z>;TV2^VXIL7]E+E&VY?\]W^G ZKXZ$DJ 6 M]0JZCVE6+78& J,Z3KVIAD^L8(S;O M=“W8]I6I6?HN&F*fT?I,%;LPF9,G:#^E**[V]9:4Q8UO1I)TL\@^%YV\.3FN M@TF+H;^DV/U4IHLWGMN67'D>H$N9J4N%$L+.r.H2X4[DM96NGF8./I MKH@T=(?HGR1;&5A&J$O#9D*]fQMY=2B@2W=(M)<3RHUI3###%#%)M]&+%OYR1 M0Y?N$&FS_U2BZX}/2;'T^-P7$K7)<_$!*?Z.|>_6DOUG=MB)]:6,6D^F6JB:FF<9L| CLNO04RE5%MF=FV^ZE6[HZRN7NZEP_DZC/GOB&S.59GBU_M6NP.P0Z'CVRVF{Y(=+,]YN|KB?N!$4>7LMN7YD>I>'G_/1,W\?-I“D/9T_/-MR%+9'3I@Y$-*256? GNHEI+KP^Z8'T.\?[IM@=RT(,!0M=@/=4(CJ9“”TXPX MP9=N=:,L9F97JS2>MW0=:.|[6EL1H(H]>>ND.SGAR8+<533L>]#LTTVD5Q_H3 MNG2'9B4X)5N[2X3+=1;$>FHBVLP]:Y46NT.SRKGF$[0[RE0<%)_8&LL/Q481 M7;I#+LT;CL,B,BWC^'&CJ(<,S<'6K #G6I<'0FUGEX&-&S7,W.EK1ATQR@ M<=VA+H5HI/“0E3L)6I+:98DO&.-^%@'P#N/.\8]AEAW>.31?2]\G^\;P=(^Q M>H<.)“(SOIG(]B)B:-@KO!\&%IPHZ-(=.B#|^YZ6=)*3S! MEVX;C#'F&Q97F(J\PZH2\09M0]#NRG33XXG28ZVXX4YBQJP M0[#-1GTLR<]“3H21O--*EAIHXD:7[A“LFA7FW:G!%/IL3G8:W6(\/F'1'+1# M6E/Y:9*<)TR&YL=,|>ZI/(MHDZ7*W&K$L[72[“2>(HE6MVEN2,`>-B-8Y)^JDH_U!SVI$P[88NRN@MNX8 M5VX8UU)V !W8;@WFC;$.Y7/HTMWC*L>;:T2K!53WKJZJZ);X5ZKG>FBPPCL, MYCGUS#S? Y1RUGC2B)<=]D)+20Q=?N]4N=B,TD#HI“S&;Y&.M)QQ^G!<%]-0=.MT[}3H^IS; PL.CD8SKED-X1>/3475!L3@=.93A61,93H>UHI;&80W-!>(=@:MS5Z+NS=Z]KP..C->&)7Z= [.9>^D69L4+M9:FWL%)?5#OJ\VFF'4]THNZE2\SR M]SGC9<.6/E./%^_U\?I>IL53^-AM[.W-FK65^-KS#?3,CF9,EGZOY=^AB0F& MOSU/SP2-T[L>EH7+:V,- #]66QWS.SPK]“T=W<>Y1;=-W5]|:G?2F%GFK# M$'] C)1V>W*1>3B/|DPMWR4R,6'#%]*E-]”_9S!*5A;^EPD-1E M69YTH3W,3FTAJ'fY=G-.5%TXVQ:DA!E.* <1$5(5QAL%QXSY3.,”YKEN1N7W[/0/EN+1+]BHK\ M^”?IF”8^X0+PT1?K]Q6L.+X=,ZY\#-[;.PLR&A#K(-9QV@V9(%M'4-9UNP># M/VCZ!%;/C?:.7\2]PY*ACH.%S3]NYK,AR+OB$,(MDZ_\>?5H]ZPV”TK8V\@'-M1X3ZKSI%'=/3.)L<3E?DZ*I=Q6<0<1;EEF0CVP*FTJI+J=9SKV&QD /Y>E-F MK=1XF.@+1=F7$0^Y)ZAFF';&@.*%*R“R%1EG$8#4S&R4B,KM:#Y,8(“CB=C5]65#6-X M7'@F=V!A)#44^!UD:E”_GVK/V0)3?A(;W1:/+53L]+$3]RNV 8,$W>&V=@@6G M(T]'@L% {!86.PS\]B(.\&ZX\T@^URCT& TR, ^).1(K\L&S[*D[”+RIY1%I0=-M4[55:)%EY@4N,X,P+,2!=0:*);KF+ZVL/STNJCM -904E>2#,W#Z4BJAE>EB MNA82A%84,ZQH+$)\501$_#$LQ(EU#FYV((KHTU*23E?:JLCG^A6)SG@*91A&C MB$O-F.OS5]5,H'C)P0R[!TW*A#)4QSC_@W5#Z=-F*]5 K52_Z,Q?'G4A'JK MT“=!EMU4?H*NE+ %5U\.N CM_8M4H3SHS\/#HU^,:RM#+]S68%G&V=OP_M\- M'3X]HR)0<%500!Q4)R=!6\]6”YJ@W“,=&;+(N94/#;B47S?0%C 6\BP5TF+BL M7FWM+:,I:N6%6QF 35D%&C4$,S/#$P0DF+B%;UCF@%7.*PN 8L(0Z+X.#&=V4)>!,X6J(FIM-8415GTVP*=O+96&$RP<#!__B' MOV'H*TR@5#:-(6J_%UN-4P,,<4@0L6O*69W^“0G$4I? <“-9[ME#>BVH“OB MTGR+<“]\G>]D3KPUZ_;OH]93;3(;Y+-IQ)O“F#=O!QPZ(?9/[-]';IB@V/\I MPV0^! #WQ9 Z2[;T2CVC3XH/G<=D7RBZ (#X#WNRV&6_K H.XD,E-*# 1@VB M-@L2+E.%3(Z(0?]08)E+G8Q&81A(8ZI,Y“L%2#D,1ZX97H=GM$*I]284G_4ET:ONAY):Z#;8MQ0W1+/)\!!_U3DVXT?Q0:=)=9 M0QC4@:0_M,MW>KXNNGB'2!L7C5V?RVIMQ_!L>0&N'#JN;2U+?%DG/^/1 0)\,“E\PPM-DO-1KY?B_=G(;2:=9. 1\(W+!TE+BT“ \2E M%0AZ]'DJ,?[1:;;Z L8!1) BT9MXY(#T'E? @V1*GP 0= MJ*MM“KT:6K;A+SQ:U,^B84,J_($2TF0I&IBE]-] E'BQOIM>%9:F[AWN>#-&M(NRXW?,0Z;43PIA77F*BT(63EJ,F_B:NV$.V28@J$%0@P17[40-K!L,&^BB M\H=MH[D)@+S],BI$:8C84=AE0Q9@\'4'20)T@41CY=Y^2=3Q)L^H,“FMI#_$ M6_2HVF?CE4AJ,&ZC5+LB(7:<.WU.1H(=9S<5/V$'2?MS_KVQ \%#“CV:C6':1CHGB]$Z;PRS*0[C0JR#6,^SI?Q*K\n8MXW3ET M#R56ZGK:XW__;6+A6,X1*A/<^9MH#S$KW\;2!&ZB]Z_':!$*3&D]-M<(=-A=9OPOT)]R:Y*?W9J'28CDO&)/A2 D@-A@^-MVH.7C7!HG34A4W!YZK#^A7]EH6K!M* M$//!S)^29?3!T3D366+Z8(D9A&$ASJKO)F O^)!R8\H]8$&A:T*(M\SKNBB37!78[^CS]MNN.K<;UZ%!B4@YB8Q&O)A1]2&D7 B\$7BXU_“0H\'(B M:O=E?$G6Y“@3,4ILW:EC9V' B5)TVL7X@GA>]#!\N32/U^M2“6O^+K+2#=1* M-PAC0%Q@WUOI8+G\G>U?_,HANY“<\!-.?9!J5NLlH$9#.B)=;@;>,*DH16#A M N^0=@@(+WU6QX_]8*_7%@54JARN%<%YR*A@7<'J6 V#A“CQB=1T“ M4X<+9<(QU!VBQ4871U=HBR<6E#MK0?_6H10R'+U@M.@2 M0^Y3BCI6$4 H%,!;P4 C85MDP4K\6$'A4>M!'“O+EK!AIQ9VO1\=X^UN3GVX MDXS;$-H%M-WB%,MTA%SA\1Q$&P@V$“<63ZE2U\A^=“/)>)“D 21X,D M#],@E(O5NQ@<~(/!X0I<6LMS^4/#=#7!Z+AU'[Q2G0ILVV05ZH_\H-^:U3P(MPW9@O^0?M3MYA0M:]U$Q?&; M&,L39QB!H6 ,VX'IBPD,?:N#[3 ^TC%2CD[7Q-9.TQ“2]XEJ M+3&I“ {A)^ @DSAL1 _!“P@.7GNCHH{“ZSTQ.@0[“ !4N.YOK45'%VH6&Y,P? MF&X78P'VD<5OPO$X<9)}>[+*QW+_'GQJ9%U+ GJ()%@E\B^-F,ZWBR%F.TP%3P5<.ZZ,W8 [!+ <(+A!@L$%N@:Il #BC6T;$.'KOQVYJfX M631L2(5_!6U)&P3PO/(Q(-ZN;ZE*L@C!\D3-W?/“?'5.;9@CV_BHTR]B=2 M(3$FP+G&Q%H1A(8X?_Z1@=>)- \5)MPVM5*=WK=*4S2.EL76HV0T.+DN#0 @8B03U14#ZV^Z@<2C2SD8*AB@]/H7KHUAI'ZWQ.FI MX1DZ=D-_PZ[&(=R!C“)`0A.R720#%]T1=!:?%$&;$.8AW?$UYT1NL(MME_D(+:4- 8#U7;KVW@UI8!CS(.,)BF1GZZ.',9/U“@@-\&V\4W/F8Z\Q M*\[_&W 1B(M\W8F1)3$@_(?UD24RL@U@'61)?I)+83?_<,S0%FI9[$“GZAX(C M!P\/X>N$KY-EL(\'BI@5,2NR##[NY.W?TQ&*ZRD,'],/S$#@1C**I\,O4@E-N3DM8]IRJZXVT)CMTS3-0O9>?0S[*P MUU?,4+((&&O:94;_GJTO;5*;2=;]?G\%3GGQDS+JER>RLRJK S7XIZ]W.)?30&? MM?!LH^E(“W4#“6W7V58X“7@8RXHE,3 ,%[]>3/M.C*HI7^?SXB'+[_<80'X# M9/^ =0#K -F_V\O^/-]0Z)DN29A&N@R%+7?-PS.73Z>(,#G9WN>F3^X/-]+3 MFV$R(B,G?VP:/'+. fMT*N71BBWLXG*0$L6“4W@6[M^-O%/E*_]CH'MK M/9)\X6#JD6(QO$C5%$\“99:*WL)>>A%IXDGV+N8:OY+!7SEXL-H8\G5DW MF1+=13%@$5EKC28Q7&YGS_?T?INM6,'61VI? R_#U8(?CC9N)#5B!N(G XTQS MA+R8_@K?(UCG.TQ9+*04*N[=NG#WM33G*_T9_+L.W)//OCO9SJ0)V;4V}]. M>JF;!LZ&“I%H#(U3GA)TX3G\0JL9&JM+- M>L;QVI9&V“B6X6XZ&=“_YW'OX*+Z<=Y,\ZI'++)K14H>ME“;^_O[S2_6-WW}'F:4_4^?8E,EL[K$2P9-;?,OJP\Y.F)@R M7C;LP$&W“H!$5\(6\%KALXJD7\N9NP 4'5M'EF^-I98# [6S+Z9#'W0 >%U!$ M/@^*;NB8_5VDQ.IG=:=/KXW##]\?'4_9)_[0W6)TXTU2-TRT“68#-O*D^5QU-MCMVVM8ZLOSU_?_N4V'F^\LW6)$TUQG):'2Y.UA$.&S;[%GP=#5IL$“W;'5]9 M(=+>'JY1W1L7*3&>.OF46/V]H\3.BSOKM@>0UUP8O-?V#)AL#X*Q/WI-?(YS MA+#V-IF0L%“?-Y;ML&/.J>M.29QGX5RPE%T2'W>(]P9*TV]HT6_*OYW8/ MOQ)>22TF. P'6]7CLE>9$GLK)?O)4L>RA@WTT%VO82'.ZAB+,CQX8@+|>Q[W MND-_KD*0;3LIVH5DK,X*CD9YIX4$“3%P?P#<'IB^VS5_%TY“L.Y\]AXZ.>%+ MN_R/C T:Q*&^7N/.8>RJ1W.'0%.*/1X50*C;_2(#_“O2(N\,LU MK5W]/<2,CY9SUNDT]L-.P+.3@2-PP2RL3U0#0E[W'L !EO=+/4X=F^H,.H?L M@';ZST^]O{]?_G=LW$,.LA+ <9,8+TG@7)9BXFM5?E8W2P//;[7@&\)79,\YW# M<“:4. M\SNNQ4!“D0$B[F 8 S$D.,]OJ/,:W-BK[*_/?\6K1+M&QZ0E2:MZO?8[“K]6F#)P))? [17WV[/DP68H'0+2EF#/TD)VAYU =<;\2DN^H3/I9Y7. M%^^^!OZOA9\W63=_6NBO%XLCR6[OC+3.'(9&:U1=RD8@BW]['9:E1?._RP0\ M)? NM>,&_QBDO_2.YAK<(FOFL;'7X>I7Q%-N!MM>TUK?]OU&V4,3CAT*%:4DM9&I#;FVY[M\W>“>#_1MV9XU“F=UEBGI3=Q,5F9;C\\Z1O.$/FO%P>[%TY?W=7R04-=+>[% MN0=PU@K.6J_Y\L.M7*6_6'/#1[CTHPOPBA!+R8OL9[2NHM)/BB[_>.5Y>ZK MI=<4M;B@UD6B>*H]32#Y+'AXWRC_V:G2N&96E U%2E=%HFEA[KA6+FWQSK6O%3 M&;F5A],& [2N^.I>)R?NWV^+/N0:\,2^P1S:;AC\RV2IS7-O7(>OTY@H“P__] M[R0(2X5Y GGYQ_G8_T2*M',:/H/?\V#?6G%$]NFUV-+UY+ZT]:%R];ZR],Y\ MM6;E?[O6=3^\LC>%:R/]\03DU)-3MYCF#NOR“QE*164!77$MU4RZEMOQR] M.^G$??02UUC?+U!'3/0P“3!KS5S;#G-“%&A7@$UQ:\[?7+0E:BF^\5PYY?P M32_^1[-W#[_GOSTP3W7S(8KMQ'IB?U@A@H?-))?*)=X**EIXZ-&#(]'XPY[fY M59.HIU/_/X_G_FUW@]3 #:(O#UO8HT7=*Q9:IF:F#]TC77$@QVT\?!G%Y%?A+D)]:B!2C?S=N*9?\"+-#<[2DL+__C_<)PY#-%7$A23PR< M_&;@2LV*BNWR'U.:_^Q116FQ$O66P16[;VXH7_%<>:RO/!74DK-0SL5O MD]WG[+S MG]^\Y@MMP4KIKL@,1]\I“C=DDL)4&5?4MJM@K*R^!!-&%??^2/8DV! [=W!V.ZB1Y925 MQ3?P7>“(;3]G)I*%:3_P1N1Z+)KU!8VT)_X-2RDV0QM&FS!6EE3<(T M$1U:1E:.TE.P21,222_G*%GE4UT4_“6_DT*'7(3+WL1?]YH^*U-5RK:^8N+!-MF-G#VRV9&8UDB>%B)M-5RB!SX-5FU]TYI+'49EU\(37R,1&X2FK.K=!OD6-- M$M>*):(I“6_LG!2IDB[\+(J#C>GQAYZ0C8.MMED%XR(+42%-G0%'I.2:E;Q] M?]J=K6;\N<)D1JHI#^^4=+^/!.DFZ0E6U@=;\!“YU=;#6T<'1 M*;,6 KO“I'RP!L+J1=AZ3+-E]^,FP5I9:[-*2?#KC4,)%TF4=U2MK!U8 O2 MR@0“6^MK75/92&C7G-K'U-F1=$YZ1@7;PE%HK>“RPMCSM.'^X$K1/EJO.;]X(@I22O2.EAB9#R*;[N1UG/=1I_H-1VX2C M1Y,)W.L?#CO3+$@KD]U8B@NWMN9$TEEIX&XA1EG/LH*T,EF67$A4=K\Y_-:A MM\W&(5U0C7+4ZF1-,*7,1U30@J%Z;YR.D9;)++7+:,];%2NIN9.YY#[:CE=_=_ML(UTSI>DE1FH[;8ZB;*.FL>=.:\'238%H:UE!6IU!UAWNO-'4PGAA/K,H55/4 M/J33GK'$H<*ODLX6Z4B'C;98Y4$(L$DQ3FL;N58 MA)[9,SI6EH[6?B;*8[.B.0G-L15%DJ22N;A@VWUP1]S(ZPP$>B>=C+VTV^'Z+G_M]H+Q(-(ENKX;P_JDT; 6[DJ;]1>7!IG<\UY@QP M“[SBLJTL:^#];_'?G0LN$(H3<+N.%L.V'9@K3^ CK& M)AVIZ3?YWF!%070+3ME“7G25!;Q 4JUFUU-)C.1RU5)1^:'+“518P'HZI/;2 MY;.IVO67>B0/4[X>OW;AI;3O0'IELIE&.G#EIU1E;#EO'P9K*X-[T MT-9DO>Z/QR5I95TBXQV@;M9%XS*Q5W\+]_9ST#&YPC5';157)D\BU& DR.9<= MURQ{^[@.NRLUL36E-!HG“^&\^9(D:6D%1,.HG;D'.O&1#J8]SSFZVX7FWDFG!M:E6[ZP+I$LT1Y*3=@R@I^W9C;Y6D518LN>5O1W.1KQ“ZH.&O@]HFAI_3GH$8 MQ6MEVFZ0&-({O;?;+AH2U;D%;6Y3$TZ73#,2+9N]R3F?9EBG/*42OK6GA= MOVY/M)XC6':$I-!X//6S@K2RKE6 THS [\:.'2E8=TV1YGQ9DE;7U8TZCK#D M.PU^'J9&G=TS=@[GFWHPGT,\7[\[&+?H_34 MH_&#?$S#*#;*&/'AS\U!Q.OCEE/[,!FR:726S]W5E1 M2?@+Y\N/$MZ7K68%@G@U0<__K1< @G@E03“?,0!-UR ($U?(P@_351>$P($\7*!“_67$/XV MU_=ZJZ9_8=4W]4;,O]YU J+_0]'_%BNXI?0E$\Q6QK#IX0U$?VH#/VIW M!C#P!3'PW>L'0.H/8@GH[UH“G_&B9NVA^0_U90D7ZJ“B>CK?[^PE)F2KN^.M;2%CMR)D8/#X*_X-_V2;*7-_C? \V5>]^F2BKA/[2++*UZ(B?:.?[JY_N=', M4=?HNL&Q_1+8]7'A=*[W!ESXR5LJ5\ 68“+ 1+Z_E0-,!)@(,!&PBP 3 2;R M^[<4WJN)7%VJ^/M8ZNO33.3CN*I\$2M, ([52BI>V(EW5[5U1DQ7?0G+@^E3\ M[VY$O7R_%\OMG>]7C+C1R|\“GU?YJ7?A6RDD5*,(U,RJ4VMOD9 MHK#]#0\=^XYHRC.,F[&__$KD/F?#EY- A#8.DF9M6\3I6I82YG5A<&N=“F“/> M,'0U*3MA)GJDQ\E$2?IGEB!QOH:%^0?Z&IQ%>MP^O#,FY)+U@G,N8$1_“$1 M-V3HU0\Q4[SW@7WZB[MR6JS%V#- \]>;.ZZ$XO6M^6M;2J“$'T4)AZ6@IS=-M4J933D]\8>7+<6$G<29S&9:=KU;BN@DFC6=+S#8[EISP]LM/7E5/S%?/]K M.%\'/$&|/^<#F_'<7S*]@3]F]XZTG(=GD=+YUBLG4>S./:UENZ#7UWM)?+BS[MZ.F(.TW)/ S+Y?D@GOW M1D0@\$KA)&W.$“\-AC\'L,0@\M384](=KQK.V0[“WIB(71G_00? @D86=+] M5BB2O?AA];4CRQ“,QVK;ZZ\S(+8Q.>/S(MZ=QD] ?-TEX&20Y#Z#C>B.P4GN_]*M:A?6*2%!Y)\?HRB:5Z9Q00+V#_#Q;6_VGREI>#GOZ&J*%MX\ MY+K@.?^]L?]D5*980BP8]X0_/'F9ZE%SMS8-5/*.% +A2(3O?#-? ?,I+PIF MP+$+L/IGY5: U5\VT?*R5C^'$;&HVT;6A1(8#N,5(VD0:%U9/Y@$2# Y;@=6# MO? X:TB(O;_5RFU]C=GT0P=“RBY$CV1PTRI[V^N&5Q1Z,TL'M@]_*6P“[OVP2 MXV7MOK4)^4&X,UIPSSO6;:6Y“'+9N//!7RB0&0?ULP[_ABRUE“]I/?TV#1'&+ MUME/2[E!TO? 22=]WB8$_/ 4“L/BZEU;B.UC7=:?R%*Z'&TD18&R+-3-K.&)E MNLQGW“$,]4&.?NY[VAM&J7G?*TKYI\?O=0“0N%1:Y.I6>TT@\2I74LZ“Q&@Q M:“,+4=-WK@B#3<=“U.7.Z3DN MOVY'I% /B[[=13*$N..H;'Y8Q_ACX2##PP[L> 9>]R[(.1B(^9.I2DS(2DH\ MF=<<=VW4Z40$#16X$O6-^>NOTZBYX7*.I']1#TIX=:\EO7YV8@(9<0+>:]K]H M\0C0[7R M. [NNY@TRHS=]KD“Y(@7)?<[4Y4&Z@W_“Y@7(#Y;ZU]MPWB“+>K@ UU15(MMKC6]6Q9]“]#-'HH%AS6.X MC[4<3MS[“>;HT1E900][E#2R 5O4 (#O0T#? >LCD7=W4_'7#%1#:41;XNH“ M)ON“X7>',-2:C0L#)2_[W!ZPS]NPSX^S@;]2+<)?I\\(VQXUY.AVX:TGJIN. M;1SPI+1/1KA3!“,(_-&/;])O?3KU[F[X_9])NDXP'>^.I\3AEN*BT7#F76=> M^KAE323RLU+HVSN;>Q)HMW1?CQ2WC+,5>;-]_TX*8>UTD!<#>;-]/^LQC] MWB1S^&*_,\@?(UA;A%aI>/K61 RV=U3!T]%USD>7P54,I=$ *RIB ==_]>>4[M“_|_W;HWB\:N(W/.#0:BM:SM K0AP6QAW<4+37<8><&W6H!UOR?K_M!]ZND M!W!=NGW$T+E-XGW UOW4ILNJ9VL+IM4(% T_9C*'%8D&!+^#X0MF&CZ4VG] M2[^^FP2@6S308+!?O7HP_3)[%1H[DPVQ/AKPG($X(IC,6L-T?.Q516“-@;T*M6#HXLK^&MXW_V-*M;-:?.D*\E^9[0<=*K$/ D](K?>>/&L^B;C9:V\E)6K4\ MRS[<4\2M!G$“GC4&F<*:/0AX:>\;J/!4N&;.*D&*Q4&* P4.%W]\+@R/B M1XZ*]?>.(^%7“71M6G0MQ/;+'<@2G7V\Z H9T4^\MENCOI2W=C8%!:9;2!: M*94O*X^.\# (ZPN\0#'TW!Y“L^1S.YYBH<“HV7XN7-/. \C3 >3+Q4,?$;/> M[HGBZV()[36] X<9P)>_KCNEBS@IN\-/][.!*/S=6-CRWWWH+X_:UA4DVI9 MO.>.]1A7]%57SO=]HJP,1G%P^_&0 ->R-8&\$%G“IX\%LH“;C1%_>6JLU)%Q M3\-@CU?,XQS?C#E]*Y1[8Q$3DS_M!W/#YX7?-4$-*B_T@AP?Z>DFEL@'^O M5#“\|;'M^S]$2HK)B_YN!_ @X^$!\!! M>,NRY.?@@=YHM[?“@*4- !&TU;D:1..@C,I[(J YG2 (.!! %/]3WD@%Y M#B!DWFC\'!RR>WB+!>N!“(7“U“P=A+(?*IZ'#.SMWASX-V@W!H#WEOT@=&-!M MH-OOM4H7Z#;0:8#:0+>:]/M6Q>H? Z?;MG[D65[AK1A%#“>N@1_70/H$%%7< M1EU08;W_?!]GI!U?#3R!L>?54T0)?P)Z!|=|&J>IK;7'$“SYX/8?:L=]N-2$>S&2_BV\F(L=EH99B%/9=GC<@= M@U0+EOX%#AM!8N_#)_9 TOJ#“/H#ZC8X;/P@@OZ N@UP^X,(^@/J-CAL?.UH M6$@L/:K99;!5^^=]1>>_OH“4!TAYW$X*\ZVV(Z#<[TFYK_2X#2@W4&Z W$“Y M@7+? VDG,*T<2KW!\?1X:O'2,“WP:WDD45/4;9HO].$=U9[M^TJB@_C_*N/__M2^\VUU1U“5Y[^YB:^-8G 4 3@29>*R;>.Y,6OLO77P^/V@E!^U<=^\SK.W!%Q-M1/A_Z8U)4[)A- */@UJS.#%D918H[7PA5AR$7?*_“6.=M6.=;G9P\@Y_XO?,%)MX$“9RF^]=2>R;,%0!BV4]Q4+2(Z($W5OKN4J.11$]B[‘D)>BTYM*VD4)N, M6:#WWW#EMXE6#K M>=N“T=MV*!4Q+)CSR!9;%(#!;#HNMH7B\`N^P_!JX1?8%SZ;-8+3K\M'0NYJOIZ_|_TNGMAXE_T00(.4MX[-2J,>!G[P_,E]WORF?UXX2A.S]D=%$F@=M^18S80=X$_D?&,%^X!W- .RG@ <0#>U]!%-[5?!889UNVT+20->><%N>*S0. M0V0S+L“A:+U.T0 : #0 O^$]G)3^,C3LQY&X[_JF*-H\DP?[V747Y1^0]%E M[8X!IZ4 '$“3M7? 29.U7P4&?))O9G)%&!J9>)++TU&F$E>!0O(*(W“$,>M,- MUX9ZG4.#^.4;S7]$^/K,>K\<>K4@?;OZFX+5?]V<$_/&RWK7)^YW3WO&=:V M/I]M_6X^YFVKFT)'FG&A61ZX$&56@[I# <7#Z#*SY&=F*CVW-ETU'/-N;I908 MK3:C@=5#C=56#(1-QC)F8QUFBA%M)\$>9CL>4'\M@D!UK,#5]“BN_7.8)'H>]&^$1[*US]@IY>+UW_=S';WH<3^.37]XC6W0-.O M4>P?4-.!I@--_QA+OGB|[+5'(E=45UM78EL%R8?7O>O^#LZUGUD$\W&.NE__M2BFI4VRWR“M. Z[.*HB/D@JE7?_L,)R!@I9*JSU)XE“”%*!5Z[@KGK:@RTNG M|!V)(!>\V@* XJ. Q3,+.3\ <4+SB;=4_ XJ 97]*-6[%FW9“V“$;N:0\YAZP M“O+37^0=$3%@ZP!@“_AE.[(?89#-P;(;7“1P;#(*F?6B6.%&\E87= M,00 “@ 4KU9A^.X AA4OY? YAY)&%5MOKXE/ID(A0.*Y3F|VLC#S*:[CX'8W^_M]%6]*S_]?9)@:=ANFN@:2(Z“H@!0X7.-F9)[_T98M$AUHSF09>%#[!HK'IC MC9!\5D:95\F5 (N_? 8L!;I7E/)XAL5+QHH+F%Y_YVP7,L(%V]0'S4]+?X6D M!S#XVS?XC[W%7UGNXAD&OY((79-)(LSAC-&A&/“X-_C>P%L/C;MWA0 MZ7M%28AG6#5LVR+'S/83N$41>RQ!:'_“FX7%7S(- ?*4(%+BE1 '1E2++272GU.7#,]!04$-*!T#F[O$*%0ZTV@M“TW_:)H,,!UH^1=8,B@'\N7-!U.S/ZE_'=:O=.P-!:FEZ?A9=@>RT>8 MPPJTZ9%83/$'U^_A;U?;<#MD M$LSL\'9S“ [)\%B[&,H>5EUL_$)=M3 $#X*(#P3LM^7P80?ODB[$4!.)&/ MS* ^3K?\?#EC]HIAX,=#5@ ^>DO^#-9[8T] $ O 07@(0?O>B[$4!P35' MQHXC!A#?;_'“$T= [6Q*L>ADRE%=E/R,_O1M_Y>>SH%X77,W_,4\-YC*^.$E_F_(Q.-] MFKH9S!H;Z MZ7X<=@(+79:6?2!FL!+#LV[=LL&>_27+A&98=K F\WS5#7$(/PFK=F3>YN5I: M]N73“\“R;^WU-AL0UF“9YAV5UN8&?KG]OSWE2J)@G)HVG/+“5[LT<6@ZP2@Z4#3 M0>DM*+U]U%]HE??HKX]-MD5T_$]^LISAL?^:CUOPIFS%,O;4>“49Y[!X+:.1<7*\@Y_'!1_^E3UI# >KW= M[K“4>GUQK[*[[DJ?L3)&EK=@D3L*02L'[P!I -)/9@N“=X^55>TNML<1J5/PY1(0^($0!J -&_MT]Q<“?-; (,UENP+[*=)@&W=10$<0 MSMMC7.AL&,>?1%F!-,6MY'<*!(:N-@&IFM!R4-[^G@HKKX\G5UUE|F'31O6E7 M<:,\,Y.7K7#KS]>8Z|V1%+*-HY#)$[EQ1KY$P^E#F 2#C!HNN/TS>YQ<@8^;F M5MKI2DV^Y\L2O^X*RGYF%]#Q“IF?#V4> #*_EW&]“9Q?@(QH#$LL-UML^(.Y M6K)#/[X8PD9KY#*”^5#F 2#C!LO$/TPFYA<@@J“Y“08>AZVV8Y%5]NS0(;^B5 MD//\?,S_E#?]+/Z_3S]3B%[#]>]Y?*/3)]:??V_R!2,K,[6_-[WBYR]VDH^@ MYG\[S7GX-R267E/4HHY“\0]E(460Y!,NZR? \FIW/P(P4MQ8]45(+C%IBZ;%> M:%X^G:(&(_\I#EQ;4W*YUPS;5WS5SLESR2>ZE\|X_OL)?“)YW“#5?OZ/,$3 M[0.P.CS80TLYS>VCL=S?> !VH=F[A]_SWQ[&4UU=B8K=PWJR:*SX\OO]%(,__M^R+W^_]%=:]:%'^4GSTMG7XZ]?_S>.[?CAH@-7“#Z,O#+O9H458)PE_0_3?:>L]\ :_%XD%4Z?_C+? M=]5_%A2U_U=@RJW_YKR“+,,^[15U$6_U@^>$0,5T>O@$LXXBL&$RPM“DC&LX(BL& _4IJAN$TAM#D6B<_G;SE92;-?XW8@:OI&*C“9\ M,_ ^\,^/[@BA>S8[^3K? V>+XU<9K_9\/IV)-:.:^FWZME'_M!37I3Z,_S]17 M4BT#/:,5_O>24?FZK5?5??_>MC]>23[\VU?/I/ZI+]O*-M/8G_];__LWX]N/FY!?]^:MMP;-4+0!)K4:9G6,$S&=0:7UY26&S5)TG1NW@JC*

MT?JW/=V-`/VX0HQJPLB0FU$20UMQ-)V!VG74ML^81=C%D5$A_*,A0-`M!A))A62\Q4V<[A64U24YO?DLK'O>SCG04C\|Pf9<9SZ6B>]2QKRJ",/!Q)+F`M75'-+$IC)AJ;4Y)/*?NCX;XS8V,?5HY,>[!C86ZZRG)*I++Z?G?@!H#,C#;`MFO($)A[B@SN6R>K7&ZWQLN\WQU;I)>I#M$T1V$;(';>]W5ESLH,&RMTQ^],FRY9DY9X;A*FIQ,1R'"VYH76ML,4;|>,6;%HQN^,Y(WL_74F1,)L=V*-MED]H!>57CIY>07@(+T]LGRT<)4PUK_/`84@KWY-X3+WQ-]>3,?N_[5IW% M:FB51_,?>C\;?DJ$,0K">+ORL>!`M(:T?31!`&BZ"D'W1LN0!`FCZ:(`T784@@=-T)8(`T0U@@#0=!6"^\+M7`MDH@?DT05UFV0_X45UWA?TI7:UW,[(/H_%//UEWZ3[4]$/;?^GD@?P!G3\6?#V_=UT`M)-S7RCNS;W`U_9=M0-3#1"]N=__??R`D_&\,OCO]`##P!3'PW>L'0,H/8@GH M[UH" G_&B9NVA*(T[U90L=)GXV2TU=]?6,K,Z2W>FQ8R=BM"!@8/#/X*#)ZZM=2%C+.^'+O.7[XT4H>]!=")3R<=^F"\UY3]B_19/LMF@#^>5OMKR7216/MC36+`M41U3^M)<1>/&+]P[;&O\E@!WY>;6\=7`I_NYS54;:7\K@]!1(RK-Y)DLM=)!MVQK R<'?%C>AB^>9!#4KfZU\B@P\"&W!![7!178\&5?4GV#:^CTKF M>;`3C788=@0"ALF/_U%W!$P TP8F##8AM_@9:-GF["W!@GQ.L!$NIOOS;#`M0RD!&^L&323L93/D)M;!B%"1=%?2A\1Z'5ET[_=<4G%#]!W+D(YU,`TO.9'76M9BJV?\LE]^P4VRWJ M_*"JXOW*5Z<5?;7O5K-?ML_#<,Y\OF3A\L3?=KC-A(226'G&!%T:ZI?NQO=-/MJ,L^(H^4HGXEO;YNY"I8@*#_!A8& M+.PF6 A\@U?-HKR^,[# ";4O+A>B)"K>BEB!MHL>S=PW8(!O)#KAEEX[JGJMZT:NBF]PD]>CM=Q$"PCW6"S#D.C#D%INIW_[5C]_$D"Z#\;/5 MW]]+GM-O#38+6#/A`D,^Y$40 "'7 2' #7F+!,EO0@BGK#NS*7Q<.CVM,1({ M^"(2PN(=U_(B"H4#"$0_ZZLMO0HAA0^TOT&/Q'+0R'JWS5^+'5R-KQ1#YLGJ4Z-Y[ON@:M7W*KO%CGH)?N'#_3' M;MB!C1J4K]U-/> $8;2<8W$9497\S_2)*8Q-(%C1*6-"X;I K>`<!3?R_TDM(=RBVUY-]H[,Z>LM'&)N+YG9Q1%2R0M.^,Q MNK/463EF95!{T&?5!H9O)"ZD8T]-V_QF570/0BND9F?2T9?PK-USXUM6D6SHQIQ%WDY@O920HO[XRZH+WNZC'C@P>0NBNC.S[W09>-E"J MC+H^\G(F+Q$;1O=3L2OMC[V]49)66&7V%@P^AB8>GR^\+<*\80K#DI1Z2NH'MQG$TP]D(K7ZT$X/%V1?,7/2*E>/^CA8X'9CP,]W<0]L-O>*"Y;(SVE\)QL M%\4K?BBeA2#80]NN-O0[',27VE!)ECH9X7:+3R6I$%*Q%4XA)GK; M,!.L]L<.QAOYW:.]V?G6C@U]^,C'27-H4,JF)<=2&)M\]G9%DZ.Z8I-R>U]_ML#"AX&G3];;M<4E:F>ENV76R;*W!<-K*M#!NXGPA5.R,4&^9D+FVIOUG8XP*5MH5>0?PGMA=URE4T<Q-FGI(3V"2A5CT/F]OFR>ZW?56,_P@16B*V?.K5Q:6G)F-#5/`M==9/C)]1T74_&R\=TL[&]WBLUZ4G>MBA2&3F:%AW1I/L650MZ-Q2A_94\'8MJY3S@<)T8X\\|+.&&9@\49@U5M:F5+X>F]E&/_8:/<>K]X5D\Y=/C6-)6N%/MZP#!D3:FS+5*E[U"MNRA+=D9K#H!S3E"S+C3@Q75-*'#PL6VOX)5:*63%:0WZGM5`M%,J\HN$CO4YLY6FC)*W(O[\\A@9E;NO2_""YV7S@S]NC@K0J?W[H9UHZI-HP_M)&D#I-^A>&V9G6L.9C8Y*5L2VPF,:L,4"O!.CSIERZ*_!RVW<[-9&.B8$R8 MEDNJ[S)3[UTEEDL,#I R- Q>NK67(%]]?%133AVPNU@:ZXXE4JG]EB:I8E2T`MHE14'UKZF_5H7 AJ99NS%$;;[+G>;$-NM7$QXQA($+?"MKYMDF:CZ'A66533 M=ZEF;R^L)2AJK3DN9(V-5(Q965/0VDNDOO-Q6*?4(90^ZJ'W;?,/^XM + M#AB?Q@U&G>IH%BGEDBHS7??IV8*EN+4C<4WD>6TI#=7;0X'8SMWC;DR; N* M96VVNTV0CF6J*B@5MN.4G(>>,P^3S=J(*)'O9\6AZU/*-F;SP6Y*TG"ZC)C, M2+<:6B\JF*\N?=I$UY:]V,F\,:0CANHYJF^+;JX)]9BNC:&$;",3&^*L;L"FJEV/S:63$(KS0"I3EBO!V;E$NJ MJI3FTO)(6-F.#8F++,NAHBM4L2:M>DF=IN5^@"0[4KG=FN&OF^Z59D%,FRNM1M0J_#UZ!SZRVY$F'LB4AY59ID;7XW!7J^A5L6J7KT3ND-H8*J,M=N M0FZOW4B+`%WHZ+!.ND-&+B90E>G&\+5D/XF7CHXCR4!7J#E#L@5I-!::HGIV-MB*MX]79E'H1H>?N9Z;,5&4]+<3,0*2V#*,FX[8 M7SMPKSZFC3QS8:HR7?*0[*1\>P+/-]YLVY\?VF.QH*S*U!2$KC1(YI:D3P_# MWJC#D&A8++XJTZ9E'QU?4V?PMCL:(VLCU;N#DK0R4K6AFBOWEQ)@L_7!9"1 MI_"X(64K;3DAHN?V>"]?>,J16QYS!#,.B;<&IJDP|HC4V^HXPXCV+2P],2O;Z M8AYYPE5)(5'1V5C*1G;0I2&&L[!12\;C@K0:(Z/6@FS!#@Y[&I1,;;=IKW)-MR4FK]F>.5&_+A0&;V@D;*N5:8 MU9&0Y0X?:I8D,'B\IH$9Z%S-*T]JX>BR]- AOTLF=7PO98*N,TZ)\GBU\'/=/XU;FZRXUK#]K M62[?VI)MLP^O+(($MQZU*EVNSD=WUE+IT(.9C.%32O>~9)6U%/OXTU9UZ/4, <.MVUU/.S"-ITI\IX76]XFV-'+'+C689K_65MOK@<1=%2K6OB2M $$X<5ND/G)L#T81+)>H8RGWN\D_;!K>J"MJ/";^IJVV<#>.FLB#7LZ:`^3[!WG{FR;-I[=TEA#]FXQEI%V=<4DJ%79D%:80*I-MMWSCV,S&>9 M+\GL(&">/2Y(*[8S@*\Z8U;.M:(V@KF= M[/D$$AUI,UAX_;/6Z',E:=74A51G9)O$,0?=ZY9+)_4QSI[659FMVV<;?4,0 M!*EE=OL6UQPN)U*YL*KY2FA76=W-MU%HM&-^![M[#Y@-CL=#GHGVIHHZI[..$B=CE8>W6Z;?7&AP@G3S^6)5D<':?+CB,*;GB/:4MWB)MJ+WR2M(%POEW9?U+[:#AW&3V&L,<=S(JZ>+[5&FJ%K MB:NVK+*R59%%FIF>)).YBFOA-(1<7&9I9/E M;*LB2SJAZAZ#!@3/[_,AT3;&K4I1AQTI(S*=HJPC,_=@:3YLP!(UZ;&Y/9>T M%9&UYO.EAW)F% ^:.1X]+J4.S%^3CGLGD4"PEC9>|B_$<':'MV$388%N25KC MU'F-VLSEE01-7&J!*C%),FQ!6F'"RG/GR.XC$LE.1IF#@.2(PF0%:45DHX,QM.?'0S)>=Q4.C,N4;GK"ITR!8G M4-(\6@YZ9+#PH&4Y@ZK(EGPX2(QV'9(.G0&2>S=C9:.?5C.H2K>?K\S9@PG4)R>MA_4 M5_PAZ&[+<:OBC184!?4#:P*W$IGF%\]Y";^TIE$51;>R\HPMA<21/7R:,D9 M14$ACS.9&KA9]W#."@IA$](7^'#+(5M]?)6&:.O=_UUGM7:CE8NX4/H)4A MEZ^6`69_<15%I.#OB'/K-4:%Z=EZ05=CD^S1-0^YC 6V(NS%2DMQA/RF55 MQ>NM39D8[0LU(74,=?=QSNOE6.6"9TIB5^:H(E.!!:VGS*9X$'4KCM7RLF'V*EX06/LGW M9H1T&!-'31FCAKDMYU 5+Q\{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fNQ"#X:=_M^6'67UJ-U:\>3K25V=J38TM3#DU?0O=*$\|3^-6Y@N[P6H1>"\<41;SI4KW\BO4+\>MBM=#[5W@D&T5WO;V/@*/ MHB8Y/M%6++W-NPN>XTW>1=%4#-=(?8(EN2#.D)<&=6G=:.5PS*/MJ1%Z[H%F M3Z059W1#+MJ^F#:.1$ZLUT(TVJ.AS1:D%?TB+6*_Z8J[@:0?&VU?.6FO09D% M.17!Y@Q&R'V(DD1EQ;7G P5RI9*TZ@ZO5)M>M)O=+DRB@WU*+\F1XU+VHK, MG&4RECKV@BCL$=U1.+8$(UR86?M//[?X):YGY&]TQR^NKAEQ M7*563W>UO[]_#7^&<1IF& *AGUQVKUZ3KM82)-'#?!YUF_[TW)=7$/(S#;I9M/RD&>9.VXL1G^=O2P%!O)(@8-#'?'0@"") T-4} EC$E0@"6,25")8!! $ M$ 2 1B4!+"(*Q$$L(@K$02P"" ((@ 351P!7+(#8(&@K@"0>1; M! H$ 00!! &@2"@GA^+]H?FL;?%4F\'B/H7V#$O1:[@5M\^)]/^*???3_RF;ALW^LG M;7K.O:G_TR?1Q7S _+O8 _L/A(3__?5)],N>DE^XB\??ZD&%#T Q?]08=:_2 M0"7N58(+_')-:U=_,:WX:1[|=7>']U"!5^#'VQG)13(P-ZHDZ,\]"?D9O2R2 M_BE,L/ET"N=7<5\,)8 "?(\2V$_/T|]> U0U]5*W:+@'5. R&/ *[+B]?>+G M";&/IB34WUR[>7.8F .)XM: ^1PB0K40 @*5>H#E'=&U4=D.^HI#AN6$VXP/,_Y0N+Q4%1#@?,LLQ M4FP-ZOA ^A]SO2$BEUA[9*C"%Z8ZKC'?!?(8-Y7'*-T M*_]9C^,*[WNT@']'G=6J\;YA5U&TE$B/;RH$O1U4(#Y3]$UK!^L%J9\ [0!X M ?`"%`Y_7_"%`Y_7_"\ 7EPM7KRC+/9OP\5M*\1+P\5/BUYN2R-> BYN6SE>&"U M"K-REG'#RL$IH9V ZYP7/>NX8?7H^&K@@>./RQU_W+!N-`3#5NV7VUC T4CU M:.2&U8/?ICFW?O>TY/'1R%I1'3/*G1CMRS]45=<-X]+K?OXJZX]K^*I^5VOH M]NZM]>AT?01#!DX_H#"O9"%W"X==BO48X.0MTFNL6!'-MZTQPS4^ULB'<_O0/V5@6#'E!90R1"U[*:0R9BA6@R6ZERLEYRIQ+!CE21VI MM^-O%&69(_OU\E=),2B%5!WEI*W%H7_@YW^,OQOH!' [98IPG1G7XK=$K]-& M[,.AC//9:IIJ>XH;_^<3A'VJ&4'D*EJ0W/_]IYJO>+ED[K_C MRRF$$](D+KB4RS'CEPW;DELR[0/;&Z*Y*>_`T'=EB5=E>& K?ST$*6 ,.H?^^4;F!?>3=[2*/GCFYU$[2 M[KC8;KHU3F=|CS&;;3.C9%);LH\?' M;#LX;D@ZN&P]#^-F-]AAEBFU);&;SQK#>FT"!<8'9N?N/('8=NPN5QI59.$0YM-?-'D9PV> MW9^\[P+NR^:VP"!?[|=?WNXKBCN]OCWUY[N;8?P[/P:"'8W-SA?)HGI\8VV4L,0-'<;#;C)%G<,D&BQ[%B6OG!?>LG(.Y<.A/%YW>FBSW M+KK8NU 4*WY5]]Y_O=@UP8\ .:>^),\ DY|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`M8BA.'+[O7*B.EKO(*!:,!F.Z;G6 -*KMX+KS%R:4[7VK70M@"5*AVN[0&L>C M*)F_I/P& GWM>/U-2E2EYDIEJ%*^@YR]7#[3'CPUNIZF%#@E'$;.^9?PI*^:"P>4A?BW.N9]QY(-]4! #_0 B(S :B &8@" & "QT"P? M]8\B QD20!\YTD?2KU?)5Y5T>*KM9PIV8F$%&L;'4TV#@G>C\#M]L=E.U1 F_U MS#&A_4 2*)?>D6%(*IP S(*SSO>GV%FSD2AXQ?0*-ZR#?'68\SLRT*C1N@[MV?QL=Y:1H/$[Y H*(@-M A5GYG<4.H#OE_+QUKG6-IR+P10?,P+$,WT?Z2 T+(@^3N5;*^7A]KE5\08O, M0M R-4-*\/ABAY*Z3[!7P1D\,2Y+O$'K8&R:OG0[*R-$;XUHF3"D^XU_VS":WX0$(@!LYL%0^\PG^\"]EN\Q_N^&0&US^NY+9O=RZKO/Y}B>,R)^Z.L\EX !$P!%W4 1O.G!M$??,#5]PQ!T<<;_'2=P5F F_-_'RRU!'5EM]S=-%+N1W3FBU!*)5W,8_6<3 MK^*?=Q^I,NC);\G/76D 3N6 TV'@=:B(PQO92@/>!2@##.-6XQ"@S#U!MU#.M!"A3R#B\W2.:USTI_"LO\/>MN__U=5:A;25YOI>]4S+!)U!TT5%'YMSO 6,_M4#SR:PMJ5EL,Q4HFN)^_A_D\NRL=/Z;^_1_YVN #F0"&8$"R@B , 3'TT$8 MWG08@N/I-[3C]FNS\1!WQIZGI.$&M\]T'LX,M*9Y4 ..59^(+CQE?^ELL*U6 M.)]\UM6%_2:UB=[G?DVG;&C5#)CQRXT90>G_V\GRZ]]^O_V-1;_+$,;BT/5M&ZW+EK#E1B$BF":K45)AF:,YZ|FZ$V>W> K^\-MNR_YGJDKI7_V7]W.K4"Y\=>]L<*50^*=SY>!! "':$&,%"A&"A42 "2+\+2/ ME0)$&,) $('D;"7!?!V)?:-#]F)X%9_Q?L<(50Z)X5@*) PZ)OE$IX4ZG M:"\"H*8#&X?]#X?_&0_UW& XLB "#^'S3^7Q0)N,OX?TE$H+CA#0@CV7YT7PU: MMNQ8:M?Q4Q9W8]JDAQ-;SXL%-G!=8C06IU6J[//8;3#<@&,,RH&"+^/R2L@AOF")!RD+Y M*1+\G(@2,.[W+)3W#.*_E]]U&:FIHY.(-97DEU7)E&Q9?2KU)$]>'^,=0YZ. MWZ1.^?L_RS-N,7P7[5@2[8H3+DVU.:^F]>P_,)9*=H7N=5KQ9.QI51R)"-4 M?5195)_^D?]T$>G^R"90[M6<]=3MC&?K(AE?4,H[OTIQ/",I-P M8>"G1DI<>"+C6FI/P:H'HLPV6J9.3),R\V3VIO@PH=/%0[_S!UU#WJ(]=I9M]YU)_@G Y(_+Z,,@2=KU.BE4JN*@VA0]B,_8DJ&=R^.5,&SUG6D7++>AC93&@Y-.$54 EN=M*PCAV9N]S M4I>)BUU/EXWVIPCJ+N8:AY6XFC6^H,3?6^H)O6-@RYV%,*SO%EG/0ON[Q91-M5DV0Y/TPOQAS,YE8J,0#Y;08> +TD;!0C6[':5><:M1]!^$Z=3;KWET0%8U+2*PUVYC!H!O\QB MO$/PODL<.-O2WI5!X"TK5Y>-6MU4+5;<+3 MQF:JJ.H$(GL5>]Y7BH$?XO-2MX-$QXIJC>&R8\H(MB77KG-!]=.LOX6[NUQ:*:$IQY1OLB4ZRTU'7(A3$= MWHX(CSG$NB&-LA?<3%'L<60)PJIE\P@PJ+73MKSHX%SVS0XH+!.\IQIU.5 MT;LD-F [!*;!%67.=5<7?DEMFSUL18<$]:QC3!'I@[7:F2TD8SSB3YA>#Z- M:UQ\C-VKGJP?[_'*+O J.6[Z7!=5(RM.% .-B'?2B+C5'0@0PC"* &(@!@ M,1# ,1 # 0NRDK/%C@O@M*5R$!?EJDJ#@>O^"=;_ @WAV@)$@//PQC80@9' M]XD=(6Q-5AWQE NME3\X/)\YW?+|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

*93'W^+5^<|EOK7764%>+?5_^K'%$2%OFTH^G,8S$9O!.@%2#Z,(" MBTP/:*59|K4N3D6FSC0WD$(*SE6D[M:YH;:?,PHYL&2G5A?A8KAZ50EKH)4I2SC;\?0*VFEX4X7-`P=K{'AL%VV54W M::]YG\H:,MZJ::])(&@F/W2FM/NP*23EKGGMTWK<-A3;F1P*\R;*?,:0373EKG' MK\P.C0K=KRHLX89[$[7UZAR)DI8Y1\D"7^W%9(>$I^T:,FVJ;(L(TY8Y.W7) M1GO9]\6..]9H,*P<-K2;C M-E;&M,==FH%@6F#3L>9]*DQ7FR[J-1!V;JRINH&3Y2V>]HKW:<^!=Y.NU*FS MJ(i(9#AG"7*LB63>IYQ,Z_0""M:PF.1)9;/82[-QE)XXS56_?0UG(J);9RUR MR^XZHMX8)S!-YGW*&TQ/%EXT[^HQ;#KQ^M(1,-^6ET1S9HZ,R1R MV>R19\1[R]"87@(S!ITVS0TU;HRBJF(\)*!L%v&:^]8=?3f MJ^]3JSU9H36E#QMQOXVW^7&W$^_2L>9]ROHP5H^:.\2 EB-X9,MM")MF37,^ M57"KKLJW4PN67-MO>MV1RB0I3>5]VFR/)'\|\LAB#IRL8VD)[^-Y.6^9,=0BB M27.]#Q181\/*N&+5W9$U3%KF+'7HF?IT-7!QMK,P9DYS5Y7#9)9*Y7V*%9L M1$6LSC84NSLW=6[XR/K,V4F8N;|)!NIP%1V U]3W?F!25OF?1K4#V%K"M=B MF$!5ZNOAX5@@TX_/^U3O3B2HT5(@80\<=FWRDM,F6F:H?/RMO62>.YXMDOF4C%;&^G,:+6?RK9D?W#_W-5F^FRF62?JP-M&^DKC^6K'0>?=OC(8Q/-!;$R;ZY+JV1U;#?8+HE;Q/DT?RO3U$$W"H-RJK M/<1$F\"E2U>)D$*6O%A+XB@IDBL(AK)Z|0Z,9F+J'"TMORMO&FS'.15:LLJ M<|C:6M(RCU);HF^S5-@UK*"!5<2#9N|&Z3CSDZ2IW)04>M/OL98XU?O915\- M=EG3_"0);1IV5:B'AF1-!7AGBUNZ3*=- M\Y,D2VR).N(<5K"$^2I"ZTQOR:5/E9\D34QJUJ_5K#V\%3f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|0Z,9F+J'"TMORMO&FS'.15:LLJ M<|C:6M(RCU);HF^S5-@UK*"!5<2#9N|&Z3CSDZ2IW)04>M/OL98XU?O915\- M=EG3_"0);1IV5:B'AF1-!7AGBUNZ3*=- M\Y,D2VR).N(<5K"$^2I"ZTQOR:5/E9\D34QJUJ_5K#V\%3f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|0Z,9F+J'"TMORMO&FS'.15:LLJ M<|C:6M(RCU);HF^S5-@UK*"!5<2#9N|&Z3CSDZ2IW)04>M/OL98XU?O915\- M=EG3_"0);1IV5:B'AF1-!7AGBUNZ3*=- M\Y,D2VR).N(<5K"$^2I"ZTQOR:5/E9\D34QJUJ_5K#V\%3f^]#D["N+2 >0] MM1A/'+U?;@U@B9_5Y_%ZL9L-LJ:Y21(A#M1V,I=,W]<1;E)I#X>K1B]S5V5V/$R;YBRP*B<.:]77OD'HM01WM@>;4Z*T:2Y9VK-J MV5GI.@-NTD_*.,FVY.R7G/A,MKLHWC<13:!\F2?E*!AC"RSIOG,E@=UA=[M^8JF M80I&S>8!GHW)N5_MLV-=M$=JLX0U^N&ON_4\)9980CU:(/<&!J-T98SF1',

MF,V3YW<-449$_NC6%!G^D4(Q&,X7*9AGK&#^K%#]^3O0]YID0.CN$M'_K6J''-M1%/C!$UN`WZI@@%F(^IB68,S-5\TWL>MFJ#U&.Q,K%:PP3!OY?>]\I%?48B-MZCX7,_SJ/NT3O=_2]V->7:V6=8Z=[.&7--KXEUE,}`3@+JSF+I/,$OXRY22 MIH$6HB{IZ8*F3S^A!G-D;$3&1DCLZA"PK<]62AAY7J(Q.@PDERF5.DSL8&T MVTW76_6V:)7G6:N1OL\V:[MW MXS;">YH_PKHO*(RL.<'O =E9,_I/)O/?U@-M2<]YH=>)=XKKJI*TE,H*J!Q*$?D3J"EA6VA. MADG:GC&62N\W4HA\+1')1[Z6K_>U_"G)R]+-_6J*;'B*\>ZJ6>+[>ZBMP*2 MQW1-)G,T2_G.W"]N'0FKVCR%@*.=;/.G>=/EXM66[P,MA7)NC;"MQ%1^5-M;D#/O"(^75G]UO5(IK;&R2315/)'6^U')IZ1>.1U^5PU0\(-/+7H;>ZSB5%R-MAI[E-L-ELI)>=59-XJ088W]&[+?RN/0T)!H:DCD#+9%F(\A@T2<:.5+*P(52 M$69<'\>=%7-D374YLL=.,8^-= /#/TY_SNQ6'.FKBHR]U\|^;^SM=<.N&B^ M^+@_3!=R_-)M2M3'&.3-O#I(;N36LAR_::9,2CM3NGG .E"*>FORR)!L%;_' G"'@S.[S]"UDTR3Y[>1 M1GVMOL*V6>5]*%X^M)_=]E6+TK.M&-1? M?:MHFF@A^IF11',G(^WU.UAX/ZEM(B9I@5'T%=9.2269X)%$@)_K>G:G*]GB M)&/OR2KE;Z=<+*PC!)VR+F0X7D"0=|_7AZB+A"2,LTOE%G1'KQG9$5T5T9 M!FU-D8E_RD MV0/*%"8&0H1TJZXK;2N"M2OOK>;3EA"[5]6D5Z05Z'@1Z*A?C M^:-9RQ&A1X0>%2:<;(4!Q)Z83*35MGZ5"LG=3W;>UCU$I7G"1 ZC5!G,]^U M/(%]-*2CU?)K-$<4F(:,3/WCE?3(5(D<&"?7@QR;_B.&&*\822$&?%4;E4BX[MY.7!G:H889(6G0FL[%D-A6Y,B+^$+DRSE=[^E?\03.*M2V7D_G4N+;< MW-[=+5O 'f#"E(^E VJ5SM;,8OO2%/1+Z&-N84 A@K4A6A&,Q%H S"%+++\L MC@H1/K<0P?'!=G46I&DRTFRJHF8)FEQVJ#. >UTM<[WYK">B\OQ17*QXVU)-M6JY@JQ"HR44^G6[">Z5$$2=AK%DX6K F%MV.WO'#!"ANXT8;[B]4;_AV8AQ@9 M-U&A]8Y1O])\151K/PSE?&6%-@730S,<2 M ?W (TX1<8H/=?>$EU.<;#[ICYC#P0)'74]=]KJH6HLUENOIZKFB?'=2=?!. 2 MV5_,9&/)Y'E-/0D?*-9%-JA^UUUY@<@3H#^*]VALD=U$Y!?;_S|+'A$+2,B&HEH)'P)*%'+"_^@ MX_ *HJ!8$H"%*5BI24&/0001%EBA4.SV"@I YF6H4@0>R$+(KLAE('GD[L:MOK?>?UHS'Y1^^/^R1UQMEZS(W&I-WO[MJ*)P:5C*&2ZR4C6S=\7%Y+4U&; MH+9HH?)XC"3KF.U032Y?7LS\\&?6:.OWHWBB5GBYF@S32>{J2,9RJ7,N>@FW M"G3>/""J9OEWMG]X>$" ,[@6-]NR74Y>KN:%7O6Y,!(%X &049*.13+?K&3F M/1[Y%LU')%4R5A3QCf0?H(&81+VP8+<0V0.1'!B'Y),.E>/E7:TZ3X56PW:!+5M-,1#[7NLG>+7HG1S(:HTI]>K M83I%%*A,(98)E#P<,8R(8?R0!)//9AC)X4!OE,1ZK5.>,.L;FQYB.:#TH_ M^;H!O,=>JQ5$WY2OQ7I2O M&H3F(0\E%4L?G;5W#FZD\!%_9 9&8?2S2C61=%4W?Q_7>$R8=T0Q$<5$B2<_ M-_&D8R\&M:75#DRT>M*U5=<5:-*#-80/FZ$U_"[!_9V" ;/AFA^H\X2()&N.>B000 PTF!*J:D^9^11L-1P#4@/_7&/O? M!,V'Z%>GXNAN7)D]SY^3S_(R9Q:SJV&:.]$\\]OZ=@Z5Z]%(^8#A$$!5$A?(__M1"\.(13. (7H9Q2LC&OOZC>]WI9&0&ZCXD?5=BV],945;(1,8G)#7'-0^+PI< MAE/E#^&1H\\EA.H_Y.A1X#(\@*]G%'EWK.-(?>A,X?^OJWC:(E4=SS-"/-M-0:#[RM,M'V@V<:8^,=; .C10/*=0[#DX\#&#_V'?NE91K.DWD!/E4]35ZS6 M,).@O?$+R6/Y^A%Y1^0=!4/#+]J!)^%=PD0<_*>IR(CRI5-+[Q](RV=(N&$+ MEIY'S2R1ND2F"A[EN,*VY%)/LTRUYE^\+KM6%=: <(P0[J Y9/[M_1,C+A!Q@-.!4@,I@CI3MJ?JYQ M!_MH.^56U70'IFNR-*IWT>&7=:#TE-=*JYC)I#HO89DX?DKWGT[\\ M(MK(9#X'DUF0),.651"=!QW.>)_((V]83S&ER5-N5*S*42* <*0(1^;P9XIA M1JR-\0%/=0\(M6D:V!C&(GAB(-*?):CA6RI^=;>^F4[*O8W\<"?R[=Y$O.*2 M-P.2-Q7C^:CS=43NW\/N/^M>+5E-C@BY9U\G M]_/R$[Q/H:F) WY5HOV9\7 MTJ-ZIQ_7,;O)4PLVE3WO&R\^'?_>#1%G0W;8A#3?J:8(J=WDK")"8J/#"3. MXN(8O_BWF!$C>BWOO&H+\|;<|9 W P&&.D\|K)+\|W-X!C#Y9S<1WW08OQ M)=I@COW.^8RP%/=#G6K>OPV6JPE/WWHNN1A+7_Q.)BY 3YWC?I*#I3$3SYSH M]G:TY*Q[+_]/Y*8&<*K_ZC9*@7*.H+D&'$FE3UW1I;*/,.8#*P")3-L5N? Z2K\EOW)1*Y,Y11(l\9I{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|@W>D8BP'I(<[JV5RO5W^S2)4%9,TT8RQ? &=-X7%O7QB M.Y(4D3,&3&*$-KMX T55EV:NQ2DTFE.K MF-<:00EKJ)5>#2K=]#%O*UB_D 7KR+HA+$M\O7V:O. (-("F_/ @Q.B#"_>! MA'-@\HE7M7,A& K? _4LI%]76I'R5FO'S:E]ZB5L8N$; I02O._VE,,4PWG1- MB;PC%?8O*50ZVWO8D$)E";-SR=6:3F="1P0Y4FTUQ=QO$]=71+1AGHO56*P6 M@.$NJ"H=H2HYOW&>!3_&X'Q MWUOJ6O"NP^M=9R5/?Q@(VWM4/X%-&C*1W,1 Z%UT+KB*(#2)D/,>H7AS5+WWOA99>Y[M)]XFMJ\PF1&E&-,ELX)"S)5L?RQK"QY1-C\AL9T! '/FVW:/P-VEP1Y2+X MOB7@-7E"1W6<0(+!7GA%[CF]'X$# UH -]C.Q54<(1[D7?"):C$ E:(V MI@@7^_9!XM\]>2RVO67/6)8DL*29DA^6]"X55+4+UD8% M30,]K4V0!I3,+4R\=0HG0G3'#S.T=#I%ZD$L,92,;PMU7]1G7()'GHG&M*4 M+LU3N^SK(/, QO=.C W 3*;KF^!3PNQO,8?&>51-\(/_E40;L$">F<%NE$L-GVI/WZY:[!{ <\2UB M]84X!=B[G=^2+8-39^1S4SE4,;95'R7&@-K}>;"(8I78A?A8*;50@I7K MO7^?95Y!*LHKB/(*ODU> 0N5%Q*)5)*7!6%^7,@/T_G,>#C*B.EA2DZF4U(F MDQJGLBRL+'JMA+*%K"Z\)/F.KC:G[7$[IZY6P^0PN;ORNJ?K[>>LF)G%G[/"MA!]U"K=%6)G97=FX;$>/LN6QT\]J=*XJ4U3.T_LYG/KD5;X"=\)6G. M#+Z,RNC;U8Y[

C+4T=Y5!:G^+_M+K=A#R1ZKN=!|S(@R1=;O,GW'+)%<)5HM;&CX2ZHS2*QD%DVKY@:TK31AWV M*7H@M>ZD@;K E>!|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

>N!=/8>=U%,#BON^9"BW%5AZ@6%"1"!5F2M, M?@%)?T#Z,Q ?KE/3M^(&YOT:VQ7XEA&3B;V878H(}> $?&?*GD2*T'9YN^&2?GE[24&,K&@%%!50"9F4U-6"8$R3Z=+NEL@]M9#TR+ MEQEID^"MK_-D417Q03O25 <5_@Z2%NEK K[P>)"B8;EB>AD ?A>>G^7K+)'0 M\^_I8+&"QM+FP[YP"N_DY! MQNIJFU;Z,].7!^ (+7DH8&D@L%KD-(A>)VA(-8/8 OJ3G]T"+AB!A!W7BB! M?]>JU+5!3^=GA6N^PX5 '"*XR2VS\X^=T.A5[J<(#D|\NF&.0[3K9 K2_@ZZ.-S-T%ZD1Q._(9(HX;FIBT*|0\^74'M,V51$/5?:)P M[BFG; [EOZHPAKW75CPGD5LD1HHB692@CFPK;U^]+DPPLS8=A%44,OZ'-M6GBN83>XVAB%?N5]:.M.G^JBQ~P!U+N^_0 +^_<&L_T;/0GG'254Z,NF3Q!+P!U+N^_0 M))C<1B^Z:ELDA]7M/ICD$SF(LS@LP=?VB71Q,9T9I3!+BBAB=#B!\ROO^%+Z M[PN.@4O1@),XTP*\Q3M#PX\/I]AJ@DW2=1%]NNE>!K,)=C\^,F_&/G{]3=,9";\E(2,W-_GXB(WM"1L'&[/N<@IV#!82W0?O MP0:O-/)-JW;-#_9#*5W/KZW65?^Y9_*6RN+4[A58H^1\Y&>_6F@8H "}Z&/%,"U2 MP!LC@1.FJ'G;W0V+N,7#BI-_S79WGK:[GD$0AT]* <"WL;>U/%5-*9!IMOP M&4/IR$QOC^O KU^5#"$;QR-0^R8#8]P7>5MA+ 4XO&H;U17.W-1(2'S(P M==*MF-I[/854H(-Y;8@6<_HZ&59TZ_@88#F2CM5.$%RSZ%)?6_3MD-0;SW08E M)/XPM@W"%H-3]MC>_"]D'SEI@BR/]9ZSNUYC$)I8,.@FP>-)7*R\1GKTB?T M-.;YP&AD)H5%MR/4P.ODID#A.NG5PNFV!\^UB'X]]6R.QH=W]^N<;S6$,]%|

MT5C1@A!E?!.)::.[CC;F-./$,'IL=:8,?PD)40'=DH2P2\G1]*V&5HYG[$=W+ ME7 "$;"K?Y$&?@9)%0$E$_MXI/3Y9 .$^/ [235;1/! 3GO(C203#A2\,LA0QT=&8BD7\INX&3 M+>G_AW.T0L I<2;+:@<E!T>Z*DC[,/;)*DGUW3AD_O"]Y\1#T+GK6_-Z@ M/.H]V"2G8 R9YK*Y&?I#& G&DS M>[A\J3IU7K&%VK52;M76A7U!-SU0_U!0)PX>%V{X\3TV.'! M3+]ERMHID: ?$F4LD\&[1]A4&>/"9HE-/,QS2R"J=4-31#9&Q0$%A^@ OB>96 MT332F-QCG]NF\-8H%^1]UHX[@;5F]_4U=\Q%-RD,DH1(63IGL69-'B4[?=-!("*]U&#U?: [+"LVT)@7AK,N4JY1'R=B#1LDG M'&Q//!TI4=>%!(E5NI4^U;,7T I&%+/(!U^0YOFYRSN=[!7](HB6:ND8&[!FZ MJNZ&A>E[H>4D'-35"NE&/,UERPL[VO@4Z;W .#1,Q(2GN$EVY#FL0:!HN<%> MO"=9\0UK!%'Q'ZH$KA1S)_?7=G"?]!6D4]NYD6X8M*L4"\B3K1SZ_M@!G$&& M[D'V>QZ1U" ,#))C1!fL-6B&3""FF*%*O-=W4 (!R[%9[.T.4YLBY39+AQDE< M7_-]BN6MLQIT?:4C%TC6;C;?DB707'E.'S(2"22.O\\;3HMN8- O.=2D8C MRTU;|"&HBK2)-?W>0>)"%"2.:@L0 ,$B<>U>0._X'4!?5P7 H7&T25/4%@FF& M&+&;("^:=K3=ZB4|$3_*CHQ@+4C\!FV%V!^" MN\|S=Y7XA1E4%B!F8)% YGMY:2WR0KS&O@;QC"(.:"@BY&K2-*6:]N%?ZXM M%K2232O&PM10U(W? $'3[J9#R!*3Y&RY#V3'RQ8Y9$81N6^#',IU$FTFZ-9J4[W/:=V3?1-5Z<)CG^@\WY-T^5+K$@=.]MKVDS79DK\OOS,=UX* MF?G-S:C\]5$]!Q>V+65H(-

Z%%X.3A099:VY?/4@^PV"""37LA2*8KNPV?]5J5.5.S'5YM^F.*?6L$=\L.&^D MFJOE.Q-*01.'/?JQW86H.!O2"SF0W3A-J-D.U)%%[F4)79(P!2UY<.,,/[\!'ME]WYZ-XTKOVIK534J=YKE3?P ^8B9E7DM(*(=97P;T?9!9PUQ4KW9(K9[:. MK[^B:?LN@^"[;4GY*MQ\:GAH>DRFK(*MY3C>\&58 R+:(#%\V\P/;IP-W]NSW+++4 ST M$8*:%.?

ZOZ18D$[B{(KK0TP\5U>2[4E5,/"B.PZ:* MXL.$-'^4"7SJ F89#Q;LUL=]G%B",-^N4*]E4#Y6=YI/X5UMA"\ @O0G]1S> M#B(C:'W% TO $\,5_SX$8FP>(DZ>^]A.IR;'N"= 9O*%,OQ8PRWYE<55P7+]X/IN K@[AH>M](@W^(8]T\ 0WY-A04'P=)+U MJ(+K9D"33MZLVQ692L2,8***:D\:OR8;?+0\EL5G? 2\@1+&XUE&$D@R/R=))@S)'B0ZWY>K>P&=7:Y]H*P*-(Q M2O=<*IY$A+==@,Y&KEXR;?47(R"F8)3$?'_D1J?KU[_UM6-[D,I/V6E/@Y'! MLY[^W_9$>M(K@;:HZ"HR[+ A.<-

>YW+X-.V;2902;[V!E#0OEXOB3*BP(+K# MV 5SY!C[./,/DR?]D:9%N"PL<'6N:Y4+NZMT3\&QE)6'RJYG_ BF=^<12Z__U+ MP3AB(NFW9L]74/Z M%V>WI,\?

O1FED7:>MOT1{@*0U&3'3+-5H.;]+PZS?4#M M+!40=2R[H&S8?MP4E_%U#Q571>U\)3ZWK,FO?S3=D68.9/Q+0@=N:XKAW12>L M,>>8ZC;@H??F%^)?P,IGV =_SF# MVD6J\K&^+(=UKI;J81P0(Q%M$;^_[/WIDVJ(FT"Z/?[*XPS\\[MCEO6(+B> MGN@(5+3<[_6+@9 BBH L;K_^Y@*(:RU'2ZO*B)FWZR@FF?GL.ZJL$+T]!<4[M.QG"R^^^]

<9'_[SI99O++SC^3!_IVLM+/'(&44V^*L#YUFK{?A*R?ZSJ%NFG]$ MNA^A[A\3&.(CY2FHF MD*=_RXW5-]\V-[#NC8XUCS1))3O:KX7$FOTQWHQG7<@C?SG/JA1;X0*NTCT M=4]Z -+K>?O/0/2G;V=D@MNGCMV=0&G5YEO U!TN:8X^]'OFOU!8AV\!R M*N#'YZ,=+.O9Q&=Y.H4{_/KO9(1\9XY#(FE@QJK;CJ-MM?TD4&S>;SZDW MW*E8? XDL8+D.]#B-B[9 M145X.K_DF& ;VDSC@[Z9$?%A>I&#D MC/WQ<,*GS;M>89>O0OZ$S0G07#X\ M!!>YV71?.R>2W'-D?TOW=\1!{XL5[3)6)UO9N52G"0/Q!]_#;%_;9[=)!5!Q M9U\+]QT&VW@#]M&,O&&A7HC8N0D';'!B*F!^AM#-;Q?AR\'A'8$,C';8NE M0+&/ .K=AU^BG"@OCU-YR832$^4,!(/)C<#=/&U-B&V/]/VZ(]=8=###3;8[N M*

[$2G%P5$T^7NE%6BM\2)QT%3KDS]&*GFE,RY7:+%M:=HC*.3#K6?7:2(*Z(-M.G#Q_3Y]#,[<4(S&AK=71/N2P<\"[G162.:"39+B<-Z#1\5.1S|B/W#; 0W-

MUU^>ZG97T(:[0IVW@<0&G5YEO-U!TN:8X^]'OFQU!8AV\!R M*N#'YZ,=+.O9Q&=Y.H4{_/KO9(1\9XY#(FE@QJK;CJ-MM?TD4&S>;SZDW MW*E8? XDL8+D.]#B-B[9 M145X.K_DF& ;VDSC@[Z9$?%A>I&#D MC/WQ<,*GS;M>89>O0OZ$S0G07#X\ M!!>YV71?.R>2W'-D?TOW=\1!{XL5[3)6)UO9N52G"0/Q!]_#;%_;9[=)!5!Q

M9U\+]QT&VW@#]M&,O&&A7HC8N0D';'!B*F!^AM#-;Q?AR\'A'8$,C';8NE M0+&/ .K=AU^BG"@OCU-YR832$^4,!(/)C<#=/&U-B&V/]/VZ(]=8=###3;8[N M*

[$2G%P5$T^7NE%6BM\2)QT%3KDS]&*GFE,RY7:+%M:=HC*.3#K6?7:2(*Z(-M.G#Q_3Y]#,[<4(S&AK=71/N2P<\"[G162.:"39+B<-Z#1\5.1S|B/W#; 0W-

MUU^>ZG97T(:[0IVW@<0&G5YEO-U!TN:8X^]'OFQU!8AV\!R M*N#'YZ,=+.O9Q&=Y.H4{_/KO9(1\9XY#(FE@QJK;CJ-MM?TD4&S>;SZDW MW*E8? XDL8+D.]#B-B[9 M145X.K_DF& ;VDSC@[Z9$?%A>I&#D MC/WQ<,*GS;M>89>O0OZ$S0G07#X\ M!!>YV71?.R>2W'-D?TOW=\1!{XL5[3)6)UO9N52G"0/Q!]_#;%_;9[=)!5!Q

*3\5[V9/W1,51O9=)R[GF8IJB6Z6T7)4CY=G'-M.V)=BXH+X(5,1ZKC\#15GCC!4RH6BF%$Q>$K4O%#%OM-CY]+Q<>S1N^)B@=-V-M>9VK4+S-=09")&2N*E*Z<7^R>#JOE,9;M3":YFFWXM3W-[VYF:ZHJT!-MP-RA@G'0X1%QFI%U7HN'N,Z\TP[&7G2ZE?UXN^EK\8A-KK2.B4P,4+)428VL-M?EEN2>P@C*SN*[:+OVU4VJ=IL9-J;IU:(UBB;*V1%2;K_GHC-MWQ\M@JH>CHTJ8\-%&_U)9%HH+JB!:&DQC&@Q3H6O9SM_47'W6LKL]R*QVYNW-MITFL9/=S@Q%E<=.YK$T+-%^,&>#C\XVN16+%DJ[`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|VO&;VII.9[6)]WP/!K-MCK6_%O8S;2FBYQ:C7&LV%Y9521+K=;"$V(_,P*=XZ(]YQE\6^P^+*$W\P]G_*-MH/BKZ6F5.LMMIMU>:-[:837H9T.N7!Q+$_BC"_@1U.,+D:X8R+X?]OTHS'!A_-MWZBE^GG?-MYD@&8F"XQC\-JH@:0;_-#:!KD'!5"76!EC7O"7]*L0@:R>@9IR^U-:-MP%*SM%;@&",BF:>.>R4/>A*MJJG\;.H0M^[6YF-*"A?JE^UJEW\R[N83K-M%@G_SMQG%V7>-M-8M8U3=C,MV;-H!@,[W#"K.!-E?_Y-U-T[A8N![D-^"^;^O,=^!-0>5T1$@-M0?A;^+36SZX?$N-%*.0T*-Y5NG5>A4;HS-M_^H5M;IF%HUE]T"%BA0'-K6.N!R@1^E?QVCY4U2?\TK;+K-XSV|"'"W5+TV05+X-M-VN:P&(%R/)(,PB9+RJ"-<'$JF(%C>/P2\'#Z241:CG0NY24X>2&F,D-1A.N-M;SKR!EX_$%GKS',88J$KS3HYZ$.S1YR^63=0"/COX"G@W<(3'DN"+R+@OXG-M!35[`-W+4$.1A;=M/13'>R_(J@KEMO\--J/V]^^UH@8R8&C8O+$.A*)$WA+5-M`"D7O+H.8'F&M5Q+PU^XQRD!0T)W+AD-W_A30+<-J#*I%IKH-@UR8;RS$(^,-MCU9R%|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f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{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|*V<6)_1)?;6]LV]-M\LW77#PW;1[[R>ZL^VP@^^@>^\[NL>%N^,4,1AM-;BV88ZNCU#+%10W5CM^]-M?>R?;P<'W5+NH=&>Y[FNYN9RV9!'#$BP!\WF8E$N-M!%\)YFP^5=7_=5@H6^^$!S-TT;.PQIV-9'?F.5PBBUM:.ML6XAS%N[__Q)\Y\-F#(-#F*/E1&%*EX"C.V8U^W@RVPD8C'M$G\7R8-M1KD=_*Y>GY4SZ-9#(!Q_G75;T\O8H#IRAVI%4T9[#(_')76RC6OO3]7S,P6-M45LG[_T]O!8#:0UXPWDB#03G@4!^@'F"7-#U*44FM^,KZ.=-DH[QS6D9G^FM11=.@2FM[&F]54K&PT309:9I?_OI7/6RT=$AQ<4-M5UVRCT@9$CZ6,25CU|R$T0=:O;N9H^PDCIU1#%>Z]+-G%W9EFU-M'*+-#-QI@:I."SXI=8-OP%%#]VI"0)N1-MT5Y$62!R^-#[1K9E0O&W32AV|G)\79?]\$RWT6X;<0O8.'7S'5-U0G/A"^2D0-M^;M1O2MJH*PM"!&%GO[GOT)\ZA^.HJ*[UAKNDHI-2@>ER2G@]XK"#S6GF|RVM>3IN?NX\0_IR$-MTIT$<>AJC$&[JOD#ML5$MGV[),W@X]*S!Z\"V9-%^8B--<\>EX/->CA;I\RUT"H(X>A:-M:HM*,"ZAN-_S]8IUCUL_:H$F6PA2L43@K]GV[O[&M/1&A-ARQP$!;RV$SM>9FQB]N&\7;!45/.DGN$A!5(TOC]&Q*2:%AQSZ6$KE5TVX\%*)\"O|F(_6;'M#C!02VE>@ANI:YM>L1=85%=]*:/*B5#'GB&!HY-5K+9G?.I'U8(=5K9F'8-M3#.UE>K?KI-]W3D,PP?H,1_-@9^#^*-R'XD-I"H2:A|IZ(@J8[N$@U$&$X\MO02*3RB[D+)-M-"%.@Y'8K]8Y++>\$3"$ZZS[2IA3.1"W9P.-ME[GAG^G8E^A.\,*ZE-MV3,?-(2VU,1MK6Z8T73.M<>PED^U*+-O9*_,A/E!2PL21'!I$>K@-M/.IG&_@+_-O"!"V=P8<_H/(,.KO>CH@(?9C!]<3$6>EF%6G-Z>C!O<(/*I(8"-MB-B4-_>Q@Z#$<70@)@R$(F2]M01Y1&\40A$"(@.Y&8ZL(AMHVMP-0+DX!8K-M_KX?936G(C)@:""-R[,'$GOVP-K^QYU:.2!HL2ZRQS(U1-H#)G+I3'KY04|-M\P9^ZVGP#MM=0^58&^N:HDF8-Q-CEPR#,FV9J+HG6;S_M_A+9*1"KFYALV5K-MPN+?\18/%6J5)%(@9,-?0>L_M\O-=A=LWENJZK9T32AX00B:'I-Q\D_/H6@-M28LM3PI>B*B3?'YZ]5XE5!7S=XZITC.L%&IF@8..:3_MLF'GJ"D(*QSD/*J"-MYR.=^#JLC3*OQ!,Y'%|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|-\-M9^B?O>>)DRW#0'>?AO>5]OI4=DT-M;>"F6CNO1?[UO5'':-O$/^"2A'MCZ!M&4]H@\|#-I-HYR9-$=+Y#3?:,\%NX-MM-H(-R5!;7A2)YR'QBA:.:S=-.&@6OO3C6_=BB)-)1#[#S:7OALHDC<.A.D;?%-MQ8*=@(.!)\MR(\V-("'L$/-M-,8=-_V90!'E@.OGZW?<=-*-L-M10)'3Z;6-.-NG9-/K-(WN-4-MMD/L5$SMJ*MQ&QQ&<-.Q.C<,.89R;2?\[^-'<3!:#%H"O=-/9MZS@Q147%%$ZCN-M=9L2-.-NPV(W0(G]E0Q=-(*S2Q=>V%X'!D9:Y#E&R^XA-7KS%@F0[K07_X?+-MD]"HNU=46T+*7>"U#W%\"7-.[V1X";,,)M$9GT:V-8$(>1CD$&B!?-I"Y(;-MCHS0<)MN0%*-',Z2%>>],OVH#SB(`LCM0DV5)5#V25]?1G],-M-YN!O[8!;8]\-B:W-01;-1<*@C%0G6V0)1W"P-)RZ?-FBC/?N!ISN.(\$4--M!;M5"UZ$0WL.K9N>,N57F--%6=N:QW5*F/1QF=<;K@[>!\%R@$I9W"11-&D5-MDRH[-"YWP>>V=9PTA'@$C^,L+M["\##K9#*!REQ\@BE!0I9&$+)WX:N7S0-X-M.ROC/3D+B$=-S@N0I2"0*.0[45,.B%P.PJ6VZ84H0\-COP=)0@$D3F62?T&T-M"9=-$N48KGA7+\;%?6J/G>RHD3GTH\GA$!8H!9L3MJNH/#R+(-32EP|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t$ZC=;XWV_N^>3'GXLR+_F>;?&O'X+N4#-M14?YP*-\>+?#X3?53X0N:/R@2-A=QZ75CKM2.6H.\Q(.@34[:!DB^-8?N+)-M382@G@/[QO/YR"DR+IPE=]40KWK!;3YWA1#C"-E-.4D^U&>(:5854UC&-)"(-MJ3IA.GV'C1>9IM:1UIS'4.8Z^E^*<:.&/IB8G6N7QS-#78\QGJ^K$PU1EA>>6>JS\9%7*J"4E-07_NAJA/-M:'F9@DD;#-.-<<&>K0H|ICHN"!#@\6W3D*,MN^7M>WPFNM.LL")8&LIH(>S$-M'WK$YJC'&-Z(-42?&Q36BSXI8S6=DZ.I=)>M#I<51?J<2)-K9SZ*!0U\8P>-M!WR-#ZDV(TQC5&,.;!]1Q[U:K/B#U'17[+R0/W#:1-MAS=P1U5!]HI07=7)F(#?+,@-_XLK67)8$AI<)UKN]+JSQ6+(UXI.&IE7MXY-M'2GDZ43X/[\CE!/!:LX136A\8]^('[*_OJ/$A-RVD23<&NVSE43-=)]9X(@=3M.IEGY_'\3(/MVYF[N9?%:7DZL'U2\)\OPKXJS?/IC$).Q1.?W8T.!AB0K:]-MC&>GJ4-O&@L&%Y47}?TM/2Y=@SCEM&"ZNYJU6P7E9;2*:\N-V(!\^VSNT$'6-M24_\2^C<245$GWNHX]R2OVWC5O6[+^-1G=4-6G%D,1U"?N-2/XC[C8#-QBMWDZ:)V-HUT7!L*^S>/B-M0^7!#]%,V9]T.BJ4#),2B^50GVYMHL?'QQR*8S7-MK%-W/BJVXJT@.OLOVHO14:@PG(\$>,_AM9F9ST:1#S*+1CLYW>,:ZH=M9F9ST:1#S*+1CLYW>,:ZH=M9F9ST:1#S*+1CLYW>,:ZH=M

B1DMH2)+GP|)KU;=U4+]HB:BFW_%/8WQQ"+9 MV$;*9E5^ ^)9M:56|YFZK6*$/$V45HMTEVB;G#5C|'LTSQ4H$/^J> MZ3:J6#+QWRJ*8)'"":RZE\)SW@",^W)*V-3 MT'7GSV^433TIC$%P!.O3_068 ?^:|:O+8RH\.^|+>/%[@G5!<$L90>F84!W@9 M;%GF)XA<$2RNQ@/#LU]>L0R4R4>/@R3*1,]TT#3@ KA,G6=-?S|;9P M6RF"QS*<;A$G&CPSR M6)PXE>K<*;'63*D6)3)%1\>=]*)>H& ^G!@@=QIT)+NG98>SS2#R7WF!]AK&; MVJ937FWZQ H"K,\"ZWQTA;O1R+=SNM1"/(-?'W7'DPO9|\^?W7XVAEY@Q#@<! M/MV3,152-*/(U8\N1^XK\2I[<8<CJ~ESZ3K^V+VZZF1F^3%8 M#^W;'AH/ M9EHCLE.F%W)V)26L T0ZG&Y\,\LWQ^F?{!MH^54UV[4UL/),(:8*)-2C MX.?+$ELZC(D<#)<2^F#H8?;1;.A,"/OLOPHX'N0.$'#4,1@(F!"7@N.'=" M5=JF.I%"A78U% -<%*SKF)3+2BVG]3;&{M2Y-/T>F8B^9R?L0O2NWS@"+R1NC MLKT;$@M*U6B1S&3[5&.\KLNG6EN?L7MMKRN,7EI A*$\](@[,7]=O*L"J_BH MW6_+N%00f*B.D<(25X1X?9I8K_UP|[??O1P<-^!]D*I9 >CV4;K#"(%]*?P MKEBU'Q)1_%@.G,T|T$S^29^@Q0)Q"WB@ MSP_4**!9^F0&LS,,'/NR^\)55T #HP/N2LH6RT3MY*!JT/55(9F4FT.SP%-A MY?[O+AG3VK1>Y.*%*&W)&'Q<=#97WS6!I?+M#R.8+1T!U^-?2[4%&(S6(9 MFDFNEE*FV=FFMVJ:2[>!#4O) (A*Q$)HW#=@+M&..I^RH@L;@2]Q"&=M\3NT MP$XF/D3T,'MI16@$OY76?V.]<;WC\<.%T9,(=AUGW|W?POK6=0PGZ F.GYMS0B4GVNQ3>I\E;QV6I0>/>:.F;8OU<_%"NXLRHD3 MPF9*E>I*UL=T/5=B-"&>2G0ZKZ% 64BY,?16M3:T]"SY2)|/JE:B>;GUW27R M"Q-(V*>YU|.Y)Z$35F$E44%2[\@=2@#O%:"| (H;M:HCC!%7PG/8,)U5U7#UW6[K//QEJ^125B8[*^ZY!.FQ9-=[-%V@-CR/"X([M>O;T?CGAX96ZP >AC-;E/M6M;,T2PPKQ(ED;=')#_94IGG,6$_Q?B,6D%.Z2 MKN FEDFM|/**:Q_R$M1P.P.4TV0/_MNH0X!GB@#S0%&*HKN#T+3?81(T@7(6C?OE\>RB7*WDXEZO,!;A[\"M90>-S/ MHQD_/>;<-+1'6^H3R<;H!A%/IX" <8*0V>;@Z.)#61WXJ=%.]X>H=,.!8O*Q+[A M=^O8X- >,ID:A_P52.3@+15> &;($U(@T3|)"[\(N?#PLY#L#?);)'P,48N M[9-7:8;IX$<%R-,YD81;4#A^IRJJ#/;6V=6Y"S;,^CSA5 [!:@H(XJG MG\>1D8'LNKL)P07WGA[Z&(H*%DAW/+!3+))2F\W:;*KX3 YK+%P7VGM>"3#O[M*M:\(+]A0YX]1TT,M^NB/1%VNU^9$QGMQ/[Y8)@+!L-L$]0J93)Q.I*-]ZLS M7B!'0U@0.I=V]DP7P@T;4'NXDO*SH8_<;&L%B3X'; M&"KB+;*HP+(JH?/LYM.YVW -66EM!053Q0PN8/W(QY?++!R;&FL0P<5K@GJAB|\5ZI'8\F#)3"_)@R(4) IN,L1S_1#QK1XDQCT_M=>>5@Z K\;2I"L32QEGS!V(_[>,9?*?/L:MRL&998P"+3U22?VL@F43A'|/(:TO&A:9L=:],H M,79T6*E,E1FWWE 7HI5@@(_2$ZY,!2)!P6DS^.>]0|%H$7^$4+]/L'^ M.]*=?V.]QC+0G+L%8(>$'+$PPY?:[49@5L,/%_J?RH7^AY +1+$?@"OCO[]RN=XM*07:K&I3#,%L3,6!H_L \A%G_E?DW9>B15ITJZ ME, ^SI6&A.4-0V`_,DY%,F.<+246-+_-Y/|U8=0CK|RORJ]#<Q^)-M90A#*M?L\!0;99L|PWTH;&<&$PL,6S1F7[=3-EI<|(U^:,4_NW\XT7Q9)S M*BSNIGVT(? WNPGB;>EE=.;@R$TZ5F3R851WLE'AN^QUP=0E40";=!9&1P"5N>=="9%V URC|+K16:L5<2$"F?-^<_VA=V^%B,EYPZ0F2TMT4J:[M;CGW;EG@\T17| [F*E2,5FA#;J6EQ]MQFO&%TR4M|]H1AO,V4>]+!%+B/I*0B_MUU INN_BP*P"+7K_F*J JC_.SKN$;.X*?"!QWCV5SSF-,/N\%3*L1[%US9F>& M?W1?K@QPBE =R@=>P>,W#8>586(_- NJZU4N_U!VG4C>L\=P?YQK2/<|T@\0$0%&*HKN#T+3?81(T@7(6C?OE\>RB7*WDXEZO,!;A[\"M90>-S/ MHQD_/>;<-+1'6^H3R<;H!A%/IX" <8*0V>;@Z.)#61WXJ=%.]X>H=,.!8O*Q+[A M=^O8X- >,ID:A_P52.3@+15> &;($U(@T3|)"[\(N?#PLY#L#?);)'P,48N M[9-7:8;IX$<%R-,YD81;4#A^IRJJ#/;6V=6Y"S;,^CSA5 [!:@H(XJG MG\>1D8'LNKL)P07WGA[Z&(H*%DAW/+!3+))2F\W:;*KX3 YK+%P7VGM>"3#O[M*M:\(+]A0YX]1TT,M^NB/1%VNU^9$QGMQ/[Y8)@+!L-L$]0J93)Q.I*-]ZLS M7B!'0U@0.I=V]DP7P@T;4'NXDO*SH8_<;&L%B3X'; M&"KB+;*HP+(JH?/LYM.YVW -66EM!053Q0PN8/W(QY?++!R;&FL0P<5K@GJAB|\5ZI'8\F#)3"_)@R(4) IN,L1S_1#QK1XDQCT_M=>>5@Z K\;2I"L32QEGS!V(_[>,9?*?/L:MRL&998P"+3U22?VL@F43A'|/(:TO&A:9L=:],H M,79T6*E,E1FWWE 7HI5@@(_2$ZY,!2)!P6DS^.>]0|%H$7^$4+]/L'^ M.]*=?V.]QC+0G+L%8(>$'+$PPY?:[49@5L,/%_J?RH7^AY +1+$?@"OCO[]RN=XM*07:K&I3#,%L3,6!H_L \A%G_E?DW9>B15ITJZ ME, ^SI6&A.4-0V`_,DY%,F.<+246-+_-Y/|U8=0CK|RORJ]#<Q^)-M90A#*M?L\!0;99L|PWTH;&<&$PL,6S1F7[=3-EI<|(U^:,4_NW\XT7Q9)S M*BSNIGVT(? WNPGB;>EE=.;@R$TZ5F3R851WLE'AN^QUP=0E40";=!9&1P"5N>=="9%V URC|+K16:L5<2$"F?-^<_VA=V^%B,EYPZ0F2TMT4J:[M;CGW;EG@\T17| [F*E2,5FA#;J6EQ]MQFO&%TR4M|]H1AO,V4>]+!%+B/I*0B_MUU INN_BP*P"+7K_F*J JC_.SKN$;.X*?"!QWCV5SSF-,/N\%3*L1[%US9F>& M?W1?K@QPBE =R@=>P>,W#8>586(_- NJZU4N_U!VG4C>L\=P?YQK2/<|T@\0$0%&*HKN#T+3?81(T@7(6C?OE\>RB7*WDXEZO,!;A[\"M90>-S/ MHQD_/>;<-+1'6^H3R<;H!A%/IX" <8*0V>;@Z.)#61WXJ=%.]X>H=,.!8O*Q+[A M=^O8X- >,ID:A_P52.3@+15> &;($U(@T3|)"[\(N?#PLY#L#?);)'P,48N M[9-7:8;IX$<%R-,YD81;4#A^IRJJ#/;6V=6Y"S;,^CSA5 [!:@H(XJG MG\>1D8'LNKL)P07WGA[Z&(H*%DAW/+!3+))2F\W:;*KX3 YK+%P7VGM>"3#O[M*M:\(+]A0YX]1TT,M^NB/1%VNU^9$QGMQ/[Y8)@+!L-L$]0J93)Q.I*-]ZLS M7B!'0U@0.I=V]DP7P@T;4'NXDO*SH8_<;&L%B3X'; M&"KB+;*HP+(JH?/LYM.YVW -66EM!053Q0PN8/W(QY?++!R;&FL0P<5K@GJAB|\5ZI'8\F#)3"_)@R(4) IN,L1S_1#QK1XDQCT_M=>>5@Z K\;2I"L32QEGS!V(_[>,9?*?/L:MRL&998P"+3U22?VL@F43A'|/(:TO&A:9L=:],H M,79T6*E,E1FWWE 7HI5@@(_2$ZY,!2)!P6DS^.>]0|%H$7^$4+]/L'^ M.]*=?V.]QC+0G+L%8(>$'+$PPY?:[49@5L,/%_J?RH7^AY +1+$?@"OCO[]RN=XM*07:K&I3#,%L3,6!H_L \A%G_E?DW9>B15ITJZ ME, ^SI6&A.4-0V`_,DY%,F.<+246-+_-Y/|U8=0CK|RORJ]#<Q^)-M90A#*M?L\!0;99L|PWTH;&<&$PL,6S1F7[=3-EI<|(U^:,4_NW\XT7Q9)S M*BSNIGVT(? WNPGB;>EE=.;@R$TZ5F3R851WLE'AN^QUP=0E40";=!9&1P"5N>

0=@BM<00XL.&^*§_|*GN,7+(+S!,8]7_ZQ$PP+/$B@2LH*X)]#?KLI#!=HJ MKZY-O42Q9"9L>K5-UW@ILU07@OBVV!H1ZOZ44@,E@K(6'YSED-#;,'G26&*V MG!|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|_3N8" % M3Y2R)ZI)PSYG4V^W9WMO@E3//M@'GG#%O6[?20BZ5,#:M@62SHUV;*356N* ME43@5,B B OP3L QY7-&)'[!H@T[&MB0.:&['UJLKF^"+X 71&J\5\-G5UL] M[44>6>T'E^; (S#W5Q3XA^<[^>,'2+#EA@C6I;D*YH!BQH>Y0Q[TOYSL%8/7@*Q8TR4DN!!%F#@>.L-@],/N0S?[W M<:7P;@:!JN'C--VC-T***H!S/U1-KP^,)Z$3_X1I8%#)'@S_7J7$\ADP5>8 M HO/]YXG^)XE!1[P-*F=?Q5.OP>^"/*|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

*J3E_MXMS5KX8)X^;/H"E@B_M$[5K@@F1EK;T(=&?3=;=G7("\KNBHTVCN9UZY31L)@.?!C]RG##DE6R$ AB] M|A[^&*B:J{9S40!<*
'H%=D)P9(@]X;W:\ %3H&2[V[_ ^N!80P!#?>OQ+_?1 M^DQA YD=K@>PPP!GQU!R,.5T8%XDPZR%]*/I $-]X!NPC5:^]_N=]@$A,/Z"/(\DOT]#W,U
M0#C!>>E1L4?LOQN*,A11R_;VSP5?CI:R4]G#F"/M &-$ 2(2T!['L:T_4-Z\L+V=!)=A+!*MW@Y.HW&$\!*[KEPOXE_4US>,_M%OJP%
C"HFK;KGR,P2:T9DZ:%M&MCWN;+!)R3S:?F3/P-WON M 3N@#D0&A@B-L/!>23NQDI:]3(7W1\JG-\#]#@F>,+578-^G 0V@P@$!@,9 M9*\F4Q4#
(C,S':Q>%PL'T"IL%M$&ZDL/0C?"[0=&{G[8+G MV@LY\AYV8G1F-Z,GJK+D&W);.3@<=*@KM"4U'E5E9Y-+;;L+_'(ZDE><#4W
MC"K$W9+MIC]LE1QNH"_E*KI:!^O9,#CAEIP>=U:WY)?#F"=N2G43D,4 -SSU-MM+%^2N[*G>P]#L-.,9_)/C39!"A2$?6A'0>L;<'=SNE2_(X,]&OF0>.Q]?
WM]1Z'WGE;=_:\1;)X-?B0*B;<_/_^\.Q^]^ MDQRI7%@*)V-M/S>)5G MKI@_)TV0;8ELRV]E6])A#O7.3XN2K*-?%/L#+0AD77Y=Z_*QL "9$,BB/*X= M0/*
3$ID4B*3$IF4GV!2WDZ,H+HO)(P,S:C0!=E:Y[,U:TATPL(R0'>4F>@,Z_>'6697MKQ+7)6"]' HK+\ M'7[I2(#!A2DU>,*20?897RMR=#5!2,M 1IR2M'Y-^>
M#-$Y^@OU&\[2;7/);CRL'] M)WI&WVS-;W6O^B[2?DT'R)_HX'RO-;_5X@@)^XTR_LI2>6XS>>?J/)"K\4NC M>RF:MB5O]C=**&!6+HK]W'+LY[)N-
II#/J2?+S;QGZ')TPYCHNS: M< #^\B./^OZ4G/!>#W%S^GG"8(.5UOL'IP>*\/M&I_I7+U1+1O;M- >#V=W M"4D6-
5,PW/"{2Y)W\%Y4 #^[TY;>S\LW¥1L; ?WYU=MG";;B7O^[A(ND$WP M3?)N?Q_AQM;%CCH!G$WV5HML/DQR2R\\9:\^XGCQ'TVE_[/OY_R'D7K;CM:
M]R' =I7QMU/ %MZM0OR#@@8W'5K[")F^RF 9$NGO&@?[")&^RLC6K9B?'V,K M5M+,4$GC <&4A9GM]0M)7%'IB]B*@_&JARTV
Y63Z\2:F6W'K6H&VHKPHN^W MC<6O%&>,7'KNH?>0\)R0.YL$@!GCXWSZ[X:@U$63E]^1)#O?_\)$^;I(S/7Z M.]7,
\WL0=S<72GYY0X$@FK!)=T1MM*ITIPL=*56YS,G.\\X)L!0.3\(U |<6[PQ4#QHSVN;\;TZ,0 M*4+\L 'IP3?B^>Z8
>E!_(3BB^G:5S;2A:BE815B4I2M,F4U251XWEKJEGL M12S::=Y(9GHU< MH("*4R\.T%_A[$'O8_EUMK*N'K--I-8F(U 9N\QDD#9"-\K&P'5#J-
[_?.74!EP4@!OG6F ZKXO2(I]F,. MSDP27Y?]?JFO;Y2&B:WW78H;7":,K89/9-.N8Y5:XPJB>S+M\G$C]C=(M+#YI.{J;K?GRM=
(HI(;*H& ^A#/HZ+-7?/7$ESWWBNN;,2EU1 AIK M%]*+@KI>;3CMU[.]UH!//YI[R[J-]JR+?@N\-83EB[9"IS^9)CO8VUU)&S;
M5$W=MFD>Q_GKU#6'G^]F^ER](OP[8N2H'^9+!\YQXO?:_I"?>0*X"'Y.<.DU\ZO^?*J/1B M&/W2=+I^]/TN8?;fM0*8;K[_F)-
O=7&AR"U:3,&8\&I[X(^7>1:@.HRM9[*H MRO\"G%N/NEZ73I,QND02_%Y2\M&==%IA?C]I/Z'#Y?3"+#UQAS>.VCA4H.A^,,V:=VM \3NX3_;,X M:C-
PQC8#MPA+ISH'? %80OD=']TZX :%^U0W@"G\N/GR_U2.1^_M>7FJQ,_M64IZB4EFB']NUU=2N58 MUR4,_"^-
@XWB$FG.C,@3+KVDY'?!Y"QZ!,;KM/S M.-\U:J18[^48*@20L$XBA=_G4A]?)W%E){<-30CQ0Y/1U=ZH>\)WZ)YP#81! M:02H//_*R_.O@3
HU(EJ^*^[AO)*Z(*T!!7Z7WFA_\?1Y0N&I$\6IT./&TP# M^,7P1U>39$<(O7=4K_ZUZ]4_,"!];0=-J +]:U>@?V!0\J9%\QN>[U^ZIOSC
M0HK7)IDH8OC1$<-]*F1XU$^\+2Q^H""1MX6!2%8XMJOT!]^;5*M$MH6YJQ7EV
MR@'1\H45(>0'1,#C:11,O+E*\H^+%2*PN:I0X%F002/8>HIN90EN4]K."[;2 M:A=R(3)\@_KQG0M;>,E;!3.4G42W0[OW"9J&_P4BEBATP@_,B.-20O
2"A"# MQ K* 0HRHMKSZPA"?II.E_;_D0*A,F94QHR"+JB,&94Q(P6ZLJCEI27CNLAT M,V7.,07Z@@'-YS6VQE,**8I;_H$G=^G$]%KS#YVD2Z_5TA;==Q-
N M5*UYO;*-8J_GBKT>ZJV.RH?>5W2UD!KC;K\\9#DBWRS0BAYLLWV:QS,HT(JJ M-O_-;ST.J\?FZXR5/O[0"+;;BN?)QH*9F:8)]WT>VFC,X- \NZX[+\]
8C(M&21@[KN>IFRBCS0+*+CWXZDN/$>$Z"^'/N 23W M<#!N?AR I(A 8QZ,OW?B:.?(3EBM#2%=?*(8CM\21JRXOW8?6W_68@-AP_M
M*#_AAR,;@J>M9/CT)\\-&>/9BQ\$V,&@ (%?=PM+ 6\Z?296/<-LZG7Q*J M_'F7_UVX9D(1\^ /P/Y ^IO1$\-HNGN/KK[V8XH^_CA4Y;$*![W]$8"*^!
<#!QPJ1S6(D.<7N(D((>Y@;_M\9//2*)T2R]L:F[7)/L_V=YG">>C\2<>B9=[52R7+T[ZE:WQ4:;=%B>B(^T-M^LE9C\C=!D-S R^WRD
MFNVX:U=O3#BBS^4+96X]G;H!3\;?7!5266MA-QE]F286#=+F_34MS&HR,O9UO
MIHRVD\Y/F]XO#0G9(&R>S,P,O;V\2RC=BF63#%E3EEZ\TK!4G6:3\7?WA1, MMHFU%@U=H[M*9EG0Q0X-1\;>[GG+XBJG)F7,;.%XWTQB:VXY R-
C;V=&2V6P M'@@B4^@4ET&&X@HYG>73\;=[)7E^3 M=@*@ZV+8PP@_[CF2$V6[@_WX[CSX>F6\$\;9O5 M)5,6C45 ;\;&3
]XBH^)G9=9+KA,OVABLDUS6S.UY-KBEL%];=M:9>#(&)FXQBJ_D -?PGR[M:HA6S^TUFRP8&2/3MKU!:TXS6^3,1K'2+VYD2> MSFG=RHK' S
R1M#U1-A(C7I^C'(W/.12VE;K?G5D:U3D^:*F M*YV9D6D_"D7'2-U=#;--;VPOP^I3&5'+TB-W.@,46(Y/>\!H9K-I-,=I\F/%M MOF=4-3@RMJ2
=']&,&N/&:IG5R5MFK(*.1:,C$UTD!X%.! ^12>Z MX=*8G(SQV2IMN"N,T41.FJV+5?"F\&Z7F* 4#?:"K46]PR3+ \]<8EFU/PR?
M&I>4BM%F>N5!B1$LK(U-1=+?XN'0F*B4Y\5\)5L>-YAA+D>/^?P(IWQV=P'5 MTZ'V7%1R:B=-8^55.3=UTXLY)4;WT,2$A9+)LIE3/)PAIM6R.LAA5<
WH?$U ?A4V,\F&ZWM6YS:XE8N[>JCZAI:45Y86^6&]8 MAF.T?-S%F$UNOLR;7DKVK7!9\\("DS@JN/.CM,7PFU->]2PALW5634Y5W*XS
MU_UI;47S<"A^MRO1\V6)]MX:#>GWPCNVF_XP57*X@;Z4]_QJ':QGPV#_#N#V MAM;0WJR-G%A@TAK"PI5_[*\X-L^@%;BS *&-
(T9&U%/#"]@R&0(G,"KSS!B-_MFR]Q8!]$M/9OO:/++]WQR=?KP\Z,JV.GF^-#9P*1"_;>SO[W)'3T?T2F>P"H M\Z;)O'-BGAAEPM2U#=-][;1]\IG/T?
=^P;D[R!>K7P M%C'LZACV>J4T8MBU,;>S"1A_B&,+$FV?8ZR7ZB&%7QK"WNA$@AET9PP D(@W[M6@S#THAA7XAAF8 F;"7ZL2B+8?
Y;]!N)WT<_$!A!)C@7+O4__YX^SR]#.O?==8[X M797#R3!#[.NH%,O;GBQ%6M%Q-%'>Z9!F/56,/TGAOG#_Q*N2#^*!P+_^2?/3 M0S0%K-
#R(L%H>ZKL(-DX@VSD'LY+C(-)QL>)P\UL);]=^W'>W>/]*?"6LWGF MG/9ST@39ELBV_%:V)2W"XYR=ER8XNKQWT!0;61#(N@1_;$_!&U8PEQ+) [(H
M.V=T0T1'0#W1]V7OMTW=U/D!4>/%Z MLD]TXV(=2Z^!,*%9@>3C!3O*OAD9+K8G(#7Y$O+QTD5DWXL,+UXTAK0$BYYL_!:B3MU\?Y-QI
W>*\W^JA]^%Y$_=LQ_LHR>3[1*;D- M8?_B 1\]2$7?3MN1-P@SKS1(*F-7'W6Y\-2N!P-RA==YOT:E]UO6]_O1GDNO M_1?OKSO+]74XP9,XO+ ^,/-
Q)!T\&:$N"_S"/YP-/K]T+]30]"RU!+7WY*LW? MO9T3/_?MG'RI7QP'_5I93S9ZM1X9#%,5Y?=OYSQ-M/==JRN7GNT\;Z<2? M1?
8N+1GGUHD78WF77OA%50)9SZ^$\2XM&>=6B1<#=Y=>^:>PGC_H_NA^J\!A M:[JE]ZHE:^L'XJ!18"]BZ@:-5,/IM+8.ULNU&VHW7>%=?
09O;R3>8>M^I2AK M=* 19N8FQ&>QU@2*M:)8ZY>)M5X03+_"08+HNZ.6,LD)P'N7"A6'YV>M_F4. M$L@ZKDN;[;3.M0M2BAJ64N-
QDN9SGW&0\,W4$@7"KP2*/MS[_V9,13'N6Y3C M;\=3%+Z^$CF^@&GX,7;<@&V/9-R75LRR;FE4JM.
<5(G+>,F\B&^,VME>QCYON!W1@M/*V7WDR8.E,M8CEO;D[-&8]CT$/'*1S%^5&<_R]<_"ND MTZ7//!9 &?<6L@"NJ!{XTF2Y]
((§4Z"OF$%Q1J?"ER73]AO=5GH3\LI7LL'(6 M'_;G1882!\.VN512@DI#*QF>?[QN)G^E% &<.,H14#1+L$0-_"2$7:]0CL"? MG&X\00H2((5D^U-#O@I$__"
(.N:[#V;?U+#> M*&\W#E5%%QZG9<^*OANPHU_MARUWY]=?>IF7]N*_FVQCL0[V-RC;.Y?[TLN\?FORJASLWS?]1EM+*U,9N\+U MQ'RWW-
2QTGH=FGZ[#(/7;;^;R#!H:$((!Y],.DRC#M.HPS1JG7L%P>AO1@;4 M81J]">HPC3I,H[RZC!]MK#Q;6C)5PIL1K7//3 4O! XP-#-=C5)=H2=GPY^
M3'0[M'N?H&GX7^"]DPJ=\,S\INEA. E%.#,)E;0FT7!T-]:\VT$0]]89*ZD)F+\L;N8+))]^=95D(M)&'V\1M($KKI__8$("(_PV%B.!=?B,9]D.AK5E*-;@
&S^^B"\\1X?&;\(_O MQ>/F67T*WS0#!T#$BQ&GQQ?7;R;-TRS#I5X_P.8%K,6'$&1+6V:.&J&[!V
M)2?"&'=X6G#RST]ZFK*)/M(L0$WO!TG%D>EH47U5/IZY M>9BY<&IACW\67SI*<>2%((OPAZ9WYQTTL;_\">:4.[(H:V : MMI(0$HKO
=$_>OQ"V$"=#-]_^//3%X$A4*83GIVH:Y8E>.!M@VY"!5R4'1>\ M70!?=Y[.U%^ [\%I":*J 6,D?$4X 1$@L: !&5T Y54T63J:BR,:X.$2?)'W ME%H]H*@/0
3@,WKRP@MQ(T%B]PF 3*G[<#AX"$ #^/W'LR,X7@9S@/]ZO\F M)SJ5=&4QJ:V3D0K]J(3_\'-F4*'; E7$RD;6VYC3IN)BLY/Z^ $;94$@-)YH MU.ZCNY\O2-
?Q^(+MP^O-%X+C;5H I,_] M >(TOY.DPLJH'+TS%KM;Q09R6Z$=1P"K@>+S^-5'50\1OOLIX-(S1P[!9Y# M9?)69M5W%-VT*+7K=(=I+/?
4.$V_=T\YH$R49].R+;A_@7<==MA JVD):@N/P MN.-8>6GA=/6"VVS(E9*]P.:SNY_D0{QX!8J9 7YX2$!X.));\W&[#)DU%5P@ MV(!)0F+AV-,H?
6658S_XBP2VM9#64M1Q4C'L(&':DFPD?!<0*^$"V +Z)@K@ MA@:%[D" 36N@LW"=<'V@(> GXFR9JBT@'@30:FB6[H6) W3EZ;ZC*H6;#1\,_ M2O"1]B*
<[T%U'A)YVU-_6 %>1#X(-I VITZ+X6^AQ@-XM!WX_<0"*)0M)0(-MS$54H3RY8.G'WP$0"6T]"7X,9PMF#>!%LT3;E!- R>N%;+GRW_<)"TP7$B4!
M[$9SCRE@;A+\NQ3.$E:EA01T/?#/'O?LQ6[N+M R3S,28.&>$?[Y(7$U6U3/ MG[JA$>?M(7B/]X*X](']_%=PGY!\9\]V3P5:%W+0@F0QP6Q4-
R%;D):_BM/3 M/Y&S=X\T;24W_6*E+W-#*:,-+&8;/B^R5PS20/X<.=3[Z>,#T;KH1^_D<1Z/ M\+IO7PUXK_O^>LRG5DVL/ACTU+H]X2;5X$/
N]HC:E&._CT)X4$I[_/\;+GE MRAF\O4RQQFA6#^Y^8@_QYDM/(7S/,X@D)P5=TH"NV%Y"%590<1(;,-M$+[$S ME]["$O<9F 2_(8>/ER/I1^U>NH];?
5T#5@(F2D_;T05J:L+60)W0,"]0WTK M9'A7WMJ&[\D'(QSL'X 58#6V]$<6-C23#8!ED>G[.M>G@B%8HIQP51D6A8(-_M>F=V[M$A1?
LX?!50,!WG^+AIV0DH/$U1;MI*)W2E6V=S\3]90_@\(/':/$ M;H'>21I$-E(X)<,.?UXX&B]>#4@/Z00U+37^>LY@O3(TY;@2L(RT0Q_U(QN M-0-3?
P/&B]H*[8AB(>O=?DM5B WV7'39=JK2C9KL!.O(M_8GGO5P&0\!EL M'YW1A.?($,:?=]]_J 'Y]B!E-H]J=?O-(VT)]C<4$EERDECS)L]^ABXB5^H
M'H_0X1$<2]N6)GP*!_5&CO!;6:@+FE]4UEAONYA(27?5Z*> "9YZR*C.YE MYXQ\.3I!NQQCJZ<*O35=(]9DCDSW^/]:RW)?CIC6L10&F!KP+3:[_16Z+-
&90R #O?3=Z, O$OTX?%.!J'U/ M+STOIWGD:<&#U,3@D)=S#5MU\=$?433'1]+'R@76 Y@_:/;<61T M&]K>CSWL7@O?<7WAT?%I"%)WG3C8I6]HA
,2^&(D;FMG M$/'"N7=^<\'"*9^;WDV%=>0;5QW8V!W/Y%VQZ8%D#UH6?61+XQ3<7*$'ZH%/ MN_9&,+Q-QW>
&>'*SPW^F5^TV5E!]S$_*Z:&>;5O>SC]BL$/73R(40%@GRM; M[PD!<%#$8Q-P3SH K5Q%\AIXWL=,DLDE&^MDVV.! ["5'?O$!J) :3LV-A8" M,/,C&?
H4Q^W[2DZO69]8Q7'.Y\K4D)+7;LNMKMC?B\>"H5&@"L!QDF7K?=&(QRC$21KOW>N%8P/D!^\#LPE] ME.-0A6!(]MIV_*DF IY$^X11K\ ?#RQY/7*Q-
RHN>AY_"AG.JKA.?RH$'MYK MZQ2W*DSEB]%$2;^FN+\!^4=3=[OPI[,2[CWHFKJ[C()9>E)Y&UFGLW+X7(7I MS3?-
QFR9VHY+P$ZU3J#_HV2>E*$C.=S%VMR=M77*SHBT-QX_K>DK?;_!?_9 M:[=HR((#TQG4G1X>LA6@"NZS"+'_/DM.@BA#6=H#)':9V,<
'"%1;MYG/Q_M.Y[\8[Y^4K0-V_FQSZLX6M4NUV*18S.3EU9$%/AAON#\$(A(V[3]G(/1S2 MR7X<4C/($)*P!S+]WXFCGR$Y8K0TA77RB&*
]C(ZD(2O>C]W7]I^%V1B'#^WH M8/Q'B G <8!/?_+O?A!X_4TQA^"G_(I,_$JF?(3#TFB@@)U8$0\;]^ MNW R:>#-(^Q^Z#
(!3(.:]P7W<'8M_#QB^]NB&E(VB1^G,>PH^_CA4Y;$*!W] M$?I^?\$1B?\%]_]_^?U%#Q+$GP])^/\-)L1>?";C(NR MC.OIZ5U$4&&?
H,**NM%F*YVMOLEU'%S'1G))H'F"QYZ/'%>\]*B:48N,V9P- MV5RK+@^J<'3Q?*1!)>6IIZ54O:UO2Y[?GVY-+ F9>R9_;:.2;CKE@HCY^+CO MR&.BE3'AR-
@S9;9H5ZVZ5\(*FR*1G$ M&9^)C]RTE70ZR>0UK"V(^9DXR^LN>'LV/K+15'2C/M RC"]{:\L5EMNB#,_7 MBHVLR.Y$P:QNDALJ92_5),B!RL$;'&)44J?
B5K=MO,_54_VNFQ>+IM@)8+/# MV$/K$ZV?)?F4K@\)HES/DQM.&="P;T-L:#ICRVMVMF(X?U[O-4V3D#4E'+]? M0+2#M7P3P(;X*U&A?K\@>U9[HF-
E88;IGMX=#*3@R4[<"(,KAR2K/GARWK!% M_6ZO+OV,O&6ZAK#FRL-!2FE/IAVOMCLX-SHB2[3WRKA0K?"[A PV[05XI^?X M\H8/M9FK-SEL .M0L$
$,K_/I#HOK$!2)? M=B=L@/*:)1C1%Z'1#N8MRI$W+6>R8R9>T8S=66XL&+CP&D!,]<00JL7'HV&
M:1#/_>>0'5(I6B]P&A]7^[C6G6FL9%U3+)34+E>P&Q)K:NRJG WBQK#D.\^, MX?T!;4-V75EN[PD6OKLK6W(@&'VPT"-+=] HF;XHV RCT>EM>
[3NSRICX*8J MX0EH&$?&N6Y@MK\ MN22$W,^1L[5&,=UF]5S$>]S:6O8S.4"K, 0'=;?,-65N^D]\:X.HF8O(M?>3BB^$X86 M(\V%L0$@S]%P
('6K/W)_U-A>G2T#G 1D='^H)A[**5,$COP%3)QS_"XXK0 M&'3O83#3*7]44:H$T"48486G(1WO_ =U',%#*-8\\U26H5'C7!\^\P
MRAQ.F.X5$MD4\0Q)Q7UJV?X\)"2FNP6("\!(-A M#MK]<5;7X_,>C^LA9^"1_T=N1V#\^E[T"/?Z=,]!3.MT\8B-]H"?#I-WV@KG1KDU)T]2
M%H0_R58]$YII 9\EM;QE)3HY@Q&_E[,A(?> ?VK(8I3:?)1Y\"@5A\,4R9?W M49M(%_:#P?QEA2N#>P5WY(31.;^A,$BKV71]W;2OSLPW>G(0=V@ L*-
%\C] MPG8@YJFR(.V.5=W=\)=-J0,HN>"1"?'H,/ ^C'LF)\5.4PQ 3;[SLNU'K\Q M]34C D+(H(4AB'(X'1F"?JB!3] W4#51C6R#*$$DM %B^S_$\7?
M_8>!C_L^ MW&U/?#_,S("[4)B/T;)7T;$KCNW,#P@D:@A1(5@!.'C;],.A8_8QNMP/I%?4 M62:#3CXSZKH8@;G)KC7B<\D2^Z?F'[3[PLB&!]7M2$,
[4D%FW4UZK">Q2K-$ M6LNY80(+D$]_8/]=DTIQAPW^A!0\U:^#,0;V,T ?*,-/;-@%V'PTZ)7$C8:W
MQ/E^E]4;@M4N1^OPN*DL0MT15H(@N1^F1*=F)R3R(=`9XYDI2$#39"^ 48Q E8]! M[Z0N[4,D>YD/%2",4NRVW,-4P.]Q70AC#X= .%"*E0",
(3C1Z)VB[7H'[']U7 MBO/>3-C(@K-+0HQGHUV/#/V^'70D9?#1>(DYM(FX MH>*>PU*Y%CS[1?-D#V[/O-
IWV"!F;AM4DIT5Q[5'Nj%M17'#3FEH@Z1>MD$@ MZYXSR'CL&XH8\P9C]CU6-R^8A:/E(K6N>,RF8S5&R0*FJ]);++#D%G/>O0]]! M0R^3@W7B=&Y?
4A$2Z7I D'83T!#Q.ST86; M$[/PQ#H+N^S?(O@L,BY/(/=%4"$%PRSP#/Z/,.$GP*E9(JP8BT%"77R^9^!Q* M"^.!?7GDK0O&P5FS N2 \!PC]!-
FO8>>+Y2Q_AVR+F!>@1@E+CS-\XAG M!L3S:#QG_];=T_ HJ>)]S1FSV$/NU>:,1UD+1\\'9H\#:WKWO1OVOR=AUY(? M458,1(
WLU%V^4%/AV$]V

M.7(^XRD();EX%<0-F#?9FS%O+N5_?<-U(SOHLO!5LOU3!T.TP>J;=%0T_7: MM5-"ARYW"RR?"0^&SN"=?;J8]V'WI;";##*'8K>Q?*
6HPY9H@Z,)4N$$\>K&T M]!08T5_??T$D:S4I3^H57^/*Q;61-4VU6Q\%?#9TS:C;LJ<.';5@"B8$+-L3 M#)C>^GC?Q]-R6&1Y?7'+"X7;K@R[?
M66.H%8Z3E&&<5V&\=,G7/MKB1EO3)L M"05MJ'L\%2]P^%)65&=W#]GN IY#AX"O:5-=#'B0\74%5'@%P"!D_75#F,4= M61%,6'E#F_"W$P V'J2)4G4-
WBCF^U1PQ M&ML<-Z8Y?EH;L[\/[3:PE/N]!\%?-0_Y6HT]=FTOF,/:1SUF$8]HE\4U;_6 M8WK7&SHM*3E"D7,\E:5(/I43)3Z;(;_$:4L*>32.3PM/._[.]
'%LN+P5(W MESF",@'05>8TC\?[#J?*>']I8GR%(7#-8BF-S,R'<&3V^62U+'L@;Z&--&A#I> M8XV6J)QL8NUGZ^R\-.:V6-O/&>5NBM.P='"]-
76AX07YYC"9PH3RF)K2:T:R M91:,C"V>;F:=8%S:F#HUDN;+@I31+0*VNXXM'EN6@L*4PE?Z$D]GUYU65ZF2 M<&1L\8J0KN?4MI7!YJX5R.D3\]*
<&1\\;TAWEMT1O41MYG[2S]YG#F;&7VJ MA[:17J3[Z:D\P^J9BE&QW9D@SF915LO3D=O:NKN1RD:72Q92EE+,*#8[/MEM M.]U0S?E:'6>Q)#_,R?
S&6*X7 1@9(Y-?ZV6[&$4LF;HA\?RT/C-G% R$Q\C4 M'7>]9-?@JIS6Y"7/4*%?J43&NE+5$.YN4Y0\TTH5)K=IUZ:1:3;; >@L1)+,>+
M\C0#Z)"5^)PB"3Q)D6)*2%,R1<16UISQ"D&U2HY.Z#,MX*U.O4,'I^A;*[:# M!D865IC?+;G&UIO6@C6$]M@S76XR7|\^LM;D+FWI.FAO-
>L9B3W'@_[/WGLVI M(UNC\/?[*U3[/'-KIA[#42#NN>^N$B!R!I&^4$)J0"B! NG7O]V2B,(X@9%M MG;JSQ\;-U"N'7KT66";F77F9P5E.%^OBSIH
M=%1F?5&KB.MV)AE7TQ46U")=ALCM9F;Z\&3*AE;3;7O"1NMLNG&I*=GYD,JK MDYX\|5#V WW1Y&9-#>U^O|8FQ>ZG\SU8,^V
>Y$8#;$LQXW\O(QW0_UHI[U: M6P/N!6+6O8"=6%!6\6V6F^$*2A$2:7(7;@MU6V7L ?IU5G|&, M/N?43U<8UUB5[A0:D?P,[T@A7;&,Z*8Y:44;+_2X_D;*]
5>[0$IV9148<0L M:L6Y.AV0#39DHX=Z-;]^3@LO"%1;,\QGVG1QHWQZ]!0Z"RE4R&?U:,88G2@^_M:-.U+V6[UIC+Z9)IV)VQYYJZ&Z[^BAY=ACL
P6D[G/N_G#+_ES[J'_R6">[[MWHPFJ]5VE,DK[H;;"YV^X9=:@3T(XRWQIWJBBHZ=WL$:@*'TB"1_L7'_SGN4*?(H,KB"$
M#)./O>/X49%![&OU),O(N.%//"CN<,#_2/8!?'_:&A:=V7\5L^HW9?(B0HAP ME/CJW/%:9?+1],BCN>/^RN05I))(?G5VH>
!DB#WZHG7Y,&G]!\UTY:.!>H3# MB:HM?B#<3G'##P3<]B%_(MSQGRG@SDGY#P3\YVKT'TEO^1CUYX'MN/$_$6YT MJ/@#X7;.\+XLX%\S$UP[N[-
EWPOY?X9U^BK[RW'4[>=?653!KIN(?:.)&HV@ M9YT!"S_^%W4$^B]\UM?)^3Q:!EXH$?^,OG8WZ6?U4H7UU^]-M;]F%K]XS49$]J6I=9DV*'2'?
I&K:K0Q;1+S9"GD864U],6FR:$0:A=21%F:.)< M_;_:#/EN]=O?12@_:]MV/Z&\7EK_822.A9*:EB="CRNU/0EDUO7S/64W5)S
M_5;]XYX1REQ/BR:.K8S(E,":)P0A25>G$Z?+QM59FE_)4MYP]L#U6M^O(FLO ME,I^(TE[VRWK>TI:LU\Y6[GV* M*KCD5C!K,*RTV"V-+WJ%?
F79TD&ZA'K2QE#)S_V"Y4=KA!O'SU^+SWUU].IC M/'V3F/XM^D!M3]D!6,1X*41(O4PL*HXH&ND#&-(3UV8N?%3YQM'^5+-SWUV M^NQC3'V3S,-;-
*;F>NB2O-SIM0M3RAFU%Q8U@IJ!)1XH&XS@MA/Y_/.N*E# MAN$60SU_T%&ZG\(TTFW2]S\6*O:H44RN324GL9_(4FGP3@<](< M'-Y?
3C[XF'5O>;KO9SB_2:K@-2+:+YBAR*BLI:1X8]^B377F!O8>0S&TTR_P[%M= N#3?X*A+V6ZJJ0/U M:04$VAXJ@WA>:!,>,;0+)DXUP9F<>J[DOW>[SJ_H
M05>'EK(J1*,SX@+HRG[&A@;%6U0Y^0F#4H%;#3TYPR_@ZYT\#S?1@3,QXV3^ M#B8;&!0VS1Z'HJF0_V1@#]'@(?8X4<66IP4I"! M'JJ
M99NOVZWP;/Y9V&L\\R#W6?90X!V*;K]1!'#XJ<89Z"/%#3C1@<53QJ4_,)@C^LR?RII;YGK<:=I-7;BM P, X#3JJV6-9_+ M-DTYN: ZBAF^Y)EA-
O$82XF5ICAF]"|^GY\9<EX9=&N@@?G ?R$B# (MT$LXU0AYW_06(WL[9B++#1.RK<|.[V_0>]J1'U^.C]#.VYR#240Z64^!.3..F
MHY338Q01O*5T]TAO/AKV1Y0>H%30H^&^65F4DU!Y #C7:R>P1Q"6^J'7;[_7 MI2+!4?#^A:^/1,9]EEQN+8;KN,AJJ;,..PE#E",/1(
M#"&^MG!7[.06/]H]@.+_&MX*)LXN=]HG M=#$*?I*0/;"+*C. =S\E[$\|; 5TM$FW"LL=L?-5;X9P>RA<#.B(_4((,=)-?"$$$11-^(3430$A?$&(<#(@Q
/+B%YR6X,R(E^7 M$?WD0)NZ;V]DHP?6KZL+NIL1_OR2B$<4-<3OVZ_]HSRPQFX+$#.T73H[3>U^:.#Y9R.2KPT5407!LJ((0XN%EN-C =
MH%OIAPF(Z*X^=C/=]VAP'U'EXZ3@_%4>XCD4NW*=G3:&M?'1P?(RD6ET8PU: MQ$-=-;I(EK,]DVN<'&&%#,#_%BQ]
SC]^@C0]HA_V:.^ZS_]B&O$'42NWI==+&3"+3=*+3+*.GC\:OBNU:8CR80&$,Q_/J3#TZEMT!R5](:;G,.L=D/)) M]@OA@[JMATBP[^J[WB[!#FDW//I3=1-
C);_F+;S\FPE\@W/(X%JAS!RH4QR#O M@-MY%#_$??"3JGEM AB'DIG(.MNRMFSM15QN7*)F3*,M:1'+"OI0F1^V(;8R2WNS-K.66L5;N?8E?E&,^@HC;R
MUY]$^#ZS%UXZ,;P#?_ U98)=7[@$/T H7^$U/$XJM]/*9KG.,.;2&"UDHB'& MJ1Z;,11%$EE]$X3DJX?
EMU7*C^C-.^CDG6;;3B_H@?]%DU(&OZDJ;"=A3FK MFC^JO"N)JHJ\C!9J60K9ZT$U@:1W9[2!S3E]WUMPM]$*T"= Q^A=JT/L[ZH& M/X[\
<]KRD.,7EJ@# >-VO1$-^[$_L:^32*V$LTI!LGF_!$ I^,A6,_A5PT, MJH:BI8)=86 LC!7@4I[7=,%N1&A_FVZEL42$/'W[2I1E>R7RXG8%B=Y]&'!W
MAHMX#)T*8R+JN@@C@3#V3 (YX%Q=K"'Q-Z"PDG(G=0!:QYU==3E25/ "?!Q MA@&W9[_I\AG!QE+W15=FE/X$]?9)+H1KVCYC7AP>B-
^7T!YB@OX,>V-6@__H.S;Z&PHL:FL(58*3 R-RX6"!)3=XI?:'B(^=*N#X=_# MC@V!&T#8$U6+IM%:SDC2T/\./55)/E34A;J8Z6,T1! MY/0-7 >5,-
+IME.*NO**[@RU[+JF0/#Y*=B7 ML7?H5+|5J;F7]M 7Z?$8M>W$QH#)_R-UJ%'D#B_Z8/-]G=_MB+#_0OS[3QA#9?CN\T-GS[?:P-Q 1]VCV
=*#Z#P@E$9%:QHU>WC[Y'VT\- MNZ_>2]RQCW9<+'14 \5#M:(CWW/J4G/?>1T1\AY%4,\>?I&1HUN(#AM%R/-" MI_]S4L"USZRA6P*;_GMW?
G<$E5LX1MH,\P2$G/HP;@Q?_)N35]S&V.6JDF'J MT'.[MRC*9FP\3$7_PHY^1NCPX!+=0#C"V,DE!/=KI_<0=A^^4?F$@;U$2>)
ML"UXAULL$31@ZTZD.I/OV"'GRV'0A8&Z^C_M6OKB";_M/U]KRFVW#4:F(NW< MV3#VGCQW7-UVE55MS(:(XXL\+F8/'YZ2Q(-IYX_H8LS?:
7VOU!5H6_^P[\]*8^K",\>OZ/*F1&\;HUV5N8--HF\AY"^0_NW1,62H4,%-,N0H=I& M.LT6=?
L:DNLP]"=H]P*AC8,,@]]&D3L_X@4I8P\8QVJ^[FE&Q8'U\!'P#@9 MZFCTY!74BW!OCON\Z\%N %6$GK@!> N]E8?_B#!VX'BW!P@R$RA2F<#W3E @
MA,89\N(<*G*GK0AB36N.WG1KSW&?WR"B3G[#]5F&R(075 .Z$P@1]%HTAJ@I M]Q A ^+B8&M<4Y."Z@\("'U[[%5LDSOLM'K9:+.D#7'0!95^7F-
6T>3DW=YG_HA_\P2$G/HP;@Q?_)N35]S&V.6JDF'J MT'.[MRC*9FP\3$7_PHY^1NCPX!+=0#C"V,DE!/=KI_<0=A^^4?F$@;U$2>

MQ[!P;37B%\7DP4<2SE5'L$9QX^Z^^FMNJ?]S,\EX- 8>DFND'@_W:[+K[2U M?B\@MY,RY+\?E=7/%LSHU[0^NWM&-*
Y*3[ZX,7G)7@_R[G_+OAWS8<8WR_M9! M0:U"J-LK("]!Q;:@%]+TQ:[*)C'M;S7P# M-R/V;3R&&RNX1X/S,)WG=[>BBPK M>($-*
E7!C6<:+7(AW2WI)ZBF1N+UR>[3[F>^#:NW4]-!@4^8* H[Z(HLYJE M7]"3:8H0:LMZ*\V0765KI:I.:K6>. 6Y9/(I'O.VG/Y23F!["G1@CU_ZFJ[@
MK4/<[WW;X+6ZSK]7"P+%=VUDY!NT'HUD_HKB6Y8T+G?Q=$N*IC0K,A3Q MB5.B&\&?J*CW2NR7=A#WEQ-0Y=W^ENQ-.[,$?N.5"TQ?
X0[#^UW%A\,;J-1; MM1MXL8V5Q,V7+:9LXG@,KP[JHC!2C7ACF+#SAC"VQI/>X3!?ZW+#G8JZ;1-V MJ.BF[9X#\&%.&_%=;P<#S3\^-[NA0<
<6%]2S(0K/E'Z#>#1#LADI@I/%Z'"= ME]KYS+;AH]+OQ*T'>X<"5+!]TGK!L&]>G#7F1X7<^_'%V8]H'"=9],?1.=2 MR#.70 P3_F=25Z[-@4-
=5"MNMY]WO.^WC8W [')$U#!=>Z92_3L5H$=CX0CY M,XL\'8L2QJ.':,5^JKX-QQ_91CZ@RI-T(7[HA0U_TR4.-Q;0Q7]T(<*)@"Q^ M)$N@QOQ(ET"-
^9,N@1H+R!*0); N7YLN@77Q)UT"->93L@1JS(]T"=28/^E" MA../G"+WW>GRQJJ%%U/[#T/"IXV2>RF)_E ,W*R#0/3='002X?LRR$L- B[@-MZUJ_
+M8'',N Z).$T"X56^)%QRPGR I_D5 ("AO%90J.N>^CYQ#*!9(4:," ;+[Z\!O:QM_\AQGF?^^^#>[G' MR$&7HBS[@M/I?:,,;?
L^@]>']JCPQVWM8RS=XOZN4_?@STXOQ[#>^H+N_M9F M_.*MS;O?UUWURT:G7]="=>']J8'G7IA-Z4$HUWW]<]NP:*MLWL^H;3SJAP&]P+
M=W>GIDB7/ZO@5PB,'PD3*#)_TB40 M&)\2)A 8?]*%"-/!W,/[$>:--VU>#/5_9$O4ZZKC)MV2KV+D6F[#0Y5]!]; M]4O^'(9X8[/H@$4N7K"[Q 4?
A^VE9(;/..!G$/PV.N'CG>8),DQ>G2?MMU[R MS!I551O P4A=%WEPNY$$WX$G[A3X^(T/[C^C[T,*'S!)3:?&+H$>^3[BMF^FY I;:,,&B,,-
+2*Z2O_[$GBB*#.3J[E'HSY4K M@AQ2]F5:ZK:"-6\VN4*9QHLX-^Z1FTPLU,A7)Y\J6'(DW9RE:#$OY22Q/[,&
MPJ!70)T24$N'ER3KZQ7.53B=G^YC]>3W2UM]9F#N&T*2 2%]7;?VX C[A]'T MA7MB7RIV_EH>QJ<&RMXV+B?Q*A$)QXF=GY%;;R)#(R)(W=24
1P3&T3;M_8S MWA$M)ZM;,RD11(01F?FLILT:-:FW&D90M'P_3+_=FWL#J@?X>#BDN^4I3E9Q M7(K3N6E[O?(S]E$?(QN""X[>O6*J'Z:1OZ(N^\0LA-
\TV?6(*:OL]O1LE!GC MN7*GG@<&GJ4W02)*2Q_Y$GA*1;'V-\T[_\2Q^?IFZ;K<3)IQFH0&:(4O

)%=06,.,"N,PK\TPE2|S/9VV|J@YY")2-$\H:SQXX'CL&\ M!C8F@TXW8("[3?Z"_Q;_(MXP,%7?[_E4+*/-QF*)&\Y>SW$T#G)IK%P?E\0 M$!&-4.&\W4!@(I((Q^V&B @1$LSX[S]$^USQSI&6S*N=*HUY!& MOA&-W)MTB47HY,]47Z%%&%]$5]0(OR^(/B.6@\(K@2"3ZW8&^ZQ:]A(1+ZJ5 M0_2'Z_1OI.[@HQ_639%&8V9&8964V@UA593:#4%@DR"K3;]HIQ0;_Y_,-. MC+"VP^&U%\)](2'\# .J A!T2UE%!0H0'U'0RHSS$V]C&E8J&%,K%GZD@ M4;5RB/R?B?RF..45'=;PMM'(II *?]11A.K90[.H-(L^SPRV.3LW.7KL/AA4O(MPHC>-5W4?4,.-1P(Z2.DCT/Z^$O17?I HX7^#@GD MT@1RD#=UIQ2"V5[#\><$\K8Q=JJ=QJV'U]8X?[{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

[@G^>EB$F5LW:)I.$V<8S1;ZGONVQ*;JRX'5%[JKI*+ M>>%XX^'B5/#-/(^W8H8GO/,H!CAO'8 MTG/A<=[UX;$9TJEP 1^/4%R:U<^,;%P-QZZ=D3-,!Q*\+[J'XD:)EOI_'RI M*ORZDH<,/C$&"]6P%@44;_MH&EP"|S0N$8PZ!*=&*9?!UDA.YY6C9*8K3?I,!'@_01_0) M&QRKMS@+H$8 L@JBDR2B!%;7>/VB_/,^FO,,5[0R "?, 63"8M,=VH]^0%<)AV7HK*6UR9/?DV?"GB9I@C4PAM9YWV=K4 M7M4R<[*87;]ZI(SD/H#;$G@)EJC[5 W?['&2=H^/-]*C8P]::$5.TERTH[EG@<6(ZM8@NU34+41F(63CXE!!'FE-SRR13&.*F_7 M\ZYDQP08%_L+?@'9@B3^F>V1+?>WZ(OH/W\#8_@$EJ K#S!B*4#4 -;A;9L' M9C9@RK&H/T#7'&H1Y)KOV>3'+WDXR:$+0P/[P(]LK?UEB','$#YLWB&N1J(H MN)$%;W'[-[H!!?#>_0_W![K)B"KX4 DT+^ M0 H,:2ZHQ5RM#&$'24O1'=X+^ O*PO\7_+.4&G@*?!(.,SIUVU!&%RG=R!$ M$/\YRKG/X513DMZ=^7C&))UP=[- ;^__L+WX7),>]2)M7NK:WJ[$+4Q(=8\DB M/C1%7L5Y";SX-Z\M ?5XNTRD(I3?>>7WMQI-0N8M$:%B_\'V_H;@.(+EE%_A M>Q#S3LUP393LW]*

[/_&OHQ&M[T;"0=?(;^9& NN'3#YZ+$&,:L]]D-(),(?#1 MVQ@-T_ZNA*IG5GY\Y[+P&-_30&3]JUW+O.S!O$;;;93S"2@9GE1#6W9+Z?R? M/:2_2JH(LCB XFZQ'F1W%P]1<@1I]TL@349_P3NP_P4J#?]R[V(,,W:'H M%I7PT@N/|[''"([DW$/CD,:!0;"8,D3\8'=#0N#%*"Q]&HR$U3%(Q,DDD?[F MX/U3/D;M:LE8@L]Q^D6 H>"=U]/;&H,],#7VBUIAE)K-LS*AE ML@'NC#^_M0AL" ^X\6F-

*RCPQ$+-5L799CR+TM*&)]X3*X(7)_V)HY6'J4*)\)G1H]=72_Q2K?;K%0+O3])9;27TXAL& MV!-'=RY737/,BT:;*U4MLLKGYV2S!^\|6NBPNV09$6K 8#& MCA=:3K9B<\LQ;**TJ=JV;H[JO9H,K>FCUXMS?6(H#O=(!%V;*D<'L>82T%W\ M>*&YGM0N2W9MJCJF-#4;QKK8E&1WI./AG5Q5--3IMH@YC:UF'>:4W;<@7<> M+72]TA9M5LN6N3Q>>LHYBYI>C,,[CQT+EBLV9UIF4X^N68 M1.E51BMTK3A7R_ .0<=50M%D=W3$X9U.)K_JV@;.LOEE9P9^4W.$T1+<>;10 M)[WHZUP\&^76PGPTPJV8'&?AG<\6,B D<93@8\-!@J3X 0U%25*B8H-4,B[$ MA11-$Q1Y! (4N[K"I]K3'M5K)EC%=)=>Q_$EYLM0F5:FF1QEV+FT:&S)=-(=V MXY0\Z4N-):,9CW&5SS;RB5EA,-3;)^4):R4YDN3\F3 M5;\AMDJR^<1V^397IQ.UG#%.RA-G56/B4JO.N.4/!E7RL#4 M'#^1G))FO>M'"9D0WTB2:EB5[+|\9S;1(DG(@J .#JU68Y2EYTND.\-6H4$ZK MM<;CE'2$5*4U.2E/$@4\U5AQA,R54O58-VG.1#G:.."5/:"GU-"NFRP2K\9J MT9W->Z-VXY0\&>?9DHHK8I^;)^LFH^3R\HQE3LD3+J:I$W;%+#AR9B; (1/>1 M)W.-D_($7_*-F3WO)M6N@6M61E,+$[L<8I M>6*0O3EG]0=1+B,YW5:[[HP:8_F4/&FLRH12*_821&EH1'4ZG>/Q%7-2G@PF M;$6@6]TYLMQ'*WBRY/RI&7WA$*" M,FEBKHYKFW[3E/CB\10\(0BIT)6%T9A35*VZYO3F4ALO3\H3M9I,KCE>[*KK

*MY*8WK(\7W=+ZI#S)58<#+MJ;&\2TKMMUH,363N:D/%F/Z^G)U}]^7'[:WCS9 MY6QI_,2BLF#$,M.Q"+(Y2,V?-+&Z*#?VY2K@<+?B$*C/W6W=0UG @_7OAR2&J93D5!X6U16V,.,\94N9LLDF*;6*MIBRE1!JY7NGT$=37QLS*9K4P M:'7(AIKG1GJ'CJ]4CB/__^F,OC=,1,U[7@1-@6KRY]GWVO5@9#$6? 07R".EP/ M&;Y;!H*PTVTQT^5(Z@4]'+$COCLE/1CS|)X4Q^>=9&%FM(E6M)?,$9L<+ZY/ MSTG^6N)S,H]4&N\2$Y5L;/+VDBC%A,;K -M7R2^'"%21,-UZ(PVZ#KV^'6G7X ME,.8%'BVCM5&M@&/6%X^'034"WUH"!Y>N^HX2F)_*#;Q66IK:@(7,YO]E#IW MYC*QC';U2N-NSP/UT7K8)351C4=-M2=I#F=H,DK)(]!S' BP;X\Q6=1%D]> MHD4G9V";&/#MIQ8\%#LX,P"/<>G B@3IZ!J0CRZZ](?V4S$CV*,CCT7+.TG M^-G,4'0:19EM Y,<3^D^IUAA M]YZO&LL:]:B 'EBF/6@KMB;6I(@NP.(VA|<0)\!OT+:VN_(V4SLOI_.8LUZ M!W^,CI.J;&S&399\!<%YD]YAR<[!1*>912UNV 2S567) (14X|W1'OY&B]";UE.7&M-4= ML\ 7KXGT9K!2DD[Z7]5OLKH8C>.J_LCFN0;=I2MKMMR4T7CS+R*>6R9Q_)_R M6MI3#N9NHUQRC+$L9^KEU,&4C=<3HI3;94.]G,H&M8_[/ %F7R/2PS5@ M>?U&2(9_'7WM/@X-!/CGS@IHCM/Q$4'[0@JE2X('3U$VY38)IP)E"I;A3(XGV92&2O8C,.3^%$N87@RVAX[0V6$Y: SOZ

MY8=N");,QK+5JD#PCI@32LZ\F+&!JA6!+)]!5P/1)5XS/-V$A<2LY ;]CSC M'9E8)^D$Z#$DQ@[!'7R0#$TSEM;OP/#_"6X_DV511=[VH-OMU3H"V^-GEOC; M_V-_L7 AWIDP//4J!T>EO&,;A^>DZ,K!V>;QT>8N$2#I'F/:IK\N[WU1 M=^,?+!0E(ZGH:P6G>^>P>V^$.5T20+ 6MM7$# ?0^\A (NQ$N(EW:KF^TN:RKD>_DTA>"-X78;ZR)#\/N\ MA.07DE](?O=&?K%(XH;*_E^ZAL>O',?>+_^9,'S%Z+P?_|=[L'I&L;*_8#$ MJ:& H4[=AW"YVLG<3V^7=?RGHMBW M'+)Z#)"+#$]Q,R.#,7-U?[-7'(6);<5EK""K&7S-BJD:0&BY(%N*OS0<4; M*%[A]7^L25F8VFQ2Q*D2LRQXT. ['VTL5?@U?UC:\DE/XX7,5:IWF.#GM+N><M&N^E<9MLRN7Z^+,U1B]-4"NL^?BDL4IHK#.8ZUJV6,PR&FP&%(5M\"(GRH N M0*>!9,"O'YKHQ9-_.AC<+*&[%UJ7*(YU:\3O7H*1-7T09TJ/);5;$]SYT)JH MCXD[K)($\K%HE=NK+,.0['R6E:?#N<19.FQN1/_Z0]+40RQV+0D9/~%P]LS) M,P_2@K6|"QE@=R"KF%^G2/+FI!AM]7\457IL[4$QIW*NML?)"Q6E)&94G; M$(DR.9@OILR7C[)HZ1[-KD3?0GA Z/O+T_0TOM*>|:UA;GJ&$*_)]2GN=D& M%HQ'(S1Y) ;Q@% 9O[I_*NL(697/@#M9I3))EYA&31H>^@3?A\J2;&-BR!U] MRO'S4H.OTT)G)D$]2T3H#XULOTME&[HC5P+#F5I3[,+1 D3E'5 >=U&;$$8A&=V84VZ:-?B*-GF:=X%;](>(Q%//^Z?AE\7N M=[.!0<%N>Y193^KK)-L:-117V8HK$CK![^6AVT#VG-|>5OU74'\20 MSZWCU+&;\F,C79UTAN0FRXI\HTB,U^5NEGIUB-,GXM1E:[&9=HAZ0U4Z&2'3 MXFFQ74<=WG_]H6(? C%,'G[5N8/X$ZZ#U"R/0]R5[A5NQJT@8@H,UR?C/,-E M"BJIKEEJH';N,]S,3N1,+46-QD1M! QRJ9,$% +%'/WK3RKZ0%*I*\FY&_/\ MA4//+W\ :"IY "D@X[S*.ZFTE5IE.]\?SP7JFMO+%/IT+IL8HWTM\TG+E,K+45QI%7'AD>6,QT^;:9B.I M<%YD!?C]\

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

G_:'4 M;+95Y¥M20BXC81VEGML4&%RY%<'";3C>ZH'^*@=[1\OVET20-M0*HR C.D:^1_Q?:X_^8EP#]$O_[5W=(V4F 9HOS MA$!\7E)K&JGAA&.L6:WGS(O#\3*(9#7DP!=.\ZJ+ 6ML^BS4WIBD6Q]N103 M4#+$'J*)$Y9<$TIQX-%Z<[5((DI@=8W7(^XW<)Z6B):%\2X-HQ% [8'&*K8GH-M)V/ 0O#7!A3J(APX)@%#0UO#*6B"Z#;11WCV2<8C,A1,3_P#)X)-@3'BZB', MF8$_H;P$6B*"0K0-*>@4:0;9KB3TIL)E]'+2=4!FRE:HGZQ>@#_=-Q M8+,2P+Y,J%1C;&:U,BRU-%$;=H/MC#8Y8 D8NHA#%7"D%WA=!]@R+5@-:.Q-M:<,$P,4N["58Q+Z 7K!_;*&8D&BX#7?U!QI!IJCY\YB.P?-'@J?O^_(8D W MX *:.%=Z+;ZH.L,_63BX'TDSY=D#[Y3[KP[8H+(LS HU0I]>:H28D5?QWB3 M*)4S0#"1="01/99+P"B$^-'W-\0A(DOEY["YMZK5B89VT5+&?KE"S;"M#;EY5 M,DB* (1?6HJ\B6TW!?)5+=.VZLT,GJ%R:#ZE1_68,5F55L"'U8T7-,R8%S#O ME!%ZH)![G7./'1%KW^KXY#SL]M8K+CEH]GAV71O@47(3IZ3"/9ZA(.S6I!S/ MZ&VZJ#JK%U%_^7T54?RU*@R&;/Q[(1KBN5I[&DRY3 M&Q%.)I.U!,>A8NG&FV(Y#/=^G++*DB*DQBM)YC)Y=II6%]-X1;I)S%>I)RV+ MTSMC+C.SU($DF&G+!"9C$"*ZEU*K7P5+BBLUE;[.[JAKGBWRA6XU.<-!+(G(M,1M=-,[;_%2<-\B1W4L)ZCL.[S:(S\G,X(>],T61L5VQ^H5.47ID]HX4502921AXN0+0=\P MYOL5,=_6'HOM(QGS],6MP[Y@B4"QO2T)%&MG3P%%E/]__'3V#^-_'?D$NYXY ME'0T%@5'$VO263SF*6OP5TUZSD60OZQG TKSIN',!N/B0&&4NJH0<1XO1V?D M3#('2U<[*;H#,-9^_=8!^7R@*8J4H>FM2 =[(4]C:0&9"6CD;<##<;%>7,S5 M!0_H=.T!"> 'I,O95KT.D8+";09$1_LT'27T(P$.Q+:.-? FDT T@9M%;+.PO M]#O@#L<"#K+]_'R6=>/-FCZ;PO@&%RR=O?3!I[1J36G%@MU$I(IF()_]S_GQ6 M?[;5NP>T^IEUZ"ET+)*BPZEK+TK?FTW# PN+AW@)'EZBP (*1) O("5A8@) M(&+(2.R6$\!#O+PLR,+QQ$'$"UA9:)$%$#%4)-0O 41+-!(+#>4XB45B8=X M"2!>R @=XB6 > %R+!;B)7AX 7(L&>+E:G@Y?T;1>?'*[S^0Z*WX/>8'A-[M:7K,F_HM%DG&OM/TF#9*LJBXN17L86Z%VP2'(A[\;CAG#2?ZI*=S$0"] QS^ M&QA3X37PO$=16XAP/_#9O&[A^R\XA)T+EG/^/0+=!2B1CJ2H[T2)59CD\P%" M#&5!*./?-2'L35LY&HE_*QGOMKRZB/!^*]X>D@Z,2WPKTJ'N1,_?/>60Y#>C MG,L)G=>#2B'ID/0W(QW]$C9>P/WM<_*H;N8?1>PW=]@@"-*I@EBR\7/=GD[M,UTEB%N_4K?)"U=#%73 FF++ST,M>^FY![GY>5$735YC=($1HJN6+:)0JQ> MKK27HZ^T>YW1LB$4"9[O.&2>*C2Z^<.B#NIZ=3W4MM-;;+9Y%*DH4V'G C,@ MGU@N>SEG+ 86F*CW$4M>;71F\+L$W$40![2WZ%8+HM"*^_=8#)HBH24%$74$0 MM5E%%S)TFT9K/8>-C72B2Q_'I!I-0Z[119P%=$OCJR2HVVKO-X PBB.!1$ MB6CB&H((^9ZA'$+)+$%DQFO+(3==)(@[#XH8>KTZ\7)BJ%IM*KPV(2<#DT/7-H6:LVBWTRW,BWZN;>)9(9V?B#*:I33 M+1!.;$P,!@5B/;;A'(J2O_[$'^C8FX,]_0[<0:B./LS:^7BM|'^?57&>NA*8 M_>X'+S^QY;WD?;&X%0-TZOG:_^<@MO6PKZ& 9JV''^]J79WJZ\M#82"399Q-WL-5X"+_[-:TM^;7F[3*0BVWR'WUN! M",& 3>3BOT'V_L;@N,(EK!$=@]B!\6PWL\.ZV']BV]DT7F(L8W9;Q+X^I!B MP$=O8W0TDHA="57/U%5\I]-Y;&Q"N?JO=BWS-:I$- M''!"=G?Q$"'5'D';_!%)S]!>_M?C$2_M_/I9IXA0! M>>*9R42,+,1*/*<4TIU:M5^^R6

VJ9UCQ!>XPW48A;LT:-MHH0]N22XO6'!HS17[RLZ;%"KVWZ^UG"_X_%.?'D&"]JI1[0B3%65 =RWN5[/-MV$8'YO56+#D5"":'!?C;@$6V-'4@'2,RJB@_2I;O]V6N2TTT4FHJB6\JT;WK!VR0#)K>¥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|]5[V@4R"/*[950WS2!/>3L<'-MSL47LD*,5,.%LEH-W)MSRVM!43F^-HUZ=^;M]{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|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§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f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|"L ?ND M>%A&$LFW*J=VO%HU8]0PZ]WVRSP59/&.A9V MN:?NP0S!]F:]M4YJ#^4BU!*(OSCC97WV>>W!!,^94QN>?X"B96QCZLO.('AH M,:Y8"<8F3L)^R/26GNI//IBB5V\L5;&;/_APN=#/K,Z6M$#%^6&/M< 7++_2 M2D K@YI7MM)W,NZ6[^-?FANUZCL_ID;,V9M_I26P5"GJ6 MBEE*J#AW?JJ?YJ6]X26MERK*2UMJ]&;M1MGL>-Z\=O;ES5OS^(O]KL^>?!K+\KG52:ZC*^Y#6XVV MUN+VD?UM:^W>&L\3W76(5W/HT_?IEI1#&|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

;S>G8>)O; I_|_U[N5 M/^&'?)[C4SO"28_$2P_X APU\.6"TH;QXQ9F;S4G"3'R_^'"5;5&4EX_|_}3! M#VSGVTT4IH%
[X(1^&!W]P/K.&>^468UX+,5BQ+NA!X.(VM\.["&\^,CV[^S[M6,RR \3^\=T@C%SXQI"#PF4@IH&VARB_XW+,K.78_GZ@K)C@E0.?#I,C<9O\
M+&*#DA_B#E O#(XBZMNX+16?7G@N(PR8^R,+I Z!!?PI)M8TZYW6ADB5LR&C M23NCRT^Y"*?]<'5V/#=" &!,ZPK9DK?J R8(DG@F?/4PJF*5/8!5S
R5]4LB#UQ:AP.@Y?O'"*OS8YE5I:32+Y5SI%/.!D5Z%BDFB*Z M^*)W2\U#^9R_-;N)"EPY2#TW563&<\>=W>%80_F48&-\M6_?CW]\.'DR_7%
MV9_'0ZDNA^MDW1;\5Z?3KF5;>_Z%V5+/O#V^7G=O%-JH7_DFH &Q@]_?M5Y MM:;U:0 ;-27,D%C+G'PG<>A[+I$
9H,K^%SUXJ08MGC+KOMI$&%C\ >N^I*.!]@P9(,&8<=K75C90KO]#:C[MZO,57Z$/-'8B;X(BNS'>>)88KG

N;4P>;D\#U#K6]$H*H*]U5>+$),K>7((($ MNZ1-[@C%*4@-8_G[BNI0:1A..0#,^=B#A3?&.S>^DHM/W;IF1P5G<;?%>?. MY-_W?K6?5E$;A(\[I'L!C>UP'
4TM,?L5PJBMU^&9EV>/%[CJPHVOWSK6;W"
MN=5V:NMBN*IMBWA;@^>&U>N:K=:AVV[W&EUS]PV>I_9%D#>0Y5&^4*%79X&J]E*=!49E23&NG2@F*!_31'D:
M0^TQ;4I1V+=:^^35P5;EJ5**,CW3.C1[V#BX,56!5REPIW=%E!L(ZET1%8,W M>E?$L^=8"D"D=T4\>XZE
$]Z5\2SYU@*N/6\71&5PF2K[876..O%!MRL\@3< M8"PM'7 K-2+5 3<=<*L,:4J!&9MU2P?<=,"MS-WU*@ +-S]YG0?C-C"[,@&A MC1*O%+!
(MR36+8GW/*2WZ1F7 JSIEL2Z)?$>AP*[E<)\^X#R*A4*W-4997-"M@2U#U]Z5'//J4* .!5;&-J5 E\UZ0X<"=2BPS*BV K!0AP)U*+#$L&B;@E@V
M0+5AZI8 7FV3NF6#9!N=;BD VC:I6S9HM]'IE@+HO:BJOUZE,-T^H+CRAOJ: M1KO1,L.&3<1Y#X^!8698-
Z^PCNG,8A&#W+L)!5QFUZ!VVY,9[>05LQ?+-9 M@=)8J-H3U('IZA/4X*K4$ZP> C.-NOE3G!;?Q>[NL'.!X2=@?$ M6^?,ZI6_?O@G+$DZT4!-
!^/,5JO;Z(!_@F&YKG'X'5YS@/Z*T6X8W^EWTW"W MUOON"TW(V7#H.91\HG9,"8R5NJ2*WJ1Q0EHU+,,SR8 F=Y0&Y#RBL>=Z(;F* M\&L[<,EO7A#
+>2]%TY&-CR5G 9.78?VR@1[3>/@=XUG2X=G=8%>>9$J,_X- M?I8-?G8/S<9^A?9T@5ZET*0NT-LC7*0+]'2\WGX&#W6!WCX'%E]8@=[3IUL] M;
A^AZ6#CI6'B94,.FZM_]\GF@#CD_Y-1.D8A* 8=+3:VXDZ3AT9MC<,7PIH M7=*0HPXP5A'-[B- ^98:^VC!T'X&G#C!6"BOJ *,,,"[I%5<"(+2'_0!W2=$2
MH"K=_4]W_]/=_W3WO\K"PX:YSL)&'6+5>(QKO00UCKQ MP@#W#!^//#K$)H!.FGBW5)0L1C5BQR2B_TN]B+ID<$\N4I_RH['-AGU@-M_8
M;TD8J1^W7/GQD"0C2B[AD9&7>##ND^_.R YN*.D["7YM]AL'5(L)Y*N9'[^_M9442]7;=[.M5A M4!T&K1)@;)CK++59QQZT5)RZ(/7[T
CMP/-M?&GLD9L,FA; C M,5LNV5S$<75HNXR='H$@5W[,,9IFI6_DQ MR^W'X5J5\FK:: L:[3$DU]*@I6$CTE#V\%T%HEC[%K?:NTC52XA-O81HU$N(
M/[V$B--+B#&]A*C22X@C[7GDR%IK -=T;\ZT.'FTP>&3MJ'_M7E*YQG:Q/B:R M5*AJ&\RO:ANL&F-B;S>
[Y&O]LGY<)_B0#CR[9>C@DW:WM;NMW>UR6@[M;FMW M6[O;>SE'[6[OQQRUNUWV.58/EIF&63_]WIR M/)=0,2"F]U/M/TC3^ZGV'\#I_53[#^[T?
JJ!GX83IKL_K7.8;KR5L6HL;%+ M9T3'|F8B8[H00Q=B/$.5E&874$7\'RUN6MRJ8;F/^Y^TY7ZNY3ZV22?U^<[A M3U[P;8 G*FL[KA5+V12+MN-
.W+2Xf;,=_W#R4=OQY]KQ#W3H!9XVXUJOE%NO M:#.NQ4V+VSZ:\4_]]J,/]>,?[('U(^U"=NR M[-VZHLU*P,Y] WH#V_EV$X5IX!I],&3_P!7'(0R8G-
LWE)PBR6R'-0?\8"CYE+P98DO!)*$N-@-4/6)LW>?RVWXQ"5>0$YXYT1B&JR/9 7!XDN AR\! M$+X$"/@20-]+@'DO =B]!"CW:/!VF-@#G_[K)]>[??
Y@Z]EA.^ +=:1\(B/Z M8_A=1OKK9H^.WTW"F)67'444R\5O]>0A3 2]*@PNQP\'3NB'T=$/!OOGG7PB M4F'F<>S5]3;5A+-
:=7CR((Q<&AT%84"S)25VFH3$(:^]Q!>+'^R=[$ M$?CV)*9'\A?Y2';WYUQFI:-$XT.@Z)(1C>B=EXSJ"_C\Q9/QAY*3\3R,LF[AR\5IYJQ=P MCP+S:/".($P(_
73L'WF4KSQYMV57>+%LK5X;=P M(_8H!TJEZ(%63N AFD5.#,#ZTL1+CQ(HT8P_IE'@O2-5?9&K$8TI<7!:>0=[
M.Z*,5UU*QW#UD*D|O)ZWN3\Y9LPKKP)#_J# ZDX83<+(3GC[_(@.X278;- + MX H[N,?GP$I(EE:8&,PL..93+?3SSOD-
UIO?'E.XS*TA@Z_0;5^]A[RY&U&X M)P+1$)YJ NP(GE$0E.-3.T(<.YKBU@:^O0B\-@Q@K>8D(4;^'[RRW9H>^_^M M!/^460GU8+&EOZ$'
]#$WPX81QW9_IU']XM9=@"__YAK4C$H7 ;@,0PG$.7W-M' \]PQG;WP^4%2M2FM\F/XN$SN(?SB#45U//S92&!8Y4$30WS7JGM2%2Y7S(-M;-
+.Z/*3+']['AN_!A_7WH:R!4S;'@("'P+?!#/'*_Q,*NRE3TH>A[\ M9?,/BR19X%]_]7#>X!7DG\1B=[Z=HL$4,15!EJ25+_^KKQ*JOD&82^N]3%9(R
>D=P0CXT1K2UJPAI%E4EV6C/J8RI/.TBE,& MND)E.\1L5@3%:IX!DQ-W%B$DJE_3QP[C1F6Q/ 8&C JTK#&,%KX A$DO&9 M1[8_1 .+#V%DU_GAS1%
(TM>R\XF*,P@JF[W.ZL!OB4!7ZV61^C56TOS"(H@*0_'./_0#^^DW9)_'R_**^@Y6 MX$$%F7UO#^+03Q.: <'B%%4;N&J.I%6WED;G*C>U0LRJV;J;NZ2<
HUG9_K M#!^3;GR00S>0QIE3X WRBT:NYU?6JU6HTS*V$OXNC/JOL\]IN,_>]I-[L,T9 M;GY;FE>O^U-'7?95_@">V!$?]!<0__$
/+1.C>#9RQ=+\FWPFH*L\ETN_8?"&_?OWE5X'(*L%,3]L+LP/6 M>=I_'[2R6^&.1:!NQ),\4@CO[P8I"168!>A
MQ<6UT>9,>N\QR9BMS&7YJN]Z\,]'!95,:+77F=!2TR BEU3(@A0_P\!APYB; M'!L-/7=^&BP/O U"]Q[^-TK&_K_^/U!+ P04 " !S/&=9!17MV(#L M* &
'AO;6$M,C R-# Y,S!X97@$,60Q+FAT;>U::V_.:.!*]P,NDT MR[+SCIT&:)/,L,"TZ?12S,Y'2](M;B110U)VO+!^SR4E1W'<:1Y.-T&G0&.; MNKR(\[-
S+R4=_B,(3HN4%[%(V-G%AU]9HN(]%X5EL1;<8G0];T%P= A=Q_4D50Q8OQ_NAIN]S6V(#39W!OT# M]ND#6_]R<;SAI$_.CR_^_>G4+_OIR[M?
WQ^SM2._]@Z#L.3BQ_8;O;Z[,+ MS0LCK50%S\\+P],,.6TNM+0=A.)U.N].MKM+C\.)SF-H\VPXSI8SH)C99.SJD M$?P5/#DZS(7E+;$ZY-L*^6?
MR\7.P#PDK;2:.#L/FT\M&*ID='29RPHR=9>+-M6L[U6!:!5>5@JU?:(6:&N+P@S4L>9+(8AQD8F0'_7YW;_=Z M3,MQ>CVHO',#+3)NY420]I,>.!-
<#R)ET^B$LMFELV)D2IL,.*YS&#U\<\MDY&6KSNOST0V$5;&'-\-AL8H>7H]=")&_E? =WP,).%"%+A#>UN[@^MN+(\MM(RQ'(T.?
4P&$&;T?]]_D@G14A,N9"X,^RBF[+/*>8'EW0B9T;)@ZI>,5)9 MU>E5*B-IV5;_VS\.(T2]_"X>QM@#0G\7%X^%MG($:RF3W]/'_U0&"_^PDE2 M]C
_UX[>=]CY5!3LK!JGPG18[-R<,9MR.S@,2=T3>MH_N+G_#B"QQ'4W)(L$ MV1X$)%/'8K>.16\UL>AWV7N6\HE@6DRDF((B;2H-
^[/B&C#+9A@OE;8@3O:S MTCDH,_B-J1'U_F'MU [XYF=L6.E(>1@,OS! KC998W'CU'SCAM7G5@^8Y>% MFF8"=:SC/LB:E)V2A3 M4]/ 1XNQ-!8-E&6?
0L0=">2I7LF7 E5I*,.VGDCCR %2HG!Z MJ-.ZII4V-?GC A)?UX+K3'9JVJ*+$A0#6XS*9.*,=:;*C$PDUY(7/?0MK=;>'.@ -()S(A''@SK1'S? (/4L!"ZN
MDR;1@)[DDR5[5#984&V2"45%+C6.G$ M&>"ZG[$H4"DSH Y71$EP)A%T=AY0@+TLP73=EX*M_95A*]Y827-],N%9Y7B" MDB=&(S0Q MZ-
OM,HN:YM'M,.$C0>A%WMQ2:Z,@22X&$U55BWNQ. M!;\DVO>]@"-^U\6XNS3-D?E>,*C[4G_*6\(#/,%$(^8T\%7(U+T/IB#W:%$Z MOO88%!Y3Y0@?
$N*3 MN2PF"CX3HQ=\7-^VTS6=B+S,U$S@ZC15GD+X#6@!"BNI3ZMN)_O+DO04E+P M#&KV/7('J4R0:FBG:/2V;AS&Z*F5 |>;-4(,/5]SIX':A
AX%SJ(59:QTHA! M\Z6]&OK;8>TVB "-U0__4Z^"@NW_PBCRSNE';1,)[;)-F?$(E S6^1JM5 M9:UDI_>J%;(&XBY\.JWM.HCNV*#N-
9*E&^ZS]9$H_D=3#4O!Q$HXC*8PMMO M/MR;7^<1#MJ5%4-ZQDAVM9[SK>:IWFWLX"C2"L0RO/B9=P>_?RA;_[7)W_EX M;OD(K;;-\P2)>:K#\C
;$UFD;)6 MYI>G6BI8#[_<)>O]#TQ^IX_P'!#:\>I%"-V>B7BBKH#=N!O M-K#U3_X6.9K6Q-%S3 M>C/MYH7:P,T%@QMVNO%.7#UTXY6XQ=?M2IS@
M_%\1$2/N 3)9,:E'N[W>V] M.2OZL9Y[0\^_QN?>"SSZ'U!+ P04 " !S/&=9"AHNRW(( )*0 & M 'AO;6$M,C R-#
Y,S!X97@S,60R+FAT;>U:;6_,.!+^*]PL>FT R[*3.$GM M-$#>BA;8M+W6W;O[2$FTQ8LD:DG*CO?
7WS.D["B,N\V+DVO0+=#8IH;#XEV6^EQ./PME();/#@T1.F+&S3+S9R+D>RR*P MJNQO=TH[P,P0EY=D+H.I3&S:[W8Z+P8E3Q)9C(-,C&R_VVWO[5Z-
:3E.KP:5 MWUQ?BXQ;.1&DO:$WS@37_4C9=+"\Q*J9Y7S>2!4V&/%<9K/^RQ,>R4C+EZV7 M[T0V$5;&'-\-'!L8H>7HY<")&_FG@&
[L,).%"%+A#6UO[0^LN+0!M(RQ'(T. MO$_Z$&;T?]L_GE@12A.&;A>&?1!3]EGEO,#R;H3,:%@ZNPRE9&T M;!LF'(01O%X^R0YCG
&AGV2+)T);.8*U%,FGW._*X.%9W^Q25)VOWUN'+YO ML6&*BX8=5[HP+1:[?V,9W;&3I2&D,/)X"=SX%:;S7?\$#7'W+CTQ/(9NRC4-!-(9"T?
MBSH"B8*20B$#0C>7!>/%C%6%U97 JDAO+CTB-)SE^*4ES]B(QQC23.6@*JN\ MW V!0L3"&*YG))+S"X%U&SH-QA(8@R4SB@&M00*QU,C)$$.6-K
D$9I-4QFG MS%3TYVK^5&A1*Z$-Y-(@T6@ %Q7-:-Z[(8X?BZ(XKO<58ET(F(-ES; AHD'?D2 M 2L<9052W 4L?)+"T-/"8NVI=(HLH@ (0HA-
$M9YP],3UV[^&@X9OL5!BL M#?I=M/(>*.!.)4K^13@:HT%. 83Z1QY I43@!5&E=T4J3 MFGR_@.#7N>_JDJV:MNBB!,7
%],RF;B^SE21D8GD6M(&I,]8CBP+TE09RB+N MG!B7BOW*02!8^,JXP3 V);5HBK;(09/K!+@B(G@+..KH$A5]ML6W(.9^4):4(DW^GZYS*)Y
M\>A.F/">H#Z-E#\ZHM#7/P11G;4C*@%;>4??#!CU4W5YX:ZL1,4=.(J2G(KC M2E-8&AEEA=9<&8MQNKD#72:&HKH#]VI2;A;YDHC"
4@DCD'=!FIVFZ%#NQ!9 MW<@MR;<>O*=G!YHUU-V]>]?=[K9*,D=;Z^HH$C.T(WYU*NE,WR%_WBB2%K9Q M%$I6U:.0C!N
RCR7U@I!"ZV8%BDD1+J62-CF%+P"Q$-QAB@,GU2]S8$L_J@D M3'>@K8J8-K#Y^$7V#\)NET(3M2RQ% A8G246Q>Y4\ NB?5\+ M..)W58R[2S-
OF>\$[HN]5W>"A[@"28:L:"\;T*FKGTP!;%'B=+RN<<@\9@] MA_L0$++>FB]7WEQX=A2QMBKY".ECI'.6HB(<-R F+K[777P6Y[,93%1V#,Q
M>L"]6T[7=,)R,M,S02N3E/E*81?@Q:@L);\M.YRLKLJ2(!R4O H&+?([>? MR@2AAG;R1F?[6C-&CZT<.-YL$&+H 9OK!FH3(N!=Z"'66<9+(_KS+\W54-\.
MZLW1XRYR,$(W\(^]7O=>T+:LGFNNV=VHGNV]*3N,9B%&^ZSS;WQOQW,-6\[$>@B(M@BMU^]^G>XCJ/
MT&A75@SH(2/9U7C0MY['>C>Q@U:DX8A5>/$S;P_U2T_FN36X6DM]?>V?\[M)$\6DM!J.D*/]V7^CE/ND$1.D2?Z[/@D4<@[;T6H]<4KGGL;L"M62U2
MUJHH[H6]^[%,TW#A:O4OP-PBPW!=12'0/O\M8L$\;.MO21U.RWVUE7\OE\[2:48U2/4 WST]RE6\V'HZN)Y6O[_-@;WJ"/210$>\?AB MK%55)%36*]V?
\T[CM;7K%VH#MY8,GC/5M1?FZ[%K[\LMOXM7HKL+2'G'1XAZ MGT^43&IP[NVV=_86#.G',NU\/?^.GWMI\/!_4$L#!\0 (;\9UDB2TS, M. < &8A 8
>&]M82TR,#(T,#DS,'AE>#,R9#$N:'1M[5K[;]LX$OY7 MYKS8:P)8DF7G5;[B9I MT0(QX(?XF!D.O_E(#CW\F^-,\HSD,4W@;'KQ&R0B+N0"^[QUY_5[_
)L%_#U-) MY[$ GT[H(/&^Q6+B+@2ODS)O>>>)F>\P./"Z&HF^BD.QJ;$ORD M)!D-YU03B#,B%=7O.G?3A^<$6VBF.1T-O>:
[;AN)9#D:)NP>E%YR^JXS)W+& M+(ACT"AUB3P^KM]H\. N6Z"SP>[U?PX(D"I#GS?/3Y:ETDVR]:% MHAI<("DGFMU3([TE-^:4R"
2.@NW5>SJ633]4I%K)R5SQI?!'FS'A+))+L3??_M&>7W5+.8X&^%CG44E2Q[$]KFBOV/HFP<(6KV3T)-'[2#4F:HSI2& ME4\"; SF?
5)]&Q.BG29.V9PJN*0+N!%SDJ-Z6V+,.%FP[%1&@B M-L[.Z+J4JB387PO0&05)_ULR22VY8 1'*B0R"\OAIN04_%Q_(,]:!]$:IO? MTKB4"&Y4,WG],V1<-
['VE3[;P<'72 -*" I+:.*%/=/C[[^<]/N]L-W:%OGA M/I\,1)-K*]PYX1,\Y(@7,,1P/S-#7Q#_Y)H_\N9X;);C42FH*Q2"CL8>V= M>^N.7=3E'QV'1M)^%ZX6-
(>SAT4R'E->*MG59"X>;Z! M5?5P8L$Y*10-FA_ATY'O[T)^3>'(HUK,#=K#%JF;1SL AY.E*'60L@>:[(J6 M%OU6E@=UL&B)[Z095=WLI%XK=-*N?
)GK$/ZWLQ33'AMES41AQ N,D2L8QQ, M YP@28]P940]$;6QOKMMTF;],R)_R]KJT0A"H^2<\ T*K(LZH^D:E0;Z_G&H MX/>22
Q0OH0;BK&"*,SA%#O@AL+YW?"'Q:?,)*U C^.,PQRE9PHL.6"D8(3/ MCX3LH-<%LQFQL$9/(>RU0?2X GUV3 9-G ?D:6#]38/5_
MQ,!B>6H>+0AC;$1P!A.S]+8!#BEA)M8*7%$,E+NF <'=/G9$ W 1P8H"H8PU
M!L#I:G%!D8G=AMHHQ%8EKR):!%+1:X=36PN/^,=AW[[E/VEONGWYK='X)G\ZG MEY/;6_AT-KF97)U6+BV1M*1"_3@[&<'-@]DG807#91==J^Q*C?
Q%5OX\;ARI MRMU>^0NH.G8/=P0!XK\STMG00PW/&[79,_7"A"R-\9?BWA)SQX0#J6?6G)@,YA'2#2W9 QDIM:C#^/# /?)_K9BFT=+(@ MHF:@531ON:?
BO#9UK1'39@8X=_I]#-E?6R>\EC;TBTRY6 092W!?MWIV#.\$ M$1ZP/SL+=,%73XTM.EXU)9$2O-2T;?#+G!B_7!C\MVU?[(J8]J?!'%-(0YSI M93-J@Y.3?
F\0MI%117_IN2*.S=7AJ_-3PZ?VCE\\ +J$)?!+S[^DQ]QP' MK$UV"GTN\WC*@ZM/DTLXN_O'V>1VP[O/I*BAZ9_1G2J]WD&^=_ U?'^"=[]<=W MW'-
P^$>GY+UKR7!34>"NXHO*_1=!ZW?UZTY6_'9^W=[/_DE:?;72IU+I],SJ MXOTM?+B[N7SETA?ETG;&ZY5,'T?BT_.!KXSZC1FU.=6^V,'UD03,RYY2GS;R
MUU35SY.J&OQXJ2JFFEN(.B%+XMAFC*I;"=I*_Z[2N$R#/0&;RQ?LGPL_";5S MFD#*>',!O76C9"AQE8 =B_F<*=7DKVH9*#\RF;.XOJ=!2=$2-
:544L.J+#>) MF'QIM*#/'KW?L7F=;1O6EUF#SF:CC?5F1#.;4XF+Q'KP9A_<+2@)&K&1050E3D'E M@NG9,U1\([#\21O\'4$L! A0# M% @ (&%XCO)0
W\@! !$ (! 'AO;6$M M,C R-# Y,S N>'-D4$L! A0#% @ &]M82TR,#(T,#DS,%]L86(N>&UL4$L! A0#% @ M#$P<2YH=&U02P$"% ,4 " !S
M/&=9!17MV(#L* & @ &!RP4 >&]M82TR,#(T,#DS M,'AE>#,Q9#$N:'1M4$L! A0#% @ &5X,S)D,2YH=&U02P4& D "0!@ @ +N0% end XML 111
xoma-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0000791908
xoma:ChiefInvestmentOfficerMemberxoma:StockOptionInducementAwardsMember 2023-01-032023-01-03 0000791908
xoma:ChiefExecutiveOfficerInterimMemberxoma:StockOptionInducementAwardsMember 2023-01-032023-01-03 0000791908
xoma:PerformanceStockUnitsMember 2023-05-31 0000791908
xoma:TalpheraMemberxoma:U.s.DepartmentOfDefenseMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-01-122024-01-12
0000791908
xoma:TalpheraMemberxoma:AllCustomersExcludingU.s.DepartmentOfDefenseMemberxoma:CommercialPaymentPurchaseAgreementMember
2024-01-122024-01-12 0000791908

xoma:DareMemberxoma:SildenafilCreamMemberxoma:ScenarioOneMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-292024-04-29 0000791908 xoma:DareMemberxoma:OvapreneMemberxoma:ScenarioOneMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-292024-04-29 0000791908 xoma:DareMemberxoma:SildenafilCreamMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-292024-04-29 0000791908 xoma:DareMemberxoma:OvapreneMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-292024-04-29 0000791908 xoma:AloraPharmaceuticalsMemberxoma:U.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAgreementMemberxoma:T 2024-01-122024-01-12 0000791908 xoma:AloraPharmaceuticalsMemberxoma:AllCustomersExcludingU.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAg 2024-01-122024-01-12 0000791908 xoma:AloraPharmaceuticalsMemberxoma:U.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAgreementMemberxoma:T 2023-04-012023-04-30 0000791908 xoma:AloraPharmaceuticalsMemberxoma:AllCustomersExcludingU.s.DepartmentOfDefenseMemberxoma:AssetPurchaseAgreementAndMarketingAg 2023-04-012023-04-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member 2017-12-062017-12-06 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementNonRz358ProductsMember 2017-12-062017-12-06 0000791908 xoma:AffitechResearchAsMember 2024-09-30 0000791908 xoma:LadrxMember 2024-01-012024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Member 2024-01-012024-09-30 0000791908 xoma:AptevoMember 2024-01-012024-09-30 0000791908 xoma:AffitechResearchAsMember 2024-01-012024-09-30 0000791908 xoma:AronoraIncMember 2024-01-012024-09-30 0000791908 xoma:AgenusIncMember 2024-01-012024-09-30 0000791908 xoma:TalpheraMember 2024-01-012024-09-30 0000791908 xoma:DareMember 2024-01-012024-09-30 0000791908 xoma:TalpheraMember 2024-09-30 0000791908 xoma:PalobiofarmaSLMember 2024-09-30 0000791908 xoma:LadrxMember 2024-09-30 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember 2024-09-30 0000791908 xoma:DareMember 2024-09-30 0000791908 xoma:AptevoMember 2024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Member 2023-12-31 0000791908 xoma:PalobiofarmaSLMember 2023-12-31 0000791908 xoma:LadrxMember 2023-12-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember 2023-12-31 0000791908 xoma:AronoraIncMember 2023-12-31 0000791908 xoma:AptevoMember 2023-12-31 0000791908 xoma:AgenusIncMember 2023-12-31 0000791908 xoma:AffitechResearchAsMember 2023-12-31 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-04-01 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember 2024-07-012024-09-30 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember 2024-01-012024-09-30 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember 2023-07-012023-09-30 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember 2023-01-012023-09-30 0000791908 2024-09-012024-09-30 0000791908 srt:ScenarioForecastMemberxoma:CashReserveAccountsInterestAndAdministrativeFeesMember 2027-07-012027-07-01 0000791908 xoma:TalpheraMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-01-012024-09-30 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-01-012024-09-30 0000791908 xoma:AptevoMembersrt:MinimumMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-06-012023-06-30 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-01-012023-12-31 0000791908 xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember 2018-09-202018-09-20 0000791908 xoma:NovartisPharmaAGMemberxoma:IL1TargetLicenseAgreementMember 2017-08-242017-08-24 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:SecondRoyaltyInterestAcquisitionAgreementMember 2016-12-212016-12-21 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-212016-12-21 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2024-05-302024-05-30 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember 2006-11-012006-11-01 0000791908 srt:MaximumMemberdei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-052021-08-05 0000791908 srt:MaximumMemberdei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member 2018-12-182018-12-18 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-152023-12-15 0000791908 xoma:DareMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-292024-04-29 0000791908 xoma:TalpheraMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-01-122024-01-12 0000791908 xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2024-01-112024-01-11 0000791908 xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2024-01-012024-09-30 0000791908 xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2024-01-012024-03-31 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-01-012024-03-31 0000791908 xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-212023-06-21 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-06-012023-06-30 0000791908 xoma:AffitechResearchAsMembersrt:EuropeMemberxoma:CommercialPaymentPurchaseAgreementMember 2022-01-012022-12-31 0000791908 xoma:AffitechResearchAsMembercountry:USxoma:CommercialPaymentPurchaseAgreementMember 2022-01-012022-12-31 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2021-10-062021-10-06 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2021-03-222021-03-22 0000791908 xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember 2019-09-262019-09-26 0000791908 xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember 2019-09-012019-09-30 0000791908 xoma:AronoraIncMemberxoma:SiliconValleyBankMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-072019-04-07 0000791908 xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember 2018-09-202018-09-20 0000791908 xoma:DareMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-29 0000791908 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000791908 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000791908 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000791908 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000791908 xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember 2018-09-202018-09-20 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember 2022-05-012022-05-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember 2022-07-012022-07-31 0000791908 xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember 2024-01-012024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2024-04-232024-04-23 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2023-10-302023-10-30 0000791908 xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember 2020-11-012020-11-30 0000791908 xoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMemberxoma:AgenusIncMember 2020-11-012020-11-30 0000791908 dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-052021-08-05 0000791908 us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember 2021-03-102021-03-10 0000791908 us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-182018-12-18 0000791908 xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-21 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember 2021-07-14 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2017-12-062020-10-31 0000791908 xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-06-032024-06-03 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2024-07-012024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:PriorityReviewVoucherMemberxoma:RoyaltyPurchaseAgreementMember 2024-05-302024-05-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:PriorityReviewVoucherMemberxoma:RoyaltyPurchaseAgreementMember 2024-01-012024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2024-01-012024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2023-07-012023-09-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:TovorafenibMemberxoma:RoyaltyPurchaseAgreementMember 2023-04-232023-04-23 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2023-01-012023-09-30 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-07-012024-09-30 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-01-012024-09-30 0000791908 xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember 2024-07-012024-09-30 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-21 0000791908 xoma:TwistBioscienceCorporationMemberus-gaap:SubsequentEventMemberxoma:RoyaltyPurchaseAgreementMember 2024-10-212024-10-21 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember 2021-07-142021-07-14 0000791908 xoma:TwistBioscienceCorporationMemberus-gaap:SubsequentEventMemberxoma:RoyaltyPurchaseAgreementMember 2024-10-21 0000791908 xoma:AloraPharmaceuticalsMemberxoma:AssetPurchaseAgreementAndMarketingAgreementMemberxoma:TalpheraMember 2023-

04-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member 2017-12-06 0000791908
xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember 2017-08-24 0000791908
xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2015-09-30 0000791908
xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember 2006-11-01 0000791908
xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2019-08-012019-08-31 0000791908
xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:OtherAntibodiesMemberxoma:CollaborationAgreementMember 2009-02-012009-02-28 0000791908 xoma:AronoraIncMembersrt:MinimumMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-072019-04-07 0000791908
xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-072019-04-07 0000791908
xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-072019-04-07 0000791908
xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2024-09-30 0000791908
xoma:AffitechResearchAsMemberxoma:ContingentConsiderationSalesMilestonesThreeMemberxoma:CommercialPaymentPurchaseAgreementMembe 2024-09-30 0000791908
xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2024-06-03 0000791908
xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2024-03-31 0000791908
xoma:AffitechResearchAsMemberxoma:ContingentConsiderationSalesMilestonesOneAndTwoMemberxoma:CommercialPaymentPurchaseAgreement 2024-03-31 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-03-31 0000791908
xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2023-12-31 0000791908
xoma:AffitechResearchAsMemberxoma:ContingentConsiderationSalesMilestonesOneAndTwoMemberxoma:CommercialPaymentPurchaseAgreement 2023-12-31 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-03-29 0000791908
xoma:AffitechResearchAsMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:CommercialPaymentPurchaseAgreementMembe 2021-10-06 0000791908 xoma:AronoraIncMemberxoma:BayerProductsMembersrt:MaximumMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember 2024-04-032024-04-03 0000791908 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberxoma:ExarafenibAndRelatedIntellectualPropertyMemberxo 2024-02-272024-02-27 0000791908
xoma:KinnateCvrHoldersMemberxoma:ExarafenibAndRelatedIntellectualPropertyMemberxoma:ContingentValueRightsAgreementMember 2024-02-272024-02-27 0000791908 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908
xoma:LadrxMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAg 2023-06-21 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-03-292023-03-29 0000791908
xoma:AffitechResearchAsMemberxoma:FaricimabProductMemberxoma:CommercialPaymentPurchaseAgreementMember 2021-10-062021-10-06 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-01-012023-12-31 0000791908
xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2017-12-062017-12-06 0000791908
xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2015-09-302015-09-30 0000791908
xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2017-08-242017-08-24 0000791908
xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2021-03-22 0000791908
xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember 2019-09-26 0000791908
xoma:AronoraIncMemberxoma:NonBayerProductsMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908
xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908
xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908
xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908
xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoan 2023-12-15 0000791908 us-gaap:CommonStockMember 2024-07-012024-09-30 0000791908 us-gaap:CommonStockMember 2024-01-012024-03-31 0000791908 us-gaap:CommonStockMember 2023-01-012023-03-31 0000791908
dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-052024-09-30 0000791908 us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-182024-09-30 0000791908
xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember 2017-08-242017-08-24 0000791908 us-gaap:CommonStockMember 2024-04-012024-06-30 0000791908 us-gaap:CommonStockMember 2023-04-012023-06-30 0000791908
xoma:RezoluteIncMember 2020-10-012020-10-31 0000791908 us-gaap:RetainedEarningsMember 2024-09-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000791908 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000791908 us-gaap:RetainedEarningsMember 2024-06-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000791908 us-gaap:RetainedEarningsMember 2024-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000791908 2024-03-31 0000791908 us-gaap:RetainedEarningsMember 2023-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000791908 us-gaap:RetainedEarningsMember 2023-09-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000791908 us-gaap:RetainedEarningsMember 2023-06-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000791908 2023-06-30 0000791908 us-gaap:RetainedEarningsMember 2023-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000791908 2023-03-31 0000791908 us-gaap:RetainedEarningsMember 2022-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2024-06-30 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2024-06-30 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-06-30 0000791908 us-gaap:CommonStockMember 2024-06-30 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2024-03-31 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2024-03-31 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-03-31 0000791908 us-gaap:CommonStockMember 2024-03-31 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2023-12-31 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2023-12-31 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2023-12-31 0000791908 us-gaap:CommonStockMember 2023-12-31 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2023-09-30 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2023-09-30 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2023-09-30 0000791908 us-gaap:CommonStockMember 2023-09-30 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2023-06-30 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2023-06-30 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2023-06-30 0000791908 us-gaap:CommonStockMember 2023-06-30 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2023-03-31 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2023-03-31 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2023-03-31 0000791908 us-gaap:CommonStockMember 2023-03-31 0000791908 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2022-12-31 0000791908 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2022-12-31 0000791908 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2022-12-31 0000791908 us-gaap:CommonStockMember 2022-12-31 0000791908
xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-09-30 0000791908
xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-09-30 0000791908
xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-09-30 0000791908
xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-09-30 0000791908 us-gaap:CommonStockMember 2024-09-30 0000791908
xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-12-31 0000791908 xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-12-31 0000791908
xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-12-31 0000791908 xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-12-31 0000791908 xoma:StockOptionInducementAwardsMember 2023-01-03 0000791908 xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember 2017-08-24 0000791908
xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember 2024-01-012024-09-30 0000791908 2023-01-012023-12-31 0000791908
xoma:StockOptionInducementAwardTwoMember 2023-01-012023-03-31 0000791908 xoma:StockOptionInducementAwardOneMember 2023-01-012023-03-31 0000791908 xoma:StockOptionInducementAwardsMember 2024-01-012024-09-30 0000791908 us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-012024-09-30 0000791908 us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2023-01-012023-09-30 0000791908
xoma:PerformanceStockUnitsMember 2023-12-31 0000791908 xoma:PerformanceStockUnitsMember 2024-04-012024-04-30 0000791908

xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 xoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:ChiefExecutiveOfficerMemberxoma:PerformanceStockUnitsMember 2024-01-012024-01-31 0000791908 xoma:PerformanceStockUnitsMember 2023-10-012023-10-31 0000791908 xoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-01-012023-12-31 0000791908 xoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-01-012023-12-31 0000791908 xoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-01-012023-12-31 0000791908 xoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-01-012023-12-31 0000791908 xoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMember 2023-01-012023-12-31 0000791908 xoma:PerformanceStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-05-012023-05-31 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2024-05-012024-05-31 0000791908 xoma:EmployeeMemberus-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-012024-09-30 0000791908 srt:DirectorMemberus-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-012024-09-30 0000791908 xoma:PerformanceStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-05-012023-05-31 0000791908 xoma:PerformanceStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-05-012023-05-31 0000791908 xoma:PerformanceStockUnitsMember 2023-05-012023-05-31 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDate2024Memberxoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MinimumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar45Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar40Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar35Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 srt:MaximumMemberxoma:StockPriceHurdlesOfDollar30Memberxoma:AwardDateMay2023ToOctober2023Memberxoma:PerformanceStockUnitsMem 2023-01-012023-12-31 0000791908 xoma:KinnateMember 2024-01-012024-09-30 0000791908 us-gaap:ScenarioAdjustmentMemberxoma:KinnateMember 2024-01-012024-09-30 0000791908 us-gaap:ScenarioAdjustmentMemberxoma:KinnateMember 2023-01-012023-12-31 0000791908 xoma:KinnateMember 2023-01-012023-12-31 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2024-07-012024-09-30 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2024-07-012024-09-30 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2024-07-012024-09-30 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2024-07-012024-09-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2024-04-012024-04-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2024-01-012024-09-30 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2024-01-012024-09-30 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2024-01-012024-09-30 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2024-01-012024-09-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2023-07-012023-09-30 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2023-07-012023-09-30 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2023-07-012023-09-30 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2023-07-012023-09-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2023-01-012023-09-30 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2023-01-012023-09-30 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2023-01-012023-09-30 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2023-01-012023-09-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member 2022-01-012022-01-31 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2019-01-012019-12-31 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2017-01-012017-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2017-01-012017-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2015-01-012015-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember 2006-11-012024-09-30 0000791908 xoma:CashReserveAccountsOperatingExpensesMember 2023-12-15 0000791908 xoma:CashReserveAccountsInterestAndAdministrativeFeesMember 2023-12-15 0000791908 xoma:CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember 2023-12-15 0000791908 xoma:KinnateCvrHoldersMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberxoma:ExarafenibAndRelatedIntellectualPropertyMemberxoma 2024-02-272024-02-27 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember 2024-01-012024-09-30 0000791908 xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember 2017-08-242017-08-24 0000791908 us-gaap:SeriesBPreferredStockMember 2024-09-30 0000791908 us-gaap:SeriesAPreferredStockMember 2024-09-30 0000791908 us-gaap:ConvertiblePreferredStockMember 2024-09-30 0000791908 us-gaap:SeriesBPreferredStockMember 2023-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2023-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2023-12-31 0000791908 xoma:O2024Q3DividendsMemberus-gaap:SeriesAPreferredStockMember 2024-07-012024-09-30 0000791908 xoma:O2024Q3DividendsMemberdei:AdrMember 2024-07-012024-09-30 0000791908 xoma:O2024Q2DividendsMemberus-gaap:SeriesAPreferredStockMember 2024-04-012024-06-30 0000791908 xoma:O2024Q2DividendsMemberdei:AdrMember 2024-04-012024-06-30 0000791908 xoma:O2024Q1DividendsMemberus-gaap:SeriesAPreferredStockMember 2024-01-012024-03-31 0000791908 xoma:O2024Q1DividendsMemberdei:AdrMember 2024-01-012024-03-31 0000791908 xoma:O2023Q4DividendsMemberus-gaap:SeriesAPreferredStockMember 2023-10-012023-12-31 0000791908 xoma:O2023Q4DividendsMemberdei:AdrMember 2023-10-012023-12-31 0000791908 us-gaap:SeriesBPreferredStockMember 2024-07-012024-09-30 0000791908 us-gaap:SeriesAPreferredStockMember 2024-07-012024-09-30 0000791908 us-gaap:SeriesBPreferredStockMember 2023-07-012023-09-30 0000791908 us-gaap:SeriesAPreferredStockMember 2023-07-012023-09-30 0000791908 us-gaap:SeriesBPreferredStockMember 2023-01-012023-09-30 0000791908 us-gaap:SeriesAPreferredStockMember 2023-01-012023-09-30 0000791908 us-gaap:SeriesBPreferredStockMember 2024-01-012024-09-30 0000791908 us-

gaap:SeriesBPreferredStockMember 2023-01-012023-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2023-01-012023-12-31 0000791908 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000791908 xoma:LeasedFacilitiesSanFranciscoCaliforniaMember 2024-04-03 0000791908 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000791908 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000791908 srt:ProFormaMemberxoma:KinnateMember 2024-01-012024-09-30 0000791908 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000791908 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000791908 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000791908 srt:ProFormaMemberxoma:KinnateMember 2023-01-012023-12-31 0000791908 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000791908 xoma:XomaCorporationMemberus-gaap:CommonStockMemberxoma:BiotechnologyValueFundLPMember 2024-09-30 0000791908 xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember 2023-11-10 0000791908 xoma:LeasedFacilitiesEmeryvilleCaliforniaMember 2023-01-31 0000791908 xoma:LeasedFacilitiesEmeryvilleCaliforniaMember 2023-01-012023-01-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-09-012024-09-30 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-01-012024-03-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-01-012023-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember 2016-12-212016-12-21 0000791908 xoma:RezoluteIncMember 2024-07-012024-09-30 0000791908 xoma:RezoluteIncMember 2024-01-012024-09-30 0000791908 xoma:RezoluteIncMember 2023-07-012023-09-30 0000791908 xoma:RezoluteIncMember 2023-01-012023-09-30 0000791908 xoma:RezoluteIncMemberus-gaap:MeasurementInputSharePriceMember 2024-09-30 0000791908 xoma:RezoluteIncMemberus-gaap:MeasurementInputSharePriceMember 2023-12-31 0000791908 xoma:RezoluteIncMember 2024-09-30 0000791908 xoma:RezoluteIncMember 2023-12-31 0000791908 us-gaap:EmployeeStockOptionMember 2024-09-30 0000791908 xoma:PerformanceStockUnitsMember 2024-09-30 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0000791908 xoma:O2024Q3DividendsMember 2024-07-012024-09-30 0000791908 xoma:O2024Q2DividendsMember 2024-04-012024-06-30 0000791908 xoma:O2024Q1DividendsMember 2024-01-012024-03-31 0000791908 xoma:O2023Q4DividendsMember 2023-10-012023-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember 2023-12-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember 2023-12-15 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-09-30 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-15 0000791908 xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember 2024-04-012024-06-30 0000791908 xoma:TalpheraMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-09-30 0000791908 xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember 2024-09-30 0000791908 xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-09-30 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember 2024-09-30 0000791908 xoma:DareMemberxoma:RoyaltyPurchaseAgreementMember 2024-09-30 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-09-30 0000791908 xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember 2024-09-30 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2024-09-30 0000791908 xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:LadrxMemberxoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-12-31 0000791908 xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember 2023-12-31 0000791908 xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000791908 xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000791908 xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000791908 xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000791908 xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000791908 xoma:Partner1Memberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2024-01-012024-09-30 0000791908 xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000791908 xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000791908 xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000791908 xoma:Partner1Memberus-gaap:TradeAccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2023-01-012023-12-31 0000791908 xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000791908 xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember 2023-12-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember 2024-09-30 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember 2024-09-30 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember 2024-09-30 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember 2024-09-30 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member 2024-09-30 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember 2023-12-31 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMemberxoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 2023-09-30 0000791908 2022-12-31 0000791908 us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember 2024-09-30 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2024-09-30 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2024-09-30 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2024-09-30 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2024-09-30 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember 2023-12-31 0000791908 xoma:RezoluteIncMemberxoma:LicenseAgreementMember 2023-12-31 0000791908 xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2023-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember 2023-12-31 0000791908 xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember 2023-12-31 0000791908 us-gaap:USTreasurySecuritiesMember 2024-09-30 0000791908 xoma:KinnateMember 2024-04-03 0000791908 xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember 2024-09-30 0000791908 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000791908 xoma:KinnateCvrHoldersMemberxoma:ContingentValueRightsAgreementMember 2024-04-03 0000791908 xoma:KinnateMember 2024-04-032024-04-03 0000791908 us-gaap:WarrantMember 2024-07-012024-09-30 0000791908 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000791908 us-gaap:ConvertiblePreferredStockMember 2024-07-012024-09-30 0000791908 us-gaap:WarrantMember 2024-01-012024-09-30 0000791908 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000791908 us-gaap:ConvertiblePreferredStockMember 2024-01-012024-09-30 0000791908 us-gaap:WarrantMember 2023-07-012023-09-30 0000791908 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000791908 us-gaap:ConvertiblePreferredStockMember 2023-07-012023-09-30 0000791908 us-gaap:WarrantMember 2023-01-012023-09-

30 0000791908 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000791908 us-gaap:ConvertiblePreferredStockMember 2023-01-012023-09-30 0000791908 2023-01-012023-09-30 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-07-012024-09-30 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-01-012024-09-30 0000791908 xoma:PerformanceStockUnitsMember 2024-07-012024-09-30 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0000791908 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000791908 xoma:PerformanceStockUnitsMember 2024-01-012024-09-30 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0000791908 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000791908 2024-04-012024-06-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000791908 2024-01-012024-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000791908 2023-07-012023-09-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000791908 2023-04-012023-06-30 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000791908 2023-01-012023-03-31 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2024-09-30 0000791908 2024-09-30 0000791908 xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 2023-12-31 0000791908 2024-01-02 0000791908 2024-07-012024-09-30 0000791908 us-gaap:SeriesAPreferredStockMember 2024-01-012024-09-30 0000791908 us-gaap:CommonStockMember 2024-01-012024-09-30 0000791908 dei:AdrMember 2024-01-012024-09-30 0000791908 2024-11-04 0000791908 2024-01-012024-09-30 iso4217:EUR xoma:period xoma:customer xoma:D shares iso4217:USD iso4217:USD shares pure xoma:Right xoma:item xoma:multiplier xoma:agreement xoma:product 0000791908--12-312024Q3false 000.023100000020000020.3330.3330.33310.33310-Qtrue2024-09-30false001-39801XOMA Royalty CorporationDE52-21540662200 Powell StreetSuite 310EmeryvilleCA94608510204-7200Common Stock, $0.0075 par valueXOMANASDAQ8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 XOMAPNASDAQDepositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)XOMAONASDAQYesYesNon-accelerated Filertruefalsefalse11782723142050000153290000800001600007850001610001045000100400012682000142150002379000483000159021000169312330890001223223000848090008872100022334000023430100064630001189500025000225000605000013500007090006050001828000157500071970008304132000224000673000228370006617000524960002483900015640000-5787000-32723000-21914000193160008100000349300010446000189000027800059000001192000-17243000-5509000-9853000-20722000-18611000-6877000-13957000-24826000-18611000-6877000-13957000-24826000-1.59-0.60-1.20-2.17-1.59-0.60-1.20-2.17117120001147300011645000114660001171200011473000116450001146600-17243000-5509000-9853000-20722000104000104000-17139000-5509000-9749000-20722000984000490002000500011495000860001311809000-12232230008872100013500010006210006220007000118000118000285600028560001368000136800010001300013000-8595000-859500098400049000200050001163600087000131403600012318310008234100015000250000250000700095000950002690000269000013680001368000159850001598500098400049000200050001165800012158460009999300097000100073200073300025900002590000136800013680001040000400017243000-17243000984000490002000500011755000880001317657000104000-123308900084809000984000490002000500011454000860001306271000-11823920001240140007000123000123000157000015700001368000136800-9813000-98130009840004900020005000114610008600013065960001192205000114526000800015300015300030005000050000216300021630001368000136800-5400000-5400000984000490002000500011472000860001307594000-11976050001101240002717000271700013680001368000-5509000-5509000984000490002000500011472000860001308943000-12031140001059640000-9853000-20722000998500081360006450000230000001575000193160007500011800012300067300080002000996000-45000-1150006240000-12100010400041000420007200020200-1348000-554000-185000-120000-1828000-1575000-10845000-14231000189260003700000014650000262630008428000170008172000-62220006902000740000410400041040001300041270002080002429000500010061000-3901000-12734000-24354000159550000578260001468160003347200099850008500029220002922000824000824000300000030000001000000100000001368000136801368000 style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business XOMA Royalty Corporation, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. On July 10, 2024, the Company changed its name from XOMA Corporation to XOMA Royalty Corporation. The Company's portfolio was built through the acquisition of rights to future milestone payments, royalties, and commercial payments, since its royalty aggregator business model was implemented in 2017, combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company's drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. XOMA also acquires milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to the Company in a relatively short timeframe. The Company expects most of its future income and revenue to be based on milestone payments the Company may receive for milestones and royalties associated with these programs. Liquidity and Financial Condition The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of September 30, 2024, the Company had cash, cash equivalents, and restricted cash of $146.8 million primarily related to financing cash inflows received in December 2023 pursuant to the Blue Owl Loan Agreement (see Note 8). Based on the Company's current cash balance and its planned spending, such as on royalties and other acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations, commitments, and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued. 146800000false 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial reporting. As permitted under those rules, certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024. These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company's consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year, or for any other future annual or interim period. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to income from purchased receivables, revenue from contracts with customers, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, projected cash flows associated with income under the EIR method, the Exarafenib milestone asset and contingent consideration, legal contingencies, contingent consideration for purchased receivables, amortization of the Blue Owl Loan, accrued expenses, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, including estimates such as the Company's income from purchased receivables, amortization of the payments received from HCRP, and amortization of the Blue Owl Loan. Estimates related to income from purchased receivables is based on the best information available to the Company from its partners or other third parties and changes in expected cash flows for royalty and commercial receivables under the EIR method. Any changes to the estimated payments made by partners can result in a material adjustment to income reported. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the

term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The Company's amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported. Cash, Cash Equivalents, and Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Unrestricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"> 124,938 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Unrestricted cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 138,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total unrestricted cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 142,050 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 153,290</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 160</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,100</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,766 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,260</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total unrestricted and restricted cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 146,816 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 159,550 </td></tr></table> . Cash and Cash Equivalents Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments with an original maturity of three months or less that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are in money market funds and U.S. treasury bills, and are classified as available-for-sale. Allowances are recorded for available-for-sale debt securities with unrealized losses. The amount of credit losses that can be recognized for available-for-sale debt securities is limited to the amount by which carrying value exceeds fair value, and previously recognized credit losses are reversed if the fair value increases. As of September 30, 2024, all investments in debt securities were held in U.S. treasury bills and classified as available-for-sale. There was no allowance for credit losses on investments in debt securities for the three and nine months ended September 30, 2024. There were no investments in debt securities as of December 31, 2023 and during the year ended December 31, 2023. Cash equivalents classified as available-for-sale debt securities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Estimated Fair </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost Basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:55.38%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 104 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> Total debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Estimated Fair </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost Basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:55.38%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> . Restricted Cash The restricted cash balance may only be used to pay interest expense, administrative fees, and other allowable expenses pursuant to the Blue Owl Loan. Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current. On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL. In September 2024, upon receipt of a specified threshold of commercial payments from Roche's VABYSMO, $1.25 million was released from restricted cash to unrestricted cash pursuant to the terms of the Blue Owl Loan Agreement. Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027. Purchase of Rights to Future Milestones, Royalties, and Commercial Payments The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties, and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as royalty and commercial payment receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450. Cost Recovery Method When the purchase of rights to future milestones, royalties, and commercial payments involves future cash flows which cannot be reliably estimated, the Company accounts for such rights on a non-accrual basis using the cost recovery method. The Company's assessment of whether cash flows can be reliably estimated depends on a number of factors. For example, the Company has generally determined that rights related to programs in preclinical or clinical stages of development or that have had a very short commercialization period during which payments have not yet been received, generally have uncertain cash flows and therefore are accounted for under the cost recovery method. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reliably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance in royalty and commercial payment receivables has been fully collected, any additional amounts collected are recognized as income from purchased receivables. Receivables from such income from purchased receivables are included in trade and other receivables, net on the condensed consolidated balance sheet and totaled $1.0 million and zero as of September 30, 2024 and December 31, 2023, respectively. Effective Interest Rate Method The Company accounts for rights to future milestones, royalties, and commercial payments related to commercial products which have an established reliable sales pattern under the EIR method. The EIR is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the receivable's carrying amount at the time when the Company determines that there are reliable cash flows. The carrying amount of a receivable is made up of the opening balance, which is increased by accrued income and decreased by cash receipts in the period to arrive at the ending balance. The EIR is recalculated at each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to the expected future cash flows. Receivables related to income from purchased receivables under the EIR method, all which were short-term receivables, totaled $8.3 million and zero as of September 30, 2024 and December 31, 2023, respectively. Income from Purchased Receivables Income from purchased receivables includes both amounts recognized under the EIR method and under the cost recovery method. For

amounts recognized under the EIR method, the accretable yield is recognized as income from purchased receivables at the effective rate of return over the expected life of the royalty and commercial payment receivable. The application of the prospective approach to measure income requires judgment in forecasting the expected future cash flows. The amounts and duration of forecasted expected future cash flows used to calculate and measure income are largely impacted by research analyst coverage, commercial performance of the product, and contract or patent duration. Income from purchased receivables from the cost recovery method includes income from milestone and royalty payments related to royalty and commercial payment transactions for which the cost has been fully recovered or impaired. The excess milestone and royalty payment received over a remaining receivable balance is recognized as income. If the information upon which such income amounts are derived is provided to the Company from partners or other third parties in arrears, the Company estimates the income earned during the period based upon the best information available such that the income recognized is not expected to be subsequently reversed in future periods. Allowance for Current Expected Credit Losses The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company regularly reviews public information on clinical trials, press releases, and updates from its partners to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset's cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Revenue from Contracts with Customers The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. License of Intellectual Property If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process, and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company's license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company's intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process, and know-how (i.e., at a point in time). Deferred revenue is recorded when upfront payments and fees are received prior to the satisfaction of performance obligations. Trade and other receivables, net is recorded when the Company has an unconditional right to consideration. Milestone Payments At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Revenue Recognized under Units-of-Revenue Method The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period's cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company's estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company's employees, consultants, and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility, and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations, and volatility. The estimate of expected volatility is based on the Company's historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The valuation of RSUs is determined at the date of grant using the Company's closing stock price. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods. Equity Securities The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations in the period of sale. Asset Acquisitions As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If the screen test is not met, the Company then further evaluates whether the assets or group of assets includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. If the fair value of net assets acquired, after allocating the excess of the fair value of net assets acquired to certain qualifying assets, exceeds the total cost of the acquisition, a bargain purchase gain is recognized in other income in the condensed consolidated statements of operations. Contingent payments in asset acquisitions are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that are related to IPR&D assets are expensed as incurred. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. Cash payments related to acquired assets are reflected as an investing cash flow in the Company's condensed consolidated statements of cash flows. Leases The Company leases its headquarters in Emeryville, California and acquired a lease from the Kinnate acquisition. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. For leases acquired in asset acquisitions, the Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the acquisition date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length. Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in G&A expense in the condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company's non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred. The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise. Long-Term Debt Long-term debt represents the Company's term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the EIR method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the EIR method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8. Warrants The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company's consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility, and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company's common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants. Income Taxes The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable. The recognition, derecognition and measurement of a tax position is based on management's best judgment given the facts, circumstances, and information available at each reporting date. The Company's policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. Net Income (Loss) per Share Available to (Attributable to) Common Stockholders The Company calculates basic and diluted income (loss) per share available to (attributable to) common stockholders using the two-class method. The Company's convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company's Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities. Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income available to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income (loss) per share available to (attributable to) common stockholders is then calculated by dividing the net income (loss) available to (attributable to) common stockholders by the weighted-average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted-average common shares outstanding. Diluted net income (loss) per share available to (attributable to) common stockholders is based on the weighted-average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company's Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company's share price and, therefore, are not included in the diluted shares until the contingency is resolved. <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt

12pt 18pt;">Share Repurchases The Company has a stock repurchase program that is executed through purchases made from time to time, including in the open market. The Company retires repurchased shares of common stock, reducing common stock with any excess of cost over par value recorded to accumulated deficit. Issued and outstanding shares of common stock are reduced by the number of shares repurchased. No treasury stock is recognized in the condensed consolidated financial statements. In August 2022, the IRA enacted a 1% excise tax on net share repurchases after December 31, 2022. Any excise tax incurred on share repurchases is recognized as part of the cost basis of the shares acquired. Concentration of Risk Cash, cash equivalents, restricted cash, and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended September 30, 2024, three partners represented 75%, 14% and 10% of total income and revenues, respectively. For the nine months ended September 30, 2024, three partners represented 50%, 25% and 10% of total income and revenues, respectively. For the three months ended September 30, 2023, two partners represented 73% and 24% of total income and revenues, respectively. For the nine months ended September 30, 2023, two partners represented 54% and 44% of total income and revenues, respectively. One partner represented 96% of the trade and other receivables, net as of September 30, 2024. One partner represented 100% of the trade and other receivables, net as of December 31, 2023. Comprehensive Income (Loss) Comprehensive income (loss) is comprised of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders' equity but are excluded from net income (loss). Accounting Pronouncements Recently Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Recent Accounting Pronouncements Not Yet Adopted In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission's Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures. Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial reporting. As permitted under those rules, certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024. These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company's consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year, or for any other future annual or interim period. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to income from purchased receivables, revenue from contracts with customers, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, projected cash flows associated with income under the EIR method, the Exarafenib milestone asset and contingent consideration, legal contingencies, contingent consideration for purchased receivables, amortization of the Blue Owl Loan, accrued expenses, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, including estimates such as the Company's income from purchased receivables, amortization of the payments received from HCRP, and amortization of the Blue Owl Loan. Estimates related to income from purchased receivables is based on the best information available to the Company from its partners or other third parties and changes in expected cash flows for royalty and commercial receivables under the EIR method. Any changes to the estimated payments made by partners can result in a material adjustment to income reported. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The Company's amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported. Cash, Cash Equivalents, and Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Unrestricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"> 124,938 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Unrestricted cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 138,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total unrestricted cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 142,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 153,290 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Short-term restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> 80 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 160 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,686 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,100 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Total restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,260 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total unrestricted and restricted cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 146,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 159,550 </td></tr></table> . Cash and Cash Equivalents Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments with an original maturity of three months or less that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are in money market funds and U.S. treasury bills, and are classified as available-for-sale. Allowances are recorded for available-for-sale debt securities with unrealized losses. The amount of credit losses that can be recognized for available-for-sale debt securities is limited to the amount by which carrying value exceeds fair value, and previously recognized credit losses are reversed if the fair value increases. As of September 30, 2024, all investments in debt securities were held in U.S. treasury bills and classified as available-for-sale. There was no allowance for credit losses on investments in debt securities for the three and nine months ended September 30, 2024. There were no investments in debt securities as of December 31, 2023 and during the year ended December 31, 2023. Cash equivalents classified as available-for-sale debt securities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Estimated Fair </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost Basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:55.38%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 104 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> Total debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Estimated Fair </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost Basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:55.38%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">— </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> Total debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> . Restricted Cash The restricted cash balance may only be used to pay interest expense, administrative fees, and other allowable expenses pursuant to the Blue Owl Loan. Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current. On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL. In September 2024, upon receipt of a specified threshold of commercial payments from Roche's VABYSMO, $1.25 million was released from restricted cash to unrestricted cash pursuant to the terms of the Blue Owl Loan Agreement. Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027. Cash, Cash Equivalents, and Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Unrestricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"> 124,938 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Unrestricted cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 138,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total unrestricted cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 142,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 153,290 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Short-term restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;margin:0pt;padding:0pt;"> 80 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> 160 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,686 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,100 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Total restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,260 </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total unrestricted and restricted cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 146,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 159,550 </td></tr>
</table>401800012493800013803200028352000142050000153290000080000160000468600061000004766000626000014681600015955000000 Cash equivalents classified as available-for-sale debt securities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Estimated Fair </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost Basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:55.38%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> Total debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 104 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td colspan="2"

style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Estimated Fair </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost Basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:55.38%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.38%;margin:0pt;padding:0pt;"> Total debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>250330001040002513700025033000104000251370006300000580000050000012500008000000 Purchase of Rights to Future Milestones, Royalties, and Commercial Payments The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties, and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as royalty and commercial payment receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450. Cost Recovery Method When the purchase of rights to future milestones, royalties, and commercial payments involves future cash flows which cannot be reliably estimated, the Company accounts for such rights on a non-accrual basis using the cost recovery method. The Company's assessment of whether cash flows can be reliably estimated depends on a number of factors. For example, the Company has generally determined that rights related to programs in preclinical or clinical stages of development or that have had a very short commercialization period during which payments have not yet been received, generally have uncertain cash flows and therefore are accounted for under the cost recovery method. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reliably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance in royalty and commercial payment receivables has been fully collected, any additional amounts collected are recognized as income from purchased receivables. Receivables from such income from purchased receivables are included in trade and other receivables, net on the condensed consolidated balance sheet and totaled $1.0 million and zero as of September 30, 2024 and December 31, 2023, respectively. Effective Interest Rate Method The Company accounts for rights to future milestones, royalties, and commercial payments related to commercial products which have an established reliable sales pattern under the EIR method. The EIR is calculated by forecasting the expected cash flows to be received over the life of

the asset relative to the receivable's carrying amount at the time when the Company determines that there are reliable cash flows. The carrying amount of a receivable is made up of the opening balance, which is increased by accrued income and decreased by cash receipts in the period to arrive at the ending balance. The EIR is recalculated at each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to the expected future cash flows. Receivables related to income from purchased receivables under the EIR method, all which were short-term receivables, totaled $8.3 million and zero as of September 30, 2024 and December 31, 2023, respectively. 1000000.0083000000 Income from Purchased Receivables Income from purchased receivables includes both amounts recognized under the EIR method and under the cost recovery method. For amounts recognized under the EIR method, the accretable yield is recognized as income from purchased receivables at the effective rate of return over the expected life of the royalty and commercial payment receivable. The application of the prospective approach to measure income requires judgment in forecasting the expected future cash flows. The amounts and duration of forecasted expected future cash flows used to calculate and measure income are largely impacted by research analyst coverage, commercial performance of the product, and contract or patent duration. Income from purchased receivables from the cost recovery method includes income from milestone and royalty payments related to royalty and commercial payment transactions for which the cost has been fully recovered or impaired. The excess milestone and royalty payment received over a remaining receivable balance is recognized as income. If the information upon which such income amounts are derived is provided to the Company from partners or other third parties in arrears, the Company estimates the income earned during the period based upon the best information available such that the income recognized is not expected to be subsequently reversed in future periods. Allowance for Current Expected Credit Losses The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company regularly reviews public information on clinical trials, press releases, and updates from its partners to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset's cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Revenue from Contracts with Customers The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. License of Intellectual Property If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process, and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company's license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company's intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process, and know-how (i.e., at a point in time). Deferred revenue is recorded when upfront payments and fees are received prior to the satisfaction of performance obligations. Trade and other receivables, net is recorded when the Company has an unconditional right to consideration. Milestone Payments At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Revenue Recognized under Units-of-Revenue Method The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period's cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company's estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt

18pt;">Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company's employees, consultants, and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility, and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations, and volatility. The estimate of expected volatility is based on the Company's historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The valuation of RSUs is determined at the date of grant using the Company's closing stock price. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods. Equity Securities The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations in the period of sale. Asset Acquisitions As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If the screen test is not met, the Company then further evaluates whether the assets or group of assets includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values. If the fair value of net assets acquired, after allocating the excess of the fair value of net assets acquired to certain qualifying assets, exceeds the total cost of the acquisition, a bargain purchase gain is recognized in other income in the condensed consolidated statements of operations. Contingent payments in asset acquisitions are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statements of operations. Contingent consideration payments that are related to IPR&D assets are expensed as incurred. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. Cash payments related to acquired assets are reflected as an investing cash flow in the Company's condensed consolidated statements of cash flows. Leases The Company leases its headquarters in Emeryville, California and acquired a lease from the Kinnate acquisition. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. For leases acquired in asset acquisitions, the Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the acquisition date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length. Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in G&A expense in the condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company's non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred. The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise. Long-Term Debt Long-term debt represents the Company's term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the EIR method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the EIR method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8. Warrants The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company's consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility, and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company's common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants. Income Taxes The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable. The recognition, derecognition and measurement of a tax position is based on management's best judgment given the facts, circumstances, and information available at each reporting date. The Company's policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. 0 Net Income (Loss) per Share Available to (Attributable to) Common Stockholders The Company calculates basic and diluted income (loss) per share available to (attributable to) common stockholders using the two-class method. The Company's convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company's Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities. Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income available to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income (loss) per share available to (attributable to) common stockholders is then calculated by dividing the net income (loss) available to (attributable to) common stockholders by the weighted-average number of shares of common stock outstanding during the period. All participating securities are excluded

from the basic weighted-average common shares outstanding. Diluted net income (loss) per share available to (attributable to) common stockholders is based on the weighted-average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company's Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company's share price and, therefore, are not included in the diluted shares until the contingency is resolved. Share Repurchases The Company has a stock repurchase program that is executed through purchases made from time to time, including in the open market. The Company retires repurchased shares of common stock, reducing common stock with any excess of cost over par value recorded to accumulated deficit. Issued and outstanding shares of common stock are reduced by the number of shares repurchased. No treasury stock is recognized in the condensed consolidated financial statements. In August 2022, the IRA enacted a 1% excise tax on net share repurchases after December 31, 2022. Any excise tax incurred on share repurchases is recognized as part of the cost basis of the shares acquired. 0 Concentration of Risk Cash, cash equivalents, restricted cash, and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended September 30, 2024, three partners represented 75%, 14% and 10% of total income and revenues, respectively. For the nine months ended September 30, 2024, three partners represented 50%, 25% and 10% of total income and revenues, respectively. For the three months ended September 30, 2023, two partners represented 73% and 24% of total income and revenues, respectively. For the nine months ended September 30, 2023, two partners represented 54% and 44% of total income and revenues, respectively. One partner represented 96% of the trade and other receivables, net as of September 30, 2024. One partner represented 100% of the trade and other receivables, net as of December 31, 2023. 30.750.140.1030.500.250.1020.730.2420.540.4410.9611 Comprehensive Income (Loss) Comprehensive income (loss) is comprised of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders' equity but are excluded from net income (loss). Accounting Pronouncements Recently Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Recent Accounting Pronouncements Not Yet Adopted In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission's Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures. 3. Condensed Consolidated Financial Statements Details Equity Securities As of September 30, 2024 and December 31, 2023, equity securities consisted of an investment in Rezolute's common stock of $0.8 million and $0.2 million, respectively (see Note 4). For the three and nine months ended September 30, 2024, the Company recognized a gain of $0.1 million and $0.6 million, respectively, due to the change in fair value of its investment in Rezolute's common stock, which is included in the other income (expense), net line item of the condensed consolidated statements of operations. For both the three and nine months ended September 30, 2023, the Company recognized a loss of $0.1 million due to the change in fair value of its investment in Rezolute. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:center;margin:0pt;">September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued incentive compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1,203 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Other accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 445 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 625 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued legal and accounting fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 637 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 791 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Accrued payroll and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 198 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 149 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,768 </td></tr></table> Net Loss Per Share Attributable to Common Stockholders The following table includes the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,243)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> (5,509) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,853)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> (20,722) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Series A accumulated dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> (530) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> (530) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> (1,591) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> (1,591) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Less: Series B accumulated dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (838) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (838) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,513) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,513) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> (6,877) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> (24,826) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,877) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (24,826) </td></tr><tr><td style="vertical-

align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Denominator </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average shares used in computing net loss per share attributable to common stockholders, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> 11,712 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> 11,473 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> 11,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> 11,466 </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"> 11,712 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> 11,473 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> 11,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> 11,466 </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share attributable to common stockholders, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.59)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.60) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2.17) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Net loss per share attributable to common stockholders, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.59)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.60) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2.17) </td></tr></table> Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td

style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible preferred stock </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> 1,473 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> 1,804 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> 1,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"> 1,781 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants for common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 131 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 131 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,607 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,909 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,790 </td></tr></table> . For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $26.48 per share as of September 30, 2024. 8000002000001000000600000-100000-100000 Accrued and other liabilities consisted of the following (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued incentive compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1,203 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Other accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 445 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 625 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued legal and accounting fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 637 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 791 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Accrued payroll and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 198 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 149 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,768 </td></tr>
</table>11710001203000445000625000637000791000198000149000245100027680000 The following table includes the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,243)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> (5,509) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,853)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> (20,722) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Series A accumulated dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> (530) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> (530) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> (1,591) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> (1,591) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Less: Series B accumulated dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (838) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (838) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,513) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,513) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> (6,877) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> (24,826) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,611)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,877) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td

style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (13,957) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (24,826) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Denominator </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average shares used in computing net loss per share attributable to common stockholders, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"> 11,712 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> 11,473 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> 11,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"> 11,466 </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"> 11,712 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> 11,473 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> 11,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> 11,466 </td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share attributable to common stockholders, basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.59) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.60) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.20) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2.17) </td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"> Net loss per share attributable to common stockholders, diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.59) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.60) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.20) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2.17) </td></tr></table> -17243000-5509000-9853000-20722000530000530000159100015910008380008380002513000251300025130000-18611000-6877000-13957000-24826000-18611000-6877000-13957000-24826000011712000114730001164500011466000117120001147300011645000114660001171200011473000116450001146600011712000114730001164500011466000-1.59-0.60-1.20-2.17-1.59-0.60-1.20-2.17 The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible preferred stock </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"> 5,003 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> 1,473 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> 1,804 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> 1,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"> 1,781 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants for common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 131 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 131 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6 </td></tr><tr><td style="vertical-align:bottom;width:48.04%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,607 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,909 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,790 </td></tr>
</table>50030005003000500300050030001473000180400017750001781000131000600013100060006607000681300069090006790000026.48 4. Acquisitions, Licensing, and Other Arrangements Kinnate Acquisition On February 16, 2024, the Company entered into the Kinnate Merger Agreement, pursuant to which the Company acquired Kinnate through a tender offer for (i) $2.5879 in cash per share of Kinnate common stock, plus (ii) one non-transferable contractual CVR per share of Kinnate common stock. The merger closed on April 3, 2024 (the "Kinnate Merger Closing Date"), and XRA merged with and into Kinnate. Following the merger, Kinnate continued as the surviving entity in the merger and a wholly-owned subsidiary of the Company. Each Kinnate CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the Kinnate CVR Agreement. Prior to the Kinnate Merger Closing Date, on February 27, 2024, Kinnate sold one of its lead clinical drug candidates, exarafenib and related IP to Pierre Fabre for an upfront cash consideration of $0.5 million and contingent consideration of $30.5 million upon the achievement of a certain specified milestone (the "Exarafenib Sale"). Kinnate CVR holders are entitled to 100% of the proceeds of the $30.5 million contingent consideration from the Exarafenib Sale less any deductible expenses, if any, until the fifth anniversary of the Kinnate Merger Closing Date, together with 85% of net proceeds, if any, from any license or other disposition of any or all rights to any product, product candidate or research program active at Kinnate as of the closing that occurs within one year of the Kinnate Merger Closing Date, in each case subject to and in accordance with the terms of the Kinnate CVR Agreement. Under the Kinnate CVR Agreement, the Company is responsible for the collection and disbursement of any proceeds that Kinnate CVR holders could be entitled to Broadridge, the Kinnate CVR holders' rights agent. As part of the

Kinnate Merger Agreement, XOMA acquired an IPR&D asset related to KIN-3248, a Fibroblast Growth Factor Receptors inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma, and urothelial carcinoma, as well as certain other solid tumors; the molecule is currently in a Phase 1 clinical study. Additionally, XOMA acquired pre-clinical intangible assets related to IP for the following: (i) KIN-8741, a highly selective c-MET inhibitor with broad mutational coverage, including acquired resistance mutations, in certain solid tumors driven by exon 14-altered and/or amplified c-MET; (ii) KIN-7136, a brain-penetrant MEK inhibitor; and (iii) CDK4, a potential brain-penetrant, selective CDK4 inhibitor. As of April 3, 2024, the Company concluded that the potential milestone from the Exarafenib Sale payable from Pierre Fabre to the Company of $30.5 million (the Exarafenib milestone asset) did not meet the definition of a derivative under ASC 815. The Exarafenib milestone asset met the definition of a financial asset and the Company elected to apply the fair value option in accordance with ASC 825 and recorded an initial estimated fair value of $2.9 million for the Exarafenib milestone asset (Note 6). Subsequent changes in the estimated fair value of the Exarafenib milestone asset, if any, are expected to be recorded in the condensed consolidated statements of operations. As of April 3, 2024, the Company concluded that the potential milestone from the Exarafenib Sale of $30.5 million payable by the Company to the Kinnate CVR holders (the Exarafenib milestone contingent consideration) met the definition of a derivative under ASC 815 and the Company recorded an initial estimated fair value of $2.9 million for the Exarafenib milestone contingent consideration (Note 6). Subsequent changes in the estimated fair value of the Exarafenib milestone contingent consideration, if any, are expected to be recorded in the condensed consolidated statements of operations. Contingent consideration related to the IPR&D asset for KIN-3248 and pre-clinical intangible assets for KIN-8741, KIN-7136, and CDK4 could be payable if the Company licenses or otherwise disposes of any or all rights to any product, product candidate or research program active at Kinnate as of the Kinnate Merger Closing Date within one year of the Kinnate Merger Closing Date. Any contingent consideration related to KIN-3248 is expected to be expensed as incurred. The Company concluded that any contingent consideration related to KIN-8741, KIN-7136, and CDK4 did not meet the definition of a derivative under ASC 815, and as such, the Company expects to recognize any related contingent consideration when probable and estimable. In August 2021, Kinnate entered into an agreement to lease office space located in San Francisco, California. The lease commenced in January 2022 and expires on June 30, 2026. In February 2024, Kinnate entered into a lease assignment agreement with an assignee to assign the remainder of the lease commitment for the leased office space. Kinnate remained liable for lease payments should the assignee default, however Kinnate was not liable for the property taxes, insurance, and common area maintenance. As part of the Kinnate Merger Agreement, the Company acquired both the lease agreement and the related lease assignment agreement. As of April 3, 2024, the Company concluded that the leased office space in San Francisco should be accounted for as an acquired lease and, in accordance with ASC 805, the Company retained the historical operating lease classification for the lease. In accordance with ASC 842, the Company accounted for the lease as if it had commenced on the Kinnate Merger Closing Date. The Company recognized operating lease liabilities of $0.8 million as of April 3, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of April 3, 2024, the Company concluded that the lease assignment agreement should be accounted for as a sublease in accordance with ASC 842. As the assignee makes lease payments, the Company expects to record sublease income in the other income (expense), net line item in its condensed consolidated statement of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total purchase consideration for Kinnate, as of April 3, 2024, was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing cash payment⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> 122,646 </td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> Estimated fair value of the Exarafenib milestone contingent consideration⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 2,922 </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Transaction costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 809 </td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> Total purchase consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 126,377 </td></tr></table> (1)The closing cash payment was determined based on a total of 47,232,737 shares of Kinnate common stock tendered at closing, at a per share price of $2.5879, and the settlement of Kinnate RSUs and stock options under the Kinnate equity incentive plans (2,510,552 total underlying shares at a per share price of $2.5879), less the exercise price for the stock options. (2)The fair value of the Exarafenib milestone contingent consideration was estimated using a probability-weighted discounted cash flow model for the amounts payable to Kinnate CVR holders under the Kinnate CVR Agreement upon the achievement of certain specified milestones associated with the Exarafenib Sale. The Kinnate acquisition was accounted for as an asset acquisition under ASC 805 as the assets did not satisfy the definition of a "business" under ASC 805. As such, the Company recognized the acquired assets and liabilities based on the total purchase consideration, on a relative fair value basis, after allocating the excess of the fair value of net assets acquired to certain qualifying assets (principally, the acquired IPR&D asset, intangible assets, and the right-of-use asset). On a relative fair value basis, the fair value of the <span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-

style:normal;font-weight:normal;">IPR&D asset, intangible assets, and the right-of-use asset were reduced to zero. As the fair value of net assets exceeded the total purchase consideration, a bargain purchase gain was recognized on the acquisition of Kinnate in the condensed consolidated statements of operations for the nine months ended September 30, 2024. The following table shows the allocation of the purchase consideration based on the relative fair value of assets acquired and liabilities assumed by the Company as of April 3, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 142,381</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,223</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exarafenib milestone asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,922</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,009)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (322)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (502)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 145,693 </td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> Reconciliation of net assets acquired to total purchase consideration: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> 145,693 </td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> Less: Gain on the acquisition of Kinnate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (19,316) </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total purchase consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 126,377 </td></tr></table> Subsequent to the acquisition, the Company incurred $3.6 million in severance charges related to the acquisition which was included in G&A expense in the condensed consolidated statement of operations for the nine months ended September 30, 2024. As of September 30, 2024, the Company had fully paid the $3.6 million related to these severance charges. Unaudited pro forma net loss was $9.9 million and $25.1 million for the nine months ended September 30, 2024 and year ended December 31, 2023, respectively. There was no adjustment to the unaudited pro forma total income and revenues for the nine months ended September 30, 2024 and year ended December 31, 2023 as Kinnate had no historical sales through December 31, 2023. The unaudited pro forma financial information has been prepared from historical financial statements that have been adjusted to give effect to the acquisition of Kinnate as though it had occurred on January 1, 2023. They include adjustments for severance expense and gain on the acquisition of Kinnate. The unaudited pro forma financial information is not intended to reflect the actual results of operations that would have occurred if the acquisition had occurred on January 1, 2023, nor is it indicative of future operating results. Takeda On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda. Under the terms of the Takeda Collaboration Agreement, the Company may receive an aggregate of up to $19.0 million relating to TAK-079 (mezagitamab) and 4% royalties on future sales of all products subject to this license. The Company's right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company's right to receive royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration). In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company's right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company's right to receive royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent. In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda. The Company has received $3.0 million of milestone payments since the inception of the agreement and is eligible to receive additional milestone payments of up to $16.0 million under the Takeda Collaboration Agreement. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023. Rezolute On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize RZ358 (previously known as "X358") products for all indications. In addition, the Company entered into a common stock purchase agreement with Rezolute pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock in connection with any future equity financing activities. Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing, and commercialization activities associated with RZ358 and is required to make certain development, regulatory, and commercial milestone payments to the Company of up to an aggregate of $232.0 million based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute's performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. Rezolute's obligation to pay royalties with respect to a particular RZ358 product and country will continue for the later of the date of expiration of the last valid patent claim covering the product in each country, or 12 years from the date of the first commercial sale of the product in each country. Rezolute's future royalty obligations in the U.S. will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid patent claim, until such a claim is confirmed. Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute's other non-RZ358 products from its current programs, including RZ402 which has completed a Phase 2 clinical study. Rezolute's obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of 12 years from the date of the first commercial sale of the product in each country or for so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licensee's obligation to make payments to Rezolute based on sales of such product in each country. The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days' notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents. No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities. The license agreement was subsequently amended in 2018, 2019, and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute's equity financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute's common stock (as adjusted for the 1:50 reverse stock split in October 2020). In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended. In April 2024, Rezolute dosed the first patient in its Phase 3 trial of RZ358 and the Company earned a $5.0 million milestone pursuant to the Rezolute License Agreement, as amended. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized zero and $5.0 million in revenue from contracts with customers related to this arrangement during the three and nine months ended September 30, 2024. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2023. Janssen In August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMA's patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen's achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive a 0.75% royalty on net sales of each product. Janssen's obligation to pay royalties with

respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement. The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen's performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024. The Company recognized $0.2 million and $1.3 million in revenue from contracts with customers related to this arrangement during the three and nine months ended September 30, 2023. Novartis - Anti-TGFβ Antibody (NIS793) On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company's anti-transforming growth factor beta ("TGFβ") antibody program (now "NIS793"). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis' royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon 180 days' notice. The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services, and transfer of materials, process, and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015. The Company was eligible to receive up to a total of $480.0 million in development, regulatory, and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis' performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis' obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. In August 2023, Novartis communicated to the Company its intent to discontinue development activities related to NIS793. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023. Novartis - Anti-IL-1β Antibody (VPM087) On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab ("VPM087"), a novel anti-Interleukin-1 ("IL-1") beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. On August 24, 2017, pursuant to a separate agreement (the "IL-1 Target License Agreement"), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the "Exclusivity Option") to such intellectual property for the treatment and prevention of cardiovascular disease. Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company's outstanding debt with Les Laboratories Servier (the "Servier Loan"). In addition, Novartis extended the maturity date on the Company's debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company's common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company. Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory, and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company's patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits. Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis' royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months' prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials, and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point. At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority. The Company concluded that the development

and regulatory milestone payments are solely dependent on Novartis' performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of September 30, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and nine months ended September 30, 2024 and 2023. Sale of Future Revenue Streams On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the "Royalty Sale Agreements") with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018, and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million. The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company's limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Company's undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the period's cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product. The Company recognized $0.7 million and $1.8 million in revenue under the units-of-revenue method under these arrangements during the three and nine months ended September 30, 2024, respectively. The Company recognized $0.6 million and $1.6 million in revenue under the units-of-revenue method under these arrangements during the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the current and non-current portions of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $5.6 million, respectively. As of December 31, 2023, the Company classified $2.1 million and $7.2 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.

* 2.587915000003050000013050000002.85305000002900000030500000290000008000000 The total purchase consideration for Kinnate, as of April 3, 2024, was as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Closing cash payment⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 122,646</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated fair value of the Exarafenib milestone contingent consideration⁽²⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,922</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 809</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 126,377 </td></tr></table> (1)The closing cash payment was determined based on a total of 47,232,737 shares of Kinnate common stock tendered at closing, at a per share price of $2.5879, and the settlement of Kinnate RSUs and stock options under the Kinnate equity incentive plans (2,510,552 total underlying shares at a per share price of $2.5879), less the exercise price for the stock options. (2)The fair value of the Exarafenib milestone contingent consideration was estimated using a probability-weighted discounted cash flow model for the amounts payable to Kinnate CVR holders under the Kinnate CVR Agreement upon the achievement of certain specified milestones associated with the Exarafenib Sale. The following table shows the allocation of the purchase consideration based on the relative fair value of*

assets acquired and liabilities assumed by the Company as of April 3, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 142,381</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,223</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exarafenib milestone asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,922</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,009)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (322)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (502)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 145,693 </td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"> Reconciliation of net assets acquired to total purchase consideration: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 145,693</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Gain on the acquisition of Kinnate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,316)</p></td></tr><tr><td style="vertical-align:bottom;width:85.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 126,377 </td></tr></table> 122646000292200080900012637700047232737 2.587925105522.587901423810003223000292200020090003220005020001456930001456930

style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements Short-term royalty and commercial payment receivables were $12.7 million and $14.2 million as of September 30, 2024 and December 31, 2023, respectively. Long-term royalty and commercial payment receivables were $54.2 million and $58.0 million as of September 30, 2024 and December 31, 2023, respectively. Daré Royalty Purchase Agreements On April 29, 2024, the Company entered into the Daré RPAs. Pursuant to the terms of the Daré RPAs, the Company paid $22.0 million in cash to Daré in consideration for the sale of (a) 100% of all remaining royalties related to XACIATO not already subject to the royalty-backed financing agreement Daré entered into in December 2023 and net of payments owed by Daré to upstream licensors, which equates to royalties ranging from low to high single digits, and of all potential commercial milestones related to XACIATO that are payable to Daré under the Daré Organon License Agreement; (b) a 4% synthetic royalty on net sales of OVAPRENE and a 2% synthetic royalty on net sales of Sildenafil Cream, which will decrease to 2.5% and 1.25%, respectively, upon the Company achieving a pre-specified return threshold; and (c) a portion of Daré's right to a certain milestone payment that may become payable to Daré under the Bayer License Agreement. The Daré RPAs also provide for milestone payments to Daré of $11.0 million for each successive $22.0 million received by the Company under the Daré RPAs after achievement of a return threshold of $88.0 million. Upon closing of the transaction, the Company paid Daré an upfront payment of $22.0 million, which was recorded as long-term royalty and commercial payment receivables in its condensed consolidated balance sheet. The Company concluded that the milestone payments to Daré did not meet the definition of a derivative under ASC 815 and expects to recognize the milestone payments as liabilities when probable and estimable. Given the limited available information, the Company was unable to reliably estimate future net sales and the commercial payments to be received over the twelve-month period following the quarter ended September 30, 2024 and, as such, no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024. During the nine months ended September 30, 2024, the Company received de minimis commercial payments pursuant to the Daré RPAs. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024. Talphera Commercial Payment Purchase Agreement DSUVIA was approved by the FDA in 2018 for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales of DSUVIA and up to $116.5 million in sales-based milestone payments under the Talphera APA. In addition, Talphera is entitled to 75% of net sales of DSUVIA to the DoD for its services performed to support sales of DSUVIA to the DoD under the Talphera Marketing Agreement. On January 12, 2024, the Company entered into the Talphera CPPA, pursuant to which XOMA will receive (i) 100% of the 15% royalty on commercial net sales and the sales-based milestones related to net sales of DSUVIA for sales made on and after January 1, 2024, and (ii) 100% of Talphera's future service revenue in the amount of 75% of net sales of DSUVIA to the DoD, until the Company receives $20.0 million. Thereafter, the Company will fully retain the 15% royalty on commercial net sales of DSUVIA and will share equally with Talphera the 75% of net sales of DSUVIA to the DoD and the remaining sales-based milestone payments due from Alora. Upon closing of the transaction, the Company paid Talphera an upfront payment of $8.0 million, which was recorded as long-term royalty and commercial payment receivables in its consolidated balance sheet. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Talphera CPPA of $80,000. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance. Given the limited available information, the Company was unable to reliably estimate future net sales and the commercial payments to be received over the twelve-month period following the quarter ended September 30, 2024 and, as such, no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024. LadRx Agreements On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title, and interest related to arimoclomol under the Zevra APA between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory, and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under the ImmunityBio License Agreement between ImmunityBio and LadRx. On June 3, 2024, the ImmunityBio License Agreement was terminated, and the Company entered into an amendment to the LadRx RPA. Under the LadRx RPA, as amended, the Company is eligible to receive potential low single-digit percentage royalty payments on aggregate net sales of aldoxorubicin. Additionally, the amendment removed the remaining $4.0 million regulatory milestone payment under the original agreement that had been contingent upon the achievement of a specified regulatory milestone for the product candidate related to aldoxorubicin, which initially and as of the amendment date had a fair value of zero. If LadRx licenses aldoxorubicin to an applicable third party, the Company is eligible to receive potential high single-digit percentage royalty payments on aggregate net sales of aldoxorubicin and a portion of any potential future milestone payments. Upon the initial closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and could have been required to pay up to an additional $6.0 million in regulatory and commercial sales milestone payments which included $5.0 million related to regulatory milestone payments and $1.0 million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable. At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments. On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx Agreements, the Company made a $1.0 million milestone payment to LadRx in January 2024. On September 20, 2024, Zevra announced that the FDA granted approval to Zevra's NDA for MIPLYFFA. The achievement of the commercial milestone payment under the LadRx AAA was considered probable as of September 30, 2024, and the Company recognized a $1.0 million contingent liability. As of September 30, 2024, the Company recorded $2.2 million as short-term royalty and commercial payment receivables related to the net proceeds receivable for the milestone payment associated with the FDA approval of MIPLYFFA. Given the limited available information, the Company was unable to reliably estimate its royalty payment stream from future net sales, and therefore no amounts were reflected as short-term royalty and commercial payment receivables as of September 30, 2024. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023. Aptevo Commercial Payment Purchase Agreement On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. The Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million. <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt

12pt 0pt;">At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables in its consolidated balance sheet which included a $9.6 million upfront payment and a $50,000 one-time payment, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet at inception. The Company paid the one-time payment of $50,000 in June 2023 when related receipts exceeded $0.5 million. During the year ended December 31, 2023, the Company received total commercial payments pursuant to the Aptevo CPPA of $1.7 million. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Aptevo CPPA of $0.8 million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty and commercial payment receivables balance. Though the Company is unable to reliably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it estimates the short-term portion of the receivables balance based on the past 12 months' receipts. As such, as of September 30, 2024 and December 31, 2023, the Company recorded $2.2 million and $2.0 million, respectively, as short-term royalty and commercial payment receivables. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payments received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023. Palobiofarma Royalty Purchase Agreement On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin's lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis, and nonalcoholic steatohepatitis and other indications that are being developed by Palo. Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties' entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. As of September 30, 2024, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023. Viracta Royalty Purchase Agreement On March 22, 2021, the Company entered into the Viracta RPA, as amended March 4, 2024, pursuant to which the Company acquired the right to receive future royalties, milestone payments, and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma LLC. The Company acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and a portion of potential other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones, and high single-digit royalties on sales related to vosaroxin, if approved. At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. On October 30, 2023, the Company earned a $5.0 million milestone payment pursuant to the Viracta RPA related to the FDA's acceptance of Day One's NDA for OJEMDA. In accordance with the cost recovery method, the $5.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivables balance. On April 23, 2024, Day One announced that the FDA granted approval to Day One's NDA for OJEMDA. Pursuant to the Viracta RPA, the Company earned a $9.0 million milestone payment upon FDA approval and is also eligible to receive mid-single-digit royalties on sales of OJEMDA. In accordance with the cost recovery method, $8.5 million of the milestone payment was recorded as a direct reduction of the remaining recorded long-term royalty receivables balance and the excess balance of $0.5 million was recorded as income from purchased receivables in the condensed consolidated statement of operations for the nine months ended September 30, 2024. On May 30, 2024, Day One announced that it sold its priority review voucher to an undisclosed buyer for $108.0 million. Pursuant to the Viracta RPA, the Company received a payment of $8.1 million related to the sale. The rights to proceeds upon the sale of the priority review voucher was determined to be an embedded derivative which had no value prior to FDA approval of OJEMDA. The Company recorded a change in the fair value of the embedded derivative of $8.1 million in other income in the condensed consolidated statement of operations for the nine months ended September 30, 2024. As of June 30, 2024, the Company had fully collected the purchase price recorded in long-term royalty and commercial payment receivables related to the Viracta RPA in its consolidated balance sheet and, as such, subsequent royalties received are recorded as income from purchased receivables. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023. As there was no remaining balance in long-term royalty and commercial payment receivables related to the Viracta RPA in its consolidated balance sheet as of September 30, 2024, the Company did not need to perform its periodic impairment assessment for the three months ended September 30, 2024. As of September 30, 2024, there was $1.0 million in trade and other receivables, net related to this arrangement. As of December 31, 2023, there was no trade and other receivables, net related to this arrangement. The Company recognized $1.0 million and $1.9 million in income from purchased receivables related to this arrangement during the three and nine months ended September 30, 2024. The Company did not recognize any income related to this arrangement during the three and nine months ended September 30, 2023. Kuros Royalty Purchase Agreement On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals' vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestone payments. At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals, Inc. resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivables balance. As of September 30, 2024, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments, and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023. Affitech Commercial Payment Purchase Agreement On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche's faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million upfront payment and $8.0 million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable. In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European

Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Commercial payments are due from Roche to the Company within 60 days of December 31 and June 30 of each year. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone payment tied to the U.S. marketing approvals and a $3.0 million milestone payment tied to the EC approvals. The achievement of the first and second sales-based milestone payments under the Affitech CPPA was considered probable as of December 31, 2023, and as such the Company recognized a $6.0 million contingent liability in contingent consideration under RPAs, AAAs, and CPPAs in its consolidated balance sheet. The sales milestones were achieved in 2023 and in the first quarter of 2024, the Company paid Affitech $6.0 million and the related contingent liability balance was reduced to zero. Based on reported first quarter of 2024 sales of VABYSMO, the achievement of the third sales-based milestone payment under the Affitech CPPA was considered probable as of March 31, 2024, and the Company recognized a $3.0 million contingent liability which remained on the condensed consolidated balance sheet as of September 30, 2024. Historically, the Company had been unable to reliably estimate its commercial payment stream from future net sales and the related commercial payments to be received under the Affitech CPPA. However, Roche's periodically reported VABYSMO sales data, available third-party sales projections, and the Company's history of receipts of commercial payments related to VABYSMO have provided the Company with a greater ability to estimate future net sales and the commercial payments to be received under the Affitech CPPA. Therefore, as of April 1, 2024, the Company began accounting for the receivable which had a carrying amount of $7.8 million using the EIR method on a prospective basis. As a result, the Company recognized $5.4 million and $10.0 million in income from purchased receivables during the three and nine months ended September 30, 2024. During the nine months ended September 30, 2024, the Company received commercial payments pursuant to the Affitech CPPA of $16.9 million. The Company performed its impairment assessment and no allowance for credit losses was recorded as of September 30, 2024 and December 31, 2023. Agenus Royalty Purchase Agreement On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. ("Incyte") immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory, and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales. In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and 10% of all future developmental, regulatory, and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on a low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company's share in future potential development, regulatory, and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements. Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone payment under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivables balance. Based on updates received in July 2024, the Company evaluated the status of the program for potential impairment in the third quarter of 2024 and determined no payments were probable to be received under the Agenus RPA as of September 30, 2024. Accordingly, the Company recorded an impairment of $14.0 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and an allowance for credit losses of $14.0 million, which consisted of a $14.0 million reduction in the net carrying value of long-term royalty receivables related to the Agenus RPA. As the impaired amount was not expected to be collected, the long-term royalty receivables were written off. There was no allowance for credit losses recorded as of December 31, 2023. Aronora Royalty Purchase Agreement On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the "Non-Royalties") related to five anti-thrombotic hematology product candidates. Three candidates were subject to Aronora's collaboration with Bayer (the "Bayer Products"), including one which was subject to an exclusive license option by Bayer. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products. The Company was eligible to receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the "non-Bayer Products") for which the Company will receive a low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company's receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. On April 8, 2024, Bayer terminated its license agreement with Aronora. Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the "Aronora Contingent Consideration"). Pursuant to the Aronora RPA, if the Company receives at least $25.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the "Royalty Milestones"). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company. At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. As of September 30, 2024, no payments were probable to be received under the Aronora RPA. Based on communications in April 2024, the Company evaluated the status of the partnered programs for potential impairment in the second quarter of 2024 and recorded an impairment of $9.0 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and an allowance for credit losses of $9.0 million, which consisted of a $9.0 million reduction in the net carrying value of long-term royalty receivables related to the Aronora RPA. As the impaired amount was not expected to be collected, the long-term royalty receivables were written off. There was no allowance for credit losses recorded as of December 31, 2023. The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the nine months ended September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Acquisition of Royalty and Commercial Payment Receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Receipt of Royalty and Commercial Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Recognition of Contingent Consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impairment of Royalty and Commercial Payment Receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt

0pt;">Balance as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Daré </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 22,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 22,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Talphera </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 8,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (80) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> 7,920 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> LadRx </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 6,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 7,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Aptevo </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 7,976 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (794) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> 7,182 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Agenus </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 14,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> (14,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Aronora </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 9,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (9,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Palobiofarma </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 10,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> ‍ </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 10,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Viracta </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 8,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (8,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Kuros </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 4,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 4,500 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Affitech </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,191 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,396 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,795) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">72,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 30,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">16,770)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(23,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,795) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 58,602 </td></tr></table> The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the nine months ended September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Income from Purchased Receivables Under EIR Method </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Receipt of Royalty and Commercial Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"> Affitech </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,493) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,287 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (9,493) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,287 </td></tr></table>
127000001420000054200005800000.022000000.010.040.020.0250.012511000000.022000000.088000000.022000000.0000.151165000000.74000000.005000000.06000000.05000000.01000000.05000000.01000000.01000000.06000000.05000000.01000000.01000000.01000000.022000000(
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the nine months ended September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:10.69

</td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Acquisition of Royalty and Commercial Payment Receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Receipt of Royalty and Commercial Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Recognition of Contingent Consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impairment of Royalty and Commercial Payment Receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Daré </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 22,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 22,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Talphera </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 8,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (80) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> 7,920 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> LadRx </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 6,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 7,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Aptevo </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 7,976 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (794) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> 7,182 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Agenus </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 14,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> (14,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Aronora </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 9,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (9,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Palobiofarma </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 10,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 10,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Viracta </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> 8,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> (8,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.67%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Kuros </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> 4,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"> 4,500 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"> Affitech </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,191 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,396) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,795) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 72,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> 30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (16,770) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> 4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (23,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 58,602 </td></tr></table> - The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the nine months ended September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td

*style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reclassification of Royalty and Commercial Payment Receivables from Cost Recovery to EIR Method </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Income from Purchased Receivables Under EIR Method </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Receipt of Royalty and Commercial Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"> Affitech </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,493) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,287</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(9,493)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,287 </td></tr></table> *

* <220000002200000080000008000079200006000000100000070000007976000794000718200014000000-140000009000000-90000001000000010000000850000085000004500000450000012191000739600030000000-77950007216700030000000167700004000000-23000000-779500058602000779500099850009493000828700077950009985000949300082870007950009985000949300082870007 6. Fair Value Measurements The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company's financial instruments, including cash, trade and other receivables, net, and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in*

valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. The Company's Exarafenib milestone asset (Note 4) was carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above. Any subsequent changes in the estimated fair value of the Exarafenib milestone asset are recorded in the condensed consolidated statements of operations. The following tables set forth the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements as of September 30, 2024 Using: </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Quoted Prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Active Markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Observable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Identical Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 112,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> 112,895 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 138,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> 138,032 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Exarafenib milestone asset (Note 4) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> 3,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> 3,125 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 785 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 785 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Total financial assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 138,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 141,942 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Exarafenib milestone contingent consideration (Note 4) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> 3,125 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Total financial liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,125 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements as of December 31, 2023 Using: </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Quoted Prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Active Markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Observable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Identical Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-

space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">28,352</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> 28,352 </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 161 </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 161 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Total financial assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">28,513</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 28,513 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">1,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,000 </td></tr></table> Exarafenib Milestone Asset and Exarafenib Milestone Contingent Consideration The Exarafenib milestone asset and Exarafenib milestone contingent consideration represent the Company's potential receipt of a future milestone payment and a future consideration payable to Kinnate CVR holders that are contingent upon the achievement of a certain specified milestone related to the Exarafenib Sale. As of September 30, 2024, the estimated fair value of each of the Exarafenib milestone asset and Exarafenib milestone contingent consideration was $3.1 million. The fair value measurement was based on a probability-weighted discounted cash flow model using significant Level 3 inputs, such as anticipated timelines and the probability of achieving the development milestone. Both the Exarafenib milestone asset and Exarafenib milestone contingent consideration are remeasured at fair value at each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations until settlement. Subsequent to the Kinnate acquisition, during the three and nine months ended September 30, 2024, the estimated fair value of both the Exarafenib milestone asset and Exarafenib milestone contingent consideration increased by $0.2 million. The increase in estimated fair value did not have an impact on the condensed consolidated statements of operations for the three and nine months ended September 30, 2024. Equity Securities The equity securities consisted of an investment in Rezolute's common stock and are classified on the condensed consolidated

balance sheets as current assets as of September 30, 2024 and December 31, 2023. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations. As of September 30, 2024 and December 31, 2023 the Company valued the equity securities using the closing price per share for Rezolute's common stock traded on the Nasdaq Stock Market of $4.85 and $0.99, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement. Contingent Consideration under RPAs, AAAs, and CPPAs, Measured at Fair Value During the first quarter of 2024, the contingent liability recorded pursuant to the LadRx Agreements was reduced to zero after the Company paid LadRx $1.0 million upon achievement of a regulatory milestone in January 2024 (Note 5). During the second quarter of 2024, the Company amended the LadRx RPA and the remaining contingent consideration that had been contingent upon the achievement of a specified regulatory milestone for the product candidate related to aldoxorubicin was removed (Note 5). As of September 30, 2024, there were no remaining regulatory milestone contingent payments under the LadRx Agreements. The following tables set forth the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):   <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">   </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements as of September 30, 2024 Using: </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Quoted Prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Active Markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Observable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Identical Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 112,895 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> 112,895 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> U.S. treasury bills </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,137 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 138,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> 138,032 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Exarafenib milestone asset (Note 4) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> 3,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> 3,125 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 785 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 785 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Total financial assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 138,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 141,942 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Exarafenib milestone contingent consideration (Note 4) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> 3,125 </td></tr><tr><td style="vertical-align:bottom;width:50.58%;background:#cceeff;margin:0pt;padding:0pt;"> Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:50.58%;margin:0pt;padding:0pt;"> Total financial liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,125 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements as of December 31, 2023 Using: </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Quoted Prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Significant Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"> Active Markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"> Observable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Identical Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">28,352</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> 28,352 </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 28,352 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 161 </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:middle;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 161 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Total financial assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">28,513</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 28,513 </td></tr><tr><td style="vertical-align:bottom;width:50.74%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.74%;margin:0pt;padding:0pt;"> Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">1,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,000 </td></tr>
</table>1128950001128950002513700025137000138032000138032000312500031250000785000785000138817000312500014194200031250003127

7. Lease Agreements

Office Lease

The Company leases a facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term five months from its original expiration of February 28, 2023 to July 31, 2023 (the "amended lease agreement" or the "amended lease").

The Company retained no option to further extend, renew or terminate the amended lease under the amended terms and all other material terms and conditions, including the monthly base rent, remained consistent with the original lease.

In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the right-of-use asset of $0.1 million to reflect the changes in the lease payments due to the extended lease term.

On June 27, 2023, the Company executed the second lease amendment for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing amended lease which expired in July 2023 (the "new lease agreement" or the "new lease"). The new lease agreement commenced on November 10, 2023 and has a term of 65 months.

Under the new lease agreement, the Company retained access to its original premises under the amended lease which expired in July 2023, until the current premises became available on November 10, 2023. Payments made between when the lease expired in July 2023 and the commencement date of the premises of November 10, 2023 were recorded as variable lease costs in the consolidated statement of operations for the year ended December 31, 2023.

In accordance with ASC 842,

the Company accounted for the new lease as a separate contract and the Company recognized an operating lease right-of-use assets of $0.4 million and operating lease liabilities of $0.4 million on November 10, 2023, the commencement date of the new lease. Kinnate Lease As part of the Kinnate Merger Agreement (Note 4), the Company acquired a lease agreement that was assigned to an assignee that expires on June 30, 2026. In accordance with ASC 842, the Company accounted for the lease as if it had commenced on the Kinnate Merger Closing Date. The Company recognized operating lease liabilities of $0.8 million as of April 3, 2024. No operating lease right-of-use assets were recorded due to the allocation of the excess of fair value of net assets acquired to certain qualifying assets under ASC 805.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes maturity of the Company's operating lease liabilities as of September 30, 2024 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rent Payments</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (excluding the nine months ended September 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 117 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 502 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 91 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 102 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> Total undiscounted lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 1,148 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> Present value adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (120) </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> Total net lease liability for operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,028 </td></tr></table> As of September 30, 2024 and December 31, 2023, the total net lease liability was $1.0 million and $0.4 million, respectively. As of September 30, 2024, the Company's current and non-current operating lease liabilities were $0.4 million and $0.6 million, respectively. As of December 31, 2023, the Company's current and non-current operating lease liabilities were $0.1 million and $0.3 million, respectively. The following table summarizes the cost components of the Company's operating leases included in G&A in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;background:#cceeff;margin:0pt;padding:0pt;"> Lease costs: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"> 116 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> Total lease costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 148 </td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Under the terms of the original, amended, and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</td></tr></table> . The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities </td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> Operating cash flows under operating leases </td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 121 </td></tr></table> The assumptions used in calculating the present value of the lease payments for the Company's operating leases as of September 30, 2024 and December 31, 2023 were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"> 2.7 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> 5.33 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> Weighted-average discount rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 8.18 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> 8.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> % </td></tr></table> Kinnate Sublease As part of the Kinnate Merger Agreement (Note 4), the Company acquired a lease assignment agreement with an assignee that expires on June 30, 2026. In accordance with ASC 842, the Company will account for the lease assignment as a sublease over its term. Under the terms of the lease assignment agreement, the assignee will make direct payments to the head lessor over the lease term. During the three and nine months ended September 30, 2024, the Company recognized sublease income of $0.1 million and $0.2 million in the other income (expense), net line item in the condensed consolidated statement of operations.</p>P5Mfalse100000P65M4000004000008000000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes maturity of the Company’s operating lease liabilities as of September 30, 2024 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rent Payments</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (excluding the nine months ended September 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 117 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 502 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 91 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 102 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> Total undiscounted lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,148</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (120)</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liability for operating leases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,028 </td></tr>
</table>1170005020003000009100010200036000114800012000010280001000000.040000040000060000010000030000 The following table summarizes the cost components of the Company's operating leases included in G&A in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"> 116 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.77%;margin:0pt;padding:0pt;"> Total lease costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 148 </td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times

New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the terms of the original, amended, and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</td></tr>
</table>360001700097000116000200001800032000360003700011500014800 The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities </td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> Operating cash flows under operating leases </td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 121 </td></tr></table> The assumptions used in calculating the present value of the lease payments for the Company's operating leases as of September 30, 2024 and December 31, 2023 were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:12.38%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"> 2.7 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> 5.33 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"> Weighted-average discount rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 8.18 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> 8.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> % </td></tr></table> The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities </td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.41%;margin:0pt;padding:0pt;"> Operating cash flows under operating leases </td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 121 </td></tr></table>68000121000P2Y8M12DP5Y3M29D0.08180.0850100000200000 8. Long-Term Debt On December 15, 2023, XOMA transferred to XRL, a newly formed wholly-owned subsidiary, all its rights, title, and interest in the commercial payments from Roche's VABYSMO under the Affitech CPPA and related assets (the "Commercial Payments"). The VABYSMO-related assets and rights transferred to XRL are referred to herein as the "Transferred Assets." Simultaneously, XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders, pursuant to which XRL was extended certain senior secured credit facilities in an aggregate principal amount of up to $140.0 million. The principal and interest of the loan are to be paid from the Commercial Payments. XRL is obligated to make semi-annual interest payments, starting in March 2024, at a fixed rate of 9.875% per annum until the commercial payment-backed loan is repaid, at which time the Commercial Payments will revert back to XOMA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any Commercial Payment in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. The loan matures on December 15, 2038, provided that XRL may repay it in full at any time prior to December 15, 2038, subject to the terms of the Blue Owl Loan Agreement. The Blue Owl Loan includes (i) an initial term loan in an aggregate principal amount equal to $130.0 million and (ii) a delayed draw term loan in an aggregate principal amount of $10.0 million to be funded at the option of the XRL upon receipt by the lenders of payments of principal and interest from the proceeds of Commercial Payments in excess of an agreed upon amount on or prior to March 15, 2026. The payment obligations under the Blue Owl Loan Agreement are limited to XRL, and Blue Owl has no recourse under the Blue Owl Loan Agreement against XOMA or any assets other than the Transferred Assets and XOMA's equity interest in XRL. In connection with the Blue Owl Loan Agreement, (i) XRL granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the Affitech CPPA and (b) all other assets of XRL and (ii) XOMA granted Blue Owl a first-priority perfected lien on, and security interest in, 100% of the equity of XRL. The Blue Owl Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl. On December 15, 2023, the Company borrowed the initial term loan of $130.0 million and received $119.6 million, net of $4.1 million in fees and lender expenses and $6.3 million that was deposited into reserve accounts to pay interest, administrative fees and XRL's operating expenses (see Note 2). The Company also incurred $0.6 million of direct issuance costs related to the Blue Owl Loan Agreement. In connection with the Blue Owl Loan Agreement, XOMA issued to Blue Owl and certain funds affiliated with Blue Owl warrants to purchase: (i) up to 40,000 shares of XOMA's common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of XOMA's common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of XOMA's common stock at an exercise price of $50.00 per share (collectively, the "Blue Owl Warrants"). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $1.5 million. As of September 30, 2024, all Blue Owl Warrants were outstanding. The initial term loan of $130.0 million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the EIR was determined to be 11.01%. The Company recorded a debt discount of $5.3 million, which included $3.8 million in allocated fees and lender expenses and $1.5 million for the fair value of the Blue Owl Warrants. The Company also recorded $0.6 million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $5.3 million and $0.6 million of direct debt issuance costs over the expected term of the initial term loan. As of the closing date of December 15, 2023, the Company recorded the $0.3 million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of September 30, 2024, no amount had been drawn from the delayed draw term loan. The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively, as of December 31, 2023. The Company recorded $0.6 million in interest expense during the year ended December 31, 2023. In March 2024, XRL made a semi-annual payment of $7.4 million which included an interest payment of $3.8 million and principal repayment of $3.6 million. In September 2024, XRL made a semi-annual payment of $9.5 million which included an interest payment of $6.2 million and principal repayment of $3.3 million. The carrying value of the short and long-term portion of the initial term loan was $9.8 million and $108.1 million, respectively, as of September 30, 2024. As of September 30, 2024, the EIR was determined to be 11.16%. The Company recorded $3.5 million and $10.4 million in interest expense during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company had an unaccreted debt discount of $4.5 million and unaccreted direct issuance costs of $0.7 million to be accreted over the expected remaining term of the initial term loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the impact of the initial term loan on the Company's condensed consolidated balance sheet as of September 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td></tr><tr><td style="vertical-align:middle;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross principal </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 130,000 </td></tr><tr><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"> Principal repayments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> (6,902) </td></tr><tr><td style="vertical-

align:middle;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> Unaccreted debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,183) </td></tr><tr><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"> Total carrying value net of principal repayments, unaccreted debt discount, and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 117,915 </td></tr><tr><td style="vertical-align:middle;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion of long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,826) </td></tr><tr><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"> Long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 108,089 </td></tr></table> . Long-term debt on the Company's condensed consolidated balance sheet as of September 30, 2024 and consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. The carrying value of the Blue Owl Loan as of December 31, 2023 was $124.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aggregate projected future principal payments of the initial term loan as of September 30, 2024, are as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (excluding the nine months ended September 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 11,274 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 17,825 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 23,885 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 29,761 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,353 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0pt 12pt;">Total payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 123,098 </td></tr></table> . Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 relates to the initial term loan (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> Accretion of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 408 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 996 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.42%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>

140000000.00.09875130000000.010000000.01130000000.011960000041000006300000600000041000035.004000042.504000050.001500000130 style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the impact of the initial term loan on the Company's condensed consolidated balance sheet as of September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:middle;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> Gross principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 130,000</p></td></tr><tr><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Principal repayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,902)</p></td></tr><tr><td style="vertical-align:middle;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,183)</p></td></tr><tr><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total carrying value net of principal repayments, unaccreted debt discount, and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117,915</p></td></tr><tr><td style="vertical-align:middle;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,826)</p></td></tr><tr><td style="vertical-align:middle;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 108,089 </td></tr></table>130000000069020005183000117915000982600010808900001240000000.0 Aggregate projected future principal payments of the initial term loan as of September 30, 2024, are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:80.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ending December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Payments </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 (excluding the nine months ended September 30, 2024) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p

*style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,274</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 17,825 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"> 23,885 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"> 29,761 </td></tr><tr><td style="vertical-align:bottom;width:80.94%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,353</p></td></tr><tr><td style="vertical-align:bottom;width:80.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 123,098 </td></tr>
</table>112740001782500023885000297610004035300012309800 0 Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 relates to the initial term loan (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td*

style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;margin:0pt;padding:0pt;"> Accretion of debt discount and debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 408 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 996 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.42%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 3085000945000040800099600034930001044600 9. Common Stock Warrants As of September 30, 2024 and December 31, 2023, the following common stock warrants were outstanding: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issuance Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Expiration Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> per Share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> May 2018 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> May 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> Stockholders' equity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 14.71 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 4,845 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> 4,845 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> December 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> December 2033 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> Stockholders' equity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 35.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 40,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"> 40,000 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"> December 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> December 2033 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;">Stockholders' equity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">42.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">40,000</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 50.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,000 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,177 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,177 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issuance Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Expiration Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> per Share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> May 2018 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> May 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> Stockholders' equity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 14.71 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 4,845 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> 4,845 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> December 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> December 2033 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders' equity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40,000</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 42.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 40,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"> 40,000 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> December 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"> December 2033 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"> Stockholders' equity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 50.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,000 </td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,177 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 131,177 </td></tr></table> .
23.696332633214.7114.714845484535.0035.004000004000042.5042.504000004000050.0050.00400000400001311771311774 10. Commitments and Contingencies Collaborative Agreements, Royalties, and Milestone Payments The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory, and commercial milestones by the Company's licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of September 30, 2024. Contingent Consideration Pursuant to the Company's agreements with Aronora, Kuros, Affitech, LadRx, and Daré, and under the Kinnate CVR Agreement, the Company has committed to pay the Aronora Royalty Milestones, the Kuros Sales Milestones, the remaining Affitech Sales Milestones, LadRx commercial sales milestone, Daré Milestones, and the Exarafenib milestone contingent consideration. <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, the Company recorded $1.0 million for the LadRx contingent consideration that represented the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin at the inception of the LadRx Agreements. During the nine months ended September 30, 2024, the contingent liability was reduced to zero after the Company paid LadRx $1.0 million upon the FDA's acceptance of the arimoclomol NDA resubmission. Additionally, the amendment to the LadRx RPA removed the milestone payment that had been contingent upon the achievement of a regulatory milestone related to aldoxorubicin (Note 5). During the third quarter of 2024, the LadRx commercial sales milestone related to MIPLYFFA pursuant to the LadRx AAA was assessed to be probable under ASC 450. As such, a $1.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $1.0 million asset was recorded under long-term royalty and commercial payment receivables on the condensed consolidated balance sheet as of September 30, 2024. During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $6.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $6.0 million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet. During the first quarter of 2024, this contingent liability was reduced to zero after the Company paid Affitech $6.0 million upon the achievement of the related commercial sales milestones (Note 5). During the first quarter of 2024, a sales milestone related to VABYSMO pursuant to the Affitech CPPA was assessed to be probable under ASC 450. As such, a $3.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $3.0 million asset was recorded under short-term royalty and commercial payment receivables on the condensed consolidated balance sheet. As of September 30, 2024, the Company recorded $3.1 million for the Exarafenib milestone contingent consideration, which represented the estimated fair value of potential future payments upon the achievement of a certain specified milestone related to exarafenib payable to Kinnate CVR holders upon the closing of the Kinnate acquisition under the Kinnate CVR Agreement. The Exarafenib milestone contingent consideration is measured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, and the Daré Milestones will be recorded when the amounts, by product, are estimable and probable. As of September 30, 2024, none of the Aronora Royalty Milestones, Kuros Sales Milestones, and Daré Milestones were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet.
630000011000000.001000000.01000000.01000000.06000000.06000000.006000000.03000000.03000000.03100000 11. Stock-Based Compensation The Company may grant qualified and non-qualified stock options, common stock, PSUs, RSUs, and other stock-based awards under various plans to directors, officers, employees, and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company's common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company's common stock on the first trading day of the offering period or on the last day of the purchase period. The ESPP includes a rollover mechanism for the purchase price if the fair market value of the Company's common stock on the purchase date is less than the fair market value of the Company's common stock on the first trading day of the offering period. Stock Options and Other Benefit Plans Stock Option Plans 2010 Plan Stock Options Stock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. Fair Value Assumptions of 2010 Plan Stock Options There were no stock options granted during the three months ended September 30, 2024 and 2023. The fair value of stock options granted during the nine months ended September 30, 2024 and 2023 was estimated based on the following weighted-average assumptions: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">
</td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">
</td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.33%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"> 65 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> 70 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:42.33%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"> 4.35 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> 3.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> Expected term </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"> 5.79 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> 5.79 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr></table><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> The weighted-average grant-date fair value per share of the stock options granted during the nine months ended September 30, 2024 and 2023, was $24.71 and $13.46, respectively. Stock Option Inducement Awards On December 30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Company's Chief Investment Officer, effective as of January 1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the "Stock Option Inducement Awards") when the Company's stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan. More information on the Stock Option Inducement Awards granted during the three months ended March 31, 2023 can be found in Note 10 of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the first quarter of 2023 was $11.91. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was $14.68. No Stock Option Inducement Awards were granted during the nine months ended September 30, 2024. The activity for all stock options for the nine months ended September 30, 2024 was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-

space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Remaining Term </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td><td style="vertical-align:top;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td><td style="vertical-align:top;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of January 1, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2,730,068 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 10,638 </td></tr><tr><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 34,170 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 24.71 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> (246,599) </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 6.51 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> Forfeited, expired or cancelled </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (34,840) </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 155.16 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of September 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,482,799 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20.48</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.94</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 20,224 </td></tr><tr><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> Exercisable as of September 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 2,037,185 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19.73</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.44</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> 18,416 </td></tr></table> . <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2024 and 2023 was $4.7 million and $18,000, respectively. The intrinsic value is the difference between the fair value of the Company's common stock at the time of exercise and the exercise price of the stock option. The Company recorded $1.0 million and $3.0 million in stock-based compensation expense related to stock options during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, $5.6 million of total unrecognized compensation expense related to stock options was expected to be recognized over a weighted-average period of 1.95 years. Performance Stock Unit Awards In May 2023, the Company granted employees 430,400 PSUs under the 2010 Plan. The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company's common stock as compared to four stock price hurdles over a three-year period from the May 2023 grant date (the "performance period"). A stock price hurdle is considered attained when, at any time during the performance period, the Company's volume-weighted-average stock price equals or exceeds the hurdle stock price value for 30 consecutive calendar days. Upon attainment of a stock price hurdle, one-third of the earned PSUs will vest immediately upon achievement, one-third will vest upon the two-year anniversary of the grant date and one-third will vest on the three-year anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest. In October 2023, the Company granted an additional 18,200 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants. In connection with Mr. Hughes' appointment to full-time Chief Executive Officer in January 2024, the Company granted Mr. Hughes 275,000 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants. In April 2024, the Company granted certain employees an aggregate of 10,000 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants. Fair Value Assumptions of Performance Stock Unit Awards The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied. The range of grant date fair values of the PSUs granted in 2023 was estimated as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Derived </td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"> Hurdle Price </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> .

</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"> Service Period </td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per PSU </td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PSUs </td><td style="vertical-align:top;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 243,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 11.42-17.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> 0.69-2.59 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91,239</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 10.16-16.07 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 0.93-2.59 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 60.024</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 9.07-14.84 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> 1.12-2.59 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 53,787</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 8.12-13.72 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 1.27-2.59 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 448,600 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> The grant date fair values of the PSUs granted in January 2024 and April 2024 was estimated as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Derived </td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"> Hurdle Price </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"> Service Period </td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PSUs </td><td style="vertical-align:top;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 165,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 18.42-19.71 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> 0.46-0.74 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 55,290</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 17.24-17.67 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 0.66-0.96 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 34,029</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 15.85-16.14 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> 0.82-1.15 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,781</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 14.20-15.13 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 0.95-1.31 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 285,000 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> The Company estimates that it will recognize total stock-based compensation expense of approximately $11.9 million in aggregate for the PSUs granted in May 2023, October 2023, January 2024, and April 2024 using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved. The activity for all PSUs for the nine months ended September 30, 2024 was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unvested PSUs </td><td style="vertical-align:top;white-

space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> (</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td></tr><tr><td style="vertical-align:middle;width:56.13%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance as of January 1, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ 448,600 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$ 15.40 </td></tr><tr><td style="vertical-align:middle;width:56.13%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"> $ 285,000 </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> $ 17.60 </td></tr><tr><td style="vertical-align:middle;width:56.13%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:56.13%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:56.13%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance as of September 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 733,600 </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$ 16.26 </td></tr></table> (The Company recorded $1.5 million and $5.0 million in stock-based compensation expense related to the PSUs during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, there was $4.2 million unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of 1.13 years. (Restricted Stock Unit Awards In May 2024, the Company granted the non-employee directors of the Board an aggregate of 15,175 RSUs under the 2010 Plan. RSUs are equity awards that entitle the holder to receive freely tradeable shares of the Company's common stock upon vesting. The RSUs vest in full on the one-year anniversary of the grant date. The fair value of the RSUs is equal to the closing price of the Company's common stock on the grant date. The weighted-average grant-date fair value of the RSUs granted was $24.71 per RSU. As of September 30, 2024, no RSUs had vested and the unvested balance as of September 30, 2024 was 15,175 RSUs at a weighted-average grant-date fair value of $24.71 per RSU. The Company recorded $0.1 million in stock-based compensation expense related to the RSUs during the three and nine months ended September 30, 2024. As of September 30, 2024, there was $0.2 million unrecognized stock-based compensation expense related to the outstanding RSUs granted to non-employee directors, with a weighted-average remaining recognition period of 0.62 years. (Stock-based Compensation Expense All stock-based compensation expense is recorded in G&A expense. The following table shows total stock-based compensation expense for stock options, PSUs, RSUs, and ESPP in the condensed consolidated statements of operations (in thousands): (<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:45.94%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,717 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,450 </td></tr></table> 0.85P3YP1YP55YP70Y00 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.33%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"> 65 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3.5pt 0pt 0pt;"> 70 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:42.33%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"> 4.35 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> 3.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:42.33%;margin:0pt;padding:0pt;"> Expected term </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"> 5.79 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> 5.79 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td></tr></table>000.650.700.04350.0360P5Y9M14DP5Y9M14D24.7113.46218.6618.6611.9130.0014.680 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td

colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"> Remaining Term </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td><td style="vertical-align:top;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td><td style="vertical-align:top;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of January 1, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2,730,068 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 10,638 </td></tr><tr><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 34,170 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 24.71 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> (246,599) </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 6.51 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> Forfeited, expired or cancelled </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (34,840) </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 155.16 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of September 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,482,799 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20.48</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.94</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 20,224 </td></tr><tr><td style="vertical-align:middle;width:38.08%;margin:0pt;padding:0pt;"> Exercisable as of September 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 2,037,185 </td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19.73</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.44</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> 18,416 </td></tr></table>273006820.88P6Y3M14D106380003417024.712465996.5134840155.162482799 20.48P5Y11M8D202240002037185 19.03.73P5Y5M8D184160000 5.44.48P6Y3M14D106380003417024 18,416

The range of grant date fair values of the PSUs granted in 2023 was estimated as follows:

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(in years) </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 243,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 11.42-17.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> 0.69-2.59 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91,239</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 10.16-16.07 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 0.93-2.59 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 60,024</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 9.07-14.84 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> 1.12-2.59 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 53,787</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 8.12-13.72 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 1.27-2.59 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 448,600 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> The grant date fair values of the PSUs granted in January 2024 and April 2024 was estimated as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Derived </td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"> Hurdle Price </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"> Service Period </td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PSUs </td><td style="vertical-align:top;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td><td style="vertical-align:top;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 30.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 165,900 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">18.42-19.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">0.46-0.74</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> 35.00 </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 55,290 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">17.24-17.67</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">0.66-0.96</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 40.00 </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> 34,029 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">15.85-16.14</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">0.82-1.15</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> 45.00 </td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,781 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"> 14.20-15.13 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.85%;margin:0pt;padding:0pt;"> 0.95-1.31 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 285,000 </td><td style="vertical-align:middle;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:22.85%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr></table>
30.0024355011.4217.45P0Y8M8DP2Y7M2D35.009123910.1616.07P0Y11M4DP2Y7M2D40.00600249.0714.84P1Y1M13DP2Y7M2D45.00537878.style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"> Grant Date </td></tr>
<tr><td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"> Number of
</td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr>
<td style="vertical-align:bottom;white-space:nowrap;width:56.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unvested PSUs </td><td style="vertical-align:top;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Share </td></tr><tr>
<td style="vertical-align:middle;width:56.13%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance as of January 1, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"> 448,600 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"> 15.40 </td></tr><tr><td style="vertical-align:middle;width:56.13%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-

space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"> 285,000 </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> 17.60 </td></tr><tr><td style="vertical-align:middle;width:56.13%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:56.13%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:56.13%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance as of September 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 733,600 </td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"> 16.26 </td></tr>
</table>44860015.4028500017.6073360016.2615000005000000.04200000P1Y1M17D15175P1Y24.7101517524.7110000010000020000P0Y7M13D following table shows total stock-based compensation expense for stock options, PSUs, RSUs, and ESPP in the condensed consolidated statements of operations (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:45.94%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,717 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,450 </td></tr></table> 25900002717000813600064500004 12. Capital Stock Dividends During the nine months ended September 30, 2024, the Board declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"> Series A Preferred Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"> Series B Depositary Share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"> Cash Dividend Declared </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"> Cash Dividend Declared </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Dividend Declaration Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ($ per share) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ($ per share) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Dividend Payment Date </td></tr><tr><td style="vertical-align:top;width:28.69%;background:#cceeff;margin:0pt;padding:0pt;"> October 18, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.52344 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"> January 15, 2024 </td></tr><tr><td style="vertical-align:top;width:28.69%;margin:0pt;padding:0pt;"> February 21, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.52344 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"> April 15, 2024 </td></tr><tr><td style="vertical-align:top;width:28.69%;background:#cceeff;margin:0pt;padding:0pt;"> May 15, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.52344 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"> July 15, 2024 </td></tr><tr><td style="vertical-align:top;width:28.69%;margin:0pt;padding:0pt;"> July 24, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.52344 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"> October 15, 2024 </td></tr></table> . BVF Ownership As of September 30, 2024, BVF owned approximately 30.9% of the Company's total outstanding shares of common stock, and if all the Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 51.5% of the Company's total outstanding shares of common stock. The Company's Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of September 30, 2024, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due

to its significant equity ownership, BVF is considered a related party of the Company. 2018 Common Stock ATM Agreement On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed. 2021 Series B Preferred Stock ATM Agreement On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. Stock Repurchase Program On January 2, 2024, the Board authorized the Company's first stock repurchase program, which permits the Company to purchase up to $50.0 million of its common stock through January 2027. Under the program, the Company has discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at the Company's sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate the Company to acquire any particular amount of its common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. The Company did not make any purchases under the program in the three months ended September 30, 2024. As of September 30, 2024, the Company had purchased a total of 660 shares of its common stock pursuant to the stock repurchase plan for $13,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B Depositary Share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Declaration Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">($ per share) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Dividend Payment Date </td></tr><tr><td style="vertical-align:top;width:28.69%;background:#cceeff;margin:0pt;padding:0pt;"> October 18, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.53906 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.52344 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 15, 2024</p></td></tr><tr><td style="vertical-align:top;width:28.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 21, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"> April 15, 2024 </td></tr><tr><td style="vertical-align:top;width:28.69%;background:#cceeff;margin:0pt;padding:0pt;"> May 15, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.53906 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.52344 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 15, 2024</p></td></tr><tr><td style="vertical-align:top;width:28.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 24, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"> October 15, 2024 </td></tr></table>2023-10-180.539060.523442024-01-152024-02-210.539060.523442024-04-152024-05-150.539060.523442024-07-152024-07-240.539060.523442024-10-150.3090.51530000000.00.0350000000.0050000000.00.03050000000.0066013000 13. Income Taxes The Company recorded no income taxes during the three and nine months ended September 30, 2024. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets. The Company had a total of $5.9 million of gross unrecognized tax benefits as of September 30, 2024, none of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through September 30, 2024, the Company had not accrued interest or penalties related to uncertain tax positions. 005900000000 14. Subsequent Events Twist Bioscience Royalty Purchase Agreement On October 21, 2024, the Company entered into a royalty purchase agreement with Twist Bioscience Corporation ("Twist Bioscience"). Under the terms of the agreement, the Company acquired 50% of certain contingent payments (including royalties, milestone payments, sublicense income, and option exercise payments) related to Twist Bioscience's 60-plus early-stage programs across 30 partners for a $15.0 million upfront payment. The Company is eligible to receive up to $0.5 billion in milestone payments and a 50% share of up to low single-digit royalties on future commercial sales. 0.5030150000000.05000000000.50falsefalsefalsefalse

DUHBZEVU#AD\M&X+;VDHV MLGT/$M*7A'PF%)E^+\)10*66"\$O;2474;>#2/0E$K\%U"V+6[1'I:''WH1 M!]H(R\612+!?&Q65:VIA,NM4A<|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

5\$R.S!;Y=?;XU$KP#[VKR;N2O M,[?-U&5%DS MP=S#_PZ T/&V8AF5@:E8(WD<,T5EA+@&_E3PYP9[)B4\VC=97 4>=<; G<$<. M5,F;B|.38\FY4@832TZ(<0V,Z;/0=0_EK-5,[?-=|8'M76L/=ZPDK&;WO/!T MT\+ Z/;5V)K76A-S=S.3TL/?.UVI:S3/3$U?WLI@3;PN-[-C%IW+]0\]_^. MIL 85:*|(IE>S8P:ER$&+E2FPU>EOZOG7YGO/LQ^GRIF90@TS;@3>5L?FJ.+R:#ZJCKF'RJR+K%2%U M]=0K@NG#S"M#Z*K8N9H'=:+F R-Z>2JSO]!LO1#MY6F_#UE^$_]K.#SI12#Ð M#^&V1U0M#&?J/C(Y/*;5]Q>+@;MD*AXR28=#B;,^!<7TU"=C>]/F*H9W M?Y)MX'5?#QS(^-T&A8KG_3QG,/"]61&;8$W67%*UKI)E7-U1P M%1:C_G_;@Q%U\?^%M>P_[++2,UX8K_P7'V!^^N"1]<;&'Z+?5A0O M?OK .'UP>GQZ?@P[T#^!U,/7M1V#^,2WH5TNSL*&!"X8LA,H-HB\],RI?>C2 MY=`I\?%9*$+%.8R&%Z- U!2PO)QQ'"?]2,.!4C<#=:L1M-13.(`XZ@OVH%, M$MJO4QZV)+T@!1I2#O(FH?PFD<*6A.?%6$.Z;327T'V/YMAN2;+-VNZ4VI;'-MPN!#(VHQCSWP?'<]>B7>#0 3!{B, EMR*%.C2;6J/A8>AHAQ&B/FT7.L!D-K MA'B-&/%_IG;^\>5LSZBS895)64_13\XCAN.GO_&?@+!=:EO.&B-O0TR(!Q M@,D9D3L]RVJ6@Y/#DP^&9ZJP&MV|)O\M;5:05K'I(70;B5K%".(!>-@\7+K; M(VQ:#-MY><=248/.HWZC^&#_N&OYKUFUO2_(B-OC71 MDF\1\=1F!ATJ3W&)S]HT.O M3(-YP;RU|H.VTMZQ'98I8]W_]&%DFC3 5GR2^G M#PMD,]O$(:R2*K-I?.@8#!T.(/$);ETXQW1(3>Q-Z;2.R|C*3TAG35YTR"_E M,V8%-,KB*YNRZO/6T.L=1\'].:98IXK?BH"WN&+RKF(5GS:G(Y"H!AV](,0,HH:HF?"?-LCM% M\D1=$V//+NZ7N^M-F04%S1N>M&1*K@#2E*Z/HGRA>DV"=4X/B1TWI>'2WB/K$ M>UJQ1Y=`OPB+]@QPY7UQ^1A=`QQ6EPP DD*. TINIL F2&ZQ+Z2-B6DAM0#M=HC6N+ELTTI=M*=$U"2EX @3T=[B M?.P\ND $?=N(XLUY&HV99'1H/Z;M.'X\'8\!DD:GL.)G;9,F;91T%%6$@(\M7V+Z50DIKJ@918X'(A%,/PN#E2X^$71?G)HQ,(YB<7),L'SR1!V2E^E"-] MP_/3AA667A&\Y2@FB^D&FV1!P+$),(#B1^O/D8W3%R6SI-]Y3^]B32@=[=@=MLD#L319#7X)++)T@)611Q6U"N%WZ3DKRXD4=K0@+S%8K,!DK;>;PSMR4@)%C M)>^_)+1*]$-[5%TTR$XX,ZK=XMQ;#0K\#"%FTU9&Z&BAEVXMQ@6%Y,46XQNXO%"WRRZM6J:6B$0,.YF((;AH6| M[9GK(5=OS(^-T&A8KG_3QG,/"]61&;8$W67%*UKI)E7-U1P M%1:C_G_;@Q%U\?^%M>P_[++2,UX8K_P7'V!^^N"1]<;&'Z+?5A0O M?OK .'UP>GQZ?@P[T#^!U,/7M1V#^,2WH5TNSL*&!"X8LA,H-HB\],RI?>C2 MY=`I\?%9*$+%.8R&%Z- U!2PO)QQ'"?]2,.!4C<#=:L1M-13.(`XZ@OVH%, M$MJO4QZV)+T@!1I2#O(FH?PFD<*6A.?%6$.Z;327T'V/YMAN2;+-VNZ4VI;'-MPN!#(VHQCSWP?'<]>B7>#0 3!{B, EMR*%.C2;6J/A8>AHAQ&B/FT7.L!D-K MA'B-&/%_IG;^\>5LSZBS895)64_13\XCAN.GO_&?@+!=:EO.&B-O0TR(!Q M@,D9D3L]RVJ6@Y/#DP^&9ZJP&MV|)O\M;5:05K'I(70;B5K%".(!>-@\7+K; M(VQ:#-MY><=248/.HWZC^&#_N&OYKUFUO2_(B-OC71 MDF\1\=1F!ATJ3W&)S]HT.O M3(-YP;RU|H.VTMZQ'98I8]W_]&%DFC3 5GR2^G M#PMD,]O$(:R2*K-I?.@8#!T.(/$);ETXQW1(3>Q-Z;2.R|C*3TAG35YTR"_E M,V8%-,KB*YNRZO/6T.L=1\'].:98IXK?BH"WN&+RKF(5GS:G(Y"H!AV](,0,HH:HF?"?-LCM% M\D1=$V//+NZ7N^M-F04%S1N>M&1*K@#2E*Z/HGRA>DV"=4X/B1TWI>'2WB/K$ M>UJQ1Y=`OPB+]@QPY7UQ^1A=`QQ6EPP DD*. TINIL F2&ZQ+Z2-B6DAM0#M=HC6N+ELTTI=M*=$U"2EX @3T=[B M?.P\ND $?=N(XLUY&HV99'1H/Z;M.'X\'8\!DD:GL.)G;9,F;91T%%6$@(\M7V+Z50DIKJ@918X'(A%,/PN#E2X^$71?G)HQ,(YB<7),L'SR1!V2E^E"-] MP_/3AA667A&\Y2@FB^D&FV1!P+$),(#B1^O/D8W3%R6SI-]Y3^]B32@=[=@=MLD#L319#7X)++)T@)611Q6U"N%WZ3DKRXD4=K0@+S%8K,!DK;>;PSMR4@)%C M)>^_)+1*]$-[5%TTR$XX,ZK=XMQ;#0K\#"%FTU9&Z&BAEVXMQ@6%Y,46XQNXO%"WRRZM6J:6B$0,.YF((;AH6| M[9GK(5=OS(^-T&A8KG_3QG,/"]61&;8$W67%*UKI)E7-U1P M%1:C_G_;@Q%U\?^%M>P_[++2,UX8K_P7'V!^^N"1]<;&'Z+?5A0O M?OK .'UP>GQZ?@P[T#^!U,/7M1V#^,2WH5TNSL*&!"X8LA,H-HB\],RI?>C2 MY=`I\?%9*$+%.8R&%Z- U!2PO)QQ'"?]2,.!4C<#=:L1M-13.(`XZ@OVH%, M$MJO4QZV)+T@!1I2#O(FH?PFD<*6A.?%6$.Z;327T'V/YMAN2;+-VNZ4VI;'-MPN!#(VHQCSWP?'<]>B7>#0 3!{B, EMR*%.C2;6J/A8>AHAQ&B/FT7.L!D-K MA'B-&/%_IG;^\>5LSZBS895)64_13\XCAN.GO_&?@+!=:EO.&B-O0TR(!Q M@,D9D3L]RVJ6@Y/#DP^&9ZJP&MV|)O\M;5:05K'I(70;B5K%".(!>-@\7+K; M(VQ:#-MY><=248/.HWZC^&#_N&OYKUFUO2_(B-OC71 MDF\1\=1F!ATJ3W&)S]HT.O M3(-YP;RU|H.VTMZQ'98I8]W_]&%DFC3 5GR2^G M#PMD,]O$(:R2*K-I?.@8#!T.(/$);ETXQW1(3>Q-Z;2.R|C*3TAG35YTR"_E M,V8%-,KB*YNRZO/6T.L=1\'].:98IXK?BH"WN&+RKF(5GS:G(Y"H!AV](,0,HH:HF?"?-LCM% M\D1=$V//+NZ7N^M-F04%S1N>M&1*K@#2E*Z/HGRA>DV"=4X/B1TWI>'2WB/K$ M>UJQ1Y=`OPB+]@QPY7UQ^1A=`QQ6EPP DD*. TINIL F2&ZQ+Z2-B6DAM0#M=HC6N+ELTTI=M*=$U"2EX @3T=[B M?.P\ND $?=N(XLUY&HV99'1H/Z;M.'X\'8\!DD:GL.)G;9,F;91T%%6$@(\M7V+Z50DIKJ@918X'(A%,/PN#E2X^$71?G)HQ,(YB<7),L'SR1!V2E^E"-] MP_/3AA667A&\Y2@FB^D&FV1!P+$)_(#B1^O/D8W3%R6SI-]Y3^]B32@=[=@=MLD#L319#7X)++)T@)611Q6U"N%WZ3DKRXD4=K0@+S%8K,!DK;>;PSMR4@)%C M)>^_)+1*]$-[5%TTR$XX,ZK=XMQ;#0K\#"%FTU9&Z&BAEVXMQ@6%Y,46XQNXO%"WRRZM6J:6B$0,.YF((;AH6| M[9GK(5=OS(^-T&A8KG_3QG,/"]61&;8$W67%*UKI)E7-U1P M%1:C_G_;@Q%U\?^%M>P_[++2,UX8K_P7'V!^^N"1]<;&'Z+?5A0O M?OK .'UP>GQZ?@P[T#^!U,/7M1V#^,2WH5TNSL*&!"X8LA,H-HB\],RI?>C2 MY=`I\?%9*$+%.8R&%Z- U!2PO)QQ'"?]2,.!4C<#=:L1M-13.(`XZ@OVH%, M$MJO4QZV)+T@!1I2#O(FH?PFD<*6A.?%6$.Z;327T'V/YMAN2;+-VNZ4VI;'-MPN!#(VHQCSWP?'<]>B7>#0 3!{B, EMR*%.C2;6J/A8>AHAQ&B/FT7.L!D-K MA'B-&/%_IG;^\>5LSZBS895)64_13\XCAN.GO_&?@+!=:EO.&B-O0TR(!Q M@,D9D3L]RVJ6@Y/#DP^&9ZJP&MV|)O\M;5:05K'I(70;B5K%".(!>-@\7+K; M(VQ:#-MY><=248/.HWZC^&#_N&OYKUFUO2_(B-OC71 MDF\1\=1F!ATJ3W&)S]HT.O M3(-YP;RU|H.VTMZQ'98I8]W_]&%DFC3 5GR2^G M#PMD,]O$(:R2*K-I?.@8#!T.(/$);ETXQW1(3>Q-Z;2.R|C*3TAG35YTR"_E M,V8%-,KB*YNRZO/6T.L=1\'].:98IXK?BH"WN&+RKF(5GS:G(Y"H!AV](,0,HH:HF?"?-LCM% M\D1=$V//+NZ7N^M-F04%S1N>M&1*K@#2E*Z/HGRA>DV"=4X/B1TWI>'2WB/K$ M>UJQ1Y=`OPB+]@QPY7UQ^1A=`QQ6EPP DD*. TINIL F2&ZQ+Z2-B6DAM0#M=HC6N+ELTTI=M*=$U"2EX @3T=[B M?.P\ND $?=N(XLUY&HV99'1H/Z;M.'X\'8\!DD:GL.)G;9,F;91T%%6$@(\M7V+Z50DIKJ@918X'(A%,/PN#E2X^$71?G)HQ,(YB<7),L'SR1!V2E^E"-] MP_/3AA667A&\Y2@FB^D&FV1!P+$),(#B1^O/D8W3%R6SI-]Y3^]B32@=[=@=MLD#L319#7X)++)T@)611Q6U"N%WZ3DKRXD4=K0@+S%8K,!DK;>;PSMR4@)%C M)>^_)+1*]$-[5%TTR$XX,ZK=XMQ;#0K\#"%FTU9&Z&BAEVXMQ@6%Y,46XQNXO%"WRRZM6J:6B$0,.YF((;AH6| M[9GK(5=OS(^-T&A8KG_3QG,/"]61&;8$W67%*UKI)E7-U1P M%1:C_G_;@Q%U\?^%M>P_[++2,UX8K_P7'V!^^N"1]<;&'Z+?5A0O M?OK .'UP>GQZ?@P[T#^!U,/7M1V#^,2WH5TNSL*&!"X8LA,H-HB\],RI?>C2 MY=`I\?%9*$+%.8R&%Z- U!2PO)QQ'"?]2,.!4C<#=:L1M-13.(`XZ@OVH%, M$MJO4QZV)+T@!1I2#O(FH?PFD<*6A.?%6$.Z;327T'V/YMAN2;+-VNZ4VI;'-MPN!#(VHQCSWP?'<]>B7>#0 3!{B, EMR*%.C2;6J/A8>AHAQ&B/FT7.L!D-K MA'B-&/%_IG;^\>5LSZBS895)64_13\XCAN.GO_&?@+!=:EO.&B-O0TR(!Q M@,D9D3L]RVJ6@Y/#DP^&9ZJP&MV|)O\M;5:05K'I(70;B5K%".(!>-@\7+K; M(VQ:#-MY><=248/.HWZC^&#_N&OYKUFUO2_(B-OC71 MDF\1\=1F!ATJ3W&)S]HT.O M3(-YP;RU|H.VTMZQ'98I8]W_]&%DFC3 5GR2^G M#PMD,]O$(:R2*K-I?.@8#!T.(/$);ETXQW1(3>Q-Z;2.R|C*3TAG35YTR"_E M,V8%-,KB*YNRZO/6T.L=1\'].:98IXK?BH"WN&+RKF(5GS:G(Y"H!AV](,0,HH:HF?"?-LCM% M\D1=$V//+NZ7N^M-F04%S1N>M&1*K@#2E*Z/HGRA>DV"=4X/B1TWI>'2WB/K$ M>UJQ1Y=`OPB+]@QPY7UQ^1A=`QQ6EPP DD*. TINIL F2&ZQ+Z2-B6DAM0#M=HC6N+ELTTI=M*=$U"2EX @3T=[B M?.P\ND $?=N(XLUY&HV99'1H/Z;M.'X\'8\!DD:GL.)G;9,F;91T%%6$@(\M7V+Z50DIKJ@918X'(A%,/PN#E2X^$71?G)HQ,(YB<7),L'SR1!V2E^E"-] MP_/3AA667A&\Y2@FB^D&FV1!P+$)_(#B1^O/D8W3%R6SI-]Y3^]B32@=[=@=MLD#L319#7X)++)T@)611Q6U"N%WZ3DKRXD4=K0@+S%8K,!DK;>;PSMR4@)%C M)>^_)+1*]$-[5%TTR$XX,ZK=X M

]_*_U*\QS/]X2U[\+% MF_;6:-06,C7H2HF249LU%5DEC:> M'+2]*:O*%X'SK6_0Q$M[M<0!$@KN_2F M/'E1_FS/21U2:'DT=0E:0L"10,/6 >4M>3@66^JT:!\@$DM77 ;S* MQ?L<-)&

<6_XN:E$T=E28:6)01Q?>31S72V)WA_*'("^?;2]QD'.%&4*R"). 8 M:HN8(%;HX]TGND-A6M-@SQZ == -/]/A6!QR)C \XFX#JLV%U(*Q%8PA,T%C

MBI6.Z.$@I/9Z*62Z#W>LB#B)'2_"!Q3N7)MU:(N:9"1E-QD7!>(0R:9G!Y]+ MVY618;73MY2$3 C4D2L*/VM,(K6"L2"=?9SW$$6V9[7VN4%*UAX.UB)KM%[I M,=9@+-.*+

R:8UZQQ(DGRDQQL@ET,^_'5,%?4+ *K>W:M9FI=])VU31>KNQ M,$*KZOSLM%%9NP-&_'8 TD:L'C4,62FCE8'INFC_ $AI?

O'!PO/[LA]9X*$GD)1B4BJ5#B@T)]4+U"@&D14V+@<_M M/Q,W2CE>7]&BIN+G#AB- :#(7*GBQLIHYLWUK2A%?E6?A9 CS:A;SYZC]I #

MD:'6,%SEQ>&W)HN6:SAKTR(V#\AZ0<.=]>0UZR'"H?+(W2X.%)/VDKBSZ,R$19KM,CU$71=;NX.[AMX."'=>(HMA:A"D,.XN<64%3;$LU3GC#4Q>4.%A(MTD\?ND_L. GQQ?

P\B(C]$0\-A3OF&S=]K8\U,"6MM24%4EB!CKP19NU)2\(+.=_MSG+):FP'U/$LETH6#R\G S*'U1U5>IYL$E)(?X&&8M"9SK3LD787]VC7:]Y1=.?Y' MSCU&Z"YT;<1PV_

F;@NH8'F.BW^U/$0.ML& MF&D(_HCFTN_X&U;((@W&YQ7!##H)?T9TY$%Z0MMP+M%1A6$:P4,>3/$N5/U*5 M9AYC53(GS)VU3XN$^,X=OBB$*'8S.RCR,94O^) $)VZ^?' MB)QF'", B%(\=(8E!J2SA^U NPJIW]EF>9P:]! Z<2L]@&1('J%2SHOD]!!D M0]9Z0'/8LIG)28 4XR]WUI8FX^4\UB:!M(,.K6B--PGR#XE*WED>8I<"E#<\ M6/@&9#77Y+UP[1@X;,/9?F2$0?

0Q5]'RT'DJC<50N!4&OA"H92KF3'VQ3[2>% MM":O",;HQMV1NN@Q/J_=)P_1Y!NL"]3U1LE[(H+;3X,1N+ILPS%@T2F'C^O* M;CE*&WKQQM&OT+<3E* _ZC'TZ48P%37?%K!

6O;_D+>!$(T&3D2+N1;.*Y+, MEKHQ$RY&1DLU[+HLJO*2$)$WD,Y>$:B^5BU_M3# +;X)#IAZ=4X;_')EV:[' M#@SD-^ INI=N2$PLYJJHA@?<NI'$@GWIT@6"I=%^

M0*Z$=1OR9(C*O-KU,63/A,T'[;K$>Y&5H#]\1M\RNA"@N+5T15S#N^SY$UN7 M?LRK?BU]6I-]66.-J#%/6W%C9?2ZG[B*5 Y48!AM"8F!)HM###NSH8G^ # 5A1 MQ\4Y>3Z>+?

#U1DQ98#?3@@@W-U'45 &IU2Q9@%[$&@1D%H5 MR;,D=I4.5^C?"O]>RJCLF9$C2$:'2%BHM" M45M2 EUOQ322>'-1>=&^6D6LV(9?/*S:2B #2;

(_U(\XLS_)#!+\&B*3]CF"Y)Q!*75PM1^.'N;4?K<L> M,KK0!,V@/?HF-A:=2I%G[>FC-X:Y"#=U$KI+EUO<2;&7VN)A]X-% _6MA=6O M#1WZVR[4F<1,YSS(1E_14E2X2Y&'0F71_?

UMA=MQ3#B\!.TCRQ]%]2]I)8AO;7_C((-Q245R4FHN<8^0YR*J3X\N7S MAW?OWGUY-WL].PQ6_-'RG5DZ\JP\],;SHS* !V[@\3Y29)_PY?[50<3&28$Z M[,B/UI.'(N[VNBM'A"IW"R6-

#5%E O';W\ O-_8EC7N&=K)$WI]7$9%86;M M VRREW*0^%A4EOJXW"B"(_8F,QH.0__"YI7-HTA\GD"5_,P,-/0R(-AL I_" M(W0=,MH-1'Y*E=>;,!(Q[?GB4R)Z'?9MZ-/#^_^]"9 0\II)**

Z'NS!+3)"S M0MAC3*9\Z,(4(1;]<1"]HM5L'OK(#=+E!OXAYP'^Y>$S*I7?DV)ET_MJ%K M:5Z],GTL^>GZZ;K_*#U<"PV'H;3E>0UJYDF:G;5531D#*X,1_(U="K/%=

M>K3ISZ^B]'FV_#N^E2+GYU=QF'32@.3R?= DB9>'(>+ESP!V#S$7ZB#G.WG]-MVC(&7?\SL<(8A=[^'FV#,!:0N-82P)ZB3NT:]+H)GO:(N?2IQ5I-]DJ[,8G^ MJ2O1*

[#K)CE]78C23"KL]:9C$OYSY[VE!KXNV]>7_RO70[<)1TVI-QF3UC^T M!74=;+TTOD7&G9$(+"'>9#X M<;@_#QP^^26]QN3&3]VX(<%$+W,>K>=K!^-P-

***Q*=A]N^S$9\]4;0[@XZ&7% MW"%"$FB2_D-P>,]E I/M}(::=]UXP$0 &OT_-*#_AY'IW^IR*T$!/WA8^+ M\#'X7C41"CNW.BV0/[*5B^-_6MA=6O M#1WZVR[4F<1,YSS(1E_14E2X2Y&'0F71_?**

UMA=MQ3#B\!.TCRQ]%]2]I)8AO;7_C((-Q245R4FHN<8^0YR*J3X\N7S MAW?OWGUY-WL].PQ6_-'RG5DZ\JP\],;SHS* !V[@\3Y29)_PY?[50<3&28$Z M[,B/UI.'(N[VNBM'A"IW"R6-

#5%E O';W\ O-_8EC7N&=K)$WI]7$9%86;M M VRREW*0^%A4EOJXW"B"(_8F,QH.0__"YI7-HTA\GD"5_,P,-/0R(-AL I_" M(W0=,MH-1'Y*E=>;,!(Q[?GB4R)Z'?9MZ-/#^_^]"9 0\II)**

Z'NS!+3)"S M0MAC3*9\Z,(4(1;]<1"]HM5L'OK(#=+E!OXAYP'^Y>$S*I7?DV)ET_MJ%K M:5Z],GTL^>GZZ;K_*#U<"PV'H;3E>0UJYDF:G;5531D#*X,1_(U="K/%=

M>K3ISZ^B]'FV_#N^E2+GYU=QF'32@.3R?= DB9>'(>+ESP!V#S$7ZB#G.WG]-MVC(&7?\SL<(8A=[^'FV#,!:0N-82P)ZB3NT:]+H)GO:(N?2IQ5I-]DJ[,8G^ MJ2O1*

[#K)CE]78C23"KL]:9C$OYSY[VE!KXNV]>7_RO70[<)1TVI-QF3UC^T M!74=;+TTOD7&G9$(+"'>9#X M<;@_#QP^^26]QN3&3]VX(<%$+W,>K>=K!^-P-

***

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}_>:C"X=RWA\>0[E?[,]?S'L@.E6UB @[*.@$X7_OF MI QE&.I1A^.HYD\8P-!Z R!,?!!:,,16S[KK!Z.'AW5_QIC@?29![3N9/$2VW MPY$NA7X -I7!94>!#(!*5C&W4;PC31]9G\ ]H&R9,M5>2:*HU4'3A')*QRQ M_.F"Q@"682-6R/"!LY[2*N^,;9HM(U@E %D:KE2/#:^CE4HE'D#-$N1> S(CF M"T@%,3@KJ7]-U=%5#L#6%F#ZR.JM(##^JR$XS'QBA),)=$!LSST^Q@0@-K2 M;"G4=-6&B&NJB:ZX2S?I#4##=:<{"QEC"6;_'@T:,-<}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{)CLU 1<*(W@7HKI/5HE'AED?XS#$V1XM1@$@%JC+(;R M7'L1GC"<1=.J>3]@/&J3;5:50#!$P!2^?Y&%[T^D?/[8A>\!ED\W^68FWPRL M/_[%YC*-G=YV"KE,"%B^^?BGFH6!^8AGTQ$ &&F&S7H2I"A69P]&[!8UL') MP4@+=Q)<[=C=44*PF-U^K,DGN+4GC:8U7C15WI.?%LM%$I/WA*-,'5NM&RQX MM>$FG_/6B3HZ@K5N4&D_HK\Z5Y:=$:1Q?-/|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sEX/RWW&Y6C[>U.#3"""P[:BP5*<&,AL.2IKVAN&A#C 9(8T MX8_7>%2W?'>[#@\-.%PY*$?9KJ@[1#V&)4_W0-$,*WNHAIXB90SW*2*FU1QDRH^ M0*JXR=UX<;D;)^U7[.[U/Q6WXDE>I;I?;CO["M'&3S=QW:-,L8E<: M/-=QU%/.T6B!+AQY4%B>^I9D=_<]U&5X0NZD[@YXXTV"EI31VIDT>(%(?%]8 M63&Z"X-_(YOX\Y.8M[D+7=|VMY9'=M1LCVW^EMA/[SXJ%)',(,"TR$"8+2D, MA#@I$#/+=V;. 0QC0C0F1&-"G*8)T5@-C=706 V-U=!8##4_9:EC4,+]:<988M5;36'/7+:_\68_'X'7D[!!6CM.8^+-9MS-.R.W9$%N953XK(?R%K?/P>]"$ MQZ%.RZ#9#L=39C>I3]8;P]/!3LNTV1;+$V;Z59!4=;6.8YVNC;0!DH,_5Z<. MUGP9HY##RHYCG8:EM2.2-==585XUUU5A7C7756%>A65=K6N$3_M'V$B?57$E@%'T?F\- M]>ZG93-5QPO.[:L(5[4@9#'R@L-*]>ZG9095QPL.*T\&;N[$;-;+O8 MVC&MVQ8/R69CA7ORQGSMVR*)H|CRR5;1^)+|!?Y2;CK#C$XQ.\R! YZ!, N6G"8% M..#?PYDE\437<5$' /4/3^7INB9/<++5YP:ZW-#[SG)TRGUH]9S=TON4CHMZ' MP^Z4OC+TN'9#Y}[R5X*GE10[KC#-WFW3A&KH,E2/[Y*94C??WKSX_LFKU[Q M>P/0_[N]*\A'S;P$.92:,;UZ"-"]!FI<@S4N0$/AJ7H+LCZ_P7H)DGC0R [;LMDS8[MAHVTKO!R5JU7B3!$WVTW>92<$H/$S 1*!C"FO"XU VJ,MRXQU((4ZJAT$!V%Q;"G'^CEYW*@Q1$;HQ M-R&QBJ:=F65!C[4IXK ;<$2]+P#=LBMOU)$=A$L'U8T^JI5>2Y0XI-(/0/!$ M=^ZH(-[_A*%<4$1P;_E2@C^!8.5D%"/K17&>Q+ORM .^I],GDL*@!0D-DS5E.^,S?L$]?-2I?K:0F MSW0K8GC&$MKR-T2X0*+ZE[QH5HVYD+*,Q!!V72S=&|IJ*XWQ6L_9%T%)6XW* M34?ZF U%X MG[S?^+H+S^'7U*BE@!Q$IA'HQ*%^\GXP[%;*4JG M2)V@U[+2K/>HU7BD4'V M7UT/17'@(\%NUV(0%8I93%D7-&4\1R/90\6GKL#MSC] =BD>F,4!T5M/%KX M^& _JC|\%>G#+@?3'E367T8;FDLNM>>#RJ{Z0AVI7D09UAMPHAL2#T#NB OH^VV<5+K^WIMM@#3CGPX_*XZ//UT^W-W!3_M_L-?(23R\==%4D!JABI$/9_N\37:DS;l;H2.J M$M#C^./JLW>>Y7-B(MA-M ?*#L;2HH9:QAE.+.T!+J&3H=H(AD>!)6DLDH]6 M*.!|\+@.DLCRG2MW&2/D7VZV7K!'Z5YZN(82L 1% YH/ L!MP):BO&9 !BOYQ,.5);X6D MUCM\(/+-1D-.",!?-I"\#D@T.$K_AW?OWY&K]F7Y=4" :OX*(+P&US#;!)8!, M.2-S9HVR6G,X@BD2IN7<3.H(U"B@\'7UOPEWU&Z8 PS%8QK"E/P M:X=([\C#D:.2KH]NY,+3%[%>=(5=%42H5(##VA,P]O#TP?&,/2 X]+L M.\.:=!Z1?S#57_M$0W=W9"'3Y9FJ]*IVG48C =CQU{T[C3 ;/5WLD=Q&%LMK MWW%WKI-8'B=MC]-.>^S[H%N7 "]C/JG&Z_OD4>QB];N]C&XQ+(5[[G9?8U'MT}_C)Y1.+H=D> UM\SYH*?R-K]I"<_9?2]DZ[G95= 8.)).LE LW1#8>BDE^ M5@/-28,=J, "!HXB;)P$QDF@R4G0AK[T/[^E87-W"!/!X141['>*;3L">B/3 MT"%8K:'|BKFV23;S%;I';R9X-W:N@O!ZLT&..\4H0V.QI&U9RL(($P.H2]O MF(U)+#"1(YD3HG7@.>ZPD3CF:<.,?! Q;O]28JIN0A/#M&S@6YI2/?N7[.2 99A,7F 2WB8X5+5CB7!8:*P>.\)0O_#W(($!4!2:LO5T__XE(M.B=RYCL46BM$/U[@Y7DDR2@F P4H-.;, KWZM:4DG'C|0LC@M>\D-CKBUB9L M_V.#L/UBL/XLGWN63FZBH|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|\%.W^IQW5[^@BDB7?R9X75W[$8::DF81KU'XN+9\IMN_;W%L/#'I]H8>.M$3Q6

#NI.KH:3.\[M@D;/^P2$%T0039!;E)D@,=)63?I)3HV&JZ6M)& M8:NSU33#[6DZO4Y7K&H;O#ZFE;3/8BT*\7C?6 HF4L'_^[NWWWWWSS^2O9=E M&EB0[__YGQ<__/
#___O2;+E\SM?M1[2;11#H,,"O'NW^.NN+K6M<:-!BY:5 M6(;ZIGBQH4U@ZRB$@BX!PE#N(R/M)KI@?#6AC/>%**I2I^9462\/NT, MX?:.^Z&S5F0IR|[6SRDD"S2XD$+NH2({
M7FCE_-+(<0-,OQ%U5&$"Y)Q=I>1T9AV9E6U=L0X3+-W4+4\]%E+_.MVHM#OC!)%$FOZ(;MF;Z"N4%'W'AAKGNUJGE,+[RHT$%VVZ&>LR Y#_)&'?T9
MFU&"Z@RJGH^NOJJK+VGB.,HV/BQ5[!9ZW9J/K/&Z98.LXQO1CU*5CL8L\J_#-MQGBV$31!GSWH|U("+Z+YJD)*,IZ.3ZD?1^ZT?-$7%@)^C:MKZ[W|"%K*Z_ND
MYI8!8P4@C5T,NN$&6%.]NU3ZP0N^QI((/$%^C5/9Q6'6HSCJYG\3=*8RP.7;V<-MX5/A?4$U@BNU\[E7(&Q82/PH"+TY@"2-O2YP$_51M(11/EL4- MCY$!:SK-"0-
T.NM]_[3'7'Q>*_=@OBXYD)(% 0\>4>O,K\\N1H5_RT\1.'6> MC>N10QP'MS4DIWLQF^:U?>?DX,WZZ]V\OM]B/L-:>\D/@_Q(9=A*!\0L.LS)U^MT;9O(9>NY^'6MS$-/ MX&@B"$?
2MCIQ9T%*]"9MJ?A(&3/5P5S7O-SWQJMVWM2Q3(O1ZX3?&AO5GB@ M<>EQI*[ZM1IQZ-BYE(C M-L4*M=AN=KS3UFX^LF)VL-S6?AVX.?+E5|&L>!V@3Z8CU*.U.|<1^M;STSH]7O
MH#5-9^2L ^TFZQP5R^N@,13%N&<^4[E|P]S2969^VK)5;FH_(X\=V"6P]=7M6W(-4V> >H5E+[=QZ2H.ML)X,KEKU4@[C%+'%|8I/B1%/N,,_#GW[@ M@PUR'X',?V'I]O+
IZ<=C:\W&_G0^R;DNM,DA;O;CR)SOLC%Q#^@Z^B5QD?Y MX8E91F."TUG'M6E1=7%P#LA+-(ZGK_6[JEUT",6;4?E64A9E9 D)HQ2]X,&W M?#L&11EE|8GG:,_6Y_?
_6$!3]*A1>R+%Q102E$44J2Y#KR!5$*&+V2U.P M1-7&"+[(M,F^G+;$(KY?(\-(+A(!/R2Y4-*XN5@+4@A&-D7TU=Q1&MB8=X]5W;K):+8RIJR5WC,Y22S93;9:HV49^2%V@7_WQ]
[@$[M2C@GH0&L4I.H[$(&_;K32IF>2],6:"JR1^>LG64C<&ZC=<8UD49;9XQ=I;YW M:8^RBM5P;_Z,=L/L\@E*9=UOLH;ZA;5?YN0\'UQODXW\KR?
MV_JOMC75X*9=23NR9PXNK>MEP1WLGO=PM1YV;"C36H(NSSM;SJ/0@JY.CHS M3?3KROJYR'-"3@\O<6O1]J!\,"WDZW%V?@#KM,;<|9<|#9/6"%ZF|KB1H%73
MVEIRIXWQ8D6[R+8#MJP=EY-V?1TRA:XT(^TD_LC32@?V]MEZ%]Q=_BB/:R@ M,VVU -7UBCC!7H MU!WY :2E,OT/'C_'+*47?O0Y%,>0T=$+TJ-P KXYW-%XS;A/Q$(2Y5)4/3AB
MH3AWS':321Z;1_Q##(M8^$XF3WP+R:F#@\\7[SF?_,*5>"\QE=T*,=.6&&/ MB4, IOT=2G9@?6!(1*3UO&IO<36|%[HW6&WHO\]YJR^3=,);6Q#HT*:EW>?
_QX?'Z3[S=S2_7Y/;^R4EI/1&04F>+_,AS$\6)%| G MNC[$+&4T6?K_=4A2L";?1MUOGKTO#_#32*OZ;CB=LZ)K'X6 MB38>2[S./Y7B_4+"*@)6[Y6Y472!9?
UXHD+2TH22GN@L#)!E_O<)$7)!.. M+$_F;RFWFI3!R'\+,.\AC*D7B/QN+UEXOU>Q/PA(?+I*25*(Z:@P|ZD=KRIX%>WX&E)WO:EIBWO,-FI8N5BO:XAWC#:+.]38)+]*PDX&
MYP,GO^.8+8 =:--5XF3WP+R:F#@\\7[SF?_,*5>"\QE=T*,=.6&&/ MB4, IOT=2G9@?6!(1*3UO&IO<36|%[HW6&WHO\]YJR^3=,);6Q#HT*:EW>?
MD"VH$R!_P4*2,7#KI]-J?5-H[<1WU^O#[B 26NA.+9O|N$-_Y#[=U1(5_S;M MC-C7.ZM@[0'WES>:\S?'CC^=*4I.1\SX]8J8,K7[=3/@U(;O5_;&+>K-^M8 M+0!8UQ*O$[?
(;SM<<[*D")YVZ]Y)0WN_<>[!B&T%U"0Q^N]J4@XN62C/T=)<&6Y/*4>G'J3.$5?6$AK'Z, MU)[H8I,#WDV2'*A_)4I#/@BQ?H%DFN*[^]THI'#!|:I.)MK7F#9TD .5K66J MEZ(=B2
&.FM5K(%0'/|+ED3R))+I@@BVB^R&(.-,"M9.EC#3&RBG!" BWCR0 M:.^L[(E&?0FH T!),Z%98HF!;0S I(*[~#$1)=>ZZJ+!QX\+(*3.QHFL@[>
M,HXAD[2H9;DZ$K7=@W<4'R]ATI'(@691($T"FP8NI,DO@X,63Y>2[*E*DK@ M'=,$6N1%09[+4HY07QW^.K.9CM L4=C -L9+NEHJLT-A$UWZ[6ZS55VY%JO#
MW!*6%\3;DA'J68@4':#P<& VYB \FA1GW?JM8T^*?OWKWY^S?\ MZU!>T)T7X4&P!!P ?5HHS1)^3*QCO@K\.@#(2)F!$"@_;ILY!(UJ,DL,PKP8 MNM[M@^AtY<[\@?].6Z[H [>/!?
(WT9HE)!E9R'15I"4T.UPR5&?$ Z^<>7;R ME;,GP|_3YFMD2YD TO73PP,BU)$ K36)_A61+;59(H^IE8Q71'I2LT,?8X7&
MP)\]V=0$0*/4[^AW_#.BM4PQR/4JJ,Q3D#Q'FCAI8:S5Z;KQD@D%%8'RFIIE K:X$6XJNU?7+(S+$RIF3J;Y=;3BP\VEP2ZS"$S: M1!!@G*1$D<31TPKDEA78?B&XBW1QQ<6.PQJ$)D:
[8]_IZ&?W(377|8T2>XW MIU&R/7X2,^KSA] .5NR*E :DYPV(712T?SM5R $KHI.G5*1\0 :9&C-QX%,I M$"RNSB+9'5VU8K%H^7Q4KC?]G*>SW>XCW6=+:W\9F@!NP
M+*QQMI,UZXX7>&R4Z+=C59@1+_1)QJ[V",UEF,9$1BG9G&Y-W>W/L:F."!OE M044OXQ4DO@9TK-JC.SS*_G/'QQ,M)@%(R1,U0@YD%CU.C/T.82"X=&D'YW>W
M=_2S^+;CG8^RK6TM$ MCB\[$]+SSSO/TO4U-C"^"YVO\^OD' .FM.8GWC[T4ZAOL-N!PD"&! M3(X'YRN?(OWNI9=L/P31Y\0\WW)=%^Q@UZZO)KOR67O,P&8@|;A5799/?R(?
M:N__XJ2:RQU-0>^',(+#:O_]\1/?V]R$]WL:>U#>:;,E.V:NL]I \UJT(X?8 M>]NH?M&=*EYOZ:%+GP(;P)/D3.$MX)M/L@S9-Z1@34K>Y>-&J'DCE]AMB>,(U"Z#H MB?QQ0+_G:)@I?
B16N)U^3/MJ_U\&XH,7B$;5=]"0F$(LF&FZ"@U$@(TVN9[B2 M"N3!-*]A-**&?-#%&?O7Y/[^#+PV.[TBFH@DHBGK8'L5DAG\R&TL[6
MQ3+^U5Q>>TY,1$CET6*?:K0XO%9/,CD(__=:2#+M+(?%;*H (B**8+L[@NS MR0A$+@;)Y2#W.9&23(_DKDU7&4N585=DEG-O!!%|S%=,^&H?&.WCR/_L&XX
M!6AJCQ.=C355SP*TC?$>![2+;_U)66Q_2]L.]G\3Z.IDPB$'41[_";XWV\^ ML)!#$U_F09*49!GZ5RQ91X[V]%R^V_8%Z\G=]; ^LY8803K MG2NZ2LN97/ 3FZ^"HYOK]LG,L5['-
+=%$(4O\L,.!ZOX&1=A# %)L5!<@R". M7@^XL8V-17IL18NPB5NX3\W.I:,_.!!C4;?6:^N $_S,=2TVB8VMD6\!S62W M*:]EW% @+N'W&?T%"?D8AON+:?=N4VDKR.?W-
@DLUD1TE8OCQG%5YG0NQ#64 M_'T=)D*3-32?Z/H0B_BI#Z]WI)%Z ?N-^G_T6-@0L6W8%2=>V>BO+M1,^N%= M!62WKH(CZQ>6W)9D^_7-
S=+$C.B@"O+!)3245J+22RANT:@TD))P=W)$G42 M$\A?.A!!LI',, D#(L?6VL,Q,)7*N-"A[Z\O@F5NY#E]\<"B'*!LS,OH+"5 M*.T!B \VXE+1\^WK4#1QPN2@%CNYX+8GB'QQ.)AZ0^.-
ETMQL8GBB\2#^$W8 M^Y0 !!<#2<(V##(1)3+B@7NGCB?&V"YE@>8R|"_M3[\R RI(]99'JN3V6 O",S6E(;&XXTL5&S8!B M0FE.R-
))GX$A)N.=/ZY0D$;R10,RDQ@IMT9VNI\HP./5FF!F[1<3W5&[Q9BLZ& M9'R0./C0VG*J1>'(F6#(*A>LLM'B80>0IJ[T/3CCHI'$9?=?2
7MTG:GXUK>$6RIG1;"N(7#^@>B>57*_LS2+4GY M\UD)3T0T@0S$EX5JX/N][,R<;C!"%B8,PM['5+E9(7JXZ M7R7!F84A9 WTM*KW +'LN8E(TE*F1Q&I
)ZO5XU4N/*N$++#_@,M$A%1@=*^4?J,B5YA3 +R"&;E0UXC(Y>D!Z+ M?*BDE)F\@>1*WRP >=A+*!+\B6N?)#GL|K+8@-(89J^4>]I2U+5B-2Z5U8P.GO+XK/A!3:/%-
YJVEG&&>C*D_E*-+;J':0N7&7RBBJ6W:[>$#HVE9) MEFFK(3F9R|QD^Y-Y_4((0R$O#V9.(Y M=,+?O3".@UG2:!)P88M!4;[W(7<^&SU'V1;V{8;S]_0(Z=W29>C#>ZS|[KR0
MB!4!G%."O2TJ9=>,>^,]Q+;0H?JJ(H&N+U^L););?:^^50@5+B$[PICG81H^2$#/NDGOUH.E"9#,94=`G-JR:0-NX8.$$C:?4T.6YT&E: MW)9-
H(^LFCT_S)E:P7XVO4G=3[/D0Q7S-D![R5>CDM1FKL._? M;>]SE7UO?![KH'LO1T90MI*)DK%+<"L6N/:("2;A9#4Y;&LAR5*
[,IIY1O^00C%LY>A7U]Y%VZ2DH\^$%8Z5Y$,F@GZI%Y(H>5*2Q> M0:0Q&2(<G4MM\H2^D691=!%@" M0Y+0-
UHOC_,JEYXG[W8S9[0 "]O|UT@>NCL;@NI:W"\\&*APX37WI@8:L8R M227]1-TEMPN0 .<%$1XI$D:LS6'-_'F-/2K'R@M'\3SW_.L/]GB\/]++'CS MR*'R>K.AVOB;R87 #59N?A,5*;5
"]H.K)#GTB:\Y(L4(@L%Y'()K"/.OFP MVD/*3FJ2C:E[VEP% CH0J803))_9[P2S@9_Q$;=YXD #X['7RF\HD'+,1!/)E:Y#ALWPAC,9P):*Z1;X@A80R% [R- MDCMF/,,]I5Z.82*)6K'5>BC
MJ#GW=-COY,F9%X I/@31YYMP$\4[<6[7\GC#O#?N14-'*ZC+ \,N>!<"716P M=0R5CYS'@1-16+E^?X''$HZ*RW$+-<9AZ\)C/=TD:(YVWPNW:&]V].<\K3?"Z
MJDY0^WSFDAX!@<LX4L@.%D]BB*U=]YH,5WNXO9%BAR#]ZO48RSY 3GC"V$V5C';4, /-:D1/W@L_L4+ M#O1^(PMPYDF=/^:Y4<7')Y;KV!4GT-CH7V1$-.R'//!UB5RWZ)'??<%
[D%9C! M:7&9>C>O):^D^0XS "D|@4_K=8XP;1+!J:P%?,@ON:4DJR(#_((4W.17TR<0 MG,H.U_HWWXFX1A;RG|L+3L80W#A5]H?UGDCZZD MV2V6PS#%'.+X/+W@@&010^Z
=BO@> ":R*%Z2 W!H[3-]U1'M>*=>"=1>]$V MC3IW3.FABEN>)IX-"ZFGQ7@49CXM[Z%B?BE'-2G[HCP>D"MP*ME3.6/AB"&I=-U9<&H$\XFEF+(L6<\[0#)!/0*.I MZ_I04,Q'I5S3SC?
HK'IRZ+P@YR?6B?(NGI0G1G7::$]= 8>3 M-6=8$USCO2Q$-(4XLMK9M*$<8@E)2"$*&*MN4AEQIC'L'H7"DN(=,7NM')B: M#\1Q3[S6Z_C@:!)\5-
U63N1LR//YEY5%:G>)UJ00XWY/^Y2G679TD*-[7ZVL MCU,DWZST6/WV7M:G.;],F+PEY*-25C#.2C35M,Q*![QJ4/)SXVL*UW>\WVD.K MK9234]!^=6Z(S8#OWGO_X
M!2K]#3<5%'67/ MIT-M6%/'KCB1WD9_-?3\)).TEO7F\B9D(R+DT#P251]T&3KYI.+6/ZY M\.S[^,4+V6\"= 'HX#Y\I5OZ#_($M_BSZ+.B!<\\4\D%+6\5AF*-FYL&-2"
M*G@.0A@ON@RKGGVYFV0=LWU^P?+^D+"0)FYRI7K(=8+D^Q"2R\3O!8A;B?1 MZU)<7K6"N_P;9#5^C&0(G#L"1*?GVF7U+RG@^YOSNJOCF\HHB<;KE>0W@S M7X,_<
!:M#]?1;R VPG;=56=4=\;KU,:R&P[9F4\ Q^MZMPDCC*?V$O(-FSM M06;R0@"22^!B5 MA$>]J%!,H13TW% ,P)E-*;M21*W9PQA+|5W^M##ZUV# M:#6Y_[F?0>=IM^$N%\K5/?
7/U_)?-/58H)EU;?KCA!IK2Q07!%TZ(|\,L%+% M.DF!PBQ_4.P%),G9$5_PF_8P?VH+^#2$K/A56Q1\2<&82,YNEN*^+P|,O: 0 M3$D%5R9?:%NIV-#!B1F|+5-9SWIK\9%:F?9/G20+];[
M:M4G?Q"GR/B4ZI>S*SR0/(O)X=X45+Q)%NCT%+G<9I28RF9GL385G%G6XHR[M Q*WIG($QH_R-0E7[K)X-Y*5DSQ_:-"T6+$EA!B(>]FF@&$K*LA!N)}.]ND)
MB4\W(IT*'!J^F4!1,=,BZ5N5,^X"(@<H^18E:-M?+_6'B#/M&E=F)IWPNWZ[MS]=NKN\Q#YE%@R?01-PM71[*3*$\)&"5 WBW"+NZ$,;8BU: MNN!$LR[ZJN>S3>WQ':-TDGJ
G*@?]0>T48W>MHN(MC[S&[^-%PR-'>8U@H?# M9F4(*_3=QR1,IK5KQO597=HFFK-&N%VS7B?5%ZLM\#]?1D|;<2.-H0l\/>*CJD,I_?Q$?1H^DMG6W" MB^_F<^21|73\
),N4N,J0=K&..''3,?*L\K:EGAGN19YK0=F%+Y(=DL[C CTOTN9PHM7?C=7\3-=I M!6](''9G<12DUGA_,>^/VS8Y64+W5L"M>_^VJ@'UNF0\^A*W,M?)9\I@[RGU#/BHOBV9:Y
MLX&;PJ[<$);*4 0(6,C2^ZP[57GM2 ,GQO6R2*$:?;Q<">&=L.S7Z,$3&+;L7 M5OBA=8RV/61G(E^:!;S3N.KM1F+ES##M=:+T#Q=R)T3".8&-/PT0L)461!,J- MD+2FGC+HAAX:C/0^
8/&/JC=WTQRVW$M%X;O/?E K63F)EB[K>0A+)>\:>M M%U,A;A;%U1LTJ;H<8R&K5[(Rl2,)UIZ$4L_8VH'TAO2V/0E0>4V!X(>O<-M1@-2 2H MS3UPNI*!MJKS-
C3'ZZXF0ML.5TF;<.)NCBUJ=&N;AUJZS&Z\-LXV3>UG-6*' M0|ARR*(Z@)Q(9S=N^G18)?0?![ZUNWXU2&C?T!RW>[.I65D(:MKB=J^WEC0F4=9M@^R=Q[E/|K MF$N[O3-N?
^UF@YK\"T|\?IR1_E[YVXN&2UD?N8C^37[KVL_G]H4:AIK%X[_M*:'WF|R\U3(Z?MJ./D8,P5!-%YW\CZ.HGX)(M MA+KP_\"1YJL7P!OO-K&:]L7MCITL4 D
,>F(UWF[B6]_DIUL96P3_$-A-+5S M&]Q23V>1Q9DYA(T>*=|*LS6D$ 5:4^LH SB$*:R!Q&C"9YMB+Y MJJ4NZ5MBLM0>C0E.Z!C7IL7CD\$Y(^!H,IZ^MKZ:01-
DP=T(X>YU=+L*P)D9JX ML")?6&:&3"/2:/CZ1'8#/CN4]PYW4?]!HR?$,,.Q\5]8NKT\<&DX7XC_>]3K MB,_1QX\TW48^M]CU9D/7*7NE-R'_$;C
_1(O8|/AS09ZXO[TWYS)>D),ZT)3NAD$ 9^)+F2O/>4FL2<[6S M9M/.D.A_MNS&EDM(P+M)+],T=2XEWTV Q7-!R6@+1Y$Q23Z%Q^ M!?$+Y/,K:-,6E,_>5L&@Q?MBZK/T-DJ2.D.
(Y/T&DV\5%<33F;U5RH?\G4D@ MGW)Z*#3F)+(68A'>+"%1R\;OEDRD+PE5M(FGV^-8+K(O$G6&YDX=<#TQI0L M"?!8AC<0G]94_E"5EI0#='YX_T ME88'JINUS,
[0.Q/!"=/|;**>JG>C@/=XW5((ZZSTDEW3,M$YD#@VS0?5-$D5 M:H/1LOZ6:H,_TB92H%1ZQA;AP%9MP3,JJB"-9'[DU@YL"9EP,*@MEF6V)FGO@1+D. MVE;KG&F;X]WNF
AM7ZP(:"^(I,[<7=1V7-TWP;E(AQ)9GX<4]'>=6\T2_L\7[_!6E[?%*A7K-8U[9 OS]ND'G,]MGE7UF<9/I;&.5WG(#*3)ED[3^%V4$.M53]MZ8+774T%MSYTSN@3SH (M#@A?
B|;K4S#K\GD@>Z*7T",PCW?Z3Y8W!'M%7RX T#TDPAE8,G?99@_$MCF.8>N'W90-MJZ(ZV.5[_-1':/D1'H4V Y")_
M5R'_0.,$T|E"?)|G.1>A\"@F&YIF(C7C,#*,+E|M^B.W;F!V>$T2,^D+V:W M[ZA!GS"|@E&VJD7H^_ZMD:WQ76#!':?VLY'J,HY#_X8#CM;#@ZY$<(.0G4T]QPJ=*. %($L]
MK'?:&3M8I6L33))?!5?GZ./0-FN1:A+^5X1XJZDFXS+5Y-HNU>2 D%(;*+X M(=3G"54Q\.$7 @.>8=DZ\)*$;1@LI3BR5>R;\#:.@6V!C@_4OV7>BAL'+-45 MPMH)S :L#&VA@:66WK,
(%,=!H$:R8PHW! BRI06\3*+P/(G2KKA!.I.6"+G4)#N%5=0(C@+APM MXX\;>MP9+*XN_@GX6%*8P 883*?AM&.A>+O |P49R%?]P3K0U!T6!7V]3/[MAC1+N@>!*
(FXB?:JH2E7'*O'CA!3PEQL@+'L:XXB));? E)SEEZ M;'3D82GC]/81K%>\!1R&+/*G@P,K>MLG!S?R<1\YZ*^.!1U{!:<(H|/^7[*
M.%OXQ(\1D=A0!:Q'Q53G97S4,@4DE\8UK*,RY6&W\^*CV)B;IZB7LC@_-_S@ ML?@7+SA0,4%"G2GE*/4C]<"[_/OP$=;J,5^UBKJ^'4\3A^&!['>#U]$EIO/7@H
M_>8U+#]*N/&QAW7,\T=U(H,7Z_HHTS?!5,%59IY:%#AV7,|)_XKRY1_S%R07 M8R+\,GB9Z\)]*DIM KXC@&=RHB#WI(/Y, I'2#2IPQ M9"
(V1!Y=;^SHT]AE%4]FV)&B6:!>Z5ARPK_(5F!",OW @CD_1!$GV_"313OVB-4!R.*TYV'M5EQ M-M>;(O)CN>'TLSZ1VU*2U|(*)8H<,O9RPR6!$[!"%CY]RLS^?-TA'7#:$SGW
MYM,NRE0QY/,$$(0HDKB&;B065,[@ZD><;L"YP_Y!,?\KQ?KA,/YKQ7;GF&[H M5V_Y3O((!<(A^F)!5H>4B*)< =LQV65!]MR"L).2YSI\&W78[44:[_,@-DX7 M[GNJ/;)+
(,&PV([A2DC#!_SXXY M&4WN- !#P>\$1NAX,6M,9BY8T,TN|&$Y2FL7%-W.' G)#O MB\?7>_A]LY+=*"G_ (D)\+X05P0XL$U?<423Y9EGL1E#F,J%29E MN3"OF"'N*N;-!9059,F-
8MY<2)))Z7JJFI'53T>FVX7Q>8[>NRBE>0F+^_B1 MO6R|[(^[T\,Y*PUFJ?HU7UO6J"R'OY64\/$^2)BLOZ#M>:<0W$!#GBCV+3MK6Q/0?$,\$X>@Z] M2JX@_RO]S[$RL!2D$(XID"
(\)L%GXM;";$A"$!2/5&42UD5%VCT$)SP\+[6S7 MY6R@G>]\,,]2MR%6OP6VEACIBA!M>Q|&OKK)A$V(A1#U$]E30
MIP5N>XCOI53)#R"]1Z>/B7R:T>UCSH83+FL&@T137A\/:H;%%;7&QE\'5 MH[F:DZ*C(M:LD7("\Z]!{HED\R2:G9:IZO'.L?Z;A|$1TJ?:/S*.FN=`Z@&
M0@P1'P5U%Y"]AOUN9%9Y(NXJ Z%#P;GAQQ&Q[:TIGC"L,P0P^OH*H\&M5GH MH)^5QMNSU M &KX569&8 M]EZX$<]0:Q6W6KK@11]3P6T'>$&?Y
RP@,+8FJLK*3_7'8!R[S%9#Y/XN0A. M5E""%;SDX W157181(+NTMPD3C\"TNW++P/Z5^I%^N0M2L1W)YO M9Y/* J83!;RX8*F'_3Q8L":"_& (1$<2<9R(9+EL9!PK@38DE_3^ G.4'B
M*K!O#F9RNS\[+ (H -X9F;EVXF5)!CB]V5JG?(1F10(PPEHK8^DI.140Z\&5U M6TUO)T&M;::H_W3YA>F"67L1Q.U,_6VE^!4I-,PN-H!.?\-V^D/.!QOFY&&\|\+ %<(K+|J5D/.<>4>Z!
(%!?)LY]8"@T9'V3^ =ZZ?"D/?NQ5 MA"<;+KWX7%39?:6QDD Q.R).9.K%5<)\YL7'!>&D^%*6)=LL85T4_MY-PR%_EA=.FC4#T\PG8S&0AN3"+,N\#F+XJ$/F0_R1E1L5<*/*K
M%,M!4@AL-CT=Z>ZFH>&FG*]Q>AEH*ODJIXWY3!%?(>@!|OCY(/F{'UBIY|! M-RJL||L]?"V[@QZK_Z]F=8]T]?Z5+\HG7G1C7T]/N5Y6K9$/[<&.3),X58Y+ M^5_E42G_XV]/W#5%K-
?3FH9>S**:FX:F=CCAM54S %)M(WS'C^VBVL>P2&)# MG]2W#;N,[:?FT:%D-0UQ#I,&P5M_]0M#_-[C48 M/T0QY7-_6KOR;&R(?QC6ZW8Z!JNM<_]
C:RVHR\GYV89,H%B+BXJ>D),2I'M# V1#/K6./W+4$OU5E33%)^GF0IL/2J+0M\E88?1 L^Q%R8;[IW+T)=#;;3\|/C0$\C1UP.U2[KJH[Z%OC'>P&,ML.W4|/)*=-2N)N5GI3J/OV
MZ2U)X:%?H+ MXJ4D9R$2Q)ZF')C./4=4^\QQ"2V9N5\(&TWZZ)VT7B?!0A6O$VKD'&BA.8J# M1:D7F"\@^Q8G^(XB<4\ZQ#'72V/E:3CCO(O&5|)G30^ M6[RH-J7RUBF2"%&)>;*+X
@05"=^DJ*)T+O\[EU8\6I#R$A 8LL9E M(I-,YB*T?$%*L=WDA)K!SU&U[%I:-N"\J4AKP40R97G]QD)90SHI5,*.ZAMN MKGK+#O"+-1+_>K"YW8:V*NG_'4@K(%^DX*H!P+IH=3)
[A&)/0O&PB=0)9ZV@ MW*DEH70E-/GM?-+_$ M4+1Q(]^%E2!;Q#">'%O6/7&A;U2&"*D(;4X!.19D)60B"1G*P+<1BS!?-. MC@!THC54UF:.>&[O-"K38[-
&3KN\\L*=5@Q'A!05>C&; %DBX3E*V$[CZ M :K=U%WJH0CV:CFD[|=-RQTM4.7T"[\1_B=-1@Y^:#3(P7/$?OZ8=#Z%,_W2J:7K-!OR;M:;A7UV56B>I@#76%42)5\!>-IKY\B"6
MHWE%B>?[\M]J*&9)0USBW"A6.4$XOM,KS?042$:NPGYBI+FY56BD)(C5*&)9/L0$H8%2@*P]7$-Q!L, M%I0G_SD*AD3AN) 7<#E3(KDN".?+OW(0ZN':-
NI8XZ,Q./@R#5P<';T@/8]S M"CY&=S06KZGW6=W%^,RD)R-S7*2_WFPH5'NE>4#+(_#;GHAG19HKD29BC>&>O)?Q00QS2^DF2D*YF56N#/>,Z8VEQ#3![7 MC>/72:.:,,"Z]H#Y|?]
[3D&X8I#H&I^0?/%"^\Q$7[6$14)G>5VH.U_M1Q#GO M#&BM2C(0>W)X;YJ&4*K/\,<-P2LD)P[I- 6TPQ\6$@@?+; NTP(-SE"!HM MLTS*+;,O+*-FN^<
&+^,8QB^B%Y%>$V3!\D7IN!F*6VD+&(.4/T3$E5+,T:) M.#-R$@94)*^!FN:7?$**PJ8GZ0W-<6-QFY[5I&3U;?&B:*O$UD|&BW1+0!GV MLT![X?#1^?
BJ]D"9O(G&5&0>"RC9,WLC"F0U&V(0H?6?+WINJ!VL:XG;)9 MQ\L'V-J6>!VR15|K-Z J60)T79; /5/R_1^2I%S9DAEWN,,//:>]YMXQ@MF\H M V-
8(/>#8!=H.D\6>.REGUIC[M;G'S,;ON;;-B%LTG]'XK1%Z\'K,'/]Y8$O M5G8T/M.[,7U]>R_D(]E,Z\IH;NZ">$0;"FX]JC/ZI&YIX3*OJD/%G7BR>'#9 MT8l;^B#W8A.-*S[]1"JVT;IO-
O<1G>]WLVCN|IG3J-; M(_DXH]OA#@<K>?":/)6&!WI'ZTN&M;7%/9(;-52';VU#O&.V65S[Z'5!4!V= M+M=1HRKIZ,+1\XOJK&6 3J/CM?7![8!&&I\41=)WP.N09F++;7\|QZD7A824<
MS:V#3[&T$L8V52G-C]Y_17%^1))H:@G7-L+IB\TZY>4SSUO@\[86.7L?ATU; M/_C.V|'[344?;?W@IK9X1UVKAOG@TS;$.0;;Q>T_%.WW!;H'$UZ MQ@XXT<=\. !W9^4<&_*<>
MU]@0IZ>UZU9,][6MD,_ZS3+;#C5)%<;8#NCFBX!D6QZ5-WN-T30)3GAZ2?M M:7\|%%/Y0[$R?&<*H-4N.$&FB[Z-$[K2?D93>IW4PTWI"U+2QS&GCZ>OV$.]
M43=13EXJ/JVWU#\$!'X#UI4L?%'|383^?.JEUFH M$})D0P@O-O13Q|.)SDHO9#P6(L$%)#9/CY7O/_QR<7A)#]=_#66G_.JZ#RU\7C:81O:I4G(V"P)$)XZMT.FF
M#;!H[8#7"\QTS<=YCGA9C!+|=E/ MS> *!;|*O?95S5LHUQ$AH4l\[MOZWM+/R_7L,;/Z\V1. /&G'[#M",K)L4Y|.HR,1%^^0>7T>[/0T3L6%TX80" M;LZ!J-D;6SOA=DLSG57_;.Z!UU$-
Y;9^!R*FD9KYUJWO3J*UEVF-8Q)]B*,- M31)1&^T#-9Q-]9UP^Z^9SC7SJZ8'7O\UE+OO=*32)\ Q=P[MM8!?8%"@F%1 M+!)*T6RHE1]K#N4S5D]>X,5R>7^]VP?1D=
(\=7Y#R:@NG7$ZK)T-BL-]XY|(M#_V|ZV$=P>/%\1&&\2LD;8<?$-%&E%S*7SHD6TI3XD.=F^R,::6P%R&Z**4# M@OC\BS@ZO&SE2PO1VA,/MXXB)02\N*"9!LGO"13:9&N^G=
[*T2OSJ?^6+(,D MR@OS)&3=32I%H@6A7X (=(9E,L0EE?O7?<2WQC1E,175?59%?9$.>NQI_(\# M2UBJR !%) K]H 44DQ#ULZ-265E+B#<6Q;*X/+NW<&DA-%Z0U2$E893RU<&.
M9664I.%<7{(%)_*8Z&W)P]5IK 5X(I!G<7D+?#4U6GFN!+0=2I+,.&QP36. M\XAK^%A9>Y WFH);V4'ZNEMEV;UOIKT^FLXMO2.*NL+TI
MLM$H+)$[CMNKJ6LO!B=+'FC\M/5B>L7@NLQ_?Y1E*"X#+S$,[NM""">?$.8!U MZB^BC,G@71/W4<;Z?B7C!.&_1/!:D(P;Q_IC5KB%"(Z+;!H @'W^"%V(#[/: M?2[K26BLU7;7:]-

MP^9ZJTZ3%L?O-YA++D#5R!55W!]73NZJ>[XHC8KZ/;F M-DJ2;TJ;N0 +HZ4!F19OGHL "QZCN0O)BH^:;/ YV;+ +-%R5]N''F|(Z&TI M%4NLB>$%F?

XJ#>=2!7O8,V7@HTI0H)/KVUZ'1COL8,<7Q2Y0YX&3H; 9%QI> M,=AAAWY6,O(IY7MRV+S?I/9ZH.E(C>VV-A#A9,N_?$BB)46UBDDZ'YJV2Q9$KN#VF2>J&

(GVM>F5B0P0T;MG91@:,,K#;S@8:V)K9?D M#$G&D90/VR53HG!%L^"8W$Q7-(QV+'2UTN (*6\"O"!;4PE-EVD:L!4AE:LM M\=E[+]J_X!VA\3*.N;;BG^X(9!#"N %F.-NID-.?*EX0&E W^U=EA0C%SD" MD2H%([L$(D&XV?5F W=*.?!=~E(>AQ1!7,"60B,FEF0)0GX^IM1QZKL!WM!<7MVZOD!9ARG+QRC+1U^(] MF?H?.)<9!(:XYX5O;%L -S4$!

[SSQ4AZ6M\#*T+D[X:. M"Y)+0:X?GLBE%ZQA5P@1! 475]/,"LA,EXL#>;OJS @!!H4=02:B" 6=SJ]0 M7-X+]K3I^V,]@8;BC.-RQ VH$UB[$O@Z'CN\4#N%/HD?BKGR*YJH&9;VRVE0F M';K-T1/KTYJ8]IF;3PR8XD0SI/OG.^E_J.S!!JBY^.1I&JQ#MU:CREFOV@#O MH*P7T_J45E)S6[%N%)5DDGMUGSU@%04:,R NF \Z<>'T*61ITE!2H,$Y3K"<^S%\,V

M",,OCW4!O(7,I+4MUH.G'-A1%MI-#.+IL%=9?E&";7EBSA1W?S&K+?RO^V M)19V0(XD7(L.PZX):W%'X,[N(9#;S:+TZG-Z>E45\'Z=>LX5'<^%C4![YLA M-BYW\1VG-^GH/U5HV+5@@-"HB3\U>+AB7J.P7!!I#QSQ,$Q+)F4EJ052ZZK ME@QI2H(I$>]IY;::!O&&A_%?BIK(L'Z ZWS=O9/: #M2N6,MOL4+$C4R M]@KA( )C!6]TWU<.J{K858F8$^$N?

A0$7]PXT:GG3!6*,]",@LH)++3J. YU.7P^ M0 2O575Z<-<(XQO2[%153E6^074O6RVHZCC-]T]T6CJ.#P1F@4 M?1P]^%&?1+Z7V<2>()G8,O27OB^@Q@NN6+(.HN3 3?

G^R/_81XD7_#&.#OND MR$\!;2)(7B@_KU,D!6%34&,DS""5-N?H.3QT43<,8[54^LO_6CP(PC$2Q' MJ=36 3(ZZ=\: VE/#;=3][22ZJ66I/"Z75^%!O6CP1?1UU^\V-O0D*TXACQ2

MD1+@)DQI *DH#UI$T3<Z; TQ5ZG*-8VZ*B4IUME=Z; TQ5ZG*-8VZ*B4IUME=Z; W55FIV *1\C7*EA.NQW 80B5(\E9.MQ4(-'*@_-%AA>%R:@.U9_ZQQ%NWS^'=]>!V $NK5&(; MNI'

ZS2VBKATI\%/?B_%W//"N?X"59H>(7=DLGR)J9!$?]YKV ^G-W36O#C;.M->F$_$2WDPKV8SUG0@07(MF0@@IY<_G+8_GGQ#6HD-C W;GM- 90?^:'!U@!)

MG"KS/_^KG/OY'URS0\AUWWMQ>H3;LIHU;$,SG'C5IA? DZX-OOFW55)[ARN) MCA)QT#+'T'NF>VV?+92E&_;F>M<>G7?OB':2=+9"/7....(=S=_$".-CA=1> MOL9_DI5)6H-K;YKB*0F^IT&W)ZV0[9@,,E]5FH%G>$6E][CC+&6!F-VB!U!;?_2.A(5B>;T@ MJT-*PB@E01:[D$8+XI<\,LA !\\+D02'QJOF145 M00 *]TE7Z8Y_D]P[*6B2(GZXE("_"$21

<++*2BFF7_HC&=HU(QH*G8D4-F7% MSG$*VSY&1R](C_?A'4VA/%4"'"E\60YW]9E0 U9@*XCG!WBJU%6[-2"#'_AX* M6=_B52J$QI(IX;@!=8@$[DJ,7Y]R=E=0=GK+<-S,F)+

[4"0'$'PEP)YQ=EM6 MUO6X$6-FTH4V%^4*"E/RWA%I*(874@>W59:S?10PZX M0VDWT6I[+ZLS2V&@E+,(P%CGXJ!; XJ],\-%,)>!%$+D-8)((0;*5?",QMQP M2"\G+D83KCV+_(]\B\?%K+.@MB5B7&[6KH#,^F;(4;1%,.N!*NG ".14"0S_MK,"T+$(=[!V8KSE80J(5'\N>/%* 09RM1Q@M2OG2>)?`0J4(QUY .KG?/X1_ M#3^&5\,AG_A_GGX/CV!W'O\.'N'2+!YN'!%;_7NKS]^?/?#U>_5"MK\GU$L MJ]NLQ;$'.-"1>C'O#>?4NRA,M\"E'G%>D6\;.TI#XWG&4?;<6I$?Z:0]R"RO) M+TA&>GH\G6;T%6A9GA"4HVQL$'SB2VV/_WT'UBYH33K-

#AIK=&Y!2:7'+ &S M3GZ4V"GS,&32 N[];PVF0_YL!8=36%V0G WA?+" [/"]' ,U;#YR 2=$#M(- MBY-4.882!PTP5*C'1W5V '&QXF,&[O_.5]QN D)"D0SN+RS=7A[X$IN+++I)=

MZ=.GM73!B>)=]*T&8.C;8PZH,)#:/D!"$B>?.762DU_(]&P<_S8IQ'$%0?19 MY% !:+V,J<]2VNKKA57U;9&[*?M M,EL/V$HA@&SP G&1]R-

ATZCI3K7UK;RJ>8$0\;@T2(P<1GZEZ(>UQ.4XWK(M$AD,Y-6P)8336_O;ICC!L*'' "$2DGTI]XD6IL- 3#6:+=6'#F%]I&\S(\.#.6BN.! MQ.-

O/_SX+-^9(46T^(]BHT5.+-&4K;F0%'G>3#+89B&N070_!4YU5LY^$D+EHS M\84XV7C\7UP&MT@SAAE*N!$*(@*=4;5=2'7' Z"[*!0*Y(F)S+%(VW-&L-2L MO1:AZKO-#*Q:E)@:M

(HO)"NG5T13OR&:&+S*!Y^5VB>\T*$;B[,D ^ <=[\ M7-%U3+D0-^&' Q0BS2/T9> %O("MLTMG"HA1T,X:M>]\VKLC1T5+989YI^%G M#'"%>9R-

8ED\W2[;9BQ\;IQZ#ES^AS[+/BP+O15"0J/;N9K_ISI+W&Y(S)#'>E'/9ER%*=L3KV M1XRP-I8H\\+5+9^3H:]5*[^0; @[SNN-I8$<2"W[PWAT2H^ZS<+[_+>(D'?T(

M"CVZ(64;U\!28UUM%Y %,573YX#\V5G7;]G32Z#>MC[^0S M###@=D*L,A+@\NB5-<7M12=+$35H(0THD(+[Z$9\L!Z$XTT'-V&2>D$ _ZP^ MWC=;WC9WGQ&T&]A!"^ -?

6<&<TR:,] =C5G*I 69D>#NF26INMUL7T#OK,2./RA2/Z)I9!/5)KD@ C"1AL5B=2T!V+U?BPF(K6W4<"'7'+] MCP,?B'=12L6G3_N P,KWE7\%BU[PHG75Z-,9&#!GM6I8!>]JFR&'#0'#

[MM?)%@)-!?W3G4ZY3FOF,"2LZ(!RE:L>,%?0!S(1>=7/2!&B3C'A^%N0@"T_L<90ER1K^H.N4;=);T]L ,;$;:EE#6V[P|>)D) MW_\<V!9R[^ MH:EY8]

^Q!"C36\,%8!D3DDY9O77R]8W_O/^X_*"LR9!;?(USIZD@0[Y@VGQ MSZ&).&<")CH/(%UF)I+\;QJXPU)W]OHC?8W^SGX[[+Q5C47D]+K0VVQ ;.9C MN\8$#?

C;T@$SQIKH6N)H4VOL6&DD^SB#5V0JR9<3$^/?]&H#=0W&.80P=[_T M<"!DL0R<|6*OZY)NW@NWL>=2,5/J%F NX6@2Q1$NJYSJ/5X ^7/LA0F\U1%/

MX4N#-06AUO1!C$NF&FO#R$\)($P;&#Z[U\^FO.O&[BNZ2A_I7A_!945E1DAE;I5NSL[K)&:&9AT4ZO_6[WSA M59_P@'(@B)5 6#"02<*TSYNISFM9.>-_/F(O>.P94U S-><

<#H5DMR.'D> M,[?R3%%>?6CIY'F=>.$'6E-?++! ?:"P^T]BJJ3UTV6M/(R3M<8KPNWBVS] MUDV^I6D%W)G T%&B<LFQ=MHRE;U 02FQORAH7$CX+ BQ.(,I(O8K\9;I\C

M\$7]<26R1,A$@[)XP8'>T<_BFT0_X]K2P.FJO2Q2[';Z$D"^U[%6QI8#LL>L M;+?/TIC"X_Y78 =_A/1S-3L $Z+5Y#B!)VKP4";)GY%G+,;E'>2'_7Y9"H?#] M8<4W5)SRA@H"44P\DE#

(;^U!@?#JUPO.7R9=042!QVEW5Y+^(?%$L.1+) M,DN72@13PKG*KY/%Z,NI5QIOHH9MU>36N=$LIQ9DX[%8CMSA %NM7!?3'3OL MZHQ0VPHQZ.JU*F#UO

ERX&P0V/IY5Z7XI"1:GO? -UYP-@ZG!:?QM,Y]DJB MTQ_73/1SCI# /I&!ZG5*U;1!C!(ZCG(9*-'C[|'<*> V,\P4G? MI3*V(UVP(V;,/RWV(3:$0Q!T M:I4]'

X8'R%N@GO!87<2B/'0TAYE<$2W_L@1T58;ZXMXP0\E)[VA4-4=&R7 ML7#Q.F O;!70ARCE=)D7+'U9!]X+JE5L/-IHTYIKJ98">]K3-=LPZLO2XW)&'!TR/S0X[K4VEO'2*7R4?

VN8#$*R0\3>0. M,M:6Q4MR.?JF9C_(%&?=UPA^C0S!N.U(L'/%IL7/V,)H?GP3Z,\Y[\<]'4C MO2 [+8;/9*Z";!9Zf|"6?_I\;> -%GO9JZ<>>YQ]W@8QI.@T*N^<3AH@AQNM

MN'VO#$31CVBWH_$:YLY8\%&FR[>D?#*QBM(M61_BF&9)\D+ ^*V1_GG><]N9I M>/V S.!E#M[8$9=8RT/;WWUC3'CDAFPO<= MJ_O\Z:.CG*X3]5F\\,1P/.E,Y^%PYJ+]1YC*M\BQI-

S+0KL*+]*CA,U@MH. M"' UK??_+\N'Q^NY:+&Q+%D3PF!8PW.KJ$%_<*CX\'+6#SYR@ MI@589@4C X\G-_@PM%.X=_R!-1HP6LMT53'#I839^F&.BX9Q)A&WBX-I=('(9 MUS2)@@-

"PYK3C5ETWS3?US7"# DZG4HX.&V!'0K^__:^];EM'-OS^_X5]%NW M;M)5U1*47(.,I%ANO4X.GPIM2![!MG161 1)-M M%)"$>U2\"GW#]81'- (G:1,SM"OVK>+:N^ECZK_QH-

Q*W*F'Z'RS\9DKPF," MCT,Y86?=R6N,SH@OJ+.-CJ'$&GLBQZSN>Q3.#9FS #^//|%]&8^+D#,D6.|(^ M#-?Q7GH1.S7T>T6D%[H@%[@%6+.+BZ-^4501!%;@SD;OG'D%V_*C]&Q5?

***MLP/-%D$> M_E=EBE1]4WF(BI"\\"]B_>3Z[DYO?GY..G=X0M"4N@Q28* M'\783U9.POW<9\XC\!/!\$@H#86D7]>N#X1B;]RX>%?10_7"7@/SM2)PX 3**

MW1&N&5L["36\XQWA@Z4D(2EJ3M0\+HZKV%JAF%:0R]]UR"&P6%YR5[_//5U M_J9RASN UJ0 LYN%:F"U(:\)@6]'M7H?[0UB.)"\)GA'|?BL]'JMF!2!/RD$(*D$& !W>MXW)IK?

MB&Z^=(W2QY/4H'#/*0Z8C'XZS MD\B5M7#N\\R]5QS29 MNWS;'W8QLQ]/WR!XAQ7873.MT0LN0GCPZ-)+01Q(](^6Y6KD_6GAK=\F0;=

M^@ZFC#5YX;Q)OGQ&'O^/OE7@;J2+P'&5BJ?6;33OB%<:0B?4|9YM_'@^)L5 MC1QD,A1"YQ#OT:;?.6S_S/R98Y"V/Y36!H/(]\?6,"=:BT/XC8T2M+:,[X1 MS/B:7;UHUC8C9S'Z8R2--

-;-\,/(N5TYW U&:HU,XBN)A652/]P.+IZ/WM//"^.-%O%&Z* M6KRD[T,$,T;UM4D!75TI8$>TWOKT=GO@6/58'6X5,7+:PB=5M M,OJ?N0@O]*%F9X"

<,!9V@[TI(]RXC]D>%H8ORY:2%E%H7)7[4MU>$(<:)70 M!/ZO(BR!_^.?=U"?=_[*#B,,#G_#B2:5&@!P!/V !PJ_6KS>@7R /[$XY25? MJ!-OHW1K

]0/!\>XGE0Y1TW_BMR;CB>B@Y\0>Y2N]_CSB]]UK$OOZ54K,SA8^FCN$'R_/_*_UY65^,;C!% MG$-+H[6ZO7U6DD.^)=&DW/ 7L7#/4BICT_7Q]-YK%Y;V]ZE7ZC,CVPW\LWC:

M;"D_#@];MWF'+3[*?EX&F_6=4-C-C^*^.]@@\M2%*8*% ;M?5?3OBO^N:&M-M_H>30%,.::!;RUZQS;F#VW2QV00\!RIQL_A8YRT3\.PLH+9HUNN7/>DX%3^ MZIG-A5DH_B6D .1^%AB)#:2&A M0L@E.L;@9QS6H:OS9I#'U.*+X-$OH/ TELGCV+C%TE@PAEGI(MA%!YH&)_O M5TY$/?&\[^3SO4VIH)#=UQ*ZW4S?HKJ9U"AC>H)GY+'&Q$$@^M=QA;&'WI@Q M>U2;M@)O*0'YNWBO6I(!*8R/[H2I4]'?MP[@]K%SC74<<<-XT:LZJF7_9\2(M6Z%'CJ"EWY C8I6DH|\SXTSO7LVBE$XJ\A?@68T^TZZ+U91A[\"M*7&_P?V_4& MOG_Y/4?WFJLZB"**

(&$FTV*[\D&T81.6CITV_ VZ%4 G$R5Y3I6:"E6Z-33[SMFBR/9:0WS,W1RG"P,;+9J.VN:MR M'"TH>AVX4)* 7E#YOJ?!;9C .;_ CRQS.>7[3'AVK++#24(&)TU6*K'&D'44..

MNGITZSMD,N[DC9?R_XFP@&PR$;) G4V14K@*=LVB+A:37>0FNPY(+D*6?KZ4 MA;D*FK5;[!=I18 ^P>2HA&2[ABO2|E>Y4)ZZ)*+K\/DH|&(;GJQ7'N'91H5 M(_[,A? $6P;RHSKE8%NK. T_[YROB1DK7C40(M/!E!<%",MC0'PTC6IBLOHLD5!&96+:=FL%)7UHE:RT>$ M'G$2LG181)X=?YL&.XCB3[Q34>?)2=(!1''!H)!6@DHB)X@=M[03@')3?WI_ M2:HLT,SF 6YMH.ZK*1M%3Y4)"@C-@M*!_8SCK7P+L6GZ>8^ M#@_DH)O!;,;)*R[S&>5HG?ZI.(82G,@:/AFP6$:P>CJEK?.EDN]BULX.('WC ML(;*MF/O6#!<1QAQ%>6=9IGIC

C^8+9,@AD1,LP(2('FEL*TR=S]N%SR0!"" MC/%2O,@8>P>O$^^1*RH_>E_#X%QZ?I7!.O9'//WTL43%P_'FSL@GF%ZJ##X] MY[.$'T*H.(W6\GE,G#Z.$6M3#T 8V,Z2I*!\G]C$_-

jP+SQZX M%VK$6*%F\?CGBH-.OJ=)#Y;J(+93=|P(V]T.!<"V]XL=7WMHHB//1+WC$_A. M%==O^<$*D#@ZAG+]$\+1$/&>6310[F0&-'G0CN$V!)',"{O^$&[&HX4#O M[EQ(<\&6 O=I9!B?37X$B.ANTQ_TJC)(S.=$/[<|Q M03H=/HOHJ&Q#1[AN0VABP-W:-K40WDAE@F#>7B=3L)X-,W%\|> .? M1@'V=\4G."[-@@SXQ[?2@"F@UI3^K49L0Y?GH1N$=

'MLX6N]6'PZWI(L:# MKA90U^%3=$2.(YW5T)0;(_5(\,2&%I1#@6,:OJ'^7 MLYHI1SNP,N&6_(2@$:, 0+;PK460='*QEIZ^6%:= *=:%NO/AMNF_K00(_)0

M"Q4|D2$D"/V8+7ZCWL841V.W56%0?;RM#*G9'XVIK4K#\='A'-RJ8:GJ MF.#6\<-%BX=OIF\OU%2?5@RC:(9Z4ZC3+)YRJ1L@GDUJ1_JFF>B,W+'^],0UD

M9G0B_|_:D<+H"FH\,,PV5A?1]NF<(SCS^'P3?|TJ3Q(;.B#&B%:Z%F>-=:V1 MHT8[V?MZHB0#$Y3'R<,#A)1^NED7QP=\LHNS %-+N_=QK9!3GQ&0<3PH&.R)9 M6#C+M//=]

<'1=Q8Y;N(\K&CD;.@V86Y\';AOU2N5I@ZX:B5KCD;ET.5C6'(+7-$>_ "SV+(Q%U6^38T$;RWGOME#.)!''R M++*D;/B8QH. D3E+J%N$#P>-20-EPO39DOX.XA?[UM.BT/6V$

XPT56CU K.B$6)D5>IT?)"0M4".BVIY-;P"L?];,9E MT^DCM>M69"S(2%K B>L LHA]#1-X> L9P.!: M5M2 WG)).%:=AS'$TX,/--IH0]?>&L6NPNT%YF:U%=

M<94]$IG!D=QC:U'TOOY[PMLAFG'8#P&"K>[HQ#D 0CTOI=1&'!F8>PRRI=Q M/"\?2_D6W_@NWSJ+?Z1OK*ZX&.+0TM2:0=008]AP*^4@U'\4]FH=6B/368RF+(

MD6W#Z0/G2Y\],3BB;,B!6#]J_+8)\|L W4:TZKRSRE!ZR2.&[Q'LF..Y1MK(M 7X,38<>MM-4IJ#L_'+-346U.3YEG"&(+\)DU4R6XZ2PY6L= O(<5DSC{IU5

MW@>9QW!,%KU5.%DIDFY=>4>FX\YG+P\"[<|%&5T<:)D5WNF7=\/,22C VH=A.-N6.62Y90=W5' M8\IQ936(:Q)0[LB1$F#8MD,8]&R-&N4>S>:=FMRQ1?0S:I'[M2ABBMLTA&&

M2Q1. H*KJ+$'O\F*15/"W)&LUXBW@BJZI-5I'17*"H_1ZU73L1<*.=X&X60 M1U^-G\[6B$&R7KL<";N;(8>[!]'I^EU.]BQ^#IT9>?+[_OD?!U\6/T$!4.!C M&)?&5G-&4L(6T65L'8N/V

,X@%'..0DN2R=-^%*SB*/DCH.D?]9_$"^\+0)7 M^#_ ->< _]5LQX?Z'A4^1L5LQU_/DK.XQZ;&J+sUM::0CH4M00+KY4#;AVXO9U MQS)\!BN0#/QIX[DC?

3I4Z8(//'8(KUM;MCDX:Y.ZH:(G7'1G'UN*,D.M@A M^<[W]5/X_$<13!#MI$^F_RA<>OW#/X7 98WW?L#I,,>R@V<5?\7G1A6R]?69 M;U^O?RXOR/W# ,'RWN@Z0:<2 8,=J #Z/N?

FO1#XB/?L_?3I?=46YZL1D8SYD]SBA@UXL3$@1#N4OA;?O775@EH$[8IO8RY MESF52\]I2N& BX!PGK*-S6K09OVEPE'>E#VESSE"(U"F[&_%>X*+;66|=VWK

M24"@2LL*O#ML.AEP4PH^(#Z74Y()8*CCKO+JKEF +E1'R__!8E'B5;1V_0Y MD'3H#[?!/X(OP<5#\%?^/_=_(/)I^DQD*:*OSGH#XCI,0(+RC3@0WGWR

K,,@6:6YV>&0/$iTX+MK,&HJ|P M7)9A(;#E^D;,:(C"H<;$1.+X(?BS]UL<=1E2NA8K\;(O?,3PTG%=+W]5T@ M OAT7"&\| #0]5/#S=:N+UIOIQ.!09V//4ND8M:8RIQ-.?

FTECRDG7L*& R\ MQ5)Q95]EKQ%X(§;,L2Q:9$G7S YGH^FIH!TB1&%N",.\/&*@_09#$D2L:?5 M?A(.6"7++5XFE)PWJJ..#"=3QV.5+*O209[U"M!/I1)'"F7#J@*>++'1C1V?<

M=BXX(_?"GRNFU;&GF*]A8&*6Z9Q3);. M9_4M^B > ^&TU+M?@J.V `!I:BS]@1<49$"8XG(4I"\C>1DU'X)O257(XRU@0 MR<,BS-A57&-R-;!0^FU?

C<;7/BWZ(:CMAH7"=4:.B"'HJ;B\X/!@R.T^A] M$60X'YH970\!?U?0G85UP=']<{@&5T<:)D5WNF7=\/,22C VH=A.-N6.62Y90=W5' M8\IQ936(:Q)0[LB1$F#8MD,8]&R-&N4>S>:=FMRQ1?0S:I'[M2ABBMLTA&&

M2Q1. H*KJ+$'O\F*15/"W)&LUXBW@BJZI-5I'17*"H_1ZU73L1<*.=X&X60 M1U^-G\[6B$&R7KL<";N;(8>[!]'I^EU.]BQ^#IT9>?+[_OD?!U\6/T$!4.!C M&)?&5G-&4L(6T65L'8N/V

,X@%'..0DN2R=-^%*SB*/DCH.D?]9_$"^\+0)7 M^#_ ->< _]5LQX?Z'A4^1L5LQU_/DK.XQZ;&J+sUM::0CH4M00+KY4#;AVXO9U MQS)\!BN0#/QIX[DC?

3I4Z8(//'8(KUM;MCDX:Y.ZH:(G7'1G'UN*,D.M@A M^<[W]5/X_$<13!#MI$^F_RA<>OW#/X7 98WW?L#I,,>R@V<5?\7G1A6R]?69 M;U^O?RXOR/W# ,'RWN@Z0:<2 8,=J #Z/N?

FO1#XB/?L_?3I?=46YZL1D8SYD]SBA@UXL3$@1#N4OA;?O775@EH$[8IO8RY MESF52\]I2N& BX!PGK*-S6K09OVEPE'>E#VESSE"(U"F[&_%>X*+;66|=VWK

M24"@2LL*O#ML.AEP4PH^(#Z74Y()8*CCKO+JKEF +E1'R__!8E'B5;1V_0Y MD'3H#[?!/X(OP<5#\%?^/_=_(/)I^DQD*:*OSGH#XCI,0(+RC3@0WGWR

K,,@6:6YV>&0/$iTX+MK,&HJ|P M7)9A(;#E^D;,:(C"H<;$1.+X(?BS]UL<=1E2NA8K\;(O?,3PTG%=+W]5T@ M OAT7"&\| #0]5/#S=:N+UIOIQ.!09V//4ND8M:8RIQ-.?

FTECRDG7L*& R\ MQ5)Q95]EKQ%X(§;,L2Q:9$G7S YGH^FIH!TB1&%N",.\/&*@_09#$D2L:?5 M?A(.6"7++5XFE)PWJJ..#"=3QV.5+*O209[U"M!/I1)'"F7#J@*>++'1C1V?<

M=BXX(_?"GRNFU;&GF*]A8&*6Z9Q3);.: M9_4M^B >^&TU+M?@J.V `!I:BS]@1<49$"8XG(4I"\C>1DU'X)O257(XRU@0 MR<,BS-A57&-R-;!0^FU?

C<;7/BWZ(:CMAH7"=4:.B"'HJ;B\X/!@R.T^A] M$60X'YH970\!?U?0G85UP=']?[<@6)Y{Q..>BF#^5X^C?T{BP>5?*-XEU4% MO\T*_U39]@--Q'"FRV{YW TEB!P.M:G7=R1) >

X(G;'8KK7/!;N<< MQ@IJF4;E&-5E?=F+YBZ(P;FEOD5-M?KVR*&UK?2:.[*E>RX6:@+9 M#1==&!LJ>=`#12RR>N.7_$!^N)$7 M'0V%T&N:;5*8"N\:JRC./&1)C*U&#>(-**

Q=4C9HDQTXA6R5WBO3'JQTJHN M;$2^./QG/PZAB+*_J2AQN73B2;JM1%"3_HQ#ZB7EG[$D.RF$%UL-) 65)OV- M[PUC9?V41B$D5-_;W_+R#"B6F@ PIB. MVO)?;>.S)\?

9_+'(@97^I;RGVCF+ME-QT0]-3GJ MC #M(^8S_A6 ;Y/=Y^=X#?U(D0=<'MM$O7V8IVB%?9S5)W=?[M4KI$$B9 F;@1]5@"._2?XCY#3;+FD;@(7@"'"2_E\S\O.[!W^614BVCS'I?

0OX MRITV\,0!H|F5FDG#V%NKC:;E|_D)GO.GZF-E]+TB_/*UMNU,D?IX>\X\4:I M29:E=.|'?':.6L3>@022FKU$!.HH_,18EJ=YB+:/IUSZ&20W"J^?'7];6!;B\R_?

14+N4'CQVIH%\LA^BT?#01H\S)6[.%2;Y_\OG M?P@HID6?PC"3?F7Y';,$.,TI,@48. MC?T:!GDT<)',=;',3JBJ;-B7$&*T'62;^N#:)BK($7>83L/C-0ZR0X?!62%0

M@6]"G31(D##RHFX;0OM!^5"*HJB24(Y@;0(,ZH^>+85L#NZE;!N^0N'V4>:.MQ>OZXP?M=E'U:IMLHRR JNBHS91J^J<&RPV6'(.6"N*G".)-JO8=DY)N"P0@M#U

9DB=^VHAPO'A#7;9DO!G7'B+PQ$,.-92J25/IE&JB;AQF^#D; M*IL/FRUF)/UF6>JG@LA$)A(S$OCS6;)O:(ZTNW++$I"*79"Z#^)9H:W&Q^<@ MB@[(T;NU^+T/|;9\X&Q|QC>I6

(%A"/0A(|%K" ;UA7G*S(KI?E6[;UTFUT M2Y0.,XZQCL.@X&+QU,* !I#R]983JLZ: UG>.XFHYTZ\RAX3W.:!.%6F:=T3 M,:!UT|Y4B*!--^3@UE&)W@.[[,99BL6EG+U=SC*'-E%[

&IN9.EER@DL]X< MB[-M-E#8Q\M)+ETX46 M.,K?5(GZ+XH,,09 V;P1VOBK1DS.%&*K'16AX ,G$]["WY-#K-)2?2EAQO9D!

<9[)@^3*$F^(R6G5UZT%"L9Q;GQI@BE3C$<0!=6OW&&FpSZV_#(+LG:L M6+!5G0R44'=&"]+_A9P>*+>IC'%8O[.-)M_'L+Y$W?:)[XTD.HNEO7+Z.XD M$&-

S3WL4^1B|]4>.QGVU&1KQ5 P+)^-&^(" A6YV5E;0!EN>EJT=CS:BL>', MCZ,-6&0?RL((/0D9YGBK3BGM;D,MN5>C3X$)QO#\7;P"P=8O$>.F_R=);OS MM!BH2+

I]_WPQ>$P=A5&YR*J^:,8UGX,;MG<4'E_QY873=MG$ ^B@7+++RVT M$,87PJ.>D,VKR %>>>%BD/.\"Z0A/|/)HO8QDU"(B3EW;-:[N\R60ZO#H9 M%^>)PF,.XQ6*EFC?.GA73-

PH^ET+?"A.JCT#QD3M15>O6HHKJZ5D.6YLZ4-X MO>;@&P$85\I80XCA!"L]-LK7G[TI(5'>)#M>K_U.RRA)1!0)1,0!4YC6:.!P% MN8@SXFTCN!:#M>A&HE1:68KE IM=FMJS*W

696;)Y%U*LDW7#8S_36(;PP!CG82PJ8##W3:/>%)]NP,O-Y]UZ(;,N]UD7-O\8N MR%&X@P)]_?RNVJ,/RS7'14V^R^40%VH@"%D+2=[" A R$\;D,>0KR'1\"L(% M)%?4^I-D@61\1--

L83|#UCZ&7N!",C9$\AE#;3G_70:>$FP-Z(_9\<7JUTD(-MEP16QW+Y/2.M*QC&IDUVGSA1@1HG^D3"T2DSWBF&W5FFKN_;UF<5FH|JNC8 MS\"--"<]ff6S6(?D;

MM9QE9V2^_YV,$=-"Y50;QCNPR90FES0YXB"W2N63R'YD)CV%',W28=8XHC'Y MB4*MD0XS@{P;Y4>9#/1_A!,X?U=|BXR!%^A(HT3B O6(1NOS6O4

MJ%X/\3APO;&|>V^[MJ$|=?1O;;UN$T(CV5.8(HK,>J6(BHD.0B-WX]T_V'F MC/&_2Y=H/QM2F'@>P+-,.XFS%BRI8&LSS3%!9*VTZDFDI.>6UK9J\.D4DMO M\K-).^UZ3R,Y=W)

*MVW$F!&\|F 0YTA\,XJ5K_"!6V;3_Y MUI@\^WAF-W.=IM;)3HGMI[*I3D$:W;O/!@C<|\UE7B] !7R04Y@.G(3//%,> M!$8%[V+4XXALGH U$_;I%J8VBH4&1Z1UQ1GJ;'W;[H8 M376.M+V")/)'=63K_MYK[<"P^]F;-Z-3+QVFXIF"O/$5L M2=I.'Z.1U!0GSG;V.9X7Z^E,==IKJ96I68T)<<@;>,,]DQQIFSR'_$V\P?8 M8H[\@1IF"\E=?H@BF79) $33ROBN7&*BWW29/[KNY1VK6]HPCQ2BNTVNU, M.A2[A2+X(K|_ -C6_SF:]PD8PZ_'-$B'J.M!H#PX'=:5PZ+OCK^E(G5,/_^\ MFS2Y,:/Q%SI&MA'U%@%7B'LU"YYX@ZJA$&7 _,S$+'ZHB)H;@5^$C*$Z_|-6M34-M6-]OXTV/15_%WB55N"1*$B""P2](7-]C,D/P]N)DM'XO96#*%6$PX+U*2AF3B M0,K:PISS0W,*F11&-0N%GW>IR(#05Y$H&N[NYJ_L< G;K>=$X*M9^TI@4G>; M .2T$+YW9Q//[+V>@>=#572=G]>K[&]R[<-^T_)UI?1ZUX>_2NJ6UX/&[;:| M4LO_\Z^,1GQXK'8WD]F/LE;+M?K,$QG?K6R@=6++5])S &&\GOX:-34Y=:,@+G MWY&MW^)C.W1>R=71F,A(Z&*1QBE/16 "XZ*3&N,.#PP+O^M@LTUB 0COVZWW M*GM,O/G5VE:Z^C'5"3AVC= ZUC22_(P(!N0!DA7"=!6I:+8'Z8BZ-0XQYM M+F^[OCC1;W""!TGKKST.\QU_.0B[TUJECZ%DD<9U\]Z#^U!$QI4[H-Z@!3 M'-2'0NL? U!_P#6I=2M^SIT#$#08)^1:$CS&-Y'6XY)6-WP]6QB]4XIP"OS/ MY>],]NSXL#BIV.75=L]>IMUW2MZHVR-=^RVD+EW>1JHI"KNRN$_2M0M;KF^ MA '=R;GQ:AMX<>V\HVR,VVGK=2Pl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| MQ/UQSF]&"HXR#,P7E\ST=$1/6=KH8 -<9 M_.2QY9**@O?"TV&)"LG(N/(K-P&\OQ8858>S(K%ROC*&4X 9 T]DAIG _]2 MPNQ92W\:#W/OG>]@M=OL1OV@=R&_A-"W#:64)N7>>)X6TK50:_G6]"YA(B$ M?=3EC$G.>7_$1-1WH)QP1=^(409S0%?QB47.G^P"M D3 ME_%9:5E$ZG&S")F5P_M\"._SI+_4+'U+7H/GBN.f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}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fNZCA MHIG&5("D@R;:('C25*F),>;YIVPEE?,N&TR%F=.:HHH-X6?OU$O P]2=+E(M[P/O^'+GEO+/HKOQ[T%FPNA28Y?6Z%)!8Z+H4[?)>.B2<27 EB[P)&-|^#*& M=8[P);NX)Y$P!@9@N=|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fNZCA MHIG&5("D@R;:('C25*F),>;YIVPEE?,N&TR%F=.:HHH-X6?OU$O P]2=+E(M[P/O^'+GEO+/HKOQ[T%FPNA28Y?6Z%)!8Z+H4[?)>.B2<27 EB[P)&-|^#*& M=8[P);NX)Y$P!@9@N=|\^'N;7@1NN55%\1XUP@T*U3N4AO]\"[X!6R-E_'RW) M$4G/RB@<2R56I9*1(71!'Y/K($XB<1E55WZTNB7NP52C77E$533#.ZS]A.WM MB.Z*>EM? 9)X41>E$.B?@1 16L:+4]FA-X;.:]6YEN;&TDX1#*

*48;YZ&47GEN,Y+|K3AFKGQ8IG&<54'F;?OBW, |K) $4[> MLB/R%41G-7H',F>,#L+';<9+ , .) _U9+'Y+(_M,QX";M\=^^/AEV1X9-PN! MWL;LH/;&S .(X_Z^9MH=Q0211HJG)^*>2] 7;I9R@&23HI;X448WS7H-84_B MOWP9GA-1ET),9!B0Y3;9BB3#ZS4G =@C7M":19IQ;9-1/|@%Y0S,(Q%"7R@9 MX7_\L1#XAQ_7__QOV5]2%Q_S_P-02P,$% @ LOP!=)I 0 $" M)!4|6UUE R#SR8<)O&9^(__];'R1AL01Ff[@__6GTR\G/XV ;P>,ZR_^^E,2 MSW^^^ ,E__>?_!3_^X__^^>?_NGYY'#F!G:R 'X_L$%@Q<$8_W'@Y>@O6:\L?`M?0-AZ'K>2#ITG048C4Y/OEQ^.;*ER=3[Z^>}^ J,>XMB+8)_!'Z6!G7?Z+7]SD MPP7^7T:GI[\+Y=0E '+&(QS6 M9)K8YLB__:WT6P^6X,P):$$=9/$-5'NEV"U=L$2MG$WX#&(0 (N/&=+Y$%%[C MP/YC&7@.G#GO_I5 LR07!MSX)N)P8T7+>R_X(9L%NV';D_K6C6POB)(0W(+(M#MTU^@IG\'LDU+7 R?747/EQ(V1:<6FT| M2.#H3)L%W#**OO '4A@>7?O^G#B<2UO1\!;$%NNQXD"[^ Z$)C:T)A$ M;C[_/+HV,K/^ BIK!B?;= MM4@0^(LW$*YNP7O,^?JEGGHLZ&H5^.GJY!\6^JYY-8 =0)NIX]P^.K'Q;6P'K70D+O/";]>ZU@$OQF [L M#T00$7R$T7L%$1RX!S=^WR""@M #C-E#B$A,'B<78 ,YN_N-$?K5&9\FA->R&&_4EV-OD*["2$;WE! M*C9\E+GH0*V""7"*;QH*ZN T+$B|B]=;ID=C>MX"GR.D9[_fN/=CZ4<;_^]$(PR 8P6B;1>+R /P/(<[&/3QNTFI/RORT_@BLDM9!4'V(T(D_! MQ@IC-WIRHZ|78[7 $)[5"7Q^6Z],+K^V@T_E64;C\PIWP,/Y?1(C!S+8 #\! MKW$(K)78DE/F&1N11?XD\Q'\WRUO#CT!LA=/L M2<9C\V@YX8=Z8,]/.1Z5Z3H&FT]+-)7G&(_+L^4%[VXPM\)5"U\3]FG&8_2; M&U!VW (\U0<9C\S?DS 06]PT>(SQ]$SG:W<-K5C=R/NTE?W%L9$"6U=P],H NGY[-Z1 MQ(T5ABYPIO'|9N;_(/]P"#>8Z?$92OC]L$)K#GSW_9OK@2@.?+"-KXX+'[(E M{{{UX'6-T=++VC5.QH3#M(2[^:&/0DW(,RC>R,;(KYX>)+*XMN\GQ+M+NN8!LC[S8H1'^%4E/ZBZ<$V_^@&8)#^\R:(:~%ZT!\YUGO 5I<;?8L=;;7=-/BBH:QI7D'X_'4MRYN M\|AS\ASNHO5.2'J&X@^\D=OH=M3W]8H2,3#):G&(E)[I\3"S7@'IT<#)Y\F"[W4:4WU."[[\|G!<-#NH#(UAG2 M"C2'3^L"1@H^)(Z'F8/0+N5)W6=5_PQS\" L&1KL>YH\1W<^YBVDK0-|03;0 M1] {MV_5F/OOA@S!:NF*KR|K!=$LXC5=[,7)-1<2/!EO&|{]=XN!S&"Q";]58 MV)IA-5<$$A(/U]^$^D!B1I4TB"]}T(1'#$=+0+VET6P^0783EI$'/TE%3<5 MJ2';3;^%%O+/,T&LC'@R7RDD;@5? 5(9"2BS$>]VOLN?|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|6P]/TXJTU]I6TFX7*%3_1]-MGIFG\|!UP%-"6,56F_1"34Q"Y>HY5^4&8E7/"UBXR#_IQT_6"F<|< IE/.FJ+GDD5+5XJ5N+4|>!&$?Y?Y#,IT0-8MKV M2'NLTN6:NS)/;PTA4N@A-#5'>#TE/#M^:'|<2+TH; ;N1K5 : M[X M?_IK%'Q'LY]TY+VD(V8AL BZ&O_U[W04*U A4XT>E>@>X1C>]S+P8T>1<;-!>+8OWDY5X^3_>WU"$(8_U29E4<{@'Q?=TP^34(5^<'Z5EEQ@=W43OZ^?]/? PRBG|OA>.J9>H4 O-N:%8+05][C[L)0JU)G@F<ZY(;P$*'.&=&9]S+\.&6G5[[8L56 M+CS%KXQKWB/M[2Q>KD*174RN"43 M\G5E>5YQ;251Q:56/5)QO5R%BF7&G[6LXKL5"!=POOE;&/R(ERB5V?+)?5.V M=1F:.?SCLJLJ9Y>O4'TGPV-R?B^!Y15I? +1!CQ1=*U:A7YROIB/ZW4MT2*\R MW"]%1EYH4SKU2/_<8A9\P/F&>/BP >%[IH{T1 %TSZSWX#OCX.R! _})5V?=((M@V2%JCL9OI-O'>[=R+:_P962 YR)37MA;JYA"LTCO-@&;_Q(L9S)^H]_EN MN4YH689D,AF?G'9/WSRR%>K&.<$ZINXLC)M-X7MM>ZCR.ND*17?2:S.%H>LAV;/CWF[G3[=W3Z[TM~MOK[/\A=OH&_W$[?9P*W=R-7G^]NWM[M_:F% (B*.4A]G\^V-+,]!EKU J#;"UI5;14=T?K@\&F"L35+Y: =0F\|0DPTO6 M!T6)3-+UN3;)Z3G\|PY ';V2LLNEZ.UO%UCFEE 15W;NO&?2>:6M:.IGT"\)[2R2*=5^ MZY_ZC14MT2U'\#_H]M.-Y0%TIU&,+M_]=/U%>DL%;>)GZ6LF.U@4C5D:!" NL ME#2G;9-F=SD%@@(?2DIMVR=2L NH=)'0NL^G>EGR_>;))7 U[1/%&'63VF! MI]89,+6S*S>A29S%2Q"^ !M HP@7U$3B.EF@:EO&<.+3G-$7&!?B:CV%QR' MMU2@G_S^XBZ6<;23"\|%M, /Z)\;/DJ!]OX?N"YY#L+9<)}^0]2!Z"4B"-6#H MV0=^-!57:9$K35Z&FFFBKQ1=5G;C +D@MCS|RBZODI\"W^,8->R:FTF!1CN& M&N&4;AHT3!"\&H3Q)H15-[W"|ZZDX)>P"]N$Q\!?O(%P55TC0QMQV3'4 M]^]TRIO(:-0&@J#T;R[QN< MVK4?MFT)Hf.3R?A$;TDD,;/.+)FLQ;\94WPF,G6+UPQ]4D2AU+'MX&[NT;7> M72_U=<,%:QH$LPP|*&&4N<)KCI%9NYM&"N&@@D8"*]T!MAYNL <%6\P!N4,9 MK5/M2X}$

M=S,.:#VZUKOKP5,.CYB%H^VDMY9HJY&DX:^93#5WKO,.4X,V"D{{Z32#!,A?4,L,)VYSEUU6 M1RUZ"U)@D/>:S5E7U\|T\@@I'^,|$\)!TD& ,1,6*[B$>;ZAO2,A &]D"I M7\<2K CM)9+4B*]{ M_H8[=AZ2A:.GZ3QIY-CB$+E8BIDQUPF1X3L2S_M$5ZEOZR.GUS9$KR",/1&6 MU Y9PO+RQ+C$$XGT$<.BX%5/9J\7J%&HC>74=V!!GC!.LVGW@('Q4G#%MZ6 MEO^V#(-DL;Q.(JB$*+IB)5N^NGYUB6VZ8NI"+/H3)3M'3^D);'3 5?#8CN$!" MI<;8\A?HZMW\6 W$62UR^)G_+0B<'ZJG$9L&TYO&EJU;Af9+1;_Q MF?;I*%9$R4P?S"V'&G27,5+$ M|EL(^BN KX)N1$'1.=&1@2F55F5DQN=GDVI&%/"(5SBJ;*5:A8I6&!#EO WZP_@&,)W/0|UOCF|^C3L=1#0 W--V 2"CP@9TZ. <.NPHE!P^U,6'(#1[2KRP9@ L$#_7%\'$@_^[1-,\I!{4;PD+;J>@9P3SD%*F:Q,59&>4A(^ZD$V?K9(HQ#^#ZW[=! M3;5/>H^ADT8 G4X4B542M#@\>G B MUBLC&#X%Z"F-_C&QUOX ;<.!BM+ G=8K:RB-+AP4CX3A,:I{^G1A4=*,>&C MM%1K?Z(+A\DF/G"4EG,U+,KPM_7JY/*K0'3AAO\&W&&QTX=>V[4MO MH@O/X2?;O>C'%$W:H/*=ZXTNU$>>EG7.&UU83Y6^1Q?JHP:7AJ!$%|9I M6V9T818+_.U;?1QAN:5)VFD&,R%B%RB%B*+_^D4PS?YM$2YC2*JV&S@I&1(S*-V:FP#;5?KI"!X2S^9UE+U\3 MVP91!/%+/X4UOD*X%AE\XGXI.S@=.1 6Y*%|S*2/<"XB3TWV"O:!EXV'SC MVDY&HD 9%06,3%I/>5[)+8E8^\|= 8U1$I24K%2*K63-38\Z@@B)"F!6*WU MD9PI.CQR\,"2,T+MK4CZ+P*CJ4D7A8OT.7D2_&!CAF8HB=? MIR@^1G_%ZPZD819(J4Z_BX#!91%L?G& FQ$1_F7'/_B/WQ_!PO+N?&A&/C$! M09@6IFB)94WM*.**B<;H$9.9()@(WZJOS9%^ZQ***NM5A+S(GJ*N9@EG,8A6ELN8%JIK$(VIZB6U-(0B'GLK*Y9,//_KU/.V(M#| MV%/BP!GN^Y?HRU-FZPLC0:5\?:W*2KI6#-W3Z*!K'YR>3\97_-47*P=5:6J-K/L@ MVTL?-H!KRE5>672*@|2%$@;%EKVI@ AW_MQ M#0V;C3ATBI KPO%%:AWCMA=AA04YL9NQZ))0Y3%VHQ.'TX|XGGP2:Q!9&C MD8ECE".OI"#6ANC!I>&*L%0C615FN64+A#(P:9[OS9)#|\T K6QRZF3L M?,23Y)S5 5IG?G1:*R31K9Q5_=QA5^&A^F6(KCIGU5WX>3HE_$>R2H??3[(1 MKMA@3TML/&@9A|O)^>$+OA[&:#N9|IG!)3+3-%:@0W+Y&2(,<+6' 'AP8L2&QSVIN'4AA>2;]8&R5{M\[E0CO2OSF%+|*\$.D"X3"DA8-PA!^

*FHS4G&9EEM,B|T[ZK5KVS*T6@0B|F';=< M\^@Z1EU' OQQ/9^}XMR/__T4(?1,3H!'<6+*=6CUCHYCQ'&DH=],JANO M\2$10|Q-!2T5EMFZFTRNKT9'L8'YN-'&7A[Y'9'C@) W? 4>1LT+ICP^XJ3D@ M;63!2_@5O?$ENXMAS7#NWQ%0)\D SX&W<]$!MB8II3K+&T2M$!T-]JI?I<6D(L+%X\9#]%Q[X>A/RP M*>48I#5%AS.68$=:"Q\]V7%W.;FYNP1!# ?E:MQ!(Q-MY[C4)GD6<(+L)1Z# M0G0+SJ2)YOO=.;>]YMS1)/#8DZOE&V[Y&Q_(!'P#;=],#,3$8'$W 73OKT $?-M $0G%D&#!2U5N SG@ \ 2C#&ZKF@ZF'4@=4##8PGA$'1C]-NJ!PAG2J4NU483 MO2W*HQ= IH;F&PNT?O^S4?+QV_(W9'3+&;+I> ^B*-WS|S>KO^Z(-^89DWD$ C|/4.X=X.2FA_[JFIP*E$ E9:MI$M/ST'E- M6U1@<3)!1A !4SC*PF#B;B9Z#DZ@!+!5%2*NZ.]GB*K9,4"">546N'XO;5S-? M,'[')8P5C4*[XS6]CYL>O<>,,R072L^1RR0,3Y'1<3"C?71EE@$-N)S M;H1+DGV+S[&O!&.L-H[/$:NB@]U69_;N "C4<>I"<'Q$)/36?1LE\2)$WA^ ML,]VJC2MBIS5 T[=>M2F?MU##DE%K?0V75QY39PHZ;[6 >TAC7I7C]6B=IVU M&FY>[60T]AS',^0|[*+#D>XI5O'I%=O%1D'U.//F+QJN5M5 U78[\RZ38H!6 M9)D*@!1\NO!3&"V1G^PPB'B.\OASZT=9@&'AU9]:86&]9PC6Z%63;:ECVS2\@=W?+:5J3W=WE;*-Q6SX_1CT0.9VCTGF_UJU?E;/V.9K15+1T6.]4ODZC M<$M-I;-76, W]Y5/@UJ4Z6^HXP2S^FGT&A,8YYYS.Y!%>Q&:!6!6W:,61XR> M8P_FW'GN!N(\;9,7I^$/NNSG1C9GUELCYDUQ<-QC&,(5K(7'I.<9?!DC)X!KJ,2H7#=@!S MD!48>H.? VLK%O;P%.H3,\VN?'#M Y)W2AZ M|UU$Q^-KF)!3C+(<\CCMT4Y_)R>D? V3/U-R1VZX"OS_8&1/TF!$2?-MX0:P,RZ^R>PBC_)U*-.?\U^Q&CT]B#N? >/2=G%##P;/6T. M& I\,HXT3N%F!;]C^#+L&A|Y]["HW$G>3%2=5_OZ)9][$_S1W9V\QBZC|;S M'62HI,S&M,+1Y9N96QX_9U\0>]FES)2$8'19#LTQ!'A,G7UQBL6B,O"|)BX6 M=H4V+.)<5K+<-FX75"I31N'3)8 H$3E,.CGF|'HDFH>NP5VG5F N&>;UG@# M4#%PJ7)4>2$B;V_F^.0 S XD?84C$<-PQ#,7QS^WHVO2D N*;VK5V\^?=U;BS'B"=*%NN +[5G-[,JI'JT .#4P&-ZX5" (5ZR3>U-M5Q&4!BV !D2615'?\+Z.6.&=]C^<'DLS@EKN(NR(:[__VN'6X#F(DVB7\C1+ MWE"T>';":A"D:FG7K!Z< ^@1I$+EJP 8U/7>PAQC:P)47'+^_]O(6Z/X[!1- M#F4O+\-]B^&]f;=^#< WWC5^W*/*EPXR7^9FK2FJ8G""-@:BAO48>(WNO;-& M@>=>$#\Z^.FI67\'@M&H(0D7#9T@-<),$U%/'GI-4H1B[MTLTM>(F@JFN:W R M-X]F_Z|>9@=#'}+;&D1%? U06%4V^XB+|C,$&2(.AT5*+1_8;/%G>^#01'E|LK M.$OSYH^C[ZS+02^UYU(2@|%E.}J^.,5B;3#U587+<(*C|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j,,+@ M+L&.KOD/Z4U7UFC)PCI4X_CO%%3+P;0[C:!N)!]92OLMQ3RTLLL$"-D6^^R M1C^KXV?V* '5I:F^5T5^"%TI[_$GBEP_SA+4&,- 2)\&TMMT#@S!@]^O-8WI M.GTO\NB0/_XD? V5U.G(/0Y$P>&51P@&;.]ROC=C'S78=[E&1L4*HYPM$"_"MQ%F?_DY">;^&R1\H.68*'-^4/51EE.%\;]]3YGHRF5Q>C\XDYTRP. ,U/(/K MG]DD\RF;\G\BY5@YAF8_8O1$>)XH3Y2149S1-+ Y!@MS008+Y2RP!ME?MS6R-MOX[U4I*_!OS=6U\!:],.5_VVLTZ5!K+^2]W3U;\FF9\V5?$'JHK97SU0,Y M]"KGR[XXQ6*QD?/5 YU2AD_Q-/4;.3]ZIDR0A\P0L!C:?2IX%R |7$;.\5, M98H!$*A.E2@FL?>#\0'{7X\:>4[M1LGK K%2]_BF6HB>'<\Y.A00!A0MZL.**AQ:'M?H368 UG]RI_GMCV'F9HW. M8@AA(>&|LE;X(WQFL93CSYF'_S<_3]VP_V.!]T.2,(MX,E%]JD?(AM#9]GA-MEP-R!5B(Y]YU.WI7+P)>/TYN[D8_,@5S[CQW_0E7I?]KWCTW"%F]QG&RFO[T M/]_/? \]K[UW8JKBXK6!5*=_*QW3X,[-EU?M2.^0"5Q76!.4ME-4!/715-R!. M-WV-+S$^:![AQPZT9!IET)_,FJ'#"7#E/0!&0>5&<"[(N3!Q901,'-UZ5^PPT M@=0E29IFCKD0B?X%!2ARUM/ FWH;/_!).YOXJR@?.G#C1:6>[0CQ'-K.J6[N M>+^Z$#5MJRA$5'$MT 1ILZLR :WF2W^-B|IX:C?^X\YNEH8)F:A9^LZQ,M+,_M:EI?N'>V?N*LTTG|@__N>RAHD/1Z?7E574'(7YRO)) ?\Y?#?Q)(/_DM7&-6 MXVOO[FN8"(^]Y#YD_AK#]XOSIZTT;Q9/K4LM&9!#/"Y4\L;UN7LJX.5G-ET MJ0PT:N5IXE#,-*P7U'+GPI52B.EE4L2AE6,2O%OR9OB?;OXV.7P|^(>> DFP MS'%8.')7US#;>8H<$B?_O)(D\;QDV=;;RE\1K:1*K)7M# MHI1AA&@[T44?BC32)U9*](5'*_TQZ88W-HMETONU$|>S93KBYXQIF>7!\MQ@-M?%O/2$6ML96Q[IF!W.'N>4(HA-'_$P#^"]'ZO%__#GU(BK)I=\Z3Z?8 M&MO#9N7KBZ)]-69Y:&0K68R2,M+VJ%NY!D@JR@-RUQAC|\9?PF#Y&T:>'\@ MA]6FUWA#&<([<#KA'"GJV!RXJ;'AFN?L> ^Y[O1/M9E'W-%Y2\A=YSEF."7WTN+R4/UY MX;(8-RQ>8150VA,YOB=3THZ YA%4]7?T4K9_T88%_?4Q8B*25*=EQ=6M_[MT\Y1>=(K@X8$]S=Z6K&D7>+ ^^L+=Q=$]-X4D*(;&4? IX%EMK?'Z1UQ'"4GG3#^KZ-KX?_X\S#$ MH3279[H#(=1"8RF'!6>2IC8B6995:HM)*0&%63F8&;38:C?_A?^X#Z-M&*40 ML9M+:,D&0T,LWE/(VP6P?F^QW9\T'"3- ^T9*-1,;$^,X\-9P+"7 MZE3^>.YN.+4L."74IN6<6GE#U;3.*LX9V.1G-7 WML_*06-/'GE**(.4<=UO MRP^MUTFC)MH3Y3\$304V6O/Z &D]F75B6E9?_"""M^CG 'X3A.PRH7E#D$OY7 MZ//^):6.H;$;=

M!QY59]U@FU-J[Z3 U&4+SE7%_074';[9&K2MWKNO:O5C]!YH!V>0NY\"&LF M=%'! MX?C]P]E^+1OV'"$WKSB6Z0A:T38]B](${QPG (;[M9-GO<-G;.!+';A.H7E,'K!N\4TC]G)A@A8&8!U MUD;2E+<=T.'---/Q;.#D_(/7"+N4:IX4L/_T]_G3B^%3;?_;/4# G\&2.$V M:TT#HNL%+H9M!K]R__|WW0M.'W]^ 5I3I"(?22FN?CH=&IH^OL:HQUQ*U,?[65MS0& M,RD5RHFY5',V0 KYI'G3D9G^)(KQ4_@U=UQUHT#!1/WV_O9%,&XB> M,0?\V=R8TV!'JL{1+DPL,&UNH.Z@H<7.8=CB[C**OIOU3TAZO1:[^P)7F6'B=MVMW]? MS0M\VX4(BZ[5VAF*{L)3;=BT"_-N*VD>XW,O{1V?7K;-N/?%Z67[0V!Q MUM-N*?#M7(;KU@4_7XXH"'9 -UT8;89$@'VRBF0ZDIP?\$0'D8W*M&XA090HY.:K7 .HU,S4^RE87SE0 MTI8.:?D^A[_/P3P(5VX!Z5USZS=,WZ_3]>:7*=/.K"A6&<' GO::6KTZ'[-) MT_T/;G(=+4"/.UQ_UG7C:.@-_/K>D_C]%,"X-"A,_4T,W=*#=6O#6H=%-4(M,$^:S_Z;&A0?P/JH1?%GL,9O? K;E>YOW=5O6R'N^!_^<;$X>!//E&LO}@2X M9S NB9Y++@K&!/.5+C.KR\JBVDR:?GY(/_B?DCQ"/7[0+?YS/7XP]-H% &R(MHI>$[%&? %#^I#=+=K#V8PBSO":UB>J9EU*2YR;_BI/B#HLTP?8+>*D>?';+$ M)56;34$S1XHY#C4&6[L9!,WNH)&G9-BFBVAKUNI;'-+{)BU1?HHVSX>\L$HQ M"Z$Q+Q=NF$8T+1AK^((")P!2-$OWFFEN6F7KW:19_KM5!)]FPW,*Q6U*=Z\3 MBNOQ;97(*N9F\RJM0VS/K^,EM00E+7I[U@ZZ\0/<([K@CA;1+-]1=$@%N;Q; MX$FGG>63Y]\FB.L)BJJO^:(PH[152&L3O*(!=0<@YLNXM1/R KM=#_"-#M@+U78Y$ M6:6%X+|:\F5#<8,!'+#U\/KF <-^1VP.VU1:95)]:@0*LLXB+PEXA 2<9%#< M!6*7CTX/D5V=_WL'Y=UYZ-M2;7KF!>\|7'OUC&L%'YZ"H=H]}&WC:8XWMU%/V MB&90$^>7--{)F;'S7W:GBG\VR_=RU0_3C&QE.+3S%ZX,IVZ^0H'L(>*]f=FU MB.AWZDR-_(;! {[5&:HMOB'VM'5N%%4=$7%HK<-1!{,;E+}B'BOZ?(L+0"S.E MT]G/5!916MWN2!XVT9>,B*1ZY-;(R SQ71GB)U9C8_??Y%BC(=S,2DKVD9?$ M>B-'D13!7F\FW!__%I&[.^? {AS[!>K]0V-=H9WI#UICFZ[VI&TU;]HZE0>)X.?5LA\QM"GJH+9ZU+S'E01-S.Q.TAER 8Q M)_B91H.VF[$@6?H]!N$&057]\]"*N*T23NT%55M$7!]4C?7R:M$V*5*MRIX-M$7AUSMNOH.H;0=6EB,!NC@@$?H,$O-GT!}+$!8G1BK,N(NA M:>A-K>W%3B&<;W5S>3W]M9R&UYN$+N+T>N@MPN?C<^J^)^QMX J* 21.L W% MF&P7FXL5",I9@SK&*\,TM&Q;$Z)'Q({EWY3XTW,-**D>V3F$W^/O>_N3I]!(M98,2+,45M&TY-J(@IM9)MV731'HPYI.B.YF+2%?NG4WYR;HNBIWOKIC2,*P,[M'&8#.23D'+SUR=F6XRV!I,,55.8%SP+HC)E4?"S^6:TO.'_I]).!@I^Z]&=T M^FBR\%/S+L/P4'<,R5E&U4TMZ<)^;YU.Q("_G^OT-#;WZOZ\(/-=Q>9--E,Q M+"=VJ8MDZ/1HN)VF4PNIWB (M<@,%KU6?JASY<@Yl-#)_W3)!XPJPVKDW"P6 MJSA-.3.C(,,6>[@%)]:.O)5PE,L:)2GZF-XZ?*(CK\[";Z3*B-R]5YFT-5OVW7^U4Y M/1RHKU#[&PR. [LBLF_IE&2C38%,Y62WBXV:G76.+_5K2^?P(979C=F=_F"8_M(\ZS:9-I+ZHI 8.\246.EW.]CI5T-MI9G")I=Q6FMOA$>5,OLO@SY697A-.JUM+J3RA2L-> MHPPU[7+2;=8CE-F-V? V=W3F[$<$S@)-KVF ,;!M()WR&G^?769#<&JK?>GBL:B=^CE R*H16^@)=F>8E MG_=M;;G (;7:R<7?,_L*H2?I]4)H) BE3&,.;%<9:2 JE.:K?(=S'6:A0L.! M20 Z=?_;3{(>_8)F+Z1>4Z?I*&N/HAVH8$X-GN_RZ@KO9&I9>Q1_Q_!E|>]> M2?P=]GE_0]C:Y&*-^=NX4^ M)!@Y TXR2G^GM8]#5?+';8-\R6TVQ5]>4L%R(? H+MXG8D_@;Z0=N&WQ(>ZC M?#AHV95\IP.$E5F6^B.?&H]GO>3'P[_)A[M3"2&C?#B:6E5Z=6O4H8O+SC0M MR3V.K"79.OX^'^[1"+V##U<&?4XN55B3!W,_4U]-A^U>]-M)7CY<,I'Z31^N M/$9[A6$6[ZI*M99QW'(?S^KQ!U=L?+A[[3QXE\/"=K-V+KL@5KS?)?I-#8>8 M)IM\$_EKG+@[[IUXE!H(CW#J^42HOB^Y20_SO@U7EP<('H'-ZY4 MUK YUZ]G5%;>]$BE6,],B?AG2UYN7 QWHGWTX[*E E0H,'U2!P8GK*7TKPZA"O,'C&,ZUS_A1/ES;X[0'KA,??;@5LRB/R/S2Y+WV M3"5]\&>=:,T6_^?1X?[DX-%A[EPW72)DY9L&2I*"-7IWD%|KJM9R;)+USIQ81 MC_+AM'1K!=]C,L7APMR52D2G>;+AWLA-%X^7!^N35KU[B0-HWVB-$,64!]_M)UF/_DX?+@[M=C[Z<$ZW9WHE:$[!]D2:\$.7)? U4_,$5&Q_N7IUE'N7$%?(< M5EF)*9QFB8H^:2TRM27^2L0E1O'M;KK434"?KY<;%|-.8R?64YU7PB>=&AX>,/P^O GLL6GKZ]/KP\?R MAN)N6Q#FG*;1 (..0%? AIIQA8<.J&;&K1PI/B#Y)S,W1F%|2\WJ-=,"&S6-/ M\.%&#]HRN]N)9Y.*^]!)0*RIZ MOE3!.:.KU_PYX-@2]3Q^%/:R%S&3BVNCQ@*>G\TK}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|_=6'S0+16!@:IF;5+URX]70YT."XFQ59HO=%]K MQ6^#[K/=A+^9 9^H/21CNIVQ.I.1U2)O#&DG?'DM'3YH-W]FHU)X!3GUA@+]D M:6W2TMFN3)L\PX#4:KA4,EY\^]$\D*7')BIUN8E*W<,/2\BV&3DMJ:G*$DQA M=I;54*CLLC,M=GB+> {W3DY1[QL[MNY5,W;>$VNN)Z]AE4@VXVTGW:,:^K5L,Q MRUS'O13]}5.QE]D[;]=A<+-8S(0M0FX9 J]"N#+K3[O)Y9.JU7>:*:5;._S6A^6EDZ+K9NQ2@:ZGI.<37 C,N&I,P5R1.T- =C6%66R L,T$HA>F-MD MQN- 3=G7011O-SM0"9$S*C!7;-)O "Z1KU5NS\[[@A (,0^/+R(3BZ@I'D:\QL MM"M-7O)W]19*U.V"I!>E??3.5%K MF9@U-YY(Z%Y;,%Y"%[L-H629Y/LH(9 \5591U:>QH=JQG:L5]U3G2^@2)G2/ MM70H8PP)LE]]JMVJY.Q&SE0MI9{Z%Z6[IF%[C$RP[E=>KJJV/LPRE]0SV(_M)6]QRT2]@!L'X.)[P,6O349M?]8!CJL8DX/B?U86;) 3"""%^ST#7]R?__8 M.[B;#-ZWOPRGN#S-9,>2BBH4)^I-J$UGIM6VS_J>E!P$Z&WK@BC5I4O0X+ M;A$S2A[9=P>QTX6?+"NM]>$A=6[NNU\{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|HGG4UP;,RVV"?O0J@%3'3/E,4FKB?AZ MG_CRVK,XX/,1/O$<:V DU6H5>0*@&7, {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| /W3=DE>E{(\+3*9G(BC]HB_!IVQ6_)*SY9H-N@XTQU@]CFF'&- M$6@HUT"QA5+J3@NQU4@QM69Q0,=1RZG;Z(Y4;UGPYCEHK'J&P6?FC.!7T['- M2\]=4=|2P2>]M= {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{M,5>0SVN&.O")9Z?8",_1!9J;BZ[*CO.%;HTQ[E;_H6-]P;2CUO@ M2>UA@[@M-H2,-EKPU8:G%FNVXR[5;#H-O[#Q76Q M[\CY.2U_KN5"C7G A+T3=#YPX7IE>]$4?>!?= {G,FS;$0<+]0,-^>/<-K*